<SEC-DOCUMENT>0001193125-19-240403.txt : 20190909
<SEC-HEADER>0001193125-19-240403.hdr.sgml : 20190909
<ACCEPTANCE-DATETIME>20190909060842
ACCESSION NUMBER:		0001193125-19-240403
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20190909
DATE AS OF CHANGE:		20190909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233446
		FILM NUMBER:		191080762

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d692844ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on September&nbsp;9, 2019 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No.&nbsp;333-233446 </B></P>  <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>AMENDMENT NO.&nbsp;1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>TO </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL" ALIGN="center"><B>EXAGEN INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of registrant as
specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>8071</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-0434866</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>1261 Liberty Way, Suite C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Vista, California 92081 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(760) <FONT
STYLE="white-space:nowrap">560-1501</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Fortunato Ron Rocca </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>President and Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>1261
Liberty Way, Suite C </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Vista, California 92081 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(760) <FONT STYLE="white-space:nowrap">560-1501</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cheston J. Larson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Matthew T. Bush</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jeffrey T. Woodley</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>12670 High Bluff
Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>San Diego, California 92130</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858)
<FONT STYLE="white-space:nowrap">523-5400</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Charles S. Kim</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Sean Clayton</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Kristin VanderPas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>4401 Eastgate Mall</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>San Diego, California 92121</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT
STYLE="white-space:nowrap">550-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared effective.
</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3">Emerging&nbsp;growth&nbsp;company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title&nbsp;of&nbsp;Each&nbsp;Class&nbsp;of&nbsp;Securities<BR>To&nbsp;Be&nbsp;Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;to&nbsp;be<BR>Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum&nbsp;Offering<BR>Price Per Share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed&nbsp;Maximum<BR>Aggregate&nbsp;Offering<BR>Price<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;of<BR>Registration&nbsp;Fee<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common Stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">3,833,334 shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$16.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$61,333,344</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$7,434</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 500,000 shares of common stock that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the Securities Act.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The registrant previously paid a registration fee of $6,969 in connection with the filing of its Registration Statement on
Form S-1 on August 23, 2019. </P></TD></TR></TABLE>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby
amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#d6284a">The information in this prospectus is not complete and may be changed. We may not sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where
the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT COLOR="#d6284a"><B>PRELIMINARY PROSPECTUS (Subject to Completion)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#d6284a"><B>September&nbsp;9,&nbsp;2019</B></FONT></TD></TR>
</TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>3,333,334&nbsp;Shares </B></P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g692844g91e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>  <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This is
an initial public offering of common stock by Exagen Inc. We are offering 3,333,334&nbsp;shares of our common stock. The initial public offering price is expected to be between $14.00 and $16.00 per share. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on the Nasdaq Global Market under the symbol
&#147;XGN.&#148; </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012, and, as such, have elected
to comply with certain reduced public company reporting requirements. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>&nbsp;&nbsp;Per&nbsp;share&nbsp;&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>&nbsp;&nbsp;Total&nbsp;&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Initial public offering price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Underwriting discounts and commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Proceeds to Exagen, before expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </P></TD></TR></TABLE>
 <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted the underwriters an option for a period of 30 days to purchase up to 500,000&nbsp;additional shares of common stock. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#toc692844_2">Risk Factors</A>&#148; beginning on page 12. </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy
of this prospectus. Any representation to the contrary is a criminal offense. </B></P>  <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of our existing stockholders, including entities affiliated with
certain of our directors, have indicated an interest in purchasing an aggregate of approximately $12.0&nbsp;million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other
purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any or all of these stockholders,
or any or all of these stockholders may determine to purchase more, less or no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these stockholders as they will on any other shares sold
to the public in this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver the shares of common stock to purchasers
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-running Managers </I></B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_9">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_13">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_14">Certain Relationships and Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_18">Material U.S. Federal Income Tax Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.
</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_22">Change in Independent Accountant</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc692844_24">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free writing
prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the
underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date,
regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery is in addition to a dealer&#146;s
obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For investors outside
of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United
States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus
outside of the United States. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider
before investing in our common stock. You should read this entire prospectus carefully, especially the section in this prospectus entitled &#147;Risk Factors&#148; and our audited financial statements and the related notes thereto included elsewhere
in this prospectus, before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company&#148; and &#147;Exagen&#148; refer to
Exagen Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Company Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are dedicated to
transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of
innovative testing products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or <FONT STYLE="white-space:nowrap">CB-CAPs,</FONT>
technology. <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus
erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or
RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel and targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing
products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently market
nine testing products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand, which we are leveraging to establish partnerships with leading pharmaceutical companies. In December 2018, we entered into a <FONT
STYLE="white-space:nowrap">co-promotion</FONT> agreement with Janssen Biotech, Inc., or the Janssen agreement, to exclusively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (golimumab), a subcutaneous, once-per-month,
anti-tumor necrosis factor, or <FONT STYLE="white-space:nowrap">anti-TNF,</FONT> biologic prescribed in combination with methotrexate, in the United States for the treatment of adult patients with moderate to severe RA and for other indicated
rheumatic diseases. Combined U.S. sales of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and SIMPONI ARIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, an intravenous formulation, were approximately $1.0&nbsp;billion
in 2018, of which we estimate approximately 50% was from sales of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We began direct promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in January 2019 and
expanded our salesforce from 31&nbsp;representatives as of December&nbsp;31, 2018 to 55 representatives in August 2019 to support these promotion efforts. Unlike many diagnostic salesforces that are trained only to understand the comparative
benefits of their tests, the specialized backgrounds of our salesforce coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly
tailored discussion with rheumatologists. We therefore believe our strategy of integrating the promotion of testing products and therapeutics uniquely positions us to expand SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#146;s
U.S. market share. We expect our SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> promotion efforts to contribute incremental revenue in 2019 with our quarterly tiered promotion fee based on the incremental increase in total
prescribed units above a predetermined average baseline of approximately 29,000 prescribed units per quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe our strategy of
integrating the promotion of testing products and therapeutics differentiates us from other diagnostic and pharmaceutical companies, and provides our specialized salesforce greater access to rheumatologists. Our integrated testing and therapeutics
strategy results in a unique opportunity to promote targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and who have a history using our portfolio of testing products.
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our lead testing product, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, enables
differential diagnosis for patients presenting with symptoms indicative of a wide variety of connective tissue diseases, or CTDs, and other related diseases with overlapping symptoms. The comprehensive nature of AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD allows for the testing of a number of relevant biomarkers in one convenient blood draw, as opposed to testing serially for individual biomarkers, which adds time and cost to the diagnostic
process. We believe AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD may provide clinical utility for over 23&nbsp;million patients in the United States suffering from these diseases, which include SLE, RA, Sj&ouml;gren&#146;s
syndrome, antiphospholipid syndrome, or APS, other autoimmune-related diseases such as autoimmune thyroid, and other disorders that mimic these diseases, such as fibromyalgia. There is an unmet need for rheumatologists to add clarity in their CTD
clinical evaluations, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. Our commitment to addressing this
need is demonstrated by our strong track record of developing innovative testing products, as illustrated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g692844g12z65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD leverages our proprietary <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> technology to differentially diagnose SLE. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD provides rheumatologists and their patients with sensitive and specific results that allow for
potentially faster and more accurate differential diagnosis of SLE as compared to other currently-marketed testing methods. Beyond SLE, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD allows rheumatologists to accurately diagnose
other overlapping autoimmune and autoimmune-related diseases, including RA, with the same blood sample. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor testing product also leverages our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology by measuring two <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> biomarkers
that offer insight into a patient&#146;s disease activity. This test is designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Depending on disease severity, AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor may be utilized by patients multiple times a year throughout their lives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our <FONT
STYLE="white-space:nowrap">RA-focused</FONT> testing products include AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX and AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP. AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX is a drug monitoring test designed to aid in the optimization of methotrexate therapy, the standard of care and first-</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
line therapy for patients with RA. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX is based on our proprietary methotrexate polyglutamate, or MTXPG, technology that measures
blood levels of MTXPGs, the active metabolite of methotrexate linked to disease control in RA patients. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate, enabling them to optimize
dosing and achieve therapeutic levels commensurate with adequate disease control. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP, which measures anti-carbamylated protein antibody, or anti-CarP, was developed by the Leiden
University Medical Center and we recently introduced it as a biomarker-driven RA prognostic test through a distribution agreement with Inova Diagnostics, Inc. with the goal of identifying patients prone to more severe disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We market our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products using our specialized salesforce. Since the launch of
AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD in 2012, we have delivered over 326,000 of these tests, representing a compound annual growth rate of 87% through December&nbsp;31, 2018, with limited incremental investment in our
commercial infrastructure. Approximately 83,000 AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests were delivered in 2018, representing 18% growth over 2017, and the number of ordering physicians in the fourth quarter of 2018
reached 1,298, representing 18% growth over the same period in 2017. In the first half of 2019, 50,792 AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests were delivered, representing approximately 30% growth over the same
period in 2018, and the number of ordering physicians in the first half of 2019 reached 1,711. In the first half of 2019, we achieved a record number of 766 adopting physicians, which we classify as those who had previously prescribed at least 11
tests in a quarter, compared to 635 in the same period in 2018. Nearly 100% of adopting physicians continue to order tests in subsequent quarters. From launch of our direct promotion of
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in January 2019 to the end of the second quarter of 2019, weekly ordering from healthcare providers increased by approximately 10% and total weekly prescriptions increased by
approximately 17%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we continue to populate a growing proprietary database of over 300,000 de-identified patient test results. We
believe the insight emerging from these results has the potential to unlock value for pharmaceutical and biotechnology companies in the commercialization of therapeutics. We believe we also have the ability to further leverage our database to
optimize patient selection in clinical trials for companies developing therapeutics for autoimmune and autoimmune-related diseases. We plan to collaborate with our existing and future pharmaceutical and biotechnology partners to help maximize the
full value of our in-house database. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe our strategy of integrating the promotion of testing products and therapeutics differentiates us
from other diagnostic and pharmaceutical companies, and provides our specialized salesforce greater access to rheumatologists. Unlike many diagnostic salesforces that are trained only to understand the comparative benefits of their tests, the
specialized backgrounds of our salesforce coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified test reports and provide unique insights in a highly tailored discussion with
rheumatologists. Our integrated testing and therapeutics strategy results in a unique opportunity to promote targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and
who have a history using our portfolio of testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We recently entered into the Janssen agreement for the promotion of SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in order to advance our integrated testing and therapeutics strategy. To support the <FONT STYLE="white-space:nowrap">co-promotion</FONT> of
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, we expanded our salesforce from 31 representatives as of December&nbsp;31, 2018 to 55 representatives in August 2019. This will enable us to conduct approximately 60,500 calls
annually to rheumatologists, which we believe will enable us to achieve the optimal reach and frequency with rheumatologists. We also have agreements with other leading pharmaceutical companies, including GlaxoSmithKline LLC, or GSK, Horizon Pharma
USA, Inc., or Horizon Therapeutics, and Corrona, LLC, that leverage our testing products and the data generated from such tests. We provide GSK, a leader in lupus therapeutics, our test result data to provide market insight into and help increase
awareness of the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
benefits of an early and accurate diagnosis of SLE. Our agreement with Horizon Therapeutics entails utilizing our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX test to
report on levels of MTXPG in patients undergoing methotrexate therapy in combination with its anti-gout product KRYSTEXXA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in an ongoing Phase 4 clinical trial. We also provide Corrona, the
operator of the largest real world observational database in RA containing data from over 40,000 patients, with testing services and support. We plan to pursue additional partnerships with a focus on integrating therapeutics that are synergistic
with our evolving portfolio of testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are led by an experienced management team with unique capabilities to execute on our strategy
of integrating the promotion of testing products and therapeutics. Our senior management has an average of over 20 years of experience in the healthcare industry and many were previously involved with successfully building Prometheus Laboratories
Inc., or Prometheus, which was focused on integrating diagnostics and therapeutics, prior to its acquisition by Nestl&eacute; Health Science S.A. in 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our
Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We develop and commercialize next-generation testing products and promote synergistic therapeutics to ultimately improve the care
continuum for patients suffering from debilitating and chronic autoimmune diseases. The key tenets of our business strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Drive additional market penetration for our testing products. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Integrate the promotion of testing products and therapeutics for autoimmune and autoimmune-related diseases.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Continue our track record of developing innovative testing products. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Establish additional therapeutic partnerships. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Achieve meaningful margin expansion. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to execute our
business strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient
revenue to achieve and maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will
need to generate sufficient revenue from these testing products to grow our business. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our future growth depends, in part, on our ability to execute on our strategy of integrating the promotion of our existing
and future proprietary testing products with the promotion of therapeutics, and we may be unsuccessful in our promotion efforts for SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which could adversely affect our ability to
implement this strategy. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may be unable to manage our ongoing and future growth effectively, which could make it difficult to execute our business
strategy. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we lose or are unable to secure partners for our integrated testing and therapeutics strategy, or if our partners do not
apply adequate resources to their relationships with us or are unable to provide, on a timely basis, an adequate and reliable supply of the therapeutics that we promote, our potential for profitability may be adversely affected.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products and
promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and we may
not be able to find replacements or transition to alternative suppliers. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our
business could suffer. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If third-party payers do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind
or modify their contracts or reimbursement policies or delay payments for our testing products or promoted therapeutics, or if we or our partners are unable to successfully negotiate payer contracts, our commercial success could be compromised.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely
basis, or at all, other testing products we are developing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We conduct business in a heavily regulated industry, and any changes in regulations or the U.S. Food and Drug
Administration&#146;s, or FDA, enforcement discretion, or violations of regulations by us, could adversely affect our business, prospects, results of operations or financial condition. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we are unable to maintain intellectual property protection or if we infringe the intellectual property of others, our
competitive position could be harmed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation
from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we changed our name to Exagen Diagnostics, Inc. In January 2019, we changed our name to Exagen Inc. Our principal executive offices are located at 1261
Liberty Way, Suite C, Vista, California 92081. Our telephone number <FONT STYLE="white-space:nowrap">is&nbsp;(760)&nbsp;560-1501.</FONT> Our website address is www.exagen.com<I>.</I> The information contained in, or accessible through, our website
does not constitute part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We use our trademarks in this prospectus as well as trademarks, tradenames and service marks that are
the property of other organizations. Solely for convenience, certain trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbols, but those references are
not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in
the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April 2012. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not
limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s
Discussion&nbsp;and Analysis of Financial Condition and Results of Operations in this prospectus; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of
2002, as amended, or the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration
statements; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may take advantage of these provisions until the last day of our
fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth
anniversary will occur in 2024. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the
Securities Exchange Act of 1934, or the Exchange Act, our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease
to be an emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure
obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
than you might receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the JOBS Act provides that an
emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected to avail ourselves of this exemption and, therefore, we may not be subject to the same implementation
timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are
no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less
than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>3,333,334&nbsp;shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option exercisable for a period of 30 days after the date of this prospectus to purchase up to 500,000 additional shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding after this offering </P></TD>
<TD>11,233,652&nbsp;shares (or 11,733,652&nbsp;shares if the underwriters exercise their option to purchase additional shares of our common stock in full). </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering for working capital purposes and other general corporate purposes, including for selling and marketing activities, research and development activities and capital expenditures. See &#147;Use
of Proceeds&#148; for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus and the other information in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;XGN&#148; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on
7,900,318&nbsp;shares of our common stock outstanding as of June&nbsp;30, 2019, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 7,816,643&nbsp;shares of our common stock
(including the conversion of 479,967,595&nbsp;shares of our Series&nbsp;H redeemable convertible preferred stock issued in July 2019 into 2,613,703 shares of our common stock) and the issuance of 20,620 shares of our common stock as a result of the
expected net exercise of certain outstanding warrants, or the Net Exercise Warrants, in connection with the completion of this offering, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the
cover page of this prospectus, which Net Exercise Warrants will terminate if not exercised prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">662,987 shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2019, with a
weighted-average exercise price of $1.24 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">812,745 shares of our common stock issuable upon the exercise of stock options, or the IPO grants, to be granted under our
2019 Incentive Award Plan, or the 2019 Plan, contingent and effective upon the effectiveness of the registration statement of which this prospectus forms a part, with an exercise price that is equal to the initial public offering price;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,013,107&nbsp;shares of our common stock issuable upon the exercise of outstanding warrants (which number does not include
the Net Exercise Warrants) as of June&nbsp;30, 2019, with a weighted-average exercise price of $3.13 per share; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,011,832&nbsp;shares of our common stock reserved for future issuance under our 2019 Plan, which will become effective in
connection with the completion of this offering (which number includes the IPO grants, but does not include any potential annual evergreen increases pursuant to the terms of the 2019 Plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">120,000&nbsp;shares of our common stock reserved for future issuance under our 2019 Employee Stock Purchase Plan, or ESPP,
which became effective on the day the ESPP was adopted by our board of directors (which number does not include any potential annual evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and
restated bylaws, each of which will occur immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of 479,967,595&nbsp;shares of our Series H redeemable convertible preferred stock in July&nbsp;2019 (including
the conversion of 148,928,337 shares of our Series G redeemable convertible preferred stock into 246,521,076 shares of our Series H redeemable convertible preferred stock in July 2019); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 7,816,643&nbsp;shares
of our common stock (including the conversion of 479,967,595&nbsp;shares of our Series&nbsp;H redeemable convertible preferred stock issued in July 2019 into 2,613,703 shares of our common stock), which will occur in connection with the completion
of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the net exercise of (1) certain outstanding warrants to purchase shares of our common stock we issued in 2013 that have an
exercise price of $1.84 per share, resulting in the issuance of an aggregate of 15,224 shares of our common stock, (2) warrants to purchase 4174,430&nbsp;shares of our Series D redeemable convertible preferred stock, resulting in the issuance of an
aggregate of 3,284 shares of our common stock, and (3) warrants to purchase 2,668,181 shares of our Series E redeemable preferred stock, resulting in the issuance of 2,112 shares of our common stock, in each case assuming an initial public offering
price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, all of which warrants will terminate if not exercised prior to the completion of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the termination of warrants to purchase 9,054 shares of our common stock, outstanding as of June&nbsp;30, 2019, with
exercise prices that are higher than the assumed initial public offering price of this offering and which will terminate if not exercised prior to the completion of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the adjustment of outstanding warrants to purchase 19,230,769&nbsp;shares of our Series&nbsp;F redeemable convertible
preferred stock into warrants to purchase 104,722&nbsp;shares of our common stock, which will occur in connection with the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of the outstanding options and warrants described above, other than the Net Exercise Warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-183.635</FONT></FONT> reverse stock split of
our common stock which we effected on September&nbsp;6, 2019; and </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock. </P></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain of our existing stockholders, including entities affiliated with certain of our directors, have indicated an interest in purchasing an
aggregate of approximately $12.0&nbsp;million in shares of our </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not
binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any or all of these stockholders, or any or all of these stockholders may determine to purchase more, less or no shares
in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these stockholders as they will on any other shares sold to the public in this offering. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated. We have derived the
summary statements of operations data for the years ended December&nbsp;31, 2017 and 2018 from our audited financial statements included elsewhere in this prospectus. The statements of operations data for the six months ended June&nbsp;30, 2018 and
2019 and the balance sheet data as of June&nbsp;30, 2019 have been derived from our unaudited financial statements included elsewhere in this prospectus. You should read this data together with our audited financial statements and the related notes
included elsewhere in this prospectus and the sections of this prospectus entitled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results
for any prior period are not indicative of our future results. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,880</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss on extinguishment of share purchase rights and 2013 Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deemed dividend recorded in connection with financing transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(520.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(293.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Weighted-average number of shares used to compute net loss per share attributable to common stockholders,
basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Pro forma weighted-average number of shares used to compute&nbsp;pro forma net loss per share attributable to
common stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,282,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,836,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We adopted ASU 2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>, as of January 1, 2018. See Note 3 to our
audited financial statements included elsewhere in this prospectus for further discussion. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Note&nbsp;2 to our audited financial statements included elsewhere in this prospectus for an explanation of the method
used to calculate the historical net loss and the historical and pro forma net loss per share attributable to common stockholders, basic and diluted, and the number of shares used in the computation of these per share amounts. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Note&nbsp;16 to our audited financial statements included elsewhere in this prospectus for a summary of the amounts
and financial statement line items impacted by the revision. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;
Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited, in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Borrowings, including current portion, net of discounts and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Capital lease obligations, including current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma balance sheet data gives effect to: </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:5.5pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">the receipt of $11.0&nbsp;million in gross proceeds from the sale of 233,446,519 shares of our Series&nbsp;H redeemable
convertible preferred stock in July 2019; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:5.5pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">the conversion of 148,928,337 shares of our Series G redeemable convertible preferred stock into 246,521,076 shares of our
Series H redeemable convertible preferred stock in July 2019; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:5.5pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of
7,816,643 shares of our common stock (including the conversion of 479,967,595 shares of our Series&nbsp;H redeemable convertible preferred stock issued in July 2019 into 2,613,703 shares of our common stock) and the resultant reclassification of
(i)&nbsp;the carrying value of the redeemable convertible preferred stock to permanent equity and (ii)&nbsp;our redeemable convertible preferred stock warrant liabilities to additional paid-in capital, a component of stockholders&#146; equity
(deficit), in connection with such conversion, all of which will occur in connection with the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:5.5pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">the issuance of 20,620&nbsp;shares of our common stock as a result of the expected net exercise of the Net Exercise Warrants
in connection with the completion of this offering, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, which Net Exercise Warrants will terminate if not
exercised prior to the completion of this offering. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted balance sheet data gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote
(1)&nbsp;above and (ii)&nbsp;the issuance and sale of 3,333,334&nbsp;shares of our common stock in this offering at the assumed initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this
prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share would increase (decrease)
the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity (deficit) by approximately $3.1&nbsp;million, assuming that the number of shares offered by us, as set forth on
the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million in the number of
shares offered by us at the assumed initial public offering price would increase (decrease) each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity (deficit) by approximately $14.0&nbsp;million.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma and pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the
actual initial public offering price and other terms of our initial public offering determined at pricing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our audited financial statements and the related
notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together
with all of the other information in this prospectus, including our audited financial statements and related notes included elsewhere in this prospectus, before making an investment decision. If any of the following risks are realized, our business,
financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business and Strategy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have a history of
losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have incurred net losses since our inception. For the years ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2019, we have
incurred net losses of $25.6&nbsp;million, $8.0&nbsp;million (as revised) and $5.5&nbsp;million, respectively, and we expect to incur additional losses this year and in future years. As of June&nbsp;30, 2019, we had an accumulated deficit of
$158.1&nbsp;million. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our testing products, to promote SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, to develop future testing products and to continue to execute our integrated testing and therapeutics strategy. We may not be able to generate sufficient revenue to achieve and maintain
profitability. Our failure to achieve and maintain profitability in the future could cause the market price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We only
recently began transitioning toward an integrated testing and therapeutics strategy. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer history of utilizing an
integrated testing and therapeutics strategy in addition to the sale of our testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>In the near-term, we expect that our financial results will
depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A significant majority of our historical revenue has been derived from the sale of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
CTD testing product, which we commercially launched in 2012. In the near term, we expect to continue to derive a majority of our revenue from sales of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD. We are in various stages of
research and development with respect to other testing products that we may offer, but there can be no assurance that we will be able to commercialize these testing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The demand for our testing products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at any point
in time we may decide to no longer commercialize any of our testing products for any number of reasons. While we have experienced revenue growth from the sale of our testing products, we may not be able to sustain this growth or maintain existing
revenue levels. Further, we cannot ensure the continued availability of our testing products in commercial quantities at acceptable costs. If we are unable to increase sales of our testing products, expand reimbursement for our testing products, or
successfully develop and commercialize additional testing products, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future growth depends, in part, on our ability to execute on our strategy of integrating the promotion of
our existing and future proprietary testing products with the promotion of therapeutics, and we may be unsuccessful in our promotion efforts for SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which could adversely affect our
ability to implement this strategy. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are in the process of integrating our historical testing products business with the promotion of
therapeutics in an integrated testing and therapeutics strategy. Our integrated testing and therapeutics strategy leverages our sales and marketing efforts, targeting rheumatologists for the commercialization of our testing products to promote
therapeutics. As a result, our future growth is dependent, in part, on our ability to leverage our unique commercial model of offering testing products combined with therapeutics, including with respect to the Janssen agreement, which we entered
into in December 2018 to exclusively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States. Pursuant to the Janssen Agreement, we are entitled to receive a tiered promotion fee based on the total number of
incremental prescriptions written above an established baseline. Our ability to effectively <FONT STYLE="white-space:nowrap">co-promote</FONT> SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> will require us to be successful in a
range of activities, including hiring, training and deploying additional sales representatives and creating demand for SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> through our commercial and sales activities as well as those of
Janssen Biotech, Inc., or Janssen. If we encounter difficulties promoting SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, our ability to generate significant revenue under the Janssen Agreement will be harmed. Janssen also has the
right to terminate the Janssen agreement with or without cause after <FONT STYLE="white-space:nowrap">30-days&#146;</FONT> notice. If Janssen were to exercise this right, we may be unable to recoup substantial investments we have made and intend to
make in order to support the promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We have a limited history partnering with pharmaceutical companies for the promotion of therapeutics. Consequently, any predictions made
about our future success or viability with respect to our promotion activities may not be as accurate as they could be if we had a history of successfully <FONT STYLE="white-space:nowrap">co-promoting</FONT> therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we fail to successfully promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, our ability to implement our integrated testing
and therapeutics strategy and generate sufficient revenue to grow and sustain our business, and our business, financial condition and results of operations, will be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be unable to manage our ongoing and future growth effectively, which could make it difficult to execute our business strategy. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to the need to scale our testing capacity, our future growth plans will also impose significant added responsibilities on management,
including the need to identify, recruit, train and integrate additional employees and the need to manage additional relationships with various partners, suppliers and other third parties. In particular, we expanded our salesforce from
31&nbsp;representatives as of December&nbsp;31, 2018 to 55 representatives in August 2019 to help increase reach and frequency and support our integrated promotion of testing products and therapeutics. In addition, rapid and significant growth may
strain our administrative and operational infrastructure and require us to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. Our
ability to manage our business and growth, as well as function as a public company, will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to
optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our ongoing and future growth effectively, it may be difficult for us to
execute our business strategy and our business could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we lose or are unable to secure partners for our integrated testing and therapeutics
strategy, or if our partners do not apply adequate resources to their relationships with us or are unable to provide, on a timely basis, an adequate and reliable supply of the therapeutics that we promote, our potential for profitability may be
adversely affected. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to the Janssen agreement, we plan to opportunistically evaluate, and may continue to enter into, additional
agreements with pharmaceutical companies to integrate the promotion of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
testing products with their therapeutics. We have also entered into, and may continue to enter into, other agreements that leverage our testing products and data generated from such tests. For
example, we provide GSK our test result data to provide market insight into and help increase awareness of the benefits of an early and accurate diagnosis of SLE; and our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX test data
is used by Horizon Therapeutics to report on levels of MTXPG in patients undergoing methotrexate therapy in combination with its anti-gout product, KRYSTEXXA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, in an ongoing Phase&nbsp;4
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amount and timing of resources applied by our current or potential future partners are largely outside of our control. For
example, we have limited control over, and rely on Janssen for, numerous activities that are critical to our ability to successfully promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, such as pricing decisions, manufacture
and supply of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, reimbursement support, marketing materials, the prosecution and enforcement of patents and other intellectual property rights related to SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and public communications and presentations regarding SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We likewise have limited control of how our other partners use the
information provided by our testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If any of our current or future partners breaches or terminates our agreements, or fails to conduct
the activities contemplated by our agreements in a timely manner, our success promoting the applicable therapeutics, testing products or information provided thereby could be diminished or blocked completely. It is possible that partners will change
their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. For example, under the Janssen agreement, Janssen is not prohibited from developing or commercializing
products that are competitive with SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. If Janssen commercializes any competing products, it may provide lower levels of support to
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or may terminate our agreement entirely. The effectiveness of our partners, if any, in marketing the applicable therapeutics will also affect our revenue and earnings. In addition, if
our other partners encounter problems with our testing products or information provided by our testing products that they rely on as part of their efforts, our reputation and that of our testing products could be damaged, and it could impair our
ability to enter into future agreements to promote therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We rely on Janssen to provide, on a timely basis, an adequate and reliable supply
of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Any delay or interruption of supply or Janssen&#146;s failure to comply with regulatory or other requirements could limit its ability to make, or cause it to cease sales, of
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Any manufacturing defect or error discovered after SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has been produced and distributed could result in even more
significant consequences, including costly recall procedures. In addition, the importation of pharmaceutical products into the United States is subject to regulation by the FDA, and the FDA can refuse to allow an imported product into the United
States if it appears that the product fails to comply with applicable laws or regulations. Moreover, Janssen and its third-party manufacturers and suppliers may experience difficulties related to their overall business and financial stability. To
the extent Janssen faces manufacturing difficulties or is unable to provide an adequate and reliable supply of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> on a timely basis, our reputation could be harmed and our business could
suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not have the capability and do not intend to discover or develop therapeutics on our own. Therefore, the success of our integrated
testing and therapeutics strategy depends in part on our ability to acquire additional rights to promote therapeutics from new or existing partners. Other companies, many of which have substantially greater financial, marketing and sales resources
than we do, also compete with us for the acquisition of rights to therapeutics. In addition, under the Janssen agreement, we are prohibited from selling or promoting certain types of products that are used to treat the same indications that SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is used to treat. We may not be able to successfully negotiate any additional agreements to promote therapeutics and, if established, these relationships may not be successful. For example,
potential partners, particularly those that are actively marketing their own therapeutics, may be unwilling to license commercialization rights to us or otherwise enter into terms that allow us to meaningfully participate in sales growth for their
products, which could limit the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
potential availability and value to us of additional agreements to promote therapeutics. The inability to enter into agreements for additional therapeutics could limit the overall growth of our
business and adversely affect our business, financial condition and results of operations. Disputes could also arise between us and our existing or future partners, as to a variety of matters, including financial and intellectual property matters or
other obligations under our agreements. These disputes would be both expensive and time-consuming and may result in delays in the success of therapeutics or could damage our relationship with a partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may experience limits on our revenue if rheumatologists decide not to order our testing products or our promoted therapeutics or if we are otherwise unable to
create or maintain demand for our testing products and promoted therapeutics. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we are unable to create or maintain demand for either our
testing products or promoted therapeutics in sufficient volume, we may not generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate rheumatologists about the benefits of our testing products
through publications in peer-reviewed medical journals, presentations at medical conferences and other similar means. We will also need to generate demand for both our testing products and promoted therapeutics through
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-on-one</FONT></FONT> education by our salesforce. We also plan to focus on educating patients about the benefits of these testing products and therapeutics, which we believe will
be necessary to generate further demand. In addition, our inability to obtain and maintain coverage and adequate reimbursement from third-party payers may limit adoption by rheumatologists. With respect to SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in particular, if we are unable to generate sales above certain thresholds agreed to with Janssen, we will not receive any payments under the Janssen agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Rheumatologists may rely on guidelines issued by industry groups regarding the diagnosis, prognosis, treatment and monitoring of autoimmune and
autoimmune-related diseases, and the monitoring of the effectiveness of therapeutic drugs used to treat such diseases before utilizing any diagnostic test or monitoring solution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products and promoted therapeutics among
rheumatologists, patients, third-party payers and others in the medical community. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our success depends on our ability to continue to develop
and market testing products and promote therapeutics that are recognized and accepted as safe, effective, reliable and cost effective, and any testing product or promoted therapeutic that we offer may not gain or maintain market acceptance among
rheumatologists, third-party payers, patients and the medical community. Market acceptance of our testing products and promoted therapeutics depends on a number of factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the perceived accuracy of our test results by rheumatologists and patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential and perceived advantages of our testing products and promoted therapeutics over alternative products and
therapeutics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the demonstration in clinical studies of the performance and clinical validity of our testing products, the results of
which studies may not replicate the positive results from earlier studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the demonstration of clinical efficacy and safety of our promoted therapeutics compared to other more-established products;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the introduction of new tests or therapeutics products that compete with our testing products or our promoted therapeutics
or the introduction of generic versions of our promoted therapeutics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product cost in relation to alternative products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any adverse effects from our promoted therapeutics; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of the target patient population to try new therapies and of rheumatologists to prescribe these therapies;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any restrictions on the use of our promoted therapeutics, if approved, together with other medications
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">publicity concerning our testing products and promoted therapeutics or competing products and treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of coverage and adequate reimbursement by third-party payers, including government authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">relative convenience and ease of administration; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effectiveness of our sales and marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, if we or our partners had to withdraw a product from the market, it could harm our business and could impact market acceptance of our other
testing products or promoted therapeutics. If our testing products and promoted therapeutics do not achieve an adequate level of acceptance by rheumatologists, hospitals, third-party payers or patients, we may not generate sufficient revenue from
that testing product or therapeutic and may not become or remain profitable. Our efforts to educate the medical community and third-party payers regarding the benefits of our testing products and promoted therapeutics may require significant
resources and may never be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The sizes of the markets for our testing products and promoted therapeutics have not been established with precision,
and may be smaller than we estimate. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our estimates of the annual total addressable markets for our current and potential future testing
products and promoted therapeutics are based on a number of internal and third-party estimates. These include, without limitation, the number of patients with autoimmune and autoimmune-related diseases and the assumed prices at which we can sell
testing products and our partners can sell therapeutics in markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the
conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current and potential future
testing products and promoted therapeutics may prove to be incorrect. If the actual number of patients who would benefit from our testing products and promoted therapeutics, the price at which we and our partners can sell future testing products, or
the annual total addressable market for our testing products and promoted therapeutics is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may expend our limited resources to pursue a particular testing product or promoted therapeutic and fail to capitalize on other testing products or promoted
therapeutics that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because we have limited financial and
managerial resources, we focus on specific testing products and promoted therapeutics. As a result, we may forego or delay pursuit of opportunities with others that could have had greater commercial potential. Our resource allocation decisions may
cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our spending on current and future research and development programs for testing products may not yield any commercially viable testing
products. If we do not accurately evaluate the commercial potential or target market for a potential testing product or promoted therapeutic, we may forego other similar arrangements which would have been more advantageous for us to pursue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict
and could cause our operating results to fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our quarterly and annual operating results
may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully market and sell our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing
products and continue to promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which our current testing and future testing products, if any, are eligible for coverage and reimbursement
from third-party payers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization
activities relating to our testing products, which may change from time to time, and our ability to successfully commercialize new testing products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of supplies, equipment and materials used for our testing products and laboratory operations, which may vary
depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional testing products and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of demand for our testing products and promoted therapeutics, which may vary significantly;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt, timing and mix of revenue for our testing products and promoted therapeutics; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and extent to which payers make an overpayment determination and require us to return all or some portion of
payments which we received in a prior period; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and success or failure of competing products, or any other change in the competitive landscape of our industry,
including consolidation among our competitors or partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The cumulative effects of these factors could result in large
fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;period-to-period&nbsp;basis</FONT></FONT> may
not be meaningful. Investors should not rely on our past results as an indication of our future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This variability and unpredictability
could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide
to the market, it could have a material adverse effect on our business, financial condition and results or operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on sole suppliers for some of
the reagents, equipment and other materials used in our testing products, and we may not be able to find replacements or transition to alternative suppliers. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our testing
products. We also purchase components used in our testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of these
materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give other
customers&#146; needs higher priority than ours. If our suppliers can no longer provide us with the materials we need to perform the tests that comprise our testing products, if the materials do not meet our quality specifications, or if we cannot
obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
acceptable substitute materials, an interruption in test processing could occur and, in certain circumstances, we may be required to amend or cancel test results we have issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, if we should encounter delays or difficulties in securing the quality and quantity of equipment we require for our testing products, we may
need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our future revenue and harm our customer relations and reputation. In addition, in order to mitigate these risks,
we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable
to support demand for our current testing products or any of our future testing products or solutions, our business could suffer. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If demand
for our testing products or any of our future testing products or solutions grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal
quality assurance program. We may also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our testing products. We cannot assure you that any increases in scale, related
improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. We will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate,
and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the necessary personnel, obtain any necessary additional equipment and increase software and
computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale
our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will not negatively affect the quality of test results. In addition, there can be no assurance
that we will have adequate space in our laboratory facility to accommodate such required expansion. We are also currently collaborating with third parties in an effort to implement multiplex technology in our laboratory. We may experience
difficulties securing a partner for this technology and integrating such technology into our existing laboratory operations, which could affect our ability to meet demand for our testing products.<B> </B>If we encounter difficulty meeting market
demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If third-party payers do not provide
coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products or promoted therapeutics, or if we or our partners are unable to
successfully negotiate payer contracts, our commercial success could be compromised. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Successful commercialization of our testing products
depends, in large part, on the availability of coverage and adequate reimbursement from third-party payers, including government payers, such as Medicare and Medicaid and private insurers. For the testing products that we develop and commercialize
as well as the therapeutics we promote, each third-party payer decides whether to cover the product, the amount it will reimburse for a covered product and the specific conditions for reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Reimbursement by third-party payers may depend on a number of factors, including the payer&#146;s determination that tests using our technologies are:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not experimental or investigational; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">medically necessary; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">demonstrated lead to improved patient outcomes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-saving or cost-effective; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">supported by peer-reviewed medical journals; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">included in clinical guidelines. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we are unable to provide third-party payers with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage,
or may provide limited coverage, which will adversely affect our revenue and our ability to succeed. In addition, clinicians may be less likely to order a test unless third-party payers pay a substantial portion of the test price. Therefore,
coverage determinations and reimbursement levels and conditions are critical to commercial success, and if we are not able to secure positive coverage determinations and reimbursement levels, our business will be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Third-party payers and other entities also conduct technology assessments of new medical tests and devices and provide and/or sell the results of their
assessments to other parties. These assessments may be used by third-party payers and health care providers as grounds to deny coverage for or refuse to use a test or procedure. In addition, third-party payers, have increased their efforts to
control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective April&nbsp;25, 2012, Palmetto GBA, the Medicare molecular diagnostic services program&#146;s, or MolDx Program&#146;s, contractor, assigned
the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX assay a unique identifier and determined that the test meets the applicable Medicare coverage criteria to support dose optimization and therapeutic decision making for patients
diagnosed with RA on methotrexate. Our current Medicare contractor, Noridian, has adopted this coverage policy. Other third-party payers make their own decisions as to whether to establish a policy to reimburse our testing products, however, and
because approvals must be sought on a payer by payer basis, establishing broad coverage is a time-consuming and costly process. There are many third-party payers who have not yet established a coverage policy applicable to our testing products. In
addition, several Blue Cross Blue Shield plans and Aetna issued <FONT STYLE="white-space:nowrap">non-coverage</FONT> policies with respect to AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus, determining that AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus does not meet the medical criteria for coverage and is considered investigational and/or experimental. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While our testing products are reimbursed by a number of third-party payers, we do not currently have contracts with significant private payers. We have
in the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payers due to changes in their internal processes, documentation requirements and other issues, which could cause
our revenue to fluctuate from period to period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we are not successful in reversing existing <FONT STYLE="white-space:nowrap">non-coverage</FONT>
policies, or if other third-party payers issue negative coverage policies, these policies could have a material adverse effect on our business and operations. Even if many third-party payers currently reimburse for our testing products, such payers
may withdraw coverage at any time, review and adjust the rate of reimbursement, require <FONT STYLE="white-space:nowrap">co-payments</FONT> from patients or stop paying for our testing products altogether, any of which would reduce our revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Billing for our testing products is complex, and we must dedicate substantial time and resources to the billing process to be paid for our testing products.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Billing for our testing products is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill
various third-party payers, including Medicare and private insurance companies, as well as patients, all of which have different billing requirements. We generally bill third-party payers for our testing products and pursue reimbursement on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis where pricing contracts are not in place. We may also face increased risk in our collection efforts, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
including long collection cycles and potential delays in claims processing, which could adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Several factors contribute to the complexity of the billing process, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">differences between the list price for our testing products and the reimbursement rates of third-party payers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with complex federal and state regulations related to billing Medicare; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes among third-party payers as to which party is responsible for payment; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">differences in coverage among third-party payers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of patient deductibles, <FONT STYLE="white-space:nowrap">co-payments</FONT> or
<FONT STYLE="white-space:nowrap">co-insurance;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">differences in information and billing requirements among third-party payers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes to billing codes used for our testing products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risk of government audits related to billing; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incorrect or missing billing information; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the resources required to manage the billing and claims appeals process. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We use standard industry billing codes, known as CPT codes, to bill for our testing products. If these codes were to change, there is a risk of an error
being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payer. Claim adjudication errors may result in a delay in payment processing or a reduction
in the amount of the payment received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As we introduce new testing products, we will need to add new codes to our billing process as well as our
financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to
evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payers deny our claims, in order to obtain reimbursement for services that we provide, we may challenge coverage and payment
denials. Payers also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payer makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior
payments we have received. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, or ACA, established a requirement for
providers and suppliers to report and return any overpayments received from government payers under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or
supplier to liability under federal false claims laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, from time to time, third-party payers change processes that may affect timely
payment. These changes may result in uneven cash flow or impact the timing of revenue recognized with these payers. With respect to payments received from governmental programs, factors such as a prolonged government shutdown could cause significant
regulatory delays or could result in attempts to reduce payments made to us by federal government healthcare programs. In addition, third-party payers may refuse to ultimately make payment if their processes and requirements have not been met on a
timely basis. These billing complexities, and the related uncertainty in obtaining payment for our testing products could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our
results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2018, Noridian posted the final Medicare Physician Fee Schedule, or MPFS, and Clinical Laboratory
Fee Schedule, or CLFS, which establishes the reimbursement rates to be paid by Medicare for our coverage area for tests performed after January&nbsp;1, 2019. We have estimated that the implementation of these reimbursement rates will result in an
approximate 10.1% reduction in anticipated reimbursements from Medicare from our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD testing product from levels experienced in 2018. Revenue from Medicare comprised 30% and 27% of our
revenue in the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, respectively. Revenue from the sale of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD testing products comprised 82% and 83% of
our revenue in the year ended December 31, 2018 and the six months ended June&nbsp;30, 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also rely on a third-party provider
to provide revenue cycle management software systems for certain processing and collection functions. In the past, we have experienced delays in claims processing as a result of our third-party provider making changes to its invoicing system, as
well as not submitting claims to payers within the timeframe required. If claims for our testing products are not submitted to payers on a timely basis, or if we are required to switch to a different systems provider, it could have an adverse effect
on our revenue and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will
discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At times, we share our proprietary technology and confidential
information, including trade secrets, with third parties that conduct studies and other services on our behalf. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other
similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information.
Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or
inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets and
despite our efforts to protect our trade secrets, a competitor&#146;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Significant safety or efficacy issues could arise for our promoted
therapeutics, which could have an adverse effect on our revenue and financial condition. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pharmaceutical products receive regulatory approval
based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive,
studies. If new safety or efficacy issues are reported or if new scientific information becomes available (including results of post-marketing Phase 4 trials), or if governments change standards regarding safety, efficacy or labeling, our partners
may be required to amend the conditions of use for a therapeutic. For example, a partner may voluntarily provide or be required to provide updated information on a therapeutic&#146;s label or narrow its approved indication, either of which could
reduce the therapeutic&#146;s market acceptance. If safety or efficacy issues with a partner&#146;s therapeutic arise, sales of the therapeutic could be halted by the partner or by regulatory authorities. Safety or efficacy issues affecting
suppliers&#146; or competitors&#146; products also may reduce the market acceptance of one of our partner&#146;s therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">New data about a
partner&#146;s therapeutics, or products similar to a partner&#146;s therapeutics, could negatively impact demand for such therapeutics due to real or perceived safety issues or uncertainty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regarding efficacy and, in some cases, could result in product withdrawal. Furthermore, new data and information, including information about therapeutic misuse, may lead government agencies,
professional societies, practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of such therapeutics or the use of related therapies or place restrictions on sales. Such
guidelines or recommendations may lead to lower sales of the applicable therapeutics and reduce our revenue or otherwise adversely affect our business, prospects, results of operations or financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to maintain or expand our sales and marketing force to adequately address our customers&#146; and current or future partners&#146; needs, our
business may be adversely affected. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We sell our testing products through our own specialized salesforce and have recently increased our
salesforce in order to achieve the optimal reach and frequency and support our strategy of integrating the promotion of testing products and therapeutics. Our testing products compete in a concentrated specialty market, that of autoimmune and
autoimmune-related diseases, and utilizing a specialized salesforce is integral to our integrated testing and therapeutics strategy. As such, we believe it is necessary to maintain a salesforce that includes sales representatives with specific
technical backgrounds and industry expertise. For example, to support the co-promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, we expanded our salesforce from 31 representatives as of December&nbsp;31, 2018 to 55
representatives in August 2019. Additional agreements for the promotion of therapeutics may require us to further expand our specialized salesforce. Training of additional sales representatives can be costly and time consuming, particularly given
the level of experience and sophistication we seek in our salesforce. In addition, until recently, not all of our sales representatives have promoted therapeutics, including SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, as part
of our organization, and they will need to complete additional training in order to effectively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and any other therapeutics that we promote through additional agreements. If we
are unable to effectively retain, train and integrate additional sales representatives, it may adversely affect our ability to effectively market and sell our testing products. In addition, competition for highly specialized sales personnel is
intense, and we may not be able to attract and retain personnel or be able to maintain an efficient and effective sales and marketing force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
future sales will depend in large part on our ability to maintain an effective salesforce. If we are unsuccessful in this regard, it could negatively impact our revenue growth and potential profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our principal competition for our testing products is traditional methods used by healthcare providers to test patients with <FONT
STYLE="white-space:nowrap">CTD-like</FONT> symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as anti-nuclear antibodies, or ANA, and anti-double-stranded DNA, or anti-dsDNA,
and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and the Mayo Clinic, all of which
have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide
<FONT STYLE="white-space:nowrap">in-house</FONT> clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and
autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc., Progentec
Diagnostics Inc., Kypha, LLC, Genalyte Inc., Protagen AG, DxTerity Diagnostics Inc., HealthTell, Inc. and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Direct competition for the promotion of
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> includes all other companies with <FONT STYLE="white-space:nowrap">anti-TNF</FONT> biologics and the marketing companies supporting their distribution and promotion. These products
include HUMIRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and RINVOQ<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> from Abbvie Inc., ENBREL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Amgen Inc., CIMZIA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from UCB, INFLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Pfizer, (biosimilar REMICADE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and RENFLEXIS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Merck&nbsp;&amp; Co. (biosimilar REMICADE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Additional competitors include companies with other biologic drugs indicated for RA that
have significant sales or sales potential. Specifically, these include ORENCIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Bristol-Myers Squibb Company, ACTEMRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Roche,
RITUXAN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Roche, XELJANZ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Pfizer, KEVZARA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Sanofi S.A. and
OLUMIANT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Eli Lilly and Company. There are also several late-stage RA drug and biosimilar development programs and several additional RA products that have minimal sales to date or that
are indicated for other rheumatic indications competitive to SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> such as psoriatic arthritis and ankylosing spondylitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence
in diagnostic results; safety and efficacy with respect to promoted therapeutics; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development
resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payers as functionally equivalent to our solution or offer solutions at prices designed
to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and
future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To compete successfully we must be able to demonstrate, among other things, that our testing products are accurate and cost effective and that we are
effective in promoting therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a
timely basis, or at all, other testing products we are developing. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will continue to devote considerable resources to the research and
development of our planned future testing products and enhancements to our current testing products. We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain
products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these
products. In order to develop and commercialize testing products, we need to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expend significant funds to conduct substantial research and development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">conduct successful validation studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">develop and scale our laboratory processes to accommodate different tests; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">achieve and maintain required regulatory certifications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">build the commercial infrastructure to market and sell new testing products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for
many reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to identify additional biomarkers to incorporate into our testing products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure or <FONT STYLE="white-space:nowrap">sub-optimal</FONT> performance of the testing product at the research or
development stage; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure of clinical validation studies to support the effectiveness of the test. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later
studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new
testing product and our ability to invest in other products in our pipeline. In addition, as we develop testing products, we will have to make significant investments in product development, marketing and selling resources. If a clinical validation
study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business.
Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Developing new
testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies,
design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive
growth opportunities, our business and results of operations may be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we cannot enter into new clinical study
collaborations, our product development and subsequent commercialization could be delayed. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the past, we have entered into clinical study
collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations.
Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations
with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The
publication of clinical data in peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for testing products such as our testing products, and our inability to control when and if results are published may
delay or limit our ability to derive sufficient revenue from any solution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may acquire businesses or assets, form joint ventures or make investments in
other companies or technologies that could harm our operating results, dilute our stockholders&#146; ownership, increase our debt or cause us to incur significant expense. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of our business strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements and
other strategic transactions or collaborations with third parties. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, make investments in other companies or
acquire ownership rights to therapeutics that are synergistic with our testing products. To date, other than our acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, we have not acquired other companies or
therapeutics and, except with respect to certain collaboration agreements executed in connection with our integrated testing and therapeutics strategy, we have limited experience with respect to the formation of strategic alliances and joint
ventures. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
business, and we could assume unknown or contingent liabilities. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent liabilities,
any of which could harm our operating results. Integration of an acquired company, business or assets also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or
complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To finance any acquisitions or investments, we may choose to issue shares of our stock as consideration, which would dilute the ownership of our
stockholders. Once we become a public company, if the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities
through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take
certain actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize or such strategic
alliance, joint venture or acquisition may be prohibited. In addition, our loan agreement restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally,
future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial
condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The diagnostics and therapeutics industries are subject to rapidly changing technology, which could make our testing products, promoted therapeutics and other
testing products we develop obsolete. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our industry is characterized by rapid technological changes, frequent new product introductions and
enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving standards of care. Our testing products could become obsolete unless we
continually innovate and expand our testing product offerings to include new clinical applications. If we are unable to develop new testing products or to demonstrate the applicability of our testing products for other diseases, our sales could
decline and our competitive position could be harmed. In addition, if our promoted therapeutics become obsolete and we are unable to expand such agreements or find new partners, our sales could decline and our competitive position could be harmed.
For example, with respect to SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and the treatment of RA, active psoriatic arthritis, or active ankylosing spondylitis, there are many novel therapeutic approaches in development and we
expect that the competition in this market will increase dramatically. If new therapeutics make SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> obsolete or diminish the degree to which rheumatologists prescribe it, our ability to
generate revenue under the Janssen agreement will be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our failure to maintain relationships or build new relationships with key opinion leaders could
materially adversely impact our business and prospects. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Key opinion leaders are able to influence clinical practice by publishing research
and determining whether new tests should be integrated into clinical guidelines. We rely on key opinion leaders early in the development process to help ensure our clinical studies are designed and executed in a way that clearly demonstrates the
benefits of our testing products to physicians and payers. Our failure to maintain or build new relationships with such key opinion leaders could affect rheumatologist and patient perception of our testing products and result in a loss of existing
and future customers and therefore materially adversely impact our business and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are sued for errors and omissions or professional liability, we could face substantial liabilities that
exceed our resources. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The marketing, sale and use of our testing products could lead to liability claims if someone were to allege that any
such testing product failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to rheumatologists or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We may
also be subject to similar types of claims related to testing products we may develop in the future. An errors and omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend.
Although we maintain professional liability insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any
such claims. Any errors or omissions or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability
lawsuit could cause injury to our reputation or cause us to suspend sales of our testing products. Similarly, any product liability lawsuit affecting our partners could also cause injury to our reputation or cause the applicable partner to suspend
sales of its therapeutics. We may also initiate a correction or removal for one of our testing products, issue a safety alert or undertake a field action or recall to reduce a risk to health posed by potential failure of our products to perform as
designed, which could lead increase costs and lead to increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our testing products and to negative publicity, including safety alerts, press releases or
administrative or judicial actions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The loss of
members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could adversely affect our business. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our success depends largely on the skills, experience and performance of key members of our executive management team, including Fortunato Ron Rocca, our
President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we continue to develop our technologies and test processes and focus on our growth. If we were to lose one
or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled
scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science
businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers of qualified personnel. We also face
competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain qualified and highly-specialized
salespeople. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our testing products and the sale of promoted therapeutics. If we are not able to attract
and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are <FONT
STYLE="white-space:nowrap">at-will,</FONT> which means that either we or the employee may terminate their employment at any time. We do not carry key man insurance for any of our employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If our sole laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility
or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on or near
earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters, including earthquake, fire, flood, power loss, communications failure or terrorism.
In particular, we store all of our flow cytometers, the instrument we use to detect <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a
natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster, we would be unable to perform these key tests as we do in the ordinary course of our business. The inability to perform the tests contained in our testing products or to reduce
the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the
future. Additionally, we store our <FONT STYLE="white-space:nowrap">bio-repository</FONT> of specimens, which were collected in collaboration with leading academic institutions and help us to further validate our testing products, at our Vista
facility. If these specimens were destroyed pursuant to a natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster or otherwise become unavailable, our ability to develop new testing products may be delayed. Furthermore, our facility and
the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility or license or transfer our
proprietary technology to a third-party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able to find a third party with such qualifications to enable us
to conduct the tests contained in our testing products, we may be unable to negotiate commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to rely on a third
party to perform the tests contained in our testing products, we would need to engage another facility with established state licensure and Clinical Laboratory Improvement Amendments of 1988, or CLIA, accreditation under the scope of which tests
could be performed following validation and other required procedures. We cannot assure you that we would be able to find another CLIA-certified facility willing to comply with the required procedures, that any such facility would be willing to
perform the tests contained in our testing products for us on commercially reasonable terms, or that it would be able to meet our quality standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to establish an additional clinical reference laboratory facility, we would have to spend considerable time and money securing adequate space,
constructing the facility, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able, or it may take considerable time, to replicate
our testing processes or results in a new facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing by several states, including California and New York, which
could take a significant amount of time and result in delays in our ability to begin operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe we have the capacity to meet our
projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. Beyond this time frame, we may need to further expand our laboratory space. Any future expansion could disrupt laboratory operations,
resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated from the use of the expanded facilities. Adverse consequences resulting from a
delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with
damage or disruption to our business, provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires,
extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third- party manufacturers to produce our testing products. Our ability to obtain
clinical supplies of our testing products could be disrupted if the operations of these suppliers were affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. In addition, our corporate
headquarters is located in Vista, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown.
The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our
testing process involves the use of sophisticated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> equipment that requires precise calibration, and issues
affecting such equipment may delay delivery or impact the quality of the test results to rheumatologists or otherwise adversely affect our operations. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of our process of determining <FONT STYLE="white-space:nowrap">CB-CAPs,</FONT> which is part of our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus product, we utilize a number of flow cytometers that require calibration and performance validation according to the requirements of the College of American Pathologists, or CAP, at
specified time intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such requirements, we cannot provide any assurance that our instruments will not fall out of specification, in which case we
would be required to <FONT STYLE="white-space:nowrap">re-calibrate</FONT> them. Failure to timely re-calibrate our instruments could negatively impact the test results, which could result in liability and harm our reputation. Patient specimens
degrade and become unusable generally within 48 hours of collection. Therefore, if we do not have other sufficient properly functioning flow cytometers due to failure to meet specifications or they otherwise become inoperable, our ability to process
patient specimens in the required timeframe would be compromised and our business could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we use hazardous materials in a manner that causes
contamination or injury, we could be liable for resulting damages. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to federal, state and local laws, rules and regulations
governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of
these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we
may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial
condition. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Information technology and telephone systems are used extensively in virtually all aspects of our business, including laboratory
testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our information systems
because: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patient specimens must be received, tracked and processed on a timely basis; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">test results must be reported on a timely basis; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">billings and collections for all customers must be managed efficiently and accurately; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third party ancillary billing services require proper tracking and reporting; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pricing and other information related to our services is needed by our salesforce and other personnel in a timely manner to
conduct business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patient-identifiable health information must be securely held and kept confidential; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory compliance requires proper tracking and reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our business, results of operations and financial condition may be adversely affected if, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our information technology, telephone or other systems fail or are interrupted for any extended length of time;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">services relating to our information technology, telephone or other systems are not kept current; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our information technology, telephone or other systems do not have the capacity to support expanded operations and
increased levels of business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">data is lost or unable to be restored or processed; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">data is corrupted due to a breach of security. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Despite the precautionary measures we have taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated
system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause us to inadvertently disclose or lose patient information could adversely affect our business, results of
operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Security breaches, loss of data and other disruptions to us, our third-party service providers or our partners could
compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the ordinary course of our business, we and our partners, and our respective third-party service providers collect and store sensitive data, such as
legally protected health information, including de-identified test reports, personally identifiable information about our patients, credit card information, intellectual property, and our proprietary business and financial information. We manage and
maintain our applications and data utilizing a combination of <FONT STYLE="white-space:nowrap">on-site</FONT> and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#146; protection of, this
critical information, including loss of access, unauthorized disclosure and unauthorized access, as well as risks associated with our ability to identify and audit such events. In addition, we have limited control over the storage of sensitive data
by our third-party therapeutics partners as well as risks related to the transfer and sale of de-identified data files to such partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The secure
processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive
information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party billing and collections provider, may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee
error, malfeasance or other activities. While we have not experienced any such attack or breach, if such an event were to occur, our networks would be compromised and the information we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or
proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Exonomic and Clinical Health
Act, or the HITECH Act, and their implementing regulations and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payers or patients,
process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and rheumatologist
education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States are often
uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our
practices, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial
condition, and harm our reputation and ability to provide testing services on a timely basis. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Expedited, reliable shipping is essential to
our operations. While we have recently begun working with United Parcel Service, we still rely extensively on a single carrier, Federal Express Corporation for reliable and secure
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-to-point</FONT></FONT> transport of patient specimens to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, or any other carrier we may use
in the future, encounter delivery performance issues such as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased
utilization from rheumatologists for our testing services and increased cost and expense to our business. In addition, any significant increase in shipping time could adversely affect our ability to receive and process patient specimens on a timely
basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we or Federal Express were to terminate our relationship, we would be required to find another party to provide expedited, reliable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-to-point</FONT></FONT> transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be
able to enter into arrangements with such other providers on acceptable terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our testing services. Even if we
were to enter into an arrangement with any such provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express. If any new provider does not provide, or if
Federal Express does not continue to provide, the required quality and reliability of transport services at the same or similar costs, it could adversely affect our business, reputation, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under Sections&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change&#148;
(generally defined as a greater than 50 percentage-point change (by value) in its equity ownership by <FONT STYLE="white-space:nowrap">&#147;5-percent</FONT> shareholders,&#148; as defined in the Code, over a three-year period), the
corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss, or NOL, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change federal taxable income and taxes, as applicable, may be limited. Under recently
enacted U.S. tax legislation, federal NOL carryforwards generated in periods after December&nbsp;31, 2017, may be carried forward indefinitely but may only be used to offset 80% of our taxable income annually. Our ability to use a portion of our NOL
carryforwards is subject to limitation under Section&nbsp;382 of the Code as a result of a prior ownership change. If we undergo an ownership change in connection with this offering, or as a result of subsequent shifts in our stock ownership, our
ability to utilize our NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes could be further limited by Sections&nbsp;382 and 383 of the Code. Similar provisions of state tax law may also apply. As a result,
if we earn net taxable income, our ability to use such <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset taxable income and taxes, as
applicable, may be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Recently enacted U.S. tax legislation, known as the Tax Cuts and Jobs Act of 2017, has significantly changed the U.S. federal income
taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes are effective immediately, without any transition periods or grandfathering for existing
transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and U.S. Internal Revenue Service, any of
which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for
computing state and local tax liabilities. Based on our current evaluation of this legislation, the reduction of the U.S. corporate income tax rate required a provisional write-down of our deferred income tax assets (including the value of our NOL
carryforwards and our tax credit carryforwards). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There may be other material adverse effects resulting from the legislation that we have not yet
identified. While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors to
determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other
obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2017, we entered into a loan and security agreement, or the loan agreement, with Innovatus Life Sciences Lending Fund I, LP, or Innovatus.
The loan agreement is collateralized by substantially all of our personal property, including our intellectual property. The loan agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to
transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to
maintain a minimum liquidity of at least $2.0&nbsp;million and achieve certain minimum amounts of annual revenue, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we
have certain limitations on the manner in which we can conduct our business, and we may be restricted from engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full
or we obtain the consent of Innovatus, which we may not be able to obtain. On December&nbsp;7, 2018, we borrowed an additional $5.0&nbsp;million under the loan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
agreement, as a result of meeting the requisite trailing twelve-month revenue and gross margin milestones. As of June&nbsp;30, 2019, there was $25.0 million in principal outstanding under the
term loan and an additional $1.0&nbsp;million outstanding representing interest at 2.5%&nbsp;per annum payable <FONT STYLE="white-space:nowrap">in-kind</FONT> by adding the amount to the outstanding principal balance of the term loans. Under the
loan agreement, we are required to repay any outstanding principal and capitalized interest in monthly installments over a <FONT STYLE="white-space:nowrap">two-year</FONT> period commencing on October&nbsp;1, 2020. We cannot be certain that we will
be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and accrued interest on our debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working
capital needs, capital expenditures and other general corporate purposes. An event of default includes, but is not limited to, our failure to pay any amount due and payable under the loan agreement, the occurrence of a material adverse change in our
business as defined in the loan agreement, our breach of any representation or warranty in the loan agreement, our breach of any covenant in the loan agreement (subject to a cure period in some cases), a change in control as defined in the loan
agreement, our default on any debt payments to a third party in an amount exceeding $500,000 or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the loan agreement,
Innovatus could foreclose on substantially all of our personal property, including our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to
Innovatus or any other debt we may incur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may require substantial additional capital to finance our planned operations, which may not be
available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or
other operations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect capital expenditures and operating expenses to increase over the next several years as we expand our
infrastructure, commercial operations and research and development activities. We believe, based on our current plan, that the net proceeds from this offering, together with our current cash and cash equivalents and anticipated future revenue, will
be sufficient to meet our anticipated cash requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating
plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as
strategic collaborations. If our available cash balances, net proceeds from this offering and anticipated future revenue are insufficient to satisfy our liquidity requirements, including because of lower demand for our testing products or promoted
therapeutics or lower-than-expected rates of reimbursement from commercial third-party payers and government payers, or other risks described in this &#147;Risk Factors&#148; section, we may seek to raise additional capital through equity offerings,
debt financings, collaborations or licensing arrangements. In the case of the incurrence of further indebtedness, the loan agreement, subject to certain customary exceptions, restricts our ability to incur additional indebtedness or encumber any of
our property without the prior consent of Innovatus. Under the loan agreement, we are required to make monthly interest payments at a rate equal to 11% (provided that 2.50% of the 11% is payable <FONT STYLE="white-space:nowrap">in-kind</FONT> by
adding the amount to the outstanding principal balance of the term loans). We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other
reasons. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The timing and amounts of our future capital
requirements are difficult to forecast and will depend on numerous factors, including: our ability to maintain and grow sales of our testing products, as well as the costs associated with conducting </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
clinical studies to demonstrate the utility of our testing products and support reimbursement efforts; our ability to successfully promote therapeutics; fluctuations in working capital; the costs
to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; the additional costs we may incur as a result of operating as a
public company and the extent to which we <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses or products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our
stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The incurrence of additional
indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity,
limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, our current loan agreement restricts our ability to incur
additional indebtedness or encumber any of our property without the prior consent of Innovatus, subject to certain exceptions. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept
unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve
certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research
and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our testing products, promoted therapeutics or market development programs, which could lower the economic value of
those programs to our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The FDA may modify its enforcement discretion policy with respect to LDTs in a risk-based manner, and we may become subject to
extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our
business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the FDA ends its policy of enforcement discretion with respect to LDTs, and our testing products become subject to the
FDA&#146;s requirements for premarket review of medical devices, we may be required to cease commercial sales of our testing products and conduct additional clinical testing prior to making submissions to the FDA to obtain premarket clearance or
approval. If we are required to conduct such clinical trials, delays in the commencement or completion of clinical testing could significantly increase our test development costs and delay commercialization of any currently-marketed tests that we
may be required to cease selling or the commercialization of any future tests that we may develop. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial
of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the
proximity of patients to clinical sites and the eligibility criteria for the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may find it necessary to engage contract research
organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research
organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory
and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and our third party contractors are required to comply with good clinical practices, or GCPs, which
are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities
enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed
unreliable and the FDA, Competent Authorities of the Member States of the EEA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to
comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet
expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or
terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the
failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our testing products. In addition, we may not be able to establish or maintain
relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our testing products, or to achieve sustained profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA requires medical device manufacturers to comply with, among other things, current good manufacturing practices for medical devices, known as the
Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; the medical device reporting regulation, which requires that
manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; labeling regulations,
including the FDA&#146;s general prohibition against promoting products for unapproved or <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses; and the reports of corrections and removals regulation, which requires manufacturers to
report to the FDA if a device correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device which may present a risk to health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we were able to obtain FDA clearance or approval for one or more of our testing products, if required, a testing product may be subject to
limitations on the indications for which it may be marketed or to other regulatory conditions. In addition, such clearance or approval may contain requirements for costly post-market testing and surveillance to monitor the safety or efficacy of the
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA has broad post-market enforcement powers, and if unanticipated problems with our testing products arise, or if we or our suppliers
fail to comply with regulatory requirements following FDA clearance or approval, we may become subject to enforcement actions such as: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of our testing
products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">operating restrictions, partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">customer notifications or repair, replacement or refunds; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusing our requests for 510(k) clearance or PMA approvals or foreign regulatory approvals of new testing products, new
intended uses or modifications to existing testing products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawals of current 510(k) clearances or PMAs or foreign regulatory approvals, resulting in prohibitions on sales of our
testing products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA refusal to issue certificates to foreign governments needed to export testing products for sale in other countries; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">criminal prosecution </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our
reputation, business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In&nbsp;addition, the FDA&#146;s and other regulatory authorities&#146;
policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approvals. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing authorization that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Regulatory and Compliance Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Healthcare policy and payment changes may have a material adverse effect on our financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Reimbursement to healthcare providers, such as specialized diagnostic service providers like us, is subject to continuing change in policies by
third-party payers including governmental payers, such as Medicare and Medicaid, private insurers and other private payers, such as hospitals and private medical groups. Statutory and regulatory changes, retroactive rate adjustments and
administrative rulings, and other policy changes may be implemented with little or no prior notice, all of which could materially decrease the range of services for which we are reimbursed or the reimbursement rates paid for our testing products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On April&nbsp;1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, implemented a new
payment system for clinical laboratory tests reimbursed under the CLFS. Under the law, clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic lab test that it furnishes. The reported data must
include the payment rate and the volume of each test that was paid by each private third-party payer. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. We bill Medicare for our
testing products, and therefore we are subject to reporting requirements under PAMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The final PAMA ruling was issued June&nbsp;17, 2016. Data for
reporting for the new PAMA process began in 2017, and in 2018, the Medicare payment rate for each clinical diagnostic lab test, with some exceptions, equaled the weighted median of the reported private third-party payer payment for the test, as
calculated using data collected by applicable laboratories during the data collection period and reported to the Centers for Medicare and Medicaid Services, or CMS, during a specified data reporting period. These revisions to the CLFS have altered
payment rates for clinical diagnostic lab tests under the CLFS, with estimated reductions in Medicare reimbursement rates for AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD of 3.2% and 10.1% in 2018 and 2019, respectively. We
cannot be sure how revisions to the CLFS will effect reimbursement rates in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other laws make changes impacting clinical laboratories,
many of which have already gone into effect. The ACA, enacted in March 2010, requires each medical device manufacturer to pay an excise tax in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
are listed with the FDA. This excise tax has been temporarily suspended until December&nbsp;31, 2019, unless additional congressional action is taken. On December&nbsp;14, 2018, a U.S. District
Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the entire ACA is invalid based primarily on the fact that the Tax Cuts and Jobs Act of 2017 repealed the <FONT STYLE="white-space:nowrap">tax-based</FONT>
shared responsibility payment imposed by the ACA, on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#147;individual mandate&#148;. While the Texas District Court
Judge, as well as the current presidential administration and CMS, have stated that this ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA
and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative
clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality
indicators in payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential
penalties for such violations. There have been judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the current presidential administration to repeal and replace the ACA, and we expect that there will be
additional challenges and amendments to the ACA in the future. We are monitoring the impact of the ACA in order to enable us to determine the trends and changes that may be necessitated by the legislation and that, in turn, may potentially impact
our business over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, the Budget Control Act of 2011, among other things, resulted in aggregate reductions to Medicare payments to
providers of 2%&nbsp;per fiscal year, beginning April&nbsp;1, 2013, and due to additional legislative amendments to the statute, these reductions will remain in effect through 2027 unless additional congressional action is taken. On January&nbsp;2,
2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some of our flow cytometry tests are reimbursed by the Medicare program under the MPFS. On April&nbsp;16, 2015, President Obama signed the Medicare
Access and CHIP Reauthorization Act of 2015, or MACRA, which, among other actions, repealed the previous statutory formula by which CMS established annual updates to MPFS rates. MACRA created the Merit-Based Incentive Payment System which, beginning
in 2019, more closely aligns physician payments with composite performance on performance metrics similar to three existing incentive programs (i.e., the Physician Quality Reporting System, the Value-based modifier program and the Electronic Health
Record Meaningful Use program) and incentivizes physicians to enroll in alternative payment methods. At this time, we do not know whether these changes to the physician payment systems will have any impact on orders or payments for our testing
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Medicare payments are significant to our business, not only because approximately 28% and 27% of the total payments we received from
payers in the year ended December&nbsp;31, 2018 and the six months ended June 30, 2019, respectively, were derived from the Medicare program, but also because other payers often use the MPFS and CLFS amounts as a benchmark to develop their payment
rates. We cannot predict whether Medicare and other third-party payer reimbursement rates that mirror Medicare&#146;s will be sufficient to make our testing products commercially attractive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, some third-party payers have implemented, or are in the process of implementing, laboratory benefit management programs, often using
third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
laboratories, such as ours, of active laboratory benefit management by third parties is unclear, and we expect that it could have a negative impact on our revenue in the short term. It is
possible that third-party payers will resist reimbursement for testing products that we offer in favor of less expensive tests, may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> for our testing products or may impose additional
pricing pressure on and substantial administrative burden for reimbursement for our testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Product pricing by companies is currently,
and is expected to continue to be, under close scrutiny. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product
pricing, review the relationship between pricing and patient programs, and reform government program reimbursement methodologies for products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United
States in which we may do business in the future, or the effect any future legislation or regulation will have on us. Although we cannot predict the full effect of the recent legislative changes discussed above, including taxes imposed by the ACA,
cost reduction measures, the expansion in government&#146;s role in the U.S. healthcare industry and PAMA&#146;s changes to the reimbursement methodology under the CLFS, such changes individually or in the aggregate may result in decreased profits
to us and/or lower reimbursement by third-party payers for our testing products, which may adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial
penalties. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans
for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient
test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA to perform testing through our accreditation by CAP. To renew this certificate, we are subject to survey and inspection
every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we are required to hold a
certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from
another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our
certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we
would be able to successfully maintain operations through either of these alternatives would depend upon the facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the
basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA program (or another accrediting organization). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA
certificate of accreditation, as well as a directed plan of correction, state <FONT STYLE="white-space:nowrap">on-site</FONT> monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and
certification to be eligible to bill for tests provided to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible
for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also
required to maintain a license to conduct testing in California. California laws establish standards for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of our clinical reference laboratory,
including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is licensed on a product-specific basis by New York as an out of state laboratory and our testing products, as LDTs, must be
approved by the New York Department of Health, or NYDOH, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis before they are offered in New&nbsp;York. We are also be subject to periodic
inspection by the NYDOH and required to demonstrate ongoing compliance with NYDOH regulations and standards. To the extent NYDOH identified any <FONT STYLE="white-space:nowrap">non-compliance</FONT> and we are unable to implement satisfactory
corrective actions to remedy such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> the State of New York could withdraw approval for our testing products. New York law also mandates proficiency testing for laboratories licensed under New York
state law, regardless of whether or not such laboratories are located in New York. Moreover, several other states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt
similar requirements in the future. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT> laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will
have such requirements in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation,
suspension or limitation, we would no longer be able to sell our testing products, which would limit our revenue and harm our business. If we were to lose our license or fail to obtain or maintain NYDOH approval for our laboratory developed tests in
New York or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states which would limit our revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business, operations and financial condition could be
adversely affected. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and our partners, including those with whom we may enter into <FONT STYLE="white-space:nowrap">co-promotion</FONT> or
<FONT STYLE="white-space:nowrap">co-marketing</FONT> arrangements, are also subject to healthcare fraud and abuse regulation by both the federal government and the states in which we or our partners conduct our business. These laws include, without
limitation, state and federal anti-kickback, self-referral, fraud and abuse, false claims, and physician sunshine laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Federal
Anti-kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to
induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service, including laboratory services, reimbursable, in whole or in part, under Medicare, Medicaid or other federally
financed healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The Federal Anti-kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and
prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly.
Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor, however, does not
make the conduct per se illegal under the Federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a
cumulative review of all of its facts and circumstances. Several courts have interpreted the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Federal Anti-Kickback
Statute has been violated. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. in order to have committed a violation In addition, the government may assert that a claim including items
or services resulting from a violation of the Federal Anti-kickback Statute constitutes a false or fraudulent claim for purposes of the false claims laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;25, 2014, the Office of Inspector General of the Department of Health and Human Services, or the OIG, released a Special Fraud Alert,
expressing concern regarding laboratory payments made to referring physicians and physician group practices for blood specimen collection, processing, and packaging. Specifically, the OIG expressed concern that such arrangements may implicate the
Federal Anti-Kickback Statute when laboratories make payments to physicians for services that are already covered and reimbursed by Medicare, or are not commercially reasonable or exceed fair market value, all in order to induce physicians to order
tests from such laboratory. Because the choice of laboratory and the decision to order laboratory tests is made or strongly influenced by the physician, with little or no input from patients, such payment may induce physicians to order more
laboratory tests than are medically necessary, particularly when the payments are tied to, or take into account, the volume or value of business generated by the physician. We had entered into certain arrangements with physicians for services
related to specimen collection, transporting and handling. Effective August 2015, we terminated all such agreements. To date, no regulatory authorities have contacted us regarding these arrangements. To the extent our prior arrangements are found to
be inconsistent with applicable laws, we may be subject to significant penalties, including criminal penalties, and exclusion from participation in U.S. federal or state health care programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Federal civil and criminal false claims law, including the False Claims Act, prohibit, among other things, any person from knowingly presenting or
causing to be presented a false claim for payment to the federal government, or knowingly making or causing to be made a false statement to get a false or fraudulent claim paid by the federal government. A claim includes &#147;any request or
demand&#148; for money or property presented to the U.S. government. In addition, private individuals have the ability to bring actions under these false claims laws in the name of the government alleging false and fraudulent claims presented to or
paid by the government (or other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as qui tam actions, have increased significantly in the healthcare industry in
recent years. In addition, the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the
person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to
items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also subject to
the federal physician self-referral prohibitions, commonly known as the Stark Law, which prohibits, among other things, physicians who have a financial relationship, including an investment, ownership or compensation relationship with an entity,
from referring Medicare patients for designated health services, which include clinical laboratory services, unless an exception applies. Similarly, entities may not bill Medicare or any other party for services furnished pursuant to a prohibited
referral. Many states have their own self-referral laws as well, which in some cases apply to all third-party payers, not just Medicare and Medicaid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, under the federal civil monetary penalties statute, a person is prohibited from offering or transferring to a Medicare or Medicaid
beneficiary any remuneration, including waivers of <FONT STYLE="white-space:nowrap">co-payments</FONT> and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#146;s selection of a
particular provider, practitioner or supplier of Medicare or Medicaid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
payable items or services. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Federal
Anti-kickback Statute and civil False Claims Act. One of the statutory exceptions to the prohibition is <FONT STYLE="white-space:nowrap">non-routine,</FONT> unadvertised waivers of copayments or deductible amounts based on individualized
determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition
applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to
defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent our patient assistance programs are found to be inconsistent with applicable laws, we may be required to restructure
or discontinue such programs, or be subject to other significant penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ACA, among other things, also imposed new reporting requirements on
manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and
their immediate family members. Manufacturers must submit reports by the 90th day of each calendar year. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting
requirements. We cannot assure you, however, that our regulators, principally the federal government, will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being
investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">It is possible
that some of our business activities could be subject to challenge under one or more of such laws, including our promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which is subject to restriction of <FONT
STYLE="white-space:nowrap">off-label</FONT> use discussions Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations.
Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend
against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or
any of the rheumatologists or entities with whom we do business are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including
administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in U.S. federal or state health care programs, such as Medicare and Medicaid in the U.S. and similar programs
outside the U.S., a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations, any of which could
materially adversely affect our ability to operate our business and our financial results. To the extent that any of our testing products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include,
for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Failure to comply with HIPAA, the HITECH Act, their implementing regulations, and similar comparable state laws and regulations affecting the transmission,
security and privacy of health information could result in significant penalties. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Numerous federal and state laws and regulations, including
HIPAA and the HITECH Act, govern the collection, dissemination, security, use and confidentiality of individually identifiable health information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of individually identifiable health information within our company and with third parties. The Standards for Privacy of Individually Identifiable Health Information, or Privacy Standards, and the
Security Standards for the Protection of Electronic Protected Health Information, or Security Standards, under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information
by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. Notably, whereas HIPAA previously directly regulated
only these covered entities, the HITECH Act, which was signed into law as part of the stimulus package in February 2009, made certain of the Security Standards directly applicable to business associates. Further, the HITECH Act and the Final HIPAA
Omnibus Rule that was promulgated in 2013, made additional parts of HIPAA directly applicable to business associates. As a result, both covered entities and business associates are now subject to significant civil and criminal penalties for failure
to comply with the Privacy Standards and/or the Security Standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">HIPAA and the HITECH Act also include standards for common healthcare
electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered entities,
such as certain health care providers, are required to conform to such transaction set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">HIPAA requires covered entities to develop and maintain policies and procedures with respect to individually identifiable health information that is
used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification requirement for breaches of individually identifiable health information, restricts
certain disclosures and sales of individually identifiable health information and provides a tiered system for civil monetary penalties for HIPAA violations. The Final HIPAA Omnibus Rule modifies the breach reporting standard in a manner that will
likely make more data security incidents qualify as reportable breaches. The HITECH Act also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney fees and costs associated with pursuing federal civil actions. Additionally, certain states have adopted comparable
privacy and security laws and regulations, some of which may be more stringent than HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we do not comply with the requirements of HIPAA, the
HITECH Act or applicable state privacy and security laws, we could be subject to criminal or civil sanctions that could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory
requirements are burdensome and could have a material adverse effect on our business. These laws are subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well
as our physician clients. In addition, we are unable to predict what changes to the HIPAA Privacy Standards and Security Standards might be made in the future or how those changes could affect our business. Any new legislation or regulation in the
area of privacy and security of personal information, including individually identifiable health information, could also adversely affect our business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and
regulations.&nbsp;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&nbsp;We can face criminal liability and other serious consequences for violations, which can harm our business.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs
regulations, various economic and trade sanctions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery
statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.&nbsp;Anti-corruption laws are interpreted
broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or
private sector.&nbsp;We may engage third parties to sell our testing products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&nbsp;We have
direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations.&nbsp;We can be held liable for the corrupt or other illegal activities of our employees,
agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and
penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks
and uncertainties. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our future growth may depend, in part, on our ability to develop and commercialize our testing products and promote
therapeutics in foreign markets. We are not permitted to market or promote any of our testing products or promote therapeutics before we or our partners receive regulatory approval from applicable regulatory authorities in foreign markets, and we or
they may never receive such regulatory approvals for any of our testing products or promoted therapeutics. To obtain separate regulatory approval in many other countries parties must comply with numerous and varying regulatory requirements regarding
safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our testing products. If we or our partners obtain regulatory approval of our testing products and promoted therapeutics, and
ultimately commercialize our testing products or promoted therapeutics in foreign markets, we would be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including
earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to maintain intellectual property protection our competitive position could be harmed. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to protect our technologies such as <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> and methotrexate polyglutamates, or MTXPGs, affects our
ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions to protect our intellectual
property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products will be considered patentable or enforceable
by the United States Patent and Trademark Office, or the USPTO, courts in the United States, or by patent offices and courts in foreign countries. If we fail to protect our intellectual property, third parties may be able to compete more effectively
against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We apply for
patents covering our testing products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important testing products and technologies in a timely fashion or at all, or we may fail to apply for
patents in potentially relevant jurisdictions, or we may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we have an exclusive license to 13 issued U.S. patents, and certain corresponding foreign
counterpart patents, relevant to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. We also own two pending U.S. patent applications relevant to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
testing products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do successfully issue, third parties
may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the further
development of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products or prevent others from designing around our claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We might not have been
the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in
interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent
applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties
bring these proceedings against our patents, we could experience significant costs and management distraction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to the protection
afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable, or that we elect not to patent, processes for which patents are
difficult to enforce and any other elements of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or
technology that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors and other advisors may
unintentionally or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements with our employees, consultants and other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or
that competitors will not know of, or independently discover, our trade secrets. We cannot assure you that others will not independently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our testing products, technologies, services or
<FONT STYLE="white-space:nowrap">know-how</FONT> or require licensing and the payment of significant fees or royalties by us in order to produce our testing products, technologies or services. Further, we cannot be certain that the steps we have
taken will prevent the misappropriation of our trade secrets and other confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Monitoring unauthorized disclosure is difficult,
and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time
consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential
information to third parties, and in particular in jurisdictions where we have not filed for patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business,
operating results and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Certain of our testing products utilize unpatented technology that is publicly available and can be used by our
competitors. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products, such as AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, utilize both patented technology and publicly available technology that is not protected by patents or other intellectual property rights. We believe that using certain publicly available
technology allows us to offer a better and more comprehensive testing product. However, the publicly available technology which we rely upon is also used in, and may continue to be used in, products which compete with our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our success is heavily dependent on intellectual property,
particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. The United States has
enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S.
Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the
future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as <FONT
STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some of the intellectual property rights we have acquired or licensed or may
acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work related to our <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> technology was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our testing products pursuant to the Bayh-Dole Act of 1980,
or Bayh-Dole Act. These U.S. government rights include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under
certain limited circumstances, to require us to grant exclusive, partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have
not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet public health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred
to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an
application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend
substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S.
industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees
that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions
of the Bayh-Dole Act may similarly apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Filing, prosecuting and defending patents on our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products in all countries
throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position may be
stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject matter
that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent costs and
focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology, which is used in our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement of such patent protection is not as strong
as that in the United States. These products may compete with our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products and our patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology
products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could
result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The patent protection and patent prosecution for some of our testing products may be dependent on third parties.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities
before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may
exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such
patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could
be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable
patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the
licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain
that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license
agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or
defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the
licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it may permit other parties to compete with us If any of our licensors or any of our future licensors or future collaborators
fail to appropriately prosecute and maintain patent protection for patents covering any of our testing products, our ability to develop and commercialize those testing products may be adversely affected and we may not be able to prevent competitors
from making, using and selling competing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, even where we have the right to control patent prosecution of patents and patent
applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent
prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often
retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make
customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to
enforce our rights to our licensed technology in the event of misuse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we are limited in our ability to utilize acquired or licensed
technologies, or if we lose our rights to critical <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology, we may be unable to successfully develop, <FONT STYLE="white-space:nowrap">out-license,</FONT> market and sell our testing products,
which could adversely affect our business. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
any limitations on our ability to utilize these technologies may impair our ability to develop, <FONT STYLE="white-space:nowrap">out-license</FONT> or market and sell our testing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience
disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a
party to a number of license agreements under which we are granted intellectual property rights that are important to our business. For example, certain patent rights related to AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus
are licensed from the University of Pittsburgh, certain patent rights related to AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX are licensed from Prometheus. Our existing license agreements as related to our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under a
license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Additionally, we may not always
have the first right to maintain, enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do
not, our ability to do so may be compromised by our licensors&#146; acts or omissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Licensing of intellectual property rights is of critical
importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including the scope of rights granted under
the license agreement and other interpretation-related issues, and whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes
over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely
affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages
over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of these fees, and our outside counsel employs an outside firm to pay these fees due to the USPTO
and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow
certain of our applications to lapse, particularly with respect to our <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> rights licensed from the University of Pittsburgh related to our <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology. The
permanent lapse of certain of these <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> rights may result in our patent position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and
third parties may be able to compete more effectively against us in countries outside the United States, including in those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier than should
otherwise have been the case, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in obtaining or maintaining necessary
rights to product components and processes for our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on
our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> proprietary rights that we identify as being necessary for
our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products, and our partner may be unable to acquire any necessary rights for our promoted therapeutics. Even if we are able to obtain a license to such proprietary rights, it
may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement
technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or
have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our
AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products or our partners consider necessary or attractive in order to promote their therapeutic. More established companies may have a competitive advantage over us due to their
size, cash resources and greater clinical development and commercialization capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, companies that perceive us to be a
competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on
our investment, or at all. If we or our partner are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to further develop our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products and promote therapeutics, and our business, financial condition and prospects for growth could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Third-party claims alleging intellectual property infringement may prevent or delay our development efforts. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount
of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents, including interference and reexamination
proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post grant review. The implementation of these
procedures bring the possibility of third party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might be able to enter the market earlier than
should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are
developing our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products may give rise to claims of infringement of the patent rights of others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
cannot assure you that any of our current or future AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products will not infringe existing or future patents. Although we are not aware of any issued patents that will prevent us
from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
marketing our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products, there may be third-party patents of which we are currently unaware with claims to materials or
methods of manufacture related to the use or manufacture of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. If a third party that owns such a patent asserts it successfully against one of our current or future
AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products, we may be unable to market our product, which could materially harm our business and because patent applications can take many years to issue and may be confidential
for 18&nbsp;months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products or our
technologies may infringe, or which such third parties claim are infringed by the use of our technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Parties making claims against us for
infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial diversion of employee resources from our business. In the event
of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees if we are found to be willfully infringing a third party&#146;s patents, obtain one or more licenses from
third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on
commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing
products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products,
which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim
technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our
patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other jurisdictions regarding our intellectual property rights with respect to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
testing products and technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be involved in proceedings to protect or enforce our patents or the patents of our licensors, which could be
expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Third parties may infringe, misappropriate or otherwise violate our existing patents, patents
that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not be able
to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering one of our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products, the defendant could counterclaim that the patent covering such AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing product is invalid and/or unenforceable.
In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such
proceedings could result in an invalidation of our patents. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no
invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
unenforceability, we would lose at least part, and perhaps all, of the patent protection on our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Such a loss of
patent protection could have a material adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Litigation proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a substantial adverse effect on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Because of the expense and uncertainty of litigation, we
may not be in a position to enforce our intellectual property rights against third parties. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because of the expense and uncertainty of
litigation, we may conclude that even if a third party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our
company or our stockholders. We are not aware of any third party infringement of our intellectual property rights that would have a materially adverse impact on our business. In addition, there can be no assurance that our licensors will be willing
to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual property is less important to the licensor&#146;s business than to ours. In such cases, we
may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third
parties. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were
previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third
parties or our employees&#146; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation
may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein.
Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to this Offering and Our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>An active, liquid
and orderly market for our common stock may not develop, and you may not be able to resell your common stock at or above the public offering price. Our stock price may be volatile, and you may not be able to sell shares of our common stock at or
above the price you paid. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock, and an active public market for our
stock may not develop or be sustained after this offering. We and the representatives of the underwriters will determine the initial public offering price of our common stock through negotiation. This price will not necessarily reflect the price at
which investors in the market will be willing to buy and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sell our stock following this offering. In addition, the trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in
response to various factors, some of which are beyond our control. These factors include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated variations in our and our competitors&#146; financial condition and results of operations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements by us or our competitors of new products, strategic partnerships or capital commitments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in reimbursement by current or potential third-party payers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issuance of new securities analysts&#146; reports or changed recommendations for our stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated changes in regulatory oversight of our testing products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments or disputes concerning our intellectual property or other proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">commencement of, or our involvement in, litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announced or completed acquisitions of businesses or technologies by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any major change in our management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in accounting principles; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future sales of our common stock by our executive officers, directors and other stockholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic conditions and slow or negative growth of our markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate
changes, may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. If the market
price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#146;s securities,
securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#146;s attention and resources. Any adverse
determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our failure to meet the continued listing requirements of the Nasdaq Global Market, or Nasdaq, could result in a delisting of our common stock. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing
bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so.
In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our
common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or
reports about our company, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The trading market for our common stock will depend in part on
the research and reports that equity research analysts publish about us and our business. Currently, we do not have any analyst coverage and we may not obtain analyst coverage in the future. In the event we obtain analyst coverage, we would not have
any control over such analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company after the completion of this offering, and such lack of research coverage may
adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing
reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future sales of shares by existing stockholders could cause our stock price to decline. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the <FONT
STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on the number of shares of common stock outstanding as of June&nbsp;30,
2019, upon the completion of this offering, we will have outstanding a total of 11,233,652&nbsp;shares of common stock, assuming the expected net exercise of the Net Exercise Warrants, no exercise of the underwriters&#146; option to purchase
additional shares and no exercise of outstanding options or warrants (other than the Net Exercise Warrants). Of these shares, all shares sold in this offering will be freely tradable, without restriction, in the public market immediately after the
offering, except for any shares purchased by our affiliates. Each of our directors and officers and substantially all of our other stockholders has entered into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters
described in &#147;Underwriting&#148; elsewhere in this prospectus, which restricts their ability to sell or transfer their shares. The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire 180&nbsp;days
from the date of this prospectus. The underwriters, however, may, in their sole discretion, waive the contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, based on shares outstanding as of June&nbsp;30, 2019, up to an additional 7,900,318&nbsp;shares of common stock will be eligible for sale in the public market,
of which 5,468,707&nbsp;shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule&nbsp;144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, 662,987&nbsp;shares of common stock that are subject to outstanding options as of June&nbsp;30, 2019 will become eligible for sale in the
public market to the extent permitted by the provisions of various option agreements, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rules&nbsp;144 and 701 under the Securities Act. We intend to file&nbsp;a registration statement
on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act covering all of the shares of common stock subject to options outstanding and reserved for issuance under our employee benefit plans. This registration statement will
become effective immediately upon filing, and shares covered by this registration statement will be eligible for sale in the public markets, subject to Rule&nbsp;144 limitations applicable to affiliates, the terms of the applicable plan and the
option agreements entered into with option holders, and any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. In addition, our directors and executive officers may establish programmed selling plans under Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by these stockholders, or the perception that those sales may occur, including the entry into such
programmed selling plans, could have a material adverse effect on the trading price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the holders of
7,880,575&nbsp;shares of common stock and holders of warrants to purchase an aggregate of 1,013,107&nbsp;shares of common stock will be entitled to rights with respect to registration of such shares under the Securities Act pursuant to an
investors&#146; rights agreement between such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
holders and us. See &#147;Certain Relationships and Related Person Transactions&#151;Investors&#146; Rights Agreement&#148; below. If such holders, by exercising their registration rights, sell a
large number of shares, they could adversely affect the market price for our common stock. If we file a registration statement for the purpose of selling additional shares to raise capital and are required to include shares held by these holders
pursuant to the exercise of their registration rights, our ability to raise capital may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an emerging growth company and a smaller
reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following
the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenue exceeds $1.07&nbsp;billion
or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an
emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval
of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have taken advantage of reduced reporting burdens in this
prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth
company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an
emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we may not be subject to the same implementation
timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are
no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal
year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a
private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In
addition, Sarbanes-Oxley, as well as rules subsequently adopted by the Securities and Exchange Commission, or the SEC, and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring
establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional
rules and regulations in these areas, such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high
level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot
currently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business,
financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our testing products or services.
For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to maintain proper and effective internal control over financial reporting, our
ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over financial
reporting beginning with the annual report for our fiscal year ending December&nbsp;31, 2020. When we lose our status as an &#147;emerging growth company&#148; and reach an accelerated filer threshold, our independent registered public accounting
firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require
significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and
management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose
confidence in our financial reporting and the trading price of our common stock may decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot assure you that there will not be material weaknesses or significant deficiencies in our
internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we
are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial
reporting once that firm begin its Section&nbsp;404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or
investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies,
could also restrict our future access to the capital markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that
stockholders may consider favorable and may lead to entrenchment of management. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and
amended and restated bylaws that will be in effect immediately prior to the consummation of this offering will contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control
or changes in our management without the consent of our board of directors. The provisions in our charter documents will include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the
membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to
elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to remove
a director for cause, and the prohibition on removal of directors without cause; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and
other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to adopt,
amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special
meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for
certain actions and proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the
ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or
to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise attempting to obtain
control of us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also subject to the anti-takeover provisions contained in Section&nbsp;203 of the Delaware
General Corporation Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions,
the board of directors has approved the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation and amended and restated bylaws will provide that
the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or
our directors, officers or employees. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws will provide
that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to
the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this
provision would not apply to suits brought to enforce a duty or liability created by Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon
federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the
Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a
stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other
employees. By agreeing to this provision, however, the stockholders will not be deemed to have waived our compliance with the Federal Securities laws and rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum
provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice
of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect
our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion to use the net proceeds from this offering and our investment of these proceeds may not yield
a favorable return. We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that
will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your
investment, and the failure by our management to apply these funds effectively could harm our business. We may also use a portion of the net proceeds of this offering for acquisitions to bolster our product offerings. We have not entered into any
agreements or commitments with respect to any specific acquisitions and have no understandings or agreements with respect to any such acquisition or investment at this time. Pending their use, we may invest the net proceeds from this offering in
short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. These investments may not yield a favorable return to our stockholders. If
we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Purchasers in this offering will experience immediate and substantial dilution in the book value of their
investment. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The initial public offering price of our common stock is substantially higher than the net tangible book value per share of
our common stock immediately after this offering. Therefore, if you purchase our common stock in this offering, you will incur immediate dilution of $10.55 in the net tangible book value per share from the price you paid, based on the assumed
initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. The exercise of outstanding options and warrants will result in further dilution. In addition, if we raise additional
funds by issuing equity securities, our stockholders may experience further dilution. For a detailed description of the dilution that you will experience immediately after this offering, see &#147;Dilution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to control or
significantly influence all matters submitted to stockholders for approval. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, our executive
officers, directors and greater than 5% stockholders, in the aggregate, will own approximately 51.5% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding
options). As a result, such persons, acting together, will have the ability to control or significantly influence all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant
transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination
involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. Moreover, certain of our existing stockholders,
including certain affiliates of our directors, have indicated an interest in purchasing shares of our common stock in this offering at the initial public offering price. Based on an assumed initial public offering price of $15.00 per share, the
midpoint of the price range set forth on the cover page of this prospectus, if our greater than 5% stockholders purchase all of the shares they have indicated an interest in purchasing in this offering, the number of shares of our common stock
beneficially owned by our executive officers, directors and greater than 5% stockholders will, in the aggregate, increase to approximately 60.0% of our outstanding common stock. However, because indications of interest are not binding agreements or
commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, less or no shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. Your ability to achieve a return on your
investment will depend on appreciation, if any, in the price of our common stock. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never declared or paid any cash dividends on our
common stock and do not intend to pay any cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the growth of our business. In addition, our loan agreement restricts our ability to pay cash dividends on
our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be
at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital
appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If an active, liquid trading market for our common stock does not develop, you may not be able to sell your
shares quickly or at or above the initial offering price. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There has not been a public market for our common stock. An active and liquid
trading market for our common stock may not develop or be sustained following this offering. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The
lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or
technologies by using our shares as consideration. You may not be able to sell your shares quickly or at or above the initial offering price. The initial public offering price will be determined by negotiations with the representatives of the
underwriters. This price may not be indicative of the price at which our common stock will trade after this offering, and our common stock could trade below the initial public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This
risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention
and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including
statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing with therapeutics strategy, the
expected benefits from our partnership or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These
statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148;
&#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements
largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this
prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely
on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by
applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. The forward-looking statements
contained in this prospectus are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act. You should, however, review the factors and risks we describe in
the reports we will file from time to time with the SEC after the date of this prospectus. See &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe
such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as well as
from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from
publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which
we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of
this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this
prospectus is reliable and based on reasonable assumptions, such data involves risks and uncertainties and is subject to change based on various factors, including those discussed in &#147;Risk Factors.&#148; These and other factors could cause
results to differ materially from those expressed in the estimates made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds to us from the sale of the common stock that we are offering will be approximately $44.2&nbsp;million (or
$51.2&nbsp;million if the underwriters exercise their option to purchase additional shares in full), assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share would increase (decrease) the net
proceeds to us from this offering by approximately $3.1&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million in the number of shares offered by us at the assumed initial public offering price would increase (decrease) the net proceeds to us
from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $14.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our common stock and
to facilitate our future access to the public equity markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently intend to use the net proceeds from this offering as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $20.0&nbsp;million for selling and marketing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $11.0&nbsp;million for research and development activities, including continued expansion of our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> product portfolio, as well as clinical studies to demonstrate the utility of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> products and support reimbursement efforts; and
</P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder for working capital purposes and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may also use a portion of the net proceeds and our existing cash and cash equivalents, to in-license, acquire, or invest in complementary businesses,
technologies, products or assets. However, we have no current commitments or obligations to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe, based on our current operating plan,
that the net proceeds from this offering and our existing cash and cash equivalents and anticipated future product revenue, will be sufficient to fund our operations for at least the next 12 months, although there can be no assurance in that regard.
The amounts and timing of our actual expenditures will depend on numerous factors, including the timing and amount of our cash receipts from the sale of our testing products and promotion of
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the development efforts for our testing products and other factors described under &#147;Risk Factors&#148; in this prospectus, as well as the amount of cash used in our operations.
For example, if our research and development of new testing products requires more time or resources than we currently anticipate or if we are required to conduct additional studies to help secure reimbursement for our testing products, we may
allocate additional proceeds of this offering to our research and development efforts. If our research and development efforts progress faster than we currently expect, or if our sales and marketing needs expand faster than we currently expect, we
may elect to reallocate a portion of the proceeds of this offering from research and development to sales and marketing activities to support our integrated promotion of testing products and therapeutics strategy. Therefore, our actual expenditures
may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations,
investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our
business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of
operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is currently
prohibited by the terms of our loan agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents, and our capitalization as of June&nbsp;30, 2019 as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to reflect (i)&nbsp;the issuance of 479,967,595 shares of our Series&nbsp;H redeemable convertible
preferred stock in July 2019 and the receipt of $11.0&nbsp;million in gross proceeds therefrom (including the conversion of 148,928,337 shares of our Series G redeemable convertible preferred stock into 246,521,076 shares of our Series&nbsp;H
redeemable convertible preferred stock in July 2019), (ii)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 7,816,643&nbsp;shares of our common stock (including the conversion
of 479,967,595&nbsp;shares of our Series&nbsp;H redeemable convertible preferred stock issued in July 2019 into 2,613,703 shares of our common stock) and the resultant reclassification of (A)&nbsp;the carrying value of the redeemable convertible
preferred stock to permanent equity and (B)&nbsp;our redeemable convertible preferred stock warrant liabilities to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, a component of stockholder&#146;s equity (deficit), in connection
with such conversion, all of which will occur in connection with the completion of this offering, (iii)&nbsp;the issuance of 20,620&nbsp;shares of our common stock as a result of the expected net exercise of the Net Exercise Warrants in connection
with the completion of this offering, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, which Net Exercise Warrants will terminate if not exercised prior to
the completion of this offering, and (iv)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to the issuance and sale of 3,333,334 shares of our common stock in
this offering at the assumed initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The pro forma and pro forma as adjusted information below is illustrative only, and our capitalization
following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our audited financial
statements and the related notes included elsewhere in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section and other financial information contained in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Pro&nbsp;Forma&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited, in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Borrowings, including current portion, net of discounts and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Capital lease obligations, including current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.001 par value per share;&nbsp;955,500,000 shares
authorized;&nbsp;681,534,421 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock, $0.001 par value per share; no shares authorized, issued or outstanding, actual; 10,000,000
shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.001 par value per share; 1,675,200,000&nbsp;shares authorized;&nbsp;63,055 shares issued
and outstanding, actual; 200,000,000&nbsp;shares authorized, pro forma and pro forma as adjusted; 7,900,318&nbsp;shares issued and outstanding, pro forma; 11,233,652&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in&nbsp;capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, the midpoint of the price
range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; equity (deficit) and total capitalization by approximately
$3.1&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us. Similarly, each increase (decrease) of 1.0&nbsp;million in the number of shares offered by us at the assumed initial public offering price per share would increase (decrease) the pro forma as adjusted amount of each of cash and cash
equivalents, total stockholders&#146; equity (deficit) and total capitalization by approximately $14.0&nbsp;million, after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares in the table above excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">662,987 shares of our common stock issuable upon exercise of stock options outstanding as of June&nbsp;30, 2019, with a
weighted-average exercise price of $1.24 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">812,745&nbsp;shares of our common stock issuable upon the exercise of stock options to be granted under our 2019 Plan,
contingent and effective upon the effectiveness of the registration statement of which this prospectus forms a part, with an exercise price that is equal to the initial public offering price; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,013,107&nbsp;shares of our common stock issuable upon the exercise of outstanding warrants (which number does not include
the Net Exercise Warrants) as of June&nbsp;30, 2019, with a weighted-average exercise price of $3.13 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,011,832&nbsp;shares of our common stock reserved for future issuance under our 2019 Plan, which will become effective in
connection with the completion of this offering (which number includes the IPO grants, but does not include any potential annual evergreen increases pursuant to the terms of the 2019 Plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">120,000&nbsp;shares of our common stock reserved for future issuance under our ESPP, which became effective on the day the
ESPP was adopted by our board of directors (which number does not include any potential annual evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the
initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As
of June&nbsp;30, 2019, we had a historical net tangible book deficit of $(127.2)&nbsp;million, or $(2,017.92) per share of common stock based on 63,055&nbsp;shares of common stock outstanding as of such date. Our historical net tangible book deficit
per share represents total tangible assets less total liabilities and redeemable convertible preferred stock, divided by the number of shares of common stock outstanding at June&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On a pro forma basis after giving effect to (i)&nbsp;the issuance of 479,967,595 shares of our Series&nbsp;H redeemable convertible preferred stock in
July 2019 and the receipt of $11.0&nbsp;million in gross proceeds therefrom (including the conversion of 148,928,337 shares of our Series G redeemable convertible preferred stock into 246,521,076 shares of our Series H redeemable convertible
preferred stock in July 2019), (ii)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 7,816,643 shares of our common stock, (including the conversion of 479,967,595&nbsp;shares
of our Series&nbsp;H redeemable convertible preferred stock issued in July&nbsp;2019 into 2,613,703&nbsp;shares of our common stock), and the resultant reclassification of (A) the carrying value of the redeemable convertible preferred stock to
permanent equity and (B) our redeemable convertible preferred stock warrant liabilities to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, a component of stockholders&#146; equity (deficit), in connection with such conversion,
all of which will occur in connection with the completion of this offering, and (iii)&nbsp;the issuance of 20,620&nbsp;shares of our common stock as a result of the expected net exercise of the Net Exercise Warrants in connection with the completion
of this offering, assuming an initial public offering price of $15.00&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, which Net Exercise Warrants will terminate if not exercised prior to the completion
of this offering, our pro forma net tangible book value as of June&nbsp;30, 2019 would have been approximately $5.8&nbsp;million, or approximately $0.74 per share of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After giving further effect to the issuance and sale of 3,333,334&nbsp;shares of our common stock that we are offering at the assumed initial public
offering price of $15.00&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro
forma as adjusted net tangible book value as of June&nbsp;30, 2019 would have been approximately $50.0&nbsp;million, or approximately $4.45&nbsp;per share. This amount represents an immediate increase in pro forma net tangible book value of
approximately $3.71 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately $10.55&nbsp;per share to new investors purchasing shares of common stock in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dilution per share to new investors is determined by subtracting pro forma as adjusted net
tangible book value per share after this offering from the assumed initial public offering price per share paid by new investors. The following table illustrates this dilution: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book deficit per share as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,017.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma increase in historical net tangible book value per share attributable to the pro forma
transactions described above</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each $1.00 increase in the assumed initial public offering price of $15.00&nbsp;per share, the midpoint of the
price range set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value per share after this offering by approximately $0.28, and decrease the dilution in pro forma net tangible book value per
share to new investors by approximately $0.28, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and the
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each $1.00 decrease in the assumed initial public offering price of $15.00 per share, the midpoint of
the price range set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by approximately $0.27, and increase the dilution in pro forma net tangible book value per
share to new investors by approximately $0.27, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and the
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each increase of 1.0&nbsp;million in the number of shares offered by us at the assumed initial public
offering price would increase our pro forma as adjusted net tangible book value per share after this offering by approximately $0.78 and decrease the dilution to investors participating in this offering by approximately $0.78 per share, after
deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. Each decrease of 1.0 million in the number of shares offered by us at the assumed initial public offering price would decrease our pro
forma as adjusted net tangible book value per share after this offering by approximately $0.93 and increase the dilution to investors participating in this offering by approximately $0.93 per share, after deducting the estimated underwriting
discounts and commissions and the estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional
shares in full in this offering, the pro forma as adjusted net tangible book value after the offering would be approximately $4.86 per share, the increase in pro forma net tangible book value per share to existing stockholders would be approximately
$4.12 per share and the dilution per share to new investors would be approximately $10.14 per share, in each case assuming an initial public offering price of $15.00&nbsp;per share, the midpoint of the price range set forth on the cover page of this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes on the pro forma as adjusted basis described above, as of June&nbsp;30, 2019, the differences between
the number of shares purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
shares issued prior to this offering and the price to be paid by new investors in this offering. The calculations below are based on the assumed initial public offering price of $15.00 per share,
the midpoint of the price range set forth on the cover page of the prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price</B><br><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders before this offering<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,900,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,121,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,333,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,233,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,121,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Certain of our existing stockholders, including entities affiliated with certain of our directors, have indicated an
interest in purchasing an aggregate of approximately $12.0&nbsp;million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because
these indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any or all of these stockholders, or any or all of these stockholders may
determine to purchase more, less or no shares in this offering. The presentation in this table regarding ownership by existing stockholders before this offering does not give effect to any potential purchases in this offering by such stockholders.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The foregoing tables and calculations (other than the historical net tangible book value calculation) are based on 7,900,318
shares of our common stock outstanding as of June&nbsp;30, 2019, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 7,816,643 shares of our common stock (including the
conversion of 479,967,595 shares of our Series&nbsp;H redeemable convertible preferred stock issued in July 2019) and the issuance of 20,620&nbsp;shares of our common stock as a result of the expected net exercise of the Net Exercise Warrants in
connection with the completion of this offering, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, which Net Exercise Warrants will terminate if not
exercised prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">662,987 shares of our common stock issuable upon exercise of stock options outstanding as of June&nbsp;30, 2019, with a
weighted-average exercise price of $1.24 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">812,745&nbsp;shares of our common stock issuable upon the exercise of stock options to be granted under our 2019 Plan,
contingent and effective upon the effectiveness of the registration statement of which this prospectus forms a part, with an exercise price that is equal to the initial public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,013,107 shares of our common stock issuable upon the exercise of outstanding warrants (which number does not include the
Net Exercise Warrants) as of June&nbsp;30, 2019, with a weighted-average exercise price of $3.13 per share; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,011,832 shares of our common stock reserved for future issuance under our 2019 Plan, which will become effective in
connection with the completion of this offering (which number includes the IPO grants, but does not include any potential annual evergreen increases pursuant to the terms of the 2019 Plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">120,000 shares of our common stock reserved for future issuance under our ESPP, which became effective on the day the ESPP
was adopted by our board of directors (which number does not include any potential annual evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To the extent any options or warrants outstanding as of June&nbsp;30, 2019 are exercised, there will be further dilution to new investors. If all of
such outstanding options and warrants had been exercised as of June&nbsp;30, 2019, the pro forma as adjusted net tangible book value per share after this offering would be $4.18, and total dilution per share to new investors would be $10.82. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares of our common stock in full:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the percentage of shares of common stock held by existing stockholders will decrease to approximately 67.3% of the total
number of shares of our common stock outstanding after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares held by new investors will increase to 3,833,334, or approximately 32.7% of the total number of shares
of our common stock outstanding after this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following tables set forth our selected historical financial data as of, and for the periods ended on, the dates indicated. We have derived the
selected statements of operations data for the years ended December&nbsp;31, 2017 and 2018 and the balance sheet data as of December&nbsp;31, 2017 and 2018 from our audited financial statements included elsewhere in this prospectus. The statements
of operations data for the six months ended June&nbsp;30, 2018 and 2019 and the balance sheet data as of June&nbsp;30, 2019 have been derived from our unaudited financial statements included elsewhere in this prospectus. You should read this data
together with our audited financial statements and the related notes included elsewhere in this prospectus and the section of this prospectus entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future results. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Statements&nbsp;of&nbsp;Operations&nbsp;Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,551</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,643</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,880</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss on extinguishment of share purchase rights and 2013 Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(549</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deemed dividend recorded in connection with financing transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(520.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(293.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Weighted-average number of shares used to compute net loss per share attributable to common stockholders,
basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Pro forma weighted-average number of shares used to compute pro forma net loss per share attributable to
common stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,282,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,836,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We adopted ASU 2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>, as of January 1, 2018. See Note 3 to our
audited financial statements included elsewhere in this prospectus for further discussion. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Note 2 to our audited financial statements included elsewhere in this prospectus for an explanation of the method used
to calculate the historical net loss and the historical and pro forma net loss per share attributable to common stockholders, basic and diluted, and the number of shares used in the computation of these per share amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Note&nbsp;16 to our audited financial statements included elsewhere in this prospectus for a summary of the amounts
and financial statement line items impacted by the revision. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance&nbsp;Sheet&nbsp;Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,270</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,390</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Borrowings, non-current portion, net of discounts and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,809</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Capital lease obligations, including current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,046</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We adopted ASU 2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>, as of January 1, 2018. See Note 3 to our
audited financial statements included elsewhere in this prospectus for further discussion. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our audited financial statements and the related
notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Note&nbsp;16 to our audited financial statements included elsewhere in this prospectus for a summary of the amounts
and financial statement line items impacted by the revision. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial
statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect
to our plans and strategy for our business and future financial performance, includes forward-looking statements that are based on current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should review the
&#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following
discussion and analysis. Please also see the section of this prospectus entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand, several of which
are based on our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and
autoimmune-related diseases, including SLE and RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our
business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently market nine testing products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand that allow for the
differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, enables differential diagnosis for patients
presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. We commercially launched AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD in 2012 and revenue from this product
comprised 82% of our revenue in the year ended December&nbsp;31, 2018 and 83% of our revenue for the six months ended June&nbsp;30, 2019. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe
there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. In order to advance our integrated testing and therapeutics strategy, in
December 2018 we entered into the Janssen agreement to exclusively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States for the treatment of adult patients with moderate to severe RA and for other indicated
rheumatic diseases. We began direct promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in January 2019 and expanded our salesforce from 31 representatives as of December&nbsp;31, 2018 to 55 representatives in August 2019.
We expect our SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> promotion efforts to contribute incremental revenue in 2019 with our quarterly tiered promotion fee based on the incremental increase in total prescribed units above a
predetermined average baseline of approximately 29,000 prescribed units per quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also have additional agreements with other leading
pharmaceutical companies, including GSK, Horizon Therapeutics and Corrona, that leverage our testing products and the information generated from such tests. We plan to pursue additional strategic partnerships with a focus on the commercialization of
therapeutics that are synergistic with our testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We perform all of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
tests in our approximately 8,000 square foot clinical laboratory, which is certified by CLIA and accredited by CAP, and located in Vista, California. Our laboratory is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
certified for performance of high-complexity testing by CMS in accordance with CLIA. We are approved to offer our products in all 50 states. Our clinical laboratory reports all AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing product results within five business days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We market our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products using our specialized salesforce. Unlike many diagnostic salesforces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of
our salesforce coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. Our
integrated testing and therapeutics strategy results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and history using
our portfolio of testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Reimbursement for our testing services comes from several sources, including commercial third-party payers, such
as insurance companies and health maintenance organizations, government payers, such as Medicare, and patients. Reimbursement rates vary by product and payer. We continue to focus on expanding coverage among existing contracted rheumatologists and
to achieve coverage with commercial payers, laboratory benefit managers and evidence review organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since inception we have devoted
substantially all our efforts developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. Although our revenue has increased sequentially year over year, we have never been profitable and, as of
June&nbsp;30, 2019 we had an accumulated deficit of $158.1&nbsp;million. We incurred net losses of $25.6&nbsp;million, $8.0&nbsp;million (as revised) and $5.5&nbsp;million in the years ended December&nbsp;31, 2017 and 2018 and the six months ended
June&nbsp;30, 2019, respectively. We expect to continue to incur operating losses in the near term as our operating expenses will increase to support the growth of our business, as well as additional costs associated with being a public company. We
have funded our operations primarily through equity and debt financings and revenue from sales of our products. Since inception and through June&nbsp;30, 2019, our operations have been financed primarily by net proceeds of approximately
$161.1&nbsp;million from sales of our common and redeemable convertible preferred stock and borrowings under various debt financings and revenue from the sales of our products. As of June&nbsp;30, 2019 we had $16.2&nbsp;million of cash and cash
equivalents. In addition, in July 2019, we raised gross proceeds of approximately $11.0&nbsp;million through the sale of our Series&nbsp;H redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Factors Affecting Our Performance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe there are
several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Continued Adoption Of Our Testing Products.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Since its launch in 2012, we have grown
the number of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests delivered at a compound annual growth rate of 87%, with limited incremental investment in our commercial infrastructure. Approximately 83,000 AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests were delivered in 2018, representing 18% growth over 2017, and the number of ordering physicians reached 1,298 in the fourth quarter of 2018, representing 18% growth over the same
quarter in 2017. In the first half of 2019, 50,792 AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests were delivered, representing approximately 30% growth over the same period in 2018, and the number of ordering physicians in
the first half of 2019 reached 1,711. More than 326,000 AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests have been delivered since launch, and in the first half of 2019, we achieved a record number of 766 adopting physicians
(defined as those who had previously prescribed at least 11 tests in a quarter) compared to 635 in the same period in 2018. Revenue growth for our testing products will depend on our ability to continue to expand our base of ordering physicians and
increase our penetration with existing physicians. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Reimbursement For Our Testing Products</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Our revenue depends on achieving broad
coverage and reimbursement for our tests from third-party payers, including both commercial </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
and government payers such as Medicare. Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a &#147;participating provider&#148; or do
not have a contract and are considered a <FONT STYLE="white-space:nowrap">&#147;non-participating</FONT> provider.&#148; Payers will often reimburse <FONT STYLE="white-space:nowrap">non-participating</FONT> providers, if at all, at a lower amount
than participating providers. We have received a substantial portion of our revenue from a limited number of third-party commercial payers, most of which have not contracted with us to be a participating provider. Historically, we have experienced
situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to
recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only
covered indications.&nbsp;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective
reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Promotion of SIMPONI</I></B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>.&nbsp;&nbsp;&nbsp;&nbsp;We
only recently began promoting SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States under the Janssen agreement. We may encounter difficulties in successfully promoting SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and generating significant revenue under the agreement. Our ability to effectively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> will require us to be successful in a
range of activities, including training and deploying additional sales representatives and creating demand for SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> through our own sales activities as well as those of Janssen. Based on
our estimate of the total U.S. addressable market for SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#146;s approved indications of $28&nbsp;billion, each incremental 1% market share we are able to capture for SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> above the predetermined baseline under the Janssen Agreement could result in incremental revenue to us of $84&nbsp;million. However, it may take longer to generate meaningful revenue than we
currently expect and we may not be successful in materially increasing market share, which would cause us to continue to rely on our existing testing products to drive revenue growth. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Development of Additional Testing Products.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We rely on sales of our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD test to generate the significant majority of our revenue. We recently launched AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP and AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> PC4d. We expect to continue to invest in research and development in order to develop additional testing products and expect these costs to increase. Our success in developing new testing
products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Margin Expansion</I></B><I></I>.&nbsp;&nbsp;&nbsp;&nbsp;We believe growth in our promotion of therapeutics will
meaningfully improve our margin profile and further support our goal of achieving profitability. We also expect an increase to our gross margins in January 2020 onwards upon the expiration of a 10% annual royalty on our <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> technology. In addition, we believe we are well positioned to drive further margin expansion through a continued focus on increasing operating leverage through the implementation of certain internal
initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payer coverage of our testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and
automation in our clinical laboratory to reduce material and labor costs. However, these potential margin increases may be partially offset by expected decreases in Medicare reimbursement rates as a result of PAMA. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Timing of Our Research and Development Expenses</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Our spending on experiments and
clinical studies may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and
development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
affect our financial results. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support
our commercialized AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various
expenses. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>How We Recognize Revenue</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Through December&nbsp;31, 2017, we recognized revenue
related to billings to payers on an accrual basis, net of contractual adjustments, only when we had established pricing with our payers as indicated by contractual pricing arrangements or when we had been able to demonstrate that a predictable
pattern of payment for our services exists. For the year ended December&nbsp;31, 2017, revenue was recognized on an accrual basis for one payer, Medicare, and totaled $8.2&nbsp;million. In the absence of a predictable pattern of reimbursement or a
contract with a payer, revenue was recognized upon cash receipt. Effective January&nbsp;1, 2018, we began recognizing revenue in accordance with the provisions of Accounting Standards Codification, or ASC, Topic 606, <I>Revenue from Contracts
with</I> <I>Customers. </I>We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payer. Changes to
such estimates may increase or decrease revenue recognized in future periods. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While each of these areas present significant
opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Janssen Promotion Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2018, we entered
into a <FONT STYLE="white-space:nowrap">co-promotion</FONT> agreement with Janssen, under which we are responsible for the costs associated with our sales force in promoting SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the
United States. Janssen is responsible for all other costs associated with our promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> under the Janssen agreement. In exchange for our sales and
<FONT STYLE="white-space:nowrap">co-promotional</FONT> services, we are entitled to a quarterly tiered promotion fee ranging from $750 to $1,250 per prescription based on the incremental increase in total prescribed units of SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for that quarter over a predetermined baseline. The predetermined average baseline for the initial term of 18 months is approximately 29,000 prescribed units per quarter, subject to adjustment
under certain circumstances. The term of the agreement expires on June&nbsp;30, 2020, unless extended by us for an additional 18 months upon 180 days written notice prior to the end of the initial term. Janssen can terminate the agreement at any
time for any reason upon 30 days&#146; notice to us, and we can terminate the agreement for any reason at the end of any calendar quarter upon 30 days&#146; notice to Janssen. Either party may terminate the agreement in the event of the other
party&#146;s default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We recognized co-promotional revenue of approximately $404,000 during the six months ended June&nbsp;30, 2019 and expect to continue to recognize
revenue as we perform co-promotional services based on the number of total prescribed units of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> over the predetermined baseline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Financial Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revision of Previously issued Financial Statements for Correction of Immaterial Errors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2019, we identified immaterial misstatements in the financial statements for the year ended December&nbsp;31, 2018 related to the carrying value
of redeemable convertible preferred stock warrant liabilities. These amounts have been adjusted in the accompanying financial statements. See Note&nbsp;16 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to our audited financial statements for a summary of the amounts and financial statement line items impacted by the revision. All amounts set forth in the discussion and year ended
December&nbsp;31, 2018 have been adjusted to reflect these revisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products and to whom results are reported are generally not
responsible for payment for these products. The parties that pay for these services, or payers, consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e. hospitals, other laboratories, etc.), and
patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Through December&nbsp;31, 2017, we recognized revenue related to billings to payers on an accrual basis, net of contractual adjustments, only when we
had established pricing with our payers as indicated by contractual pricing arrangements or when we had been able to demonstrate that a predictable pattern of payment for our services exists. For the year ended December&nbsp;31, 2017, revenue was
recognized on an accrual basis for one payer, Medicare, and totaled $8.2&nbsp;million. In the absence of a predictable pattern of reimbursement or a contract with a payer, revenue was recognized upon cash receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective January&nbsp;1, 2018, we began recognizing revenue in accordance with the provisions of ASC Topic 606, <I>Revenue from Contracts with
Customers. </I>We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payer. These assessments require
significant judgment by management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current
and future testing products, and increase our reimbursement and collection rates for tests delivered, as well as our ability to successfully promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Costs of Revenue (Excluding Amortization of
Purchased Technology) </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our
costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated
overhead, including rent and utilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each payer, commercial third-party, government, or individual, reimburses us at different amounts. These
differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payers for each month&#146;s billings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect that our costs of revenue will increase in absolute dollars as the number of tests we perform increases. However, we expect that the cost per
test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Selling, General and Administrative Expenses </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Selling,
general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology,
depreciation and utilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect that our selling, general and administrative expenses will increase in absolute dollars as
we expand our sales and sales support functions, including expansion activities related to our promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We also expect our selling, general and administrative expenses will
increase because of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance, investor relations activities and other administrative and professional services
such as accounting, legal, regulatory and tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses include costs incurred to develop our technology, testing products and product candidates, collect clinical specimens
and conduct clinical studies to develop and support our testing products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated
with setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect that our research and development expenses will increase in absolute dollars as we continue to invest in research and development activities
related to our existing testing products and product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Amortization of Intangible Assets </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Amortization of intangible assets represents the total amortization expense for our purchased technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The intangible assets recorded as of December&nbsp;31, 2017 became fully amortized in 2018; accordingly, we do not expect any future amortization
expense related to these assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Change in Fair Value of Acquisition-Related Liabilities </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc., or Cypress, in 2010, we were assigned certain
agreements with Royalty Pharma. We initially agreed to pay an additional amount not to exceed $9.0&nbsp;million in the event specified revenue, contractual and product launch milestones were achieved. In February 2017, we amended two of the
remaining agreements for which a contingent payment amount had been originally agreed to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not expect any further fair value adjustments for
these acquisition-related liabilities as the one remaining milestone is not expected to be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest expense consists of cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense associated with our financing arrangements,
including the borrowings under our current loan agreement with Innovatus and our prior term loan agreement, or the 2013 Term Loan, with Capital Royalty Partners II, L.P. and its affiliates, collectively referred to as Capital Royalty, which was
repaid in September 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect interest expense to increase in 2019 due to the draws we made under our loan agreement and to decrease in years
thereafter due to lower interest rates and lower outstanding principal balances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Loss on Extinguishment of Share Purchase Rights and 2013 Term Loan
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2016 and 2017, we entered into agreements with existing stockholders of our redeemable convertible preferred stock that contained future
purchase obligations that were required to be accounted for as liabilities and remeasured to fair value at each reporting date, with any change in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
fair value reported as a component of other income (expense). In May 2017, we completed the first closing of the sale of our Series F redeemable convertible preferred stock which resulted in the
conversion of all outstanding share purchase rights. We remeasured the share purchase right liabilities to fair value on the date of conversion and the difference between the fair value of the shares of Series F redeemable convertible preferred
stock received and the sum of the cash proceeds received and the fair value of the outstanding share purchase and tranche participation rights resulted in the recognition of a loss on extinguishment of the outstanding share purchase rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2017, we repaid our 2013 Term Loan with Capital Royalty and incurred a loss on the extinguishment of debt related to the unamortized
portion of the of the placement fees and the capitalized value of the warrants associated with the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We did not have any similar transactions
in 2018 or the six months ended June&nbsp;30, 2019 and accordingly, there were no similar charges in 2018 or the first half of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Change in Fair Value of
Financial Instruments </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As discussed above, we remeasured the share purchase right liabilities to fair value on the date of the conversion to
shares of Series F redeemable convertible preferred stock and reclassified the liabilities to permanent equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we classify our
outstanding warrants to purchase shares of our redeemable convertible preferred stock as liabilities on our balance sheets at their estimated fair value since the underlying redeemable convertible preferred stock was classified as temporary equity.
At the end of each reporting period, changes in the estimated fair value during the period are recorded as a component of other income (expense). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The outstanding warrants to purchase shares of our Series D and E redeemable convertible preferred stock will terminate if not exercised prior to the
completion of this offering and will no longer be subject to measurement once exercised or terminated. The outstanding warrants to purchase shares of our Series F redeemable convertible preferred stock will convert into warrants to purchase shares
of our common stock in connection with the completion of this offering and will no longer be subject to measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other income, net, consists primarily of interest income earned on our cash and cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Tax (Benefit) Expense </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Income taxes include
federal and state income taxes in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2018 and 2019: </I></B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited, in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Revenue
increased $5.2&nbsp;million, or 35.4%, for the six months ended June&nbsp;30, 2019 compared to the six months ended June&nbsp;30, 2018, primarily due to an increase in the number of diagnostic tests delivered and an increase in the average
reimbursement per test. The number of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests, which accounted for 83% and 86% of revenue in the six months ended June&nbsp;30, 2019 and 2018, respectively, increased to 50,792 tests
delivered in the six months ended June&nbsp;30, 2019 compared to 39,134 tests delivered in the same 2018 period. The increase is primarily due to the increased adoption of the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD test
by rheumatologists as the number of ordering physicians increased to 1,711 in the six months ended June&nbsp;30, 2019 as compared to 1,454 physicians in the same 2018 period. In addition, our average reimbursement per AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD test increased to approximately $325 per test delivered in the six months ended June&nbsp;30, 2019 from approximately $308 per test delivered in the same 2018 period, an increase of
approximately 6%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we began co-promoting SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in early 2019 and recognized
approximately $404,000 of revenue during the six months ended June 30,2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Costs of Revenue (excluding amortization of purchased technology) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs of revenue increased $1.9&nbsp;million, or 25.4%, for the six months ended June&nbsp;30, 2019 compared to the six months ended June&nbsp;30, 2018.
This increase was primarily due to increased direct costs such as materials and supplies and royalties associated with the increase in test volume in 2019 compared to 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Selling, General and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Selling,
general and administrative expenses increased $4.0&nbsp;million, or 42.1%, for the six months ended June&nbsp;30, 2019 compared to the six months ended June&nbsp;30, 2018. This increase was primarily due to increased employee related expenses as a
result of increasing the size of our sales force from 29 at March 31, 2018 to 53 at June&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses remained relatively consistent for the six months ended June&nbsp;30, 2019 compared to the six months ended
June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amortization of Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our purchased intangible assets were fully amortized at December 31, 2018, therefore there is no amortization expense recorded for the six months ended
June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest
expense increased $0.4&nbsp;million, or 29.9%, for the six months ended June&nbsp;30, 2019 compared to the six months ended June&nbsp;30, 2018. This increase was primarily due to higher principal amounts outstanding at June&nbsp;30, 2019 under our
long-term borrowing arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Change in Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The change in the fair value of financial instruments was a benefit of $0.5&nbsp;million for the six months ended June 30, 2019 and resulted from changes
in the valuation of our redeemable convertible preferred stock warrant liabilities. There was no such change in valuation for the six months ended June 30, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Income, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other income, net, remained
relatively consistent for the six months ended June&nbsp;30, 2019 compared to the six months ended June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended
December&nbsp;31, 2017 and 2018: </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(As Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general&nbsp;and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of acquisitions-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,880</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on extinguishment of share purchase rights and 2013 Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Revenue increased $5.6 million, or 21.0%, for the year ended December 31, 2018 compared to the year ended December 31, 2017, primarily due to an increase
in the number of diagnostic tests delivered and the adoption of ASU 2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>, offset by a 5.7% decrease in the average reimbursement per test. The number of AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests, which accounted for 82% and 89% of revenue in the year ended December 31, 2018 and 2017, respectively, increased to 82,657 tests delivered in the year ended December 31, 2018 compared
to 70,138 tests delivered in the same 2017 period. The increase is primarily due to the increased adoption of our products by rheumatologists as the number of ordering physicians increased to 1,298 in the fourth quarter of 2018 as compared to 1,098
physicians in the same 2017 period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The adoption of ASU 2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>, represented an increase
in revenue for the year ended December 31, 2018 of approximately $1.5 million as this adoption resulted in an acceleration of revenue recognition since we were required to estimate consideration to which we expect to be entitled rather than record
revenue on the cash basis as we had previously done for all but one customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Costs of Revenue (excluding amortization of purchased technology) </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs of revenue increased $1.2 million, or&nbsp;8.8%, in the year ended December&nbsp;31, 2018 compared to the year ended December&nbsp;31, 2017. This
increase was primarily due to&nbsp;increased direct costs such as materials and supplies and royalties associated with the increase in test volume in 2018 compared to 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Selling, General and Administrative Expenses </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Selling,
general and administrative expenses increased $0.9 million, or&nbsp;4.5%, in the year ended December&nbsp;31, 2018 compared to the year ended December&nbsp;31, 2017. This increase was primarily due to&nbsp;increased employee related expenses of $0.4
million, increased audit and legal fees of $0.4 million and increased facility related expenses of $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Expenses
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses increased $0.6 million, or&nbsp;37.0%, in the year ended December&nbsp;31, 2018 compared to the year ended
December&nbsp;31, 2017. This increase was primarily due to&nbsp;increased clinical trial expenses related to the initiation of our CARE for Lupus randomized multi-site study in 2018 of $0.4 million, increased employee related expenses of $0.1
million and increased professional service fees of $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amortization of Intangible Assets </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Amortization of intangible assets remained relatively consistent for the year ended December&nbsp;31, 2018 compared to the year ended December&nbsp;31,
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Change in Fair Value of Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The change in fair value of acquisition-related liabilities remained relatively consistent for the year ended December&nbsp;31, 2018 compared to the year
ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest expense remained relatively consistent for the year ended December&nbsp;31, 2018 compared to the year ended December&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Loss on Extinguishment of Share Purchase Rights and 2013 Term Loan </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The loss on extinguishment of share purchase rights and 2013 Term Loan decreased $6.1&nbsp;million, or 100%, in the year ended December&nbsp;31, 2018
compared to the year ended December&nbsp;31, 2017, as there were no similar charges in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Change in Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The change in fair value of financial instruments decreased $9.1&nbsp;million, or 96.6%, in the year ended December&nbsp;31, 2018 compared to the year
ended December&nbsp;31, 2017. This decrease was primarily due to&nbsp;the conversion of all outstanding share purchase rights in the year ended December&nbsp;31, 2017 thereby eliminating these items from being remeasured in the year ended
December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Income, Net </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other
income, net, remained relatively consistent for the year ended December&nbsp;31, 2018 compared to the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Tax (Benefit)
Expense </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Income tax expense increased $0.6&nbsp;million in the year ended December&nbsp;31, 2018 compared to the year ended December&nbsp;31,
2017. The income tax benefit in the year ended December&nbsp;31, 2017 resulted from the impacts of The Tax Cuts and Job Act enacted in December 2017 with no additional impact in the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have incurred net losses
since our inception. For the years ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2019, we incurred a net loss of $25.6&nbsp;million, $8.0&nbsp;million (as revised) and $5.5&nbsp;million, respectively, and we expect to
incur additional losses and increased operating expenses in future periods. As of June&nbsp;30, 2019, we had an accumulated deficit of $158.1&nbsp;million. To date, we have generated only limited revenue, and we may never achieve revenue sufficient
to offset our expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since inception and through June&nbsp;30, 2019, our operations have been financed primarily by net proceeds of
approximately $161.1&nbsp;million from sales of our equity and borrowings under various debt financings and revenue from the sales of our products. As of June&nbsp;30, 2019, we had $16.2&nbsp;million of cash and cash equivalents. In addition, in
July 2019, we raised gross proceeds of approximately $11.0&nbsp;million through the sale of our Series&nbsp;H redeemable convertible preferred stock. Cash in excess of immediate requirements is invested in accordance with our investment policy,
primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2017, we
entered into the loan agreement with Innovatus, under which we immediately drew down $20.0&nbsp;million. In December 2018, we borrowed an additional $5.0&nbsp;million under the loan agreement. The loan term is for five years with a final maturity
date of September 2022. The loan accrues interest at an annual rate of 11%, of which 2.5%, during the first 24 months, will be treated as paid in kind interest. Paid in kind interest is added to the principal balance each period. After the initial
24 months of the loan, the entire 11% will be paid in cash at the end of each period. We may, at our option, prepay the term loan borrowings by paying the lender a prepayment premium, which expires in October 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our obligations under the loan agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The
loan agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain certain levels </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of minimum liquidity (in specified instances, is either $2.0&nbsp;million or the trailing four months of cash used to fund operating activities) and achieve certain minimum amounts of revenue and
either gross margins or gross profits, and limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock,
repurchase stock and make investments, in each case subject to certain exceptions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the execution of the loan agreement, we
issued the lender a seven-year warrant to purchase 15,384,615 shares of our Series&nbsp;F redeemable convertible preferred stock at an exercise price of $0.078&nbsp;per share, and in December 2018, in connection with the additional $5.0 million
borrowed under the loan agreement, we issued to the lender a seven-year warrant to purchase 3,846,154 shares of our Series F redeemable convertible preferred stock at an exercise price of $0.078 per share. These warrants will become exercisable for
an aggregate of 104,722&nbsp;shares of our common stock upon the completion of this offering at an exercise price of $14.32&nbsp;per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Funding
Requirements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating
losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our costs of revenue, selling, general and administrative expenses, and research and development expenses will continue to
increase as we increase our test volume, expand our marketing efforts and increase our internal sales force to drive increased adoption of and reimbursement for our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products,
promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, prepare to commercialize new testing products, continue our research and development efforts and further develop our product pipeline. We expect that we will use a
substantial portion of the net proceeds of this offering, in combination with our existing cash and cash equivalents, for these purposes and for the increased expenses associated with being a public company. We believe we have sufficient laboratory
capacity to support increased test volume. Other than the addition of laboratory equipment, we expect that we will not need to make material capital expenditures in the near term related to our laboratory facilities. Cash used to fund operating
expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of
previously negotiated milestones associated with intellectual property we have licensed. Based on our current business plan, we believe that the estimated net proceeds from this offering, together with our existing cash and cash equivalents and our
anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our estimate of the
period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to maintain and grow sales of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fluctuations in working capital; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with our promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, including the
expansion of our sales capabilities, and the extent and timing of generating revenue from such promotion; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future
validation studies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payers and
adequate market share and revenue for our testing products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the additional costs we may incur as a result of operating as a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we establish additional partnerships or <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or
invest in complementary businesses or products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Until such time, if ever, as we can generate revenue to support our costs
structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding
is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or
achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development
programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our relationships with parties such as
Janssen. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cash Flows </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our cash flows for
the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cash Flows from Operating Activities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash used in operating activities for the six months ended June&nbsp;30, 2018 was $5.4&nbsp;million and primarily resulted from our net loss of
$4.9&nbsp;million adjusted for non-cash charges of $1.0&nbsp;million for depreciation, amortization, stock-based compensation and non-cash interest and changes in our net operating assets of $1.5&nbsp;million related to net decreases in accounts
payable and accrued liabilities. Net cash used in operating activities for the six months ended June&nbsp;30, 2019 was $4.1&nbsp;million and primarily resulted from our net loss of $5.5&nbsp;million adjusted for net non-cash charges of
$0.8&nbsp;million related to depreciation, amortization, stock- based compensation, non-cash interest and the revaluation of our preferred stock liabilities, and changes in our net operating assets of $0.6&nbsp;million related to net increases in
accounts payable, and accrued liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash used in operating activities for the year ended December&nbsp;31, 2017 was $11.0&nbsp;million
and primarily resulted from our net loss of $25.6&nbsp;million adjusted for non-cash charges of $9.4&nbsp;million for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
remeasurements of financial instruments, $6.1&nbsp;million for losses on extinguishment of the 2013 Term Loan and share purchase rights, and $1.7&nbsp;million for depreciation, amortization and
non-cash interest, all partially offset by a cash payment of accrued paid in-kind, or PIK, interest of $2.3&nbsp;million associated with the extinguishment of the 2013 Term Loan. Net cash used in operating activities for the year ended
December&nbsp;31, 2018 was $9.3&nbsp;million and primarily resulted from our net loss of $8.0&nbsp;million (as revised) adjusted for non-cash charges of $0.3&nbsp;million (as revised) for remeasurements of financial instruments and $1.8&nbsp;million
for depreciation, amortization and non-cash interest, partially offset by changes in our net operating assets consisting of a $2.3 million increase in accounts receivable primarily due to the adoption of ASC 606 and $1.3&nbsp;million related to net
increases in prepaid expenses and other current assets, accounts payable, and accrued liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cash Flows from Investing Activities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash used in investing activities for the six months ended June&nbsp;30, 2018 was $2.1&nbsp;million and was due to purchases of short-term
investments of $2.0&nbsp;million and purchases of property and equipment of $0.1&nbsp;million. Net cash used in investing activities for the six months ended June&nbsp;30, 2019 was $0.1&nbsp;million and was due to net purchases of property and
equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash used in investing activities for the years ended December&nbsp;31, 2017 and 2018 was $0.5&nbsp;million and $0.2&nbsp;million,
respectively, and were primarily due to purchases of property and equipment in both periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cash Flows from Financing Activities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities for the six months ended June&nbsp;30, 2018 and 2019 was $2.7&nbsp;million and $7.3&nbsp;million, respectively,
and primarily resulted from net proceeds received from the issuance of our redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash provided by financing
activities was $19.2 million for the year ended December&nbsp;31,&nbsp;2017 and primarily resulted from $14.6 million of net proceeds received from the issuance of our redeemable convertible preferred stock and stock purchase rights and net proceeds
of $4.5 million from refinancing our long-term borrowing arrangement. Net cash provided by financing activities was $11.4 million for the year ended December&nbsp;31,&nbsp;2018 and primarily resulted from $6.5 million of net proceeds received from
the issuance of our redeemable convertible preferred stock and net proceeds of $5.0 million under our long-term borrowing agreement with Innovatus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual
Obligations and Other Commitments </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our contractual obligations as of December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments&nbsp;Due&nbsp;by&nbsp;Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less</B><br><B>Than&nbsp;1<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;to&nbsp;5</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More</B><br><B>Than&nbsp;5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Contractual obligations:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating leases<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017 Term Loan<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Non-cancelable purchase obligations<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total contractual obligations:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We lease approximately 33,500 square feet of office and laboratory space in Vista, California, under leases that expire in
2021, with options to extend the leases for an additional 24-month or <FONT STYLE="white-space:nowrap">36-month</FONT> period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We will make principal and interest payments to Innovatus in accordance with the required payment schedule for the 2017
Term Loan. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents the minimum annual purchase commitment for one supplier. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The contractual obligations table does not include any additional potential contingent payments upon the future achievement by us of specified
sales-based and other milestones, or royalty payments we may be required to make under license agreements we have entered into pursuant to which we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> certain intellectual property, including our
license agreements with the University of Pittsburgh, Prometheus and Dr.&nbsp;Dervieux. See the section entitled &#147;Business&#151;Intellectual Property Overview&#151;License Agreements&#148; and Note 8 to our audited financial statements included
elsewhere in this prospectus for additional information. The timing of when these additional payments will actually be made is uncertain and the payments are contingent upon the completion of future activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Significant Management Estimates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our audited financial statements, which
have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these audited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the date of the audited financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our
historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical
and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue Recognition
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, substantially all of our revenue has been derived from sales of our testing products. We primarily market our testing products to
rheumatologists and their physician assistants in the United States. The healthcare professionals who order our services and to whom test results are reported are generally not responsible for payment for these services. The parties that pay for
these services consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e. hospitals, other laboratories, etc.) and patient self-pays. Through December&nbsp;31, 2017, we recognized revenue when the
following criteria was met (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery occurred or services have been rendered; (iii)&nbsp;the fee is fixed and determinable; and (iv)&nbsp;collectability is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our service is completed upon the delivery of test results to the prescribing rheumatologist which triggers billing for the service. Prior to January 1,
2018, we recognized revenue related to billings to payers on an accrual basis, net of contractual adjustments, only when we had established pricing with our third-party payers as indicated by contractual pricing arrangements or predictable patterns
of payment for our services. In the absence of a predictable pattern of reimbursement or a contract with a payer, revenue was recognized upon cash receipt. For the year ended December&nbsp;31, 2017, revenue was recognized on an accrual basis for one
payer, Medicare, and totaled $8.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January&nbsp;1, 2018, we early adopted ASC Topic&nbsp;606, <I>Revenue from Contracts with
Customers, </I>and began recognizing revenue in accordance with the provisions thereof<I>. </I>Our service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue
recognition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Payers are billed at our list price. Net revenues recognized consist of amounts billed net of
allowances for differences between amounts billed and the estimated consideration we expect to receive from such payers. We follow a standard process, which considers historical denial and collection experience, insurance reimbursement policies and
other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction
price is estimated using an expected value method on a portfolio basis. Our portfolios are grouped per payer (i.e. each individual third party insurance, Medicare, client payers, patient self-pay, etc.) and per test basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Collection of our net revenues from payers is normally a function of providing complete and correct billing information to the healthcare insurers and
generally occurs within 30 to 90 days of billing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The process for estimating revenues and the ultimate collection of accounts receivable involves
significant judgment and estimation by management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2018, we entered into the Janssen agreement to co-promote SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States. We are responsible for the costs associated with our sales force over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization
of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> under the Janssen agreement. In exchange for our sales and co-promotional services, we are entitled to a tiered promotion fee ranging from $750 to $1,250 per prescription based on
the incremental increase in total prescribed units of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for that quarter over a predetermined baseline. The predetermined average baseline for the initial term of 18 months is
approximately 29,000 prescribed units per quarter, subject to adjustment under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our obligations relating to sales and
co-promotion services for SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a series of single performance obligations since Janssen simultaneously receives and consumes the benefits provided by our sales and co-promotional
services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. As of December
31, 2018, there were no performance obligations under the agreement and no consideration had been received. We began co-promoting SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in early 2019 and recognized revenue of approximately
$404,000 during the six months ended June 30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Long-lived Assets </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our long-lived assets are comprised principally of our property and equipment, finite lived intangible assets, and goodwill. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We amortize all finite lived intangible assets over their respective estimated useful lives. In considering whether intangible assets are impaired, we
combine our intangible assets and other long-lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test offered by us or technology we are
developing. If we identify events or circumstances indicate that the associated carrying amount of assets within a group may not be recoverable, we will consider the assets in the group impaired if the carrying value of the group&#146;s assets and
directly associated liabilities exceed the estimated cash flows expected to be generated over the estimated useful life of the assets in the group. Management&#146;s estimates of future cash flows are impacted by projected levels of tests and levels
of reimbursement, as well as expectations related to the future cost structure of the entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Goodwill is not amortized but is tested for
impairment at least annually or more frequently whenever a triggering event or change in circumstances occurs, at the reporting unit level. For our goodwill impairment analysis, we operate in a single reporting unit, and allocate all goodwill to
this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reporting unit. We are required to recognize an impairment charge if the carrying amount of the reporting unit exceeds its fair value. Management first assesses qualitative factors to determine
whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If a quantitative assessment is deemed necessary,
management uses all available information to make this fair value determination, including the present values of expected future cash flows using discount rates commensurate with the risks involved in the assets and observed market multiples of
operating cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The judgments and estimates involved in identifying and quantifying the impairment of long-lived assets or goodwill involve
inherent uncertainties, and the measurement of the fair value is dependent on the accuracy of the assumptions used in making the estimates and how those estimates compare to our future operating performance. No goodwill impairments were recorded
during the years ended December&nbsp;31, 2017 and 2018 or the six months ended June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, our
stock price and associated market capitalization will also be considered in the determination of reporting unit fair value. A prolonged or significant decline in our share price could provide evidence of a need to record a material impairment of
goodwill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We recognize
compensation expense related to stock-based awards to employees and directors based on the estimated fair value of the awards on the date of grant over the requisite service period of the awards (usually the vesting period) on a straight-line basis.
The grant date fair value, and the resulting stock-based compensation expense, is estimated using the Black-Scholes option pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of
the respective award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We recorded stock-based compensation expense of approximately $187,000, $114,000, $90,000 and $23,000 for the years ended
December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019, respectively. We expect to continue to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation
expense recognized in future periods will likely increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Black-Scholes option pricing model requires the use of highly subjective and complex
assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share attributable to common stockholders could have been significantly
different. See Notes 2 and 12 to our audited financial statements included elsewhere in this prospectus for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the
estimated fair value of our stock options granted in the years ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations. Our
board of directors, with the assistance of management, determined the fair value of our common stock on each grant date. All options to purchase shares of our common stock are intended to be granted with an exercise price per share no less than the
fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because there has been no public market for our common stock, the fair value of the common stock that
underlies our stock options has historically been determined by our board of directors based upon information available to it at the time of grant, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">contemporaneous valuations performed by independent third-party firms; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">rights, preferences and privileges of our common stock compared to the rights, preferences and privileges of our other
outstanding equity securities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our current and projected operating and financial performance, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trends and developments in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the likelihood of achieving a liquidity event for the shares of common stock, such as an initial public offering or an
acquisition of our company given prevailing market and sector conditions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the illiquidity of our securities by virtue of being a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the valuation of publicly traded companies in our sector, as well as recently completed initial public offerings and
mergers and acquisitions of comparable companies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">stage of development; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">U.S. and global economic and capital market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The valuations of our common stock were prepared in accordance with the guidelines outlined in the American Institute of Certified Public Accountants
Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation, </I>or the Practice Aid, which prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market
approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional
or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of our company&#146;s future operations, discounting to the present value
with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. Each valuation methodology
was considered in our valuations. In determining a fair value for our common stock, we estimated the enterprise value of our business using either the market approach or income approach. In 2017 and 2018, we concluded that the market approach was
the most appropriate. In accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at each valuation date.
Until December 2018, we concluded that the Option Pricing Method, or OPM, was most appropriate for each of the valuations of our common stock performed by independent third-party valuation specialists. We believed the OPM was the most appropriate
given the expectation of various potential liquidity outcomes and the difficulty of selecting and supporting appropriate enterprise values given our early stage of development. Under the OPM, shares are valued by creating a series of call options
with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options. In December 2018, we changed to a Probability-Weighted
Expected Return Method, or PWERM, for estimating enterprise value given the increased probability of an initial public offering liquidity scenario. The PWERM is a scenario-based analysis that estimates the value per share based on the
probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we had made different assumptions than those used, the amount of our stock-based compensation expense, net loss and net loss per share attributable
to common stockholders could have been significantly different. Following the completion of this offering, the fair value per share of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
our common stock for purposes of determining stock-based compensation expense will be the closing price of our common stock as reported on the applicable grant date on the primary stock exchange
on which our common stock is traded. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the assumed initial public offering price of&nbsp;$15.00&nbsp;per share, the midpoint of the
price range set forth on the cover page of this prospectus, the intrinsic value of stock options outstanding as of June&nbsp;30, 2019 would be $9.5&nbsp;million, of which approximately $20,000 and $9.5&nbsp;million would have been related to stock
options that were vested and unvested, respectively, at that date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Estimated Fair Value of Share Purchase Rights, Redeemable Convertible Preferred Stock
Warrants and Other Financial Instruments </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time, we enter into agreements with existing stockholders of our redeemable
convertible preferred stock that contain future purchase obligations of redeemable convertible preferred stock at a fixed price. We evaluate these share purchase right agreements and assess whether they meet the definition of a freestanding
instrument and, if so, determine the fair value of the share purchase right liability and record it on the balance sheet. The share purchase right liability is revalued at each reporting period with changes in the fair value of the liability
recorded as a component of other income (expense) in the statement of operations. The share purchase right liability is revalued at settlement and the resultant fair value is then reclassified to redeemable convertible preferred stock at that time.
The estimated fair value of the share purchase right liability is determined using valuation models that consider the probability of achieving the requisite milestones, our cost of capital, the estimated time period the preferred stock right would
be outstanding, consideration received for the convertible preferred stock, the number of shares to be issued to satisfy the preferred stock purchase right and at what price, and probability of the consummation of an initial public offering, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We account for our redeemable convertible preferred stock warrant liabilities as freestanding instruments for shares that are puttable
or redeemable. These warrants are classified as liabilities on our balance sheet and are recorded at their estimated fair values. At the end of each reporting period, changes in estimated fair value during the period are recorded as a component of
other income (expense), net in the accompanying statement of operations. We will continue to <FONT STYLE="white-space:nowrap">re-measure</FONT> the fair value of the warrant liabilities until: (i)&nbsp;exercise; (ii)&nbsp;expiration of the related
warrant; or (iii)&nbsp;conversion of the preferred stock underlying the security into common stock, which will occur in connection with the completion of this offering. We estimate the fair values of our warrant liabilities using an option pricing
model based on inputs as of the valuation measurement dates, including the fair value of our redeemable convertible preferred stock, the estimated volatility of the price of our redeemable convertible preferred stock, the expected term of the
warrants and the risk-free interest rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are significant judgments and estimates inherent in the determination of the fair values of our
preferred stock purchase right liabilities and redeemable convertible preferred stock warrant liabilities. If we had made different assumptions, the carrying value of these liabilities, net loss and net loss per share attributable to common
stockholders could have been significantly different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the acquisition of the medical diagnostics division of Cypress in 2010, we initially agreed to pay an additional amount not to exceed
$9.0&nbsp;million in the event specified revenue, contractual and product launch milestones are achieved. This contingent liability required the use of inputs which were not observable in the market to assess its fair value at the end of each
reporting period. For this liability, fair value was determined based on probabilities assigned to the milestones being achieved, revenue projections, and interest rates. Changes in fair value were recorded in the statement of operations and
comprehensive loss. In February 2017, we amended two of the remaining agreements for which a contingent payment amount had been originally agreed to. One contingent payment amount remains outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We operate in, and are subject to tax authorities in, various tax jurisdictions in the United States. To date, we have not been audited by the Internal
Revenue Service or any state income tax authority, however all tax years remain open for examination by federal tax authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At
December&nbsp;31, 2018, our deferred tax assets are primarily comprised of federal and state tax net operating loss carryforwards. We have performed an analysis to determine whether an &#147;ownership change&#148; occurred from inception to
December&nbsp;31, 2013. Based on this analysis, we determined that we did experience a historical ownership change of greater than 50% in 2008. Therefore, our ability to utilize our net operating losses incurred prior to this date is limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are required to reduce our deferred tax assets by a valuation allowance if it is more likely than not that some or all of our deferred tax assets
will not be realized. We must use judgment in assessing the potential need for a valuation allowance, which requires an evaluation of both negative and positive evidence. The weight given to the potential effect of negative and positive evidence
should be commensurate with the extent to which it can be objectively verified. In determining the need for and amount of our valuation allowance, if any, we assess the likelihood that we will be able to recover our deferred tax assets using
historical levels of income, estimates of future income and tax planning strategies. As a result of historical cumulative losses and uncertainties surrounding our ability to generate future taxable income and, based on all available evidence, we
believe it is more likely than not that our recorded net deferred tax assets will not be realized. Accordingly, we have recorded a valuation allowance against all of our net deferred tax assets at December&nbsp;31, 2018. We will continue to maintain
a full valuation allowance on our deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of this allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The above listing is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular
transaction is specifically dictated by GAAP. There are also areas in which our management&#146;s judgment in selecting any available alternative would not produce a materially different result. Please see our audited financial statements and notes
thereto included elsewhere in this prospectus, which contain accounting policies and other disclosures required by GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting
Standards </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2014, the FASB issued Accounting Standards Update, or ASU, <FONT STYLE="white-space:nowrap">2014-09,</FONT> <I>Revenue from
Contracts with Customers</I>, which, along with subsequent amendments and addenda to this standard, provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize
revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We elected to early adopt this guidance on
January&nbsp;1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and accounts receivable of $3.1 million. The cumulative-effect adjustment was the result of an acceleration of revenue recognition since we are
required to estimate consideration to which we expect to be entitled rather than record revenue on a cash basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2016, the FASB issued
ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> <I>Statement of Cash Flows (Topic&nbsp;230): Restricted Cash. </I>The amendments in this update require that a statement of cash flows explain the change during the period in the total of cash,
cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. As a result, companies will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the
statement of cash flows. We adopted this guidance for our fiscal year beginning January&nbsp;1, 2018 and adjusted the presentation of our Statement of Cash Flows to include our restricted cash balance with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
our non-restricted cash balances. Our restricted cash balance consists of a federally insured certificate of deposit held with an affiliate of a large publicly traded financial institution that
secures our corporate credit card program. Due to the duration of this certificate of deposit, the amounts restricted as to use have been classified outside of cash and cash equivalents. The adoption of this guidance did not have a material impact
on our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-04,</FONT> <I>Simplifying the Test for
Goodwill Impairment</I>. This guidance is intended to simplify the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in today&#146;s <FONT STYLE="white-space:nowrap">two-step</FONT>
impairment test under the guidance contained in ASC&nbsp;350. Specifically, this guidance eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record an impairment
charge based on the excess of a reporting unit&#146;s carrying amount over its fair value. We adopted this guidance on January&nbsp;1, 2018 and the adoption did not have a material impact on our financial statements since we completed a qualitative
assessment as of December 31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT><I> Leases</I><I></I><I> (Topic&nbsp;842)</I>. The new topic
supersedes Topic&nbsp;840, Leases, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In
July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-10,</FONT> <I>Codification Improvements to Topic&nbsp;842</I>, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU <FONT
STYLE="white-space:nowrap">2018-11,</FONT> <I>Leases: Targeted Improvements</I>, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption we will not restate comparative
periods presented in our financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&nbsp;15, 2018, and periods beginning after December&nbsp;15, 2019 for private companies. ASU <FONT
STYLE="white-space:nowrap">2016-02</FONT> mandates a modified retrospective transition method. We intend to adopt this new standard using a cumulative effect adjustment to accumulated deficit and will elect the package of practical expedients, which
among other things will allow us to carry forward our historical lease classification. We are currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2018, the FASB issued ASU No. 2018-13, <I>Fair Value Measurement: Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair
Value Measurement</I>, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&nbsp;1 and
Level 2 of the fair value hierarchy, or valuation processes for Level&nbsp;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop
Level&nbsp;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective for annual periods beginning after December&nbsp;15, 2019, and interim periods within those
periods, and early adoption is permitted. We are currently evaluating the impact of ASU&nbsp;2018-13 on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined under the rules and regulations of the
SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. As of June&nbsp;30, 2019, we had
cash and cash equivalents of $16.2&nbsp;million, which consist of bank deposits and money market funds. Such interest-bearing instruments carry a degree of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
risk; however, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the
periods presented would not have had a material impact on our audited financial statements. Our long-term debt bears interest at a fixed rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>JOBS Act
Accounting Election </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an &#147;emerging
growth company.&#148; The JOBS Act permits an &#147;emerging growth company&#148; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use
this extended transition period under the JOBS Act until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a
result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our
common equity securities pursuant to an effective registration statement under the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of such five-year period, including if we become a
&#147;large accelerated filer&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Exchange Act, our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Company Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Exagen is dedicated to transforming the
care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing
products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or <FONT STYLE="white-space:nowrap">CB-CAPs,</FONT> technology. <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal
is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Our strategy includes
leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions
us to offer targeted solutions to rheumatologists and, ultimately, better serve patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently market nine testing products under our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand, which we are leveraging to establish partnerships with leading pharmaceutical companies. In December 2018, we entered into a <FONT STYLE="white-space:nowrap">co-promotion</FONT> agreement
with Janssen Biotech, Inc., or the Janssen agreement, to exclusively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (golimumab), a subcutaneous, once-per-month, anti-tumor necrosis factor, or
<FONT STYLE="white-space:nowrap">anti-TNF,</FONT> biologic prescribed in combination with methotrexate, in the United States for the treatment of adult patients with moderate to severe RA and for other indicated rheumatic diseases. Combined U.S.
sales of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and SIMPONI ARIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, an intravenous formulation, were approximately $1.0&nbsp;billion in 2018, of which we estimate
approximately 50% was from sales of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We began direct promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in January 2019 and expanded our salesforce from
31&nbsp;representatives as of December 31, 2018 to 55 representatives in August 2019 to support these promotion efforts. Unlike many diagnostic salesforces that are trained only to understand the comparative benefits of their tests, the specialized
backgrounds of our salesforce coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with
rheumatologists. We therefore believe our strategy of integrating the promotion of testing products and therapeutics uniquely positions us to expand SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#146;s U.S. market share. We
expect our SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> promotion efforts to contribute incremental revenue in 2019 with our quarterly tiered promotion fee based on the incremental increase in total prescribed units above a
predetermined average baseline of approximately 29,000 prescribed units per quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe our strategy of integrating the promotion of
testing products and therapeutics differentiates us from other diagnostic and pharmaceutical companies, and provides our specialized salesforce greater access to rheumatologists. Our integrated testing and therapeutics strategy results in a unique
opportunity to promote targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and who have a history using our portfolio of testing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our lead testing product, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, enables differential diagnosis for patients presenting
with symptoms indicative of a wide variety of connective tissue diseases, or CTDs, and other related diseases with overlapping symptoms. The comprehensive nature of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD allows for the
testing of a number of relevant biomarkers in one convenient blood draw, as opposed to testing serially for individual biomarkers, which adds time and cost to the diagnostic process. We believe
AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD may provide clinical utility for over 23&nbsp;million patients in the United States suffering from these diseases, which include SLE, RA, Sj&ouml;gren&#146;s syndrome,
antiphospholipid syndrome, or APS, other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
autoimmune-related diseases such as autoimmune thyroid, and other disorders that mimic these diseases, such as fibromyalgia. There is an unmet need for rheumatologists to add clarity in their CTD
clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have demonstrated a strong track record of developing innovative testing products that meet the needs of diagnosing, prognosing and monitoring CTDs,
as illustrated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g692844g12z65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD leverages our proprietary <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> technology to enable the differential diagnosis SLE. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD provides rheumatologists and their patients with sensitive and specific results that
allow for potentially faster and more accurate differential diagnosis of SLE as compared to other currently-marketed testing methods. Beyond SLE, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD allows rheumatologists to
accurately diagnose other overlapping autoimmune and autoimmune-related diseases, including RA, with the same blood sample. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor testing product also leverages our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology by measuring two <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> biomarkers
that offer insight into a patient&#146;s disease activity. This test is designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Depending on disease severity, AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor may be utilized by patients multiple times a year throughout their lives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our <FONT
STYLE="white-space:nowrap">RA-focused</FONT> testing products include AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX and AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP. AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX is a drug monitoring test designed to aid in the optimization of methotrexate therapy, the standard of care and first-line therapy for patients with RA. AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX is based on our proprietary methotrexate polyglutamate, or MTXPG, technology that measures blood levels of MTXPGs, the active metabolite of methotrexate linked to disease control in RA
patients. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate enabling them to optimize dosing and achieve therapeutic levels commensurate with adequate disease control. AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP, which measures anti-carbamylated protein antibody, or anti-CarP, was developed by the Leiden </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
University Medical Center, and we recently introduced it as a biomarker-driven RA prognostic test through a distribution agreement with Inova Diagnostics, Inc. with the goal of identifying
patients prone to more severe disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We market our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>testing products using our specialized salesforce. Since the launch of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD in 2012 through December&nbsp;31, 2018, we have delivered
over 326,000 of these tests, representing a compound annual growth rate of 87%, with limited incremental investment in our commercial infrastructure. Approximately 83,000 AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests were
delivered in 2018, representing 18% growth over 2017, and the number of ordering physicians in the fourth quarter of 2018 reached 1,298, representing 18% growth over the same period in 2017. In the first half of 2019, 50,792 AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD tests were delivered, representing approximately 30% growth over the same period in 2018, and the number of ordering physicians in the first half of 2019 reached 1,711. In the first half of
2019, we achieved a record number of 766 adopting physicians, which we classify as those who had previously prescribed at least 11 tests in a quarter, compared to 635 in the same period in 2018. Nearly 100% of adopting physicians continue to order
tests in subsequent quarters. From launch of our direct promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in January 2019 to the end of the second quarter of 2019, weekly ordering from healthcare providers increased by
approximately 10% and total weekly prescriptions increased by approximately 17%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we continue to populate a growing proprietary
database of over 300,000 <FONT STYLE="white-space:nowrap">de-identified</FONT> patient test results. We believe the insight emerging from these results has the potential to unlock value for pharmaceutical and biotechnology companies in the
commercialization of therapeutics. We believe we also have the ability to further leverage our database to optimize patient selection in clinical trials for companies developing therapeutics for autoimmune and autoimmune-related diseases. We plan to
collaborate with our existing and future pharmaceutical and biotechnology partners to help maximize the full value of our <FONT STYLE="white-space:nowrap">in-house</FONT> database. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe our strategy of integrating the promotion of testing products and therapeutics differentiates us from other diagnostic and pharmaceutical
companies, and provides our specialized salesforce greater access to rheumatologists. Unlike many diagnostic salesforces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our salesforce
coupled with our comprehensive training enables our sales representatives to interpret results from our <FONT STYLE="white-space:nowrap">de-identified</FONT> test reports and provide unique insights in a highly tailored discussion with
rheumatologists. Our integrated testing and therapeutics strategy results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding
relationship and who have a history using our portfolio of testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We recently entered into the Janssen agreement for the promotion of
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in order to advance our integrated testing and therapeutics strategy. To support the <FONT STYLE="white-space:nowrap">co-promotion</FONT> of SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, we expanded our salesforce from 31 representatives as of December&nbsp;31, 2018 to 55 representatives in August 2019. This will enable us to conduct approximately 60,500 calls annually to
rheumatologists, which we believe will enable us to achieve the optimal reach and frequency with rheumatologists. We also have agreements with other leading pharmaceutical companies, including GlaxoSmithKline LLC, or GSK, and Horizon Pharma USA,
Inc., or Horizon Therapeutics, and Corrona, LLC, that leverage our testing products and the data generated from such tests. We provide GSK, a leader in lupus therapeutics, our test result data to provide market insight into and help increase
awareness of the benefits of an early and accurate diagnosis of SLE. Our agreement with Horizon Therapeutics entails utilizing our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX test to report on levels of MTXPG in patients
undergoing methotrexate therapy in combination with its anti-gout product KRYSTEXXA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in an ongoing Phase 4 clinical trial. We also provide Corrona, the operator of the largest real world
observational database in RA containing data from over 40,000 patients, with testing services and support. We plan to pursue additional partnerships with a focus on integrating therapeutics that are synergistic with our evolving portfolio of testing
products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are led by an experienced management team with unique capabilities to execute on our strategy of
integrating the promotion of testing products and therapeutics. Our senior management has an average of over 20&nbsp;years of experience in the healthcare industry and many were previously involved with successfully building Prometheus Laboratories
Inc., or Prometheus, which was focused on integrating diagnostics and therapeutics, prior to its acquisition by Nestl&eacute; Health Science S.A. in 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our
Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We develop and commercialize next-generation testing products and promote synergistic therapeutics to ultimately improve the continuum
of care for patients suffering from debilitating and chronic autoimmune diseases. The key tenets of our business strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Drive additional market penetration for our testing products.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our portfolio of testing
products enables the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. We have demonstrated a strong track record of commercial growth from our testing products, leveraging our specialized
salesforce and expansive network of relationships with rheumatologists across the United States. We believe we are uniquely positioned to continue expanding our commercial presence within the autoimmune disease market and plan to continue to invest
in our salesforce in order to achieve the optimal reach and frequency with rheumatologists. This will support our strategy of integrating the promotion of testing products and therapeutics. In addition, we will continue to expand our efforts in the
targeted promotion and education of rheumatologists and payers as to the clinical and cost benefits of our testing products. We believe these efforts will position us to capture additional market share for our portfolio of testing products.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Integrate the promotion of testing products and therapeutics for autoimmune and autoimmune-related
diseases.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Our integrated testing and therapeutics strategy leverages our sales and marketing efforts, targeting rheumatologists for the commercialization of our testing products to promote therapeutics. This
establishes a compelling synergy compared to traditional pharmaceutical sales resulting in greater access to rheumatologists and positions us to potentially create value for pharmaceutical partners. In January 2019, we began our exclusive promotion
of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States, leveraging our integrated testing and therapeutics strategy, for the treatment of adult patients with moderate to severe RA and for other indicated rheumatic
diseases. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Continue our track record of developing innovative testing products.</I></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Since
inception, we have demonstrated a strong track record of developing testing products that address the challenges in the differential diagnosis, prognosis and monitoring of patients with autoimmune and autoimmune-related diseases. We are leveraging
our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> and MTXPG technologies to develop additional testing products designed to have superior clinical utility for CTDs. We believe our commitment to innovating our portfolio of testing
products will further strengthen our relationships with rheumatologists and our value proposition to our existing and future pharmaceutical and biotechnology partners. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Establish additional therapeutic partnerships.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>We believe our agreements with Janssen
Biotech, Inc., or Janssen, and other leading pharmaceutical companies validate our unique value proposition to pharmaceutical companies seeking a competitive edge for commercializing therapeutics for autoimmune and autoimmune-related diseases. We
intend to leverage our integrated testing and therapeutics strategy to establish additional partnerships with a focus on the commercialization of therapeutics that are synergistic with our testing products. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Achieve meaningful margin expansion.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We believe growth from the promotion of
therapeutics will meaningfully improve our margin profile and further support our goal of achieving profitability. We also expect an increase to our gross margins in January 2020 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
onwards upon the expiration of a 10% annual royalty on our <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology. In addition, we believe we are well positioned to drive further margin
expansion through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payer coverage of our
testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and automation in our clinical laboratory to reduce material and labor costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Autoimmune and Connective Tissue Diseases </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Autoimmune
diseases encompass a broad range of serious, chronic and debilitating conditions in which a person&#146;s immune system creates antibodies that mistakenly react against normal healthy tissues causing inflammation and irreversible tissue damage.
These antibodies are called autoantibodies and their detection through blood tests can help diagnose, prognose and monitor the course of autoimmune diseases. However, knowing when and which autoantibody to test for is challenging due to the
vagueness of symptoms, the unexplained flaring and remission of symptoms, and the many conditions which can mimic autoimmune disease. Early and accurate diagnosis of the conditions causing these overlapping symptoms is critical as an incorrect
diagnosis can lead to toxicity from inappropriate medications, irreversible tissue damage and other comorbidities associated with uncontrolled disease. There is no known cause or cure for these chronic conditions and current treatment interventions
are targeted at managing symptoms and limiting disease progression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">CTDs are a <FONT STYLE="white-space:nowrap">sub-category</FONT> of autoimmune
diseases involving inflammation of the joints, tissues and internal organs. Persons with CTDs often present to their rheumatologist with complaints of joint pain, fatigue, unexplained fever, inflammation, rash, stiffness and muscle aches. These
symptoms overlap among numerous CTDs, including SLE, one of the most severe CTDs and historically difficult to rule out, as well as other autoimmune-related diseases and other disorders that mimic these diseases, such as fibromyalgia. Based on a
study we commissioned in 2014, we estimate that there are approximately 23&nbsp;million undiagnosed patients in the United States who are symptomatic of these conditions and who may benefit from the differential diagnosis of CTDs. Of these patients,
we estimate approximately seven million are potentially referable to rheumatologists and would be candidates for an AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD test, representing a total addressable market of approximately
$3.7&nbsp;billion, based on the current Medicare allowable reimbursement rate. We estimate the total addressable market for our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products to be approximately $5&nbsp;billion,
based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Systemic Lupus Erythematosus </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">SLE, the most common and severe form of lupus, is a chronic, inflammatory disorder that can damage any part of the body, including the skin, joints and
internal organs. The blood of a person afflicted with SLE contains autoantibodies, which are the cause of the inflammation and organ damage and are one indicator of immune system abnormalities. SLE is characterized by a rise in symptoms and/or
abnormal laboratory test results. SLE varies in severity, from mild cases to those in which significant and potentially fatal damage occurs to vital organs such as the brain, heart, kidneys and lungs. Detection of these autoantibodies can assist
rheumatologists in the diagnosis of SLE. Diagnosis of SLE allows rheumatologists to initiate the most appropriate therapy to minimize irreversible organ damage and reduce morbidity and mortality. Current treatment for SLE involves the use of
antimalarials, corticosteroids, immunosuppressants and biologic agents to prevent or suppress active disease or flares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Standard laboratory tests
for diagnosing SLE include measuring immunological biomarkers, such as antinuclear antibodies, or ANA, anti-double stranded DNA, or anti-dsDNA, and other autoantibody tests. ANA are a group of&nbsp;autoantibodies&nbsp;produced by a
person&#146;s&nbsp;immune system&nbsp;when it fails to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
adequately distinguish between self and <FONT STYLE="white-space:nowrap">non-self.</FONT> The ANA test detects these autoantibodies in the blood and is a useful screening tool for SLE and other
autoimmune and autoimmune-related diseases. The vast majority of SLE patients test positive for ANA. However, the high sensitivity of ANA for SLE is counterbalanced by somewhat poor specificity. Sensitivity measures the proportion of patients who
are correctly identified as having a particular condition, while specificity measures the proportion of patients who are correctly identified as not having a particular condition. Therefore, the majority of individuals who test positive for ANA do
not have SLE. Only approximately <FONT STYLE="white-space:nowrap">11-13%</FONT> of individuals with a positive ANA test have SLE. This lack of specificity leads to many inappropriate <FONT STYLE="white-space:nowrap">non-autoimmune</FONT> referrals
to the rheumatologist from primary care physicians. For example, it has been reported that 30% of fibromyalgia patients may test positive for ANA, potentially generating as many as four&nbsp;million inappropriate rheumatology referrals. In addition,
a study published in 2012 reported the estimated prevalence of a positive ANA test in the normal, healthy, U.S. population to be 13.8%, or 32&nbsp;million people, indicating a significant need for a highly-specific test for this disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Anti-dsDNA are autoantibodies that target a person&#146;s double stranded DNA. The anti-dsDNA antibody test is a very specific test for SLE as
anti-dsDNA antibodies are rarely found in autoimmune diseases other than SLE. A strongly positive anti-dsDNA antibody test makes it very likely that a person has SLE, although if the test is negative it does not necessarily rule out SLE.
Approximately <FONT STYLE="white-space:nowrap">30-70%</FONT> of people with SLE have a negative anti-dsDNA antibody test, reaffirming the need for an effective testing product which adds clarity to the rheumatologist&#146;s clinical assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Activation of the complement system is an integral part of the disease process of SLE. Thus, rheumatologists measure components of the complement
system, including serum levels of C3 and C4, to help diagnose SLE and monitor SLE disease activity. In 2012, the Systemic Lupus Collaborating Clinics added low C3 and low C4 as immunologic criteria for classifying SLE. In active SLE, C3 and C4
complement proteins are consumed and broken down to fragments, known as complement activation products. Therefore, low levels of C3 and C4 suggest a diagnosis of SLE and that the disease is active. However, variability in the levels of C3 and C4 can
occur due to factors unrelated to SLE disease presence or disease activity, making them less reliable as biomarkers for SLE. For example, C3 and C4 are acute phase reactants and produced during inflammation. As a result, many SLE patients have
normal complement levels even when the disease is active. Although relatively specific for SLE, low complement levels can also be seen in certain chronic infections, including <FONT STYLE="white-space:nowrap">non-lupus</FONT> related kidney
inflammation, severe liver disease and other autoimmune diseases. <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> are formed when the fragments of complement activation products from C4 bind permanently to circulating cells such as red blood cells, <FONT
STYLE="white-space:nowrap">b-cells</FONT> and platelets. This binding lasts for the life of the cell and represents a more stable and reliable indicator of complement activation than measuring C3 and C4 alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2011, the first new biologic drug targeting treatment of SLE in over 50&nbsp;years, GSK&#146;s Benlysta<SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-family:ARIAL; font-size:6.5pt">&reg;</FONT></SUP>, was approved by the U.S. Food and Drug Administration, or the FDA. It is the only approved biologic for the treatment of SLE. Since its
approval, there have been a number of drug development programs that have failed in SLE, which may suggest that guidelines for classifying SLE patients and the endpoints used to determine clinical effectiveness have not adequately addressed the
complexity of the disease process and its heterogeneous population. We believe biopharmaceutical companies would benefit from the differential diagnosis enabled by our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products
in order to better identify <FONT STYLE="white-space:nowrap">sub-populations</FONT> of SLE patients for targeted therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rheumatoid Arthritis </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">RA is a chronic, systemic autoimmune disease in which the immune system attacks the joints and can also affect other organ systems. The annual incidence
and prevalence of RA in the United States is estimated to be 75,000 and 1.75&nbsp;million, respectively. Patients suffering from RA develop joint damage that is associated with painful inflammation which often progresses to irreversible damage of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
cartilage and bone leading to significant disability and a reduction in quality of life and the ability to work. Early diagnosis and effective treatment of RA is critically important to prevent
erosive bone or joint damage and disability. Rheumatologists are compelled to reach a definitive diagnosis quickly and administer effective treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Diagnosis of RA involves performing a complete medical history with physical and/or radiographic examination of the number and distribution of swollen,
tender and painful joints that have persisted for more than six weeks. Laboratory testing for rheumatoid factor, or RF, anti-cyclic citrullinated peptide, or CCP, antibodies, and testing for general, nonspecific inflammation with erythrocyte
sedimentation rate, or the ESR, and <FONT STYLE="white-space:nowrap">C-reactive</FONT> protein tests are used to assist in the diagnosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
standard of care for the treatment for RA involves the use of Disease Modifying Anti-Rheumatic Drugs, or DMARDs, which have shown, in clinical studies, the ability to slow or stop disease progression. Methotrexate remains the most commonly used
DMARD, due to its low cost, effectiveness, and the extensive clinical experience with its use. It is estimated that approximately 74% of RA patients in the United States, or 1.3&nbsp;million patients, are treated with methotrexate, either as a
monotherapy or in combination with another DMARD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Biologics DMARDs are proteins that have been genetically modified to target cellular components
of the immune system that attack healthy tissues causing the symptoms of RA. They are a targeted form of therapy, which makes them different from traditional RA treatments, such as methotrexate. The first FDA approved biologics for RA were the
anti-TNFs. ENBREL<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-family:ARIAL; font-size:6.5pt">&reg;</FONT></SUP> was approved for RA in 1998 and the latest, SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, was
approved in 2009. The anti-TNFs dominate the therapy for RA and generally are the first biologics chosen to augment methotrexate when patients are not achieving a satisfactory response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Solution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently market nine testing products under
our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA. Our product portfolio
integrates our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology, which is a stable and reliable method for differentially diagnosing SLE. We focus on leveraging our portfolio of testing products to promote therapeutics through
our sales channel targeting the approximately 5,000 rheumatologists across the United States. In December 2018, we entered into the Janssen agreement to exclusively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the
United States for the treatment of adult patients with moderate to severe RA and for other indicated rheumatic diseases. In January 2019, we began direct promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> with our
specialized salesforce. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our Proprietary Technologies </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have two core proprietary technologies, <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> and MTXPGs, which form the backbone of several of our testing
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">CB-CAPs</FONT> </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology determines the blood levels of complement activation proteins permanently
deposited on hematopoeitic cells. The determination of complement proteins in a patient&#146;s blood is a mainstay in clinical laboratory science, and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> methods traditionally rely on measurement of serum or plasma levels of soluble complements. C3 and C4 are the
most commonly determined complement proteins in the blood and the precursors to activation of complement proteins into biologically active breakdown products. However, there are limitations with measuring C3 and C4 blood levels as indicators of
complement activation. For example, increased synthesis of C3 and C4 by the liver can offset increased C3 and C4 breakdown during activation of the complement cascade, resulting in no change in serum levels. While the limitations and drawbacks of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
measuring standard components of the complement system, such as C3&nbsp;and C4, are well recognized by the medical community, these laboratory biomarkers are part of international guidelines for
the classification of SLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe the availability of novel complement biomarkers supporting or replacing standard C3 and C4 measures will be
of great value for rheumatologists and ultimately their patients. Our <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology directly measures protein products of complement activation, such as C4d, the product of C4 activation. These complement
activation products become stably attached to surfaces of circulating blood cells to become <FONT STYLE="white-space:nowrap">CB-CAPs.</FONT> As such, the determination of <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> in the blood provides benefits
when compared to the traditional complement measurement. These include the stable, accurate and unequivocal information of complement activation that enable consistent measurement and an improved ability to assess and monitor changes in biological
activity related to activation of the complement system. In a head-to-head study published in 2014, CB-CAPs (EC4d or BC4d) showed 22% higher sensitivity (66%) than C3 and C4 (44%) in diagnosing SLE, with specificity fixed at 91%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>MTXPGs </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Methotrexate is the standard of care and first-line
treatment of many autoimmune diseases including RA and psoriatic arthritis. Our proprietary technology measures blood levels of MTXPGs, which are the active metabolite of methotrexate. The technology uses a dried capillary blood-based collection
method coupled with liquid chromatographic tandem mass spectrometry and quantifies nanomolar concentrations of MTXPG using at least two orders of magnitude lower blood volume than venipuncture. MTXPG blood levels are actionable clinical utility
checkpoints and can help clinicians identify causes for a lack of response to methotrexate, such as poor activation to active metabolites, underexposure secondary to poor absorption or poor compliance, all of which are limiting factors to the
achievement of a robust clinical response with this first-line treatment. We believe we can leverage this technology to optimize <FONT STYLE="white-space:nowrap">anti-TNF</FONT> treatment by reducing the formation of anti-drug antibodies that are
known to impact the clinical efficacy of these drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Testing Products </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since inception, we have been committed to developing and commercializing innovative testing products that address the challenges rheumatologists face in
differentially diagnosing, prognosing and monitoring complex autoimmune and autoimmune-related diseases. We estimate the total addressable market for our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products to be
approximately $5 billion, based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Diagnosis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our lead testing product, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, is a comprehensive test that aids in the differential
diagnosis of SLE versus other common CTDs. The SLE portion of the test employs our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology and specifically measures activation of the complement system by quantifying the level of two <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> biomarkers in the patient&#146;s blood, <FONT STYLE="white-space:nowrap">B-cell</FONT> C4d, or BC4d, and erythrocyte bound C4d, or EC4d, which are higher in patients with SLE compared to patients with other
CTDs. In addition, the comprehensive nature of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD enables testing for a series of 22 biomarkers in one convenient blood draw to further aid in the differential diagnosis of a wide
variety of CTDs and other diseases which can be challenging to diagnose as a result of overlapping symptoms. These diseases include SLE, RA, Sj&ouml;gren&#146;s syndrome, APS, other autoimmune-related diseases such as autoimmune thyroid, and other
disorders that mimic these diseases, such as fibromyalgia. Our test&#146;s ability to allow rheumatologists to effectively rule out SLE and differentially diagnose other CTDs such as RA adds clarity to the rheumatologist&#146;s assessment, thereby
making the evaluation process more efficient and accurate. The clinical performance of our proprietary biomarkers and the convenience of a single blood draw make AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD an attractive
choice among rheumatologists. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus test employs our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT>
technology and is the cornerstone of the SLE assessment within our more comprehensive AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD testing product. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus measures
activation of the complement system by quantifying the level of BC4d and EC4d in the patient&#146;s blood. Rheumatologists choose to order the comprehensive AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD test or the more focused
AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus test based on medical necessity, which is determined by each patient&#146;s symptoms and medical history. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> APS </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>APS consists of a specialized panel
of eight autoantibody tests. This test aids in both the diagnosis and management of APS, a hyper-coagulation state leading to thrombosis, pregnancy complications, and even death. Rheumatologists would typically request the AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> APS test in patients who initially tested positive for one or more APS biomarkers contained in AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, or in the management of
patients experiencing a high-risk pregnancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Prognosis </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Prognostic </U></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE
Prognostic is a <FONT STYLE="white-space:nowrap">ten-biomarker</FONT> panel of autoantibodies that have established predictive value for assessing the potential for complications affecting the kidney, brain and cardiovascular system, including lupus
nephritis and lupus psychosis. Rheumatologists rely on insights from the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Prognostic test to help tailor their treatment approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were the first commercial laboratory to make testing for anti-CarP available in the United States with the introduction of AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP in 2018. This test uniquely addresses two major challenges facing rheumatologists today &#150; (1) patients presenting with RA symptoms but lacking the common confirmatory blood tests
for <FONT STYLE="white-space:nowrap">anti-RF</FONT> or <FONT STYLE="white-space:nowrap">anti-CCP,</FONT> known as sero-negative patients, and (2)&nbsp;the lack of a serologic indicator, which indicates a poor prognosis and helps guide treatment
decisions. Anti-CarP can be positive in up to 26% of RA patients who are negative for <FONT STYLE="white-space:nowrap">anti-CCP.</FONT> Furthermore, RA patients positive for Anti-CarP have an increased risk for more severe RA disease, including
permanent joint damage<B><I>.</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> PC4d </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> PC4d is one of our newest offerings, which reflects over 10 years of research efforts and
employs our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology. This proprietary <FONT STYLE="white-space:nowrap">CB-CAP</FONT> biomarker measures platelet- bound C4d, or PC4d, and has been shown in clinical studies to have
significant association with thrombosis and ischemic stroke in SLE. These thrombotic events can be among the most damaging and deadly forms of lupus flares and often strike without warning. Because of its strong association with thrombosis, we
believe AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> PC4d promises to be a valuable tool for SLE disease monitoring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Monitoring </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor is a <FONT STYLE="white-space:nowrap">six-biomarker</FONT> blood test that
employs our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology and is intended to assess the condition of a patient that has been diagnosed with SLE. It offers a unique combination of biomarkers that measure for EC4d, which has
shown greater accuracy in tracking disease activity than C3 and C4, and PC4d, which is associated with thrombosis risk in SLE. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor offers additional insight into a
patient&#146;s disease activity as well as possible adverse events. Rheumatologists have limited methods for evaluating the extent of disease activity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
taking place inside the body of an SLE patient. They rely on imperfect biomarkers, overt symptoms or flares, and patient reported history, all of which leave the rheumatologists looking for
greater insights. In surveys conducted with SLE patients, it has been reported that patients tend to under report their symptoms and over 70% of physicians are unaware of this bias. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE
Monitor demonstrates correlation to SLE disease activity and is therefore designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Depending on disease severity, our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor testing product may be utilized by patients multiple times a year and throughout their lives. We believe AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor
will play an increasingly important role in the management of SLE patients and further solidify the role and relationship of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products for these patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>MTX is a patented and validated
blood test that precisely measures levels of MTXPG, the active form of methotrexate, in the patient&#146;s blood. There is large variability in the way patients absorb and metabolize methotrexate, leaving rheumatologists unsure of what steps to take
when a patient has an inadequate response. Methotrexate is the most widely prescribed drug by rheumatologists in the treatment of RA. When faced with a patient who is not responding to methotrexate therapy, the options include increasing the dose,
switching to a parenteral delivery method and/or advancing to a more costly biologic therapy. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX provides crucial information as to whether a patient has achieved MTXPG blood levels
consistent with an appropriate response to methotrexate, also known as the therapeutic level, or if the MTXPG blood levels are too low to produce adequate effects. The rheumatologists can then make informed therapeutic decisions to optimize
methotrexate therapy and give patients their best chance at achieving an optimal response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX is compatible with AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
Touch, our <FONT STYLE="white-space:nowrap">low-volume</FONT> test sample collection method that allows for a micro-volume blood sample to be collected anywhere from a simple fingerstick.
AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Touch has a number of advantages, including empowering rheumatologists to collect and submit samples without full phlebotomy services, convenience for patients who have trouble with
venipuncture and potential patient self-collection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCQ </U></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCQ is a blood test designed to help rheumatologists objectively monitor levels of
hydroxychloroquine, or HCQ, in whole blood as they treat patients with SLE and other CTDs, including RA. HCQ is typically prescribed to patients to control SLE disease activity and prevent flares. However, there is large variability in the response
to HCQ therapy, the drug can sometimes take weeks or months to have a therapeutic effect and compliance has been documented to be an issue in CTD patients. We believe measuring HCQ makes the patient accountable, and also helps to determine whether
HCQ blood levels are adequate and consistent with clinical efficacy. The addition of new and costly biologic therapies approved for the treatment of SLE may drive interest by all healthcare stakeholders, especially payers, to adopt an approach that
optimizes a generic drug before advancing to a costlier alternative. AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCQ is also compatible with AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Touch. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Test Reports </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We provide the results of our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products in a comprehensive and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">easy-to-understand</FONT></FONT> test report typically sent to rheumatologists within
five business days following receipt of the blood specimen. As shown below, the result of the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus portion of the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD
report displays a gradient illustrating the likelihood of the presence of lupus, which facilitates interpretation and discussion of the result with the patient versus only reporting a numerical value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, all biomarker results for AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
CTD are reported and organized by disease state, providing clarity and convenience for the rheumatologists. A sample of the full AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD report is shown below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>CTD Report </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g692844g70h03.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P ALIGN="center" STYLE="font-family:ARIAL; font-size:0.5pt"><FONT COLOR="#FFFFFF">Order ID 200432 Provider Example Provider MD Specimen Collected 05/30/2016 Received 05/16/2016 Test Order Created
06/01/2016 Reported 06/02/2016 Patient Sample, Nancy S Gender - DOB Female - 01/25/1974 Identifier Received Exagen ID 300955 AVISE lupus Test Report AVISE Lupus Result: Positive- Index: 1.4 Tier1Tier 1 AnalytesValueInterpretationReference
RangeAssessmentAnti-dsDNA lgG20IU/mlNegative&lt;302- Negative I e 302 - PositiveConfirmation by Crithidia luciliaeN/AAnti-Smith lgG&lt;1U/mlNegative&lt;5- Negative I 5-10 - Equivocal I &gt;10- PositiveNegativeCB-CAP: EC4d - Erythrocyte-bound
C4d25Net MFIPOSITIVE&lt;15- Negative 15 -75- Positive I &gt;75- Strong PositiveCB-CAP: BC4d- B-lymphocyte-bound C4d100Net MFIPOSITIVE&lt;61- Negative I 61-200- Positive I &gt;200- Strong PositiveNote:Criteria for Tier 1 Positive not met.Tier 2Tier 2
AnalytesValueInterpretationReference RangeAssessmentANA igG40 UnitsPOSITIVE&lt;20- Negative I 2O-59- Positive I e60- Strong PositiveCB-CAP: EC4d - Erythrocyte-bound C4d25Net MFIPOSITIVE&lt;15- Negative I 15-75- Positive I &gt;75 - Strong
PositiveCB-CAP: BC4d - B-lymphocyte-bound C4d100Net MFIPOSITIVE&lt;61- Negative 161-200- Positive I &gt;200 - Strong PositiveAnti-SS-B/La lgG1U/mlNegative&lt;7 - Negative I 7-10 - Equivocal I &gt;10 -PositivePositiveAnti-Scl-70
lgG&lt;1U/mlNegative&lt;7 - Negative I 7-10 - Equivocal I &gt;10 -PositiveAnti-CENP lgG&lt;1U/mlNegative&lt;7 - Negative I 7-10 - Equivocal I &gt;10 -PositiveAnti-Jo- I1gG&lt;1U/mlNegative&lt;7 - Negative I 7-10 - Equivocal I &gt;10
-PositiveAnti-CCP lgG2U/mlNegative&lt;7 - Negative I 7-10 - Equivocal I &gt;10 - PositiveNote:This assessment is associated with an increased likelihood of SLE.Test Method Description Results were obtained using flow cytometry for complement C4d
fragment bound to erythrocytes (EC4d) and B-lymphocytes (BC4d). Autoantibodies were determined using solid phase immunoassays. ANA was determined by Indirect lmmunofluorescence and solid phase assays. ANA by solid phase assays was used for the Index
calculation. in a study of 794 subjects comprising 304 SLE patients, 285 patients with other rheumatic diSeases and 205 normal healthy controls, positivity for Tier 1 markers (anti-dsDNA, confirmed using Crithidia, anti-Sm or elevated EC4d and BC4d)
was associated with a sensitivity of 46% and a specificity of 97%. Among the 440 subjects negative In Tier 1, a positive index score composite of ANA (by ELISA), EC4d/BC4d and positivity for anti-citrullinated peptide antibodies, SS-B/La, CENP, Jo-1
or Scl-70 resulted in sensitivity of 62% for SLE and specificity of 89%. Two tier combination yielded 80% sensitivity for SLE and 86% specificity for other rheumatic diseases (98% specificity vs. healthy). Page 1 of 2 </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g692844g50a84.jpg" ALT="LOGO">
 </P> <P ALIGN="center" STYLE="font-family:ARIAL; font-size:0.5pt"><FONT COLOR="#FFFFFF">Order ID 200402 Provider Example Provider MD Specimen Collected 09/29/2016 Received 09/30/2016 Test Order Created 09/30/2016
Reported 10/02/2016 patient sample, susan s gender DOB Female -01/24/1974 identifier received Exagen id 300955 SLE- associated analytes value interpretation reference range + ANA igG 40 Units positive ELISA: &lt;20- Negative I 20-59 - Positive I
e60-Strong Positive + HEp-2 cell fluorescence Titer: 1:320 POSITIVE IFA: &lt;1:80- Negative I e1:80- Positive Nuclear Pattern: Speckled Cytoplasmic Pattern: Not Observed Anti-dsDNA- lgG 20 IU/mL Negative ELISA: &lt;302-positive :Anti-dsDNA-
confirmatory N/A IFA- using Crithidia luciliae Anti-Smith lgG 1 U/mL Negative ELISA: &lt;5- Negative I 5-10- Equivocal I &gt;10- Positive + CB-CAP: EC4d- + Erythrocyte-bound C4d 25 Net MFI positive FACS: &lt;15- Negative / 15-75- Positive I &gt;75-
Strong Positive CB-CAP: BC4d - B-lymphocyte-bound C4d 100 Net MFI POSITIVE FACS: &lt;61- Negative I 61-200- Positive I &gt;200- Strong Positive other autoimmune disease auto-antibodies value interpretation reference range Anti-U1RNP lgG 20 U/mL
POSITIVE ELISA: &lt;7- Negative I 7-10- Equivocal I &gt;10 - Positive Anti-RNP70 lgG 3 U/mL Negative ELISA: &lt;7- Negative I 7-10- Equivocal I &gt;10 - Positive Anti-Ss-A/Ro lgG 2 U/mL Negative ELISA: &lt;7- Negative I 7-10 - Equivocal I &gt;10 -
Positive Anti-ss-B/la lgG 1 U/mL Negative ELISA: &lt;7- Negative I 7-10- Equivocal I &gt;10 - Positive Anti-Scl-70 lgG &lt;1 U/mL Negative ELISA: &lt;7- Negative | 7-10- Equivocal 1 &gt;10 - Positive Anti-CENP lgG 1 U/mL Negative ELISA: &lt;7-
Negative I 7-10- Equivocal I &gt;10 - Positive Anti-Jo-1 lgG &lt;1 U/mL Negative ELISA: &lt;7- Negative I 7-10- Equivocal I &gt;10 -Positive Rheumatoid Arthritis auto-Antibodies value interpretation reference range Rheumatoid Factor lgM 2.0 U/mL
Negative ELISA: &lt;3.5- Negative I 3.5-5- Equivocal I &gt;5- Positive Rheumatoid Factor lgA 1 U/mL Negative ELISA: &lt;14- Negative I 14-20- Equivocal I &gt;20- Positive Anti-CCP lgG 2 U/mL Negative ELISA: &lt;7- Negative I 7-10 - Equivocal I
&gt;10 Positive+ Anti-Carbamylated Protein (CarP) lgG 22 U/mL POSITIVE ELISA: &lt;20 - Negative I &gt;20 .P0sitive Antiphospholipid Syndrome Auto-Antibodies Value lnterpretation Reference Range Anti-Cardiolipin lgM 2 cu Negative ELISA: &lt;20 -
Negative I &gt;20- Positive Anti-Cardiolipin lgG &lt;6 cu Negative ELISA: &lt;20 - Negative I &gt;20- Positive anti-b2 Glycoprotein 1lgG &lt;6 cu Negative ELISA: &lt;21 - Negative I &gt;21 - Positive Anti-b2 Glycoprotein 11gG &lt;6 cu Negative
ELISA: &lt;21- Negative I ~21- Positive Thyroid Auto-Antibodies Value lnterpretation reference range Anti-Thyroglobulin lgG &lt;12 IU/mL Negative ELISA: &lt;40- Negative I 40-60- Equivocal I &gt;60- Positive Anti-Thyroid Peroxidase lgG &lt;4 IU/mL
Negative ELISA: &lt;25- Negative I 25-35 -Equivocal I &gt;35 -Positive NOTES: in the context of suspected RA, elevated anti-CarP antibodies are associated with more aggressive disease. The significance of a positive anti-CarP value In the absence of
RA has not been established. References 1. Thermo Fisher/Connective Tissue Marker references and results (Phadia product inserts). 2. Manzi 5 et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis
Rheum. 50(11):3596-604.2004. 3. Kalunian et al. Measurement of cell-bound complement activation products enhances diagnaostic performance in systemic lupus erythematosus Arthritis Rheum .2012 dec; 64 (12): 4040-7Putterman et al. An Assay panel
Combining Cell Bound Complement Activation Products With Autoantibodies To Extractable Nuclear antigens and mutated citrullinated vimentin helps with the differential diagnosis of systemic lupus erythematosus. Arthristis rheumatism 2013 suppl
(s2525). Page 2 of 2 1261 Liberty Way, Vista CA CLIA #05D1075048 CAP # 7201051 I PFI #8369 Laboratory Directors: Richard Safrin. MD Thierry dervieux, PhD, dABCC Provider Relations: 888.452.1522 Exagen, AVISE and the AVISE the and exagen logos are
registered trademarks of exagen diagnostics,inc2018 all rights reserved This test is used for clinical purposes, though results are not intended to be used as the sole means for clinical diagnosis or patients management decisions. It should not be
regarded as investigational or for research. IT HAS NOT BEEN CLEARED or approved by the FDa. Exagen is regulated under the CLIA as qualified to perform high-complex testing. Sa1049 (8/18) </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Therapeutics </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2018, we entered into the Janssen agreement to exclusively promote SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the
United States for the treatment of adult patients with moderate to severe RA and for other indicated rheumatic diseases. Combined U.S. sales of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and SIMPONI ARIA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> were approximately $1.0&nbsp;billion in 2018, of which we estimate approximately 50% was from sales of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We began direct promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> with our specialized salesforce in January 2019 and
expanded our salesforce from 31 representatives as of December&nbsp;31, 2018 to 55 representatives in August 2019. This will enable us to deliver approximately 60,500 calls annually to rheumatologists, which we believe will enable us to achieve the
optimal reach and frequency, and support our strategy of integrating the promotion of testing products and therapeutics. We believe that educating providers regarding SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has and will
continue to facilitate greater acceptance of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. From the date we began our promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> through June&nbsp;30, 2019,
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> unit prescriptions increased by approximately 17%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX test can identify methotrexate patients with inadequate methotrexate exposure who are potential candidates for SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
therapy.&nbsp;Our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Anti-CarP test can identify RA patients with more severe disease requiring more aggressive therapy, such as <FONT STYLE="white-space:nowrap">anti-TNF</FONT> biologics
like SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We believe our strategy of integrating the promotion of testing products and therapeutics, combined with our specialized salesforce, uniquely position us to expand SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#146;s U.S. market share. We will receive a quarterly tiered promotion fee ranging from $750 to $1,250 per prescription based on incremental total prescribed units above a predetermined average
baseline of approximately 29,000 prescribed units per quarter for an initial term of 18 months. We estimate the total U.S. addressable market for SIMPONI&#146;s <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> approved indications,
including RA, psoriatic arthritis and ankylosing spondylitis, to be approximately $28 billion. Based on this estimated market size, each incremental 1% market share we are able to capture for
SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> above the predetermined baseline could result in incremental revenue to us of $84 million. For more information regarding the Janssen agreement, see &#147;&#151;Agreements with
Pharmaceutical Companies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In recent years, advancements in the understanding of the autoimmune and autoimmune-related disease process have
led to a significant number of novel biologic drugs and drug development initiatives, especially in RA and SLE, and we intend to leverage our integrated testing and therapeutics strategy to establish additional partnerships with a focus on the
commercialization of therapeutics that are synergistic with our testing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline and Growth Opportunities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe there is significant potential to capitalize on our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> and MTXPG technologies by
integrating those technologies with commercially validated biomarkers to develop testing products with superior clinical utility. The complement pathway is widely implicated in the pathogenesis of a variety of conditions, including autoimmune
diseases and organ transplant rejection, and emerging data suggests its implication in cancer development. We believe that our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology, owing to its stability and reliability, will allow
us to produce meaningful and differentiated proprietary solutions for rheumatologists. For example, we are focused on leveraging our proprietary <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology by developing a thrombosis risk score with
PC4d in prognosing cardiovascular events in SLE. We plan to initiate proof of concept studies to develop alternatives to biopsy in the monitoring of transplant rejection and the differential diagnosis of fibromyalgia in the primary care physician
setting. In addition, we are developing a panel of antibody systems that we believe may have high prognostic value in patients with RA, Sj&#246;gren&#146;s, fibromyalgia and autoimmune thyroid, and we continue to evaluate the use of AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Touch and microfluidics for our broader portfolio of testing products to increase convenience and cost-effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sales and Marketing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our specialized salesforce is focused on
targeting the approximately 5,000 rheumatologists across the United States. Our sales representatives generally have extensive experience in healthcare sales </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
with backgrounds in rheumatology, biologics, specialty therapeutics and/or testing. In addition, our sales representatives complete a comprehensive disease-level sales training program and are
required to participate in regular, ongoing training activities and certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our sales model involves integrating the promotion of testing
products and therapeutics in a unique approach that will enable our sales representatives to gain greater access and time with rheumatologists. The test information available to our sales representatives creates a different dynamic as compared to a
traditional drug sales representative&#146;s product detail. It enables a timely, extended, patient-focused discussion that naturally transitions to a therapeutic discussion during the same sales call. Our goal is for our sales representative to be
viewed as a collaborative consultant versus a traditional drug sales representative. We intend to capitalize on our established reputation, market presence and expertise to sell additional products and services into the autoimmune and
autoimmune-related disease market. We believe that a collaborative relationship with rheumatologists helps build a lasting sales channel through which additional products and services can be introduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, our overall sales team consisted of approximately 64&nbsp;members, including 53&nbsp;sales representatives, six regional sales
directors, two vice presidents and three managed care professionals. In connection with the promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, we expanded the number of sales representatives from 31&nbsp;representatives
as of December&nbsp;31, 2018 to 55&nbsp;representatives in August 2019, who will be managed by a team of six regional sales directors. Our increased salesforce will allow for expansion into markets not previously covered by us. In addition, this
salesforce expansion is estimated to double the number of sales calls made per year, helping us to cultivate a strong collaborative relationship with rheumatologists through increased interactions. To further support our promotional efforts, we have
a centralized, dedicated client services department with a high level of technical training that augments our specialized salesforce and marketing activities and enhances sales efficiency and customer satisfaction by providing personalized customer
support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Right Doctor, Right Message, Right Frequency </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe our sales model of integrating the promotion of testing products and therapeutics will be complemented by our focused &#147;high-touch&#148;
selling approach that emphasizes execution in three core areas: <I>targeting, messaging and call frequency</I>. We strategically <I>target</I> the highest-potential practices by utilizing various data sources (e.g., market analytics, demographic
data, historical biologic and diagnostic product usage trends). Furthermore, we believe the increased access afforded by our testing products will allow for patient-focused <I>messaging, </I>including safety and efficacy data for SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and the increased accuracy of our testing products over current standard of care diagnostic methodologies. Finally, we execute a high-<I>frequency</I> promotional strategy for our top targeted
rheumatologists and their office personnel to build knowledge, understanding and retention of the benefits of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and our testing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We plan to leverage core channels for building awareness and adoption including our participation with multiple patient advocacy organizations, such as
the Lupus Foundation of America, or LFA, and medical societies, such as the American College of Rheumatology, or ACR. We have also established strong relationships with multiple rheumatology care management organizations, or super groups, which can
be key in influencing favorable reimbursement. Our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX testing product has been included in the clinical guidelines for two of these groups. We believe our experience with advancing a
testing product from initial development through clinical adoption differentiates us and uniquely positions us to replicate success with our other testing products. Beyond working with these groups, we intend to continue to augment field selling
activity with a balanced marketing mix including print and digital advertising, direct marketing, continuing medical education programs and working with key opinion leaders to support
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peer-to-peer</FONT></FONT> educational events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reimbursement, Clinical Validation and Clinical Utility </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Reimbursement </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We seek reimbursement for our testing products
from several sources, including commercial third-party payers, government payers and patients. Payment from commercial third-party payers differs depending on whether we have entered into a contract with the payer as a participating provider or do
not have a contract and are considered to be an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-network</FONT></FONT> provider. When we contract to serve as a participating provider, reimbursements are made pursuant to a
percentage of our charges or a negotiated fee schedule amount. Currently, we are reimbursed on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-network</FONT></FONT> basis, at various rates that can be higher or lower than
participating providers. Where we are not reimbursed in full, we may elect to appeal the insurer&#146;s underpayment or denial of payment or seek payment from the patient. We continue to focus on expanding coverage among existing contracted
providers and achieving coverage with commercial payers, laboratory benefit managers and evidence review organizations. We employ a multi-pronged strategy designed to achieve broad coverage and reimbursement for our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Meet the evidence standards necessary to be consistent with leading clinical guidelines.</I>&nbsp;&nbsp;&nbsp;&nbsp;We
believe inclusion in leading clinical guidelines plays a critical role in payers&#146; coverage decisions. In order to change clinical guidelines, tests must carry a high level of published evidence demonstrating analytical validity, clinical
validity, clinical utility and cost effectiveness. When studies with such evidence are published in peer-reviewed journals, the authors of clinical guidelines may assess the level of evidence and determine whether modifying existing guidelines to
include new technology is warranted. For example, we previously conducted peer-reviewed, published clinical studies for AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX which helped us secure favorable coverage for that testing
product from the MolDx Program, Noridian and various commercial Medicare Advantage plans. The two largest rheumatology super groups have included AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX in their respective RA patient
pathway guidelines for physician adoption of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX. In addition, UpToDate, a leading evidence-based clinical decision support resource for physicians and payers, recommends the
measurement of polyglutamate levels as done by AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX. We have conducted, and continue to conduct, clinical validation and clinical utility studies for AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus, which we believe will provide a basis for the ACR and/or UpToDate to consider inclusion of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus in their respective
guidelines. In the future, we also intend to conduct similar studies in order to develop similar supporting literature with respect to our other testing products. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Execute an internal managed care policy and claims adjudication function as part of our core business
operations.</I>&nbsp;&nbsp;&nbsp;&nbsp;We employ a team of <FONT STYLE="white-space:nowrap">in-house</FONT> claims processing and reimbursement specialists who work with patients and payers to obtain maximum reimbursement. In parallel, a managed
care team collaborates with our reimbursement specialists to ensure our payer outreach strategy reacts and anticipates the changing needs of our customer base. Our customer service team is an integral part of our reimbursement strategy, working with
patients and rheumatologists to navigate the claims process. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Cultivate a network of key opinion leaders.</I>&nbsp;&nbsp;&nbsp;&nbsp;Key opinion leaders are able to influence
clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We collaborate with key opinion leaders early in the development process to ensure our clinical studies are designed and
executed in a way that clearly demonstrates the benefits of our testing products to physicians and payers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Validation </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We demonstrated the clinical validity of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus in a study of 794 patients conducted from
2010 to 2014 across multiple leading academic centers. The primary endpoint of the study was the specificity and sensitivity of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus compared to common autoantibodies used to diagnose
SLE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and other CTDs, such as ANA and anti-dsDNA. The final results of this study showed that AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus demonstrated 86% specificity and 80%
sensitivity in distinguishing SLE from other CTDs and fibromyalgia, was 33% more specific than ANA (53% specificity/89% sensitivity) and was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Utility </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have collaborated with both academic and
community clinicians to demonstrate the clinical utility of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus versus standard diagnostic tests in physician diagnosis, impact on patient management decisions, patient reported
outcomes and health economics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We sponsored a longitudinal, case-control, retrospective review of medical charts in 2016 to assess the value and
clinical utility of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus to rheumatologists. The results of this study were published in the Open Rheumatology Journal in 2016 and suggested that a positive AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus test aids in the diagnosis of SLE versus standard diagnostic tests. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In early 2018,
we initiated CARE for Lupus, a prospective, randomized, multi-site study to assess the performance of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus versus a number of other standard diagnostic tests. We submitted the Care for
Lupus manuscript for publication in July 2019, and it was accepted in August 2019. We also plan to initiate the CLEAR study in conjunction with CareFirst by late-2019 to further evaluate the clinical utility of AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus by collecting and analyzing applicable claims data. In addition, we collaborated with leading health economic experts and clinicians to conduct a health economics study. The results of that
health economics study were presented at the ACR conference in 2018, demonstrated the cost savings to a payer associated with AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus over a one to four year time horizon and were
submitted for publication in April 2019. The above referenced studies are included in the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus Dossier, which was completed in May 2019. Formal coverage determinations meetings are
expected to take place in the first half of 2020 following publications of studies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe our reimbursement strategy, including
establishing the clinical validation, clinical utility and health economics of our testing products will allow us to drive an expansion in reimbursement coverage for our testing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Laboratory Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We perform all of our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> tests in our approximately 8,000 square foot clinical laboratory, which is certified by the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American
Pathologists, or CAP, and located in Vista, California. Our laboratory is certified for the performance of high-complexity testing by the Centers for Medicare and Medicaid Services, or CMS, in accordance with CLIA. We are approved to offer our
products in all 50 states. Our clinical laboratory reports all AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing product results within five business days. We believe that our existing laboratory facilities are adequate to meet
our business needs for at least the next 12 months and that additional laboratory space will be available on commercially reasonable terms, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quality
Assurance </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our quality assurance function oversees the quality of our laboratory as well as research and development, client services, billing,
sales and marketing operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, preventive or corrective actions, and employee training processes that we
believe achieves excellence in operations. We continuously monitor and improve our processes and procedures and believe this high-quality service leads to customer satisfaction and retention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our principal competition for our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products is traditional methods used by
healthcare providers to test patients with CTD disease-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as ANA and anti-dsDNA, and serum complement, such as C3 and C4.
We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and Mayo Clinic, all of which have existing infrastructures to support the
commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide <FONT STYLE="white-space:nowrap">in-house</FONT> clinical laboratories offering
autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories,
Inc.&nbsp;Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc., Progentec Diagnostics Inc., Kypha, LLC, Genalyte Inc., Protagen AG, DxTerity Diagnostics
Inc., HealthTell, Inc. and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Direct
competition for the promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> includes all other companies with <FONT STYLE="white-space:nowrap">anti-TNF</FONT> biologics and the marketing companies supporting their distribution
and promotion. These products include HUMIRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and RINVOQ<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> from Abbvie Inc.,
ENBREL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Amgen Inc., CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from UCB, INFLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Pfizer Inc., or
Pfizer, (biosimilar REMICADE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and RENFLEXIS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Merck&nbsp;&amp; Co. (biosimilar REMICADE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Additional competitors include companies with other biologic drugs indicated for RA that have significant sales or sales potential. Specifically, these include ORENCIA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Bristol-Myers Squibb Company, ACTEMRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Roche Holding AG, or Roche,
RITUXAN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Roche, XELJANZ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Pfizer, KEVZARA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Sanofi S.A. and
OLUMIANT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Eli Lilly and Company. There are also several late-stage RA drug and biosimilar development programs and several additional RA products that have minimal sales to date or that
are indicated for other rheumatic indications competitive to SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> such as psoriatic arthritis and ankylosing spondylitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence
in diagnostic results; safety and efficacy with respect to promoted therapeutics; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development
resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payers as functionally equivalent to our solution or offer solutions at prices designed
to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and
future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Pharmaceutical Companies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Janssen Agreement </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2018, we and Janssen entered into the Janssen agreement to <FONT STYLE="white-space:nowrap">co-promote</FONT> SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States. We are responsible for the costs associated with our salesforce over the course of such <FONT STYLE="white-space:nowrap">co-promotion.</FONT> Janssen is responsible for all
other aspects of the commercialization of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> under the Janssen agreement. In exchange for our sales and <FONT STYLE="white-space:nowrap">co-promotional</FONT> services,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we are entitled to a quarterly tiered promotion fee ranging from $750 to $1,250 per prescription based on the incremental increase in total prescribed units of SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for that quarter over a predetermined baseline. The predetermined average baseline for the initial term of 18 months is approximately 29,000 prescribed units per quarter, subject to adjustment
under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The term of the Janssen agreement expires on June&nbsp;30, 2020, unless extended by us for an additional 18 months
upon 180 days&#146; written notice prior to the end of the initial term. Janssen can terminate the agreement at any time for any reason upon 30 days&#146; notice to us, and we can terminate the agreement for any reason at the end of any calendar
quarter upon 30 days&#146; notice to Janssen. Either party may terminate the agreement in the event of the other party&#146;s default of any of its material obligations under the agreement if such default remains uncured for a specified period of
time following receipt of written notice of such default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Collaboration Agreement with GSK </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2018, we entered into a collaboration agreement with GSK, pursuant to which we provide GSK with our test result data to provide market insight
into and help increase awareness on the benefits of an early and accurate diagnosis of SLE. The agreement was amended in November 2018 to, among other things, include data from our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
Prognostic and AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCQ testing products and extend the term of the agreement through December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the agreement, we are required to deliver weekly <FONT STYLE="white-space:nowrap">de-identified</FONT> data files to GSK covering all data
obtained from the performance of certain AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products, subject to applicable requirements under the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA,
internal policy requirements and other applicable laws. During the term of the agreement, the data we provide to GSK may not be provided, directly or through a third party, to any other pharmaceutical company that is marketing or developing a
product for the treatment of SLE. GSK made a single upfront payment in exchange for the right to receive the applicable data files. In addition, GSK has agreed to create a joint steering committee to cooperate with us in order to raise awareness and
physician support for our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products, including through the development and delivery of approved promotional materials and the implementation of a related training plan for each
party&#146;s sales personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The joint committee will meet at least 120 days prior to the end of the term of the agreement in order to discuss
renewal options. Either party may terminate the agreement for breach and, in certain cases, such breach must remain uncured for a certain period of time following receipt of written notice of such breach. In addition, GSK may terminate the agreement
immediately if we become insolvent or for convenience upon 60 days&#146; prior written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Master Services Agreement with Horizon Therapeutics </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2018, we entered into a master services agreement with Horizon Therapeutics, pursuant to which Horizon Therapeutics utilizes our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX test to report on levels of MTXPG in patients undergoing methotrexate therapy in combination with its anti-gout product KRYSTEXXA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in
an ongoing Phase&nbsp;4 clinical trial. Under the agreement, Horizon Therapeutics paid an initial one time <FONT STYLE="white-space:nowrap">set-up</FONT> cost and now pays an incremental fee for each specimen processed. We provide, among other
things, specimen collection kits, customized test requisition, <FONT STYLE="white-space:nowrap">pre-paid</FONT> shipping, specimen storage and individual reports for each study subject. Either party can terminate the agreement for convenience upon
30 days&#146; prior written notice to the other party. Absent early termination, the agreement will run through August 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property Overview
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain
patents for any patentable aspects of our testing products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and services and any other inventions that are important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary protection
for commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business, to defend and enforce our patents, to maintain our licenses to use intellectual property owned by third parties, to
preserve the confidentiality of our trade secrets and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on continuing technological innovation and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen, and maintain our proprietary position in the fields targeted by our testing products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are the owner or licensee of a portfolio of patents and patent applications and possess substantial <FONT STYLE="white-space:nowrap">know-how</FONT>
and trade secrets which protect various aspects of our business. The patent families comprising our patent portfolio are primarily focused on our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products for the diagnosis,
prognosis and monitoring of autoimmune and autoimmune-related diseases, and are generally directed to <FONT STYLE="white-space:nowrap">CB-CAPs,</FONT> red blood cell MTXPG exposure assessments, and <FONT STYLE="white-space:nowrap">anti-MCV</FONT>
antibodies. We intend to leverage the intellectual property surrounding our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products as an important component of our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent Protection for our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Testing Products </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our portfolio of patents and patent applications related to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products
generally relates to three aspects: <FONT STYLE="white-space:nowrap">CB-CAPs,</FONT> red blood cell MTXPG exposure assessments, and <FONT STYLE="white-space:nowrap">anti-MCV</FONT> antibodies. The patent families which we believe are important for
the protection of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are summarized below in the section entitled &#147;&#151;License Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">CB-CAPs.</FONT> </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are the
exclusive licensee of five patent families related to <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology from the University of Pittsburgh, or UPitt. We expect that these patent families (U.S. Patent Nos. 7,361,517; 7,390,631; 7,585,640;
7,588,905; 8,080,382; and 8,126,654) will expire in 2024 or 2025. A foreign patent corresponding to U.S. Patent No.&nbsp;7,361,517 has issued in Europe (EP 1,756,571). Foreign patents corresponding to U.S. Patent No.&nbsp;7,390,631 have issued in
Japan (JP 4570872 and JP 4906898). Foreign patents corresponding to U.S. Patent No.&nbsp;7,585,640 have issued in Australia (AU&nbsp;2005242719) and Canada (CA 2,564,492). A foreign patent corresponding to U.S. Patent Nos. 7,588,905 and 8,126,654
has issued in Japan (JP 4550051). We also own one issued patent (US 10,132,813) and two pending patent application families that relate to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Lupus products. Foreign patents
corresponding to US 10,132,813 have issued in Europe (EP 2,673,644) and Japan (JP 5,990,542). In order to manage our foreign filing costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of several of our
foreign patents and patent applications related to our <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology, including EP 1,432,731; EP 1,618,379; EP 1,635,692; EP 1,745,287; EP 2,214,014; EP 2,216,650, and certain of their corresponding
family members<B><I>.</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>MTX Exposure Assessment Products and Services </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are the exclusive licensee of four patents that relate to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX product and methods
for monitoring methotrexate therapy using red blood cell MTXPG exposure assessments. These patents and patent applications are owned by Prometheus and are exclusively licensed to us for all uses except for use in gastrointestinal diseases. These
patents include U.S. Patent Nos. 6,921,667; 7,563,590; 7,582,282 and 7,695,908, which are expected to expire between 2023 and 2027. We also are the exclusive licensee of two issued US patents (US 9,261,509 and US 9,822,391) that relate to our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Proprietary Rights and Processes </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may rely, in some circumstances, on proprietary technology and processes (including trade secrets) to protect our technology. However, these can be
difficult to protect. We seek to protect our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
proprietary technology and processes, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants,
scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information
technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our proprietary technology and
processes may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors, contractors, or any future collaborators use intellectual property owned by others in their work
for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. For this and more comprehensive risks related to our proprietary technology and processes, please see &#147;Risk
Factors&#151;Risks Related to our Intellectual Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Amended and Restated Exclusive License Agreement with the University of Pittsburgh </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2011, we entered into an amended and restated exclusive license agreement with UPitt, to amend and restate the exclusive license agreement we
obtained by our purchase of the medical diagnostics division of Cypress Bioscience, Inc., or Cypress, in 2010, or the Cypress Purchase, and to obtain an exclusive license to UPitt&#146;s patent rights in certain inventions, or the UPitt Patent
Rights, related to the use of <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
testing products. The agreement was amended three times, once in May 2012 to, among other things, limit the territory of the license to the United States and exclude certain foreign patents and applications from the agreement, once in September 2013
to add (1)&nbsp;an additional U.S. patent to the UPitt Patent Rights licensed under the agreement and (2)&nbsp;the field of monitoring of organ transplantation and organ rejection to the scope of the license, and once in June 2016 to, among other
things, clarify the definition of combination products for determining royalties due under the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the agreement, we are permitted to
make, use and sell products and services utilizing the UPitt Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection, and to sublicense such rights. UPitt retained the right to practice under the
UPitt Patent Rights and to use such rights for <FONT STYLE="white-space:nowrap">non-commercial</FONT> education and research purposes. In addition, this agreement is subject to the rights of the United States government, if any, as set forth in 35
U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the UPitt Patent
Rights throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In consideration for the rights granted to us under the agreement, we made certain upfront payments to UPitt on the
first and second anniversaries of the agreement that increased on the third and subsequent anniversaries of the agreement until the first sale of products or services utilizing the UPitt Patent Rights. We are required to pay UPitt a low single-digit
royalty on net sales of products or services utilizing the UPitt Patent Rights sold by us or our affiliates, subject to minimum annual royalty payments and other adjustment in certain circumstances. We also made a $0.2&nbsp;million milestone payment
to UPitt with the achievement of certain levels of net sales which we met in 2014. Our royalty obligations continue for each licensed product or service on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of the last licensed patent covering the applicable licensed product or service in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event we sublicense any of the UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense royalty on net sales
of products or services sold by our sublicensees that utilize the sublicensed UPitt Patent Rights and a low double-digit percentage of all <FONT STYLE="white-space:nowrap">non-royalty</FONT> sublicensing income received by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The agreement requires that we diligently develop and commercialize products that are covered by the
UPitt Patent Rights, and we have agreed to meet certain development and commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. In addition, if we fail to meet a milestone relating to development of the UPitt
Patent Rights in the monitoring of organ transplantation and organ rejection field, UPitt may remove that field from our licensed rights. We are currently in compliance with these milestone requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may terminate the agreement upon six months&#146; written notice to UPitt. UPitt may terminate the agreement in the event of our nonperformance of
any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early termination, the agreement
will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Exclusive License Agreement with the University
of Pittsburgh </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We made an economic decision to cease the maintenance and licensing of UPitt Patent Rights outside the United States, which led to
such rights returning to UPitt. We subsequently made the determination to <FONT STYLE="white-space:nowrap">re-license</FONT> these foreign patent rights from UPitt, but at the time of <FONT STYLE="white-space:nowrap">re-licensing</FONT> these patent
rights, a number of the foreign patent rights had permanently lapsed. Accordingly, in September 2013, we entered into an exclusive license agreement with UPitt to obtain an exclusive license to UPitt&#146;s remaining
<FONT STYLE="white-space:nowrap">ex-U.S.</FONT> patent rights in certain inventions, or the <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> UPitt Patent Rights, related to the use of <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology in the
diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the agreement, we are permitted to make, use and sell products and services utilizing the <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> UPitt
Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection outside of the United States, and to sublicense such rights. UPitt retained the right to practice under the
<FONT STYLE="white-space:nowrap">ex-U.S.</FONT> UPitt Patent Rights and to use such rights for <FONT STYLE="white-space:nowrap">non-commercial</FONT> education and research purposes. In addition, this agreement is subject to the rights of the U.S.
government, if any, as set forth in 35 U.S.C. &#167;200, et seq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In consideration for the rights granted to us under the agreement, we paid an
initial license fee to UPitt. We are also required to pay UPitt a low single-digit royalty on net sales of products or services utilizing the <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> UPitt Patent Rights sold by us or our affiliates, subject
to adjustment in certain circumstances. Our royalty obligations continue for each licensed product or service on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of the
last licensed patent covering the applicable licensed product or service in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event we sublicense any of the <FONT
STYLE="white-space:nowrap">ex-U.S.</FONT> UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed <FONT
STYLE="white-space:nowrap">ex-U.S.</FONT> UPitt Patent Rights and a low double-digit percentage of all <FONT STYLE="white-space:nowrap">non-royalty</FONT> sublicensing income received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The agreement requires that we diligently develop and commercialize products that are covered by the <FONT STYLE="white-space:nowrap">ex-U.S.</FONT>
UPitt Patent Rights, and we have agreed to meet certain commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. We are currently in compliance with these milestone requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may terminate the agreement upon six months&#146; written notice to UPitt. UPitt may terminate the agreement in the event of our nonperformance of
any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early termination, the agreement
will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>License Agreement with Prometheus Laboratories, Inc. </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the Cypress Purchase, we acquired a license agreement, dated September 2007, between Prometheus Laboratories, Inc., or Prometheus, and
Proprius Pharmaceuticals, Inc., or Proprius, a company which had been previously acquired by Cypress. Pursuant to this agreement, we obtained an exclusive, worldwide license to Prometheus&#146;s patent rights in certain inventions, or the Prometheus
Patent Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products and services. This agreement was subsequently
amended in October 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the agreement, we are permitted to research, develop, manufacture and commercialize products utilizing the
Prometheus Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with Prometheus&#146;s consent. We are not permitted to develop or commercialize products utilizing the Prometheus Patent Rights
for use in diagnosing or treating any gastrointestinal diseases or to promote any such products to gastroenterologists. Pursuant to the agreement, we are obligated to use reasonable commercial efforts to undertake certain development activities with
respect to products utilizing the Prometheus Patent Rights, including the completion of certain clinical studies. In addition, in the event that we do not timely complete these studies or approved substitute studies, we will become obligated to pay
to Prometheus a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $50,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are required to make a milestone payment of
$2.0&nbsp;million upon the achievement of certain net sales. In addition, we are required to pay Prometheus tiered royalties in the <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> range on sales of any products utilizing the Prometheus
Patent Rights by us, our affiliates or our sublicensees. Our royalty obligations continue on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">licensed-product-by-licensed-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration, lapse or invalidation of the last valid claim in a licensed patent covering the applicable licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event we sublicense any of the Prometheus Patent Rights, we are obligated to pay to Prometheus a fee based on a percentage of sublicense fees
received by us, which percentage is in the <FONT STYLE="white-space:nowrap">mid-twenties.</FONT> In addition, we are also required to pay to Prometheus a percentage of the royalty payments we receive from our sublicensees, which may not be less than
a certain low single-digit percentage of net sales of products or services sold by our sublicensees that utilize the sublicensed Prometheus Patent Rights, nor more than a certain <FONT STYLE="white-space:nowrap">mid-single</FONT> digit percentage of
such net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may unilaterally terminate the agreement for any reason upon <FONT STYLE="white-space:nowrap">60-days&#146;</FONT> written
notice to Prometheus. Either party may terminate the agreement in the event of the other party&#146;s material breach of the agreement if such breach remains uncured for a certain period of time following receipt of written notice of such breach or
in the event of the other party&#146;s insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Prometheus Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Asset Purchase Agreement with Cypress (Royalty Pharma) and Proprius </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2010, we completed the Cypress Purchase pursuant to an asset purchase agreement with Cypress and its wholly-owned subsidiary, Proprius, under
which we obtained certain assets related to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products and services. The agreement was amended six times, once in March 2011 to change certain obligations relating to certain
accounts receivable we acquired from Cypress, once in August 2012 to convert a <FONT STYLE="white-space:nowrap">one-time</FONT> payment obligation to a payment plan over four years with interest, once in February 2013 to convert a <FONT
STYLE="white-space:nowrap">one-time</FONT> contingent milestone payment obligation concerning a <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> monitoring assay to a payment plan over two years with interest, once in October 2013 to, among other
things, provide consent for Exagen to use its IP as collateral on a financing round, once in January 2016 to restate an annual sales milestone, and once in February 2017 to restate specifics of the monitoring assay royalty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2011, Royalty Pharma Collection Trust, or Royalty Pharma, acquired Cypress and became its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> under the agreement. In consideration for the acquisition, we made certain initial cash payments to Cypress and we are currently making payments to
Royalty Pharma, as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> to Cypress, pursuant to the August 2012 amendment, which payments are subject to acceleration in certain circumstances. Under
our agreements with Royalty Pharma, we are required to pay Royalty Pharma a low double-digit royalty on the world wide net sales of <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> products and a low double-digit royalty on the net sales of certain
new products in each case, for a period of eight years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we are required to make certain
<FONT STYLE="white-space:nowrap">one-time</FONT> contingent milestone payments for two third-party commercial programs, for the launch of a <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> monitoring assay, and for the achievement of an annual,
worldwide net sales level for <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> products. Our agreement with Royalty Pharma requires that we use commercially reasonable efforts to cause each of the milestones to be achieved. In December 2015, we
achieved the specified annual world-wide nets sales of <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> products which required us to make a $2.0&nbsp;million milestone payment to Royalty Pharma. We paid the applicable $2.0&nbsp;million milestone
payment in 2016. In February 2017, we amended our agreements with Royalty Pharma relating to the launch of a monitoring product using <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology. As a result of this amendment, a prior obligation to
make a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $1.0&nbsp;million upon the launch of a monitoring product incorporating <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology was replaced with an agreement to pay Royalty
Pharma a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $100,000 upon the launch of such a product, plus a 2.5% royalty based on future cash collections from sales of that product which incorporate the licensed technology. Future
royalties under this arrangement are limited to the lesser of $1,200,000 (including the upfront payment of $100,000) or the total royalty earned through January&nbsp;1, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Asset Purchase Agreement With Cellatope </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with
the Cypress Purchase, we acquired an asset purchase agreement, dated February 2009 and amended December 2012 and again in January 2017, between Cypress and Cellatope Corporation, or Cellatope. Pursuant to the amended agreement, we obtained assets
related to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. In connection with one launch of our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Monitor testing product, we paid an upfront
payment of $100,000 and we are required to pay Cellatope a <FONT STYLE="white-space:nowrap">low-single</FONT> digit royalty on net sales up to a maximum of $3.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Dr.&nbsp;Thierry Dervieux and De Novo Diagnostics, Inc. </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
September 2011, we entered into a license agreement with Dr.&nbsp;Thierry Dervieux, our Chief Scientific Officer, and his company De Novo Diagnostics, Inc., under which we obtained an exclusive, worldwide (except for Australia and New Zealand)
license to Dr.&nbsp;Dervieux&#146;s patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> in certain inventions, or the Dervieux Patent Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents
related to our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the agreement, we are permitted
to develop, manufacture and commercialize products utilizing the Dervieux Patent Rights in the human healthcare market, and to sublicense such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In considerations for the rights granted to us under the agreement, we are required to make milestone payments, up to an aggregate of $600,000, upon
achievement of certain sales milestones. In addition, we are required to pay Dr.&nbsp;Dervieux a <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalty on net sales by us or our affiliates of any products utilizing the Dervieux Patent
Rights, subject to adjustment in certain circumstances. We are also obligated to pay Dr.&nbsp;Dervieux a percentage in the <FONT STYLE="white-space:nowrap">mid-twenties</FONT> of sublicense fees and royalties received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The agreement requires that we diligently develop and commercialize products that are covered by the Dervieux Patent Rights, and we have agreed to use
commercially reasonable efforts to bring technology covered by the Dervieux Patent Rights to market as soon as practicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may unilaterally terminate the agreement upon 12 months&#146; written notice to Dr.&nbsp;Dervieux.
Either party may terminate this agreement in the event of the other party&#146;s nonperformance of any of its obligations under the agreement if such nonperformance remains uncured for a specified period of time following receipt of written notice
of such nonperformance or in the event of the other party&#146;s insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Dervieux Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Laboratory Improvement Amendments of 1988 </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a clinical reference laboratory, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our
business. Under CLIA, we are required to hold a certificate applicable to the type of laboratory tests we perform and to comply with standards applicable to our operations, including test processes, personnel, facilities administration, equipment
maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA compliance and certification to be eligible to bill for diagnostic services provided to Medicare beneficiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have current certification under CLIA to perform testing at our Vista facility. To renew our CLIA certificate, we are subject to survey and
inspection every two years to assess compliance with program standards. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Penalties for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with CLIA requirements include suspension, limitation or revocation of the
laboratory&#146;s CLIA certificate, as well as directed plan of correction, state <FONT STYLE="white-space:nowrap">on-site</FONT> monitoring, civil money penalties, civil injunctive suit or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>State Laboratory Licensing </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to federal
certification requirements of laboratories under CLIA, licensure is required and maintained for our Vista clinical reference laboratory under California law. Such laws establish standards for the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of a clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, California laws mandate proficiency testing, which involves
testing of specimens that have been specifically prepared for the laboratory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because we receive specimens from New York, our clinical reference
laboratory is required to be licensed by New York, under New York laws and regulations, which establish standards for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of a clinical
laboratory, including training and skill levels required of laboratory personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">physical requirements of a facility; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">equipment; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">validation and quality control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether such laboratories are located
in New York. If a laboratory is out of compliance with New&nbsp;York statutory or regulatory standards, the New York Department of Health, or NYDOH, may suspend, limit, revoke or annul the laboratory&#146;s New York license, censure the holder of
the license or assess civil money penalties. Statutory or regulatory noncompliance may result in a laboratory&#146;s operator being found guilty of a misdemeanor under New York law. NYDOH also must approve the LDT before the test is offered in New
York. We have received written approval from NYDOH to offer our products in New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to New York and California, other states, including Maryland, Pennsylvania and Rhode
Island, require licensing of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT> laboratories under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Federal Oversight of Laboratory Developed Tests </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The laws and
regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Clinical laboratory tests like AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> SLE Prognostic and AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX are regulated under CLIA, as
administered by CMS, as well as by applicable state laws. In addition, the Federal Food, Drug and Cosmetic Act, or FDCA, defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or
other similar or related article, including a component part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our in vitro
testing products are considered by the FDA to be subject to regulation as medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage,
recordkeeping, <FONT STYLE="white-space:nowrap">pre-market</FONT> clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe
and effective for their intended uses. In addition, the FDA regulates the export of medical devices manufactured in the United States to international markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although the FDA has statutory authority to assure that medical devices are safe and effective for their intended uses, the FDA has generally exercised
its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are designed, manufactured, and used within a single laboratory for use only in that laboratory. These tests are referred to as laboratory
developed tests, or LDTs. We believe that the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD and AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX are LDTs, as are our near-term pipeline candidate tests. As a
result, we believe many of our diagnostic services are currently subject to the FDA&#146;s enforcement discretion and are not subject to the FDA&#146;s oversight. However, reagents, instruments, software or components provided by third parties and
used to perform LDTs may be subject to regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In recent years, FDA has stated its intention to modify its enforcement discretion policy with
respect to LDTs. For example, on July&nbsp;31, 2014, the FDA notified Congress of its intent to modify, in a risk-based manner, its policy of enforcement discretion with respect to LDTs. On October&nbsp;3, 2014, the FDA issued two draft guidance
documents entitled &#147;Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs),&#148; or the Framework Guidance, and &#147;FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs),&#148; or the Reporting
Guidance. The Framework Guidance states that FDA intends to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the classification of medical devices generally in Classes I through III. The FDA
further states its intention in the Framework Guidance to publish general LDT classification guidance within 18&nbsp;months of date on which the Framework Guidance is finalized. The Reporting Guidance would further enable FDA to collect information
regarding the LDTs currently being offered for clinical use through a notification process, as well as to enforce its regulations for reporting safety issues and collecting information on any known or suspected adverse events related to the use of
an LDT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight
approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution, the FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the
enforcement of regulatory requirements. Moreover, legislative measures have recently been proposed in Congress that, if ultimately enacted, could provide the FDA with additional authority to require premarket review of and regulate LDTs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Medical Device Regulatory Framework </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we currently market our proprietary testing products as LDTs, which are currently subject to enforcement discretion, we could be subject to more
onerous FDA compliance obligations in the future. Specifically, if the FDA begins to actively regulate LDTs, then, unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the U.S. will
require either a premarket notification to the FDA requesting permission for commercial distribution under Section&nbsp;510(k) of the FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a premarket approval, or PMA,
application. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Device
Classification </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the FDCA, medical devices are classified into one of three classes-Class I, Class&nbsp;II or Class&nbsp;III depending on
the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Class&nbsp;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by
adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#146;s quality system regulation, or QSR, facility registration and product listing,
reporting of adverse events and malfunctions, and appropriate, truthful and <FONT STYLE="white-space:nowrap">non-misleading</FONT> labeling and promotional materials. Some Class&nbsp;I devices also require premarket clearance by the FDA through the
510(k) premarket notification process described below. Most Class&nbsp;I products are exempt from the premarket notification requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Class&nbsp;II devices are those that are subject to the General Controls, and special controls as deemed necessary by the FDA to ensure the safety and
effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class&nbsp;II devices are subject to premarket review and clearance by the FDA.
Premarket review and clearance by the FDA for Class&nbsp;II devices is accomplished through the 510(k) premarket notification process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Class&nbsp;III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable
devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class&nbsp;III devices cannot be reasonably assured solely by the General Controls and Special Controls
described above. Therefore, these devices are subject to the PMA application process, which is generally more costly and time-consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information
demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#146;s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device
design and development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The PMA application must
provide valid scientific evidence that demonstrates to the FDA&#146;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The Investigational Device Process </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the U.S., absent
certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an IDE application. Some types of studies deemed to present <FONT STYLE="white-space:nowrap">&#147;non-significant</FONT> risk&#148;
are deemed to have an approved IDE once certain requirements are addressed and IRB approval is obtained. If the device presents a &#147;significant risk&#148; to human health, as defined by the FDA, the sponsor must submit an IDE application to the
FDA and obtain IDE approval prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in
humans and that the testing protocol is scientifically sound. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate
IRBs at the clinical trial sites. Submission of an IDE will note necessarily result in the ability to commence clinical trials, and although the FDA&#146;s approval of an IDE allows clinical testing to go forward for a specified number of subjects,
it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#146;s safety and efficacy, even if the trial meets its intended success criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All clinical trials must be conducted in accordance with the FDA&#146;s IDE regulations that govern investigational device labeling, prohibit promotion
and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA&#146;s good clinical practice regulations for IRB approval and for informed
consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable, or, even if the intended safety and efficacy success criteria are achieved, may not
be considered sufficient for the FDA to grant marketing approval or clearance of a product. The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous
reasons, including, but not limited to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical
trial on hold; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patients do not enroll in clinical trials at the rate expected; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patients do not comply with trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patient <FONT STYLE="white-space:nowrap">follow-up</FONT> is not at the rate expected; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patients experience adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patients die during a clinical trial, even though their death may not be related to the products that are evaluated during
the trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">device malfunctions occur with unexpected frequency or potential adverse consequences; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">side effects or device malfunctions of similar products already in the market that change the FDA&#146;s view toward
approval of new or similar PMAs or result in the imposition of new requirements or testing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">institutional review boards and third-party clinical investigators may delay or reject the trial protocol;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule
or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations or other FDA or IRB requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third-party investigators are disqualified by the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or
consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records and reports of sponsors of clinical investigations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third-party clinical investigators have significant financial interests related to us or our study such that the FDA deems
the study results unreliable, or we or investigators fail to disclose such interests; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to
undertake corrective action or suspend or terminate our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in government regulations or administrative actions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA concludes that our trial designs are unreliable or inadequate to demonstrate safety and efficacy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The 510(k) Clearance Process </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under
the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#147;substantially equivalent&#148; to a legally marketed predicate device. A predicate device is a legally marketed
device that is not subject to a PMA, i.e., a device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device) and for which a PMA is not required, a device that has been reclassified from
Class&nbsp;III to Class&nbsp;II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#147;substantially equivalent,&#148; the proposed device must have the same intended use as the predicate device,
and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes
required to support substantial equivalence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for
substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its
review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data,
the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will
grant clearance to commercially market the device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the FDA determines that the device is not &#147;substantially equivalent&#148; to a predicate
device, or if the device is automatically classified into Class&nbsp;III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo
process. The de novo classification process is an alternate pathway to classify medical devices that are automatically classified into Class&nbsp;III but which are low to moderate risk. A manufacturer can submit a petition for direct de novo review
if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. De novo classification may also be available after receipt of a &#147;not substantially
equivalent&#148; letter following submission of a 510(k) to FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After a device receives 510(k) clearance, any modification that could
significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA requires each
manufacturer to determine whether the proposed change requires a new submission in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#146;s determination. Many minor modifications are accomplished by a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">letter-to-file</FONT></FONT> in which the manufacture documents the change in an internal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">letter-to-file.</FONT></FONT> The
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">letter-to-file</FONT></FONT> is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the FDA
disagrees with a manufacturer&#146;s determination regarding whether a new premarket submission is required for the modification of an existing 510(k)-cleared device, the FDA can require the manufacturer to cease marketing and/or recall the modified
device until 510(k) clearance or approval of a PMA application is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite application(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>The PMA Approval Process </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit
a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA has 180 days to review a filed PMA application, although the review of an application
more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant,
requesting the applicant&#146;s response to deficiencies communicated by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Before approving or denying a PMA, an FDA advisory committee may
review the PMA at a public meeting and provide the FDA with the committee&#146;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of
an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to approval of a PMA, the FDA may conduct
inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years, but may take significantly
longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the device may not be shown safe or effective to the FDA&#146;s satisfaction; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and/or clinical trials may be found unreliable
or insufficient to support approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the manufacturing process or facilities may not meet applicable requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in FDA approval policies or adoption of new regulations may require additional data. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains
a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of
the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#146;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue
a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an
amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been
approved by the FDA for marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or
facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission
of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive
technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In approving a PMA application,
as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a <FONT STYLE="white-space:nowrap">follow-up</FONT> study or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide
additional or longer term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things,
restrictions on labeling, promotion, sale, distribution and use. New PMA applications or PMA supplements may also be required for modifications to any approved diagnostic tests, including modifications to our manufacturing processes, device labeling
and device design, based on the findings of post-approval studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Federal and State Physician Self-Referral Prohibitions </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar state law restrictions, such as
California&#146;s Physician Ownership and Referral Act, or PORA, and other comparable state laws. Together these restrictions generally prohibit us from billing a patient or any governmental or private payer for certain designated health services,
including clinical laboratory services, when the physician ordering the service, or any member of such physician&#146;s immediate family, has a financial interest, such as an ownership or investment interest in or compensation arrangement with us,
unless the arrangement meets an exception to the prohibition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Sanctions for a Stark Law violation include the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">denial of payment for the services provided in violation of the prohibition; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refunds of amounts collected by an entity in violation of the Stark Law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a civil penalty of up to $24,748 for each bill or claim for a service arising out of the prohibited referral;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the imposition of up to three times the amounts for each item or service wrongfully claimed; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">possible exclusion from federal healthcare programs, including Medicare and Medicaid; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a civil penalty of up to $164,992 for each arrangement or scheme that the parties know (or should know) has the principal
purpose of circumventing the Stark Law&#146;s prohibition. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These prohibitions apply regardless of any intent by the parties to
induce or reward referrals or the reasons for the financial relationship and the referral. In addition, knowing violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act, which can result in additional
civil and criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, a violation of PORA is a misdemeanor and could result in civil penalties and criminal fines. Other states
also have self-referral restrictions with which we have to comply, some of which differ from those imposed by the Stark Law or California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Federal and State
Anti-Kickback Laws </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Federal Anti-kickback Statute makes it a felony for a person or entity, including a clinical laboratory, to knowingly and
willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce business that is reimbursable under any federal health care program. A violation of the Anti-kickback
Statute may result in imprisonment for up to ten years and fines of up to $100,000 for each violation and administrative civil money penalties of $100,000 plus up to three times the amount of the remuneration paid. Convictions under the
Anti-kickback Statute result in mandatory exclusion from federal health care programs for a minimum of five years. In addition, The U.S. Department of Health and Human Services, or HHS, has the authority to impose civil assessments and fines and to
exclude health care providers and others engaged in prohibited activities from Medicare, Medicaid and other federal health care programs. In addition, the government may assert that a claim that includes items or services resulting from a violation
of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Anti-kickback Statute constitutes a false or fraudulent claim under the Federal False Claims Act, which is discussed in greater detail below. Additionally, a person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although the Anti-kickback Statute
applies only to items and services reimbursable under any federal health care program, a number of states, including California, have passed statutes substantially similar to the Anti-kickback Statute that apply to all third-party payers, including
commercial insurers, and in some states, to patients without insurance. The California Attorney General and courts have interpreted the California anti-kickback and <FONT STYLE="white-space:nowrap">fee-splitting</FONT> laws in substantially the same
way as HHS and the courts have interpreted the Anti-kickback Statute. Penalties of such state laws include imprisonment and significant monetary fines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Federal and state law enforcement authorities scrutinize arrangements between health care providers and potential referral sources to ensure that the
arrangements are not designed as a mechanism to induce patient care referrals or induce the purchase or prescribing of particular products or services. Generally, courts have taken a broad interpretation of the scope of the Anti-kickback Statute,
holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or purchases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to
statutory exceptions to the Anti-kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets the provisions of a safe harbor, it is deemed not to violate the Anti-kickback Statute. An arrangement must fully comply
with each element of an applicable safe harbor in order to qualify for protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Failure to meet the requirements of the safe harbor, however,
does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, taking into account all facts and circumstances.
There are no regulatory safe harbors under California laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other Federal and State Health Care Laws </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to the requirements discussed above, several other health care fraud and abuse laws could have an effect on our business. For example,
provisions of the Social Security Act permit Medicare and Medicaid to exclude an entity that charges the federal health care programs substantially in excess of its usual charges for its services. The terms &#147;usual charge&#148; and
&#147;substantially in excess&#148; are subject to varying interpretations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Federal False Claims Act prohibits, among other things, a person
from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval and from, making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim in order to secure
payment or retaining an overpayment by the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the
alleged fraud. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government intervenes and is ultimately successful in obtaining redress in the
matter or if the plaintiff succeeds in obtaining redress without the government&#146;s involvement, then the plaintiff will receive a percentage of the recovery. Finally, the Social Security Act includes its own provisions that prohibit the filing
of false claims or submitting false statements in order to obtain payment. Violation of these provisions may result in fines, imprisonment or both, and possible exclusion from Medicare or Medicaid programs. Several states, including California, have
enacted comparable false claims laws which may be broader in scope and may apply regardless of payer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The civil monetary penalties statute imposes
penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. A person who offers or provides to a Medicare or Medicaid
beneficiary any remuneration, including waivers of <FONT STYLE="white-space:nowrap">co-payments</FONT> and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#146;s selection of a
particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $20,000 for each wrongful act and up to three times the amount improperly claimed. Moreover, in
certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and False Claims Act. One of the statutory exceptions to the prohibition is <FONT
STYLE="white-space:nowrap">non-routine,</FONT> unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The Office of Inspector General of HHS,
or OIG, emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, applicable state laws
related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be implicated for similar practices offered to patients covered by
commercial payers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">HIPAA created new federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting
to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to
have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act
of 2010, collectively the Affordable Care Act, or ACA, among other things, also imposed annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases
their distributors to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Any failure to comply with these reporting requirements could result in significant fines
and penalties. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that the government will agree with our determination,
and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If our operations are found to be in violation of any of the fraud and abuse laws described above or any other laws that apply to us, we may be subject
to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm,
administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>International Regulations </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many countries in which we may
offer any of our testing products in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any
national health care program. In situations involving physicians employed by state-funded institutions or national health care agencies, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
violation of the local anti-kickback law may also constitute a violation of the U.S. Foreign Corrupt Practices Act, or FCPA, and/or other applicable anti-corruption laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity from offering or providing, directly or through a third
party, including any potential distributors we may rely on in certain markets, anything of value to a foreign official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct
violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate
information and control over sales and distributors&#146; activities that may fall within the purview of the FCPA, including its books and records provisions and its anti-bribery provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The standard of intent and knowledge under the FCPA&#146;s anti-bribery provisions is minimal intent and knowledge are usually inferred from the fact
that bribery took place. The FCPA&#146;s accounting provisions do not require intent. Violations of the FCPA&#146;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2&nbsp;million and officers,
directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption
regulations, such as the UK Bribery Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">When marketing our testing products outside of the U.S., we may be subject to foreign regulatory
requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our testing products or restrictions on the export of tissue imposed by countries outside of the U.S. or the import of tissue into the
U.S., and marketing approval. These requirements vary by jurisdiction, differ from those in the U.S. and may in some cases require us to perform additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical testing. In many countries
outside of the U.S., coverage, pricing and reimbursement approvals are also required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Privacy and Security Laws </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Health Insurance Portability and Accountability Act; California Consumer Privacy Act of 2018, or the CCPA </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and
Clinical Health Act, or HITECH Act, HHS has issued regulations to protect the privacy and security of protected health information used or disclosed by certain entities including health care providers, such as us. HIPAA also regulates
standardization of data content, codes and formats used in certain health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA and HITECH laws and regulations include civil and
criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Three standards have been promulgated under HIPAA&#146;s and HITECH&#146;s regulations: the Standards for Privacy of
Individually Identifiable Health Information, which restrict the use and disclosure of certain individually identifiable health information, the Standards for Electronic Transactions, which establish standards for common healthcare transactions,
such as claims information, plan eligibility, payment information and the use of electronic signatures, and the Security Standards for the Protection of Electronic Protected Health Information, or Security Standards, which require covered entities
and business associates to implement and maintain certain security measures to safeguard certain electronic health information, including the adoption of administrative, physical and technical safeguards to protect such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2009, Congress passed the American Recovery and Reinvestment Act of 2009, or ARRA, which included sweeping changes to HIPAA, including an expansion
of HIPAA&#146;s privacy and security </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
standards. ARRA includes the HITECH Act, which, among other things, made HIPAA&#146;s security standards directly applicable to business associates of covered entities effective February&nbsp;17,
2010. A business associate is a person or entity that performs certain functions or activities on behalf of a covered entity that involve the use or disclosure of protected health information for or on behalf of the covered entity. As a result,
business associates are now subject to significant civil and criminal penalties for failure to comply with applicable standards. Moreover, HITECH creates a new requirement to report certain breaches of unsecured, individually identifiable health
information and imposes penalties on entities that fail to do so. This requirement was modified and expanded by the final HIPAA Omnibus Rule of 2013. HITECH also increased the civil and criminal penalties that may be imposed against covered entities
and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney fees and costs associated with pursuing federal civil actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">HIPAA also governs patient access to laboratory test reports. Effective October&nbsp;6, 2014, individuals (or their personal representatives, as
applicable) have the right to access test reports directly from laboratories and to direct that copies of those reports be transmitted to persons or entities designated by the individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to HIPAA and HITECH, there are state data breach notification laws, state health information privacy laws, and federal and state consumer
protection laws (e.g., Section 5 of the Federal Trade Commission Act and CCPA, that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our
collaborators. The state of California, for example, recently adopted the California Consumer Privacy Act of 2018, or the CCPA, which will come into effect beginning in January 2020.&nbsp;The CCPA has been characterized as the first
&#147;GDPR-like&#148; privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the European Union General Data Protection Regulation , or the GDPR, (discussed below). The CCPA establishes a new privacy
framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and
creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches.&nbsp;Penalties for violations of the CCPA
will include civil penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>GDPR and Foreign Laws </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
are also subject to foreign privacy laws in the foreign jurisdictions in which we sell our testing products. The interpretation, application and interplay of consumer and health-related data protection laws in the U.S., Europe and elsewhere are
often uncertain, contradictory and in flux. For example, the European Union enacted Regulation (EU) 2016/679 (General Data Protection Regulation, or GDPR), has been enacted in the European Union and went into full effect in May 2018. These texts
introduce many changes to privacy and security in the European Union, including stricter rules on consent and security duties for critical industries, including for the health sector. The interpretation of some rules is still unclear, and some
requirements will be completed by national legislation. More generally, foreign laws and interpretations governing data privacy and security are constantly evolving and it is possible that laws may be interpreted and applied in a manner that is
inconsistent with current practices, subjecting entities to government-imposed fines or orders. These fines can be very high. For instance, the GDPR introduces fines of up to EUR 20&nbsp;million or 4% of a group&#146;s worldwide annual turnover for
certain infringements. In addition, privacy regulations differ widely from country to country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Billing and Government Reimbursement for Clinical Laboratory
Services </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and
necessary for the diagnosis or treatment of an illness or injury. With </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
respect to Medicare coverage, Palmetto GBA, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare&#146;s molecular diagnostic services program, or MolDX Program,
issued a local coverage determination, or LCD, that provides coverage for our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> MTX test. The MAC responsible for administering Medicare claims submitted by our laboratory, Noridian
Healthcare Solutions, has adopted Palmetto&#146;s positive coverage policy, along with a related local coverage article that identifies a unique billing identifier for this test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under Medicare, payment for our laboratory tests are generally made under the Clinical Laboratory Fee Schedule, or CLFS, with payment amounts assigned
to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act, or PAMA, which included substantial changes to the way in which clinical laboratory services will be paid under Medicare. Under PAMA,
laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or the Physician Fee Schedule are required to report to CMS, beginning in 2017 and every three years thereafter (or annually for &#147;advanced
diagnostic laboratory tests&#148;), private payer payment rates and volumes for their tests. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. As required under PAMA, CMS uses
the rates and volumes reported by laboratories to develop Medicare payment rates for laboratory tests equal to the volume-weighted median of the private payer payment rates for the tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;23, 2016, CMS published the final rule implementing the reporting and rate-setting requirements under PAMA. For tests furnished on or after
January&nbsp;1, 2018, Medicare payments for clinical diagnostic laboratory tests are based upon these reported private payer rates. For clinical diagnostic laboratory tests that are assigned a new or substantially revised CPT code, initial payment
rates will be assigned by the <FONT STYLE="white-space:nowrap">gap-fill</FONT> methodology, as under prior law. Initial payment rates for new advanced diagnostic laboratory tests will be based on the actual list charge for the laboratory test. Any
reductions to payment rates resulting from the new methodology are limited to 10% per test per year in each of the years 2018 through 2020 and to 15% per test per year in each of the years 2021 through 2023. PAMA&#146;s impact on Medicare
reimbursement for AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD in 2018 was <FONT STYLE="white-space:nowrap">-3.2%</FONT> and is expected to be <FONT STYLE="white-space:nowrap">-10.1%,</FONT> in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">PAMA also authorizes the adoption of new, temporary billing codes and unique test identifiers for <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> or
approved tests, as well as advanced diagnostic laboratory tests. The AMA&#146;s CPT Editorial Panel has approved a proposal to create a new section of billing codes to facilitate implementation of this section of PAMA. These proprietary laboratory
analyses codes, or PLA codes, may be requested by a clinical laboratory or manufacturer to specifically identify their test. If approved, the codes are issued by the AMA on a quarterly basis. While our testing products are not presently identified
by any PLA codes, we may seek a specific PLA code or codes to describe some of our testing products in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Billing for diagnostic testing
can be complicated. Depending on the billing arrangement and applicable law, we must bill various payers, such as insurance companies, Medicare, Medicaid, physicians, hospitals, employer groups and patients, all of which have different billing
requirements. Additionally, compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further complexity to the billing process. Changes in laws and regulations could negatively impact our ability to
bill our clients or increase our costs. CMS also establishes new procedures and continuously evaluates and implements changes to the reimbursement process for billing government programs. Missing or incorrect information on test requisitions adds
complexity to and slows the billing process, creates backlogs of unbilled tests, and generally increases the aging of accounts receivable and bad debt expense. Failure to timely or correctly bill may lead to our not being reimbursed for our services
or an increase in the aging of our accounts receivable, which could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
adversely affect our results of operations and cash flows. Failure to comply with applicable laws relating to billing federal healthcare programs could also lead to various penalties, including:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overpayments and recoupments of reimbursement received; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exclusion from participation in Medicare/Medicaid programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">asset forfeitures; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">civil and criminal fines and penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the loss of various licenses, certificates and authorizations necessary to operate our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any of these penalties or sanctions could have a material adverse effect on our results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Healthcare Reform </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2010, the ACA was enacted in the
U.S. The ACA made a number of substantial changes to the way healthcare is financed by governmental and private insurers. For example, the ACA requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such
manufacturer sells its medical devices. The medical device tax has been suspended until December&nbsp;31, 2019, but is scheduled to return beginning in 2020. It is unclear at this time when, or if, the provision of our LDTs will trigger the medical
device tax if the FDA ends its policy of general enforcement discretion and regulates certain LDTs as medical devices, and it is possible that this tax will apply to some or all of our existing testing products or testing products we may develop in
the future. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters and fraud and abuse, which we expect will impact our industry and our
operations in ways that we cannot currently predict. Additionally, on December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the entire ACA is invalid based primarily on the
fact that the Tax Cuts and Jobs Act of 2017 repealed the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA, on certain individuals who fail to maintain qualifying health coverage for all or part of a
year, which is commonly referred to as the &#147;individual mandate&#148;. While the Texas District Court Judge, as well as the current presidential administration and CMS, have stated that this ruling will have no immediate effect, it is unclear
how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additional state and federal health
care reform measures may be adopted in the future, any of which could have a material adverse effect on the clinical laboratory industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, we had 144 employees, all but two of whom were full time, 26 of whom work in laboratory operations, six in research and
development, 68 in sales and marketing and 44 in general and administrative functions. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Suppliers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We rely on sole suppliers for the critical
supply of reagents, equipment and other materials that we use to perform the tests that comprise our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing products. We also purchase components used in our AVISE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We lease approximately 14,000 square feet of
office and laboratory space in Vista, California, under a lease that expires in 2021, with options to extend the lease for an additional <FONT STYLE="white-space:nowrap">36-month</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
We also lease an additional approximately 19,500 square feet of office space in Vista, California, under a lease that is <FONT STYLE="white-space:nowrap">co-terminus</FONT> with our other lease
expiring in 2021. We believe that our existing facilities and arrangements are adequate to meet our business needs for at least the next 12 months and that additional space will be available on commercially reasonable terms, if required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Environmental Matters </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our operations require the use of
hazardous materials (including biological and chemical materials) which subject us to a variety of federal, state and local environmental and safety laws and regulations. We could be held liable for damages and fines as a result of our business
operations. We cannot predict how changes in laws or regulations will affect our business, operations or the cost of compliance. We mitigate this risk by being in compliance with these laws and the CAP checklists. We have established Universal
Precautions, as mandated by the Occupational Safety&nbsp;&amp; Health Administration, to be practiced to prevent employee exposure to blood and other potentially infectious materials. Engineering and work practice controls are used to eliminate or
minimize employee exposure. Personal protective equipment is used when occupational exposure may occur even though the engineering and work practice controls are in place. This Injury and Illness Prevention Program, or IIPP, is designed to furnish
employees with a safe and healthy place of employment. This IIPP describes specific requirements for program responsibility, compliance, communication, hazard assessment, accident/exposure investigations, hazard correction, training and
recordkeeping. In addition, appropriate biohazardous, chemical and sharps waste disposal are in place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we
believe are likely to have a material adverse effect on our business, operating results or financial condition. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless
of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table
sets forth the name, age and position of each of our executive officers, key employees and directors as of August&nbsp;31, 2019. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Fortunato Ron Rocca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Kamal Adawi</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">40</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief&nbsp;Financial&nbsp;Officer&nbsp;and&nbsp;Corporate&nbsp;Secretary&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Thierry Dervieux, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">51</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Brian Birk<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Chet Burrell<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">72</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Jeff Elliott<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">41</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Tina S. Nova, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">66</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Ebetuel Pallares, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">46</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Bruce C. Robertson, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">James L.L. Tullis<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">72</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of the audit committee </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of the compensation committee </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of the nominating and corporate governance committee </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Fortunato Ron Rocca</I> has served as
our President and Chief Executive Officer and as a member of our board of directors since December 2011. From 2005 to October 2011, Mr.&nbsp;Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus, a specialty
pharmaceutical and diagnostic company which was acquired by Nestl&eacute; SA in 2011, where he was responsible for leading the commercial organization, strategic planning and implementation of projects designed to maximize brand sales. Prior to
joining Prometheus, Mr.&nbsp;Rocca served as the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr.&nbsp;Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a
neuroscience-focused biotechnology company and Janssen Pharmaceuticals, Inc., a pharmaceutical subsidiary of Johnson&nbsp;&amp; Johnson. Mr.&nbsp;Rocca received a B.S. in Marketing and Personnel Management from Towson State University.
Mr.&nbsp;Rocca&#146;s extensive knowledge of our business, as well as his over 25 years of experience in the diagnostic and pharmaceutical industries, contributed to our board of directors&#146; conclusion that he should serve as a director of our
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Kamal Adawi</I> has served as our Chief Financial Officer since June 2017 and as our Corporate Secretary since September 2017. From
2014 to 2017, Mr.&nbsp;Adawi served as the Chief Financial Officer, Corporate Secretary and Treasurer at Pathway Genomics Corporation, or Pathway Genomics, a global genetic testing company. Prior to joining Pathway Genomics, from March 2014 to
December 2014, Mr.&nbsp;Adawi served as our Director of Financial Planning and Analysis. Earlier in his career, Mr.&nbsp;Adawi managed the finance departments for GenMark Diagnostics, Inc., serving as its Manager of Financial Planning and Analysis,
and Digirad Corporation, serving as its Manager of Financial Planning and Analysis, both publicly traded diagnostic companies. Mr.&nbsp;Adawi also served in various capacities in the finance and accounting departments at Becton, Dickinson and
Company, a global medical technology company. Mr.&nbsp;Adawi received a B.A. in Finance from Michigan State University, an M.B.A. from Oakland University with a focus on management, and a M.S. in Finance from San Diego State University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Thierry Dervieux, Ph.D. </I>has served as our Chief Scientific Officer and Medical Laboratory
Director since October 2010. Prior to joining Exagen, from 2008 to October 2010, Dr.&nbsp;Dervieux served as Vice President of Research and Development with Cypress, a pharmaceutical company with a focus on drugs to treat central nervous system
disorders, where he developed our current portfolio in the rheumatology space. Dr.&nbsp;Dervieux previously served as Senior Director Research&nbsp;and Development of Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized
medicine company focused in rheumatology and pain management, until its acquisition by Cypress. Earlier in his career, Dr.&nbsp;Dervieux served as Principal Scientist and Director of Research&nbsp;and Development of Prometheus. Dr.&nbsp;Dervieux has
nearly 20 years of experience with the development of drug monitoring and molecular diagnostic assays in partnership with academia and diagnostic industry. Dr.&nbsp;Dervieux is board certified by the American Board of Clinical Chemistry and holds
certificates of qualification as medical laboratory director in the categories of cellular immunology, clinical chemistry, drug monitoring and diagnostic immunology. Dr.&nbsp;Dervieux holds Pharm.D. and Ph.D. degrees from Claude Bernard University
in Lyon, France, an inter-university diploma in biostatistics from the University of Pierre et Marie Curie in Paris, France, and trained at St. Jude Children&#146;s Research Hospital in Memphis, Tennessee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Brian Birk</I> has served as a member of our board of directors since June 2008. In 2006, Mr.&nbsp;Birk
<FONT STYLE="white-space:nowrap">co-founded</FONT> Sun Mountain Capital, a boutique private equity firm focused on the southwest and Rocky Mountain regions which currently manages direct investment funds and funds of funds vehicles and where he
serves as Managing Partner. Prior to forming Sun Mountain Capital, Mr.&nbsp;Birk served as a Vice President and Director of Private Equity at Fort Washington Capital Partners, a professional investment management services company. Mr.&nbsp;Birk also
served as the Vice President of Technology Commercialization at Applied Minds, LLC, a technology consulting company, and the President of a division at BiosGroup Inc., a company which commercialized complex science software. Earlier in his career,
Mr.&nbsp;Birk held a senior manager position at the Boston Consulting Group, Inc., a global management consulting firm, and finance manager positions at General Electric Company, an American multinational conglomerate, and GE Capital Corporation,
its financial services unit. Mr.&nbsp;Birk is currently a member of the board of directors of several private companies, including Agilvax, Inc., Aspen Avionics, Inc., Avisa Pharma, Inc., Green Theme Technologies, Inc. and Respira Therapeutics, Inc.
Mr.&nbsp;Birk received a B.A. in Economics from Carleton College and an M.B.A. from Northwestern University&#146;s Kellogg School of Management. Mr.&nbsp;Birk&#146;s experience as a venture capitalist and prior executive experience contributed to
our board of directors&#146; conclusion that he should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Chet Burrell</I> has served as a member of our board
of directors since July 2019. In mid-2018, Mr.&nbsp;Burrell founded Silavon Healthcare Holdings, LLC, an entity he established in to pursue investments in the healthcare field and where he serves as Managing Member. Prior to forming Silavon
Healthcare Holdings, from December 2007 to June 2018, Mr.&nbsp;Burrell served as President and Chief Executive Officer of CareFirst BlueCross BlueShield, a health insurer and health benefit services company. Prior to his role at CareFirst BlueCross
BlueShield, Mr.&nbsp;Burrell served as Chairman and Chief Executive Officer of RealMed Corporation, a provider of online claims processing services for the health care industry, and as Founder, Chairman and Chief Executive Officer of Novalis
Corporation, a managed care technology and consulting company. Mr.&nbsp;Burrell also served as an executive officer of numerous other U.S. healthcare companies in both the public and private sectors. Mr.&nbsp;Burrell currently serves as a member of
the board of directors of several private companies and organizations in the healthcare field, including the Committee on Affordable and Quality Healthcare, America&#146;s Health Insurance Plans, and the National Blue Cross and Blue Shield
Association. Mr.&nbsp;Burrell received a B.A. in Sociology and Political Science from Allegheny College and a M.P.A. from the State University of New York at Albany. Mr.&nbsp;Burrell&#146;s extensive chief executive and leadership experience in the
healthcare field and his service as a leader and director of numerous healthcare companies and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
organizations contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Jeff Elliott</I> has served as a member of our board of directors since March 2019. Mr. Elliott has served as Chief Financial Officer of Exact
Sciences Corporation, a molecular diagnostics company, since November 2016. Prior to his appointment as Chief Financial Officer, Mr. Elliott served as the Vice President, Business Development and Strategy of Exact Sciences from June 2016 to November
2016. From 2007 to 2016, Mr. Elliott was with Robert W. Baird &amp; Co., where from June 2012 to June 2016 he was a senior research analyst who covered diagnostics and life science tools companies. Earlier in his career, Mr. Elliott worked in a
supply chain role for Walgreens and as a consultant at Cap Gemini Ernst &amp; Young. Mr. Elliott earned a B.S. in business administration from the University of Illinois at Urbana-Champaign and an M.B.A. from the University of Chicago Booth School
of Business. Mr. Elliott is a CFA charterholder. Mr. Elliott&#146;s executive experience and experience in the diagnostics and life sciences industries contributed to our board of directors&#146; conclusion that he should serve as a director of our
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Tina S. Nova, Ph.D.</I>, has served as a member of our board of directors since July 2019. Dr.&nbsp;Nova has served as President and
Chief Executive Officer of Decipher Biosciences, Inc. (formerly GenomeDx, Inc.), a molecular diagnostics company, since September 2018. Dr.&nbsp;Nova served as President and Chief Executive of Molecular Stethoscope, Inc., a diagnostics company from
September 2015 to August 2018. Dr.&nbsp;Nova served as Senior Vice President and General Manager of Illumina Inc.&#146;s oncology business unit from July 2014 to August 2015. Dr.&nbsp;Nova was a <FONT STYLE="white-space:nowrap">co-founder</FONT> of
Genoptix, Inc., a medical laboratory diagnostics company, and served as its President from 2000 to April 2014. Dr.&nbsp;Nova also served as the Chief Executive Officer of Genoptix and as a member of its board of directors from 2000 until Novartis AG
acquired Genoptix in March 2011. Dr.&nbsp;Nova was a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Nanogen, Inc., a provider of molecular diagnostic tests, and she served as its Chief Operating Officer and President from 1994 to 2000.
Dr.&nbsp;Nova served as Chief Operating Officer of Selective Genetics, a biotechnology company, from 1992 to 1994, and in various director-level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, from 1988
to 1992, most recently as Executive Director of New Leads Discovery. Dr.&nbsp;Nova has also held various research and management positions with Hybritech, Inc., a former subsidiary of Eli Lilly&nbsp;&amp; Company, a pharmaceutical company.
Dr.&nbsp;Nova serves as a member of the board of directors of Arena Pharmaceuticals, Inc., a biopharmaceutical company, Veracyte, Inc., a diagnostics company, and OpGen, Inc., an infection prevention and treatment company. Within the past five
years, Dr.&nbsp;Nova also served as a member of the board of directors of Adamis Pharmaceuticals Corporation, a biopharmaceutical company, NanoString Technologies, Inc., a provider of life science tools, and Cypress Biosciences, Inc., a
pharmaceutical company. Dr.&nbsp;Nova holds a B.S. in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside. Dr.&nbsp;Nova&#146;s extensive leadership, business and
scientific expertise in the biopharmaceutical and diagnostics industries, and her experience in successfully developing, launching and commercializing medical products contributed to our board of directors&#146; conclusion that she should serve as a
director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Ebetuel Pallares, Ph.D.</I> has served as a member of our board of directors since October 2012. In December 2014,
Dr.&nbsp;Pallares founded Proficio Capital Management (PCM), LLC, a seed and early-stage venture fund headquartered in El Paso, TX, and he has served as its General Partner since that time. Through PCM, Dr.&nbsp;Pallares manages several investments,
including PCM/Exagen L.P. In June 2009, he <FONT STYLE="white-space:nowrap">co-founded</FONT> Cottonwood Capital Partners, the general partner of Cottonwood Technology Fund, a seed and early-stage venture fund with headquarters in El Paso, Texas,
and he served as its Managing Partner until December 2014. In 2006, Dr.&nbsp;Pallares founded Joseph Advisory Services, LLC, a strategic consulting firm, and has served as its Manager since that time. He also currently manages investments on behalf
of a family office, managing fund commitments and direct investments into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
private operating companies. His investment sectors span healthcare, medical diagnostics, therapeutics, IT, materials sciences and nanotechnology, education technology, AR/VR and financial
technology companies. Dr.&nbsp;Pallares also serves on several corporate and <FONT STYLE="white-space:nowrap">non-profit</FONT> boards, as an advisor to the UT Horizon Fund, the venture capital investment fund of the University of Texas system, as
an Investor in Residence for New Mexico State University&#146;s Arrowhead Center and on the limited partnership advisory committee for several venture funds. He received a B.A. in economics from Brandeis University, an M.B.A. from The University of
Texas at El Paso, or UTEP, and a Ph.D. in International Business from UTEP. Dr.&nbsp;Pallares&#146;s extensive venture capital experience and his service as a director for numerous companies contributed to our board of directors&#146; conclusion
that he should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Bruce C. Robertson, Ph.D.</I>, has served as a member of our board of directors since July
2019. Since 2005, Dr.&nbsp;Robertson has served as Managing Director of H.I.G. Capital, LLC, a global private equity and investment firm. Dr.&nbsp;Robertson previously served as a Managing Director at Toucan Capital, an early-stage venture capital
firm. Dr.&nbsp;Robertson serves as a member of the board of directors of Apollo Endosurgery, Inc., a medical device company. Dr.&nbsp;Robertson holds a B.S.E. in Chemical Engineering and B.A. in Mathematics from the University of Pennsylvania, an
M.B.A. from Harvard Business School, and a Ph.D. in Chemical Engineering from the University of Delaware. Dr.&nbsp;Robertson&#146;s medical and research background and his extensive experience as an investor in the medical technologies industry
contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>James L.L. Tullis</I> has served as a
member of our board of directors since May 2015. In 1986, Mr.&nbsp;Tullis founded Tullis Health Investors, a venture capital firm specializing in investments in the healthcare industry and served as its Chief Executive Officer from its inception
until December 2018. Since January 2019, Mr.&nbsp;Tullis has served as its Chairman. Earlier in his career, Mr.&nbsp;Tullis was a Senior Vice President at E.F.&nbsp;Hutton&nbsp;&amp; Co., a stock brokerage firm, and a principal at Morgan
Stanley&nbsp;&amp; Co., where he worked with the healthcare investment research and banking teams. Since 2006, Mr.&nbsp;Tullis has served as a member of the board of directors and since January 2017 as chair of the board of directors of Lord
Abbett&nbsp;&amp; Co. Mutual Funds, an investment management firm. Since 1998, he has served as a member of the board of directors of Crane Co., an industrial products manufacturing company, where he also serves as Chair of the Management
Organization and Compensation Committee. Mr.&nbsp;Tullis also currently serves as a member of the board of directors of Alphatec Spine, Inc., a medical technology company, electroCore Inc., a bioelectronic medicine company, and a private company,
SupplyPro, Inc., an inventory management solutions company. Mr.&nbsp;Tullis holds a B.A. from Stanford University and an M.B.A. from Harvard Business School. Mr.&nbsp;Tullis&#146;s extensive experience serving as a venture capitalist and board
member for numerous companies in the health care industry contributed to our board of directors&#146; conclusion that Mr.&nbsp;Tullis should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition and Election of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Director Independence
</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors currently consists of eight members. Our board of directors has determined that all of our directors, other than
Mr.&nbsp;Rocca, are independent directors in accordance with the listing requirements of Nasdaq. The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years,
one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to
each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our
board of directors reviewed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and our management.
There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Classified Board of Directors </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect immediately prior to the completion of
this offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election
and qualification until the third annual meeting following election. Effective upon the completion of this offering, our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;I directors will be Mr.&nbsp;Birk, Dr.&nbsp;Nova and Dr.&nbsp;Pallares, and their terms will expire at our
first annual meeting of stockholders following this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;II directors will be Mr.&nbsp;Burnell, Mr.&nbsp;Elliott and Mr.&nbsp;Tullis, and their terms will expire at
our second annual meeting of stockholders following this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;III directors will be Mr.&nbsp;Rocca and Dr.&nbsp;Robertson, and their terms will expire at our third annual
meeting of stockholders following this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation that will go into effect
immediately prior to the completion of this offering will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors
will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered
three-year terms may delay or prevent a change of our management or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least two thirds of our outstanding voting stock then
entitled to vote in the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors is currently led by its chairman, Brian Birk. Our board of directors recognizes that it is important to determine an optimal board
leadership structure to ensure the independent oversight of management as we continue to grow. We separate the roles of chief executive officer and chairman of the board in recognition of the differences between the two roles. The chief executive
officer is responsible for setting the strategic direction for our company and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership and performance of our company, while the chairman of the board
of directors provides guidance to the chief executive officer and presides over meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to managing the board of directors and
overseeing our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has concluded that our current leadership structure is appropriate at this time. However, our board
of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of Board in
Risk Oversight Process </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has responsibility for the oversight of our risk management processes and, either as a whole or
through its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees
and members of senior management to enable our board to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic
and reputational risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The audit committee reviews information regarding liquidity and operations, and oversees our
management of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with
our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our
compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the board, corporate disclosure practices, and potential
conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board is regularly informed through committee reports about such risks. Matters of significant strategic
risk are considered by our board as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees and Independence </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of which
operates under a charter that has been approved by our board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The audit committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements. This
committee&#146;s responsibilities include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appointing our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating the qualifications, independence and performance of our independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approving the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent
registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical
accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">discussing with management and the independent registered public accounting firm the results of our annual audit and the
review of our quarterly unaudited financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory
requirements as they relate to financial statements or accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board any changes to such
investment policy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results
of operations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and
ethics; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of
the audit committee with its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The members of our audit committee are Mr.&nbsp;Elliott, Mr.&nbsp;Burrell and
Dr.&nbsp;Nova. Mr.&nbsp;Elliott serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has
determined that Mr.&nbsp;Elliott is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Nasdaq rules and regulations. Our board of directors has determined each of Mr.&nbsp;Elliott, Mr.&nbsp;Burrell and Dr.&nbsp;Nova are independent under the applicable rules of the SEC and Nasdaq.
Under the applicable Nasdaq rules, we are permitted to phase in our compliance with the independent audit committee requirements of Nasdaq on the same schedule as we are permitted to phase in our compliance with the independent audit committee
requirements pursuant to Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, which require: (i)&nbsp;one independent member at the time of listing, (ii)&nbsp;a majority of independent members within 90 days of listing and
(iii)&nbsp;all independent members within one year of listing. We will comply with the <FONT STYLE="white-space:nowrap">phase-in</FONT> requirements of the Nasdaq rules, and within one year of our listing on Nasdaq, all members of our audit
committee will be independent under Nasdaq rules and Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> Upon the listing of our common stock on Nasdaq, the audit committee will operate under a written charter that satisfies the applicable standards
of the SEC and Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee approves
corporate goals and objectives relevant to the compensation of our chief executive officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these
officers based on such evaluations. The compensation committee also approves the issuance of stock options and other awards under our equity plan. The compensation committee will review and evaluate, at least annually, the performance of the
compensation committee and its members, including compliance by the compensation committee with its charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The members of our compensation
committee are Dr.&nbsp;Robertson, Dr.&nbsp;Nova and Mr.&nbsp;Tullis. Dr.&nbsp;Robertson serves as the chairperson of the committee. Our Board has determined that each member of this committee is independent under the applicable rules and regulations
of Nasdaq and is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Upon the listing of our common stock on Nasdaq, the
compensation committee will operate under a written charter, which the compensation committee will review and evaluate at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nominating and
Corporate Governance Committee </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The nominating and corporate governance committee is responsible for assisting our board of directors in
discharging the board&#146;s responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of
stockholders at which directors are to be elected), and the selection of candidates to fill any vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for
overseeing our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The members of our nominating and corporate
governance committee are Mr.&nbsp;Birk, Dr.&nbsp;Pallares and Dr.&nbsp;Robertson. Mr.&nbsp;Birk serves as the chairman of the committee. Our board has determined that each member of this committee is independent under the applicable rules and
regulations of Nasdaq relating to nominating and corporate governance committee independence. Upon the listing of our common stock on Nasdaq, the nominating and corporate governance committee will operate under a written charter, which the
nominating and corporate governance committee will review and evaluate at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">None of the members of our compensation committee has ever been one of our officers or employees. None of our executive officers currently serves, or has
served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Diversity </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on
an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for
election or appointment, the nominating and corporate governance committee, in recommending candidates for election, and the board of directors will take into account many factors, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">personal and professional integrity, ethics and values; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly-held company;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience as a board member or executive officer of another publicly-held company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">strong finance experience; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of
residence and specialized experience; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience relevant to our business industry and with relevant social policy concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">relevant academic expertise or other proficiency in an area of our business operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently, our board of directors evaluates, and following the completion of this offering will evaluate, each individual in the context of the board of
directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We plan to adopt a
written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions, which will be effective upon the completion of this offering. Upon the completion of this offering, our code of business conduct and ethics will be available under the Corporate Governance section of our website at www.exagen.com. In
addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute
incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This section discusses the material
components of the executive compensation program for our executive officers who are named in the &#147;2018 Summary Compensation Table&#148; below. In 2018, our chief executive officer and our two other highest-paid executive officers, or our named
executive officers, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Fortunato Ron Rocca, President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Kamal Adawi, Chief Financial Officer and Corporate Secretary; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Thierry Dervieux, Ph.D., Chief Scientific Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding
future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ materially from the currently planned programs summarized in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2018 Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets
forth information concerning the compensation of our named executive officers during the fiscal year ended December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name&nbsp;and&nbsp;Principal&nbsp;Position:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fortunato Ron Rocca</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">348,113</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">157,357</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53,499</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">567,219</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kamal Adawi</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Financial Officer and Corporate Secretary</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">271,039</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">61,088</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13,910</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">354,287</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thierry Dervieux, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">278,391</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">62,920</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16,050</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">365,611</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">With respect to Mr. Adawi, amounts reflect the aggregate grant date fair value of stock options granted in 2018 and with
respect to Mr.&nbsp;Rocca and Dr.&nbsp;Dervieux, amounts reflect the incremental fair value of stock options granted pursuant to our <FONT STYLE="white-space:nowrap">one-time</FONT> stock option exchange in October 2018, as explained further below,
each as computed in accordance with ASC Topic 718, <I>Compensation-Stock Compensation</I>. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the
exercise of the stock options, or the sale of the common stock underlying such stock options. The assumptions that we used to calculate these amounts are discussed in Note 12 to our audited financial statements appearing elsewhere in this
prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents employer matching contributions under our 401(k) plan on behalf of each named executive officer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2018 Salaries </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The named executive officers receive a
base salary to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and
responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2018 base salaries for Messrs. Rocca and Adawi and Dr.&nbsp;Dervieux were $348,113, $271,039, and $278,391,<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2018 Bonuses </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our named executive officers were eligible to earn cash bonuses based on Company performance during the year ended December&nbsp;31, 2018, as determined
by our board of directors in its sole discretion. For 2018, Mr. Rocca was eligible to receive a target bonus of up to 50% of his base salary and Mr. Adawi and Dr.&nbsp;Dervieux were eligible to receive a target bonus of up to 25% of their respective
base salaries, each pursuant to the terms of his employment agreement described below under &#147;&#151;Agreements with our Named Executive Officers.&#148; Our board of directors will generally consider each named executive officer&#146;s individual
contributions towards reaching our annual corporate goals but does not typically establish specific individual goals for our named executive officers. There is no minimum bonus percentage or amount established for the named executive officers and,
as a result, the bonus amounts vary from year to year based on corporate and individual performance. The 2018 bonuses for Messrs. Rocca and Adawi and Dr. Dervieux were $157,357, $61,088, and $62,920, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We typically grant equity awards to key
new hires upon their commencing employment with us. We historically have used stock options as the primary incentive for long-term compensation to our named executive officers because they are able to profit from stock options only if our stock
price increases relative to the stock option&#146;s exercise price, which generally is set at the fair market value of our common stock as of the applicable grant date. Generally, the stock options we grant vest as to 25% of the total number of
option shares on the first anniversary of the date of grant and in equal monthly installments over the ensuing 36 months, subject to the employee&#146;s continued service with us on the vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2018 we awarded a stock option to Mr.&nbsp;Adawi covering 84,162&nbsp;shares. Mr.&nbsp;Adawi&#146;s stock option vests in accordance with our typical
vesting schedule described above. In addition, the stock option will become exercisable subject to Mr.&nbsp;Adawi&#146;s continuous service with respect to (i) 75% of the underlying shares upon the later to occur of (A)&nbsp;the applicable vesting
date and (B)&nbsp;the closing of an initial public offering, and (ii)&nbsp;the remaining 25% of the underlying shares upon the later to occur of (A)&nbsp;the applicable vesting date and (B)&nbsp;the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of an initial public offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2018 Stock Option Exchange </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2018 we approved a <FONT STYLE="white-space:nowrap">one-time</FONT> stock option exchange whereby certain underwater stock options, including
those held by our named executive officers, were exchanged for replacement stock options to purchase shares of common stock having a lower exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each replacement stock option was granted with an exercise price of $0.2571&nbsp;per share, which our board of directors determined was the fair market
value of our common stock on the grant date of the replacement option. In addition, each replacement option vests with respect to 25% of the shares underlying the option on the first anniversary of the grant date and with respect to the remaining
shares, on each monthly anniversary thereafter, subject to the option holder&#146;s continued service. Further, Mr.&nbsp;Rocca&#146;s replacement option will also vest in full upon a termination of service due to a termination by us without cause or
for good reason, or due to Mr.&nbsp;Rocca&#146;s death or disability, in each case, on or within 12 months following an initial public offering. For purposes of Mr.&nbsp;Rocca&#146;s replacement option, &#147;cause&#148; means: (i)&nbsp;a conviction
for, or guilty plea to, a felony involving moral turpitude; (ii)&nbsp;an uncured willful refusal to comply with our lawful and reasonable instructions, or to otherwise perform duties as we lawfully and reasonably determine; (iii)&nbsp;any willful
act of dishonesty intended to result in material gain or personal enrichment at the expense of us or any of our customers, partners, affiliates or employees; or (iv)&nbsp;any uncured willful act of gross misconduct that is injurious to us.
&#147;Good reason&#148; means, without consent, and in the absence of cause, (i)&nbsp;any material reduction of base compensation; or (ii)&nbsp;any material reduction in title, authority or duties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table shows the number of options exchanged for and received by our named executive
officers as part of this option exchange. Mr.&nbsp;Adawi did not participate in the stock option exchange. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Named&nbsp;Executive&nbsp;Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options<BR>Exchanged</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options<BR>Received</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The replacement options held by our named executive officers will become exercisable subject to the
executive&#146;s continuous service with respect to (i) 75% of the underlying shares upon the later to occur of (A)&nbsp;the applicable vesting date and (B)&nbsp;the closing of an initial public offering, and (ii)&nbsp;the remaining 25% of the
underlying shares upon the later to occur of (A)&nbsp;the applicable vesting date and (B)&nbsp;the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of an initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other than the stock option granted to Mr.&nbsp;Adawi and the awards granted as part of our <FONT STYLE="white-space:nowrap">one-time</FONT> option
exchange, none of our named executive officers received a stock option, or other equity award, in 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Stock options granted to our named
executive officers may be subject to accelerated vesting in certain circumstances. For additional discussion, please see &#147;&#151;Offer Letters with Our Named Executive Officers&#148; and &#147;&#151;Other Elements of Compensation&#151;Severance
and Change in Control Benefits&#148; below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>IPO-Related Equity Grants </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors approved a grant of stock options pursuant to the 2019 Plan (as defined and further described below) to certain of our directors
and employees, including our named executive officers, in connection with this offering, effective as of immediately following the determination of the initial public offering price per share of our common stock. These stock options cover an
aggregate of 812,745&nbsp;shares of our common stock. Of these, the stock options granted to our named executive officers, Messrs.&nbsp;Rocca and Adawi and Dr.&nbsp;Dervieux, cover 138,659, 21,635 and 10,891&nbsp;shares of our common stock,
respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These stock option grants will be effective as of immediately following the determination of the initial public offering price
per share of our common stock. The stock options granted to our named executive officers will vest as to 1/4th of the shares underlying the option on the one-year anniversary of the grant date and as to 1/48th of the shares underlying the option on
each monthly anniversary of the grant date thereafter, subject to the executive&#146;s continued service through the applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Equity
Compensation Plans </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">2013 Stock Option Plan </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently
maintain the 2013 Stock Option Plan, as amended from time to time, or the 2013 Plan, in order to provide additional incentives for our employees, directors and consultants, and to provide incentives to attract, retain and motivate eligible persons
whose present and potential contributions are important to our success. We offer stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For additional information about the 2013 Plan, please see the section titled &#147;2013 Stock Option Plan&#148; below. As mentioned below, in
connection with the completion of this offering, no further awards will be granted under the 2013 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">2002 Stock Option Plan </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also currently have awards outstanding under our 2002 Stock Option Plan, or the 2002 Plan. Generally, the stock options granted under the 2002 Plan
vested as to 25% of the total number of option shares on the first anniversary of the date of grant and in equal monthly installments over the ensuing 36 months, subject to the employee&#146;s continued service with us on the vesting date. The 2002
Plan expired in accordance with its terms in December 2012 and no additional awards have been granted under the 2002 Plan since its expiration. For additional information about the 2002 Plan, please see the section titled &#147;2002 Stock Option
Plan&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">2019 Incentive Award Plan </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection
with this offering, we have adopted, and our stockholders have approved, a 2019 Incentive Award Plan, referred to in this prospectus as the 2019 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including
our named executive officers) and consultants of our company and certain of our affiliates and to enable our company and certain of our affiliates to obtain and retain services of these individuals, which is essential to our long-term success. Upon
the effectiveness of the 2019 Plan, no further grants will be made under the 2013 Plan. However, the 2013 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. In addition, shares of our common stock
subject to awards granted under the 2013 Plan that expire, lapse or are terminated, exchanged for or settled in cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following the effective date of the 2019 Plan
will become available for issuance under the 2019 Plan in accordance with its terms. For additional information about the 2019 Plan, please see the section titled &#147;2019 Incentive Award Plan&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Elements of Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Retirement Plans </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently maintain a 401(k) retirement savings plan that allows eligible employees to defer a portion of their compensation, within limits prescribed
by the Code, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis through contributions to the plan. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees generally.
Currently, we make employer matching contributions under the 401(k) plan up to a specified percentage, and these matching contributions are fully vested as of the date on which the contribution is made. We believe that providing a vehicle for <FONT
STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) plan, and making matching contributions, adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our
named executive officers, in accordance with our compensation policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Employee Benefits and Perquisites </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our named executive officers are eligible to participate in our health and welfare plans to the same extent as all full-time employees generally,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">medical, dental and vision benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">medical and dependent care flexible spending accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">short-term and long-term disability insurance; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">life insurance and accidental death and dismemberment insurance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not provide our named executive officers with any other perquisites or other personal benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>No Tax <FONT STYLE="white-space:nowrap">Gross-Ups</FONT> </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
generally have not made <FONT STYLE="white-space:nowrap">gross-up</FONT> payments to cover our named executive officers&#146; personal income taxes that may pertain to any of the compensation paid or provided by our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Severance and Change in Control Benefits </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our named executive officers may become entitled to certain benefits or enhanced benefits upon a qualifying termination of employment pursuant to their
offer letters, as explained in further detail below. In addition, stock options granted to our employees, including our named executive officers, may be subject to acceleration in connection with a change in control under our equity plans, and for
Mr.&nbsp;Rocca, subject to acceleration upon a qualifying termination in connection with an initial public offering. For additional discussion, please see &#147;&#151;Equity Compensation&#148; above and &#147;&#151;Offer Letters with our Named
Executive Officers.&#148; and &#147;&#151;Equity Incentive Award Plans&#148; below. Other than the benefits described above, none of our named executive officers are entitled to any severance or change in control benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Offer Letters with our Named Executive Officers </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Offer Letter with
Fortunato Ron Rocca </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2011, we entered into an offer letter with Mr.&nbsp;Rocca, which was amended in September 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Mr.&nbsp;Rocca&#146;s offer letter provides for at-will employment, and an annual base salary and bonus. Pursuant to Mr.&nbsp;Rocca&#146;s offer letter,
if we terminate Mr.&nbsp;Rocca&#146;s employment without cause, Mr.&nbsp;Rocca will be entitled to a lump sum cash payment in an amount equal to nine months of his annual base salary as in effect immediately prior to the date of termination, subject
to his delivery and non-revocation of a general release of claims in favor of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Offer Letter with Kamal Adawi </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, we entered into an offer letter with Mr.&nbsp;Adawi, which was amended in September 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Mr.&nbsp;Adawi&#146;s offer letter provides for at-will employment, and an annual base salary and bonus. Pursuant to Mr.&nbsp;Adawi&#146;s offer letter,
if we terminate Mr. Adawi&#146;s employment without cause, Mr.&nbsp;Adawi will be entitled to a lump sum cash payment in an amount equal to six months of his annual base salary as in effect immediately prior to the date of termination, subject to
his delivery and non-revocation of a general release of claims in favor of our company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Offer Letter with Thierry Dervieux, Ph.D. </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2010, we entered into an offer letter with Dr.&nbsp;Dervieux, which was amended in September 2011 and September 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dr.&nbsp;Dervieux&#146;s offer letter provides for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, an annual base salary and eligibility to
participate in our management bonus plan, with the goals and payments under the management bonus plan to be defined and approved by our board of directors. Pursuant to the offer letter, Dr.&nbsp;Dervieux received options to purchase 544 shares of
our common stock in connection with the commencement of his employment. Such options were exchanged for replacement stock options to purchase shares of common stock having a lower exercise price as part of our
<FONT STYLE="white-space:nowrap">one-time</FONT> stock option exchange in October 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to Dr.&nbsp;Dervieux&#146;s offer letter, if we
terminate Dr.&nbsp;Dervieux&#146;s employment without cause or Dr.&nbsp;Dervieux resigns for good reason, Dr.&nbsp;Dervieux will be entitled to a lump sum cash payment in an amount equal to his annual base salary as in effect immediately prior to
the date of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at 2018 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December&nbsp;31, 2018. Unless
otherwise indicated, each option listed in the following table was granted under the 2013 Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options&nbsp;
(#)<BR>Exercisable<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options&nbsp;
(#)<BR>Unexercisable<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Price($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,702</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kamal Adawi</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,162</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thierry Dervieux, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,110</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The option vests with respect to 25% of the shares underlying the option on the first anniversary of the grant date and
with respect to the remaining shares, on each monthly anniversary over the three-year period thereafter, subject to the grantee&#146;s continued service. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The option will become exercisable subject to the grantee&#146;s continuous service with respect to (i)&nbsp;75% of the
underlying shares upon the later to occur of (A)&nbsp;the applicable vesting date and (B)&nbsp;the closing of an initial public offering, and (ii)&nbsp;the remaining 25% of the underlying shares upon the later to occur of (A)&nbsp;the applicable
vesting date and (B)&nbsp;the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of an initial public offering. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Mr.&nbsp;Rocca&#146;s option will also vest in full upon a termination of service due to a termination by us without cause
or by Mr. Rocca for good reason, or due to Mr.&nbsp;Rocca&#146;s death or disability, in each case, on or within 12&nbsp;months following an initial public offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2018 Director Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth information for the year ended December&nbsp;31, 2018 regarding the compensation awarded to, earned by or paid to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors who served on our board of directors during 2018. Mr.&nbsp;Rocca, who served as our President and Chief Executive Officer during the year ended December&nbsp;31, 2018, and continues to serve
in that capacity, does not receive additional compensation for his service as a director, and therefore is not included in the Director Compensation table below. All compensation paid to Mr.&nbsp;Rocca is reported above in the &#147;2018 Summary
Compensation Table&#148;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dan Burrell<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">James L.L. Tullis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arthur Weinstein, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,769</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts reflect the aggregate grant date fair value of stock options granted in 2018, computed in accordance with the
provisions of ASC Topic&nbsp;718, Compensation-Stock Compensation. These amounts do not reflect the actual economic value that will be realized by the director upon the vesting of the stock options, the exercise of the stock options, or the sale of
the common stock underlying such stock options. The assumptions that we used to calculate these amounts are discussed in Note 12 to our audited financial statements elsewhere in this prospectus. As of December&nbsp;31, 2018, the following
outstanding option awards were held by members of our Board: Mr.&nbsp;Birk, 19,422 shares, Mr.&nbsp;Burrell, 12,948 shares, Dr.&nbsp;Pallares, 12,948 shares, Mr.&nbsp;Tullis, 12,948 shares and Dr.&nbsp;Weinstein, 14,172 shares.
</P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Messrs. Burrell and Weinstein resigned from our board of directors on July&nbsp;12, 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amount paid to Dr.&nbsp;Weinstein reflects payments for his services as a consultant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2013, we entered into a director and consulting services agreement with
Dr.&nbsp;Weinstein, pursuant to which he receives $18,000 per year, payable monthly, for his service as a member of our board of directors. In addition, in September 2017, we entered into a consulting services agreement with Dr.&nbsp;Weinstein, as
amended in May 2018, that supplanted the prior director and consulting services agreement and pursuant to which he receives a <FONT STYLE="white-space:nowrap">bi-weekly</FONT> fee for his services as our Chief Medical Officer for 20 hours per week.
In 2018 this <FONT STYLE="white-space:nowrap">bi-weekly</FONT> fee was $4,615.39 and was increased effective June&nbsp;4, 2018 to $5,000. Dr.&nbsp;Weinstein&#146;s consulting services agreement provides for a stock option grant upon approval by our
board of directors, as well as hotel reimbursement and a Company-provided cell phone. Mr.&nbsp;Weinstein resigned from our board of directors in July 2019, but continues to provide services under this consulting services agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2019, we appointed Jeff Elliott as a member of our board of directors. In connection with his appointment, we entered into an offer letter with
Mr.&nbsp;Elliott pursuant to which he will receive $40,000 per year for his services, payable quarterly, which will be paid no later than the fifteenth day following the end of each calendar quarter. The compensation Mr.&nbsp;Elliott is eligible to
receive under his offer letter will be superseded by our new non-employee director compensation program, as described below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2019, we
appointed Tina Nova as a member of our board of directors. In connection with her appointment, we entered into an offer letter with Ms.&nbsp;Nova pursuant to which she will receive $50,000 per year for her services, and an additional $7,500 per year
for each committee on which she serves, payable quarterly, which will be paid no later than the fifteenth day following the end of each calendar quarter. The compensation Ms.&nbsp;Nova is eligible to receive under her offer letter will be superseded
by our new non-employee director compensation program, as described below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director IPO Grants </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect to grant a stock option covering 13,613 shares of our common stock to each of Ms.&nbsp;Nova and Messrs.&nbsp;Elliot and Burrell in connection
with this offering, effective as of immediately following the determination of the initial public offering price per share of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each award will vest as to 1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares underlying the option on each monthly anniversary
of the grant date, subject to such director&#146;s continued service through the applicable vesting date. In accordance with our Director Compensation Program, as defined and further described below, each such award will vest in full upon a change
in control of our company (as defined in the 2019 Plan). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Post-IPO</FONT> Director Compensation Program </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to adopt a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program (the
&#147;Director Compensation Program&#148;), which provides for annual retainer fees and long-term equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors (each, an &#147;Eligible Director&#148;). The material terms of
the Director Compensation Program are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Director Compensation Program to consists of the following components: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><U>Cash Compensation </U> </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Annual Retainer: $50,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Annual Committee Chair Retainer: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Audit: $12,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Compensation: $10,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Nominating and Corporate Governance: $9,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Annual Committee Member <FONT STYLE="white-space:nowrap">(Non-Chair)</FONT> Retainer: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Audit: $7,500 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Compensation: $7,500 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Nominating and Corporate Governance: $7,500 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Annual Chairman of the Board Retainer: $20,000 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The annual cash retainer will be paid in quarterly installments in arrears. Annual cash retainers will be
<FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial calendar quarter of service. All cash compensation payable to the directors designated by or affiliated with Sun Mountain Capital, H.I.G. Capital, LLC or Tullis-Dickerson Capital
Focus III, L.P. is paid to Sun Mountain Capital, H.I.G. Capital, LLC or Tullis-Dickerson Capital Focus III, L.P., as applicable. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><U>Equity
Compensation </U> </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Initial Grant</I>: Each Eligible Director who is initially elected or appointed to serve on the Board after the
effective date of this offering automatically shall be granted an option to purchase 15,000 shares of our common stock on the date on which such Eligible Director is appointed or elected to serve on the Board, and shall vest as to 1/36th of the
shares underlying the option on each monthly anniversary of the grant date, subject to such Eligible Director&#146;s continued service through the applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Annual Grant</I>: An Eligible Director who is serving on the Board as of the date of the annual meeting of the
Company&#146;s stockholders each calendar year beginning with calendar year 2020 shall be granted, on such annual meeting date, an option to purchase 9,000 shares of our common stock, which shall vest in full on the earlier to occur of (i)&nbsp;the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the applicable grant date and (ii)&nbsp;the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, each such award which vests and becomes exercisable will remain exercisable until the earlier of the maximum term of the option and the
one-year anniversary of the Eligible Director&#146;s termination of service, other than for cause. Further, each such award will vest in full upon a change in control of our Company (as defined in the 2019 Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compensation under our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will be subject to the annual limits on <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2019 Plan, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity Incentive Award Plans
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following summarizes the material terms of the 2002 Plan and 2013 Plan, under which we have previously made periodic grants of equity
and equity-based awards to our named executive officers and other key employees, and the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2002 Stock Option Plan </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January&nbsp;29, 2002, our board of directors and our stockholders approved the 2002 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2002 Plan expired in accordance with its terms in December 2012 and no additional awards have been granted under the 2002 Plan since its expiration.
As of June&nbsp;30, 2019, 4,694 shares of our common stock were subject to outstanding option awards under the 2002 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Administration.</I>&nbsp;&nbsp;&nbsp;&nbsp;The board of directors administers the 2002 Plan. Subject to the terms and conditions of the 2002 Plan,
the administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each person, determine the number of awards to grant, determine the number of shares to be subject to
such awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable for the administration of the 2002 Plan. The plan administrator is also authorized to
establish, adopt, amend or revise rules relating to administration of the 2002 Plan, subject to certain restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Options were able to be granted to individuals who are then
our employees, consultants and members of our board of directors. Only employees may be granted ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The
2002 Plan permitted the award of stock options. Only stock options were granted under the 2002 Plan. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Corporate Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a corporate transaction where the acquirer does not assume awards granted under
the 2002 Plan, awards issued under the 2002 Plan will terminate as of a date to be fixed by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2013 Plan </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors and certain of our stockholders approved the 2013 Plan, which became effective in December 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2013 Plan was amended in October 2018 to increase the share reserve to 669,806. As of June&nbsp;30, 2019, 658,293 shares of our common stock were
subject to outstanding option awards and 10,999 shares of our common stock remained available for future issuance. The 2013 Plan will expire in December 2022 unless earlier terminated by our board of directors. Following the effectiveness of the
2019 Plan, the 2013 Plan will terminate and we will not make any further awards under the 2013 Plan. However, any outstanding awards granted under the 2013 Plan will remain outstanding, subject to the terms of the 2013 Plan and applicable award
agreement. Shares of our common stock subject to awards granted under the 2013 Plan that expire, lapse or are terminated, exchanged for or settled in cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following
the effective date of the 2019 Plan will become available for issuance under the 2019 Plan in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;The board of directors administers the 2013 Plan. Subject to the terms and conditions of the 2013 Plan,
the administrator has the authority to select the persons to whom option awards are to be made, determine the number of option awards to grant, determine the number of shares to be subject to such option awards, and the terms, the exercise price of
such option awards, subject to the limits established in the 2013 Plan, conditions and restrictions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable for the administration of the
2013 Plan. The plan administrator is also authorized to establish, adopt, amend or revise rules relating to administration of the 2013 Plan, subject to certain restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Options may be granted to individuals who are then our employees, consultants and members of our board of
directors. Only employees (including directors who are also employees) may be granted ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2013 Plan
permits the award of stock options. Only stock options have been granted under the 2013 Plan to date. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Nonqualified stock options. Nonqualified stock options, or NSOs, provide for the right to purchase shares of our common
stock at a specified price which may not be less than the fair market value of a share of stock on the date of grant, and usually will become exercisable (at the discretion of our board of directors) in one or more installments after the grant date,
subject to the participant&#146;s continued employment or service with us and/or subject to the satisfaction of performance targets established by our compensation committee (or the board of directors, in the case of awards to <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors). NSOs may be granted for any term specified by our compensation committee (or the board of directors, in the case of awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors),
but the term may not exceed ten years. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Incentive Stock Options. Incentive Stock Options, or ISOs, are designed to comply with the provisions of the Code and are
subject to specified restrictions contained in the Code applicable to ISOs. Among such restrictions, ISOs must have an exercise price of not less than the fair market value of a share of common stock on the date of grant, may only be granted to
employees, must expire within a specified period of time following the optionee&#146;s termination of employment, and must be exercised within the ten years after the date of grant. In the case of an ISO granted to an individual who owns (or is
deemed to own) more than 10% of the total combined voting power of all classes of our capital stock on the date of grant, the 2013 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the
date of grant and the ISO must expire on the fifth anniversary of the date of its grant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Corporate
Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a corporate transaction, all outstanding stock options will become fully vested and exercisable for the <FONT STYLE="white-space:nowrap">30-day</FONT> period immediately preceding the closing
of such transaction (provided that the exercise of any stock option that would have been unvested but for the consummation of the change in control is contingent upon and will be subject to the closing of the transaction). In addition, in the event
of a corporate transaction, the board of directors may provide for the termination of all outstanding stock options in exchange for a cash payment in an amount equal to the fair market value of the shares of our common stock subject to the stock
option immediately prior to the consummation of such transaction less the exercise price of such option. Any options that are outstanding as of the consummation of a corporate transaction will expire automatically unless the acquirer assumes such
awards or are otherwise continued in effect pursuant to the terms of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Amendment or Termination of the 2013
Plan</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may terminate, amend or modify the 2013 Plan, provided that any termination of the plan must be upon 30 days&#146; written notice to participants. However, stockholder approval of any amendment
to the 2013 Plan must be obtained to reduce the option price per share after the option has been granted or the extent necessary and desirable to comply with any applicable law, regulation or stock exchange rule. As described above, the 2013 Plan
will terminate as of the effective date of the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2019 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have adopted, and our stockholders have approved, the 2019 Incentive Award Plan, or the 2019 Plan under which we may grant cash and equity incentive
awards to eligible service providers in order to attract, motivate and retain the talent for which we compete. The material terms of the 2019 Plan are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Eligibility and Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our employees, consultants and directors, and employees, consultants and directors of our
subsidiaries will be eligible to receive awards under the 2019 Plan. Following our initial public offering, the 2019 Plan will be administered by our board of directors with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors and by our compensation committee with respect to other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below),
subject to certain limitations that may be imposed under the 2019 Plan, Section&nbsp;16 of the Exchange Act, and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations
under, prescribe all forms for use with, and adopt rules for the administration of, the 2019 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2019 Plan,
including any vesting and vesting acceleration conditions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Shares Available</I>.&nbsp;&nbsp;&nbsp;&nbsp;An aggregate of
2,011,832&nbsp;shares of our common stock will be available for issuance under awards granted pursuant to the 2019 Plan, which shares may be authorized but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
unissued shares, or shares purchased in the open market. Notwithstanding anything to the contrary in the 2019 Plan, no more than 25,000,000&nbsp;shares of our common stock may be issued pursuant
to the exercise of ISOs under the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares available for issuance will be increased by (i)&nbsp;the number of shares
represented by awards outstanding under our 2013 Plan that expire, lapse or are terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully experienced or forfeited following the effective date of the
2019 Plan, with the maximum number of shares to be added to the 2019 Plan equal to 663,000&nbsp;shares, and (ii)&nbsp;an annual increase on the first day of each calendar year beginning January 1, 2020 and ending on and including January&nbsp;1,
2029, equal to the lessor of (A) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If an award under the 2019 Plan expires, lapses or is terminated, exchanged for or settled for cash, surrendered, repurchased, cancelled without having
been fully exercised or forfeited any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used again for new grants under the 2019 Plan. Further, shares delivered to us to satisfy the applicable
exercise or purchase price of an award under the 2019 Plan or the 2013 Plan and/or to satisfy any applicable tax withholding obligations (including shares retained by us from the award under the 2019 Plan or the 2013 Plan being exercised or
purchased and/or creating the tax obligation) will become or again be available for award grants under the 2019 Plan. The payment of dividend equivalents in cash in conjunction with any awards under the 2019 Plan will not reduce the shares available
for grant under the 2019 Plan. However, the following shares may not be used again for grant under the 2019 Plan:&nbsp;(i)&nbsp;shares subject to stock appreciation rights, or SARs, that are not issued in connection with the stock settlement of the
SAR on exercise, and (ii)&nbsp;shares purchased on the open market with the cash proceeds from the exercise of options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Awards granted under the
2019 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available
for grant under the 2019 Plan but will count against the maximum number of shares that may be issued upon the exercise of ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2019 Plan
provides that the sum of any cash compensation and the aggregate grant date fair value (determined as of the date of the grant under ASC Topic 718, or any successor thereto) of all awards granted to a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any calendar year may not exceed the amount equal to $750,000, increased to
$1,000,000, in the fiscal year of a non-employee director&#146;s initial service as a non-employee director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan provides for the grant of stock options, including ISOs and NSOs, SARs, restricted stock, dividend
equivalents, restricted stock units, or RSUs, and other stock or cash based awards. Certain awards under the 2019 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional
requirements on the terms and conditions of such awards. All awards under the 2019 Plan will be evidenced by award agreements, which will detail all terms and conditions of the awards, including any applicable vesting and payment terms and
post-termination exercise limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type follows.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Stock Options and SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the purchase of shares of our common stock
in the future at an exercise price set on the grant date. ISOs, in contrast to NSOs, may </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. SARs entitle their
holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The exercise price of a stock option or SAR may not be less than 100% of the fair market
value of the underlying share on the grant date (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The term of a stock
option or SAR may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Restricted Stock</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is an award of nontransferable shares of our common stock
that are subject to certain vesting conditions and other restrictions. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;RSUs are contractual promises to deliver shares of our common stock in the future,
which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of common stock prior to the delivery of the underlying shares (i.e.,
dividend equivalent rights). The plan administrator may provide that the delivery of the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to RSUs will be
determined by the plan administrator, subject to the conditions and limitations contained in the 2019 Plan. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Other Stock or Cash Based Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Other stock or cash based awards are awards of cash, fully
vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash based awards may be granted to participants and may also be available as a payment
form in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Dividend Equivalents</I>.&nbsp;&nbsp;&nbsp;&nbsp;Dividend equivalents represent the right to receive the equivalent
value of dividends paid on shares of our common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are credited as of the dividend record dates during the period between the date an award
is granted and the date such award vests, is exercised, is distributed or expires, as determined by the plan administrator. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Certain Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator has broad discretion to take action under the 2019 Plan, as well as make
adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events affecting our common
stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders
known as &#147;equity restructurings,&#148; the plan administrator will make equitable adjustments to the 2019 Plan and outstanding awards. In the event of a change in control of our company (as defined in the 2019 Plan), to the extent that the
surviving entity declines to continue, convert, assume or replace outstanding awards, then all such awards will become fully vested and exercisable in connection with the transaction. Awards under the 2019 Plan are generally non-transferrable,
except by will or the laws of descent and distribution, or, subject to the plan administrator&#146;s consent, pursuant to a domestic relations order, and are generally exercisable only by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Foreign Participants, Claw-Back Provisions, Transferability, and Participant Payments</I>.&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may modify
award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules of countries outside of the
United States. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy and/or in the applicable award agreement. With regard to tax withholding, exercise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
price and purchase price obligations arising in connection with awards under the 2019 Plan, the plan administrator may, in its discretion, accept cash or check, shares of our common stock that
meet specified conditions, a &#147;market sell order&#148; or such other consideration as it deems suitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Plan Amendment and
Termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may amend or terminate the 2019 Plan at any time; however, no amendment, other than an amendment that increases the number of shares available under the 2019 Plan, may materially and
adversely affect an award outstanding under the 2019 Plan without the consent of the affected participant, and stockholder approval will be obtained for any amendment to the extent necessary to comply with applicable laws or to increase the director
limit. The plan administrator will have the authority, without the approval of our stockholders, to &#147;reprice&#148; any stock option or SAR, or cancel any stock option or SAR in exchange for cash or another award when the option or SAR price per
share exceeds the fair market value of the underlying shares. The 2019 Plan will remain in effect until the tenth anniversary of the date the board of directors adopted the 2019 Plan, unless earlier terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2019 Employee Stock Purchase Plan </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with
this offering, we adopted, and our stockholders approved, the ESPP, which became effective on the day the ESPP was adopted by our board of directors. The material terms of the ESPP are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Shares Available; Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;A total of 120,000&nbsp;shares of our common stock is initially reserved for issuance
under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the
aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors. In no event will more than 5,000,000&nbsp;shares of
our common stock be available for issuance under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors or a committee designated by our board of directors will have
authority to interpret the terms of the ESPP and determine eligibility of participants. The compensation committee will be the administrator of the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may designate certain of our subsidiaries as participating &#147;designated
subsidiaries&#148; in the ESPP and may change these designations from time to time. Employees of our company and our designated subsidiaries are eligible to participate in the ESPP if they meet the eligibility requirements under the ESPP established
from time to time by the plan administrator. However, an employee may not be granted rights to purchase stock under the ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of
the total combined voting power or value of all classes of our common or other class of stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the grant of a purchase right under the ESPP to
any eligible employee who is a citizen or resident of a foreign jurisdiction would be prohibited under the laws of such foreign jurisdiction or the grant of a purchase right to such employee in compliance with the laws of such foreign jurisdiction
would cause the ESPP to violate the requirements of Section&nbsp;423 of the Code, as determined by the plan administrator in its sole discretion, such employee will not be permitted to participate in the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Eligible employees become participants in the ESPP by enrolling and authorizing payroll deductions by the deadline established by the plan administrator
prior to the relevant offering date. Directors who are not employees, as well as consultants, are not eligible to participate. Employees who choose not to participate, or are not eligible to participate at the start of an offering period but who
become eligible thereafter, may enroll in any subsequent offering period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Participation in an Offering</I>.&nbsp;&nbsp;&nbsp;&nbsp;We intend for the ESPP to qualify under
Section&nbsp;423 of the Code and stock will be offered under the ESPP during offering periods. The length of offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. Employee payroll deductions
will be used to purchase shares on each purchase date during an offering period. The number of purchase periods within, and purchase dates during, each offering period will be established by the plan administrator. Offering periods under the ESPP
will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ESPP will permit participants to purchase our common stock through payroll deductions of up to&nbsp;20% of their eligible compensation, which will
include a participant&#146;s gross base compensation for services to us, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The plan
administrator will establish a maximum number of shares that may be purchased by a participant during any offering period or purchase period, which, in the absence of a contrary designation, will be 100,000&nbsp;shares. In addition, no employee will
be permitted to accrue the right to purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock
as of the first day of the offering period). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On the first trading day of each offering period, each participant automatically will be granted
an option to purchase shares of our common stock. The option will be exercised on the applicable purchase date(s) during the offering period, to the extent of the payroll deductions accumulated during the applicable purchase period. We expect that
the purchase price of the shares, in the absence of a contrary determination by the plan administrator, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the applicable
purchase date, which will be the final trading day of the applicable purchase period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Participants may voluntarily end their participation in the
ESPP at any time at least one week prior to the end of the applicable offering period (or such longer or shorter period specified by the plan administrator), and will be paid their accrued payroll deductions that have not yet been used to purchase
shares of common stock. Participation ends automatically upon a participant&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Transferability</I>.&nbsp;&nbsp;&nbsp;&nbsp;A participant may not transfer rights granted under the ESPP other than by will, the laws of descent and
distribution or as otherwise provided in the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Certain Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain transactions or
events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and
outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control, the plan administrator may provide for (i)&nbsp;either the replacement of outstanding rights
with other rights or property or termination of outstanding rights in exchange for cash, (ii)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, (iii)&nbsp;the
adjustment in the number and type of shares of stock subject to outstanding rights, (iv)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and
termination of any rights under ongoing offering periods or (v)&nbsp;the termination of all outstanding rights. Under the ESPP, a change in control has the same definition as given to such term in the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Plan Amendment; Termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may amend, suspend or terminate the ESPP at any time. However,
stockholder approval of any amendment to the ESPP must be obtained </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for any amendment which increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of corporations whose
employees are eligible to participate in the ESPP, or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will terminate on the
tenth anniversary of the date it is initially approved by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and officers to
the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the&nbsp;following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to authorize
corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability
does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that we shall have the power to indemnify our
employees and agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this
capacity, regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our
amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts
incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation and
amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and
our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may
discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit
us and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we
aware of any pending or threatened litigation that may result in claims for indemnification by any director or&nbsp;officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_14"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following includes a summary of transactions since January&nbsp;1, 2016 to which we have been a party in which the amount involved exceeded or will
exceed $120,000 (or, if less, 1% of the average of our total assets amounts as of December&nbsp;31, 2016, 2017 and 2018), and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital
stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described
under &#147;Executive and Director Compensation.&#148; We also describe below certain other transactions with our directors, executive officers and stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Redeemable Convertible Preferred Stock, Convertible Promissory Notes and Warrant Financings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series E Redeemable Convertible Preferred Stock and Warrant Financing. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2016, we entered into an agreement to issue shares of Series E redeemable convertible preferred stock, pursuant to which we sold to investors
in an initial closing and subsequent closing in January 2016 and March 2016, respectively, in private placements an aggregate of 83,406,724 shares of Series E redeemable convertible preferred stock at a purchase price of $0.25 per share, for an
aggregate purchase price of $16.9&nbsp;million, including the conversion of previously outstanding convertible promissory notes and accrued interest thereon of approximately $11.6&nbsp;million. Pursuant to the purchase agreement, we also issued to
the investors warrants, or the 2016 Warrants, exercisable for up to an aggregate of 908,385 shares of our common stock. The 2016 Warrants are immediately exercisable at an exercise price of $1.84 per share, and expire in 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In conjunction with the issuance of the Series E redeemable convertible preferred stock pursuant to the purchase agreement, existing investors exchanged
an aggregate of 105,610, 41,509,393, 7,112,819, and 34,415,512, of previously outstanding shares of Series <FONT STYLE="white-space:nowrap">A-3,</FONT> Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C, and Series D redeemable convertible
preferred stock, respectively, for an aggregate of 83,143,334 shares of Series E redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a result of the Series
E financing, outstanding warrants issued in October 2015, or the 2015 Warrants, became exercisable for 2,688,181 shares of our Series E redeemable convertible preferred stock. The 2015 Warrants are immediately exercisable at an exercise price of
$0.25 per share, and expire in October 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2016 and 2017 Convertible Promissory Note Financings. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2016, we entered into a note purchase agreement with certain existing holders of our redeemable convertible preferred stock pursuant to which we
sold, in a private placement, an aggregate of $2.1&nbsp;million of convertible promissory notes, or the June 2016 Notes. The June 2016 Notes accrued interest at a rate of 8% per annum and were due six months from the date of issuance, subject to
their earlier conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time prior to the maturity date or upon the occurrence of a liquidation (as defined in
our sixteenth amended and restated certificate of incorporation). In December 2016, we entered into an amendment to the convertible promissory notes issued in June 2016 to extend the maturity date to June&nbsp;12, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2016, we entered into a note purchase agreement with certain existing holders of our redeemable convertible preferred stock pursuant to which
we sold, in a private placement, an aggregate of $1.0&nbsp;million of convertible promissory notes, or the August 2016 Notes. The August 2016 Notes accrued interest at a rate of 8% per annum and were due six months from the date of issuance,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
subject to their earlier conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time prior to the
maturity date or upon the occurrence of a liquidation (as defined in our sixteenth amended and restated certificate of incorporation). In March 2017, we entered into an amendment to the convertible promissory notes issued in August 2016 to extend
the maturity date to December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2016, we entered into a note purchase agreement with certain existing holders of our
redeemable convertible preferred stock pursuant to which we sold, in a private placement, an aggregate of $1.0&nbsp;million of convertible promissory notes. The October 2016 Notes accrued interest at a rate of 8% per annum and were due six months
from the date of issuance, subject to their earlier conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time prior to the maturity date or upon the
occurrence of a liquidation (as defined in our sixteenth amended and restated certificate of incorporation). In March 2017, we entered into an amendment to the convertible promissory notes issued in October 2016 to extend the maturity date to
December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2016, we entered into a note purchase agreement with certain existing holders of our redeemable convertible
preferred stock pursuant to which we sold, in a private placement, an aggregate of $1.0&nbsp;million of convertible promissory notes. The November 2016 Notes accrued interest at a rate of 8% per annum and were due six months from the date of
issuance, subject to their earlier conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time prior to the maturity date or upon the occurrence of a
liquidation (as defined in our sixteenth amended and restated certificate of incorporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2016, we entered into a note purchase
agreement with certain existing holders of our redeemable convertible preferred stock pursuant to which we sold, in a private placement, an aggregate of $1.0&nbsp;million of convertible promissory notes. The December 2016 Notes accrued interest at a
rate of 8% per annum and were due six months from the date of issuance, subject to their earlier conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time
prior to the maturity date or upon the occurrence of a liquidation (as defined in our sixteenth amended and restated certificate of incorporation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2017, we entered into a note purchase agreement with certain existing holders of our redeemable convertible preferred stock pursuant to which
we sold, in a private placement, an aggregate of $1.0&nbsp;million of convertible promissory notes. The January 2017 Notes accrued interest at a rate of 8% per annum and were due six months from the date of issuance, subject to their earlier
conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time prior to the maturity date or upon the occurrence of a liquidation (as defined in our sixteenth
amended and restated certificate of incorporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2017, we entered into a note purchase agreement with certain existing holders of
our redeemable convertible preferred stock pursuant to which we sold, in a private placement, an aggregate of $1.5&nbsp;million of convertible promissory notes. The February 2017 Notes accrued interest at a rate of 8% per annum and were due six
months from the date of issuance, subject to their earlier conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time prior to the maturity date or upon the
occurrence of a liquidation (as defined in our sixteenth amended and restated certificate of incorporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2017, we entered into a note
purchase agreement with certain existing holders of our redeemable convertible preferred stock pursuant to which we sold, in a private placement, an aggregate of $1.3&nbsp;million of convertible promissory notes. The April 2017 Notes accrued
interest at a rate of 8% per annum and were due six months from the date of issuance, subject to their earlier </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
conversion in the event we completed a qualified equity financing or a qualified initial public offering, or at the option of the investor at any time prior to the maturity date or upon the
occurrence of a liquidation (as defined in our sixteenth amended and restated certificate of incorporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The June 2016 Notes, August 2016
Notes, October 2016 Notes, November 2016 Notes, December 2016 Notes, January 2017 Notes, February 2017 Notes and April 2017 Notes are collectively referred to herein as the 2016 / 2017 Notes. Each of the 2016 / 2017 Notes were subordinated to
borrowings under our Term Loan Agreement, dated October&nbsp;10, 2013, with Capital Royalty Partners II L.P., Capital Royalty Partners&nbsp;II&#151;Parallel Fund &#147;A&#148; L.P., Parallel Investment Opportunities Partners II L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, in conjunction with the issuance of Series F redeemable convertible preferred stock, the outstanding principal and accrued interest thereon
of each of the 2016 / 2017 Notes, totaling $10.2&nbsp;million, was converted into 163,785,334 shares of Series F redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series F Redeemable Convertible Preferred Stock Financing. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, we entered into an agreement to issue shares of Series F redeemable convertible preferred stock, which agreement was subsequently amended in
August 2017, pursuant to which we sold to investors in an initial closing in May 2017 and subsequent closings between August 2017 and January 2018, in private placements an aggregate of 339,484,788 shares of Series F redeemable convertible preferred
stock at a purchase price of $0.078 per share, for an aggregate purchase price of $23.9&nbsp;million, including the conversion of the outstanding principal and accrued interest on the 2016/2017 Notes of approximately $10.2&nbsp;million into
163,785,334 shares of our Series F redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series G Redeemable Convertible Preferred Stock Financing. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2019 we entered into an agreement to issue shares of our Series&nbsp;G redeemable convertible preferred stock, which agreement was
subsequently amended in May 2019, pursuant to which we sold to investors in an initial closing in January 2019 and subsequent closings in March 2019 and May 2019, in private placements an aggregate of 148,928,337&nbsp;shares of our Series&nbsp;G
redeemable convertible preferred stock at a purchase price of $0.078 per share, for an aggregate purchase price of approximately $11.6&nbsp;million. In addition, in May 2019, the Series&nbsp;G preferred stock agreement was amended to include a right
by us to require certain holders of Series&nbsp;G redeemable convertible preferred stock, including NMSIC Focused LLC, Hunt Holdings, Limited Partnership and Tullis-Dickerson Capital Focus III, L.P., who are holders of more than 5% of our capital
stock, to purchase an additional 32,051,280&nbsp;shares of Series&nbsp;G redeemable convertible preferred stock at $0.078&nbsp;per share, for total aggregate proceeds of $2.5&nbsp;million, at any time after July&nbsp;31, 2019 and prior to
May&nbsp;31, 2020. This right terminated in connection with our Series H redeemable convertible preferred stock financing in July 2019, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series H Redeemable Convertible Preferred Stock Financing and Series G Conversion </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2019 we entered into an agreement to issue shares of our Series&nbsp;H redeemable convertible preferred stock, pursuant to which we sold to
H.I.G. Bio-Exagen, L.P. in a single closing in July 2019, in a private placement an aggregate of 233,446,519&nbsp;shares of our Series H redeemable convertible preferred stock at a purchase price of $0.04712 per share, for an aggregate purchase
price of approximately $11.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In conjunction with the issuance of the Series H redeemable convertible preferred stock, each share of
issued and outstanding Series G redeemable convertible preferred stock was converted into 1.6553 shares of Series H redeemable convertible preferred stock, for a total of 246,521,076&nbsp;shares of Series H redeemable convertible preferred stock.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each of the warrants to purchase shares of Series E redeemable convertible preferred stock
identified in the following table will terminate if not exercised prior to the completion of this offering. Based on an assumed initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this
prospectus, we expect that the holders of such warrants will net exercise these warrants, resulting in an issuance of an aggregate of 2,112 shares of our common stock. Each share of Series&nbsp;F redeemable convertible preferred stock and Series H
redeemable convertible preferred stock will convert into 0.0054 share of common stock upon completion of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table
sets forth the aggregate number of these securities acquired by the listed directors, executive officers or holders of more than 5% of our capital stock, or their affiliates since January&nbsp;1, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;E<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants<BR>to&nbsp;Purchase<BR>Series&nbsp;E<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;F<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;H<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Common&nbsp;&nbsp;&nbsp;&nbsp;<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants&nbsp;to<BR>Purchase<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>5%&nbsp;or&nbsp;Greater Stockholders<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with NMSIC <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,239,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,958,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,054,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Tullis-Dickerson Capital Focus III, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,251,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,166,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,102,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">H.I.G. Bio-Exagen, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,446,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Hunt Holdings, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,096,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,028,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,145,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gerrit Johan Krediet</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,276,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ebetuel Pallares, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,423,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,970,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">James L.L. Tullis<SUP STYLE="font-size:85%; vertical-align:top">(2)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,991,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are provided herein under &#147;Principal
Stockholders.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities held by NMSIC <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, L.P. and NMSIC Focused
LLC. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities held by Tullis-Dickerson Capital Focus III, L.P., Tullis Growth Fund, L.P. and Tullis Growth Fund
II, L.P. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities held by PCM/Exagen, L.P. (formerly known as CCP/Exagen, L.P.). </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities held by James L.L. Tullis, Linda A. Tullis and the HPS Irrevocable Trust #3 U/A Dtd 7/6/93.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts include shares issued upon conversion of Series&nbsp;G redeemable convertible preferred stock, as described above
in more detail under &#147;&#151;Series&nbsp;H Redeemable Convertible Preferred Stock Financing and Series&nbsp;G Conversion.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some of our directors are associated with our principal stockholders as indicated in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Principal&nbsp;Stockholder</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Brian Birk</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">NMSIC&nbsp;Co-Investment&nbsp;Fund,&nbsp;L.P.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Bruce C. Robertson, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">H.I.G. Bio-Exagen, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">James L.L. Tullis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tullis-Dickerson&nbsp;Capital&nbsp;Focus&nbsp;III,&nbsp;L.P.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We entered into an amended and restated investors&#146; rights agreement in July 2019 with the holders of our redeemable convertible preferred stock,
including entities with which certain of our directors are affiliated. This agreement provides for certain rights relating to the registration of their shares of common stock issuable upon conversion of their redeemable convertible preferred stock
and certain additional covenants made by us. Except for the registration rights (including the related provisions pursuant to which we have agreed to indemnify the parties to the investors&#146; rights agreement), all rights under this agreement
will terminate upon completion of this offering. The registration rights will continue following this offering and will terminate three years following the completion of this offering, or for any particular holder with registration rights, at such
time following this offering when such holder holds less than one percent of our outstanding common stock and may immediately sell all of such shares pursuant to Rule 144 under the Securities Act in a <FONT STYLE="white-space:nowrap">90-day</FONT>
period. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stockholders&#146; Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We entered into an amended and restated stockholders&#146; agreement in July 2019, by and among us and certain of our stockholders, pursuant to which the
following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to serve: Brian Birk, Chet Burrell, Jeff Elliott, Tina&nbsp;S. Nova, Ph.D. Ebetuel Pallares, Ph.D., Bruce&nbsp;C.
Robertson, Ph.D., Ron Rocca and James&nbsp;L.L. Tullis. Pursuant to the amended and restated stockholders&#146; agreement, Mr.&nbsp;Rocca, as our Chief Executive Officer, was initially selected to serve on our board of directors as a representative
of holders of our common stock, as designated by a majority of our common stockholders. Mr.&nbsp;Birk, Mr.&nbsp;Tullis, Dr.&nbsp;Pallares and Dr. Robertson were initially selected to serve on our board of directors as representatives of holders of
our redeemable convertible preferred stock, as designated by NMSIC <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, L.P., Tullis-Dickerson Capital Focus III, L.P., PCM/Exagen, L.P. (formerly known as CCP/Exagen, L.P.) and H.I.G. BioHealth
Partners, LLC or its affiliates, respectively. Mr.&nbsp;Burrell, Mr.&nbsp;Elliott and Dr.&nbsp;Nova were selected to serve on our board of directors as designated by the holders of a majority of our outstanding Series&nbsp;H, Series&nbsp;F,
Series&nbsp;E, Series&nbsp;D, Series&nbsp;C, and <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> redeemable convertible preferred stock, voting together as a single class. The amended and restated stockholders&#146; agreement also provides
for certain other rights, including among others, a right of first refusal to purchase future securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amended and restated
stockholders&#146; agreement, and all the rights granted pursuant to it, will terminate upon the completion of this offering, and members previously elected to our board of directors pursuant to this agreement will continue to serve as directors
until they resign, are removed or their successors are duly elected by holders of our common stock. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Board Composition and Election
of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>New Mexico Lease </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2016 and 2017,
we leased office space in New Mexico from a third party which specializes in providing outsourced information technology support services, and a partner in this company was an immediate family member of Wendy Rollstin, our former Chief Financial
Officer. We also used the information technology support services of this third party during 2016 and 2017. As of December&nbsp;31, 2017, we no longer lease this facility and Ms. Rollstin is no longer employed by us. Total expenses related to rent
expense and information technology support services provided by this related party for the years ended December&nbsp;31, 2017 and 2016 was $179,000 and $194,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into an offer
letters with each of our named executive officers. For more information regarding these agreements, see the section in this prospectus entitled &#147;Executive and Director Compensation&#151;Narrative Disclosure to Summary Compensation
Table&#151;Offer Letters with our Named Executive Officers.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreement with Dr.&nbsp;Dervieux </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2011, we entered into a license agreement with Dr.&nbsp;Dervieux and his company, DeNovo. The license agreement, covering novel methods for
monitoring <FONT STYLE="white-space:nowrap">low-dose</FONT> methotrexate therapy, relates to technology developed by Dr.&nbsp;Dervieux prior to joining us. The technology has yet to be used by us. Under the agreement, Dr.&nbsp;Dervieux would be
eligible to receive up to $600,000 when and if we achieve certain sales milestones and a single-digit percentage royalty on sales on an ongoing basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into
indemnification agreements with each of our directors and executive officers prior to the completion of this offering. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related
venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the director or executive officer
in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of our directors and
officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have entered into indemnification agreements with each of our directors and officers, and we have purchased a policy of directors&#146; and officers&#146;
liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For further information, see &#147;Executive and Director Compensation&#151;Limitations of
Liability and Indemnification Matters.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Option Grants to Executive Officers and Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have granted stock options to our executive officers and certain of our directors as more fully described in the section entitled &#147;Executive and
Director Compensation.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Participation in this Offering </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain affiliates of our directors and other existing stockholders have indicated an interest in purchasing an aggregate of approximately
$12.0&nbsp;million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding
agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any or all of these stockholders, or any or all of these stockholders may determine to purchase more, less or no shares in this
offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors will adopt written related person transaction policy, to be effective upon the completion of this offering, setting forth the
policies and procedures for the review and approval or ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item&nbsp;404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the
Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 (or, if less, 1% of the
average of our total assets at year-end for the last two completed fiscal years) and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related
person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that
could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our common stock as of June&nbsp;30, 2019, and as adjusted to
reflect the sale of shares of common stock in this offering, by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our executive officers and directors as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules,
beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 7,879,698 shares of common stock outstanding as of June&nbsp;30, 2019, which gives effect
to the automatic conversion of all outstanding shares of redeemable convertible preferred stock into 7,816,643 shares of common stock (including the conversion of 479,967,595 shares of our Series&nbsp;H redeemable convertible preferred stock issued
in July 2019 into 2,613,703 shares of common stock). Our calculation of beneficial ownership after the offering gives additional effect to (1)&nbsp;the issuance of 20,620 shares of common stock as a result of the expected net exercise of the Net
Exercise Warrants in connection with the completion of this offering, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, which warrants will terminate if not
exercised prior to the completion of this offering, and (2)&nbsp;the issuance of 3,333,334&nbsp;shares of common stock in this offering at the assumed initial public offering price of $15.00 per share, the midpoint of the price range set forth on
the cover page of this prospectus. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person that are
currently exercisable or will become exercisable within 60 days of June&nbsp;30, 2019 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, the address of each beneficial owner listed below is c/o&nbsp;Exagen Inc.,
1261&nbsp;Liberty Way, Suite&nbsp;C, Vista, California 92081. We believe, based on information provided to us that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the
stockholder unless noted otherwise, subject to community property laws where applicable. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain of our existing stockholders, including
entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $12.0&nbsp;million in shares of our common stock in this offering at the initial public offering price per share and on the
same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any or all
of these stockholders, or any or all of these stockholders may determine to purchase more, less or no shares in this offering. The following table does not reflect any such potential purchases by these stockholders or their affiliated entities. If
any shares are purchased by these stockholders, the number of shares of common stock beneficially owned after this offering and the percentage of common stock beneficially owned after this offering would increase from that set forth in the table
below. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially</B><br><B>Owned Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially&nbsp;Owned</B><br><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name&nbsp;of&nbsp;Beneficial&nbsp;Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with NMSIC <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,610,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,591,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities Affiliated with Tullis-Dickerson Capital Focus&nbsp;III, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,088,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,077,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Hunt Holdings, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,506,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,496,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">H.I.G. Bio-Exagen, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,271,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,271,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gerrit Johan Krediet</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kamal Adawi</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Brian Birk<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,610,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,591,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chet Burrell</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jeff Elliott</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tina S. Nova, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ebetuel Pallares, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bruce C. Robertson, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,271,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,271,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">James L.L. Tullis<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,135,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">All executive officers and directors as a group (10&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,133,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 659,711&nbsp;shares of common stock held by NMSIC <FONT STYLE="white-space:nowrap">Co-Investment</FONT>
Fund, L.P., or NMSIC, and (b)&nbsp;1,580,863&nbsp;shares of common stock and 369,648&nbsp;shares of common stock issuable upon the exercise of warrants held by NMSIC Focused, LLC, or NMSIC Focused. In addition, beneficial ownership after the
offering gives additional effect to the issuance of 894 shares of common stock as a result of the expected net exercise of outstanding warrants to purchase shares of Series E redeemable convertible preferred stock held by NMSIC Focused, assuming an
initial public offering price </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, which warrants will terminate if unexercised prior to the completion of this offering.
Excludes 2,281&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate in connection with this offering because the exercise prices for these warrants are higher than the initial
public offering price of this offering. The general partner of NMSIC is Sun Mountain Capital Partners LLC, or Sun Mountain. NMSIC is the sole member of NMSIC Focused. The members of Sun Mountain are Brian Birk, one of our directors, Sally Corning,
Lee Rand and Leslie Shaw. As a result, each of Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand and Ms.&nbsp;Shaw may be deemed to possess voting and investment control over, and may be deemed to have indirect beneficial ownership with
respect to, all shares held by NMSIC or NMSIC Focused. Neither Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand nor Ms.&nbsp;Shaw owns directly any of the shares. Each of Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand and
Ms.&nbsp;Shaw disclaims beneficial ownership of the shares held by NMSIC or NMSIC Focused, except to the extent of their pecuniary interest therein. The address for each of the NMSIC entities is 301 Griffin Street, Santa Fe, New Mexico 87501.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (a)&nbsp;1,103,125&nbsp;shares of common stock and 119,579&nbsp;shares of common stock issuable upon the
exercise of warrants held by Tullis-Dickerson Capital Focus III, L.P., or Tullis, (b)&nbsp;578,374&nbsp;shares of common stock and 181,900&nbsp;shares of common stock issuable upon the exercise of warrants held by Tullis Growth Fund, L.P, and
(c)&nbsp;105,453&nbsp;shares of common stock held by Tullis Growth Fund II, L.P. In addition, beneficial ownership after the offering gives additional effect to the issuance of 1 and 516 shares of common stock as a result of the expected net
exercise of outstanding warrants to purchase shares of Series E redeemable convertible preferred stock held by Tullis and Tullis Growth Fund, L.P., respectively, assuming an initial public offering price of $15.00 per share, the midpoint of the
price range set forth on the cover page of this prospectus, which warrants will terminate if unexercised prior to the completion of this offering. Excludes 1,361&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common
stock, which warrants will terminate in connection with this offering because the exercise prices for these warrants are higher than the initial public offering price of this offering. Tullis-Dickerson Partners III, LLC and Tullis Growth Fund, L.P.
are general partners of Tullis. James L.L. Tullis, one of our directors, is a Principal of Tullis-Dickerson Partners III, LLC., Tullis Growth Fund, L.P. and Tullis Growth Fund II, L.P. As a result, each of Tullis-Dickerson Partners III, LLC, Tullis
Growth Fund, L.P., Tullis Growth Fund&nbsp;II, L.P. and Mr.&nbsp;Tullis may be deemed to possess voting and investment control over, and may be deemed to have an indirect beneficial ownership with respect to, all shares held by Tullis, and
Mr.&nbsp;Tullis may be deemed to possess voting and investment control over, and may be deemed to have an indirect beneficial ownership interest with respect to, all shares held by Tullis Growth Fund, L.P. and Tullis Growth Fund II, L.P. The address
for each of the Tullis entities is 500 West Putnam Avenue, Suite 400, Stamford, Connecticut 06830. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 1,294,353&nbsp;shares of common stock, and 212,568&nbsp;shares of common stock issuable upon the exercise of
warrants held by Hunt Holdings, L.P. In addition, beneficial ownership after the offering gives additional effect to the issuance of 476 shares of common stock as a result of the expected net exercise of outstanding warrants to purchase shares of
Series E redeemable convertible preferred stock held by Hunt Holdings, L.P., assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, which warrants will terminate
if unexercised prior to the completion of this offering. Excludes 1,434&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common stock held by Hunt Holdings, L.P., which warrants will terminate in connection with this
offering because the exercise prices for these warrants are higher than the initial public offering price of this offering. The address of Hunt Holdings, L.P. is c/o Josph Advisory Services, LLC, 3800 N. Mesa St., Suite A-2, #371, El Paso, Texas
79902. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 120,788&nbsp;shares of common stock and 28,531&nbsp;shares of common stock issuable upon the exercise of
warrants held by PCM/Exagen, L.P., or PCM. In addition, beneficial ownership after the offering gives additional effect to the issuance of 173 shares of common stock as a result of the expected net exercise of outstanding warrants to purchase shares
of Series E redeemable convertible preferred stock held by PCM, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, which warrants will terminate if
unexercised prior to the completion of this offering. Excludes 199&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common stock held by PCM, which warrants will terminate in connection with this offering because the
exercise prices for these warrants are higher than the initial public offering price of this offering. Dr.&nbsp;Pallares, one of our directors, is a <FONT STYLE="white-space:nowrap">co-manager</FONT> of PCM. As a result, each of PCM and
Dr.&nbsp;Pallares may be deemed to possess voting and investment control over, and may be deemed to have an indirect beneficial ownership interest with respect to, all shares held by PCM. Prior to August&nbsp;6, 2015, PCM was previously known as
CCP/Exagen L.P. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">H.I.G. Capital, LLC has sole voting and investment control over the shares owned by H.I.G. Bio-Exagen, LLC. Bruce C.
Robertson, Ph.D. is a managing director of H.I.G. Capital, LLC and may be deemed to share voting and investment control over, and may be deemed to have an indirect beneficial ownership interest with respect to, all shares held by H.I.G. Bio-Exagen,
L.P. The address of H.I.G. Bio-Exagen, LLC is 1450 Brickell Avenue, 31st Floor, Miami, FL 33131. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (a)&nbsp;41,592&nbsp;shares of common stock held by James L.L. Tullis, (b)&nbsp;1,431&nbsp;shares of common
stock held by Linda&nbsp;A. Tullis, and (c)&nbsp;4,537&nbsp;shares of common stock held by the HPS Irrevocable Trust&nbsp;#3 U/A Dtd 7/6/93. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following description summarizes some of the
terms of our amended and restated certificate of incorporation and amended and restated bylaws, our outstanding warrants, the amended and restated investors&#146; rights agreement and of the Delaware General Corporation Law. Because it is only a
summary, it does not contain all the information that may be important to you. For a complete description you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, warrants and amended and restated
investors&#146; rights agreement, copies of which have been filed or incorporated by reference as exhibits to the registration statement of which the prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, our authorized capital stock will consist of 200,000,000 shares of common stock, $0.001 par value per
share, and 10,000,000&nbsp;shares of preferred stock, $0.001&nbsp;par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, there were 7,900,318&nbsp;shares of our common stock outstanding and held of record by 75&nbsp;stockholders, assuming
(i)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into shares of common stock, which will occur immediately prior to the completion of this offering, and (ii)&nbsp;the issuance of
20,620&nbsp;shares of common stock as a result of the expected net exercise of the Net Exercise Warrants in connection with the completion of this offering, assuming an initial public offering price of $15.00 per share, the midpoint of the price
range on the cover page of this prospectus, which Net Exercise Warrants will terminate if not exercised prior to the completion of this offering. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a
vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the
directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the
affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also
provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote
thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt
any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#151;Amendment of
Charter Provisions.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are
entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share
ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have
no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the
closing of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, all of
our previously outstanding shares of redeemable convertible preferred stock will have been converted into common stock, there will be no authorized shares of our previously redeemable convertible preferred stock and we will have no shares of
preferred stock outstanding. Under the terms of our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, our board of directors has the authority, without further action
by our stockholders, to issue up to 10,000,000&nbsp;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences
and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then
outstanding. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of
delaying, deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, options to
purchase 662,987&nbsp;shares of our common stock were outstanding under our 2002 Plan and 2013 Plan, of which 20,180 were vested and exercisable as of that date. For additional information regarding the terms of our 2002 Plan and 2013 Plan, see
&#147;Executive and Director Compensation&#151;Equity Incentive Award Plans.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, 934,789&nbsp;shares of our common stock were issuable upon the exercise of outstanding warrants to purchase common stock, with
a weighted-average exercise price of $8.49 per share. Following the completion of this offering, 908,385 of these warrants to purchase shares of our common stock will be exercisable for an aggregate of 908,385&nbsp;shares of our common stock at an
exercise price of $1.84 per share. If the remaining warrants to purchase common stock are not exercised prior to the completion of this offering, they will terminate. Of the remaining warrants, we expect warrants to purchase 17,350&nbsp;shares of
common stock with an exercise price of $1.84 per share to be net exercised in connection with the completion of this offering, resulting in the issuance of an aggregate of 15,224&nbsp;shares of our common stock assuming an initial public offering
price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, 4,174,430
shares of our Series D redeemable convertible preferred stock were issuable upon exercise of outstanding warrants, with an exercise price of $0.25 per share. These warrants are immediately exercisable. Warrants to purchase 3,186,430 shares of our
Series D redeemable convertible preferred stock expire in October 2023 and warrants to purchase 988,000 shares of our Series D redeemable convertible preferred stock expire in November 2023. We expect these warrants to be net exercised in connection
with the completion of this offering, resulting in the issuance of an aggregate of 3,284 shares of our common stock assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this
prospectus. If these warrants are not exercised prior to the completion of this offering, they will terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, 2,688,181 shares of our Series E redeemable convertible preferred stock
were issuable upon exercise of outstanding warrants with an exercise price of $0.25 per share. These warrants are immediately exercisable and expire in October 2020. We expect these warrants to be net exercised in connection with the completion of
this offering, resulting in the issuance of an aggregate of 2,112 shares of our common stock assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. If these
warrants are not exercised prior to the completion of this offering, they will terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, 19,230,769 shares of our Series
F redeemable convertible preferred stock were issuable upon exercise of outstanding warrants with an exercise price of $0.078 per share. Upon conversion of the Series F redeemable convertible preferred stock into common stock in connection with the
completion of this offering, these 19,230,769 warrants to purchase shares of our Series F preferred stock warrants will become exercisable for an aggregate of 104,722&nbsp;shares of our common stock at an exercise price of $14.32 per share. These
warrants are immediately exercisable. Warrants to purchase 15,384,615 shares of our Series F redeemable convertible preferred stock will expire in September 2024 and warrants to purchase 3,846,154 shares of our Series F redeemable convertible
preferred stock will expire in December 2025. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each of the above warrants has a net exercise provision under which the holder may, in lieu of
payment of the exercise price in cash, surrender the warrant and receive a net amount of shares of our common stock based on the fair market value of our common stock at the time of the net exercise of the warrant after deduction of the aggregate
exercise price. These warrants also contain provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon the exercise of the warrants in the event of stock dividends, stock splits, reorganizations and
reclassifications and consolidations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, upon the completion of this offering, holders of 7,880,575&nbsp;shares of our common stock, which includes all of the shares of
common stock issuable upon the automatic conversion of our redeemable convertible preferred stock immediately prior to the completion of this offering, and holders of warrants to purchase an aggregate of 1,013,107&nbsp;shares of common stock, will
be entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to an investor rights agreement by and among us and certain of our stockholders. The registration of shares of
common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Form <FONT
STYLE="white-space:nowrap">S-1.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></I>If at any time for a period of three years following the completion of this offering, the holders of at least 50% of the registrable securities request in writing that we effect a
registration with respect to their shares in an offering, we may be required to register their shares. We are obligated to effect at most two registrations for the holders of registrable securities in response to these demand registration rights,
subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Form S-</I>3.&nbsp;&nbsp;&nbsp;&nbsp;If at any time beginning 180 days following the completion of this offering
and we become entitled under the Securities Act to register our shares on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> a holder of registrable securities requests in writing that we register their shares for public resale on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> and the price to the public of the offering is $1.0&nbsp;million or more, we will be required to provide notice to all holders of registrable securities and to use our best efforts to effect such registration;
provided, however, that we will not be required to effect such a registration if, within the preceding 12 months, we have already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In each of the above registrations, if the holders requesting registration intend to distribute their shares by means of an
underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If at any time for a period of three years following the completion of this offering we propose to register any shares of our common stock under the
Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an
underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expenses </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ordinarily, other than underwriting
discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing
expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Termination of Registration Rights </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The registration
rights terminate upon the earlier of three years after the completion of this offering, or for any particular holder with registration rights, at such time following this offering when such holder holds less than one percent of our outstanding
common stock and may immediately sell all of such shares pursuant to Rule 144 under the Securities Act in a <FONT STYLE="white-space:nowrap">90-day</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could
make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these
provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the
market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover
bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the
proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ability of our board
of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change
control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stockholder Meetings </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws
provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president, or by a resolution adopted by a majority of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and
the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent
without a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Staggered Board </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of
directors is divided into three classes. The directors in each class will serve for a three-year term (other than the directors initially assigned to Class&nbsp;I whose term shall expire at our first annual meeting of stockholders), one class being
elected each year by our stockholders. For more information on the classified board, see &#147;Management&#151;Board Composition and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third-party
from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Removal of Directors </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated
certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the
total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stockholders Not Entitled to Cumulative Voting
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors.
Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our
preferred stock may be entitled to elect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested stockholders&#148; from
engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person
became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years
prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a
financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate
of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (i)&nbsp;any derivative action or proceeding brought on
our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
employees or agents to us or our stockholders, creditors or other constituents; (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law
of the State of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or
(v)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the
Securities Act or the rules and regulations thereunder. In any case, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of
forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our restated certificate of
incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment of Charter Provisions </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amendment of any
of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of
discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions
may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best
interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is 250&nbsp;Royal Street, Canton, Massachusetts 02021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Global Market </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied to have our common
stock listed on the Nasdaq Global Market under the symbol &#147;XGN.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For a discussion of liability and indemnification, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification
Matters.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in the public
market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we intend to apply to have our common stock listed on Nasdaq, we cannot assure you that there will be an active public market
for our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the number of shares of our common stock outstanding as of June&nbsp;30, 2019 and assuming (i)&nbsp;the issuance
of 3,333,334&nbsp;shares in this offering, (ii)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 7,816,643&nbsp;shares of our common stock, which will automatically occur immediately prior to
the completion of the offering, (iii)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares of common stock, (iv)&nbsp;the expected net exercise of the Net Exercise Warrants and (v)&nbsp;no exercise of outstanding options
or warrants (other than the Net Exercise Warrants), we will have outstanding an aggregate of approximately 11,233,652&nbsp;shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except
for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below, other than the holding
period requirement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The remaining 7,900,318&nbsp;shares of common stock will be &#147;restricted securities,&#148; as that term is defined in
Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or 701 under the Securities Act,
each of which is summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, of the 662,987&nbsp;shares of our common stock that were subject
to stock options outstanding as of June&nbsp;30, 2019, options to purchase 20,180 of such shares of common stock were vested as of such date. Upon exercise, these shares will be eligible for sale subject to the lock&#150;up agreements described
below and Rules 144 and 701 under the Securities Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We, along with our directors, executive officers and substantially all of our securityholders have agreed with the underwriters that for a period of 180
days, after the date of this prospectus, subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common
stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
period, certain of our stockholders and warrantholders will have the right to require us to register their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and &#147;Description of Capital Stock&#151;Registration
Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC, Cantor Fitzgerald&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C. may, in their sole discretion
and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, without public notice, release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. There are no existing agreements between the underwriters and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement providing consent to the sale of shares prior to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all
of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, certain of our officers, directors and significant stockholders may adopt written plans, known as Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these
<FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer, director
or stockholder. Such sales would not commence until the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer, director or stockholder in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Affiliate Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of
ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain &#147;riskless
principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately&nbsp;112,336&nbsp;shares
immediately after this offering; or </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume in our common stock on Nasdaq during the four calendar weeks preceding the filing of a
notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Affiliate resales under Rule 144 are also subject to the availability of current
public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form
144 with the SEC and the Nasdaq Global Market concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate
of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares
subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule&nbsp;144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of
Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, under Rule 701, any of
an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement
under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the
holding period requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to file one or more registration
statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issuable under our equity incentive plans and ESPP. We expect to
file the registration statement covering shares offered pursuant to these stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market
without restriction under the Securities Act and the sale by affiliates in the public market subject to compliance with the resale provisions of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, upon the
completion of this offering, holders of 7,880,575 shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our redeemable convertible preferred stock immediately prior to the completion
of this offering, or their transferees, and holders of warrants to purchase an aggregate of 1,013,107 shares of common stock, will be entitled to various rights with respect to the registration of these shares under the Securities Act upon the
completion of this offering. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for
shares purchased by affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or
release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax consequences
to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax
effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S. Internal
Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect as of
the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion is
limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not
address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the alternative minimum tax or the Medicare contribution tax on net
investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors
therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to the stock being
taken into account in an &#147;applicable financial statement&#148; (as defined in the Code). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If an entity treated as a
partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner
level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>
OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL
ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that
is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United
States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As described in the section entitled
&#147;Dividend Policy,&#148; we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will
constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax
purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital
gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to the discussion below on
effectively connected income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate
specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required
documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult
their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax
treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from
the U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT>
certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale or Other Taxable Disposition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property
holding corporation, or USRPHC, for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Gain described in the first bullet point above generally
will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such
lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Gain described in the
second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax
returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming,
a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other
business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established
securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable
disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and
Backup Withholding </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding
agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns
are required to be filed with the IRS in connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or
other taxable disposition of our common stock within the United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the
certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the
tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Backup withholding
is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the
required information is timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act,
or FATCA) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on
dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a
<FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to
the diligence and reporting requirements in (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States
persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT>
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our common
stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, recently proposed Treasury Regulations eliminate FATCA withholding on payments
of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the common stock being offered. Subject
to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of our common stock set forth opposite its name below. Cowen and Company, LLC, Cantor Fitzgerald&nbsp;&amp; Co.
and William Blair&nbsp;&amp; Company, L.L.C. are the representatives of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,333,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions
precedent and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the option to purchase
additional shares described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting
agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities
Act, and to contribute to payments the underwriters may be required to make in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters are offering the shares, subject
to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify
offers to the public and to reject orders in whole or in part. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain of our existing stockholders, including entities affiliated with certain
of our directors, have indicated an interest in purchasing an aggregate of approximately $12.0&nbsp;million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers
in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any or all of these stockholders, or any or
all of these stockholders may determine to purchase more, less or no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these stockholders as they will on any other shares sold to the
public in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Option to Purchase Additional Shares. </I>&nbsp;&nbsp;&nbsp;&nbsp;We have granted to the underwriters an option to
purchase up to&nbsp;500,000&nbsp;additional shares of common stock at the public offering price, less the underwriting discount. This option is exercisable for a period of 30 days. To the extent that the underwriters exercise this option, the
underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Discounts and
Commissions. </I>&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the public offering price, underwriting discount and proceeds, before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146;
option to purchase additional shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that the total expenses of the offering, excluding underwriting discount, will be
approximately $2.3&nbsp;million and are payable by us. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $40,000. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without</B><br><B>Option to<BR>Purchase<BR>Additional<BR>Shares</B><br><B>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With</B><br><B>Option&nbsp;to<BR>Purchase<BR>Additional<BR>Shares</B><br><B>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters propose to offer the shares of common stock to the public at the public offering price set forth
on the cover of this prospectus. The underwriters may offer the shares of common stock to securities dealers at the public offering price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Discretionary Accounts. </I>&nbsp;&nbsp;&nbsp;&nbsp;The underwriters do not intend to confirm sales of the shares to any accounts over which they
have discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Market Information. </I>&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for shares
of our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations will
include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the history of, and prospects for, our company and the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our past and present financial information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an assessment of our management; its past and present operations, and the prospects for, and timing of, our future revenue;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the present state of our development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in activities
similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">An active trading market for the shares may not develop. It is also possible that after the offering the shares
will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on the Nasdaq Global
Market under the symbol &#147;XGN.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Stabilization. </I>&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, the underwriters may
engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a
specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares
the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the option to purchase additional
shares. In a naked short position, the number of shares involved is greater than the number of shares in the option to purchase additional shares. The underwriters may close out any short position by exercising their option to purchase additional
shares and/or purchasing shares in the open market. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been
completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared
with the price at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a
naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of
the shares in the open market that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock
originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our
common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor
the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the Nasdaq Global Market, in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Passive Market Making. </I>&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, underwriters and selling group members may engage in passive
market making transactions in our common stock on the Nasdaq Global Market in accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending through the
completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, such bid
must then be lowered when specified purchase limits are exceeded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements.
</I>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to certain <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, we and our executive officers, directors and substantially all of our securityholders have agreed, subject to certain exceptions,
not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the
economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the SEC a registration statement under the Securities Act relating to, any common
stock or securities convertible into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC, Cantor Fitzgerald&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C., for a period of 180
days after the date of the pricing of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to
securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
power of disposition. The <FONT STYLE="white-space:nowrap">lock-up</FONT> provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the
ordinary course of their business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC, Cantor Fitzgerald&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C., in their
sole discretion, may release our common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. When determining whether or not to release our common stock
and other securities from <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, Cowen and Company, LLC, Cantor Fitzgerald&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C. will consider, among other factors, the holder&#146;s reasons
for requesting the release, the number of shares for which the release is being requested and market conditions at the time of the request. In the event of such a release or waiver for one of our directors or officers, Cowen and Company, LLC, Cantor
Fitzgerald&nbsp;&amp; Co. and William Blair&nbsp;&amp; Company, L.L.C. shall provide us with notice of the impending release or waiver at least three business days before the effective date of such release or waiver and we will announce the
impending release or waiver by issuing a press release at least two business days before the effective date of the release or waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Electronic
Offer, Sale and Distribution of Shares. </I>&nbsp;&nbsp;&nbsp;&nbsp;A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this
offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling group members for sale to their online
brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the
information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied
upon by investors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Other Relationships. </I>&nbsp;&nbsp;&nbsp;&nbsp;Certain of the underwriters and their affiliates have provided in the
past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they
have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf
of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions.
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Canada</I>. &nbsp;&nbsp;&nbsp;&nbsp;The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that
are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and are permitted clients, as defined in National
Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not
subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT>
<I>Underwriting Conflicts </I>(NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of
interest in connection with this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>European Economic Area</I>. &nbsp;&nbsp;&nbsp;&nbsp;In relation to each member state of the
European Economic Area (each, a &#147;Member State&#148;), no shares have been offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been
approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation), except that offers of
shares may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:ARIAL">(a) to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:ARIAL">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to
obtaining the prior consent of the underwriter for any such offer; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:ARIAL">(c) in any other circumstances falling within
Article&nbsp;1(4) of the Prospectus Regulation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to
Article&nbsp;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the purposes
of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered
so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>United Kingdom</I>. &nbsp;&nbsp;&nbsp;&nbsp;In addition, in the United Kingdom, this document is being distributed only to, and is directed only at,
and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within
Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated)
falling within Article&nbsp;49(2)(a) to (d) of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares
in the United Kingdom within the meaning of the Financial Services and Markets Act 2000 (as amended). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any person in the United Kingdom that is not
a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken
exclusively by relevant persons. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>France</I>. &nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been prepared in the context of a public
offering of financial securities in France within the meaning of <FONT STYLE="white-space:nowrap">Article&nbsp;L.411-1</FONT> of the French Code Mon&eacute;taire et Financier and Title&nbsp;I of Book&nbsp;II of the Reglement G&eacute;n&eacute;ral of
the Autorit&eacute; des march&eacute;s financiers, or the AMF, and therefore has not been and will not be filed with the AMF for prior approval or submitted for clearance to the AMF. Consequently, the shares of our common stock may not be, directly
or indirectly, offered or sold to the public in France and offers and sales of the shares of our common stock may only be made in France to qualified investors (investisseurs qualifi&eacute;s) acting for their own, as defined in and in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
accordance with Articles <FONT STYLE="white-space:nowrap">L.411-2</FONT> and <FONT STYLE="white-space:nowrap">D.411-1</FONT> to <FONT STYLE="white-space:nowrap">D.411-4,</FONT> <FONT
STYLE="white-space:nowrap">D.734-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French Code Mon&eacute;taire et Financier. Neither
this prospectus nor any other offering material may be released, issued or distributed to the public in France or used in connection with any offer for subscription on sale of the shares of our common stock to the public in France. The subsequent
direct or indirect retransfer of the shares of our common stock to the public in France may only be made in compliance with Articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT
STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the French Code Mon&eacute;taire et Financier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Germany. </I>&nbsp;&nbsp;&nbsp;&nbsp;Each person who is in possession of this prospectus is aware of the fact that no German securities prospectus
(wertpapierprospekt) within the meaning of the securities prospectus act (wertpapier-prospektgesetz), or the act, of the federal republic of Germany has been or will be published with respect to the shares of our common stock. In particular, each
underwriter has represented that it has not engaged and has agreed that it will not engage in a public offering in the federal republic of Germany (&ocirc;ffertliches angebot) within the meaning of the act with respect to any of the shares of our
common stock otherwise than in accordance with the act and all other applicable legal and regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Switzerland.
</I>&nbsp;&nbsp;&nbsp;&nbsp;The shares common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does
not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art.&nbsp;652a or art.&nbsp;1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art.&nbsp;27&nbsp;ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to
the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Neither this document nor any other
offering or marketing material relating to the offering, us, or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be
supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to
acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Netherlands</I>.
&nbsp;&nbsp;&nbsp;&nbsp;The offering of the shares of our common stock is not a public offering in The Netherlands. The shares of our common stock may not be offered or sold to individuals or legal entities in The Netherlands unless (i)&nbsp;a
prospectus relating to the offer is available to the public, which has been approved by the Dutch Authority for the Financial Markets (Autoriteit Financi&euml;le Markten) or by the competent supervisory authority of another state that is a member of
the European Union or party to the Agreement on the European Economic Area, as amended or (ii)&nbsp;an exception or exemption applies to the offer pursuant to Article 5:3 of The Netherlands Financial Supervision Act (Wet op het financieel toezicht)
or Article 53 paragraph 2 or 3 of the Exemption Regulation of the Financial Supervision Act, for instance due to the offer targeting exclusively &#147;qualified investors&#148; (gekwalificeerde beleggers) within the meaning of Article 1:1 of The
Netherlands Financial Supervision Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Japan</I>. &nbsp;&nbsp;&nbsp;&nbsp;The shares have not been and will not be registered under the
Financial Instruments and Exchange Act. Accordingly, the shares may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including
any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to
an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Hong Kong</I>. &nbsp;&nbsp;&nbsp;&nbsp;The shares have not been offered or sold and will not be
offered or sold in Hong Kong, by means of any document, other than (i)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (ii)&nbsp;in
other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No
advertisement, invitation or document relating to our common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to our common stock which are or are intended to be disposed of only to persons outside
Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Singapore</I>. &nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly,
this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an
invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA,
(ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA
by a relevant person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of
the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Solely for the purposes of its obligations pursuant to Section&nbsp;309B of the SFA, we have determined, and
hereby notify all relevant persons (as defined in the CMP Regulations 2018), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT
STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not authorized and do not authorize the making of any offer of securities through any
financial intermediary on our behalf, other than offers made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other
than the underwriters, is authorized to make any further offer of shares on our behalf or on behalf of the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San Diego, California. The
underwriters are being represented by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The financial statements as of December&nbsp;31, 2018 and 2017 and for the years then ended included in this prospectus and in the registration
statement have been so included in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, appearing elsewhere herein and in the registration statement, given on the authority of said firm as experts in auditing and
accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_22"></A>CHANGE IN INDEPENDENT ACCOUNTANT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;15, 2017, the Audit Committee of the board of directors dismissed PricewaterhouseCoopers LLP, or PwC, and retained BDO USA, LLP, or BDO, as
our independent registered public accounting firm on July&nbsp;14, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">PwC did not issue a report on our audited financial statements for each of
the two fiscal years ended December&nbsp;31, 2018 and December&nbsp;31, 2017. We had no disagreements with PwC on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements,
if not resolved to its satisfaction, would have caused PwC to make reference in connection with its opinion to the subject matter of the disagreement during its audits for each of the two fiscal years prior to its dismissal or the subsequent interim
period through June&nbsp;15, 2017. During the two most recent fiscal years preceding PwC&#146;s dismissal, and the subsequent interim period through June&nbsp;15, 2017, there were no &#147;reportable events&#148; as such term is defined in Item
304(a)(1)(v) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have provided PwC with a copy of the foregoing disclosure and have
requested that PwC furnish us with a letter addressed to the SEC stating whether or not PwC agrees with the above statements and, if not, stating the respects in which it does not agree. A copy of the letter from PwC is filed as an exhibit to the
registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the two years ended December&nbsp;31, 2016 and the subsequent interim period
through July&nbsp;14, 2017, neither we, nor anyone acting on our behalf, consulted with BDO on matters that involved the application of accounting principles to a specified transaction, either completed or proposed, the type of audit opinion that
might be rendered on our audited financial statements, and neither a written report nor oral advice was provided to us by BDO that BDO concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or
financial reporting issue or any other matter that was the subject of a disagreement as that term is used in Item 304 (a)(1)(iv) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and the related instructions to Item 304 of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> or a reportable event as that term is used in Item 304(a)(1)(v) and the related instructions to Item 304 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_23"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. Upon the completion of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. You may read and copy this information at the Public
Reference Room of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the public reference rooms by calling the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC also maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address
of that website is <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, we will become subject to the information and periodic reporting
requirements of the Exchange Act and, in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and
copying at the public reference room and website of the SEC referred to above. We maintain a website at www.exagen.com. Upon the completion of this offering, you may access our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT>
quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the
information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXAGEN INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc692844_24"></A><A NAME="toc692844_24"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin692844_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin692844_2">Balance Sheets </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin692844_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin692844_4">Statements of Cash Flows </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin692844_5">Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit
</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin692844_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin692844_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Stockholders and the Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Exagen Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Vista, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have audited the accompanying balance sheets of Exagen Inc. (&#147;the Company&#148;) (formerly known as Exagen Diagnostics, Inc.) as of
December&nbsp;31, 2017 and 2018, the related statements of operations, redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the
&#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2017 and 2018, and the results of its operations and its cash flows for
the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Change in Accounting Method Related to
Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As discussed in Notes 2 and 3 to the financial statements, the Company has changed its accounting method for revenue from contracts with
customers effective January 1, 2018 due to the adoption of Accounting Standards Codification 606, <I>Revenue from Contracts with Customers</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for
Opinion </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting.
Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ BDO USA, LLP </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Diego, California </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">May 31, 2019, except for Note&nbsp;16, which is as of
August&nbsp;23, 2019 and the &#147;Reverse Stock Split&#148; paragraph of Note 17 which is as of September&nbsp;9, 2019 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin692844_2"></A><A NAME="fin692844_2"></A>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share
and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B><br><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds received prior to issuance of Series&nbsp;G redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Borrowings&#151;non-current</FONT> portion, net of discounts and debt
issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.001 par value&#151;750,300,000, 750,300,000 and 955,500,000 shares
authorized at December 31, 2017 and 2018 and June&nbsp;30, 2019 (unaudited), respectively; 497,691,757, 532,606,084 and 681,534,421 shares issued and outstanding at December 31, 2017 and 2018 and June&nbsp;30, 2019 (unaudited), respectively;
liquidation preference of $131,390, $163,316 and $180,741 at December 31, 2017 and 2018 and June&nbsp;30, 2019 (unaudited), respectively; no shares issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Common stock, $0.001 par value&#151;1,470,000,000, 1,470,000,000 and 1,675,200,000 shares authorized at
December 31, 2017 and 2018 and June&nbsp;30, 2019 (unaudited), respectively; 63,005, 63,005 and 63,055&nbsp;shares issued and outstanding at December&nbsp;31, 2017 and 2018 and June&nbsp;30, 2019 (unaudited), respectively; 7,900,318&nbsp;shares
issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin692844_3"></A>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Operations </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands,
except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,880</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,868</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on extinguishment of share purchase rights and 2013 Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deemed dividend recorded in connection with financing transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders (Note 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted (Note 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(520.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(293.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average number of shares used to compute net loss per share attributable to common stockholders,
basic and diluted (Note 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted (Note 2,
unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted-average number of shares used to compute net loss per share attributable to common
stockholders, basic and diluted (Note 2, unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,282,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,836,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin692844_4"></A>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Cash Flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands)
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months<BR>Ended </B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Revaluation of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Amortization of debt discount and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Revaluation of embedded derivatives, share purchase rights, and warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss on extinguishment of share purchase rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Loss on extinguishment of 2013 Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">(Gain) loss on disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Changes in assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Repayment of accrued PIK interest in conjunction with repayment of 2013 Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Principal payment on capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from the issuance of preferred stock purchase rights, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from issuance of 2017 Term Loan, net of issuance costs of $465 and $5, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Repayment of 2013 Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from the issuance of preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds received prior to and for the issuance of Series G redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash paid for interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> items:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion to redemption value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Equipment purchased under capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Fair value of warrant liabilities recorded as discount on debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Costs incurred, but not paid, in connection with capital expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred offering costs included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Fair value of financial instruments extinguished in connection with financing transactions
(Note&nbsp;10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Fair value of tranche participation rights recognized in connection with financing transactions
(Note&nbsp;10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Beneficial conversion feature recognized in connection with financing transactions (Note&nbsp;10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deemed dividend recorded in connection with financing transactions (Note&nbsp;10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Adjustment upon adoption of ASC 606</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin692844_5"></A>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(122,007</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Beneficial conversion feature</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series F redeemable convertible preferred stock for aggregate proceeds of $0.078 per share, net
of issuance costs of $81, in the first tranche closing of the Series F financing (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series F redeemable convertible preferred stock upon the conversion of outstanding stock purchase
rights in the first tranche closing of the Series&nbsp;F financing (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series F redeemable convertible preferred stock for aggregate proceeds of $0.078 per share, net
of issuance costs of $10, upon the exercise of the tranche participation rights in the second tranche closing of the Series F financing (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series F redeemable convertible preferred stock for aggregate proceeds of $0.078 per share, net
of issuance costs of $10, in the third tranche closing of the Series F financing (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cumulative effect of changes in accounting principle related to revenue recognition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series F redeemable convertible preferred stock for aggregate proceeds of $0.078 per share, net
of issuance costs of $7, in the third tranche closing of the Series F financing (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss (as revised)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2018 (as revised)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds of $0.078 per share, net
of issuance costs of $96 (Note 10) (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at March&nbsp;31, 2019 (unaudited) (as revised)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">630,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155,268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds of $0.078 per share, net
of issuance costs of $28 (Note 10) (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss (unaudited) </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,785</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at June 30, 2019 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(158,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>Convertible<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(147,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(96,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cumulative effect of changes in accounting principle related to revenue recognition (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series F redeemable convertible preferred stock for aggregate proceeds of $0.078 per share, net
of issuance costs of $7, in the third tranche closing of the Series F financing (Note 10) (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at March&nbsp;31, 2018 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balances at June 30, 2018 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(149,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(103,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin692844_6"></A>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 1. Organization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Description of Business </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Exagen Inc. (the Company) was incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, Exagen
Corporation changed its state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which the Company changed its name to Exagen Diagnostics, Inc. In January 2019, the Company changed its name to
Exagen Inc. The Company is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has suffered recurring losses
and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had cash and cash
equivalents of $13.2&nbsp;million and $16.2&nbsp;million, respectively, and had an accumulated deficit of $152.6 million (as revised) and $158.1&nbsp;million, respectively. Based on the Company&#146;s current business plan, management believes that
its existing capital resources will be sufficient to fund the Company&#146;s obligations for at least the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To execute its
business plans, the Company will need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its
operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional
financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay,
reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company&#146;s business, operating results and financial condition and the
Company&#146;s ability to achieve its intended business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Basis of Presentation and Use of Estimates </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company&#146;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.
Actual results could materially differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Significant estimates and assumptions made in the accompanying financial statements
include, but are not limited to revenue recognition, the fair value of the Company&#146;s common and redeemable convertible preferred stock, the fair value of financial instruments measured at fair value, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis
using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Interim Financial Information </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
accompanying interim balance sheet as of June 30, 2019, the statements of operations, and cash flows for the six months ended June&nbsp;30, 2018 and 2019 and the statements of redeemable convertible preferred stock and stockholders&#146; deficit for
the three and six months ended June&nbsp;30, 2018 and 2019 and the related footnote disclosures are unaudited. In management&#146;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial
statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position as of June&nbsp;30, 2019 and its results of operations and cash flows for the six
months ended June&nbsp;30, 2018 and 2019 in accordance with GAAP. The results for the six months ended June&nbsp;30, 2019 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Information </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The unaudited pro
forma balance sheet information as of June&nbsp;30, 2019 assumes (i)&nbsp;the receipt of aggregate gross proceeds of $11.0&nbsp;million from the sale of Series&nbsp;H redeemable convertible preferred stock in July 2019 (Note&nbsp;17), (ii)&nbsp;the
conversion of all outstanding shares of redeemable convertible preferred stock (including Series&nbsp;H) into 7,816,643 shares of the Company&#146;s common stock and the related reclassification of (a)&nbsp;the carrying value of the redeemable
convertible preferred stock to permanent equity and (b)&nbsp;the redeemable convertible preferred stock warrant liabilities to additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital,</FONT></FONT> a component of
stockholders&#146; deficit, each of which will occur immediately prior to the completion of the Company&#146;s planned initial public offering (IPO), and (iii)&nbsp;the issuance of 20,620&nbsp;shares of common stock upon the net exercise of all
outstanding common stock and preferred stock warrants that have an exercise price less than the assumed initial public offering price of $15.00&nbsp;per share, the midpoint of the price range set forth on the cover page of the prospectus included in
the S-1&nbsp;Registration Statement, and if not exercised prior to the IPO would terminate. Shares of common stock issued in the IPO and any related net proceeds are excluded from the pro forma information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The unaudited pro forma basic and diluted net loss per share attributable to common stockholders has been computed to give effect to (i) the conversion
of all convertible preferred stock into 7,816,643&nbsp;shares of common stock as if the conversion had occurred as of the later of the beginning of the period or the original date of issuance; and (ii) the issuance of 20,620&nbsp;shares of common
stock upon the assumed net exercise of all outstanding common stock and preferred stock warrants that have an exercise price less than the assumed initial public offering price of $15.00 per share, the midpoint of the price range set forth on the
cover page of the prospectus included in the <FONT STYLE="white-space:nowrap">S-1&nbsp;Registration</FONT> Statement, and if not exercised prior to the completion of the IPO would terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentration of Credit Risk and Other Risk and Uncertainties </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable.
Substantially all the Company&#146;s cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Significant payers are those which represent more than 10% of the Company&#146;s total revenue or
accounts receivable balance at each respective balance sheet date. For each significant payer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Medicare</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Blue Shield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">United Healthcare</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Medicare Advantage</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">less than 10% </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accounts Receivable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Medicare</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Blue Shield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">United Healthcare</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Medicare Advantage</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the years ended December 31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019, approximately 89%,
82%, 86%, and 83%, respectively, of the Company&#146;s revenue was related to the AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is dependent on key suppliers for certain laboratory materials. An interruption in the supply of these materials would temporarily impact
the Company&#146;s ability to perform testing services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The carrying value of the Company&#146;s cash and cash equivalents, other assets and accrued liabilities approximate fair value due to the short-term
nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company&#146;s long term borrowings approximates its fair
value, which is considered a Level&nbsp;2 input. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Fair value is defined as the exchange price that would be received for an asset or an exit price
paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use
of observable inputs and minimize the use of unobservable inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fair value hierarchy defines a three-level valuation hierarchy for disclosure
of fair value measurements as follows: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;1<FONT STYLE="font-size:0.5pt">&nbsp;</FONT>&#151;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Unadjusted quoted prices in active markets for identical assets or liabilities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;2<FONT STYLE="font-size:0.5pt">&nbsp;</FONT>&#151;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are
not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;3<FONT STYLE="font-size:0.5pt">&nbsp;</FONT>&#151;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is
significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s acquisition-related liabilities, share purchase rights, tranche participation rights,
and redeemable convertible preferred stock warrant liabilities are measured at fair value on a recurring basis and are classified as Level&nbsp;3 liabilities. The Company records subsequent adjustments to reflect the increase or decrease in
estimated fair value at each reporting date in current period earnings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash
equivalents and are stated at cost, which approximates fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2016, the Company entered into an arrangement with a financial institution
with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $100,000 certificate of deposit with this financial institution as collateral for the balances borrowed
on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program
at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the adoption of ASC 606 on January 1, 2018, accounts receivable are recorded net of estimated contractual allowances on an accrual basis for tests
billed (see revenue recognition discussion below). As a result, there was no bad debt expense recorded for the year ended December&nbsp;31, 2018 or the six months ended June&nbsp;30, 2018 and 2019 because any accounts receivable balance outstanding
more than twelve months is considered as current period changes in allowances and recorded as reductions to revenues. Prior to January 1, 2018, the Company recorded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
an allowance for doubtful accounts against its accounts receivable based on estimates consistent with historical payment experience. The Company&#146;s allowance for doubtful accounts as of
December 31, 2017 was $48,000 and total bad debt expense recorded for the year ended December 31, 2017 was $34,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has deferred offering costs consisting of legal, accounting and other fees and costs directly attributable to its planned IPO. The deferred
offering costs will be offset against the proceeds received upon the completion of the planned IPO. In the event the planned IPO is terminated, all of the deferred offering costs will be expensed within the Company&#146;s statements of operations.
As of December 31, 2018 and June&nbsp;30, 2019, $0.4 million and $1.2&nbsp;million, respectively, of deferred offering costs were recorded within other assets in the accompanying balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and equipment are
stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a
straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or
otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in other income or expense in the statements of operations in the period realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Long-lived Assets </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s long-lived
assets are comprised principally of its property and equipment, finite lived intangible assets, and goodwill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the Company identifies a change in
the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment
analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#146;s carrying amount. Any required impairment loss would be
measured as the amount by which the asset&#146;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates
in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining
whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a
quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount,
goodwill is not considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
impaired; otherwise, an impairment loss is recorded. There was no indication of impairment of goodwill for any periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Studies </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time, the Company
engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or
research institution) for each subject enrolled in a clinical study, and the Company accrues expenses associated with these efforts as subjects are enrolled in each study. Expenses associated with clinical study activities are recorded in research
and development expenses in the accompanying statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has multiple classes of redeemable convertible preferred stock, all of which are classified as temporary equity in the balance sheet. Shares
of Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock have been classified as temporary equity in the balance sheet as holders of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> redeemable
convertible preferred stock can cause the redemption of the shares upon certain events such as a change in control or a significant transfer of the Company&#146;s assets to a third party, which are outside of the Company&#146;s control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Shares of Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C, Series D, Series E, Series F and Series G redeemable convertible preferred stock
are redeemable at any time after December 28<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2023, upon the written request of the holders of 52% of the outstanding shares of these issuances, voting together as a single class. Redeemable
convertible preferred stock which is redeemable on or after a certain date at the option of the holder is accreted to its redemption value from the date of issuance to the earliest redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Redeemable Convertible Preferred Stock Warrants </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company accounts for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of each instrument. The redeemable convertible preferred stock warrants classified as liabilities are recorded on
the Company&#146;s balance sheets at their fair value on the date of issuance and are revalued on each subsequent balance sheet date, with fair value changes recognized as increases or reductions in the statement of operations. The Company adjusts
the liability for changes in fair value of these redeemable convertible preferred stock warrants until the earlier of: (i)&nbsp;exercise of warrants; (ii)&nbsp;expiration of redeemable convertible preferred stock warrants; (iii)&nbsp;a change of
control of the Company; or (iv)&nbsp;the consummation of the Company&#146;s IPO. At that time, the redeemable convertible preferred stock warrant liabilities will be adjusted to fair value in the statement of operations with the final fair value
reclassified to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Substantially all of the Company&#146;s revenue has been derived from sales of its testing products and is primarily comprised of a high volume of
relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company&#146;s testing products and to whom
test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payers) consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e.,
hospitals, other laboratories, etc.), and patient self-pay. The Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Payers are billed at the Company&#146;s list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts
billed and the estimated consideration the Company expects to receive from such payers. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a
standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in
estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company&#146;s portfolios are grouped per payer
(i.e. each individual third party insurance, Medicare, client payers, patient <FONT STYLE="white-space:nowrap">self-pay,</FONT> etc.) and per test basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Collection of the Company&#146;s net revenues from payers is normally a function of providing complete and correct billing information to the healthcare
insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company early adopted Topic 606 as of January&nbsp;1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and
accounts receivable of $3.1&nbsp;million. See Note 3 for further discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Janssen Promotion Agreement </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2018, the Company entered into a <FONT STYLE="white-space:nowrap">co-promotion</FONT> agreement with Janssen, or the Janssen agreement, to <FONT
STYLE="white-space:nowrap">co-promote</FONT> SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the United States. The Company is responsible for the costs associated with its sales force over the course of such <FONT
STYLE="white-space:nowrap">co-promotion.</FONT> Janssen is responsible for all other aspects of the commercialization of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> under the Janssen agreement. In exchange for the
Company&#146;s sales and <FONT STYLE="white-space:nowrap">co-promotional</FONT> services, the Company is entitled to a quarterly tiered promotion fee ranging from $750 to $1,250 per prescription based on the incremental increase in total prescribed
units of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for that quarter over a predetermined baseline. The promotion fee is determined on a sliding rate, ranging from the high hundreds of dollars to the low one thousands per
prescribed unit of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, depending on the number of increased prescriptions, and varies per increased prescription. In addition, during the term of the Janssen agreement, the Company is
restricted from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for the treatment of indications covered by the agreement without first obtaining Janssen&#146;s written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The term of the Janssen agreement expires on June&nbsp;30, 2020, unless extended by the Company for an additional 18 months upon 180 days written notice
prior to the end of the initial term. Janssen can terminate the agreement at any time for any reason upon 30 days&#146; notice to the Company, and the Company can terminate the agreement for any reason at the end of any calendar quarter upon 30
days&#146; notice to Janssen. Either party may terminate the agreement in the event of the other party&#146;s default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following
receipt of written notice of such default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s obligations relating to sales and
<FONT STYLE="white-space:nowrap">co-promotion</FONT> services for SIMPONI&reg; is a series of single performance obligations since Janssen simultaneously receives and consumes the benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
provided by the Company&#146;s sales and <FONT STYLE="white-space:nowrap">co-promotional</FONT> services. The method for measuring progress towards satisfying the performance obligations is based
on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. As of December&nbsp;31, 2018, there were no performance obligations under the agreement or consideration received.
The Company began <FONT STYLE="white-space:nowrap">co-promoting</FONT> SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in early 2019 and recognized revenue of approximately $404,000 during the six months ended June&nbsp;30, 2019.
The related expenses for marketing SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are included in selling, general and administrative expenses and are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs associated with
research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting
up and conducting clinical studies and allocated overhead including rent and utilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Advertising and Marketing Costs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.3
million, $1.4 million, $0.7&nbsp;million, and $0.7&nbsp;million for the years ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019, respectively, and are included in selling, general and administrative expenses
in the accompanying statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Shipping and Handling Costs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately
$1.1&nbsp;million, $1.2&nbsp;million, $0.6&nbsp;million, and $0.7&nbsp;million for the years ended December&nbsp;31, 2017 and 2018 and six months ended June&nbsp;30, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company recognizes
compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock
options is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The BSM option pricing model incorporates various estimates, including the fair value of the Company&#146;s common stock, expected volatility, expected
term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company&#146;s limited historical experience. In
addition, due to the Company&#146;s limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free
interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the
foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Due to the absence of a public market for the Company&#146;s common stock, it has been necessary to
estimate the fair value of the common stock underlying the Company&#146;s stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company&#146;s stock-based
awards was assessed on each grant date by the Company&#146;s board of directors (Board of Directors). All options to purchase shares of the Company&#146;s common stock have been granted with an exercise price per share no less than the fair value
per share of the Company&#146;s common stock underlying those options on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There
have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company&#146;s comprehensive loss was the same as its reported net loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company accounts for income taxes
under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax
assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The
effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including
future reversals of existing taxable temporary differences, projected future taxable <FONT STYLE="white-space:nowrap">income,&nbsp;tax-planning&nbsp;strategies,</FONT> and results of recent operations. If management determines that the Company would
be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company records uncertain tax positions on the basis of <FONT STYLE="white-space:nowrap">a&nbsp;two-step&nbsp;process</FONT> whereby
(i)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii)&nbsp;for those tax positions that meet
<FONT STYLE="white-space:nowrap">the&nbsp;more-likely-than-not&nbsp;recognition</FONT> threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax
authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Loss Per Share </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic net loss per share
attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common
stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock and
options outstanding under the Company&#146;s stock option plan. For the years ended December&nbsp;31, 2017 and 2018 and for the six months ended June&nbsp;30, 2018 and 2019, there is no difference in the number of shares used to calculate basic and
diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the
Company&#146;s net loss per share (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended </B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As<BR>Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deemed dividend recorded in connection with financing transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(520.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(293.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so
would be anti-dilutive are as follows (in common stock equivalent shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,012,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,202,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,202,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,013,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,220,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,023,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,410,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,836,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the Company&#146;s unaudited pro forma net loss per share (in thousands, except share and per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Add:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deemed dividend recorded in connection with financing transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average number of common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma adjustments to reflect:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,199,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,752,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed net exercise of warrants to purchase common stock and redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares used to compute pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,282,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,836,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Segment Reporting </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the
chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent Accounting Pronouncements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time,
new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued
standards that are not yet effective will not have a material impact on the Company&#146;s financial position or results of operations upon adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT><I>&nbsp;Leases</I><I></I><I>&nbsp;(Topic 842)</I>. The new topic
supersedes Topic 840,&nbsp;Leases, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In
July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-10,</FONT> <I>Codification Improvements</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<I>to Topic 842</I>, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT> <I>Leases:
Targeted Improvements</I>, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements.
The effective date of this guidance for public companies is for reporting periods beginning after December&nbsp;15, 2018, and periods beginning after December&nbsp;15, 2019 for private companies. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT>
mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the
Company to carry forward its historical lease classification. The Company is currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2018, the FASB issued ASU No.&nbsp;2018-13, <I>Fair Value Measurement: Disclosure Framework&#151;Changes to the Disclosure Requirements for
Fair Value Measurement</I>, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&nbsp;1 and
Level&nbsp;2 of the fair value hierarchy, or valuation processes for Level&nbsp;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop
Level&nbsp;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective for annual periods beginning after December&nbsp;15, 2019, and interim periods within those
periods, and early adoption is permitted. The Company is currently evaluating the impact of ASU&nbsp;2018-13 on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted
Accounting Standards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2014, the FASB issued ASU 2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>, which, along with
subsequent amendments and addenda to this standard, provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods
or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company elected to apply Topic 606 to all contracts as of the adoption date. The Company
early adopted this guidance on January 1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and accounts receivable of $3.1 million. The cumulative-effect adjustment was the result of an acceleration of revenue
recognition since the Company was required to estimate consideration to which it expects to be entitled rather than record revenue on a cash basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> <I>Statement of Cash Flows (Topic&nbsp;230): Restricted Cash.
</I>The amendments in this update require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. As a result,
entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company adopted this guidance for its fiscal year beginning January&nbsp;1, 2018 and
adjusted the presentation of its statements of cash flows to include its restricted cash balance with non-restricted cash balances for the periods presented. The Company&#146;s restricted cash balance consists of a federally insured certificate of
deposit held with an affiliate of a large publicly traded financial institution that secures the Company&#146;s corporate credit card program. Due to the duration of this certificate of deposit, the amounts restricted as to use have been classified
outside of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
cash and cash equivalents. The adoption of this standard did not have a material impact on its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-04,</FONT> <I>Simplifying the Test for Goodwill Impairment</I>. This guidance
is intended to simplify the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in today&#146;s <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test under the guidance
contained in ASC&nbsp;350. Specifically, this guidance eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a
reporting unit&#146;s carrying amount over its fair value. The Company adopted this guidance on January&nbsp;1, 2018, and the adoption did not have a material impact on its financial statements since the Company completed a qualitative assessment at
December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 3. Adoption of ASU 2014-09, Revenue from Contracts with Customers (Topic&nbsp;606) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As discussed above, the Company early adopted Topic&nbsp;606 as of January&nbsp;1, 2018 using a cumulative-effect adjustment to the opening balance of
accumulated deficit and accounts receivable of $3.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to January&nbsp;1, 2018, the Company recognized revenue when the following
criteria was met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the fee is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured. The assessment
of the fixed or determinable nature of the fees charged and the collectability of those fees required significant judgment by management and revenue was recognized upon cash receipt until it had a contractual pricing arrangement with a payer or
sufficient history to reliably estimate payment patterns. For the year ended December&nbsp;31, 2017, revenue was recognized on an accrual basis for one payer, Medicare, and totaled $8.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the adoption, the Company utilized the following practical expedients and exemptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Costs to obtain or fulfill a contract are expensed when incurred because the amortization period would have been one year
or less. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">No adjustments to promised consideration were made for financing as the Company expects, at contract inception, that the
period between the transfer of a promised good or service and when the customer pays for that good or service will be one year or less. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following is the impact of the adoption on the Company&#146;s statement of operations for the year
ended December&nbsp;31, 2018 and balance sheet as of December&nbsp;31, 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;under<BR>previous<BR>guidance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Impact&nbsp;of<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><U>Year ended December&nbsp;31, 2018</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><U>Statement of Operations:</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(293.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(316.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><U>Balance Sheet at December&nbsp;31, 2018:</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Disaggregation of revenue </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table includes the Company&#146;s revenues as disaggregated by payer category (in&nbsp;thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Healthcare insurers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Government</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Client</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Janssen (SIMPONI<SUB STYLE="font-size:85%; vertical-align:bottom"><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">As noted above, amounts for the year ended December&nbsp;31, 2017 are presented as originally reported based upon the
accounting standards in effect for that period. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Includes patient <FONT STYLE="white-space:nowrap">self-pay</FONT> that is immaterial. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 4. Other Financial Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Prepaid Expenses and Other Current Assets </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prepaid
expenses and other current assets consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Diagnostic&nbsp;testing&nbsp;supplies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid product royalties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid maintenance and insurance contracts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other prepaid assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and equipment consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture&nbsp;and&nbsp;fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Depreciation and amortization expense for the years ended December&nbsp;31, 2017 and 2018 and the six months ended
June&nbsp;30, 2018 and 2019 was approximately $484,000, $590,000, $285,000, and $363,000, respectively. At December&nbsp;31, 2018 and June&nbsp;30, 2019, the gross book value of assets under capital lease was $412,000 and $712,000, respectively, and
is classified in &#147;Laboratory equipment&#148; in the table above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accrued Liabilities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accrued liabilities consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued&nbsp;payroll&nbsp;and&nbsp;related&nbsp;expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued purchases of goods and services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued royalties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued clinical study activity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Capital lease obligations, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 5. Share Purchase Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2016 and 2017, the Company entered into a series of agreements with existing holders of its redeemable convertible preferred stock to raise the
following amounts in each respective period through the issuance of the following similar financial instruments (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Agreement&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">December 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">January 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">February 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">April 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each tranche of these share purchase rights had an initial maturity date set at six months from the date of issuance
(e.g. the June 2016 share purchase rights were set to mature in December 2016). In December of 2016, the holders of these financial instruments agreed to extend the maturity date of the June 2016 instruments until June 2017. In March of 2017, the
holders of these financial instruments agreed to extend the maturity date of the August 2016 purchase rights and the October 2016 purchase rights until December 2017. Upon the maturity of each of these instruments, the notional amount of each
instrument, plus all accrued interest, was set to convert into shares of Series E redeemable convertible preferred stock at a rate of $0.25 per share. The notional amount of each instrument accrued interest at an annual rate equal to 8%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each of these instruments contained a number of additional settlement features which were exercisable by the investors upon the occurrence of certain
events: (i)&nbsp;Upon the occurrence of an IPO or subsequent issuance of preferred stock whose aggregate proceeds exceed $10,000,000, all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
instruments issued prior to December 2016 would convert into shares of common or preferred stock (as applicable to the class of shares issued) at an 80% discount to the issuance price of those
shares. The instruments issued in February and April of 2017 did not provide for such a discount upon the issuance of preferred stock, but did provide for an 80% discount upon the occurrence of an IPO; (ii)&nbsp;Upon an event which results in the
conversion of the outstanding shares of Series E redeemable convertible preferred stock to shares of common stock, or upon the election by the holders of these notes, these instruments would convert into shares of Series E redeemable convertible
preferred stock at a rate of $0.25 per share; (iii)&nbsp;Upon a change of control of the Company, and with the consent of the Company&#146;s senior lenders, these instruments would be redeemed for 120% (200% for the instruments issued in February
and April of 2017) of the principal and accrued interest of these instruments. If the consent of the senior lenders is not received in conjunction with a change in control of the Company, these instruments were to convert into shares of Series E
redeemable convertible preferred stock at a rate of $0.25 per share; (iv)&nbsp;Upon a liquidation of the Company, and with the consent of the Company&#146;s senior lenders, these instruments were to be redeemed for 100% of the principal and accrued
interest of these instruments. If the consent of the senior lenders was not received in conjunction with a liquidation of the Company, these instruments were set to convert into shares of Series E redeemable convertible preferred stock at a rate of
$0.25 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on an evaluation of the terms of these instruments, the Company concluded each of these instruments represented a single
freestanding financial instrument providing each investor the ability to purchase shares of Series E redeemable convertible preferred stock at $0.25 per share upon maturity, and which contain a number of additional settlement features which were
exercisable based on the occurrence of events outside of each investor&#146;s control. As a result of the contingent redemption features present in the Series E redeemable convertible preferred stock (Note 10), the Company concluded these
instruments require classification as liabilities whose fair value will be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">marked-to-market</FONT></FONT> each reporting period. The Company valued these instruments using a method
that considered the expected fair value of each of the potential settlement alternatives available to the investors. The application of this method incorporated management&#146;s assumptions related to the likelihood and timing of events which give
rise to each settlement alternative available to the investors under the terms of these instruments. The significant assumptions used in the valuation of these instruments include (i)&nbsp;Management&#146;s assumptions related to likelihood and
timing of occurrence for each settlement feature and (ii)&nbsp;the fair value of the consideration that would be received upon the exercise of each settlement feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the ranges for the significant assumptions utilized in management&#146;s estimates for the year ended December&nbsp;31,
2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Estimated per share fair value of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$0.11 - $0.13</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assessed likelihood of settlement into preferred shares of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">65%&nbsp;-&nbsp;100%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected time to settlement event</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.1&nbsp;years&nbsp;-&nbsp;0.5&nbsp;years</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, as a result of the Series F financing transaction (Note 10), all outstanding share purchase rights were
converted into 163,785,334 shares of Series F redeemable convertible preferred stock in accordance with the settlement terms described above and as amended to allow a 20% discount to the per share issuance price for the share purchase rights issued
in February 2017 and April 2017. Based on the estimated fair value and number of Series F redeemable convertible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
preferred stock issued based on the settlement terms, the fair value of the outstanding share purchase rights was estimated at $19.5&nbsp;million, which resulted in expense of $10.1&nbsp;million
representing the change in the fair value of these financial instruments upon settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 6. Borrowings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2017 Term Loan </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2017, the Company executed a
term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0&nbsp;million, $17.8&nbsp;million of which was immediately used to repay the Company&#146;s existing loan with Capital Royalty
Partners II L.P. and its affiliates. On December&nbsp;7, 2018, the Company borrowed an additional $5.0&nbsp;million under the 2017 Term Loan. At December&nbsp;31, 2018 and June&nbsp;30, 2019, no additional amounts remain available to borrow under
the 2017 Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The interest rate on all borrowings under the 2017 Term Loan is 11.0%, of which 2.5% is paid
<FONT STYLE="white-space:nowrap">in-kind</FONT> in the form of additional term loans, or PIK Loans, until September of 2019, after which interest accrues at an annual rate of 11.0%. The Company has estimated the effective interest rate of this loan
to be approximately 14%. Accrued interest is due and payable monthly, unless the Company elects to pay PIK interest. The outstanding principal and accrued interest on the 2017 Term Loan will be repaid in twenty-four equal monthly installments
commencing in October 2020. Upon repayment of the final installment under the 2017 Term Loan, the Company is required to pay an additional fee of $1.0&nbsp;million. This obligation is being accreted into interest expense over the term of 2017 Term
Loan using the effective interest method. For the years ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019, the Company issued PIK Loans totaling $159,000, $518,000, $251,000 and $320,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the 2017 Term Loan is repaid prior to the September 7, 2019, the Company will be required to issue Innovatus a warrant to purchase 3,000,000 shares
of Series F redeemable convertible preferred stock at an exercise price of $0.078 per share, and pay an additional prepayment premium which ranges between 0.25% and 2.5% of the outstanding term loan principal. If the 2017 Term Loan is prepaid after
September 7, 2019, but before September&nbsp;7, 2020, the 2017 Term Loan requires a prepayment premium of 3% of the aggregate outstanding principal. The prepayment premium decreases by 1% during each subsequent twelve-month period after
September&nbsp;7, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2017 Term Loan is collateralized by a first priority security interest on substantially all of the Company&#146;s
assets, including intellectual property. The affirmative covenants of the 2017 Term Loan require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt
notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The affirmative covenants require that the Company achieve a specified level of revenue, and either (i)&nbsp;gross margins, or (ii)&nbsp;gross profits
(collectively referred to as the Interest Only Milestones), as measured quarterly on a rolling twelve month basis, and commencing with the quarter ending December&nbsp;31, 2017 (1)&nbsp;the interest rate on the 2017 Term Loan will increase by 8% and
(2)&nbsp;repayment will commence on the date it is determined the Interest Only Milestones have not been met and over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the following eighteen months in equal monthly installments. The consequences of failing to achieve the Interest Only Milestones will be waived if, within sixty days of failing to achieve the
Interest Only Milestones, the Company issues additional equity securities or subordinated debt with net proceeds of at least $9.5&nbsp;million. In addition, the 2017 Term Loan requires that the Company maintain certain levels of minimum liquidity.
If the Company has achieved the Interest Only Milestones, the Company is required to maintain an unrestricted cash balance of $2,000,000. If the Interest Only Milestones are not met, the Company must maintain unrestricted cash balances totaling at
least the trailing four months cash used to fund operating activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The negative covenants provide, among other things, that without the prior
consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company&#146;s property, pay dividends
on the Company&#146;s capital stock or make prohibited investments. The 2017 Term Loan agreement provides that an event of default will occur if, among other triggers, (i)&nbsp;the Company defaults in the payment of any amount payable under the
agreement when due, (ii)&nbsp;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company&#146;s business, operations or condition, or on the Company&#146;s ability to perform its
obligations under the agreement, (iii)&nbsp;the Company becomes insolvent, (iv)&nbsp;the Company undergoes a change in control or (v)&nbsp;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a
cure period, otherwise neglects to perform or observe any material item in the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2018 and June&nbsp;30, 2019, the
Company was in compliance with all covenants of the 2017 Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon an event of default in any of the 2017 Term Loan covenants, the repayment
of the 2017 Term Loan may be accelerated and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes
acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the 2017 Term Loan due beyond twelve months of the balance sheet date as
<FONT STYLE="white-space:nowrap">non-current.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the 2017 Term Loan, the Company paid issuance costs of $449,000 to
Innovatus and an additional $119,000 to third parties. These fees were recorded as discounts to the carrying value of the 2017 Term Loan. The Company also issued Innovatus warrants (i)&nbsp;on the closing date of the 2017 Term Loan, to purchase
15,384,615 shares of Series F redeemable convertible preferred stock at an exercise price of $0.078 per share and (ii) on December 7, 2018, to purchase 3,846,154 shares of Series F redeemable convertible preferred stock at an exercise price of
$0.078 per share (Note 7). These warrants are immediately exercisable and will expire if unexercised seven years after their issuance. The fair value of the warrants on each of their dates of issuance, determined using BSM option pricing model, was
recorded as a discount to long-term debt and an offsetting amount recognized as a liability. The resulting debt discount is being amortized to interest expense using the effective interest method over the term of the 2017 Term Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2013 Term Loan </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2013, the Company executed a term
loan agreement (the 2013 Term Loan) with Capital Royalty Partners II L.P. and its affiliates Parallel Fund &#147;a&#148; L.P. and Parallel Investment Opportunities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Partners II L.P. (collectively Capital Royalty). The total outstanding principal borrowed under the 2013 Term Loan was $15.0&nbsp;million dollars. Amounts borrowed on the 2013 Loan accrued
interest at 14.0% per annum with interest-only payments due on a quarterly basis with payment dates fixed at the end of each calendar quarter, or Payment Dates, through September&nbsp;30, 2017. Under the terms of the loan, the Company elected to pay
interest as follows: 10.0% per annum in cash and 4.0% per annum paid <FONT STYLE="white-space:nowrap">in-kind</FONT> in the form of additional term loans, or PIK Loans. For the year ended December&nbsp;31, 2017, the Company issued PIK Loans totaling
$342,000. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the 2013 Term Loan, the Company issued a total of 4,174,430 warrants to purchase shares of Series D redeemable
convertible preferred stock (Note 7) and an additional 17,350&nbsp;warrants to purchase shares of common stock (Note 7) to Capital Royalty and a third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2017, at the time of the repayment of all outstanding amounts, the difference between the carrying value of the 2013 Term Loan and the
total principal and accrued interest of $306,000 was recorded within Loss on extinguishment of share purchase rights and 2013 Term Loan in the accompanying statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Future Minimum Payments on the Outstanding Borrowings </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Future
minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Term Loan are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unamortized debt discount and issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total borrowings, net of discounts and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 7. Warrants to Purchase Common or Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Warrants to Purchase Common Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2013 Loan Common Stock Warrants
</I></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the 2013 Term Loan issued in October 2013 (Note 6), the Company issued warrants, or the 2013 Loan Common Stock Warrants,
to purchase 17,350 shares of common stock exercisable at $1.84 per share. The 2013 Loan Common Stock Warrants are classified as a component of equity and are immediately exercisable and have a <FONT STYLE="white-space:nowrap">ten-year</FONT>
contractual term. The warrants expire in October 2023 and remain outstanding as of December&nbsp;31, 2018 and June&nbsp;30, 2019. All outstanding 2013 Loan Common Stock Warrants terminate if not exercised prior to the completion of an IPO. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2016 Common Stock Warrants </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the issuance of Series E redeemable convertible preferred stock during 2016, the Company issued 908,385 warrants to purchase common
stock, or the 2016 Common Stock Warrants, exercisable at $1.84 per share. The 2016 Common Stock Warrants are classified as component of equity and are immediately exercisable and have a <FONT STYLE="white-space:nowrap">ten-year</FONT> contractual
term. The 2016 Common Stock Warrants remain outstanding as of December&nbsp;31, 2018 and June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to the above, the Company
has 9,054 common stock warrants outstanding as of December&nbsp;31, 2018 and June&nbsp;30, 2019 which are currently exercisable at $688.63 per share. These common stock warrants expire between May 2019 and October 2021. No amounts have been recorded
for these common stock warrants as their fair value was determined to be immaterial. These common stock warrants terminate if not exercised prior to the completion of an IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Warrants to Purchase Redeemable Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2013
Loan Redeemable Convertible Preferred Stock Warrants </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the 2013 Term Loan issued in October 2013 (Note&nbsp;6), the Company
issued 3,186,430 and 988,000 warrants to purchase shares of Series&nbsp;D redeemable convertible preferred stock at $0.25 per share to its lender, Capital Royalty, and a third-party investment adviser, respectively. The Company collectively refers
to the warrants described above as the 2013 Loan Redeemable Convertible Preferred Stock Warrants. The $1.0&nbsp;million aggregate fair value of the warrants was recorded as a discount to the carrying value of the 2013 Term Loan and was amortized to
interest expense over its respective term. The 2013 Term Loan was repaid in conjunction with the issuance of the 2017 Term Loan (Note 6). The 3,186,430 warrants issued to Capital Royalty and the 988,000 warrants issued to the third-party investment
adviser are immediately exercisable and expire in October 2023 and November 2023, respectively, and remain outstanding at December&nbsp;31, 2018 and June&nbsp;30, 2019. All outstanding 2013 Loan Redeemable Convertible Preferred Stock Warrants
terminate if not exercised prior to the completion of an IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2013 Loan Redeemable Convertible Preferred Stock Warrants are classified as
liabilities, with changes in fair value recorded through earnings, as the underlying shares of Series&nbsp;D redeemable convertible preferred stock can be redeemed by the holders of these shares upon the occurrence of certain events that are outside
of the control of the Company (Note&nbsp;10). The Company estimated the fair value of the 2013 Loan Redeemable Convertible Preferred Stock Warrants using an option pricing model. The significant inputs to this valuation methodology included the
rights and preferences of each class of Company&#146;s shares (Note&nbsp;10), Management&#146;s assumptions related to the expected timing of a liquidation event, and the Company&#146;s estimated equity value and volatility assumptions on the
valuation date, which are based on management&#146;s analysis of comparable publicly traded peer companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the years ended December&nbsp;31,
2017 and 2018, the change in fair value of 2013 Loan Redeemable Convertible Preferred Stock Warrants was a benefit of $37,000 and an expense of $17,000 (as revised), respectively. For the six months ended June&nbsp;30, 2018 and 2019, the change in
the fair value of 2013 Loan Redeemable Convertible Preferred Stock Warrants was $0 and an expense of $87,000, respectively. All changes in fair value were recorded in change in fair value of financial instruments in the accompanying statements of
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2015 Warrants </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2015, the Company issued a variable number of warrants, the 2015 Warrants, which became a fixed and immediately exercisable warrant to purchase
2,688,181 shares of Series&nbsp;E redeemable convertible preferred stock at an exercise price of $0.25 per share as a result of the issuance of Series&nbsp;E redeemable convertible preferred stock in January 2016. Upon issuance, the Company
estimated the fair value of the 2015 Warrants to be $87,000. The 2015 Warrants expire in October 2020 and remain outstanding at December&nbsp;31, 2018 and June&nbsp;30, 2019. All outstanding 2015 Warrants terminate if not exercised prior to the
completion of an IPO, a change in control, reorganization, or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2015 Warrants are classified as liabilities, with changes in fair
value recorded through earnings, as the underlying shares of Series&nbsp;E redeemable convertible preferred stock can be redeemed by the holders of these shares upon the occurrence of certain events that are outside of the control of the Company
(Note&nbsp;10). For the years ended December&nbsp;31, 2017 and 2018, the Company recognized a benefit of $19,000 and an expense of $5,000 (as revised), respectively, for the change in fair value of the 2015 Warrants. For the six months ended
June&nbsp;30, 2018 and 2019, the change in the fair value of the 2015 Warrants was $0 and a benefit of $40,000, respectively. All changes in fair value of the 2015 Warrants were recorded in change in fair value of financial instruments in the
accompanying statements of operations and were computed using the methodology described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>2017 and 2018 Warrants </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the issuance of the 2017 Term Loan (Note&nbsp;6) in September 2017, the Company issued warrants to Innovatus (the 2017 Warrants),
which are immediately exercisable to purchase 15,384,615 shares of Series F redeemable convertible preferred stock at an exercise price of $0.078 per share. The 2017 Warrants are classified as liabilities, with subsequent changes in fair value
recorded through earnings, as the underlying shares of Series&nbsp;F redeemable convertible preferred stock can be redeemed by the holders of these shares upon the occurrence of certain events that are outside of the control of the Company
(Note&nbsp;10). Upon their issuance, the fair value of the 2017 Warrants were estimated to be $1.0&nbsp;million using the methodology described above. Since the 2017 Warrants are to be measured at fair value and were issued in conjunction with the
2017 Term Loan, the estimated fair value of the warrants issued was recorded as a discount to the carrying value of the 2017 Term Loan upon issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with additional borrowings made in December 2018 under the 2017 Term Loan (Note&nbsp;6), the Company issued warrants to Innovatus (the
2018 Warrants), which are immediately exercisable to purchase 3,846,154 shares of Series&nbsp;F redeemable convertible preferred stock at an exercise price of $0.078 per share. The 2018 Warrants are classified as liabilities, with subsequent changes
in fair value recorded through earnings, as the underlying shares of Series&nbsp;F redeemable convertible preferred stock can be redeemed by the holders of these shares upon the occurrence of certain events that are outside of the control of the
Company (Note&nbsp;10). Upon their issuance, the fair value of the 2018 Warrants was estimated to be $0.3&nbsp;million using the methodology described above. Since the 2018 Warrants are to be measured at fair value and were issued in conjunction
with the 2017 Term Loan, the estimated fair value of the warrants issued was recorded as a discount to the carrying value of the 2017 Term Loan upon issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the year ended December&nbsp;31, 2017, the change in the fair value of the 2017 Warrants was a benefit of $185,000. For the year ended December 31,
2018, the change in the fair value of the 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and 2018 Warrants was an expense of $296,000 (as revised). For the six months ended June&nbsp;30, 2018 and 2019, the change in the fair value of the 2017 and 2018 Warrants was $0 and a benefit of
$514,000, respectively. These changes in fair value of the 2017 and 2018 Warrants were recorded in change in fair value of financial instruments in the accompanying statements of operations and were computed using the methodology described above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2017 and 2018 Warrants will expire in September 2024 and December 2025, respectively, and remain outstanding at December&nbsp;31, 2018 and
June&nbsp;30, 2019. All outstanding 2017 and 2018 Warrants terminate if not exercised prior to the completion of a change in control. If, in the Company&#146;s next round of equity financing, the Company issues preferred stock at a price per share
lower than $0.078, the 2017 and 2018 Warrants will become exercisable at the issuance price of, and for that class of preferred shares issued. The number of such shares to be issued will be adjusted to equal $1,500,000 divided by the issuance price.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 8. Commitments and Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company leases approximately 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in January 2021, with
options to extend the lease for two additional <FONT STYLE="white-space:nowrap">36-month</FONT> periods. In addition, the Company also leases approximately 19,500 square feet of office space in Vista, California, under a lease that expires in
January 2021 with an option to extend the lease for an additional <FONT STYLE="white-space:nowrap">24-month</FONT> period. The Company&#146;s lease payments under each of these leases are subject to escalation clauses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Minimum annual lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease arrangements at December&nbsp;31, 2018 are as follows
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Year&nbsp;Ending&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: amount representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Present value of future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long-term capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the years ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019, rent expense
was $424,000, $446,000, $227,000, and $235,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Acquisition-related liabilities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain
amounts in the event that certain revenue milestones </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. The
Company has accounted for the related liabilities at fair value at each period end, using a probability weighted discounted revenue model. At December&nbsp;31, 2016, the fair value of the obligations under these agreements was $51,000 and related to
licensing agreements with Cellatope and Royalty Pharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January of 2017, the Company amended its agreements with Cellatope. As a result of this
amendment, the obligation to pay Cellatope a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $3.0&nbsp;million upon the launch of a monitoring product incorporating Cell-Bound Complement Activation Products (CB-CAPs) technology was
replaced with an agreement to pay Cellatope a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $100,000 upon the launch of such a product, plus a 7.5% royalty based on future cash collections from sales of that product which incorporate
the licensed technology. Future royalties payable under this arrangement are limited to the lesser of $3,000,000 (including the upfront payment of $100,000) or the total royalty earned through January&nbsp;1, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February of 2017, the Company amended its agreements with Royalty Pharma relating to the launch of monitoring product using <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> technology. As a result of this amendment, the obligation to make a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $1.0&nbsp;million upon the launch of a monitoring product incorporating <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> technology was replaced with an agreement to pay Royalty Pharma a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $100,000 upon the launch of such a product, plus a 2.5% royalty based on future
cash collections from sales of that product which incorporate the licensed technology. Future royalties under this arrangement are limited to the lesser of $1,200,000 (including the upfront payment of $100,000) or the total royalty earned through
January&nbsp;1, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on an evaluation of the facts and circumstances leading to these amendments, including the length of time between these
amendments and the original agreements with Cellatope and Royalty Pharma that were assigned to the Company in the acquisition of Cypress Bioscience, Inc. in 2010, and the concessions offered by the licensees, the Company concluded that these
amendments should be accounted for separately from the original agreements with Cellatope and Royalty Pharma. As such, future royalties from the sale of monitoring products which incorporate the licensed technologies will be accrued upon the
collection of cash from sale of such products and the Company will no longer recognize or remeasure a contingent liability for these obligations. As a result of the derecognition of this liability upon the execution of these amendments, the Company
recorded a benefit of $51,000 to change in fair value of acquisition-related liabilities in the accompanying statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Also in
connection with the acquisition of Cypress Bioscience, Inc. in 2010, the obligation for an additional $2.0&nbsp;million milestone payment to Prometheus exists for which the fair value of the obligation was determined to be nil at December 31, 2017
and 2018 and June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Licensing Agreements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described
above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from 3.0% to 20.0%. Royalties are accrued when earned and recorded in costs of
revenue in the accompanying statement of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Supply Agreement </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2018, the Company entered into a supply agreement with one supplier for reagents which includes a minimum annual purchase commitment of $3.25
million for each of the three years covered by the agreement, which terminates in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide
for general indemnifications. The Company&#146;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters
when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is not a party to any litigation and does not have contingent reserves established for any litigation liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 9. Fair Value Measurements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets
forth the Company&#146;s financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The inputs and assumptions used to estimate the fair value of, warrants to purchase redeemable convertible preferred
stock and acquisition-related liabilities are discussed in Note 7 and Note 8, respectively. The fair value of the Company&#146;s money market funds is based on quoted market prices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table includes a roll-forward of the financial instruments measured on a recurring basis
and classified within Level&nbsp;3 of the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Amounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquisition-<BR>Related<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liability<BR>Classified<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>Purchase<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tranche<BR>Participation<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balances at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of share purchase rights for cash (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of share purchase rights in connection with the first tranche issuance of Series F redeemable
convertible preferred stock (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of tranche participation rights in connection with the first tranche closing of Series F redeemable
convertible preferred stock (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercise of tranche participation rights in connection with second tranche closing of Series F redeemable
convertible preferred stock (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection
with 2017 Term Loan (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balances at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection
with 2017 Term Loan (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balances at December&nbsp;31, 2018 and March&nbsp;31, 2019 </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balances at June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in the fair value of the Company&#146;s acquisition-related liabilities are recorded in the line item change in
fair value of acquisition-related liabilities in the accompanying statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in the fair value of the Company&#146;s
liability classified warrants, share purchase rights, and tranche participation rights are recorded in the line item change in fair value of financial instruments in the accompanying statement of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 10. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Description of Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January 2, 2019, the Company amended and restated its restated certificate of incorporation to, among other things, increase its authorized shares of
convertible preferred stock from 750,300,000 to 955,500,000 shares, of which 205,200,000 shares are designated as Series G convertible preferred stock and set forth the rights, preferences and privileges of the Series G convertible preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2017, the Company&#146;s redeemable convertible preferred stock consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Redemption<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,369,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,030,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,637,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,533,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,550,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,570,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497,691,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2018, the Company&#146;s redeemable convertible preferred stock consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Redemption<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,369,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,030,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,637,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,533,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,550,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,484,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,606,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At June&nbsp;30, 2019, the Company&#146;s redeemable convertible preferred stock consists of the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>Redemption<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,369,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,030,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,637,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,533,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,550,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,484,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series G</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,928,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">955,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681,534,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The significant rights and preferences of the Company&#146;s redeemable convertible preferred stock are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With the exception of Series <FONT
STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock, each holder of preferred stock is entitled to noncumulative dividends at an annual rate of $0.02 per share when and if declared by the Board of Directors. Dividends are
paid in the following order of preference: (i)&nbsp;Series G, (ii)&nbsp;Series F, (iii)&nbsp;Series E, (iv)&nbsp;Series D (v) Series C, (vi)&nbsp;Series <FONT STYLE="white-space:nowrap">B-3,</FONT> (vii) Series
<FONT STYLE="white-space:nowrap">A-3,</FONT> and (viii)&nbsp;common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">No dividend shall be declared or be payable on the outstanding shares of
the Series <FONT STYLE="white-space:nowrap">B-3</FONT> redeemable convertible preferred stock without the consent of the holders of at least 53% of the outstanding shares of the Series G, Series F, Series E, Series D, and Series C redeemable
convertible preferred stock, voting together as a single class, and no dividend shall be declared or be payable on the outstanding shares of the Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock or the common
stock, other than a dividend on shares of common stock payable entirely in shares of common stock, without the consent of the holders of at least 52% of the outstanding shares of the Series G, Series F, Series&nbsp;E, Series D, Series C, and Series <FONT
STYLE="white-space:nowrap">B-3</FONT> redeemable convertible preferred stock. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Board of Directors has not declared any dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of a liquidation, the Series
G liquidation preference is paid prior to any other preferences. Upon the satisfaction of the Series G preference, the Series F liquidation preference is paid prior to any additional preferences. Upon the satisfaction of the Series&nbsp;G and Series
F preferences, incremental proceeds from a liquidation event will be split between holders of Series F and Series E shares based on the ratio of the total aggregate purchase price of Series F shares and Series E shares, respectively, to the sum of
the aggregate purchase price of Series F shares and the aggregate liquidation preference of the then outstanding Series E shares until the incremental proceeds received by Series E holders in this manner equals the Series E liquidation preference.
After the Series E liquidation preference has been satisfied, the Series D liquidation preference is paid prior to the preferences for Series C, Series <FONT STYLE="white-space:nowrap">B-3,</FONT> and Series
<FONT STYLE="white-space:nowrap">A-3,</FONT> the Series C liquidation preference is paid prior to the preferences for Series <FONT STYLE="white-space:nowrap">B-3</FONT> and <FONT STYLE="white-space:nowrap">A-3,</FONT> the Series <FONT
STYLE="white-space:nowrap">B-3</FONT> liquidation preference is paid prior to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
preference for Series <FONT STYLE="white-space:nowrap">A-3,</FONT> then the Series <FONT STYLE="white-space:nowrap">A-3</FONT> preference is paid. Following the satisfaction of the liquidation
preferences, all shares participate in any remaining distribution based on the number of common shares into which their shares are convertible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each share of redeemable convertible preferred stock is automatically convertible into common stock at its then effective conversion price
(discussed above) (i) upon the election of the holders of at least 52% of the then outstanding shares of preferred stock, voting together as a single class, or (ii)&nbsp;upon the completion of a firm underwritten public offering of the
Company&#146;s common stock with net proceeds (after underwriter&#146;s discounts and commissions) of at least $30.0&nbsp;million, at a minimum valuation of $130,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, each share of the Company&#146;s redeemable convertible preferred stock are convertible, at the option of the holder, into shares of common
stock by dividing the initial conversion prices by the conversion price in effect at the time of conversion. As a result of the issuance of Series F redeemable convertible preferred stock in 2017, the conversion price of Series <FONT
STYLE="white-space:nowrap">B-3,</FONT> Series C, Series D and Series E redeemable convertible preferred stock was adjusted to $14.32. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
following table summarizes the number of shares of common stock into which each share of redeemable convertible preferred stock can be converted at December&nbsp;31, 2018 (for all Series other than Series G) and June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Initial<BR>Conversion<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current<BR>Conversion<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Ratio&nbsp;to<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,377.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series G</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The conversion price of Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C, Series D, Series E, Series F
and Series G redeemable convertible preferred stock is subject to adjustment for recapitalization (i.e. stock dividends, stock splits, reorganization, reclassification, combination of shares), or upon the issuance of shares at a price less than the
then current conversion price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With the
exception of the Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock, the holder of each share of preferred stock is entitled to one vote for each share of common stock into which it would convert. The holders
of Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock have no voting rights, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Redemption
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the request in writing of the holders of 52% of the outstanding shares of Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C,
Series D, Series E, Series F, and Series G redeemable convertible preferred stock, voting together </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
as a single class, at any time after December 28, 2023, the holders may redeem the outstanding Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C, Series D, Series E, Series F and
Series G redeemable convertible preferred stock at the stated redemption price as noted in the table above, plus any declared but unpaid dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December 31, 2018, the Company was accreting the carrying amounts of the preferred stock up to the redemption amount at May&nbsp;10, 2022, the
earliest possible redemption date at that time, using the effective interest method. On January 2, 2019, upon the amendment of its Amended and Restated Certificate of Incorporation, the Company began accreting the carrying amounts of the preferred
stock up to the redemption amount at December 28, 2023, the earliest possible redemption date, using the effective interest method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Shares of
Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock have been included in temporary equity in the balance sheets as certain events such as a change in control or a significant a transfer of Company assets to a
third party can compel the Company to redeem the shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock. These events have been deemed to be outside the control of the Company because they can be
compelled by the holders of the Company&#146;s Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C, Series D, Series E, Series F and Series G redeemable convertible preferred stock through their voting interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series F Financing </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, the Company entered
into an agreement with certain existing preferred shareholders, who were also the holders of the Company&#146;s then outstanding share purchase rights (Note 5), to issue shares of Series F redeemable convertible preferred stock (Series F) in
multiple separate closings at per share price of $0.078 in each closing. All investors in the first tranche closing were obligated to participate in a second tranche closing, and had the option to participate in any additional closings the Company
might offer. The second tranche closing required all investors in the first closing to purchase an aggregate of 48,076,833 additional shares of Series F at $0.078 per share. Shares of Series F were issuable under the Series F preferred stock
purchase agreement until the earlier of December&nbsp;31, 2017 or the issuance of all authorized Series F shares, as specified in the Company&#146;s amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the first tranche closing of the Series F financing in May, 2017, the Company issued 48,076,833 shares of Series F at $0.078 per share for aggregate
proceeds of $3.7&nbsp;million and an additional 163,785,334 shares of Series F in exchange for the extinguishment of the outstanding notional amount (including accrued interest) of all outstanding share purchase rights (Note 5), which totaled
$10.2&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The issuance price of Series F also resulted in adjustments to the conversion rates of the Company&#146;s previously
outstanding shares of Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C, Series D and Series E redeemable convertible preferred stock. Prior to the issuance of shares of Series F, each of these shares were convertible into a single share
of common stock. As a result of the issuance of shares of Series F, each of these shares is convertible into 0.0175 shares of common stock. As a result of the change in the conversion ratio, the Company recognized a beneficial conversion feature
totaling $485,000 as a discount to the carrying value of the Company&#146;s preferred stock and an increase to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital in the accompanying balance sheet. This discount will be accreted
against income available to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
common stockholders through the fifth anniversary of the issuance of Series F, which is the earliest period these preferred shares can be redeemed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company concluded that the first closing of the Series F preferred stock purchase agreement contained two freestanding financial instruments:
(1)&nbsp;shares of Series F and (2)&nbsp;tranche participation rights which, for a fixed amount of consideration in the second closing, required investors to purchase Series F in the second tranche closing at a fixed price of $0.078 per share. The
Company evaluated the various conversion and redemption features embedded in shares of Series F (which are summarized above) and concluded that none of these features should be bifurcated from the Series F share and accounted for as a separate
derivative instrument. The Company further evaluated the conversion features embedded in shares of Series F and determined they did not represent beneficial conversion features, as described in the related accounting literature. The Company
determined there were no embedded features requiring bifurcation in the tranche participation rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company estimated the total fair value of
Series F and participation rights purchased by investors that were issued in the first closing as $26.7&nbsp;million. The Company estimated the fair value of a share of Series F using an option pricing method (OPM) which estimates the fair value of
each class of equity securities as the net value of a series of call options, representing the present value of the expected future returns to each class of equity securities. The Company determined that the tranche participation rights represented
a liability of $2.3&nbsp;million on the date of the Series F financing as it was predominantly indexed to an obligation to purchase shares of Series F. This liability was marked to market through earnings. Due to the short duration of the
participation rights, the Company estimated the fair value of the tranche participation rights using a method that considered the difference between the estimated fair value and issuance price of shares of Series F to be issued in the second tranche
closing and the time value of money. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since all investors in the first closing are existing preferred stockholders of the Company, the Company
accounted for the $5.7&nbsp;million difference between the fair value of shares of Series F, the proceeds received, the tranche participation rights issued, and the carrying value of the share purchase rights converted as a loss on the
extinguishment of the share purchase rights, which was recorded in Loss on extinguishment of share purchase rights and 2013 Term Loan in the accompanying statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2017, the investors in the first tranche closing modified the terms of the participation rights to reduce the number of shares of Series F
required to be purchased at $0.078 per share to 38,461,539 and to allow for the participation of an additional investor in the second tranche closing. As a result of this modification, the Company estimated the fair value of the tranche
participation right to be $1.8&nbsp;million and recorded the resulting benefit of $462,000 through earnings in the line item change in fair value of financial instruments in the accompanying statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2017, the Company completed the second tranche closing with an additional investor under the Series F preferred stock purchase agreement. The
Company concluded that the second tranche closing of the Series F preferred stock purchase agreement contained a single freestanding financial instrument, shares of Series F, and, as discussed above, the Company determined there were no embedded
features requiring bifurcation in shares of Series F. The Company determined that the change in the fair value of the tranche participation rights between the dates of the first and second </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
closing was immaterial. The second tranche closing resulted in the issuance of 38,461,539 additional shares of Series F for aggregate proceeds of $3.0&nbsp;million, and the reduction of
$1.8&nbsp;million to the estimated fair value of the previously recognized tranche participation rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table presents a summary of
the accounting for the completion of the first and second tranche closings (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value of Series F shares issued</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash received upon issuance of Series F shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of share purchase rights in conjunction with first tranche closing (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of tranche participation rights in conjunction with modification in second tranche
closing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on extinguishment of share purchase rights in conjunction with first and second tranche
closing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2017, the Company&#146;s Board of Directors authorized a third tranche closing of the Series F financing,
which was completed between December 2017 and January 2018. In December 2017, a group of existing investors of the Company purchased 54,246,756 shares of Series F at a per share price of $0.078 for aggregate cash proceeds of $4.2&nbsp;million. In
early January 2018, a group of existing investors of the Company purchased an additional 34,914,327 shares of Series F at a per share price of $0.078 for aggregate cash proceeds of $2.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company concluded that the third tranche closing of the Series F preferred stock purchase agreement contained a single freestanding financial
instrument, shares of Series F, and the Company determined there were no embedded features requiring bifurcation in the shares of Series F issued in the third tranche closing. The Company accounted for the difference between the estimated fair value
and the $0.078 per share purchase price of shares of Series F issued in the third tranche closing as a deemed dividend since all investors in the third closing are existing preferred shareholders of the Company, and the Company did not identify any
elements to the transaction which it believes were compensatory in nature. As a result, the Company recognized a deemed dividend in the amount of $1.8&nbsp;million and $1.2 million in the years ended December 31, 2017 and 2018, respectively, that
was recorded as additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital (in the absence of retained earnings) in the accompanying statement of redeemable convertible preferred stock and stockholders&#146; deficit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series G Financing </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2019, the Company
entered into an agreement with new and certain existing preferred shareholders to issue shares of Series G redeemable convertible preferred stock (Series G) in multiple separate closings at per share price of $0.078 in each closing. Shares of Series
G were issuable under the Series G preferred stock purchase agreement until the earlier of March 31, 2019 or the issuance of all authorized Series G shares, as specified in the Company&#146;s amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2019 and March 2019, the Company sold 88,030,905 and 9,615,384 shares, respectively, of Series G redeemable convertible preferred stock for
aggregate gross proceeds of approximately $7.6 million to new and existing investors, of which $3.75 million of gross proceeds had been received as of December 31, 2018 and are included in the accompanying December 31, 2018 balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2019, the Company sold an additional 51,282,048 shares of Series&nbsp;G redeemable convertible
preferred stock for aggregate gross proceeds of approximately $4.0&nbsp;million to existing investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, in May 2019, the Series&nbsp;G
Preferred Stock Agreement was amended to include the right of the Company to require certain holders of Series&nbsp;G redeemable convertible preferred stock to purchase an additional 32,051,280 shares of Series&nbsp;G redeemable convertible
preferred stock at $0.078 per share, for total aggregate proceeds of $2.5&nbsp;million, at any time after July&nbsp;31, 2019 and prior to May&nbsp;31, 2020. This right terminated in connection with the issuance of the Series H redeemable convertible
stock in July (see Note 16). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company concluded that the closings of the Series G preferred stock purchase agreement in January and March 2019,
contained a single freestanding financial instrument, shares of Series G, and the Company determined there were no embedded features requiring bifurcation in the shares of Series G issued. The Company concluded the closing in May 2019 contained two
freestanding financial instruments, shares of Series G and the Company call right, and the Company concluded there were no embedded features requiring bifurcation in the shares of Series G issued. The Company call right was deemed to have nominal
value since it was with insiders with knowledge of the imminent closing of Series H redeemable convertible stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 11. Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Common stockholders are entitled to
dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common
stock is entitled to one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, the Company&#146;s certificate of incorporation was amended and restated to authorize the issuance of
up to 550,000,000 shares of Series F redeemable convertible preferred stock, and increase the number of authorized shares of common stock from 850,000,000 to 1,470,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January 2, 2019, the Company amended and restated its restated certificate of incorporation to (i)&nbsp;increase its authorized shares of common
stock from 1,470,000,000 to 1,675,200,000 shares and (ii)&nbsp;increase its authorized shares of convertible preferred stock from 750,300,000 to 955,500,000 shares, of which 205,200,000 shares are designated as Series G convertible preferred stock.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company had common shares reserved for future issuance upon the exercise or conversion of the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,012,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,202,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,013,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock option grants issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common shares available for grant under the stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total common shares reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,228,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,036,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,847,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 12. Stock Option Plan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2012, the Company&#146;s Board of Directors adopted the 2013 Stock Option Plan (the Plan). Pursuant to the Plan, employees, consultants, and
directors may be granted either incentive stock options or <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options to purchase shares of the Company&#146;s common stock. In October 2018, the shares reserved for future issuance under the
2013 Stock Option Plan were increased by 621,378 shares to a total of 669,806 shares. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, 12,856 shares and 10,999 shares, respectively, remained available for future awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The exercise price of each stock option is established by the Board of Directors and is based on the estimated fair value of the Company&#146;s common
stock on the grant date. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally no longer than four years from the date of grant.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Activity under the Company&#146;s stock option plans is set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">639,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding, June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested and expected to vest, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options exercisable, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested and expected to vest, June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options exercisable, June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted-average grant date fair value per share of employee options granted to employees during the years
ended December 31, 2017 and 2018 was $0.59 and $0.17, respectively. The intrinsic value is calculated as the difference between the fair value of the Company&#146;s common stock and the exercise price of the stock options. The fair value of the
Company&#146;s common stock is $0.37&nbsp;per share, $9.92&nbsp;per share and $14.14 per share at December&nbsp;31, 2017 and 2018 and June&nbsp;30, 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fair value of
employee stock options was estimated using the following assumptions to determine the fair value of stock options granted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">48%&nbsp;-&nbsp;70%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.9%&nbsp;-&nbsp;1.4%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.4%&nbsp;-&nbsp;2.6%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.4%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.6%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#150;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.08</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.08</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.08</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.08</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Total <FONT STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation expense recorded
related to options granted in the statement of operations is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2017 and 2018 and June&nbsp;30, 2019, total unrecognized compensation cost was $117,000,
$112,000 and $102,000, respectively, which is expected to be recognized over a remaining weighted-average vesting period of 1.3 years, 3.8 years and 3.3&nbsp;years, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 13. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The (benefit) provision for income
taxes consists of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">(Benefit) provision for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Tax Cuts and Jobs Act (the Act) was enacted on December&nbsp;22, 2017. The Act reduces the U.S. federal corporate
tax rate from 35% to 21%. At December&nbsp;31, 2017, the Company <FONT STYLE="white-space:nowrap">re-measured</FONT> its deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally
21%. As a result of the <FONT STYLE="white-space:nowrap">re-measurement</FONT> of the Company&#146;s deferred tax assets and liabilities, the Company recognized income tax expense of $10.6&nbsp;million. This amount was offset by a reduction in the
valuation allowance of $11.1&nbsp;million. $549,000 of the reduction in the valuation allowance resulted from the reclassification of certain of the Company&#146;s deferred tax assets as indefinite-lived, as a result of the Act, which are now able
to offset the Company&#146;s indefinite-lived deferred tax liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The effective tax rate of our (benefit) provision for income taxes differs from the federal statutory
rate&nbsp;as&nbsp;follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State income taxes, net of federal tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of share purchase rights and preferred stock liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on extinguishment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Enactment of Tax Cuts and Job Act</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Significant components of the Company&#146;s deferred tax assets at December&nbsp;31, 2017 and 2018 are shown below. A
valuation allowance has been established as realization of the Company&#146;s deferred tax assets has not met the more <FONT STYLE="white-space:nowrap">likely-than-not</FONT> threshold requirement. If the Company&#146;s judgment changes and it is
determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued revenue<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accruals, reserves and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basis differences in fixed and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing and acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Indefinite lived assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The deferred tax liability for uncollectible accounts has been netted with the accrued revenue deferred tax asset for
presentation purposes as the nature of these deferred items are related. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in the valuation allowance for deferred tax assets during the years ended December&nbsp;31,
2017 and 2018, which related primarily to increases in net operating loss carryforwards, accrued revenue and accruals and reserves, and impacts of the Tax Cuts and Jobs Act were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(As&nbsp;Revised)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation&nbsp;allowance&nbsp;at&nbsp;the&nbsp;beginning&nbsp;of&nbsp;the&nbsp;year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decreases recorded as benefits to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2017 and 2018, the Company had federal net operating loss carryforwards of approximately
$77.8&nbsp;million and $80.8&nbsp;million, respectively. At December 31, 2017 and 2018, the Company had state net operating loss carryforwards of $30.3 million and $30.6 million (as revised), respectively. Approximately $77.7&nbsp;million (as
revised) of the federal tax loss carryforwards will begin to expire in 2022, unless previously utilized. The federal net operating loss carryforwards generated in 2018 of $3.1&nbsp;million (as revised) will carryforward indefinitely and be available
to offset up to 80% of future taxable income each year. The Company&#146;s state tax loss carryforwards will expire in 2032, unless previously utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to Internal Revenue Code (IRC), Section&nbsp;382 and 383, use of the Company&#146;s U.S. federal and state net operating loss and research and
development income tax credit carryforwards may be limited in the event of a cumulative change in ownership of more than 50.0% within a three-year period. The Company had an ownership change in 2008 and, as a result, certain carryfowards are subject
to an annual limitation, reducing the amount available to offset income tax liabilities absent the limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is subject to taxation
in the U.S. and in various state jurisdictions. The Company&#146;s tax years for 2002 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and
development credits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company recognizes interest and / or penalties related to income tax matters in its provision for income taxes. The
Company does not have any accruals for, and did not recognize any, interest or penalties in these financial statements in any period presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Uncertain Tax
Positions </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2017 and 2018, the Company had no unrecognized tax benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 14. Related Parties </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company entered into various
agreements under which directors of the Company are paid for consulting services and for serving on the Board of Directors. In June of 2017, two members of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Company&#146;s Board of Directors resigned their position as members of the Board of Directors and the Company terminated all previously existing agreements which required payments to board
members for their services. Total compensation expense paid to board members under these various agreements for the year ending December&nbsp;31, 2017 was $81,000, which was recorded in selling, general&nbsp;and administrative expenses in the
accompanying statements of operations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2017, the Company entered into a consulting services agreement with a member of the
Company&#146;s Board of Directors under which this board member will provide certain scientific consulting services to the Company. Under this agreement, this board member was compensated at a <FONT STYLE="white-space:nowrap">bi-weekly</FONT> rate
of $4,615 (plus reimbursement for certain administrative and travel related expenses) and received options to purchase 544&nbsp;shares of common stock in November 2017. This agreement was amended in June 2018 and the biweekly compensation rate
increased to $5,000. Total amounts paid to this board member under this agreement for the years ending December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019, were $52,000, $126,000, $61,000, and $65,000, respectively,
which was recorded in research and development expenses in the accompanying statements of operations. The Company accounted for the grant of options as an award to a <FONT STYLE="white-space:nowrap">non-employee</FONT> and measures compensation cost
for this award based on the value of the award at the date the consulting services are complete. The options granted to this board member were granted at an exercise price of $0.367 (the estimated fair value of share of common stock on the grant
date using an OPM model), and vests over a three-year term expected to coincide with the period the board member is expected to provide consulting services to the Company. The estimated fair value of the awards and related compensation cost
recognized during the year ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019 was immaterial. All compensation cost related to these awards is recorded in research and development expenses in the accompanying
statements of operations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2016, the Company leased office space in New Mexico on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis from a third party which specializes in providing outsourced information technology support services, and a partner in this company was an immediate family member of an executive at the
Company. At December 31, 2017, the Company no longer leases this facility and this executive is no longer employed by the Company. Total expenses related to information technology support services provided by this related party for the years ended
December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019, was $159,000, $157,000, $83,000, and $89,000, respectively. The total rent expense related to this rental agreement for the year ending December&nbsp;31, 2017 was
$20,000, which was recorded in selling, general&nbsp;and administrative expenses in the accompanying statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2011,
the Company entered into a license agreement with the Company&#146;s Chief Scientific Officer, and a related company, De&nbsp;Novo. The license agreement, covering novel methods for monitoring <FONT STYLE="white-space:nowrap">low-dose</FONT>
methotrexate therapy, relates to technology developed by the Company&#146;s Chief Scientific Officer prior to joining the Company. The technology has yet to be used by the Company. Under the agreement, the Company&#146;s Chief Scientific Officer
will be eligible to receive up to $600,000 upon the achievement of certain sales milestones and an ongoing royalty of 5% on sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The share
purchase rights described in Note 5 were issued to existing holders of the Company&#146;s preferred stock. The first and third tranche closings of the Series&nbsp;F financing and the closings of the Series&nbsp;G financing described in Note 10 were
issued to existing holders of the Company&#146;s redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 15. 401(k) Plan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section&nbsp;401(k) of the Code. Participating
employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For the years ended December&nbsp;31, 2017 and 2018 and the six
months ended June&nbsp;30, 2018 and 2019, the Company made contributions to the Plan at 3% of qualified employee compensation, which totaled approximately $362,000, $357,000, $152,000, and $183,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 16. Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December&nbsp;31, 2018 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2019, Company management identified immaterial misstatements in the financial statements for the year ended December&nbsp;31, 2018 related to the
carrying value of redeemable convertible preferred stock warrant liabilities. Based on a quantitative and qualitative analysis of the error as required by authoritative guidance, management concluded that the correction, which decreased the carrying
value of the redeemable convertible preferred stock warrant liabilities with a corresponding decrease in net loss, had no material impact on the Company&#146;s previously issued financial statements as of and for the year ended December&nbsp;31,
2018. These amounts have been adjusted in the accompanying balance sheet and statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The revision to the Company&#146;s previously
reported balance sheet are identified in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The revision to the Company&#146;s previously reported statement of operations are identified in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For Year Ended December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,659</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(312.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(293.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A revised rollforward of the Company&#146;s warrant liabilities is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance, December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of warrants to purchase shares of Series&nbsp;F redeemable convertible preferred stock in
connection with 2017 Term Loan (Note&nbsp;6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance, March&nbsp;31, 2019 (unaudited) (as revised)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note 17. Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale of
Series&nbsp;H Redeemable Convertible Preferred Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2019, the Company entered into an agreement with a new investor to issue shares of
Series H redeemable convertible preferred stock (Series&nbsp;H) at a per share price of $0.04712. Pursuant to the terms of the agreement, the new investor purchased 233,446,519&nbsp;shares of Series&nbsp;H for gross proceeds of $11.0&nbsp;million.
In connection with the Series H financing, the Company converted all of the 148,928,337 outstanding shares of the Company&#146;s Series G redeemable convertible preferred stock into 246,521,076&nbsp;shares of Series&nbsp;H on a dollar-for-dollar
basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company agreed to reimburse the new investor up to $100,000 of legal expenses incurred in connection with the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Amended and Restated Certificate of Incorporation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July
2019, the Company amended and restated its restated certificate of incorporation to, among other things, (1)&nbsp;increase its authorized shares of common stock from 1,675,200,000 to 1,970,000,000&nbsp;shares, (2)&nbsp;increase its authorized shares
of convertible preferred stock from 955,500,000 to 1,038,667,059&nbsp;shares, of which 479,967,595&nbsp;shares are designated as Series&nbsp;H, and (3)&nbsp;set forth the rights, preferences and privileges of the Series&nbsp;H. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the liquidation preferences, redemption prices and non-cumulative
dividends authorized as a result of the adoption of this amendment and restatement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Redemption<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Non-<BR>Cumulative<BR>Dividends</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,369,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,030,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,637,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,708,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,238,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358,715,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series H</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">479,967,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">.04712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">.04712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,038,667,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the earliest possible redemption date for the outstanding shares of the redeemable convertible preferred
stock is now July&nbsp;12, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2013 Stock Option Plan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2019, the number of shares of common stock reserved for issuance under the Plan was increased from 669,806 shares to 1,663,681 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2019 Incentive Award Plan </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2019 and September
2019, the Company approved a grant to certain employees, executive officers and members of the board of directors of options to purchase an aggregate of 812,745&nbsp;shares of common stock under the 2019 Incentive Award Plan (the 2019 Plan),
contingent and effective upon the approval of the 2019 Plan and the effectiveness of the Form&nbsp;S-1 Registration Statement filed with the Securities and Exchange Commission, with an exercise price that is equal to the initial public offering
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2019, the Board of Directors adopted, and the Company&#146;s stockholders approved the 2019 Plan. Under the 2019 Plan, the
Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. A total
of (i) 2,011,832 shares of common stock plus (ii) the number of shares subject to awards granted under the 2013 Plan on or before the effective date of the 2019 Plan that become available for issuance under the 2019 Plan will initially be reserved
for issuance under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be increased annually on the first day of each fiscal year during the term of the 2019 Plan, beginning with the 2020
fiscal year, by an amount equal to 4% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year or such smaller other amount as the Board of Directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Approval of the Employee Stock Purchase Plan </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September
2019, the Board of Directors adopted the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by our Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions
of up to 20% of their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Information
as of June&nbsp;30, 2019 and thereafter and for the six months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2018 and 2019 is unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
eligible compensation. A total of 120,000 shares of common stock is initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under
the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2020 fiscal year, by an amount equal to 1% of the total number of shares of common stock outstanding on the effective date of
the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reverse Stock Split </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On September&nbsp;6,
2019, the Company effected a one-for-183.635 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and
outstanding common stock and the conversion ratio of the redeemable convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:55pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>3,333,334 Shares </B></P>  <P STYLE="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g692844g91e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:55pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table indicates the expenses to be incurred in connection with the offering described
in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission, or the SEC, registration fee, the Financial Industry
Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Market listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount paid<BR>or to be paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,434</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,866</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a
corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly
violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director of the Registrant shall
be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of
Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the General
Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership,
joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or
proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court
determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem
proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation, which will become effective immediately prior
to the completion of this offering, provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us)
by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with,
another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses
(including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he
or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of
incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a
director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or
by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with
such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect
to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such
expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in
connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into indemnification agreements with
each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a
director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims
based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In any underwriting agreement we enter into in connection with the sale of
common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, or Securities Act,
against certain liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Set forth below is information regarding shares of capital stock issued by us since January&nbsp;1, 2016. Also included is the consideration received by
us for such shares and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Sales of Capital Stock, Warrants to Purchase Capital Stock and Convertible Promissory Notes </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In 2015, we issued a variable number of warrants, which became a fixed and immediately exercisable warrant to purchase
2,688,181 shares of our Series E redeemable convertible preferred stock at an exercise price of $0.25 per share as a result of the issuance of our Series E redeemable convertible preferred stock in January 2016. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In January 2016 and March 2016, we issued an aggregate of 166,550,058 shares of our Series&nbsp;E redeemable convertible
preferred stock at a purchase price of $0.25 per share and warrants to purchase 908,385&nbsp;shares of our common stock, for (i) aggregate consideration of approximately $9.3&nbsp;million in cash, (ii) the cancellation of the outstanding principal
and accrued interest on previously outstanding convertible promissory notes issued in February 2015, July 2015 and October 2015, which totaled $4.9&nbsp;million, $3.2&nbsp;million, and $3.5&nbsp;million, respectively, and (iii) the exchange of
105,610, 41,509,393, 7,112,819, and 34,415,512, of previously outstanding shares of our Series <FONT STYLE="white-space:nowrap">A-3,</FONT> Series <FONT STYLE="white-space:nowrap">B-3,</FONT> Series C, and Series D redeemable convertible preferred
stock, respectively, previously held by investors. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">From June 2016 to April 2017, we sold an aggregate of approximately $9.8&nbsp;million of convertible promissory notes. In
May 2017, these convertible promissory notes were converted into an aggregate of 163,785,334 shares of our Series F redeemable convertible preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">From May 2017 to January 2018, we issued an aggregate or 339,484,788 shares of our Series&nbsp;F redeemable convertible
preferred stock at a purchase price of $0.078 per share, for (i)&nbsp;aggregate consideration of approximately $13.7&nbsp;million in cash and (ii) the cancellation of the outstanding principal and accrued interest on the outstanding convertible
promissory notes issued in 2016 and 2017, which totaled approximately $9.8&nbsp;million in the aggregate. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In September 2017 and December 2018, in connection with the execution of the loan and security agreement with Innovatus
Life Sciences Lending Fund&nbsp;I, LP, we issued warrants to purchase an aggregate of 19,230,769 shares of our Series&nbsp;F redeemable convertible preferred stock at an exercise price of $0.078 per share. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">From January 2019 to May 2019, we issued an aggregate of 148,928,337 shares of our Series G redeemable convertible
preferred stock at a purchase price of $0.078 per share, for aggregate consideration of approximately $11.6&nbsp;million in cash. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In July 2019, we issued 233,446,519 shares of our Series&nbsp;H redeemable convertible preferred stock at a purchase
price of $0.04712 per share, for aggregate consideration of approximately $11.0&nbsp;million, and converted 148,928,337 shares of our Series G redeemable convertible preferred stock into 246,521,076 shares of our Series H redeemable convertible
preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Grants and Exercise of Stock Options </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Since January&nbsp;1, 2016, we granted stock options to purchase an aggregate of 645,503&nbsp;shares of our common stock
at a weighted-average exercise price of $0.342&nbsp;per share, to certain of our employees, consultants and directors in connection with services provided to us by such persons. In August 2019, we approved the grant of stock options to purchase
811,832&nbsp;shares of our common stock, which grant is contingent and effective upon the effectiveness of the registration statement of which this prospectus forms a part and will have an exercise price that is equal to the initial public offering
price. In September 2019, we approved the grant of stock options to purchase 913&nbsp;shares of our common stock, which grant is contingent and effective upon the effectiveness of the registration statement of which this prospectus forms a part and
will have an exercise price that is equal to the initial public offering price. Of these, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
options to purchase 50&nbsp;shares of our common stock have been exercised through June&nbsp;30, 2019. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a)&nbsp;of Item 15 were issued to
investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not
involving any public offering, to the extent an exemption from such registration was required. All holders of securities described above represented to us in connection with their purchase or issuance that they were accredited investors and were
acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an
indefinite period of time. The holders received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such
registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of
Item&nbsp;15 were issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the
Securities Act or the exemption set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate
information about us or had access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All of the foregoing securities are deemed
restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15 included appropriate legends setting forth that the securities had not been registered and the
applicable restrictions on transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>(a) Exhibits.</B> See Exhibit Index attached to this registration statement, which is incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>(b) Financial Statement Schedules.</B> Schedules not listed above have been omitted because the information required to be set forth therein is not
applicable or is shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement, certificates in such
denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The undersigned hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of
the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The undersigned registrant hereby undertakes that, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of
and included in the registration statement as of the date it is first used after effectiveness. <I>Provided</I>, <I>however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The undersigned registrant hereby undertakes that, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any
purchaser in the initial distribution of the securities in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(1) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(2) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the
undersigned registrant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(3) The portion of any other free writing prospectus relating to the offering containing material information about the
undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(4) Any other communication that is an offer
in the offering made by the undersigned registrant to the purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex11.htm">Form of Underwriting Agreement. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex31.htm">Amended and Restated Certificate of Incorporation, as amended (currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex32.htm">Bylaws (currently in effect). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex33.htm">Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the completion of this
offering).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex34.htm">Form of Amended and Restated Bylaws (to be effective immediately prior to the completion of this offering).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors&#146; Rights Agreement, dated July&nbsp;
12, 2019, by and among the Registrant and certain of its stockholders.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders&#146; Agreement, dated July&nbsp;12, 2019, by and among the Registrant and certain of its
stockholders.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Form of Common Stock Purchase Warrant issued to investors by the Registrant in connection with private placement financings.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex45.htm">Form of Preferred Stock Purchase Warrant issued to Capital Royalty Partners and related advisors by the Registrant in connection with the Term
 Loan Agreement, by and between Capital Royalty Partners II L.P., Capital Royalty Partners&nbsp;II&#151;Parallel Fund &#147;A&#148; L.P., Parallel Investment Opportunities Partners II L.P. and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex46.htm">Form of Warrant to Purchase Shares of Preferred Stock issued to investors by the Registrant in October 2015.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex47.htm">Amendment to Convertible Promissory Notes and Warrants, dated January&nbsp;19, 2016. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex48.htm">Form of Common Stock Purchase Warrant to purchase common stock issued to investors by the Registrant in 2016.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex49.htm">Form of Warrant to Purchase Stock issued to Innovatus Life Sciences Lending Fund I, LP in connection with the Registrant&#146;s 2018 loan agreement.
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex51.htm">Opinion of Latham&nbsp;&amp; Watkins LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex101.htm">Exagen Corporation 2002 Stock Option Plan, as amended, and form of option agreement thereunder.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex102.htm">Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex103.htm">Exagen Inc. 2019 Incentive Award Plan.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex104.htm">Form of Option Agreement under Exagen Inc. 2019 Incentive Award Plan</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex105.htm">Exagen Inc. 2019 Employee Stock Purchase Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex105.htm">License Agreement, dated September&nbsp;
13, 2007, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Proprius, Inc.).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex106.htm">First Amendment to License Agreement, dated October&nbsp;
23, 2013, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Cypress Bioscience, Inc.).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex107.htm">Asset Purchase Agreement, dated February&nbsp;
9, 2009, by and between the Registrant (as successor in interest to Cypress Bioscience, Inc.) and Cellatope Corporation. </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex108.htm">Amendment No. One to Asset Purchase Agreement, dated December&nbsp;14, 2012, by and between the Registrant and Cellatope
Corporation.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex109.htm">Amendment No. Two to Asset Purchase Agreement, dated January&nbsp;11, 2017, by and between the Registrant and Cellatope
Corporation.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1010.htm">Asset Purchase Agreement, dated October&nbsp;8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1011.htm">Amendment No. One to Asset Purchase Agreement, dated March&nbsp;
10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1012.htm">Amendment No. Two to Asset Purchase Agreement, dated August&nbsp;
21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1013.htm">Amendment No. Three to Asset Purchase Agreement, dated February&nbsp;
6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1014.htm">Amendment No. Four to Asset Purchase Agreement, dated October&nbsp;
8, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1015.htm">Amendment No. Five to Asset Purchase Agreement, dated January&nbsp;
26, 2016, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1016.htm">Amendment No. Six to Asset Purchase Agreement, dated February&nbsp;
16, 2017, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1017.htm">Amended and Restated Exclusive License Agreement, dated August&nbsp;
2, 2011, by and between the University of Pittsburgh&#151;Of the Commonwealth System of Higher Education and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1018.htm">First Amendment to Amended and Restated Exclusive License Agreement, dated May&nbsp;
17, 2012, by and between the University of Pittsburgh&#151;Of the Commonwealth System of Higher Education and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1019.htm">Second Amendment to Amended and Restated Exclusive License Agreement, dated September&nbsp;
30, 2013, by and between the University of Pittsburgh&#151;Of the Commonwealth System of Higher Education and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1020.htm">Third Amendment to Amended and Restated Exclusive License Agreement, dated June&nbsp;
24, 2016, by and between the University of Pittsburgh&#151;Of the Commonwealth System of Higher Education and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1021.htm">Exclusive License Agreement, dated September&nbsp;
30, 2013, by and between the University of Pittsburgh&#151;Of the Commonwealth System of Higher Education and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1022.htm">Exclusive License Agreement, dated September&nbsp;5, 2011, by and between Thierry Dervieux, Ph.D. and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1023.htm"><FONT STYLE="white-space:nowrap">Co-Promotion</FONT> Agreement, dated December&nbsp;
10, 2018, by and between Janssen Biotech, Inc. and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1024.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated January&nbsp;13, 2012, by and between RGS Properties and the Registrant.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1025.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated December&nbsp;
1, 2013, by and between RGS Properties and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1026.htm">Lease, dated May&nbsp;7, 2013, by and between The Regents of the University of New Mexico and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1027.htm">First Amendment to Lease by and between The Regents of the University of New Mexico and the Registrant.
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1028.htm">Second Amendment to Lease by and between The Regents of the University of New Mexico and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1029.htm">Third Amendment to Lease by and between The Regents of the University of New Mexico and the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1030.htm">Standard Industrial/Commercial Single-Tenant Lease, dated September&nbsp;4, 2014, by and between Geiger Court, LLC and the
Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1031.htm">Master Lease Agreement, dated February&nbsp;
1, 2018, by and between Celtic Commercial Finance, a division of MB Equipment Finance, LLC and the Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1032.htm">Loan and Security Agreement, dated September&nbsp;7, 2017, by and between Innovatus Life Sciences Lending Fund I, LP and the Registrant.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.34#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex1034.htm">Offer Letter, dated October&nbsp;12, 2010, by and between Thierry Dervieux, Ph.D. and the Registrant, as amended on September&nbsp;9, 2011 and September&nbsp;6, 2019. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.35*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm">Form of Indemnification Agreement for Directors and Officers.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.36#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex1036.htm">Offer Letter, dated October&nbsp;7, 2011, by and between Fortunato Ron Rocca and the Registrant, as amended on September&nbsp;4, 2019.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.37#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex1037.htm">Offer Letter, dated May&nbsp;16, 2017, by and between Kamal Adawi and the Registrant, as amended on September&nbsp;4, 2019.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.38#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex1038.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>16.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex161.htm">Letter regarding change in certifying accountant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex231.htm">Consent of BDO USA, LLP, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d692844dex51.htm">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844ds1.htm#sig">Power of Attorney (included on signature page). </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been omitted for confidentiality purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Vista, State of California, on this 9th&nbsp;day of September, 2019. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fortunato Ron Rocca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;and&nbsp;Chief&nbsp;Executive&nbsp;Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held
on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/ Fortunato Ron Rocca</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">President, Chief Executive Officer and&nbsp;Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/ Kamal Adawi</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Kamal Adawi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Corporate Secretary</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(Principal Financial and Accounting
Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Chet Burrell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Jeff Elliott</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Tina S. Nova, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Bruce C. Robertson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">James L.L. Tullis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;9,&nbsp;2019</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Fortunato Ron Rocca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fortunato Ron Rocca</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d692844dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is hereby certified that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIRST: The present name of the corporation is Exagen Inc. (hereinafter called the &#147;<U>Corporation</U>&#148;), which was originally
incorporated under the name Exagen Diagnostics, Inc.; and the date of filing of the Corporation&#146;s original Certificate of Incorporation with the Secretary of State of the State of Delaware was November&nbsp;17, 2003. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND: The Certificate of Incorporation of the Corporation is hereby amended and restated to read as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE
OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN
INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE FIRST </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NAME </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Corporation is Exagen Inc. (the &#147;<U>Corporation</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE SECOND </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REGISTERED OFFICE
AND AGENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the Corporation&#146;s registered office in the State of Delaware is 1209 Orange Street, city of Wilmington,
County of New Castle, State of Delaware, 19801. The name of the Corporation&#146;s registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE THIRD </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PURPOSE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purposes for which the Corporation is formed are to engage in any lawful act or activity for which corporations may be organized under the
Delaware General Corporation Law and to possess and exercise all of the powers and privileges granted by such law and any other law of Delaware. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE FOURTH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CAPITAL STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. The Corporation
is authorized to issue two classes of stock: Common Stock and Preferred Stock. The total number of shares which the Corporation may issue is 3,008,667,059 shares, of which: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) 1,369,185 shares are <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series</U><U></U><U>&nbsp;A</U><U><FONT STYLE="white-space:nowrap">-3</FONT> Preferred Stock</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) 3,030,584 shares are <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series</U><U></U><U>&nbsp;B</U><U><FONT STYLE="white-space:nowrap">-3</FONT> Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) 16,637,570, shares are Series&nbsp;C Convertible Preferred Stock and of a par value of
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series</U><U></U><U>&nbsp;C Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) 9,708,328 shares are Series&nbsp;D Convertible Preferred Stock and of a par value of
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series</U><U></U><U>&nbsp;D Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) 169,238,239 shares are Series&nbsp;E Convertible Preferred Stock and of a par value of
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series</U><U></U><U>&nbsp;E Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) 358,715,558 shares are Series F Convertible Preferred Stock and of a par value of <FONT STYLE="white-space:nowrap">one-thousandth</FONT>
of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series F Preferred Stock</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) 479,967,595 shares are
Series H Convertible Preferred Stock and of a par value of <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series H Preferred Stock</U>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) 1,970,000,000 shares are Common Stock and of a par value of <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001)
each (hereinafter referred to as the &#147;<U>Common Stock</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the filing of this Amended and Restated Certificate of
Incorporation with the Secretary of State of the State of Delaware (the &#147;<U>Effective Time</U>&#148;), every share of Series G Preferred Stock then issued and outstanding or held in the treasury of the Corporation immediately prior to the
Effective Time shall automatically be converted into 1.6553 shares of Series H Preferred Stock, without any further action by the holders of such shares (the &#147;<U>Series G Conversion</U>&#148;). The Series G Conversion will be effected on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">holder-by-holder</FONT></FONT> basis, and any fractional shares resulting from such conversion shall be rounded down to the nearest whole share on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">holder-by-holder</FONT></FONT> basis. No fractional shares shall be issued in connection with the Series G Conversion. The Series G Conversion shall occur automatically without any further action by the holders of the
shares of Common Stock and Preferred Stock affected thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Common Stock may be increased or decreased (but not below
the number of shares of Common Stock then outstanding) by the affirmative vote of the holders of a majority of the outstanding stock of the Corporation entitled to vote (voting together on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Following the filing of this Amended and Restated Certificate of Incorporation, the
rights, preferences, privileges, restrictions and other matters relating to the Preferred Stock are as set forth in this Part B. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Part B, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Additional Shares of Common Stock</U>&#148; shall mean all shares of Common Stock issued (or, pursuant to Section&nbsp;4.4(b), deemed
to be issued) by the Corporation on or after the Filing Date, other than (i)&nbsp;shares of Series H Preferred Stock issued pursuant to the Series H Preferred Stock Purchase Agreement and (ii)&nbsp;shares of Common Stock issued or issuable (or so
deemed to be issued): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) upon conversion of shares of Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) upon the exercise of warrants outstanding as of the Filing Date to purchase 171,669,387 shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to officers, directors or employees of, or consultants to, the Corporation for up to 305,510,110 shares of Common Stock pursuant to any
stock option, incentive, bonus or compensation program approved by the Board of Directors; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by way of dividend or other distribution on
shares of Preferred Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) for which adjustment is made in the Conversion Price pursuant to Section&nbsp;4.4(e) or (f); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, before which or
in connection with which all outstanding shares of Preferred Stock will be automatically converted into Common Stock pursuant to Section&nbsp;4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; (i) with respect to vSpring SBIC, L.P., shall include any affiliate of vSpring Capital, LLC, (ii)&nbsp;with
respect to Wasatch Venture Fund III, L.L.C., shall include any venture capital fund managed by the general partners of Wasatch Venture Fund III, L.L.C., (iii) with respect to NMSIC <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, L.P.,
shall include any affiliate of Sun Mountain Capital Partners, LLC, (iv)&nbsp;with respect to PCM/Exagen, L.P., shall include Hunt Holdings L.P., and (v)&nbsp;with respect to Tullis-Dickerson Capital Focus III, L.P., shall include any pooled
investment vehicle managed by Tullis Health Investors of FL, LLC, and any of its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Date</U>&#148; shall
have the meaning set forth in Section&nbsp;4.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Price</U>&#148; shall mean the price at which shares of Common Stock
shall be deliverable upon conversion, which shall initially be equal to (a)&nbsp;with respect to a share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock, $7.50, (b) with respect to a share of
<FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, $0.078, (c) with respect to a share of Series C Preferred Stock, $0.078, (d) with respect to a share of Series D Preferred Stock, $0.078, (e) with respect to a share of Series
E Preferred Stock, $0.078, (f) with respect to a share of Series F Preferred Stock, $0.078, and (g)&nbsp;with respect to a share of Series H Preferred Stock, $0.04712, in each case subject to appropriate and proportionate adjustments for any stock
dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, such shares, as applicable, and further subject to adjustment (in order to adjust the number of shares of Common Stock
into which such Preferred Stock is convertible) as provided in Section&nbsp;4.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Rights</U>&#148; shall have the
meaning set forth in Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Convertible Securities</U>&#148; shall mean any evidences of indebtedness, shares or other
securities directly or indirectly convertible into or exercisable or exchangeable for Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Filing Date</U>&#148; means
the date of the filing of this Amended and Restated Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>H.I.G.</U>&#148; shall mean H.I.G. <FONT
STYLE="white-space:nowrap">Bio-Exagen,</FONT> L.P. and affiliates thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liquidation</U>&#148; shall have the meaning set
forth in Section&nbsp;3.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liquidation Preference&#148; </U>shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) with respect to a share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock, the Liquidation Value specified for
such share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) with respect to a share of <FONT
STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, the sum of (i)&nbsp;the Liquidation Value for such share of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, plus (ii)&nbsp;an amount equal to any other
dividends then declared but unpaid thereon; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) with respect to a share of Series&nbsp;C Preferred Stock, the sum of (i)&nbsp;the
Liquidation Value for such share of Series&nbsp;C Preferred Stock, plus (ii)&nbsp;an amount equal to any other dividends then declared but unpaid thereon; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) with respect to a share of Series&nbsp;D Preferred Stock, the sum of (i)&nbsp;the Liquidation Value for such share of Series&nbsp;D
Preferred Stock, plus (ii)&nbsp;an amount equal to any other dividends then declared but unpaid thereon; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) with respect to a share of
Series&nbsp;E Preferred Stock, the sum of (i)&nbsp;the Liquidation Value for such share of Series&nbsp;E Preferred Stock, plus (ii)&nbsp;an amount equal to any other dividends then declared but unpaid thereon; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) with respect to a share of Series F Preferred Stock, the sum of (i)&nbsp;the Liquidation Value for such share of Series&nbsp;F Preferred
Stock, plus (ii)&nbsp;an amount equal to any other dividends then declared but unpaid thereon; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) with respect to a share of Series H Preferred Stock, the sum of (i)&nbsp;the Liquidation
Value for such share of Series&nbsp;H Preferred Stock, plus (ii)&nbsp;an amount equal to any other dividends then declared but unpaid thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liquidation Value</U>&#148; shall mean (a)&nbsp;with respect to a share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT>
Preferred Stock $7.50, (b) with respect to a share of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, $0.25, (c) with respect to a share of Series C Preferred Stock, $0.50, (d) with respect to a share of Series D Preferred
Stock, $0.375, (e) with respect to a share of Series E Preferred Stock, $0.127, (f) with respect to a share of Series F Preferred Stock, $0.074, and (g)&nbsp;with respect to a share of Series H Preferred Stock, $0.04712, in each case subject to
appropriate and proportionate adjustments for any stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, such shares, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Option</U>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire either Common Stock or
Convertible Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Original Issue Price</U>&#148; shall mean (a)&nbsp;with respect to a share of <FONT
STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock, $7.50, (b) with respect to a share of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, $0.25, (c) with respect to a share of Series C Preferred Stock, $0.25,
(d) with respect to a share of Series D Preferred Stock, $0.25, (e) with respect to a share of Series E Preferred Stock, $0.25, (f) with respect to a share of Series F Preferred Stock, $0.078, and (g)&nbsp;with respect to a share of Series H
Preferred Stock, $0.04712, in each case subject to appropriate and proportionate adjustments for any stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, such shares,
as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PCM/Hunt</U>&#148; shall mean PCM/Exagen, L.P. and Affiliates thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Preferred Stock</U>&#148; shall mean the <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock, the <FONT
STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock, the Series E Preferred Stock, the Series F Preferred Stock and the Series H Preferred Stock, collectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Redemption Date</U>&#148; shall mean the requested date of redemption pursuant to Section&nbsp;6.1 or Section&nbsp;6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Redemption Event</U>&#148; shall mean the failure by the Corporation to perform or observe any material provision of the
Corporation&#146;s Amended and Restated Certificate of Incorporation or any one or more of the Series H Preferred Stock Purchase Agreement, the Amended and Restated Investors&#146; Rights Agreement or the Amended and Restated Stockholders&#146;
Agreement, each dated on or about the Filing Date and as amended and/or restated from time to time, among the Corporation and certain of its stockholders, copies of which are on file and available for inspection at the office of the Corporation,
unless such failure, if curable, is cured within a period of sixty (60)&nbsp;days, provided that the Requisite Majority (as defined hereafter), give to the Corporation a written notice of such redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Redemption Price</U>&#148; shall mean, (a)&nbsp;with respect to a share of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT>
Preferred Stock, an amount equal to the Liquidation Value for such share of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, (b)&nbsp;with respect to a share of Series&nbsp;C Preferred Stock, an amount equal to the
Liquidation Value for such share of Series&nbsp;C Preferred Stock, (c)&nbsp;with respect to a share of Series&nbsp;D Preferred Stock, an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount equal to the Liquidation Value for such share of Series&nbsp;D Preferred Stock, (d)&nbsp;with respect to a share of Series&nbsp;E Preferred Stock, an amount equal to the Liquidation Value
for such share of Series&nbsp;E Preferred Stock, (e)&nbsp;with respect to a share of Series&nbsp;F Preferred Stock, an amount equal to the Liquidation Value for such share of Series&nbsp;F Preferred Stock, and (f)&nbsp;with respect to a share of
Series&nbsp;H Preferred Stock, an amount equal to the Liquidation Value for such share of Series&nbsp;H Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Requisite Party</U>&#148; shall be any of H.I.G., Sun Mountain (as defined below), Tullis (as defined below) or PCM/Hunt, each for so
long as it holds at least fifty percent (50%) of the shares of Preferred Stock that such party or its Affiliates held as of the date of the Series H Preferred Stock Purchase Agreement (as defined herein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Requisite Majority</U>&#148; shall mean (A)&nbsp;for so long as H.I.G. is a Requisite Party and three other Requisite Parties exist,
either (i)&nbsp;any three Requisite Parties or (ii)&nbsp;H.I.G. and any other single Requisite Party, (B)&nbsp;for so long as H.I.G. is a Requisite Party and two other Requisite Parties exist, H.I.G. and any other single Requisite Party,
(C)&nbsp;for so long as H.I.G. is a Requisite Party and one or no other Requisite Party exists, H.I.G., (D) if H.I.G. is not a Requisite Party, the majority of shares of Preferred Stock then held by the Requisite Parties, or (E)&nbsp;if no Requisite
Party exists, Investors holding at least a majority of the shares of Senior Preferred Stock (as defined below) then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sun Mountain</U>&#148; shall mean NMSIC <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, L.P. and Affiliates thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tullis</U>&#148; shall mean Tullis-Dickerson Capital Focus III, L.P. and Affiliates thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Senior Preferred Stock</U>&#148; shall mean the <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, the Series C
Preferred Stock, the Series D Preferred Stock, the Series E Preferred Stock, the Series F Preferred Stock and the Series H Preferred Stock, collectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Series H Preferred Stock Purchase Agreement</U>&#148; shall mean that certain Series H Preferred Stock Purchase Agreement, dated on
or about the Filing Date, among the Corporation and the other parties named therein, as amended and/or restated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to
Sections in this Article Fourth are references to Sections of this Article Fourth unless otherwise specifically set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDEND
RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1. <U>Series H Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The outstanding shares of Series&nbsp;H Preferred Stock shall be entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT>
dividends at a rate of $0.00377 per share (the &#147;<U>Series H Dividends</U>&#148;) (subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like
occurrences with respect to the Series H Preferred Stock) per annum, out of any assets at the time legally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available therefor, when, as and if declared by the Board of Directors, prior and in preference to the payment of any dividends to the holders of Series F Preferred Stock, Series E Preferred
Stock, Series D Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock and the Common Stock. The Series H Dividends shall
be payable only when, as and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series&nbsp;H Dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the
Corporation (other than dividends on shares of Common Stock payable entirely in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Corporation&#146;s Amended and Restated Certificate of
Incorporation) the holders of the Series H Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series H Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the
amount of the aggregate Series H Dividends on such share of Series H Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per
share of Series H Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and
(2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series H Preferred Stock in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a
dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series H Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by
the original issuance price of such class or series of capital stock (subject to appropriate and proportionate adjustments for any stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences
with respect to, such shares) and (2)&nbsp;multiplying such fraction by an amount equal to the Original Issue Price for the Series H Preferred Stock; provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on
shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series H Preferred Stock pursuant to this Section&nbsp;2 shall be calculated based upon the dividend on the class or Series of
capital stock that would result in the highest dividend being paid to the holders of the Series H Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2.
<U>Series F Dividends</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The outstanding shares of Series&nbsp;F Preferred Stock shall be entitled to receive <FONT
STYLE="white-space:nowrap">non-cumulative</FONT> dividends, only after the payment of dividends to the holders of Series H Preferred Stock pursuant to Section&nbsp;2.1 above, at a rate of $0.00624 per share (the &#147;<U>Series F
Dividends</U>&#148;) (subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to the Series F Preferred Stock) per
annum, out of any assets at the time legally available therefor, when, as and if declared by the Board of Directors, prior and in preference to the payment of any dividends to the holders of Series E Preferred Stock, Series D Preferred Stock, Series
C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock and the Common Stock. The Series F Dividends shall be payable only when, as and if
declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series&nbsp;F Dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall not declare, pay or set aside any dividends on shares of any other
class or series&nbsp;of capital stock of the Corporation (other than dividends on shares of Common Stock payable entirely in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Corporation&#146;s
Amended and Restated Certificate of Incorporation) the holders of the Series&nbsp;F Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series&nbsp;F Preferred Stock in an amount
at least equal to the greater of (i)&nbsp;the amount of the aggregate Series&nbsp;F Dividends on such share of Series&nbsp;F Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or
series&nbsp;that is convertible into Common Stock, that dividend per share of Series&nbsp;F Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series&nbsp;determined, if applicable, as if all
shares of such class or series&nbsp;had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series&nbsp;F Preferred Stock in each case calculated on the record date for
determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series&nbsp;that is not convertible into Common Stock, at a rate per share of Series&nbsp;F Preferred Stock determined by
(1)&nbsp;dividing the amount of the dividend payable on each share of such class or series&nbsp;of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate and proportionate adjustments for any
stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, such shares) and (2)&nbsp;multiplying such fraction by an amount equal to the Original Issue Price for the
Series&nbsp;F Preferred Stock; provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series&nbsp;of capital stock of the Corporation, the dividend payable to the holders of
Series&nbsp;F Preferred Stock pursuant to this Section&nbsp;2 shall be calculated based upon the dividend on the class or Series&nbsp;of capital stock that would result in the highest dividend being paid to the holders of the Series&nbsp;F Preferred
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3. <U>Series E Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The outstanding shares of Series&nbsp;E Preferred Stock shall be entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT>
dividends, only after the payment of dividends to the holders of Series H Preferred Stock pursuant to Section&nbsp;2.1 above and to the holders of Series F Preferred Stock pursuant to Section&nbsp;2.2 above, at a rate of $0.00624 per share (the
&#147;<U>Series E Dividends</U>&#148;) (subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to the Series E
Preferred Stock) per annum, out of any assets at the time legally available therefor, when, as and if declared by the Board of Directors, prior and in preference to the payment of any dividends to the holders of Series D Preferred Stock, Series C
Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock and the Common Stock. The Series E Dividends shall be payable only when, as and if declared
by the Board of Directors and the Corporation shall be under no obligation to pay such Series&nbsp;E Dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall not declare, pay or set aside any dividends on shares of any other
class or series&nbsp;of capital stock of the Corporation (other than dividends on shares of Common Stock payable entirely in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Corporation&#146;s
Amended and Restated Certificate of Incorporation) the holders of the Series&nbsp;E Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series&nbsp;E Preferred Stock in an amount
at least equal to the greater of (i)&nbsp;the amount of the aggregate Series&nbsp;E Dividends on such share of Series&nbsp;E Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or
series&nbsp;that is convertible into Common Stock, that dividend per share of Series&nbsp;E Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series&nbsp;determined, if applicable, as if all
shares of such class or series&nbsp;had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series&nbsp;E Preferred Stock in each case calculated on the record date for
determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series&nbsp;that is not convertible into Common Stock, at a rate per share of Series&nbsp;E Preferred Stock determined by
(1)&nbsp;dividing the amount of the dividend payable on each share of such class or series&nbsp;of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate and proportionate adjustments for any
stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, such shares) and (2)&nbsp;multiplying such fraction by an amount equal to the Original Issue Price for the
Series&nbsp;E Preferred Stock; provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series&nbsp;of capital stock of the Corporation, the dividend payable to the holders of
Series&nbsp;E Preferred Stock pursuant to this Section&nbsp;2 shall be calculated based upon the dividend on the class or Series&nbsp;of capital stock that would result in the highest dividend being paid to the holders of the Series&nbsp;E Preferred
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4. <U>Series D Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The outstanding shares of Series&nbsp;D Preferred Stock shall be entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT>
dividends, only after the payment of dividends to the holders of Series H Preferred Stock pursuant to Section&nbsp;2.1 above, to the holders of Series F Preferred Stock pursuant to Section&nbsp;2.2 above and to the holders of Series E Preferred
Stock pursuant to Section&nbsp;2.3 above, at a rate of $0.00624 per share (the &#147;<U>Series D Dividends</U>&#148;) (subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of,
and recapitalizations and like occurrences with respect to the Series D Preferred Stock) per annum, out of any assets at the time legally available therefor, when, as and if declared by the Board of Directors, prior and in preference to the payment
of any dividends to the holders of Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock and the Common Stock. The Series D Dividends
shall be payable only when, as and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series&nbsp;D Dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series&nbsp;of capital stock of the
Corporation (other than dividends on shares of Common Stock payable entirely in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Corporation&#146;s Amended and Restated Certificate of
Incorporation) the holders of the Series&nbsp;D Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series&nbsp;D </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series&nbsp;D Dividends on such share of Series&nbsp;D Preferred Stock and not previously paid
and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series&nbsp;that is convertible into Common Stock, that dividend per share of Series&nbsp;D Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on
each share of such class or series&nbsp;determined, if applicable, as if all shares of such class or series&nbsp;had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of
Series&nbsp;D Preferred Stock in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series&nbsp;that is not convertible into Common Stock, at a
rate per share of Series&nbsp;D Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series&nbsp;of capital stock by the original issuance price of such class or series of capital stock
(subject to appropriate and proportionate adjustments for any stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, such shares) and (2)&nbsp;multiplying such fraction
by an amount equal to the Original Issue Price for the Series&nbsp;D Preferred Stock; provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series&nbsp;of capital stock of
the Corporation, the dividend payable to the holders of Series&nbsp;D Preferred Stock pursuant to this Section&nbsp;2 shall be calculated based upon the dividend on the class or Series&nbsp;of capital stock that would result in the highest dividend
being paid to the holders of the Series&nbsp;D Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5. <U>Series C Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The outstanding shares of Series&nbsp;C Preferred Stock shall be entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT>
dividends, only after the payment of dividends to the holders of Series H Preferred Stock pursuant to Section&nbsp;2.1 above, to the holders of Series F Preferred Stock pursuant to Section&nbsp;2.2 above, to the holders of Series E Preferred Stock
pursuant to Section&nbsp;2.3 above and to the holders of Series D Preferred Stock pursuant to Section&nbsp;2.4 above, at a rate of $0.00624 per share (the &#147;<U>Series C Dividends</U>&#148;) (subject to appropriate and proportionate adjustments
for stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to the Series C Preferred Stock) per annum, out of any assets at the time legally available therefor, when, as and
if declared by the Board of Directors, prior and in preference to the payment of any dividends to the holders of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred
Stock and the Common Stock. The Series&nbsp;C Dividends shall be payable only when, as and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series&nbsp;C Dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series&nbsp;of capital stock of the
Corporation (other than dividends on shares of Common Stock payable entirely in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Corporation&#146;s Amended and Restated Certificate of
Incorporation) the holders of the Series&nbsp;C Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series&nbsp;C Preferred Stock in an amount at least equal to the greater of
(i)&nbsp;the amount of the aggregate Series&nbsp;C Dividends on such share of Series&nbsp;C Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series&nbsp;that is convertible into
Common Stock, that dividend per share of Series&nbsp;C Preferred Stock as would equal the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of (1)&nbsp;the dividend payable on each share of such class or series&nbsp;determined, if applicable, as if all shares of such class or series&nbsp;had been converted into Common Stock and
(2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series&nbsp;C Preferred Stock in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a
dividend on any class or series&nbsp;that is not convertible into Common Stock, at a rate per share of Series&nbsp;C Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series&nbsp;of
capital stock by the original issuance price of such class or series of capital stock (subject to appropriate and proportionate adjustments for any stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and
like occurrences with respect to, such shares) and (2)&nbsp;multiplying such fraction by an amount equal to the Original Issue Price for the Series&nbsp;C Preferred Stock; provided that, if the Corporation declares, pays or sets aside, on the same
date, a dividend on shares of more than one class or series&nbsp;of capital stock of the Corporation, the dividend payable to the holders of Series&nbsp;C Preferred Stock pursuant to this Section&nbsp;2 shall be calculated based upon the dividend on
the class or Series&nbsp;of capital stock that would result in the highest dividend being paid to the holders of the Series&nbsp;C Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6. <U>Series <FONT STYLE="white-space:nowrap">B-3</FONT> Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The outstanding shares of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock shall be entitled to receive <FONT
STYLE="white-space:nowrap">non-cumulative</FONT> dividends, only after the payment of dividends to the holders of Series H Preferred Stock pursuant to Section&nbsp;2.1 above, to the holders of Series F Preferred Stock pursuant to Section&nbsp;2.2
above, to the holders of Series E Preferred Stock pursuant to Section&nbsp;2.3 above, to the holders of Series D Preferred Stock pursuant to Section&nbsp;2.4 above and to the holders of Series C Preferred Stock pursuant to Section&nbsp;2.5 above, at
a rate of $0.00624 per share (the &#147;<U>Series <FONT STYLE="white-space:nowrap">B-3</FONT> Dividends</U>&#148;) (subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of,
and recapitalizations and like occurrences with respect to the Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock) per annum, out of any assets at the time legally available therefor, when, as and if declared by the Board of
Directors, prior and in preference to the payment of any dividends to the holders of <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock and the Common Stock. The <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Dividends
shall be payable only when, as and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series&nbsp;of capital stock of the
Corporation (other than dividends on shares of Common Stock payable entirely in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Corporation&#146;s Amended and Restated Certificate of
Incorporation) the holders of the <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of
<FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Dividends on such share of <FONT
STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series&nbsp;that is convertible into Common Stock, that dividend per share of <FONT
STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series&nbsp;determined, if applicable, as if all shares of such class or series&nbsp;had
been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series&nbsp;that is not convertible
into Common Stock, at a rate per share of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series&nbsp;of capital stock by the
original issuance price of such class or series of capital stock (subject to appropriate and proportionate adjustments for any stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with
respect to, such shares) and (2)&nbsp;multiplying such fraction by an amount equal to the Original Issue Price for the <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock; provided that, if the Corporation declares, pays or sets
aside, on the same date, a dividend on shares of more than one class or series&nbsp;of capital stock of the Corporation, the dividend payable to the holders of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock pursuant to this
Section&nbsp;2 shall be calculated based upon the dividend on the class or Series&nbsp;of capital stock that would result in the highest dividend being paid to the holders of the <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.7. <U>No Other Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No dividend shall be declared or be payable on the outstanding shares of the Series H Preferred Stock, Series F Preferred Stock, Series D
Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock or <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock or the Common Stock (other than a dividend on shares of Common
Stock payable entirely in shares of Common Stock) without the consent of the Requisite Majority and, for so long as H.I.G. is a Requisite Party, H.I.G. Nothing in this Section&nbsp;2.7 shall preclude the payment of an amount equal to any Series H
Dividends, Series F Dividends, Series D Dividends, Series C Dividends or Series <FONT STYLE="white-space:nowrap">B-3</FONT> Dividends as part of the Liquidation Preference or Redemption Price, as applicable, with respect to the Series H Preferred
Stock, Series F Preferred Stock, Series D Preferred Stock, Series C Preferred Stock or Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, as applicable. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIQUIDATION
RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1. <U>Right to Liquidation Value</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event of any Liquidation, either voluntary or involuntary, before any distribution or payment shall be made to the holders of any
Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock or
Common Stock, each holder of Series&nbsp;H Preferred Stock shall be entitled to receive out of the assets of the Corporation legally available for distribution or payment (or the consideration received in a transaction which is a Liquidation), on
account of each <FONT STYLE="white-space:nowrap">then-outstanding</FONT> share of Series&nbsp;H Preferred Stock held by them, the Liquidation Preference specified for such share of Series&nbsp;H Preferred Stock. If, upon the Liquidation, the assets
of the Corporation (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of the Series&nbsp;H Preferred Stock of the full Liquidation Preference of the Series&nbsp;H Preferred Stock, then
such assets (or consideration) shall be distributed or paid among the holders of Series&nbsp;H Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) After the payment of the full Liquidation Preference of the Series H Preferred Stock as
set forth in Section&nbsp;3.1(a), and before any distribution or payment shall be made to the holders of any Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred
Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock or Common Stock, each holder of Series&nbsp;F Preferred Stock shall be entitled to receive out of the assets of the Corporation legally available for distribution or
payment (or the consideration received in a transaction which is a Liquidation), on account of each <FONT STYLE="white-space:nowrap">then-outstanding</FONT> share of Series&nbsp;F Preferred Stock held by them, the Liquidation Preference specified
for such share of Series&nbsp;F Preferred Stock. If, upon the Liquidation, the assets of the Corporation (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of the Series&nbsp;F Preferred
Stock of the full Liquidation Preference of the Series&nbsp;F Preferred Stock, then such assets (or consideration) shall be distributed or paid among the holders of Series&nbsp;F Preferred Stock at the time outstanding, ratably in proportion to the
full amounts to which they would otherwise be respectively entitled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) After the payment of the full Liquidation Preference of the
Series H Preferred Stock as set forth in Section&nbsp;3.1(a) and the full Liquidation Preference of the Series F Preferred Stock as set forth in Section&nbsp;3.1(b), and before any distribution or payment shall be made to the holders of any Series D
Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock or Common Stock, each holder of Series E Preferred Stock shall be
entitled to receive out of the assets of the Corporation legally available for distribution or payment (or the consideration received in a transaction which is a Liquidation), on account of each
<FONT STYLE="white-space:nowrap">then-outstanding</FONT> share of Series&nbsp;E Preferred Stock held by them, the Liquidation Preference specified for such share of Series&nbsp;E Preferred Stock. If, upon the Liquidation, the assets of the
Corporation (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of the Series&nbsp;E Preferred Stock of the full Liquidation Preference of the Series&nbsp;E Preferred Stock, then such
assets (or consideration) shall be distributed or paid among the holders of Series&nbsp;E Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) After the payment of the full Liquidation Preference of the Series H Preferred Stock as set forth in Section&nbsp;3.1(a), the full
Liquidation Preference of the Series F Preferred Stock as set forth in Section&nbsp;3.1(b) and the full Liquidation Preference of the Series E Preferred Stock as set forth in Section&nbsp;3.1(c), and before any distribution or payment shall be made
to the holders of any Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock or Common Stock, each holder of Series&nbsp;D Preferred Stock
shall be entitled to receive out of the assets of the Corporation legally available for distribution or payment (or the consideration received in a transaction which is a Liquidation), on account of each
<FONT STYLE="white-space:nowrap">then-outstanding</FONT> share of Series&nbsp;D Preferred Stock held by them, the Liquidation Preference specified for such share of Series&nbsp;D Preferred Stock. If, upon the Liquidation, the assets of the
Corporation (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of the Series&nbsp;D Preferred Stock of the full Liquidation Preference of the Series&nbsp;D Preferred Stock, then such
assets (or consideration) shall be distributed or paid among the holders of Series&nbsp;D Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) After the payment of the full Liquidation Preference of the Series H Preferred Stock as
set forth in Section&nbsp;3.1(a), the full Liquidation Preference of the Series F Preferred Stock as set forth in Section&nbsp;3.1(b), the full Liquidation Preference of the Series E Preferred Stock as set forth in Section&nbsp;3.1(c), and the full
Liquidation Preference of the Series D Preferred Stock as set forth in Section&nbsp;3.1(d), and before any distribution or payment shall be made to the holders of any Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, <FONT
STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock or Common Stock, the holders of Series&nbsp;C Preferred Stock shall be entitled to receive out of the assets of the Corporation legally available for distribution or payment (or the
consideration received in a transaction which is a Liquidation), on account of each <FONT STYLE="white-space:nowrap">then-outstanding</FONT> share of Series&nbsp;C Preferred Stock held by them, the Liquidation Preference specified for such share of
Series&nbsp;C Preferred Stock. If, upon the Liquidation, the assets of the Corporation (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of the Series&nbsp;C Preferred Stock of the full
Liquidation Preference of the Series&nbsp;C Preferred Stock, then such assets (or consideration) shall be distributed or paid among the holders of Series&nbsp;C Preferred Stock at the time outstanding, ratably in proportion to the full amounts to
which they would otherwise be respectively entitled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) After the payment of the full Liquidation Preference of the Series H Preferred
Stock as set forth in Section&nbsp;3.1(a), the full Liquidation Preference of the Series F Preferred Stock as set forth in Section&nbsp;3.1(b), the full Liquidation Preference of the Series E Preferred Stock as set forth in Section&nbsp;3.1(c), the
full Liquidation Preference of the Series D Preferred Stock as set forth in Section&nbsp;3.1(d) and the full Liquidation Preference of the Series C Preferred Stock as set forth in Section&nbsp;3.1(e), and before any distribution or payment shall be
made to the holders of any Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock or Common Stock, the holders of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock shall be entitled to receive out of the assets of the
Corporation legally available for distribution or payment (or the consideration received in such transaction), on account of each then-outstanding share of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock held by them, the
Liquidation Preference specified for such share of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock. If the assets of the Corporation shall be insufficient to make payment in full to all holders of the <FONT
STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock of the full Liquidation Preference of the <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock, then such assets (or consideration) shall be distributed or paid
among the holders of <FONT STYLE="white-space:nowrap">Series&nbsp;B-3</FONT> Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) After the payment of the full Liquidation Preference of the Series H Preferred Stock as set forth in Section&nbsp;3.1(a), the full
Liquidation Preference of the Series F Preferred Stock as set forth in Section&nbsp;3.1(b), the full Liquidation Preference of the Series E Preferred Stock as set forth in Section&nbsp;3.1(c), the full Liquidation Preference of the Series D
Preferred Stock as set forth in Section&nbsp;3.1(d), the full Liquidation Preference of the Series C Preferred Stock as set forth in Section&nbsp;3.1(e) and the full Liquidation Preference of the Series <FONT STYLE="white-space:nowrap">B-3</FONT>
Preferred Stock as set forth in Section&nbsp;3.1(f), and before any distribution or payment shall be made to the holders of any Common Stock, the holders of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock shall be entitled to
receive out of the assets of the Corporation legally available for distribution or payment (or the consideration received in such transaction), on account of each then-outstanding share of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred
Stock held by them, the Liquidation Preference specified for such share of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock. If the assets of the Corporation shall be insufficient to make payment in full to all holders of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock of the full Liquidation Preference of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock, then such assets (or consideration) shall be distributed or paid
among the holders of <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) After the payment of the full Liquidation Preference of the Preferred Stock as set forth
in Sections 3.1(a), 3.1(b), 3.1(c), 3.1(d), 3.1(e), 3.1(f) and 3.1(g) above, all of the remaining assets of the Corporation (or consideration received in such transaction) shall be distributed or paid with equal priority and <I>pro rata</I> among
the holders of the then outstanding Preferred Stock and holders of the then outstanding Common Stock in proportion to the number of shares of Common Stock then held by such holders, treating in such circumstances each then outstanding share of
Preferred Stock as if it had been converted into Common Stock at the then applicable Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2.
&#147;<U>Liquidation&#148; Defined</U>. Each of the following events shall be considered a &#147;<U>Liquidation</U>&#148;: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any
liquidation, dissolution or winding up, either voluntary or involuntary, of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) a statutory share exchange,
reorganization, merger or consolidation of the Corporation with or into any other entity or entities or any other transaction or series&nbsp;of related transactions (but excluding any sale of stock by the Corporation for capital raising purposes),
as a result of which stockholders of the Corporation immediately prior to the consummation of the statutory share exchange, reorganization, merger, consolidation, transaction or series&nbsp;of related transactions hold less than a majority of the
voting securities of the surviving entity or the entity whose securities are issued pursuant thereto or hold greater than a majority of the voting securities of the surviving entity or the entity whose securities are issued pursuant thereto but in
proportions that are not substantially equivalent to the proportions in which such stockholders held the Corporation&#146;s voting securities immediately prior to such transaction; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) a sale, lease, license or other disposition of all or substantially all of the assets of the Corporation (whether held directly or
indirectly through one or more controlled subsidiaries) by means of any transaction or series of related transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3.
<U>Preferential Payment</U>. All of the preferential amounts to be paid to the holders of the Preferred Stock pursuant to this Section&nbsp;3 shall be paid or set apart in trust for payment before the payment or setting apart for payment of any
amount for, or the distribution of any assets of the Corporation (or compensation received in the transaction) to, the holders of the Common Stock in connection with such Liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4. <U>Allocation of Escrow or Contingent Payment</U>. In the event of any transaction or event constituting a Liquidation
pursuant to Section&nbsp;3.2(b), if any portion of the consideration payable to the Corporation or its stockholders is placed into escrow and/or is payable to the Corporation or its stockholders at a future date and/or subject to contingencies, the
definitive agreements shall provide that (a)&nbsp;the portion of such consideration that is not payable at a future date, not placed in escrow and not subject to any contingencies (the &#147;<U>Initial Consideration</U>&#148;) shall be allocated
among the holders of capital stock of the Corporation in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with Section&nbsp;3.1 as if the Initial Consideration were the only consideration payable in connection with such Liquidation and (b)&nbsp;any additional consideration which becomes
payable to the Corporation or its stockholders upon release from escrow or satisfaction of contingencies or otherwise shall be allocated among the holders of capital stock of the Corporation in accordance with Section&nbsp;3.1 after taking into
account the previous payment of the Initial Consideration as part of the same transaction. In the event of a Liquidation pursuant to Section&nbsp;3.2(a) or Section&nbsp;3.2(c), if any portion of the consideration payable pursuant to such Liquidation
is placed into escrow, is payable at a future date and/or is payable subject to contingencies, then (x)&nbsp;the portion of the consideration that is not payable at a future date, not placed into escrow and not subject to any contingencies (the
&#147;<U><FONT STYLE="white-space:nowrap">Non-Contingent</FONT> Consideration</U>&#148;) shall be distributed to the holders of the capital stock of the Corporation in accordance with Section&nbsp;3.1 as if such
<FONT STYLE="white-space:nowrap">Non-Contingent</FONT> Consideration were the only consideration payable in connection with such Liquidation and (y)&nbsp;any additional consideration which becomes payable upon release from escrow or satisfaction of
contingencies or otherwise shall be paid or distributed to the in accordance with Section&nbsp;3.1 after taking into account the previous payment of the <FONT STYLE="white-space:nowrap">Non-Contingent</FONT> Consideration as part of the same
transaction. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERSION RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of the Preferred Stock shall have conversion rights as follows (the &#147;<U>Conversion Rights</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1.
<U>Right to Convert</U>. Each share of Preferred Stock shall be convertible at the option of the holder thereof at any time and without the payment of any additional consideration therefor into that number of fully paid and nonassessable shares of
Common Stock as is determined by dividing the Original Issue Price for such share of Preferred Stock by the then effective Conversion Price (determined as hereinafter provided) in effect at the time of conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2. <U>Mandatory Conversion</U>. Each share of Preferred Stock shall automatically be converted into that number of fully paid
and nonassessable shares of Common Stock as is determined by dividing the Original Issue Price for such share of Preferred Stock by the then effective Conversion Price for such Preferred Stock, as adjusted pursuant to Section&nbsp;4.4, upon
(a)&nbsp;the affirmative vote or written consent of (i)&nbsp;the Requisite Majority and (ii)&nbsp;solely in the event of the mandatory conversion of the Preferred Stock pursuant to clause (a)(i) of this Section&nbsp;4.2 in connection either
(1)&nbsp;with the consummation of a Liquidation pursuant to which the holders of Series H Preferred Stock will be entitled to receive consideration per share of Series H Preferred Stock, following its conversion to shares(s) of Common Stock, with a
value (as determined in good faith by the Board of Directors) that is less than $0.09424 or (2)&nbsp;the closing of the sale of shares of Common Stock to the public at a price per share less than $0.07539 (subject to appropriate adjustment in the
event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock) in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act,
H.I.G. for so long as it is a Requisite Party, or (b)&nbsp;the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock
for the account of the Corporation to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public in which the Corporation actually receives net proceeds of at least $40,000,000 (after deduction of underwriters&#146; discounts and commissions), at a minimum valuation of $0.09424 per
share of Common Stock, and following which the Common Stock of the Corporation is traded or listed for quotation on a nationally recognized United States stock exchange; provided, that the conversion provided for in this Section&nbsp;4.2(b) shall be
conditioned upon the closing of the sale of securities pursuant to such offering and the person(s) entitled to receive the Common Stock issuable upon such conversion of the Preferred Stock shall not be deemed to have converted such Preferred Stock
until immediately prior to the closing of the sale of such securities. In any case where a particular series of Preferred Stock is to be converted (and expressly excluding the case where all Preferred Stock is to be converted in accordance with the
immediately preceding sentence) then, and only then, shall the following thresholds apply: (t)&nbsp;each outstanding share of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock shall automatically be converted into shares of Common
Stock at the then-effective Conversion Price for such share immediately upon the affirmative vote or written consent of the holders of at least a majority of the <FONT STYLE="white-space:nowrap">then-outstanding</FONT> Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock (voting as a single class), (u)&nbsp;each outstanding share of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred shall automatically be converted into shares of Common Stock at the
then effective Conversion Price for such share immediately upon the affirmative vote or written consent of the holders of at least a majority of the then outstanding Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred (voting as a single
class), (v) each outstanding share of Series C Preferred Stock shall automatically be converted into shares of Common Stock at the then effective Conversion Price for such share immediately upon the affirmative vote or written consent of the holders
of at least a majority of the then outstanding Series C Preferred Stock (voting as a single class), (w) each outstanding share of Series D Preferred Stock shall automatically be converted into shares of Common Stock at the then effective Conversion
Price for such share immediately upon the affirmative vote or written consent of the holders of at least a majority of the then outstanding Series D Preferred Stock (voting as a single class), (x) each outstanding share of Series E Preferred Stock
shall automatically be converted into shares of Common Stock at the then effective Conversion Price for such share immediately upon the affirmative vote or written consent of the holders of at least a majority of the then outstanding Series E
Preferred Stock (voting as a single class), (y) each outstanding share of Series F Preferred Stock shall automatically be converted into shares of Common Stock at the then effective Conversion Price for such share immediately upon the affirmative
vote or written consent of the holders of at least a majority of the then outstanding Series F Preferred Stock (voting as a single class), and (z)&nbsp;each outstanding share of Series H Preferred Stock shall automatically be converted into shares
of Common Stock at the then effective Conversion Price for such share immediately upon the affirmative vote or written consent of the holders of at least a majority of the then outstanding Series H Preferred Stock (voting as a single class). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3. <U>Mechanics of Conversion</U>. No fractional shares of Common Stock shall be issued upon conversion of Preferred Stock. In
lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then fair market value of a share of Common Stock as determined in good faith by the Board of
Directors. For such purpose, all shares of Preferred Stock held by such holders shall be aggregated together, and any resulting fractional share of Common Stock shall be paid in cash. Before any holder of Preferred Stock shall be entitled to convert
the same into full shares of Common Stock, such holder shall surrender at the office of the Corporation or of any transfer agent for the Preferred Stock the certificate or certificates therefor, duly endorsed or assigned in blank, or if such
certificate or certificates have been lost, stolen or destroyed, a certificate in form </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and substance reasonably satisfactory to the Corporation certifying to such fact, together with an agreement reasonably satisfactory to the Corporation to indemnify the Corporation from any loss
incurred by the Corporation in connection with such certificate or certificates, and shall give written notice (a &#147;<U>Conversion Notice</U>&#148;) to the Corporation at such office that he elects to convert the same and shall state therein his
name or the name or names of his nominees in which he wishes the certificate or certificates for shares of Common Stock to be issued, together with the applicable federal taxpayer identification number; provided, that in the event of an automatic
conversion of any shares of Preferred Stock pursuant to Section&nbsp;4.2, the outstanding shares of Preferred Stock so converted shall be converted automatically without any further action by the holders of such shares and whether or not the
certificates representing such shares are surrendered to the Corporation or any transfer agent for the Preferred Stock; provided further, however, that the Corporation shall not be obligated to issue certificates evidencing the shares of Common
Stock issuable upon such automatic conversion unless the certificates evidencing such shares of Preferred Stock (or if such certificate or certificates have been lost, stolen or destroyed, a certificate in form and substance reasonably satisfactory
to the Corporation certifying to such fact, together with an agreement reasonably satisfactory to the Corporation to indemnify the Corporation from any loss incurred by the Corporation in connection with such certificate or certificates) are
delivered to the Corporation or such transfer agent. Any Conversion Notice may state the date on or the time at which the conversion provided for therein is to be deemed effective and any conditions to such effectiveness. The Corporation shall, as
soon as practicable after the Conversion Date, issue and deliver to such holder of Preferred Stock, or to his nominee or nominees, at such place designed by such holder, a certificate or certificates for the number of shares of Common Stock to which
he shall be entitled, together with cash in lieu of any fraction of a share. If a Conversion Notice states a date or time on or at which the conversion provided for therein is to be effective or states any conditions to such effectiveness, then such
conversion shall be deemed to have made on or at such date or time or the satisfaction of such conditions, as applicable. If the Conversion Notice does not state any date or time on or at which the conversion provided for therein is to be effective
or state any conditions to such effectiveness, then such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of Preferred Stock to be converted pursuant to
Section&nbsp;4.1, and the holder of Preferred Stock entitled to receive the shares of Common Stock issuable upon conversion shall be treated for all purposes as the record holder of such shares of Common Stock on such date. The date or time at which
any conversion of shares of Preferred Stock is deemed effective under Section&nbsp;4.2 or this Section&nbsp;4.3 is referred to herein as the &#147;<U>Conversion Date</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4. <U>Adjustments to Conversion Price for Diluting Issues</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Adjustment of Conversion Price</U>. Subject to the provisions of Section&nbsp;4.4(e) and Section&nbsp;4.4(f), no adjustment in the
number of shares of Common Stock into which a series of Senior Preferred Stock is convertible shall be made by adjustment in the Conversion Price for such series of Senior Preferred Stock in respect of the issuance of Additional Shares of Common
Stock, unless the consideration per share for such Additional Shares of Common Stock issued or deemed to be issued by the Corporation is less than the Conversion Price for such series of Senior Preferred Stock in effect on the date of, and
immediately prior to, the issue of such Additional Shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Issue of Options and Convertible Securities Deemed Issue of Additional Shares of
Common Stock</U>. In the event the Corporation at any time or from time to time on or after the Filing Date shall issue any Options or Convertible Securities or shall fix a record date for the determination of holders of any class of securities
entitled to receive any such Options or Convertible Securities, then the maximum number of shares (as set forth in the instrument relating thereto without regard to any provisions contained therein for a subsequent adjustment of such number and
whether or not such Options or Convertible Securities or the right to convert, exercise or exchange such Options or Convertible Securities are immediately exercisable) of Common Stock issuable upon the exercise of such Options or, in the case of
Convertible Securities and Options therefor, the conversion, exercise or exchange of such Convertible Securities, shall (except as provided in the definition of &#147;Additional Shares of Common Stock&#148;) be deemed to be Additional Shares of
Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date; <U>provided</U> that Additional Shares of Common Stock shall not be deemed to have been issued
unless the consideration per share (determined pursuant to Section&nbsp;4.4(d)) of such Additional Shares of Common Stock would be less than the applicable Conversion Price for the relevant series of Senior Preferred Stock in effect on the date of
and immediately prior to such issue, or such record date, as the case may be; and <U>provided</U>, <U>further</U>, that in any such case in which Additional Shares of Common Stock are deemed to be issued: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) no further adjustment in the Conversion Price shall be made upon the subsequent issue of Convertible Securities or shares of Common Stock
upon the exercise of such Options or conversion, exercise or exchange of such Convertible Securities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) if such Options or Convertible
Securities by their terms provide, with the passage of time or otherwise, for any increase in the consideration payable to the Corporation, or decrease in the number of shares of Common Stock issuable, upon the exercise, conversion or exchange
thereof, then the Conversion Price computed upon the original issue thereof (or upon the occurrence of a record date with respect thereto), and any subsequent adjustments based thereon, shall, upon any such increase or decrease becoming effective,
be recomputed to reflect such increase or decrease insofar as it affects such Options or the rights of conversion, exercise or exchange under such Convertible Securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) upon the expiration of any such Options or any rights of conversion, exercise or exchange under such Convertible Securities which shall
not have been converted, exercised or exchanged, the Conversion Price computed upon the original issue thereof (or upon the occurrence of a record date with respect thereto) and any subsequent adjustments based thereon shall, upon such expiration,
be recomputed as if: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) in the case of Convertible Securities or Options for Common Stock, the only Additional Shares of Common Stock
issued were the shares of Common Stock, if any, actually issued upon the exercise of such Options or the conversion, exercise or exchange of such Convertible Securities and the consideration received therefor was the consideration actually received
by the Corporation for the issue of all such Options, whether or not exercised, plus the consideration actually received by the Corporation upon such exercise, or for the issue of all such Convertible Securities which were actually converted,
exercised or exchanged, plus the additional consideration, if any, actually received by the Corporation upon such conversion, exercise or exchange, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) in the case of Options for Convertible Securities, only the Convertible Securities, if
any, actually issued upon the exercise thereof were issued at the time of issue of such Options, and the consideration received by the Corporation for the Additional Shares of Common Stock deemed to have been then issued was the consideration
actually received by the Corporation for the issue of all such Options, whether or not exercised, plus the consideration deemed to have been received by the Corporation (determined pursuant to Section&nbsp;4.4(d)) upon the issue of the Convertible
Securities with respect to which such Options were actually exercised; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) no readjustment pursuant to clause (ii)&nbsp;or (iii) above
shall have the effect of increasing the Conversion Price to an amount which exceeds the lower of (x)&nbsp;the Conversion Price on the original adjustment date, or (y)&nbsp;the Conversion Price that would have resulted from any issuance of Additional
Shares of Common Stock between the original adjustment date and such readjustment date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) if the terms of any Options or Convertible
Securities are revised in any manner which has the effect of either increasing the number of shares of Common Stock issuable upon the exercise, conversion or exchange thereof or decreasing the consideration payable to the Corporation, then the
Conversion Price computed upon the original issue thereof (or upon the occurrence of a record date with respect thereto), and any subsequent adjustments based thereon, shall, upon any such increase or decrease becoming effective, be recomputed to
reflect such increase or decrease insofar as it affects such Options or the rights of conversion, exercise or exchange under such Convertible Securities; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) if such record date shall have been fixed and such Options or Convertible Securities are not issued on the date fixed therefor, the
adjustment previously made in the Conversion Price which became effective on such record date shall be canceled as of the close of business on such record date, and thereafter the Conversion Price shall be adjusted pursuant to this
Section&nbsp;4.4(b) as of the actual date of their issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Adjustment of Conversion Price Upon Issuance of Additional Shares of
Common Stock</U>. In the event the Corporation at any time or from time to time on or after the Filing Date shall issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
Section&nbsp;4.4(b)) without consideration or for a consideration per share less than the Conversion Price for a series of Senior Preferred Stock in effect immediately prior to such issue, then and in such event, the Conversion Price for such series
of Senior Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest cent) equal to the consideration per share received by the Corporation for such issue or deemed issue of the Additional Shares of Common
Stock; provided that if such issuance or deemed issuance was without consideration, then the Company shall be deemed to have received an aggregate of $0.001 of consideration for all such Additional Shares of Common Stock issued or deemed to be
issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Determination of Consideration</U>. For purposes of this Section&nbsp;4.4, the
consideration received by the Corporation for the issue of any Additional Shares of Common Stock shall be computed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
<U>Cash and Property</U>: Such consideration shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) insofar as it consists of cash, be computed at the aggregate amount of cash
received by the Corporation, excluding amounts paid or payable for accrued interest or accrued dividends; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) insofar as it consists of
property other than cash, be computed at the fair value thereof at the time of such issue, as determined in good faith by the Board of Directors; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for
consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (1)&nbsp;and (2) above, as determined in good faith by the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for Additional Shares of Common Stock
deemed to have been issued pursuant to Section&nbsp;4.4(b), relating to Options and Convertible Securities, shall be determined by dividing (x)&nbsp;the total amount, if any, received or receivable by the Corporation as consideration for the issue
of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such
consideration until such subsequent adjustment occurs) payable to the Corporation upon the exercise of such Options or the conversion, exercise or exchange of such Convertible Securities or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion, exercise or exchange of such Convertible Securities, by (y)&nbsp;the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number until such subsequent adjustment occurs) issuable upon the exercise of such Options or the conversion, exercise or exchange of such Convertible Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Adjustment for Dividends, Distributions, Subdivisions, Combinations or Consolidation of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Stock Dividends, Distributions or Subdivisions</U>. In the event the Corporation at any time or from time to time on or after the
Filing Date shall declare or pay any dividend or make any other distribution on the Common Stock payable in Common Stock or effect a subdivision of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a
dividend in Common Stock), then and in any such event, the Conversion Price for each series of Preferred Stock in effect immediately prior thereto shall be proportionately decreased to reflect such dividend, distribution or subdivision as of: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) in the case of any such dividend or distribution, immediately after the close of
business on the record date for the determination of holders of any class of securities entitled to receive such dividend or distribution, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) in the case of any such subdivision, at the close of business on the date immediately prior to the date upon which such corporate action
becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If such record date or other effective date shall have been fixed and such dividend, distribution or subdivision shall not have been
fully paid or effected on the date fixed therefor, the adjustment previously made in the Conversion Price which became effective on such record date or other date shall be canceled as of the close of business on such record date or other date, and
thereafter the Conversion Price shall be adjusted pursuant to this Section&nbsp;4.4(e) as of the time of actual payment of such dividend, distribution or effectiveness of such subdivision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Combinations or Consolidations</U>. In the event the outstanding shares of Common Stock shall at any time or from time to time on or
after the Filing Date be combined or consolidated, by reclassification or otherwise, into a lesser number of shares of Common Stock, the Conversion Price for each series of Preferred Stock in effect immediately prior to such combination or
consolidation shall, concurrently with the effectiveness of such combination or consolidation, be proportionately increased. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
<U>Adjustment for Reclassification or Reorganization</U>. In case of any capital reorganization or reclassification of the capital stock of the Corporation (other than a reclassification covered by Section&nbsp;4.4(e)(ii)), each share of Preferred
Stock shall thereafter be convertible into the number of shares of stock or other securities or property to which a holder of the number of shares of Common Stock of the Corporation deliverable upon conversion of such Preferred Stock would have been
entitled upon such reorganization or reclassification. In any such case, appropriate adjustment (as determined by the Board of Directors) shall be made in the application of these provisions set forth with respect to the rights and interest
thereafter of the holders of the Preferred Stock, to the end that these provisions (including provisions with respect to changes in and other adjustments of the Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in
relation to any shares of stock or other property thereafter deliverable upon the conversion of the Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5.
<U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this Section&nbsp;4, the Corporation at its expense shall promptly compute such adjustment or readjustment in accordance
with these terms and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, upon the written
request at any time of any holder of Preferred Stock, furnish or cause to be furnished to such holder a like certificate setting forth (i)&nbsp;such adjustments and readjustments, (ii)&nbsp;the Conversion Price at the time in effect, and
(iii)&nbsp;the number of shares of Common Stock and the amount, if any, of other property which at the time would be received upon the conversion of such holder&#146;s Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6. <U>Notices of Record Date</U>. In the event of (i)&nbsp;any taking by the
Corporation of a record date of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, or (ii)&nbsp;any capital reorganization of the Corporation, any
reclassification or recapitalization of the capital stock of the Corporation, any merger or consolidation of the Corporation, and any transfer of all or substantially all of the assets of the Corporation to any other entity or person, or any
Liquidation, the Corporation shall mail to each holder of Preferred Stock at least 20 days (or 30 days in the case of an acquisition of the Corporation through a merger or consolidation of the Corporation, the sale, lease, license or other
disposition of all or substantially all of its assets and properties or any transaction or series of related transactions) prior to the record date specified therein, a notice specifying (A)&nbsp;the date on which any such record is to be taken for
the purpose of such dividend or distribution and a description of such dividend or distribution, (B)&nbsp;the date on which any such reorganization, reclassification, transfer, consolidation, merger or Liquidation is expected to become effective,
and (C)&nbsp;the time, if any, that is to be fixed, as to when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or other property deliverable
upon such reorganization, reclassification, transfer, consolidation, merger or Liquidation. Notwithstanding the requirements of this Section&nbsp;4.6 and subject to compliance with the Delaware General Corporation Law, this Section&nbsp;4.6 shall
not be applicable and no such notice shall be required with respect to any action that is, or has been, approved by the Requisite Majority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7. <U>Common Stock Reserved</U>. The Corporation shall reserve and keep available out of its authorized but unissued Common
Stock such number of shares of Common Stock as shall from time to time be sufficient to effect conversion of all outstanding shares of Preferred Stock. If any shares of Common Stock to be reserved for the purpose of conversion of shares of Preferred
Stock require registration or listing with, or approval of, any governmental authority, stock exchange or other regulatory body under any federal or state law or regulation or otherwise, before such shares may be validly issued or delivered upon
conversion, the Corporation will in good faith and as expeditiously as possible endeavor to secure such registration, listing or approval, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8. <U>Other Events Altering Conversion Price</U>. Upon the occurrence of any event not specifically described in this
Section&nbsp;4 as reducing the Conversion Price that, in the reasonable exercise of the business judgment of the Board of Directors of the Corporation reached in good faith, requires, on equitable principles, the reduction of the Conversion Price,
the Conversion Price will be so equitably reduced. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1. <U>General</U>. Except as otherwise required by law and the provisions of this Section&nbsp;5 and Section&nbsp;7 below, the
holders of the Senior Preferred Stock and the holders of the Common Stock shall be entitled to notice of any stockholders&#146; meeting and to vote together as a single class of capital stock upon any matter submitted to a stockholder for a vote,
except as to matters pertaining to the rights or obligations of holders of Preferred Stock, when they shall vote as a class, on the following basis: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Holders of Common Stock shall have one vote per share; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Holders of Senior Preferred Stock shall have that number of votes per share as is equal to the number of shares of Common Stock into which
each such share of Senior Preferred Stock held by such holder is convertible at the time of such vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As to all matters with respect to which the Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred
Stock is entitled to vote as a single class, each share of the Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock shall have one vote. As to all matters with respect to which the Series C Preferred Stock is entitled to vote as a
single class, each share of the Series C Preferred Stock shall have one vote. As to all matters with respect to which the Series D Preferred Stock is entitled to vote as a single class, each share of the Series D Preferred Stock shall have one vote.
As to all matters with respect to which the Series E Preferred Stock is entitled to vote as a single class, each share of the Series E Preferred Stock shall have one vote. As to all matters with respect to which the Series F Preferred Stock is
entitled to vote as a single class, each share of the Series F Preferred Stock shall have one vote. As to all matters with respect to which the Series H Preferred Stock is entitled to vote as a single class, each share of the Series H Preferred
Stock shall have one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law, the holders of the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock
shall have no voting rights. As to all matters with respect to which the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock is entitled to vote as required by law, each share of Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Preferred Stock shall have one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2. <U>Election of Board of Directors</U>. The size of the Corporation&#146;s board of
directors shall be fixed at eight (8)&nbsp;members, which number shall not be increased or decreased without the approval or written consent of the Requisite Majority. The holders of the Senior Preferred Stock and the holders of the Common Stock
shall be entitled to vote upon the election of directors on the following basis: (i)&nbsp;four (4) members of the board of directors (&#147;<U>Preferred Directors</U>&#148;) of the Corporation shall be appointed by the vote of holders of a majority
of the Senior Preferred Stock, voting as a separate class; (ii)&nbsp;one (1) member of the board of directors of the Corporation shall be appointed by the vote of the holders of at least a majority of the Common Stock, and (iii)&nbsp;the remaining
members of the board of directors of the Corporation shall be appointed by the vote of the holders of a majority of the Senior Preferred Stock and Common Stock, voting together as a single class. Each director shall serve until he or she resigns,
dies, becomes incapacitated or is removed. A director may only be removed and/or replaced by the holders of that percentage of the class or classes or series of stock which were entitled to appoint him or her. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANDATORY
REDEMPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1. <U>Upon a Redemption Event</U>. Assuming funds are available within the Corporation and redemption would
not put the Corporation at a financial risk, upon the request in writing of the Requisite Majority, on or after a Redemption Event, the Corporation shall redeem, and every holder of Senior Preferred Stock desiring to sell shall sell its outstanding
shares of Senior Preferred Stock at the Redemption Price per share, payable in cash, in each case in accordance with this Section&nbsp;6. The determination of whether funds are available with the Corporation and whether the redemption would put the
Corporation at financial risk shall be made by the Board of Directors and the Requisite Majority , as defined hereinafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2. <U>Upon the Fifth Anniversary of the Initial Issuance of
Series</U><U></U><U>&nbsp;H Preferred Stock</U>. Upon the request in writing of the Requisite Majority, at any time after July&nbsp;11, 2024, the Corporation shall redeem and every holder of Senior Preferred Stock desiring to sell shall sell its
outstanding shares of Senior Preferred Stock at the Redemption Price per share, payable in cash, in each case in accordance with this Section&nbsp;6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3. <U>Mechanics of Redemption</U>. The following provisions shall apply to any redemption pursuant to this Section&nbsp;6: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the Redemption Date, the Corporation shall deposit for the benefit of the holders of the shares of the outstanding Senior Preferred
Stock to be redeemed the funds necessary for the redemption of such outstanding shares of Senior Preferred Stock with a bank or trust company, having a capital and surplus of at least $50,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Holders of shares of Series H Preferred Stock, prior to any redemption of any shares of Series F Preferred Stock, Series E Preferred
Stock, Series D Preferred Stock, Series C Preferred Stock or Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, shall thereafter have the right to receive (i)&nbsp;payment of the Redemption Price for such shares by surrendering to
the Corporation, at its principal office or at such other office or agency maintained by the Corporation for that purpose, a certificate or certificates representing the shares of Series H Preferred Stock or (ii)&nbsp;a certificate or certificates
for the number of shares of Common Stock into which such holder&#146;s shares of Series H Preferred Stock are then convertible pursuant to Section&nbsp;4 hereof, by surrendering a certificate or certificates representing the shares of Series H
Preferred Stock in accordance with the provisions of Section&nbsp;4 hereof, accompanied by any documentation required therein. If the Corporation does not have sufficient funds legally available to redeem all shares of Series H Preferred Stock to be
redeemed pursuant to this Section&nbsp;6.3, then it shall so notify such holders and shall redeem such shares pro rata (based on the portion of the aggregate Redemption Price for the Series H Preferred Stock payable to them) to the extent possible
and shall redeem the remaining shares to be redeemed as soon as sufficient funds are legally available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Holders of shares of Series
F Preferred Stock, prior to any redemption of any shares of Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock or Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, shall thereafter have the right to
receive (i)&nbsp;payment of the Redemption Price for such shares by surrendering to the Corporation, at its principal office or at such other office or agency maintained by the Corporation for that purpose, a certificate or certificates representing
the shares of Series F Preferred Stock or (ii)&nbsp;a certificate or certificates for the number of shares of Common Stock into which such holder&#146;s shares of Series F Preferred Stock are then convertible pursuant to Section&nbsp;4 hereof, by
surrendering a certificate or certificates representing the shares of Series F Preferred Stock in accordance with the provisions of Section&nbsp;4 hereof, accompanied by any documentation required therein. If the Corporation does not have sufficient
funds legally available to redeem all shares of Series F Preferred Stock to be redeemed pursuant to this Section&nbsp;6.3, then it shall so notify such holders and shall redeem such shares pro rata (based on the portion of the aggregate Redemption
Price for the Series F Preferred Stock payable to them) to the extent possible and shall redeem the remaining shares to be redeemed as soon as sufficient funds are legally available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Holders of shares of Series E Preferred Stock, prior to any redemption of any shares
of Series D Preferred Stock, Series C Preferred Stock or Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, shall thereafter have the right to receive (i)&nbsp;payment of the Redemption Price for such shares by surrendering to the
Corporation, at its principal office or at such other office or agency maintained by the Corporation for that purpose, a certificate or certificates representing the shares of Series E Preferred Stock or (ii)&nbsp;a certificate or certificates for
the number of shares of Common Stock into which such holder&#146;s shares of Series E Preferred Stock are then convertible pursuant to Section&nbsp;4 hereof, by surrendering a certificate or certificates representing the shares of Series E Preferred
Stock in accordance with the provisions of Section&nbsp;4 hereof, accompanied by any documentation required therein. If the Corporation does not have sufficient funds legally available to redeem all shares of Series E Preferred Stock to be redeemed
pursuant to this Section&nbsp;6.3, then it shall so notify such holders and shall redeem such shares pro rata (based on the portion of the aggregate Redemption Price for the Series E Preferred Stock payable to them) to the extent possible and shall
redeem the remaining shares to be redeemed as soon as sufficient funds are legally available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Holders of shares of Series D
Preferred Stock, prior to any redemption of any shares of Series C Preferred Stock or Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, shall thereafter have the right to receive (i)&nbsp;payment of the Redemption Price for such
shares by surrendering to the Corporation, at its principal office or at such other office or agency maintained by the Corporation for that purpose, a certificate or certificates representing the shares of Series D Preferred Stock or (ii)&nbsp;a
certificate or certificates for the number of shares of Common Stock into which such holder&#146;s shares of Series D Preferred Stock are then convertible pursuant to Section&nbsp;4 hereof, by surrendering a certificate or certificates representing
the shares of Series D Preferred Stock in accordance with the provisions of Section&nbsp;4 hereof, accompanied by any documentation required therein. If the Corporation does not have sufficient funds legally available to redeem all shares of Series
D Preferred Stock to be redeemed pursuant to this Section&nbsp;6.3, then it shall so notify such holders and shall redeem such shares pro rata (based on the portion of the aggregate Redemption Price for the Series D Preferred Stock payable to them)
to the extent possible and shall redeem the remaining shares to be redeemed as soon as sufficient funds are legally available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)
Holders of shares of Series C Preferred Stock, prior to any redemption of any shares of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock, shall thereafter have the right to receive (i)&nbsp;payment of the Redemption Price for such
shares by surrendering to the Corporation, at its principal office or at such other office or agency maintained by the Corporation for that purpose, a certificate or certificates representing the shares of Series C Preferred Stock or (ii)&nbsp;a
certificate or certificates for the number of shares of Common Stock into which such holder&#146;s shares of Series C Preferred Stock are then convertible pursuant to Section&nbsp;4 hereof, by surrendering a certificate or certificates representing
the shares of Series C Preferred Stock in accordance with the provisions of Section&nbsp;4 hereof, accompanied by any documentation required therein. If the Corporation does not have sufficient funds legally available to redeem all shares of Series
C Preferred Stock to be redeemed pursuant to this Section&nbsp;6.3, then it shall so notify such holders and shall redeem such shares pro rata (based on the portion of the aggregate Redemption Price for the Series C Preferred Stock payable to them)
to the extent possible and shall redeem the remaining shares to be redeemed as soon as sufficient funds are legally available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Subject to the redemption of the Series H Preferred Stock, Series F Preferred Stock,
Series E Preferred Stock, Series D Preferred Stock and Series C Preferred Stock as provided in subsections (i), (ii), (iii), (iv) and (v)&nbsp;above, holders of shares of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock shall
thereafter have the right to receive (i)&nbsp;payment of the Redemption Price for such shares by surrendering to the Corporation, at its principal office or at such other office or agency maintained by the Corporation for that purpose, a certificate
or certificates representing the shares of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock or (ii)&nbsp;a certificate or certificates for the number of shares of Common Stock into which such holder&#146;s shares of Series <FONT
STYLE="white-space:nowrap">B-3</FONT> Preferred Stock are then convertible pursuant to Section&nbsp;4 hereof, by surrendering a certificate or certificates representing the shares of Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock
in accordance with the provisions of Section&nbsp;4 hereof, accompanied by any documentation required therein. If the Corporation does not have sufficient funds legally available to redeem all shares of Series
<FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock to be redeemed pursuant to this Section&nbsp;6.3, then it shall so notify such holders and shall redeem such shares pro rata (based on the portion of the aggregate Redemption Price for the
Series <FONT STYLE="white-space:nowrap">B-3</FONT> Preferred Stock payable to them) to the extent possible and shall redeem the remaining shares to be redeemed as soon as sufficient funds are legally available. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Any monies so deposited by the Corporation with a bank or trust company pursuant to this Section&nbsp;6.3(a) and unclaimed at the end of
one year from the Redemption Date (the &#147;<U>First Anniversary</U>&#148;) shall revert to the general funds of the Corporation. After the First Anniversary, any such bank or trust company shall, upon demand, pay over to the Corporation such
unclaimed amounts and thereupon such bank or trust company shall be relieved of all responsibility in respect thereof to such holder and such holder shall look only to the Corporation for the payment of the Redemption Price. After the First
Anniversary, any holder of shares of Senior Preferred Stock who does not surrender a certificate or certificates representing the shares of Senior Preferred Stock for conversion in accordance with the provisions of Section&nbsp;4 hereof, shall look
only to the Corporation for the payment of the Redemption Price and shall waive and forfeit any rights to convert such shares of Senior Preferred Stock granted hereunder. Any interest accrued on funds so deposited pursuant to this Section&nbsp;6.3
shall be paid from time to time to the Corporation for its own account. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon the deposit of funds pursuant to Section&nbsp;6.3(a)
necessary to effect the redemption of all outstanding shares of the Senior Preferred Stock, notwithstanding that any certificates for such shares shall not have been surrendered for cancellation, the shares represented thereby shall no longer be
deemed outstanding, the rights to receive dividends thereon shall cease to accrue from and after the Redemption Date and all rights of the holders of the shares of the Senior Preferred Stock shall cease and terminate, excepting only the right to
receive the Redemption Price therefor as provided in this Section&nbsp;6 or to convert such shares into shares of Common Stock. If the Corporation does not deposit funds pursuant to Section&nbsp;6.3(a) necessary to effect the redemption of all
outstanding shares of the Senior Preferred Stock, then each outstanding share of Series Preferred Stock shall remain outstanding and all rights of the holders thereof shall continue until such time as a certificate for such shares have been
surrendered for cancellation in connection with the payment of the Redemption Price or converted into shares of Common Stock as provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1. So long as any shares of Senior Preferred Stock shall be outstanding, the Corporation shall not, directly or indirectly by
merger, reorganization, consolidation or other means, without first obtaining the affirmative vote or written consent of the Requisite Majority in addition to any other vote or consent required under the Corporation&#146;s Amended and Restated
Certificate of Incorporation or applicable law: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) alter, change or amend, or waive any provision of, the Corporation&#146;s Amended and
Restated Certificate of Incorporation or the Corporation&#146;s bylaws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) authorize, create or issue any other class or classes of stock
or series&nbsp;of stock or other equity securities or stock appreciation rights or other similar phantom equity rights; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) increase the
authorized or designated number of shares of the Corporation&#146;s capital stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) merge or consolidate into or with another
corporation or entity, sell, lease, license or otherwise dispose of all or substantially all of the Corporation&#146;s assets (whether held directly or indirectly through one or more controlled subsidiaries), or otherwise effect a Liquidation;
provided however, that the prior affirmative vote or prior written consent of H.I.G., for so long as it is a Requisite Party, shall be required for the consummation of any such transaction or Liquidation pursuant to which the holders of Series H
Preferred Stock will be entitled to receive consideration per share of Series H Preferred Stock with a value (as determined in good faith by the Board of Directors) that is less than $0.09424 (subject to appropriate and proportionate adjustments for
stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to the Series H Preferred Stock); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) acquire (whether directly or through a subsidiary) another entity or an interest in another entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) pay or declare any dividend or other distribution on any shares of Common Stock or other securities of the Corporation (except as provided
by Section&nbsp;2); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) increase or decrease the number of directors constituting the Board of Directors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) apply any of its assets to the redemption, retirement, purchase or other acquisition directly or indirectly, through subsidiaries, if any,
or otherwise, of any shares of its capital stock or debt securities, except as provided in Section&nbsp;6 or from officers, directors or employees of or consultants to the Corporation upon termination of employment pursuant to written agreements in
effect on the Filing Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) enter into any agreement to borrow money that would increase the Corporation&#146;s total indebtedness to
be greater than $500,000; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) incur capital expenditure in respect of a single item (or related series of items) in
excess of $500,000 in any one fiscal year of the Corporation or in an aggregate amount in excess of the amount provided for in the annual budget for that fiscal year as approved by the Board of Directors, in each case unless approved by the Board of
Directors (including the approval of a majority of the Preferred Directors); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) reclassify or recapitalize any of its outstanding capital
stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) assign any intellectual property rights of the Corporation or enter into any material agreement with respect to any
intellectual property rights of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) engage in any business outside of the molecular diagnostics or therapeutics industry;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) increase the number of shares reserved for issuance under employee stock incentive plans; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) issue any shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-3</FONT>
Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, or Series F Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2. So long as any shares of Series C Preferred Stock shall be outstanding, the Corporation shall not, directly or indirectly by
merger, reorganization, consolidation or other means, without first obtaining the affirmative vote or written consent of the holders of at least a majority of the then-outstanding shares of Series C Preferred Stock, amend, repeal or modify any of
the rights, privileges or preferences of the Series C Preferred Stock in a manner that disproportionately and adversely affects the voting or other powers, preferences or other special rights or restrictions of the Series C Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3. So long as any shares of Series D Preferred Stock shall be outstanding, the Corporation shall not, directly or indirectly by
merger, reorganization, consolidation or other means, without first obtaining the affirmative vote or written consent of the holders of at least a majority of the then-outstanding shares of Series D Preferred Stock, amend, repeal or modify any of
the rights, privileges or preferences of the Series D Preferred Stock in a manner that disproportionately and adversely affects the voting or other powers, preferences or other special rights or restrictions of the Series D Preferred Stock.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4. So long as any shares of Series E Preferred Stock shall be outstanding, the Corporation shall not, directly or indirectly by
merger, reorganization, consolidation or other means, without first obtaining the affirmative vote or written consent of the holders of at least a majority of the then-outstanding shares of Series E Preferred Stock, amend, repeal or modify any of
the rights, privileges or preferences of the Series E Preferred Stock in a manner that disproportionately and adversely affects the voting or other powers, preferences or other special rights or restrictions of the Series E Preferred Stock.: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5. So long as any shares of Series F Preferred Stock shall be outstanding,
the Corporation shall not, directly or indirectly by merger, reorganization, consolidation or other means, without first obtaining the affirmative vote or written consent of the holders of at least a majority of the then-outstanding shares of Series
F Preferred Stock, amend, repeal or modify any of the rights, privileges or preferences of the Series F Preferred Stock in a manner that disproportionately and adversely affects the voting or other powers, preferences or other special rights or
restrictions of the Series F Preferred Stock.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6. So long as any shares of Series H Preferred Stock shall be outstanding,
the Corporation shall not, directly or indirectly by merger, reorganization, consolidation or other means, without first obtaining the affirmative vote or written consent of the holders of at least a majority of the then-outstanding shares of Series
H Preferred Stock and, for so long as H.I.G. is a Requisite Party, H.I.G., amend, repeal, waive or modify any of the rights, privileges or preferences of the Series H Preferred Stock in a manner that disproportionately and adversely affects the
voting or other powers, preferences or other special rights or restrictions of the Series H Preferred Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NO IMPAIRMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Corporation will not, by amendment of its Amended and Restated Certificate of Incorporation or through any reorganization, transfer of capital stock or assets, consolidation, merger, dissolution, issue of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of the Preferred Stock set forth herein, but will at all times in good faith assist in the carrying out of all such terms. Without limiting the generality of the foregoing, the
Corporation (a)&nbsp;will not increase the par value of any shares of stock receivable on the conversion of any shares of Preferred Stock above the Original Issue Price for such shares of Preferred Stock, and (b)&nbsp;will take such action as may be
necessary or appropriate in order that the Corporation may validly and legally issue fully paid and nonassessable shares of stock on the conversion of the Preferred Stock from time to time outstanding. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESIDUAL
RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All rights accruing to the outstanding shares of the Corporation not expressly provided for to the contrary shall be vested in
the Common Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NO REISSUANCE OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No share or shares of Preferred Stock acquired by the Corporation by reason of redemption, purchase, conversion or otherwise shall be
reissued, and all such shares shall be canceled, retired and eliminated from the shares which the Corporation shall be authorized to issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE FIFTH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATTERS AS TO CREDITORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever a compromise or arrangement is proposed between the Corporation and its creditors or any class of them and/or between the Corporation
and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver
or receivers appointed for the Corporation under Section&nbsp;291 of Title 8 of the Delaware General Corporation Law or on the application of trustees in dissolution or of any receiver or receivers appointed for the Corporation under
Section&nbsp;279 of Title 8 of the Delaware General Corporation Law order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of the Corporation, as the case may be, to be summoned in such manner as
the said court directs. If a majority in number representing <FONT STYLE="white-space:nowrap">three-fourths</FONT> in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of the Corporation, as the case
may be, agree to any compromise or arrangement and to any reorganization of the Corporation as consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which
the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of the Corporation, as the case may be, and also on the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE SIXTH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LIMITATION OF
LIABILITY; INDEMNIFICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors of the Corporation shall be entitled to the benefits of all limitations on the liability of
directors generally that are now or hereafter become available under the Delaware General Corporation Law. Without limiting the generality of the foregoing, no director of the Corporation shall be liable to the Corporation or its stockholders for
monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s duty of loyalty to the Corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the Delaware General Corporation Law or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit. If the Delaware
General Corporation Law is amended after the filing of the Amended and Restated Certificate of Incorporation of which this article is a part to authorize corporate action further eliminating or limiting the personal liability of directors, the
liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. Any repeal or modification of the foregoing paragraph shall be prospective only, and
shall not affect, to the detriment of any director, any limitation on the personal liability of a director of the Corporation existing at the time of such repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall, to the fullest extent permitted by the provisions of Section&nbsp;145 of the General Corporation Law of the State of
Delaware, as the same may be amended and supplemented, indemnify past and present directors, and may indemnify any and all persons whom it shall have power to indemnify under said section from and against any and all expenses, liabilities, or other
matters referred to in or covered by said section, and the indemnification provided for herein shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any <FONT STYLE="white-space:nowrap">by-law,</FONT>
agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director,
officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE SEVENTH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">BY-LAWS</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The original <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Corporation shall be adopted by the incorporator. Thereafter, the
Directors of the Corporation shall have the power to adopt, amend or repeal the <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Corporation, subject to the approval of the required stockholders in accordance with this Amended and Restated
Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE EIGHTH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ELECTION OF DIRECTORS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
election of the directors of the Corporation need not be by written ballot unless the <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Corporation shall so provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE NINTH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPURCHASES OF
COMMON STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with repurchases by the Corporation of its Common Stock from employees, officers, directors, advisors,
consultants or other persons performing services for the Corporation or any subsidiary pursuant to agreements under which the Corporation has the option to repurchase such shares at cost upon the occurrence of certain events, such as the termination
of employment, Sections 502 and 503 of the California Corporations Code shall not apply in their entirety or in part with respect to such repurchases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE TENTH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CORPORATE
OPPORTUNITIES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation renounces any interest or expectancy of the Corporation in, or in being offered an opportunity to
participate in, any Excluded Opportunity. An &#147;<U>Excluded Opportunity</U>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of, any director of
the Corporation who is also a partner, member, stockholder, manager or employee of a Fund (as defined below) or a partner, member, stockholder, manager or employee of an entity that serves as the general partner or in a similar capacity for or
manages such Fund, and that may be a corporate opportunity for both the Corporation and such Fund or any entity in which such Fund hold an investment or interest; provided, however, that nothing herein or otherwise shall limit the Corporation&#146;s
right to pursue or consummate any transaction related to any Excluded Opportunity even if originated by any director or any Fund. For purposes of this Article Tenth, a &#147;<U>Fund</U>&#148; shall mean an entity (or any partner, member, director,
stockholder, employee or agent of any such entity, other than someone who is an employee of the Corporation or any of its subsidiaries) that is a holder of Preferred Stock and that is in the business of investing and reinvesting in other entities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp; * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIRD: This Amended and Restated Certificate of Incorporation has been duly adopted by the Board of Directors of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOURTH: This Amended Restated Certificate of Incorporation has been duly adopted in
accordance with the provisions of Sections 228, 242 and 245 of the Delaware General Corporation Law, chapter 1, title 8, of the Delaware Code and has been approved by a sufficient number of votes cast by the stockholders of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned, the President and Chief Executive Officer of the above
named Corporation, has hereunto signed this Amended and Restated Certificate of Incorporation on the 11<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of July, 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Rocca</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Rocca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exagen Inc.
(the &#147;<U>Corporation</U>&#148;), which originally filed its Certificate of Incorporation with the Secretary of State of Delaware on November&nbsp;17, 2003 under the name Exagen Diagnostics, Inc., and is organized and existing under the General
Corporation Law of the State of Delaware, hereby certifies as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;That the Board of Directors of said
Corporation duly adopted resolutions proposing and declaring advisable the following amendments of the Amended and Restated Certificate of Incorporation (the &#147;<U>Certificate</U>&#148;) of said Corporation. The resolution setting forth the
proposed amendments is as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that Section A of Article Fourth of the Certificate is hereby amended and restated in
its entirety as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;A.&nbsp;&nbsp;&nbsp;&nbsp;The Corporation is authorized to issue two classes of stock:
Common Stock and Preferred Stock. The total number of shares which the Corporation may issue is 1,063,667,059 shares, of which: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;1,369,185 shares are Series A 3 Convertible Preferred Stock and of a par value of one thousandth of
one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series A 3 Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;3,030,584 shares are Series B 3 Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series B 3 Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;16,637,570, shares are Series C Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series C Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;9,708,328 shares are Series D Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series D Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;169,238,239 shares are Series E Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series E Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;358,715,558 shares are Series F Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series F Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;479,967,595 shares are Series H Convertible Preferred Stock and of a par value of <FONT
STYLE="white-space:nowrap">one-thousandth</FONT> of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series H Preferred Stock</U>&#148;); and </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;25,000,000 shares are Common Stock and of a
par value of one thousandth of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Common Stock</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Effective upon the
filing of this Certificate of Amendment with the Secretary of State of the State of Delaware, a <FONT STYLE="white-space:nowrap">1-for-183.635</FONT> reverse stock split for each share of Common Stock outstanding or held in treasury immediately
prior to such time shall automatically and without any action on the part of the holders thereof occur (the &#147;<U>Reverse Stock Split</U>&#148;). The par value of the Common Stock shall remain $0.001 per share. This conversion shall apply to all
shares of Common Stock. No fractional shares of Common Stock shall be issued upon the Reverse Stock Split or otherwise. In lieu of any fractional shares of Common Stock to which the stockholder would otherwise be entitled upon the Reverse Stock
Split, the Corporation shall pay cash equal to such fraction multiplied by the then fair market value of the Common Stock as determined by the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All certificates representing shares of Common Stock outstanding immediately prior to the filing of this Certificate of Amendment shall
immediately after the filing of this Certificate of Amendment represent instead the number of shares of Common Stock as provided above. Notwithstanding the foregoing, any holder of Common Stock may (but shall not be required to) surrender his, her
or its stock certificate or certificates to the Corporation, and upon such surrender the holder may request that the Corporation issue a certificate for the correct number of shares of Common Stock to which the holder is entitled under the
provisions of this Certificate of Amendment. Shares of Common Stock that were outstanding prior to the filing of this Certificate of Amendment, and that are not outstanding after and as a result of the filing of this Certificate of Amendment, shall
resume the status of authorized but unissued shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Common Stock may be increased or
decreased (but not below the number of shares of Common Stock then outstanding) by the affirmative vote of the holders of a majority of the outstanding stock of the Corporation entitled to vote (voting together on an as if converted basis).&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;That thereafter, pursuant to a resolution of the Board of Directors and in lieu of a meeting of stockholders,
the stockholders gave their approval of said amendment by written consent in accordance with the provisions of Section&nbsp;228 of the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;That the aforesaid amendment was duly adopted in accordance with the provisions of Sections 242 and 228 of the
General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;That said amendment shall be executed, filed and recorded in
accordance with Section&nbsp;103 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left
Blank</I>] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Certificate of Amendment has been executed by a duly
authorized officer of the Corporation on this 6th day of September, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Fortunato Ron Rocca</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Fortunato Ron Rocca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d692844dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g692844g69j63.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT
 COLOR="#FFFFFF">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $.01 COMMON STOCK Patient Focused. Discovery Driven. Certificate Number ZQ00000000 EXAGEN INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS
CERTIFIES THAT is the owner of Shares * * 000000 ****************** * * * 000000 ***************** **** 000000 **************** ***** 000000 *************** ****** 000000 ************** SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 30068X 10 3 ** Mr.
Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample
**** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. MR. Alexander
David SAMPLE Sample **** Mr. Alexander David &amp;Sample MRS. Sample **** Mr. Alexander SAMPLE David Sample **** Mr. Alexander &amp; David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr
Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample
**** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander MR. David Sample SAMPLE **** Mr. Alexander David Sample **** &amp;Mr. Alexander MRS. David Sample
SAMPLE **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander
David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.
Sample **** Mr. Sample **000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares ****000000**Shares****000000**Shares****000000**Shares***
*000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares ****000000**Shares****000000**Shares****000000**Shares**** 000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares
****000000**Shares****000000**Shares****000000**Shares****0 00000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares ****000000**Shares****000000**Shares****000000**Shares****00 ***ZERO&acirc;&euro;^HUNDRED THOUSAND
0000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares ****000000**Shares****000000**Shares****000000**Shares****000 000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares
****000000**Shares****000000**Shares****000000**Shares****0000 00**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares ****000000**Shares****000000**Shares****000000**Shares****00000
0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares ****000000**Shares****000000**Shares****000000**Shares****000000 ZERO HUNDRED AND ZERO*** **Shares****000000**Shares****000000**Shares****000000**Shares****000000
**Shares****000000**Shares****000000**Shares****000000**Shares****000000* *Shares****000000**Shares****000000**Shares****000000**Shares****000000 **Shares****000000**Shares****000000**Shares****000000**Shares****000000**
Shares****000000**Shares****000000**Shares****000000**Shares****000000 **Shares****000000**Shares****000000**Shares****000000**Shares****000000**S THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT
www.computershare.com FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Exagen Inc. (hereinafter called the &#147;Company&#148;), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this
Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held subject to all of the provisions of the Articles of Incorporation, as amended, and the By-Laws, as amended, of the Company (copies of
which are on file with the Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Witness the facsimile
seal of the Company and the facsimile signatures of its duly authorized officers. Chief Executive Officer Chief Financial Officer DATED DD-MMM-YYYY COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND &euro;^REGISTRAR,
By AUTHORIZED SIGNATURE SECURITY INSTRUCTIONS ON REVERSE PO BOX 43004, Providence, RI 02940-3004 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares
123456 DTC 12345678 123456789012345 Certificate Numbers Num/No. Denom. Total 1234567890/1234567890 1 1 1 1234567890/1234567890 2 2 2 1234567890/1234567890 3 3 3 1234567890/1234567890 4 4 4 1234567890/1234567890 5 5 5 1234567890/1234567890 6 6 6
Total Transaction 7 Printed by DATA BUSINESS FORMS 1234567 </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g692844g12m29.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">EXAGEN INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH
SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH
PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE ARTICLES OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY,
AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR
DESTROYED STOCK CERTIFICATE, OR HIS LEGAL REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH
CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM&#151;as tenants in common UNIF
GIFT MIN ACT - Custodian (Cust) (Minor) TEN ENT- as tenants by the entireties under Uniform Gifts to Minors Act (State) JT TEN - as joint tenants with right of survivorship UNIF TRF MIN ACT - Custodian (until age ) and not as tenants in common
(Cust) under Uniform Transfers to Minors Act (Minor) (State) Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received, hereby sell, assign and
transfer unto (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the Common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock
on the books of the within-named Company with full power of substitution in the premises. Dated:20 Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers,
Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. Signature: Signature: Notice: The signature to this assignment must correspond with the name as
written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever. SECURITY INSTRUCTIONS THIS IS WATERMARKED PAPER, DO NOT ACCEPT WITHOUT NOTING WATERMARK. HOLD TO LIGHT TO VERIFY WATERMARK. The
IRS requires that the named transfer agent (&#147;we&#148;) report the cost basis of certain shares or units acquired after January 1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or
units using a specific cost basis calculation method, then we have processed as you requested. If you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor
if you need additional information about cost basis. If you do not keep in contact with the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property
laws and transferred to the appropriate state. 1234567 </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d692844dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2">


<IMG SRC="g692844dsp01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12670 High Bluff Drive,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego,
California 92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1.858.523.5400 Fax: +1.858.523.5450</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">September&nbsp;9, 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abu Dhabi</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barcelona</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beijing</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brussels</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Doha</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dubai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D&uuml;sseldorf</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frankfurt</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburg</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los Angeles</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Madrid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Milan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moscow</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Munich</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Jersey</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orange County</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paris</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Riyadh</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rome</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silicon Valley</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tokyo</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington, D.C.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exagen Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1261 Liberty Way, Suite C</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vista CA 92081</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Statement No.</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;333-233446;</FONT> 3,833,334
shares of Common Stock, par value $0.001 per share</U> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special counsel to Exagen Inc., a Delaware corporation (the &#147;Company&#148;), in connection with the proposed issuance of
up to 3,833,334 shares (including up to 500,000 shares subject to the underwriters&#146; option to purchase additional shares) of common stock, $0.001 par value per share (the &#147;Shares&#148;). The Shares are included in a registration statement
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as amended (the &#147;Act&#148;), filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on February&nbsp;1, 2019 (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-233446)</FONT> (as amended, the &#147;Registration Statement&#148;). The term &#147;Shares&#148; shall include any additional shares of common stock registered by the Company pursuant to Rule 462(b) under the
Act in connection with the offering contemplated by the Registration Statement. This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no
opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related Prospectus, other than as expressly stated herein with respect to the issue of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.
With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law
of the State of Delaware and we express no opinion with respect to any other laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set
forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company
against payment therefor in the circumstances contemplated by the form of underwriting agreement most recently filed as an exhibit to the Registration Statement, the issue and sale of the Shares will have been duly authorized by all necessary
corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated
shares provided in the General Corporation Law of the State of Delaware. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>September 9, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g692844dsp02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by
you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under the heading
&#147;Legal Matters.&#148; We further consent to the incorporation by reference of this letter and consent into any registration statement filed pursuant to Rule 462(b) with respect to the Shares. In giving such consent, we do not thereby admit that
we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>d692844dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 INCENTIVE AWARD PLAN </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan&#146;s purpose is to enhance the Company&#146;s ability to attract, retain and motivate persons who make (or are expected to
make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article&nbsp;XI. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION AND DELEGATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Administration</U>. The Plan is administered by the Administrator. The Administrator has authority to determine
which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan,
to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile
inconsistencies in the Plan or any Award Agreement as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#146;s determinations under the Plan are in its sole discretion and will be final and binding on all
persons having or claiming any interest in the Plan or any Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Appointment of Committees</U>. To the
extent Applicable Laws permit, the Board or the Administrator may delegate any or all of its powers under the Plan to one or more Committees or committees of officers of the Company or any of its Subsidiaries. The Board or the Administrator, as
applicable, may rescind any such delegation, abolish any such committee or Committee and/or <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself any previously delegated authority at any time. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK
AVAILABLE FOR AWARDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Number of Shares</U>. Subject to adjustment under Article&nbsp;VIII and the terms
of this Article&nbsp;IV, the maximum number of Shares that may be issued pursuant to Awards under the Plan shall be equal to the Overall Share Limit. As of the Effective Date, the Company will cease granting awards under the Prior Plan; however,
Prior Plan Awards will remain subject to the terms of the applicable Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Share Recycling</U>. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated,
exchanged for or settled in cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Award or Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the
Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. In addition, Shares delivered (either by actual delivery or attestation) to the
Company by a Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation with respect to an Award (including Shares retained by the Company from the
Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any
outstanding Awards shall not count against the Overall Share Limit. Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the Shares authorized for grant under Section&nbsp;4.1 and shall not be
available for future grants of Awards: (i)&nbsp;Shares subject to a Stock Appreciation Right that are not issued in connection with the stock settlement of the Stock Appreciation Right on exercise thereof; and (ii)&nbsp;Shares purchased on the open
market with the cash proceeds from the exercise of Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Stock Option Limitations</U>.
Notwithstanding anything to the contrary herein, no more than 25,000,000&nbsp;Shares may be issued pursuant to the exercise of Incentive Stock Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Substitute Awards</U>. In connection with an entity&#146;s merger or consolidation with the Company or the
Company&#146;s acquisition of an entity&#146;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such entity or its affiliate.
Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute
Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the
exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a
<FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such
<FONT STYLE="white-space:nowrap">pre-existing</FONT> plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration
payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not
be added to the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the <FONT
STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees, Consultants or Directors prior to such acquisition or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation</U>. Notwithstanding any provision to
the contrary in the Plan, the Administrator may establish compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT> Directors from time to time, subject to the limitations in the Plan. The sum of any cash compensation, or other
compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a
<FONT STYLE="white-space:nowrap">non-employee</FONT> Director as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director during any fiscal year of the Company may not exceed $750,000 increased to $1,000,000 in
the fiscal year of a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director&#146;s initial service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director (the &#147;<B><I>Director Limit</I></B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTIONS AND STOCK APPRECIATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to
the limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the
Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock
Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a
combination of the two as the Administrator may determine or provide in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The Administrator will establish each Option&#146;s and Stock Appreciation Right&#146;s exercise price and specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market Value on the
grant date of the Option (subject to Section&nbsp;5.6) or Stock Appreciation Right.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, in the case of an Option or a Stock Appreciation Right that is a Substitute Award, the exercise price per share
of the Shares subject to such Option or Stock Appreciation Right, as applicable, may be less than the Fair Market Value per share on the date of grant; provided that the exercise price of any Substitute Award shall be determined in accordance with
the applicable requirements of Sections 424 and 409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Duration</U>. Each Option or Stock
Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that, subject to Section&nbsp;5.6, the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding the foregoing and
unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (other than an Incentive Stock Option)&nbsp;(i) the exercise of the Option or Stock Appreciation Right is
prohibited by Applicable Law, as determined by the Company, or (ii)&nbsp;Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is 30 days after
the end of the legal prohibition, <FONT STYLE="white-space:nowrap">black-out</FONT> period or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the
ten year term of the applicable Option or Stock Appreciation Right. Notwithstanding the foregoing, to the extent permitted under Applicable Laws, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure
agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#146;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall
terminate immediately upon such violation, unless the Company otherwise determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>. Options
and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation
Right, together with, as applicable, payment in full (i)&nbsp;as specified in Section&nbsp;5.5 for the number of Shares for which the Award is exercised and (ii)&nbsp;as specified in Section&nbsp;9.5 for any applicable taxes. Unless the
Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment </U><U>Upon</U><U> Exercise</U>. Subject to Section&nbsp;10.8, any Company insider trading policy
(including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;cash, wire transfer of immediately available funds or by check
payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;if there is a public market for Shares at the time of exercise, unless the Company otherwise determines,
(A)&nbsp;delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay
the exercise price, or (B)&nbsp;the Participant&#146;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the
exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned
by the Participant valued at their Fair Market Value; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;to the extent permitted by the Administrator,
surrendering Shares then issuable upon the Option&#146;s exercise valued at their Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;to the extent permitted by the Administrator, delivery of a promissory note or any other property that the
Administrator determines is good and valuable consideration; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;to the extent permitted by the Company, any
combination of the above payment forms approved by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Terms of Incentive Stock
Options</U>. The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Code, respectively, and any
other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value
on the Option&#146;s grant date, and the term of the Option will not exceed five years. All Incentive Stock Options will be subject to and construed consistently with Section&nbsp;422 of the Code. By accepting an Incentive Stock Option, the
Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i)&nbsp;two years from the grant date of the Option or
(ii)&nbsp;one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in
such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#147;incentive stock option&#148; under
Section&nbsp;422 of the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code for any reason, including becoming exercisable with respect to Shares
having a fair market value exceeding the $100,000 limitation under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.422-4,</FONT> will be a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED
STOCK; RESTRICTED STOCK UNITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. The Administrator may grant Restricted Stock, or the right
to purchase Restricted Stock, to any Service Provider, subject to the Company&#146;s right to repurchase all or part of such Shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such Shares)
if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in
an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Restricted Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends</U>. Participants holding Shares of Restricted Stock will be entitled to all ordinary cash dividends
paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or
distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to
which they were paid. Notwithstanding anything to the contrary herein, with respect to any award of Restricted Stock, dividends which are paid to holders of Common Stock prior to vesting shall only be paid out to the Participant holding such
Restricted Stock to the extent that the vesting conditions are subsequently satisfied. All such dividend payments will be made no later than March&nbsp;15 of the calendar year following the calendar year in which the right to the dividend payment
becomes nonforfeitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Certificates</U>. The Company may require that the Participant deposit in
escrow with the Company (or its designee) any stock certificates issued in respect of Shares of Restricted Stock, together with a stock power endorsed in blank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>6.3&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Units. </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement</U>. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as
soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#146;s election, in a manner intended to comply with Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder Rights</U>. A Participant will have no rights of a stockholder with respect to Shares subject to any
Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER STOCK OR CASH BASED AWARDS; DIVIDEND EQUIVALENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Stock or Cash Based Awards</U>. Other Stock or Cash Based Awards may be granted to Participants, including
Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any
conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is
otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp; <U>Dividend Equivalents</U>. A grant of Restricted Stock Units or Other Stock or Cash Based Award may provide a
Participant with the right to receive Dividend Equivalents, and no Dividend Equivalents shall be payable with respect to Options or Stock Appreciation Rights. Dividend Equivalents may be paid currently or credited to an account for the Participant,
settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Award with to which the Dividend Equivalents are paid and subject to other terms and conditions as set forth in the Award Agreement.
Notwithstanding anything to the contrary herein, Dividend Equivalents with respect to an Award shall only </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
paid out to the Participant to the extent that the vesting conditions are subsequently satisfied. All such Dividend Equivalent payments will be made no later than March&nbsp;15 of the calendar
year following calendar year in which the right to the Dividend Equivalent payment becomes nonforfeitable, unless determined otherwise by the Administrator or unless deferred in a manner intended to comply with Section&nbsp;409A. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJUSTMENTS FOR CHANGES IN COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND CERTAIN OTHER EVENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity </U><U>Restructuring</U>. In connection with any Equity Restructuring, notwithstanding anything to the
contrary in this Article&nbsp;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding
Award and/or the Award&#146;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section&nbsp;8.1 will be nondiscretionary and final and
binding on the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate Transactions</U>. In the event of any dividend or other distribution (whether in the form of cash,
Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially
all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate
transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems
appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of
time after such change) and either automatically or upon the Participant&#146;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to
(x)&nbsp;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&nbsp;to facilitate such transaction or
event or (z)&nbsp;give effect to such changes in Applicable Laws or accounting principles: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To provide for the
cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the
Participant&#146;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s
rights, in any case, is equal to or less than zero, then the Award may be terminated without payment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To
provide that such Award shall vest and, to the extent applicable, be exercisable as to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof,
or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and/or applicable exercise or purchase price, in
all cases, as determined by the Administrator; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To make adjustments in the number and type of Shares (or other
securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&nbsp;IV on the maximum number and kind of shares which
may be issued) and/or in the terms and conditions of (including the grant or exercise price or applicable performance goals), and the criteria included in, outstanding Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;To replace such Award with other rights or property selected by the Administrator; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable
event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of <FONT STYLE="white-space:nowrap">Non-Assumption</FONT> in a Change in Control</U>.
Notwithstanding the provisions of Section&nbsp;8.2, if a Change in Control occurs and a Participant&#146;s Awards are not continued, converted, assumed, or replaced with a substantially similar award by (a)&nbsp;the Company, or (b)&nbsp;a successor
entity or its parent or subsidiary (an &#147;<B><I>Assumption</I></B>&#148;), and provided that the Participant has not had a Termination of Service, then, immediately prior to the Change in Control, such Awards shall become fully vested,
exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse, in which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to
receive the Change in Control consideration payable to other holders of Common Stock (i)&nbsp;which may be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without
limitation, any escrow, <FONT STYLE="white-space:nowrap">earn-out</FONT> or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and (ii)&nbsp;determined by reference to the number of Shares
subject to such Awards and net of any applicable exercise price; provided that to the extent that any Awards constitute &#147;nonqualified deferred compensation&#148; that may not be paid upon the Change in Control under Section&nbsp;409A without
the imposition of taxes thereon under Section&nbsp;409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents); and
provided, further, that if the amount to which the Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. The
Administrator shall determine whether an Assumption of an Award has occurred in connection with a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Administrative Stand Still</U>. In the event of any pending stock dividend, stock split, combination or exchange
of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any
Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to 60 days before or after such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. Except as expressly provided in the Plan or the Administrator&#146;s action under the Plan, no
Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or
other corporation. Except as expressly provided with respect to an Equity Restructuring under Section&nbsp;8.1 or the Administrator&#146;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into
Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#146;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will
not affect or restrict in any way the Company&#146;s right or power to make or authorize (i)&nbsp;any adjustment, recapitalization, reorganization or other change in the Company&#146;s capital structure or its business, (ii)&nbsp;any merger,
consolidation dissolution or liquidation of the Company or sale of Company assets or (iii)&nbsp;any sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat Participants and
Awards (or portions thereof) differently under this Article&nbsp;VIII. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS APPLICABLE TO AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>. Except as the Administrator may determine or provide in an Award Agreement or otherwise for
Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except for certain beneficiary designations, by will or the laws of descent and
distribution, or, subject to the Administrator&#146;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. Any permitted transfer of an Award hereunder shall be
without consideration, except as required by Applicable Law. References to a Participant, to the extent relevant in the context, will include references to a Participant&#146;s authorized transferee that the Administrator specifically approves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Documentation</U>. Each Award will be evidenced in an Award Agreement, which may be written or electronic, as
the Administrator determines. The Award Agreement will contain the terms and conditions applicable to an Award. Each Award may contain terms and conditions in addition to those set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Discretion</U>. Except as the Plan otherwise provides, each Award may be made alone or in addition or in
relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Status</U>. The Administrator will determine how an authorized leave of absence or any other
change or purported change in a Participant&#146;s Service Provider status affects an Award and the extent to which, and the period during which the Participant, the Participant&#146;s legal representative, conservator, guardian or Designated
Beneficiary may exercise rights under the Award, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>. Each Participant must pay
the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by Applicable Law to be withheld in connection with such Participant&#146;s Awards by the date of the event creating the tax liability. The Company
may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of
any kind otherwise due to a Participant. In the absence of a contrary determination by the Company (or, with respect to withholding pursuant to clause (ii)&nbsp;below with respect to Awards held by individuals subject to Section&nbsp;16 of the
Exchange Act, a contrary determination by the Administrator), all tax withholding obligations will be calculated based on the maximum applicable statutory withholding rates. Subject to Section&nbsp;10.8 and any Company insider trading policy
(including blackout periods), Participants may satisfy such tax obligations (i)&nbsp;in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the
foregoing payment forms if one or more of the payment forms below is permitted, (ii)&nbsp;to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the
Award creating the tax obligation, valued at their Fair Market Value on the date of delivery, (iii)&nbsp;if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A)&nbsp;delivery
(including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax
obligations, or (B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv)&nbsp;to the extent permitted by the Company, any combination of the
foregoing payment forms approved by the Administrator. Notwithstanding any other provision of the Plan, the number of Shares which may be so delivered or retained pursuant to clause (ii)&nbsp;of the immediately preceding sentence shall be limited to
the number of Shares which have a Fair Market Value on the date of delivery or retention no greater than the aggregate amount of such liabilities based on the maximum individual statutory tax rate in the applicable jurisdiction at the time of such
withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America); provided, however, to the extent such Shares were
acquired by Participant from the Company as compensation, the Shares must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#146;s earnings for financial reporting purposes; provided,
further, that, any such Shares delivered or retained shall be rounded up to the nearest whole Share to the extent rounding up to the nearest whole Share does not result in the liability classification of the applicable Award under generally accepted
accounting principles in the United States of America. If any tax withholding obligation will be satisfied under clause (ii)&nbsp;above by the Company&#146;s retention of Shares from the Award creating the tax obligation and there is a public market
for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#146;s behalf some or all of the Shares retained
and to remit the proceeds of the sale to the Company or its designee, and each Participant&#146;s acceptance of an Award under the Plan will constitute the Participant&#146;s authorization to the Company and instruction and authorization to such
brokerage firm to complete the transactions described in this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment of Award; Repricing</U>.
The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. The Participant&#146;s consent to such action will be required unless (i)&nbsp;the action, taking into account any related action, does not materially and adversely affect the
Participant&#146;s rights under the Award, or (ii)&nbsp;the change is permitted under Article&nbsp;VIII or pursuant to Section&nbsp;10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the
approval of the stockholders of the Company, (i)&nbsp;reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or (ii)&nbsp;cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or
Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions on Delivery of Stock</U>. The Company will not be obligated to deliver any Shares under the Plan or
remove restrictions from Shares previously delivered under the Plan until (i)&nbsp;all Award conditions have been met or removed to the Company&#146;s satisfaction, (ii)&nbsp;as determined by the Company, all other legal matters regarding the
issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such
representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#146;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is
necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceleration</U>. The Administrator may at any time provide that any Award will become immediately vested and
fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Cash Settlement</U>. Without limiting the generality of any
other provision of the Plan, the Administrator may provide, in an Award Agreement or subsequent to the grant of an Award, in its discretion, that any Award may be settled in cash, Shares or a combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Broker-Assisted Sales</U>. In the event of a broker-assisted sale of Shares in connection with the payment of
amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&nbsp;9.5: (i) any Shares to be sold through the broker-assisted sale will be sold on the day the payment
first becomes due, or as soon thereafter as practicable; (ii)&nbsp;such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (iii)&nbsp;the applicable Participant will be
responsible for all broker&#146;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (iv)&nbsp;to the
extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (v)&nbsp;the Company and its designees are under
no obligation to arrange for such sale at any particular price; and (vi)&nbsp;in the event the proceeds of such sale are insufficient to satisfy the Participant&#146;s applicable obligation, the Participant may be required to pay immediately upon
demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#146;s obligation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1&nbsp;&nbsp;&nbsp;&nbsp;<U>No Right to Employment or Other Status</U>. No person will have any claim or right to be granted an Award, and
the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company or any of its Subsidiaries. The Company and its Subsidiaries expressly reserves the right at any time to
dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement or in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2&nbsp;&nbsp;&nbsp;&nbsp;<U>No Rights as Stockholder; Certificates</U>. Subject to the Award Agreement, no Participant or Designated
Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise
determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as
applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Date and Term of Plan</U>. Unless earlier terminated by the Board, the Plan will become effective on
the day prior to the Public Trading Date (the &#147;<B><I>Effective Date</I></B>&#148;) and will remain in effect until the tenth anniversary of the earlier of (i)&nbsp;the date the Board adopted the Plan or (ii)&nbsp;the date the Company&#146;s
stockholders approved the Plan, but Awards previously granted may extend beyond that date in accordance with the Plan. Notwithstanding anything to the contrary in the Plan, an Incentive Stock Option may not be granted under the Plan after 10 years
from the earlier of (i)&nbsp;the date the Board adopted the Plan or (ii)&nbsp;the date the Company&#146;s stockholders approved the Plan, but Awards previously granted may extend beyond that date in accordance with the Plan. If the Plan is not
approved by the Company&#146;s stockholders, the Plan will not become effective, no Awards will be granted under the Plan and the Prior Plan will continue in full force and effect in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment of Plan</U>. The Board may amend, suspend or terminate the Plan at any time; provided that no
amendment, other than an increase to the Overall Share Limit, may materially and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adversely affect any Award outstanding at the time of such amendment without the affected Participant&#146;s consent. No Awards may be granted under the Plan during any suspension period or after
the Plan&#146;s termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder
approval of any Plan amendment to the extent necessary to comply with Applicable Laws, or any amendment to increase the Director Limit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Provisions for Foreign Participants</U>. The Administrator may modify Awards granted to Participants who are
foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency,
employee benefit or other matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. The Company intends that all Awards be structured to comply with, or be exempt from,
Section&nbsp;409A, such that no adverse tax consequences, interest, or penalties under Section&nbsp;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#146;s consent,
amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any
such actions intended to (A)&nbsp;exempt this Plan or any Award from Section&nbsp;409A, or (B)&nbsp;comply with Section&nbsp;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an
Award&#146;s grant date. The Company makes no representations or warranties as to an Award&#146;s tax treatment under Section&nbsp;409A or otherwise. The Company will have no obligation under this Section&nbsp;10.6 or otherwise to avoid the taxes,
penalties or interest under Section&nbsp;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant
&#147;nonqualified deferred compensation&#148; subject to taxes, penalties or interest under Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Separation from Service</U>. If an Award constitutes &#147;nonqualified deferred compensation&#148; under
Section&nbsp;409A, any payment or settlement of such Award upon a termination of a Participant&#146;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&nbsp;409A, be made only upon the Participant&#146;s
&#147;separation from service&#148; (within the meaning of Section&nbsp;409A), whether such &#147;separation from service&#148; occurs upon or after the termination of the Participant&#146;s Service Provider relationship. For purposes of this Plan
or any Award Agreement relating to any such payments or benefits, references to a &#147;termination,&#148; &#147;termination of employment&#148; or like terms means a &#147;separation from service.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments to Specified Employees</U>. Notwithstanding any contrary provision in the Plan or any Award Agreement,
any payment(s) of &#147;nonqualified deferred compensation&#148; required to be made under an Award to a &#147;specified employee&#148; (as defined under Section&nbsp;409A and as the Administrator determines) due to his or her &#147;separation from
service&#148; will, to the extent necessary to avoid taxes under Section&nbsp;409A(a)(2)(B)(i) of the Code, be delayed for the <FONT STYLE="white-space:nowrap">six-month</FONT> period immediately following such &#147;separation from service&#148;
(or, if earlier, until the specified employee&#146;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such <FONT STYLE="white-space:nowrap">six-month</FONT> period or as soon as administratively
practicable thereafter (without interest). Any payments of &#147;nonqualified deferred compensation&#148; under such Award payable more than six months following the Participant&#146;s &#147;separation from service&#148; will be paid at the time or
times the payments are otherwise scheduled to be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations on Liability</U>. Notwithstanding any
other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will
not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary. The Company will
indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#146;s administration or interpretation, against any
cost or expense (including attorneys&#146; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#146;s approval) arising from any act or omission concerning this Plan unless arising from such person&#146;s own
fraud or bad faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.8&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>. The Company may, at the
request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares
or other Company securities during a period of up to 180 days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Data Privacy</U>. As a condition for receiving any Award, each Participant explicitly and unambiguously
consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the
Participant&#146;s participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#146;s name, address and telephone number; birthdate; social security,
insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the
&#147;<B><I>Data</I></B>&#148;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#146;s participation in the Plan, and the Company and its
Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#146;s country, or elsewhere, and the
Participant&#146;s country may have different data privacy laws and protections than the recipients&#146; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in
electronic or other form, to implement, administer and manage the Participant&#146;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any
Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#146;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding
such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this
Section&nbsp;10.9 in writing, without cost, by contacting the local human resources representative. If the Participant refuses or withdraws the consents in this Section&nbsp;10.9, the Company may cancel Participant&#146;s ability to participate in
the Plan and, in the Administrator&#146;s discretion, the Participant may forfeit any outstanding Awards. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources
representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any portion of the Plan or any action taken under it is held illegal
or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be
null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.11&nbsp;&nbsp;&nbsp;&nbsp; Governing Documents. If any contradiction occurs between the Plan and any Award Agreement or
other written agreement between a Participant and the Company (or any Subsidiary) that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. The Plan and all Awards will be governed by and interpreted in accordance with the laws of
the State of Delaware, disregarding any state&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles requiring the application of a jurisdiction&#146;s laws other than the State of Delaware.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Claw-back Provisions</U>. All Awards (including, without limitation, any proceeds, gains or other
economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any Shares underlying the Award) shall be subject to the provisions of any claw-back policy implemented by
the Company, including, without limitation, any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as and to the
extent set forth in such claw-back policy or the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Titles and Headings</U>. The titles and
headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#146;s text, rather than such titles or headings, will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Conformity to Securities Laws</U>. Participant acknowledges that the Plan is intended to conform to the extent
necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws permit, the Plan and all Award Agreements will be
deemed amended as necessary to conform to Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.16&nbsp;&nbsp;&nbsp;&nbsp;<U>Relationship to Other Benefits</U>. No payment
under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in
such other plan or an agreement thereunder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in
the Plan, the following words and phrases will have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Administrator</I></B>&#148; means the Board or a Committee to the extent that the Board&#146;s powers
or authority under the Plan have been delegated to such Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Applicable Laws</I></B>&#148;
means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which
the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Award</I></B>&#148; means, individually or collectively, a grant under the Plan of Options, Stock
Appreciation Rights, Restricted Stock, Restricted Stock Units, Dividend Equivalents, or Other Stock or Cash Based Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Award Agreement</I></B>&#148; means a written agreement evidencing an Award, which may be electronic,
that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Board</I></B>&#148; means the Board of Directors of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Change in Control</I></B>&#148; means and includes each of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A transaction or series of transactions (other than an offering of Common Stock to the general public through a
registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&nbsp;and (ii) of subsection&nbsp;(c) below) whereby any &#147;person&#148; or related
&#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections&nbsp;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries
or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board
together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a)&nbsp;or (c)) whose election by the Board or nomination for
election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Directors then still in office who either were Directors at the beginning of the
<FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The consummation by the Company (whether directly involving the Company or indirectly involving the Company through
one or more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related
transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to
represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or
substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#147;<B><I>Successor Entity</I></B>&#148;)) directly or indirectly, at least a majority of the combined voting
power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;after which no person or group beneficially owns voting securities representing 50% or more of the combined voting
power of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause (ii)&nbsp;as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result
of the voting power held in the Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Change in
Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&nbsp;409A, to the extent required to avoid the imposition of additional taxes under
Section&nbsp;409A, the transaction or event described in subsection&nbsp;(a), (b) or (c)&nbsp;with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such
transaction also constitutes a &#147;change in control event,&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall have full and final authority, which shall be exercised in its
discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of
authority in conjunction with a determination of whether a Change in Control is a &#147;change in control event&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> shall be consistent with such
regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, and the
regulations issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Committee</I></B>&#148; means one or more committees or
subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> it
is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3;</FONT> however, a Committee member&#146;s failure to qualify as a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> will not invalidate any Award granted by the Committee that is otherwise validly granted under the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.10&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Company</I></B>&#148; means Exagen Inc., a Delaware corporation, or any successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Consultant</I></B>&#148; means any person, including any adviser, engaged by the Company or any of
its Subsidiaries to render services to such entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Designated Beneficiary</I></B>&#148; means
the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#146;s rights if the Participant dies or becomes incapacitated. Without a Participant&#146;s
effective designation, &#147;Designated Beneficiary&#148; will mean the Participant&#146;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Director</I></B>&#148; means a Board member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.14&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Dividend Equivalents</I></B>&#148; means a right granted to a Participant under the Plan to receive
the equivalent value (in cash or Shares) of dividends paid on Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.15&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Employee</I></B>&#148;
means any employee of the Company or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.16&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Equity Restructuring</I></B>&#148; means,
as determined by the Administrator, a <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transaction between the Company and its stockholders, such as a stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off</FONT> or
recapitalization through a large, nonrecurring cash dividend, or other large, nonrecurring cash dividend, that affects the Shares (or other securities of the Company) or the share price of Common Stock (or other securities of the Company) and causes
a change in the per share value of the Common Stock underlying outstanding Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.17&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Exchange
Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.18&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B><I>Fair Market
Value</I></B>&#148; means, as of any date, the value of a share of Common Stock determined as follows: (a) if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock
as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; (b) if the
Common Stock is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date
preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal </I>or another source the Administrator deems reliable; or (c)&nbsp;without an established market for the Common Stock, the Administrator will determine the
Fair Market Value in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, with respect to any Award granted on the pricing date of the
Company&#146;s initial public offering, the Fair Market Value shall mean the initial public offering price of a Share as set forth in the Company&#146;s final prospectus relating to its initial public offering filed with the Securities and Exchange
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.19&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Greater Than 10% Stockholder</I></B>&#148; means an individual then owning (within
the meaning of Section&nbsp;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined in Section&nbsp;424(e) and (f)&nbsp;of the Code,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.20&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Incentive Stock Option</I></B>&#148; means an Option intended to qualify as an
&#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.21&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</I></B>&#148; means an Option, or portion thereof, not intended or not qualifying as an Incentive Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.22&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Option</I></B>&#148; means an option to purchase Shares, which will either be an Incentive Stock
Option or a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.23&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Other Stock or
Cash Based Awards</I></B>&#148; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property awarded to a Participant under Article&nbsp;VII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.24&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Overall Share Limit</I></B>&#148; means the sum of (a) 2,011,832&nbsp;Shares; (b)&nbsp;any shares of
Common Stock which are subject to Prior Plan Awards which become available for issuance under the Plan pursuant to Article IV (which number added to the Overall Share Limit shall not exceed 663,000&nbsp;shares of Common Stock); and (c)&nbsp;an
annual increase on the first day of each calendar year beginning January&nbsp;1, 2020 and ending on and including January&nbsp;1, 2029, equal to the lesser of (i) 4% of the aggregate number of shares of Common Stock outstanding on the final day of
the immediately preceding calendar year and (ii)&nbsp;such smaller number of Shares as is determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.25&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Participant</I></B>&#148; means a Service Provider who has been granted an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.26&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B><I>Performance Criteria</I></B>&#148; mean the criteria (and adjustments) that the Administrator may
select for an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based
compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit
or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or
cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses;
working capital; earnings or loss per share; adjusted earnings or loss per share; price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives
relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer
service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity,
activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be
measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#146;s performance or the performance of a Subsidiary, division, business segment or
business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.27&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Plan</I></B>&#148; means this 2019 Incentive Award Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.28&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Prior Plan</I></B>&#148; means the Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.29&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Prior Plan Award</I></B>&#148; means an award outstanding under the Prior Plan as of the Effective
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.30&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Public Trading Date</I></B>&#148; means the first date upon which the Common Stock is
listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system, or, if earlier, the date on
which the Company becomes a &#147;publicly held corporation&#148; for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.162-27(c)(1).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.31&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Restricted Stock</I></B>&#148; means Shares awarded to a Participant under Article&nbsp;VI subject to
certain vesting conditions and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.32&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Restricted Stock Unit</I></B>&#148; means an
unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date awarded to a Participant under
Article&nbsp;VI subject to certain vesting conditions and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.33&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.34&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A of the Code and
all regulations, guidance, compliance programs and other interpretative authority thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.35&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.36&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Service Provider</I></B>&#148; means an Employee, Consultant or Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.37&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Shares</I></B>&#148; means shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.38&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Stock Appreciation Right</I></B>&#148; means a stock appreciation right granted under Article&nbsp;V.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.39&nbsp;&nbsp;&nbsp;&nbsp; <B><I>&#147;Subsidiary&#148;</I></B> means any entity (other than the Company), whether domestic or
foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or
interests in one of the other entities in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.40&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Substitute Awards</I></B>&#148; means
Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Subsidiary or
with which the Company or any Subsidiary combines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.41&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Termination of Service</I></B>&#148; means
the date the Participant ceases to be a Service Provider. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>d692844dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019
INCENTIVE AWARD PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exagen Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;) has granted to the participant listed below
(&#147;<B><I>Participant</I></B>&#148;) the stock option (the &#147;<B><I>Option</I></B>&#148;) described in this Stock Option Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;), subject to the terms and conditions of the Exagen Inc. 2019
Incentive Award Plan (as amended from time to time, the &#147;<B><I>Plan</I></B>&#148;) and the Stock Option Agreement attached hereto as <B>Exhibit A</B> (the &#147;<B><I>Agreement</I></B>&#148;), both of which are incorporated into this Grant
Notice by reference. Capitalized terms not specifically defined in this Grant Notice or the Agreement have the meanings given to them in the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[Can be no less than 100% of the FMV on the Grant Date]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shares Subject to the Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Final Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[Can be no later than 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> anniversary of Grant Date]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Commencement Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[To be specified]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[Incentive Stock <FONT STYLE="white-space:nowrap">Option]/[Non-Qualified</FONT> Stock Option]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By accepting (whether in writing, electronically or otherwise) the Option, Participant agrees to be bound by
the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and
fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan,
this Grant Notice or the Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXAGEN INC.</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PARTICIPANT</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[Participant Name]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant of Option</U>. The Company has granted to Participant the Option effective as of the grant date set forth
in the Grant Notice (the &#147;<B><I>Grant Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Incorporation of Terms of Plan</U>. The
Option is subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERIOD OF
EXERCISABILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Commencement of Exercisability</U>. The Option will vest and become exercisable
according to the vesting schedule in the Grant Notice (the &#147;<B><I>Vesting Schedule</I></B>&#148;) except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable
only when a whole Share has accumulated. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, unless the Administrator otherwise determines, the Option will immediately expire and be forfeited as to any portion
that is not vested and exercisable as of Participant&#146;s Termination of Service for any reason (after taking into consideration any accelerated vesting and exercisability which may occur in connection with such Termination of Service). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Duration of Exercisability</U>. The Vesting Schedule is cumulative. Any portion of the Option which vests and
becomes exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Expiration of Option</U>. The Option may not be exercised to any extent by anyone after, and will expire on, the
first of the following to occur: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The final expiration date in the Grant Notice; <I>provided</I>, however, such
final expiration date may be extended pursuant to Section&nbsp;5.3 of the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as the Administrator
may otherwise approve, the expiration of [three months / one year]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>from the date of Participant&#146;s Termination of Service, unless
Participant&#146;s Termination of Service is for Cause (as defined below) [or by reason of Participant&#146;s death or disability]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;[Except as the Administrator may otherwise approve, the expiration of one year from the date of Participant&#146;s
Termination of Service by reason of Participant&#146;s death or disability;]<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Except as the Administrator may otherwise approve, Participant&#146;s Termination of Service for Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this Agreement, &#147;<B><I>Cause</I></B>&#148; means any of the following events that the Board has determined, in </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: Insert <FONT STYLE="white-space:nowrap">one-year</FONT> for board members. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: Do not include for board members. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: Do not include for board members. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
good faith, has occurred: (i)&nbsp;Participant&#146;s failure to substantially perform Participant&#146;s duties (other than a failure resulting from Participant&#146;s disability), including
Participant&#146;s failure to follow any lawful directive from the Board or Participant&#146;s immediate supervisor; (ii)&nbsp;Participant&#146;s violation of any code or standard of behavior generally applicable to Employees or executives of the
Company; (iii)&nbsp;engaging in conduct that may reasonably result in reputational, economic or financial injury to the Company or its affiliates; (iv)&nbsp;Participant&#146;s commission of, indictment for or plea of nolo contendere to a felony, any
crime involving fraud or embezzlement under federal, state or local laws or a crime involving moral turpitude; (v)&nbsp;Participant&#146;s failure to devote substantially all of Participant&#146;s working time to the business of the Company and its
affiliates; (vi)&nbsp;Participant&#146;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its affiliates or while performing Participant&#146;s duties and responsibilities for
the Company or any of its affiliates; (vii)&nbsp;Participant&#146;s commission of an act of fraud, willful misconduct or gross negligence with respect to the Company or its affiliates, or Participant&#146;s material breach of fiduciary duty against
the Company or any of its affiliates; (viii)&nbsp;Participant&#146;s engaging in misconduct in connection with the performance of any of Participant&#146;s duties, including by embezzlement or theft from the Company or its affiliates,
misappropriating funds from the Company or its affiliates or securing or attempting to secure personally any profit in connection with any transaction entered into on behalf of the Company or its affiliates; or (ix)&nbsp;Participant&#146;s active
disloyalty to the Company or its affiliates, including willfully aiding a competitor or improperly disclosing confidential information. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE
OF OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Person Eligible to Exercise</U>. During Participant&#146;s lifetime, only Participant may
exercise the Option. After Participant&#146;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by Participant&#146;s Designated Beneficiary as provided in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial Exercise</U>. Any exercisable portion of the Option or the entire Option, if then wholly exercisable,
may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Withholding</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall withhold, or cause to be withheld, Shares otherwise vesting or issuable under this Option in
satisfaction of any applicable withholding tax obligations. The number of Shares which may be so withheld or surrendered shall be limited to the number of Shares which have a fair market value on the date of withholding no greater than the aggregate
amount of such liabilities based on the maximum individual statutory withholding rates in Participant&#146;s applicable jurisdictions for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such taxable
income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in
connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option. Neither the Company nor any Subsidiary makes any representation or
undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure
the Option to reduce or eliminate Participant&#146;s tax liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments</U>. Participant acknowledges that the Option is subject to adjustment, modification and termination
in certain events as provided in this Agreement and the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notice to be given under the
terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#146;s Secretary at the Company&#146;s principal office or the Secretary&#146;s then-current email address or facsimile number. Any notice
to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant&#146;s last known mailing address, email address or
facsimile number in the Company&#146;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received,
when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized
express shipping company or upon receipt of a facsimile transmission confirmation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Titles</U>. Titles are
provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Conformity to Securities Laws</U>. Participant acknowledges that the Plan, the Grant Notice and this Agreement
are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple
assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of
the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations
Applicable to Section</U><U></U><U>&nbsp;16 Persons</U>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option
will be subject to any additional limitations set forth in any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3)</FONT> that are requirements for the
application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. The Plan, the Grant Notice and this Agreement (including any exhibit&nbsp;hereto)
constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement Severable</U>. In the event that any provision of the Grant Notice or this Agreement is held illegal
or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation on Participant&#146;s Rights</U>. Participation in the Plan confers no rights or interests other than
as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets.
Participant will have only the rights of a general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a
general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Not a Contract of Employment</U>. Nothing in the Plan, the Grant Notice or this Agreement confers upon
Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or
terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. The Grant Notice may be executed in one or more counterparts, including by way of any
electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Stock Options</U>. If the Option is designated as an Incentive Stock Option: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the
option with respect to the shares is granted) with respect to which stock options intended to qualify as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, including the Option, are exercisable for the first time by Participant
during any calendar year exceeds $100,000 or if for any other reason such stock options do not qualify or cease to qualify for treatment as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, such stock options (including the
Option) will be treated as <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. Participant further acknowledges that the rule set forth in the preceding sentence will be applied by taking the Option and other stock options into
account in the order in which they were granted, as determined under Section&nbsp;422(d) of the Code. Participant also acknowledges that if the Option is exercised more than three months after Participant&#146;s Termination of Service, other than by
reason of death or disability, the Option will be taxed as a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Participant will give prompt written notice to the Company of any disposition or other transfer of any Shares
acquired under this Agreement if such disposition or other transfer is made (a)&nbsp;within two years from the Grant Date or (b)&nbsp;within one year after the transfer of such Shares to Participant. Such notice will specify the date of such
disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>d692844dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019
EMPLOYEE STOCK PURCHASE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purposes of
this Exagen Inc. 2019 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the &#147;<B><I>Plan</I></B>&#148;) are to assist Eligible Employees of Exagen Inc., a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of
Section&nbsp;423(b) of the Code, and to help Eligible Employees provide for their future security and to encourage them to remain in the employment of the Company and its Designated Subsidiaries. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
AND CONSTRUCTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context
clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates. Masculine, feminine and neuter pronouns are used interchangeably and each comprehends the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Administrator</I></B>&#148; shall mean the entity that conducts the general administration of the Plan
as provided in Article&nbsp;XI. The term &#147;Administrator&#148; shall refer to the Committee unless the Board has assumed the authority for administration of the Plan as provided in Article&nbsp;XI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Applicable Law</I></B>&#148; shall mean the requirements relating to the administration of equity
incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and
rules of any foreign country or other jurisdiction where rights under this Plan are granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Board</I></B>&#148; shall mean the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Change in Control</I></B>&#148; shall mean </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A transaction or series of transactions (other than an offering of Common Stock to the general public through a
registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&nbsp;and (ii) of subsection&nbsp;(c) below) whereby any &#147;person&#148; or related
&#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections&nbsp;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries
or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board
together with any new director(s) of the Company (other than a director </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a)&nbsp;or (c)) whose election by the Board or nomination for
election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in office who either were directors at the beginning of the
<FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The consummation by the Company (whether directly involving the Company or indirectly involving the Company through
one or more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related
transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to
represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or
substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#147;<B><I>Successor Entity</I></B>&#148;)) directly or indirectly, at least a majority of the combined voting
power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;after which no person or group beneficially owns voting securities representing 50% or more of the combined
voting power of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause (ii)&nbsp;as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a
result of the voting power held in the Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Change
in Control constitutes a payment event with respect to any portion of any right that constitutes &#147;nonqualified deferred compensation,&#148; the transaction or event constituting the Change in Control with respect to such right (or portion
thereof) must also constitute a &#147;change in control event&#148; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.409A-3(i)(5))</FONT> to trigger the payment event for such right, to the extent required by
Section&nbsp;409A of the Code. The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the
occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#147;change in control event&#148; as defined in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> shall be consistent with such regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Code</I></B>&#148; shall mean the Internal Revenue Code of 1986, as amended and the regulations issued
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Common Stock</I></B>&#148; shall mean the common stock of the Company and such other
securities of the Company that may be substituted therefor pursuant to Article&nbsp;VIII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Company</I></B>&#148; shall mean Exagen Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Compensation</I></B>&#148; of an Eligible Employee shall mean the gross cash compensation received by
such Eligible Employee as compensation for services to the Company or any Designated Subsidiary, including prior week adjustment and overtime payments, but excluding vacation pay, holiday pay, jury duty pay, funeral leave pay, military leave pay,
commissions and periodic bonuses, one-time bonuses (e.g., retention or sign on bonuses), education or tuition reimbursements, travel expenses, business and moving reimbursements, income received in connection with any stock options, stock
appreciation rights, restricted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock, restricted stock units or other compensatory equity awards, fringe benefits, other special payments and all contributions made by the Company or any Designated Subsidiary for the
Employee&#146;s benefit under any employee benefit plan now or hereafter established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Designated
Subsidiary</I></B>&#148; shall mean any Subsidiary designated by the Administrator in accordance with Section&nbsp;11.3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Effectiv</I></B>e <B><I>Date</I></B>&#148; shall mean the date the Plan is adopted by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Eligible Employee</I></B>&#148; shall mean an Employee who does not, immediately after any rights
under this Plan are granted, own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of Common Stock and other stock of the Company, a Parent or a Subsidiary (as determined under
Section&nbsp;423(b)(3) of the Code). For purposes of the foregoing sentence, the rules of Section&nbsp;424(d) of the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock
that an Employee may purchase under outstanding options shall be treated as stock owned by the Employee; <U>provided</U>, <U>however</U>, that the Administrator may provide in an Offering Document that an Employee shall not be eligible to
participate in an Offering Period if: (a)&nbsp;such Employee is a highly compensated employee within the meaning of Section&nbsp;423(b)(4)(D) of the Code, (b)&nbsp;such Employee has not met a service requirement designated by the Administrator
pursuant to Section&nbsp;423(b)(4)(A) of the Code (which service requirement may not exceed two years), (c) such Employee&#146;s customary employment is for 20 hours or less per week, (d)&nbsp;such Employee&#146;s customary employment is for less
than five months in any calendar year and/or (e)&nbsp;such Employee is a citizen or resident of a foreign jurisdiction and the grant of a right to purchase Common Stock under the Plan to such Employee would be prohibited under the laws of such
foreign jurisdiction or the grant of a right to purchase Common Stock under the Plan to such Employee in compliance with the laws of such foreign jurisdiction would cause the Plan to violate the requirements of Section&nbsp;423 of the Code, as
determined by the Administrator in its sole discretion; <U>provided</U>, <U>further</U>, that any exclusion in clauses (a), (b), (c), (d) or (e)&nbsp;shall be applied in an identical manner under each Offering Period to all Employees, in accordance
with Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.423-2(e).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Employee</I></B>&#148; shall mean any officer or other employee (as defined in accordance with
Section&nbsp;3401(c) of the Code) of the Company or any Designated Subsidiary. &#147;Employee&#148; shall not include any director of the Company or a Designated Subsidiary who does not render services to the Company or a Designated Subsidiary as an
employee within the meaning of Section&nbsp;3401(c) of the Code. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company or
Designated Subsidiary and meeting the requirements of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2).</FONT> Where the period of leave exceeds three months and the individual&#146;s right to reemployment is not
guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three -month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Enrollment Date</I></B>&#148; shall mean the first Trading Day of each Offering Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Exchange Act</I></B>&#148; shall mean the Securities Exchange Act of 1934, as amended from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.15&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of Common Stock
determined as follows: (a)&nbsp;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such
date, the last day preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable; (b)&nbsp;if the Common Stock is </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date
preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable; or (c)&nbsp;without an established market for the Common Stock, the Administrator will determine the
Fair Market Value in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.16&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Offering Document</I></B>&#148; shall have the meaning given
to such term in Section&nbsp;4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.17&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Offering Period</I></B>&#148; shall have the meaning given to
such term in Section&nbsp;4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.18&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Parent</I></B>&#148; shall mean any corporation, other than the
Company, in an unbroken chain of corporations ending with the Company if, at the time of the determination, each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock
in one of the other corporations in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.19&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Participant</I></B>&#148; shall mean any Eligible
Employee who has executed a subscription agreement and been granted rights to purchase Common Stock pursuant to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.20&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Plan</I></B>&#148; shall mean this Exagen Inc. 2019 Employee Stock Purchase Plan, as it may be amended
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.21&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Purchase Date</I></B>&#148; shall mean the last Trading Day of each Purchase
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.22&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Purchase Period</I></B>&#148; shall refer to one or more periods within an Offering
Period, as designated in the applicable Offering Document; <U>provided</U>, <U>however</U>, that, in the event no Purchase Period is designated by the Administrator in the applicable Offering Document, the Purchase Period for each Offering Period
covered by such Offering Document shall be the same as the applicable Offering Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.23&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Purchase
Price</I></B>&#148; shall mean the purchase price designated by the Administrator in the applicable Offering Document (which purchase price shall not be less than 85% of the Fair Market Value of a Share on the Enrollment Date or on the Purchase
Date, whichever is lower); <U>provided</U>, <U>however</U>, that, in the event no purchase price is designated by the Administrator in the applicable Offering Document, the purchase price for the Offering Periods covered by such Offering Document
shall be 85% of the Fair Market Value of a Share on the Enrollment Date or on the Purchase Date, whichever is lower; <U>provided</U>, <U>further</U>, that the Purchase Price may be adjusted by the Administrator pursuant to Article&nbsp;VIII and
shall not be less than the par value of a Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.24&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Securities</I></B> <B><I>Act</I></B>&#148; shall
mean the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.25&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Share</I></B>&#148; shall mean a share of Common
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.26&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Subsidiary</I></B>&#148; shall mean any corporation, other than the Company, in an
unbroken chain of corporations beginning with the Company if, at the time of the determination, each of the corporations other than the last corporation in an unbroken chain owns stock possessing 50% or more of the total combined voting power of all
classes of stock in one of the other corporations in such chain; <U>provided</U>, however, that a limited liability company or partnership may be treated as a Subsidiary to the extent either (a)&nbsp;such entity is treated as a disregarded entity
under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3(a)</FONT> by reason of the Company or any other Subsidiary that is a corporation being the sole owner of such entity, or (b)&nbsp;such entity elects to be classified
as a corporation under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3(a)</FONT> and such entity would otherwise qualify as a Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.27&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Trading</I></B> <B><I>Day</I></B>&#148; shall mean a
day on which national stock exchanges in the United States are open for trading. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES SUBJECT TO THE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Number of Shares</U>. Subject to Article&nbsp;VIII, the aggregate number of Shares that may be issued pursuant
to rights granted under the Plan shall be 120,000 Shares. In addition to the foregoing, subject to Article&nbsp;VIII, on the first day of each calendar year beginning on January&nbsp;1, 2020 and ending on and including January&nbsp;1, 2029, the
number of Shares available for issuance under the Plan shall be increased by that number of Shares equal to the lesser of (a) 1% of the Shares outstanding on the final day of the immediately preceding calendar year and (b)&nbsp;such smaller number
of Shares as determined by the Board. If any right granted under the Plan shall for any reason terminate without having been exercised, the Common Stock not purchased under such right shall again become available for issuance under the Plan.
Notwithstanding anything in this Section 3.1 to the contrary, the number of Shares that may be issued or transferred pursuant to the rights granted under the Plan shall not exceed an aggregate of 5,000,000 Shares, subject to Article 8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Distributed</U>. Any Common Stock distributed pursuant to the Plan may consist, in whole or in part, of
authorized and unissued Common Stock, treasury stock or Common Stock purchased on the open market. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING PERIODS; OFFERING DOCUMENTS; PURCHASE DATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Offering Periods</U>. The Administrator may from time to time grant or provide for the grant of rights to
purchase Common Stock under the Plan to Eligible Employees during one or more periods (each, an &#147;<B><I>Offering Period</I></B>&#148;) selected by the Administrator. The terms and conditions applicable to each Offering Period shall be set forth
in an &#147;<B><I>Offering Document</I></B>&#148; adopted by the Administrator, which Offering Document shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate. The Administrator shall establish
in each Offering Document one or more Purchase Periods during such Offering Period during which rights granted under the Plan shall be exercised and purchases of Shares carried out during such Offering Period in accordance with such Offering
Document and the Plan. The provisions of separate Offering Periods under the Plan need not be identical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2
&nbsp;&nbsp;&nbsp;&nbsp;<U>Offering Documents</U>. Each Offering Document with respect to an Offering Period shall specify (through incorporation of the provisions of this Plan by reference or otherwise): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the length of the Offering Period, which period shall not exceed 27 months; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the length of the Purchase Period(s) within the Offering Period; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;the maximum number of Shares that may be purchased by any Eligible Employee during such Offering Period, which, in
the absence of a contrary designation by the Administrator specified in the applicable Offering Document, shall be 100,000 Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;in connection with each Offering Period that contains more than one Purchase Period, the maximum aggregate number
of Shares which may be purchased by any Eligible Employee during each Purchase Period, which, in the absence of a contrary designation by the Administrator specified in the applicable Offering Document, shall be 100,000 Shares; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;such other provisions as the Administrator determines are appropriate, subject to the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY AND PARTICIPATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Eligibility</U>. Any Eligible Employee who shall be employed by the Company or a Designated Subsidiary on a
given Enrollment Date for an Offering Period shall be eligible to participate in the Plan during such Offering Period, subject to the requirements of this Article&nbsp;V and the limitations imposed by Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Enrollment in Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise set forth in an Offering Document or determined by the Administrator, an Eligible Employee may
become a Participant in the Plan for an Offering Period by delivering a subscription agreement to the Company by such time prior to the Enrollment Date for such Offering Period (or such other date specified in the Offering Document) designated by
the Administrator and in such form as the Company provides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each subscription agreement shall designate a
whole percentage of such Eligible Employee&#146;s Compensation to be withheld by the Company or the Designated Subsidiary employing such Eligible Employee on each payday during the Offering Period as payroll deductions under the Plan. The designated
percentage may not be less than 1% and may not be more than the maximum percentage specified by the Administrator in the applicable Offering Document (which percentage shall be 20% in the absence of any such designation). The payroll deductions made
for each Participant shall be credited to an account for such Participant under the Plan and shall be deposited with the general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;A Participant may decrease the percentage of Compensation designated in his or her subscription agreement, subject
to the limits of this Section&nbsp;5.2, or may suspend his or her payroll deductions, at any time during an Offering Period; <U>provided</U>, <U>however</U>, that the Administrator may limit the number of changes a Participant may make to his or her
payroll deduction elections during each Offering Period in the applicable Offering Document (and in the absence of any specific designation by the Administrator, a Participant shall be allowed two decreases and one suspension (but no increases) to
his or her payroll deduction elections during each Offering Period with respect to such Offering Period). Any such change or suspension of payroll deductions shall be effective with the first full payroll period following five business days after
the Company&#146;s receipt of the new subscription agreement (or such shorter or longer period as may be specified by the Administrator in the applicable Offering Document). In the event a Participant suspends his or her payroll deductions, such
Participant&#146;s cumulative payroll deductions prior to the suspension shall remain in his or her account and shall be applied to the purchase of Shares on the next occurring Purchase Date and shall not be paid to such Participant unless he or she
withdraws from participation in the Plan pursuant to Article&nbsp;VII. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise set forth in
Section&nbsp;5.8 or in an Offering Document or determined by the Administrator, a Participant may participate in the Plan only by means of payroll deduction and may not make contributions by lump sum payment for any Offering Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Payroll Deductions</U>. Except as otherwise provided in the applicable Offering Document or Section 5.8, payroll
deductions for a Participant shall commence on the first payroll following the Enrollment Date and shall end on the last payroll in the Offering Period to which the Participant&#146;s authorization is applicable, unless sooner terminated by the
Participant as provided in Article VII or suspended by the Participant or the Administrator as provided in Section 5.2 and Section 5.6, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Enrollment</U>. A Participant&#146;s completion of a subscription agreement will enroll such
Participant in the Plan for each subsequent Offering Period on the terms contained therein until the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant either submits a new subscription agreement, withdraws from participation under the Plan as provided in Article&nbsp;VII or otherwise becomes ineligible to participate in the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation on Purchase of Common Stock</U>. An Eligible Employee may be granted rights under the Plan only
if such rights, together with any other rights granted to such Eligible Employee under &#147;employee stock purchase plans&#148; of the Company, any Parent or any Subsidiary, as specified by Section&nbsp;423(b)(8) of the Code, do not permit such
employee&#146;s rights to purchase stock of the Company or any Parent or Subsidiary to accrue at a rate that exceeds $25,000 of the fair market value of such stock (determined as of the first day of the Offering Period during which such rights are
granted) for each calendar year in which such rights are outstanding at any time. This limitation shall be applied in accordance with Section&nbsp;423(b)(8) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Decrease or Suspension of Payroll Deductions</U>. Notwithstanding the foregoing, to the extent necessary to
comply with Section&nbsp;423(b)(8) of the Code and Section&nbsp;5.5 or the other limitations set forth in this Plan, a Participant&#146;s payroll deductions may be suspended by the Administrator at any time during an Offering Period. The balance of
the amount credited to the account of each Participant that has not been applied to the purchase of Shares by reason of Section&nbsp;423(b)(8) of the Code, Section&nbsp;5.5 or the other limitations set forth in this Plan shall be paid to such
Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Employees</U>. In order to facilitate participation in the Plan, the Administrator may provide for such special terms applicable to Participants who are citizens or residents of a foreign jurisdiction, or who are employed by a Designated Subsidiary
outside of the United States, as the Administrator may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. Such special terms may not be more favorable than the terms of rights granted under the Plan to
Eligible Employees who are residents of the United States. Moreover, the Administrator may approve such supplements to, or amendments, restatements or alternative versions of, this Plan as it may consider necessary or appropriate for such purposes
without thereby affecting the terms of this Plan as in effect for any other purpose. No such special terms, supplements, amendments or restatements shall include any provisions that are inconsistent with the terms of this Plan as then in effect
unless this Plan could have been amended to eliminate such inconsistency without further approval by the stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Leave of Absence</U>. During leaves of absence approved by the Company meeting the requirements of Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2)</FONT> under the Code, a Participant may continue participation in the Plan by making cash payments to the Company on his or her normal payday equal to his or her authorized
payroll deduction. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRANT AND EXERCISE OF RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant of Rights</U>. On the Enrollment Date of each Offering Period, each Eligible Employee participating in
such Offering Period shall be granted a right to purchase the maximum number of Shares specified under Section&nbsp;4.2, subject to the limits in Section&nbsp;5.5, and shall have the right to buy, on each Purchase Date during such Offering Period
(at the applicable Purchase Price), such number of whole Shares as is determined by dividing (a)&nbsp;such Participant&#146;s payroll deductions accumulated prior to such Purchase Date and retained in the Participant&#146;s account as of the
Purchase Date, by (b)&nbsp;the applicable Purchase Price (rounded down to the nearest Share). The right shall expire on the earlier of: (x)&nbsp;the last Purchase Date of the Offering Period, (y)&nbsp;last day of the Offering Period and (z)&nbsp;the
date on which the Participant withdraws in accordance with Section&nbsp;7.1 or Section&nbsp;7.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise of Rights</U>. On each Purchase Date, each
Participant&#146;s accumulated payroll deductions and any other additional payments specifically provided for in the applicable Offering Document will be applied to the purchase of whole Shares, up to the maximum number of Shares permitted pursuant
to the terms of the Plan and the applicable Offering Document, at the Purchase Price. No fractional Shares shall be issued upon the exercise of rights granted under the Plan, unless the Offering Document specifically provides otherwise. Any cash in
lieu of fractional Shares remaining after the purchase of whole Shares upon exercise of a purchase right will be carried forward and applied toward the purchase of whole Shares for the following Offering Period, unless the Administrator provides in
the applicable Offering Document that such amounts shall be credited to a Participant&#146;s account and returned to the Participant in one lump sum payment in a subsequent payroll check as soon as practicable after the exercise date. Shares issued
pursuant to the Plan may be evidenced in such manner as the Administrator may determine and may be issued in certificated form or issued pursuant to book-entry procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro Rata Allocation of Shares</U>. If the Administrator determines that, on a given Purchase Date, the number of
Shares with respect to which rights are to be exercised may exceed (a)&nbsp;the number of Shares that were available for issuance under the Plan on the Enrollment Date of the applicable Offering Period, or (b)&nbsp;the number of Shares available for
issuance under the Plan on such Purchase Date, the Administrator may in its sole discretion provide that the Company shall make a pro rata allocation of the Shares available for purchase on such Enrollment Date or Purchase Date, as applicable, in as
uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all Participants for whom rights to purchase Common Stock are to be exercised pursuant to this Article&nbsp;VI on such Purchase Date, and
shall either (i)&nbsp;continue all Offering Periods then in effect, or (ii)&nbsp;terminate any or all Offering Periods then in effect pursuant to Article&nbsp;IX. The Company may make pro rata allocation of the Shares available on the Enrollment
Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional Shares for issuance under the Plan by the Company&#146;s stockholders subsequent to such Enrollment Date. The balance of the
amount credited to the account of each Participant that has not been applied to the purchase of Shares shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>. At the time a Participant&#146;s rights under the Plan are exercised, in whole or in part, or
at the time some or all of the Common Stock issued under the Plan is disposed of, the Participant must make adequate provision for the Company&#146;s federal, state, or other tax withholding obligations, if any, that arise upon the exercise of the
right or the disposition of the Common Stock. At any time, the Company may, but shall not be obligated to, withhold from the Participant&#146;s compensation the amount necessary for the Company to meet applicable withholding obligations, including
any withholding required to make available to the Company any tax deductions or benefits attributable to sale or early disposition of Common Stock by the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions to Issuance of Common Stock</U>. The Company shall not be required to issue or deliver any
certificate or certificates for, or make any book entries evidencing, Shares purchased upon the exercise of rights under the Plan prior to fulfillment of all of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The admission of such Shares to listing on all stock exchanges, if any, on which the Common Stock is then listed;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The completion of any registration or other qualification of such Shares under any state or federal law or
under the rulings or regulations of the Securities and Exchange Commission or any other governmental regulatory body, that the Administrator shall, in its absolute discretion, deem necessary or advisable; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The obtaining of any approval or other clearance from any state
or federal governmental agency that the Administrator shall, in its absolute discretion, determine to be necessary or advisable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The payment to the Company of all amounts that it is required to withhold under federal, state or local law upon
exercise of the rights, if any; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The lapse of such reasonable period of time following the exercise of the
rights as the Administrator may from time to time establish for reasons of administrative convenience. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITHDRAWAL; CESSATION OF ELIGIBILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Withdrawal</U>. A Participant may withdraw all but not less than all of the payroll deductions credited to his
or her account and not yet used to exercise his or her rights under the Plan at any time by giving written notice to the Company in a form acceptable to the Company no later than one week prior to the end of the Offering Period (or such shorter or
longer period specified by the Administrator in the Offering Document). All of the Participant&#146;s payroll deductions credited to his or her account during an Offering Period shall be paid to such Participant as soon as reasonably practicable
after receipt of notice of withdrawal and such Participant&#146;s rights for the Offering Period shall be automatically terminated, and no further payroll deductions for the purchase of Shares shall be made for such Offering Period. If a Participant
withdraws from an Offering Period, payroll deductions shall not resume at the beginning of the next Offering Period unless the Participant is an Eligible Employee and timely delivers to the Company a new subscription agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Future Participation</U>. A Participant&#146;s withdrawal from an Offering Period shall not have any effect upon
his or her eligibility to participate in any similar plan that may hereafter be adopted by the Company or a Designated Subsidiary or in subsequent Offering Periods that commence after the termination of the Offering Period from which the Participant
withdraws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Cessation of Eligibility</U>. Upon a Participant&#146;s ceasing to be an Eligible Employee for
any reason, he or she shall be deemed to have elected to withdraw from the Plan pursuant to this Article&nbsp;VII and the payroll deductions credited to such Participant&#146;s account during the Offering Period shall be paid to such Participant or,
in the case of his or her death, to the person or persons entitled thereto under Section&nbsp;12.4, as soon as reasonably practicable, and such Participant&#146;s rights for the Offering Period shall be automatically terminated.<B> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJUSTMENTS UPON CHANGES IN STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes in Capitalization</U>. Subject to Section 8.3, in the event that the Administrator determines that any
dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), Change in Control, reorganization, merger, amalgamation, consolidation, combination, repurchase, recapitalization, liquidation,
dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, issuance of warrants or other rights to purchase Common
Stock or other securities of the Company, or other similar corporate transaction or event, as determined by the Administrator, affects the Common Stock such that an adjustment is determined by the Administrator to be appropriate in order to prevent
dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any outstanding purchase rights under the Plan, the Administrator shall make equitable adjustments, if any,
to reflect such change with respect to (a) the aggregate number and type of Shares (or other securities or property) that may be issued under the Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including, but not limited to, adjustments of the limitations in Section&nbsp;3.1 and the limitations established in each Offering Document pursuant to Section&nbsp;4.2 on the maximum number of
Shares that may be purchased); (b) the class(es) and number of Shares and price per Share subject to outstanding rights; and (c) the Purchase Price with respect to any outstanding rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Adjustments</U>. Subject to Section&nbsp;8.3, in the event of any transaction or event described in
Section&nbsp;8.1 or any unusual or nonrecurring transactions or events affecting the Company, any affiliate of the Company, or the financial statements of the Company or any affiliate (including without limitation any Change in Control), or of
changes in Applicable Law or accounting principles, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions whenever the Administrator
determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan, to facilitate such
transactions or events or to give effect to such changes in laws, regulations or principles: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To provide for
either (i)&nbsp;termination of any outstanding right in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or (ii)&nbsp;the replacement
of such outstanding right with other rights or property selected by the Administrator in its sole discretion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To provide that the outstanding rights under the Plan shall be assumed by the successor or survivor corporation, or
a parent or subsidiary thereof, or shall be substituted for by similar rights covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and
prices; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To make adjustments in the number and type of Shares (or other securities or property) subject to
outstanding rights under the Plan and/or in the terms and conditions of outstanding rights and rights that may be granted in the future; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To provide that Participants&#146; accumulated payroll deductions may be used to purchase Common Stock prior to the
next occurring Purchase Date on such date as the Administrator determines in its sole discretion and the Participants&#146; rights under the ongoing Offering Period(s) shall be terminated; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;To provide that all outstanding rights shall terminate without being exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<U>No Adjustment </U><U>Under</U><U> Certain Circumstances</U>. No adjustment or action described in this
Article&nbsp;VIII or in any other provision of the Plan shall be authorized to the extent that such adjustment or action would cause the Plan to fail to satisfy the requirements of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4&nbsp;&nbsp;&nbsp;&nbsp;<U>No Other Rights</U>. Except as expressly provided in the Plan, no Participant shall have any rights by reason of
any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the Company or any
other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall
affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares subject to outstanding rights under the Plan or the Purchase Price with respect to any outstanding rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT, MODIFICATION AND TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment, Modification and Termination</U>. The Administrator may amend, suspend or terminate the Plan at any
time and from time to time; <U>provided</U><I>, </I><U>however</U>, that approval of the Company&#146;s stockholders shall be required to amend the Plan to: (a)&nbsp;increase the aggregate number, or change the type, of shares that may be sold
pursuant to rights under the Plan under Section&nbsp;3.1 (other than an adjustment as provided by Article&nbsp;VIII); (b) change the corporations or classes of corporations whose employees may be granted rights under the Plan; or (c)&nbsp;change the
Plan in any manner that would cause the Plan to no longer be an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Changes to Plan</U>. Without stockholder consent and without regard to whether any Participant rights
may be considered to have been adversely affected, to the extent permitted by Section&nbsp;423 of the Code, the Administrator shall be entitled to change or terminate the Offering Periods, limit the frequency and/or number of changes in the amount
withheld from Compensation during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to
adjust for delays or mistakes in the Company&#146;s processing of payroll withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of
Common Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Compensation, and establish such other limitations or procedures as the Administrator determines in its sole discretion to be advisable that are
consistent with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions In the Event of Unfavorable Financial Accounting Consequences</U>. In the
event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable, modify or amend the Plan to
reduce or eliminate such accounting consequence including, but not limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;altering the Purchase Price for
any Offering Period including an Offering Period underway at the time of the change in Purchase Price; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;shortening any Offering Period so that the Offering Period ends on a new Purchase Date, including an Offering
Period underway at the time of the Administrator action; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;allocating Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such modifications or amendments shall not require stockholder approval or the consent of any Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments Upon Termination of Plan</U>. Upon termination of the Plan, the balance in each Participant&#146;s Plan
account shall be refunded as soon as practicable after such termination, without any interest thereon. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM OF PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan
shall be effective on the Effective Date. The effectiveness of the Plan shall be subject to approval of the Plan by the stockholders of the Company within 12 months following the date the Plan is first approved by the Board. No right may be granted
under the Plan prior to such stockholder approval. No </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights may be granted under the Plan during any period of suspension of the Plan or after termination of the Plan. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Administrator</U>. Unless otherwise determined by the Board, the Administrator of the Plan shall be the
Compensation Committee of the Board (or another committee or a subcommittee of the Board to which the Board delegates administration of the Plan) (such committee, the &#147;<B><I>Committee</I></B>&#148;). The Board may at any time vest in the Board
any authority or duties for administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Action by the Administrator</U>. Unless otherwise
established by the Board or in any charter of the Administrator, a majority of the Administrator shall constitute a quorum. The acts of a majority of the members present at any meeting at which a quorum is present and, subject to Applicable Law and
the Bylaws of the Company, acts approved in writing by a majority of the Administrator in lieu of a meeting, shall be deemed the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report
or other information furnished to that member by any officer or other employee of the Company or any Designated Subsidiary, the Company&#146;s independent certified public accountants, or any executive compensation consultant or other professional
retained by the Company to assist in the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority of Administrator</U><U>.
The Administrator shall have the power, subject to,</U> and within the limitations of, the express provisions of the Plan: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To determine when and how rights to purchase Common Stock shall be granted and the provisions of each offering of
such rights (which need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To designate from time to time which Subsidiaries of the Company
shall be Designated Subsidiaries, which designation may be made without the approval of the stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To construe and interpret the Plan and rights granted under it, and to establish, amend and revoke rules and
regulations for its administration. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To amend, suspend or terminate the Plan as provided in Article&nbsp;IX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Generally, to exercise such powers and to perform such acts as the Administrator deems necessary or expedient to
promote the best interests of the Company and its Subsidiaries and to carry out the intent that the Plan be treated as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Decisions Binding</U>. The Administrator&#146;s interpretation of the Plan, any rights granted pursuant to the
Plan, any subscription agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive on all parties. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Restriction upon Assignment</U>. A right granted under the Plan shall not be transferable other than by will or
the applicable laws of descent and distribution, and is exercisable during the Participant&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lifetime only by the Participant. Except as provided in Section&nbsp;12.4 hereof, a right under the Plan may not be exercised to any extent except by the Participant. The Company shall not
recognize and shall be under no duty to recognize any assignment or alienation of the Participant&#146;s interest in the Plan, the Participant&#146;s rights under the Plan or any rights thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights as a Stockholder</U>.<B> </B>With respect to Shares subject to a right granted under the Plan, a
Participant shall not be deemed to be a stockholder of the Company, and the Participant shall not have any of the rights or privileges of a stockholder, until such Shares have been issued to the Participant or his or her nominee following exercise
of the Participant&#146;s rights under the Plan. No adjustments shall be made for dividends (ordinary or extraordinary, whether in cash securities, or other property) or distribution or other rights for which the record date occurs prior to the date
of such issuance, except as otherwise expressly provided herein or as determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest</U>.<B> </B>No interest shall accrue on the payroll deductions or contributions of a Participant under
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Designation of Beneficiary</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A Participant may, in the manner determined by the Administrator, file a written designation of a beneficiary who
is to receive any Shares and/or cash, if any, from the Participant&#146;s account under the Plan in the event of such Participant&#146;s death subsequent to a Purchase Date on which the Participant&#146;s rights are exercised but prior to delivery
to such Participant of such Shares and cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant&#146;s account under the Plan in the event of such Participant&#146;s death prior
to exercise of the Participant&#146;s rights under the Plan. If the Participant is married and resides in a community property state, a designation of a person other than the Participant&#146;s spouse as his or her beneficiary shall not be effective
without the prior written consent of the Participant&#146;s spouse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Such designation of beneficiary may be
changed by the Participant at any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#146;s death, the
Company shall deliver such Shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may
deliver such Shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All notices or other communications by a Participant to the Company under or in connection with
the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal Rights and Privileges</U>. Subject to Section&nbsp;5.7, all Eligible Employees will have equal rights and
privileges under this Plan so that this Plan qualifies as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. Subject to Section&nbsp;5.7, any provision of this Plan that is inconsistent with
Section&nbsp;423 of the Code will, without further act or amendment by the Company, the Board or the Administrator, be reformed to comply with the equal rights and privileges requirement of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Use of Funds</U>. All payroll deductions received or held by the Company under the Plan may be used by the
Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports</U>. Statements of account shall be given to
Participants at least annually, which statements shall set forth the amounts of payroll deductions, the Purchase Price, the number of Shares purchased and the remaining cash balance, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.9&nbsp;&nbsp;&nbsp;&nbsp;<U>No Employment Rights</U>. Nothing in the Plan shall be construed to give any person (including any Eligible
Employee or Participant) the right to remain in the employ of the Company or any Parent or Subsidiary or affect the right of the Company or any Parent or Subsidiary to terminate the employment of any person (including any Eligible Employee or
Participant) at any time, with or without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Disposition of Shares</U>. Each Participant
shall give prompt notice to the Company of any disposition or other transfer of any Shares purchased upon exercise of a right under the Plan if such disposition or transfer is made: (a)&nbsp;within two years from the Enrollment Date of the Offering
Period in which the Shares were purchased or (b)&nbsp;within one year after the Purchase Date on which such Shares were purchased. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other
property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. The Plan and any agreements hereunder shall be administered, interpreted and enforced under
the internal laws of the State of Delaware without regard to conflicts of laws thereof or of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Electronic Forms</U>. To the extent permitted by Applicable Law and in the discretion of the Administrator, an
Eligible Employee may submit any form or notice as set forth herein by means of an electronic form approved by the Administrator. Before the commencement of an Offering Period, the Administrator shall prescribe the time limits within which any such
electronic form shall be submitted to the Administrator with respect to such Offering Period in order to be a valid election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>8
<FILENAME>d692844dex1034.htm
<DESCRIPTION>EX-10.34
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.34</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.34 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g692844ex10_13pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;12, 2010 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thierry Dervieux </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Thierry, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am confirming our offer for you to join Exagen Diagnostics, Inc. as Vice President R&amp;D and Chief Development Officer, with a start date of
November&nbsp;1, 2010. We are offering you an annual salary of $240,000 per year, reimbursement of your moving expenses up to $5,000 and a bonus of $50,000 to be paid when you and your family permanently reside in Albuquerque which must occur on or
before June&nbsp;1, 2011. In addition you will be eligible for the management bonus plan during the year 2011. Your bonus goals and payments will be defined and approved by the board of directors prior to the end of this year. Pending approval by
the Exagen Board of Directors, you will also receive options to purchase 100,000 shares Exagen common stock, to vest in 4 annual portions beginning on the first anniversary date of your employment, at a strike price of $0.28 per share. Such options
will become fully vested upon the acquisition of the company and your employment ceases, for no cause of your own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be eligible to participate in
the Exagen benefits program, a summary of which you will receive under separate cover. Exagen currently has a safe harbor 401K plan and contributes an amount equal to 3% of your annual income into your 401K. There is no vesting period in the 401(k).
In addition, you will accrue 4 weeks (or 120 hours) of paid time off a year in addition to the ten holidays currently recognized by Exagen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will
become eligible to participate in the Exagen benefits program on the first day of the months following your hire date. With a start date of November&nbsp;1, 2010, your eligibility date for benefits is December&nbsp;1, 2010. You will receive the
benefits enrollment information upon written acceptance of the offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are terminated for other than cause you will receive severance payments as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From your start date to one year of employment: 6 months of base salary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From 1 year to 2 years of employment: 9 months of base salary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Greater than 2 years of employment: 12 months of base salary. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employment at Will: This letter is intended to communicate certain terms and conditions of employment with Exagen Diagnostics, Inc. but is not intended to be
and should not be considered an employment contract. Your employment is not for a specific duration and may be terminated by you or Exagen Diagnostics, Inc. at anytime, for any reason or for no reason whatsoever, with or without notice and with or
without cause unless otherwise specified by law. Your employment is &#147;at will.&#148; The &#147;at will&#148; status of your employment may not be altered except by a separate written contract signed by the Chief Executive Officer of Exagen
Diagnostics, Inc. No one other than the Chief Executive Officer has the authority to enter into an employment contract with you. </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will enter into an employee confidentiality and invention agreement effective during your period of
employment. You will enter into an agreement with the company for a license to your provisional patents for methotrexate and thiopuriene under mutually agreed upon terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that you will be working with the company between now and your official start date. For these efforts the company will pay you $112.50/hour or
$900/day as a private contractor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to working with you as a member of the Exagen team. We are excited about the contributions you will
make to the success of our company. If you have any further questions, please do not hesitate to contact me. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Scott Glenn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scott Glenn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">I Accept the Offer Stated Above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Thierry Dervieux</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Thierry Dervieux</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g692844ex10_13pg003.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">September&nbsp;9, 2011 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thierry Dervieux </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Thierry, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We would like to confirm the following contingent upon Board of Director approval the following modifications to your employment with Exagen
Diagnostics Inc. You have signed our offer letter dated October&nbsp;12, 2011 and an Employment Agreement date 10-31-10, both attached. We would like to add the following stipulation: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination of your employment by you for &#147;Good Reason&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Good Reason&#148; shall mean the occurrence of any of the following events without your consent; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A material reduction in your duties or responsibilities following the date of this amendment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The relocation of the company&#146;s principal business location to a point more than two hundred and fifty
(250)&nbsp;miles East of its current Albuquerque location or more than one thousand (1000)&nbsp;miles from your principal residence. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A material reduction by the company of your base salary as defined in your offer letter, as the result of a
company-wide compensation reduction or in connection with similar decreases for the management team of the company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In
the event you terminate your employment for Good reasons as defined above, then the Company shall pay to you: i) any bonus awarded not previously paid, and any accrued and unused vacation benefits. and ii) Severance pay in the form of a lump sum
payment equal to 9 months of base salary and 12 months of base salary one year following the date of this amendment, provided however, that any resignation by you due to any of the following conditions shall only be deemed for Good Reason if:
(i)&nbsp;you give the company written notice of the intent to terminate for Good Reason within ninety (90)&nbsp;days following the first occurrence of the condition(s) that you believe constitutes Good Reason, which notice shall describe such
condition(s); (ii)&nbsp;the Company fails to remedy, if remediable, such condition(s) within thirty (30)&nbsp;days following receipt of the written notice (the &#147;Cure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate &amp; Laboratory Headquarters </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Science &amp;
Technology Park&nbsp;&nbsp;|&nbsp;&nbsp;801 University Blvd. SE, Suite 103&nbsp;&nbsp;|&nbsp;&nbsp;Albuquerque, NM 87016 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIN:
505.272.7966&nbsp;&nbsp;|&nbsp;&nbsp;TOLL-FREE: 866.392.4361&nbsp;&nbsp;|&nbsp;&nbsp;FAX: 505.272.7965&nbsp;&nbsp;|&nbsp;&nbsp;www.exagen.com </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Period&#148;) of such condition(s) from you; and (iii)&nbsp;you actually resign your employment within the first fifteen (60)&nbsp;days after expiration of the Cure Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Allowance</U>: The company agrees to reimburse you for all reasonable travel expenses and accommodations associated with your commute to the company. Since
the company&#146;s offices are an extended distance from your principal residence, the company will allow you to work from your Principal residence up to 50% of the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Relocation</U>: If at a later date you and your family decide to relocate to less than (30)&nbsp;miles from the company&#146;s offices the company agrees
to reimburse you for all moving expenses. In addition the company agrees to award you a fifty thousand ($50,000) relocation bonus payable within thirty days (30)&nbsp;after your permanent move. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Best Regards,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Scott L. Glenn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scott L. Glenn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman/CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attachments:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Offer Letter</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employment Agreement</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics,
Inc.&nbsp;&nbsp;|&nbsp;&nbsp;Proprietary and Confidential </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;6, 2019 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Re:
&nbsp;&nbsp;&nbsp;&nbsp;<U>Offer Letter Amendment</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Thierry: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing you with this letter agreement (the &#147;<B><I>Letter Agreement</I></B>&#148;) to inform you that Exagen Inc. (the
&#147;<B><I>Company</I></B>&#148;) is amending your offer letter with the Company, dated October&nbsp;12, 2010, and Employment Agreement, dated October&nbsp;31, 2010, as amended on September&nbsp;9, 2011 (as amended by this Letter Agreement, the
&#147;<B><I>Offer Letter</I></B>&#148;), to clarify certain terms and conditions of your severance. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severance Payment</U>.&nbsp;&nbsp;&nbsp;&nbsp;Upon a termination of employment by the Company without cause
or by you for Good Reason (as defined in the Offer Letter), the severance payment described in your Offer Letter (the &#147;<B><I>Severance Payment</I></B>&#148;) will be paid in a lump sum on the
30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the termination date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General Release of Claims</U>. As a condition to your receipt of the Severance Payment, you must execute,
return, not rescind and comply with a general release of claims in a form prescribed by the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Code Section</U><U></U><U>&nbsp;409A</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent applicable, the Offer Letter shall be interpreted in accordance with Section&nbsp;409A of the
Internal Revenue Code of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;) and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other such guidance that
may be issued after the date hereof (collectively, &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;). Notwithstanding any provision of the Offer Letter to the contrary, in the event that following the date hereof, the Company
determines that any compensation or benefits payable under the Offer Letter may be subject to Section&nbsp;409A, the Company may adopt such amendments to the Offer Letter or adopt other policies or procedures (including amendments, policies and
procedures with retroactive effect), or take any other actions that the Company determines are necessary or appropriate to preserve the intended tax treatment of the compensation and benefits payable hereunder, including without limitation actions
intended to (i)&nbsp;exempt the compensation and benefits payable under the Offer Letter from Section&nbsp;409A, and/or (ii)&nbsp;comply with the requirements of Section&nbsp;409A, provided, however, that this Section does not, and shall not be
construed so as to, create any obligation on the part of the Company to adopt any such amendments, policies or procedures or to take any other such actions. In no event shall the Company, its affiliates or any of their respective officers, directors
or advisors be liable for any taxes, interest or penalties imposed under Section&nbsp;409A or any corresponding provision of state or local law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any right under the Offer Letter to a series of installment payments shall be treated as a right to a series of
separate payments. Notwithstanding anything to the contrary in the Offer Letter, no compensation or benefits shall be paid to you during the <FONT STYLE="white-space:nowrap">six-month</FONT> period following your &#147;separation from service&#148;
with the Company (within the meaning of Section&nbsp;409A) if the Company determines that paying such amounts at the time or times indicated herein would be a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code. If the payment of
any such amounts is delayed as a result of the previous sentence, then on the first business day following the end of such six-month </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
period (or such earlier date upon which such amount can be paid under Section&nbsp;409A without resulting in a prohibited distribution, including as a result of your death), the Company shall pay
you a <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount equal to the cumulative amount that would have otherwise been payable to you during such period (without interest). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to you under
the Offer Letter constitute &#147;deferred compensation&#148; to which Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv)</FONT> would apply, any such reimbursements or
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid or reimbursed reasonably promptly, but in no event later than December 31st of the year following the year in which the expense was incurred. The amount of any such payments
eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement in any other taxable year, and your right to such payments or reimbursements of any such expenses shall not be subject to
liquidation or exchange for any other benefit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms and provisions of the Offer Letter not amended hereby, either
expressly or by necessary implication, shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please indicate your acknowledgement of, and agreement to,
the terms and conditions set forth in this Letter Agreement by signing a copy of this Letter Agreement and returning it to the Company as soon as practicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Exagen Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Rocca</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Rocca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U><B>Acknowledged, Accepted and Agreed</B>:</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>/s/ Thierry Dervieux
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>9/6/19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>9
<FILENAME>d692844dex1036.htm
<DESCRIPTION>EX-10.36
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.36</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.36 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN DIAGNOSTICS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October&nbsp;7, 2011 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ron, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pleased to confirm our offer for you to join
Exagen Diagnostics, Inc. as President&nbsp;&amp; Chief Executive Officer, with a start date of October&nbsp;17, 2011. This position will be based in our Albuquerque offices, and you will report to the Board of Directors. We are offering you an
annual salary of $300,000, with a 50% potential bonus payment at the board&#146;s discretion which would be prorated in your first partial year of 2011. Pending approval by the Exagen Board of Directors, you will also receive a stock option for
550,000 of Exagen&#146;s common shares, to vest over our standard four year vesting including a one year cliff for the first year and monthly thereafter for 36 months beginning on the first anniversary date of your full-time employment, at a
exercise price of $0.29 per share. Exagen will also guarantee that during the first year of your employment if the company ownership is restructured or recapitalized your total stock option grant will be maintained at five (5)&nbsp;percent of the
fully diluted shares of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are eligible to participate in the Exagen benefits program, a summary of which we can send you under separate
cover. Exagen currently has a safe harbor 401K plan and contributes an amount equal to 3% of your annual income into your 401K. There is no vesting period in the 401(k). In addition, you will accrue 160 hours of paid time off a year in addition to
the ten holidays currently recognized by Exagen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will become eligible to participate in the Exagen benefits program on the first day of the month
following your date of hire. With a start date of October&nbsp;17, 2011, your eligibility date for benefits is November&nbsp;1, 2011. You will receive the benefits enrollment information upon written acceptance of the offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employment at Will: This letter is intended to communicate certain terms and conditions of employment with Exagen Diagnostics, Inc. but is not intended to be
and should not be considered an employment contract. Your employment is not for a specific duration and may be terminated by you or Exagen Diagnostics, Inc. at anytime, for any reason or for no reason whatsoever, with or without notice and with or
without cause unless otherwise specified by law. Your employment is &#147;at will.&#148; The &#147;at will&#148; status of your employment may not be altered except by a separate written contract signed by the Chairman of the Board of Exagen
Diagnostics, Inc. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ron, we look forward to working with you as a member of the Exagen team. We are excited about the
contributions you will make to the success of our company. If you have any further questions, please do not hesitate to contact me. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Accepted</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott L. Glenn</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott L. Glenn</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chairman&nbsp;&amp; CEO</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date
confirmed:</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN INC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;4, 2019 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Offer Letter Amendment</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ron: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing you with this letter
agreement (the &#147;<B><I>Letter Agreement</I></B>&#148;) to inform you that Exagen Inc. (the &#147;<B><I>Company</I></B>&#148;) is amending your offer letter with the Company, dated October&nbsp;7, 2011 (as amended by this Letter Agreement, the
&#147;<B><I>Offer Letter</I></B>&#148;), to provide for severance upon a qualifying termination of employment, subject to the terms and conditions set forth below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severance Payment</U>. Upon a termination of employment by the Company without Cause (as defined below), you
will receive an amount equal to nine months of your base salary, as in effect on the date of termination (the &#147;<B><I>Severance Payment</I></B>&#148;), payable in a lump sum on the 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day
following the termination date. &#147;<B><I>Cause</I></B>&#148; means any of the following events that the Board of Directors of the Company has determined, in good faith, has occurred: (i)&nbsp;your failure to substantially perform your duties
(other than a failure resulting from your disability), including your failure to follow any lawful directive from the Board of Directors of the Company; (ii)&nbsp;your violation of any code or standard of behavior generally applicable to employees
or executives of the Company; (iii)&nbsp;engaging in conduct that may reasonably result in reputational, economic or financial injury to the Company or its affiliates; (iv)&nbsp;your commission of, indictment for or plea of nolo contendere to a
felony, any crime involving fraud or embezzlement under federal, state or local laws or a crime involving moral turpitude; (v)&nbsp;your failure to devote substantially all of your working time to the business of the Company and its affiliates;
(vi)&nbsp;your unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its affiliates or while performing your duties and responsibilities for the Company or any of its affiliates;
(vii)&nbsp;your commission of an act of fraud, willful misconduct or gross negligence with respect to the Company or its affiliates, or your material breach of fiduciary duty against the Company or any of its affiliates; (viii)&nbsp;your engaging in
misconduct in connection with the performance of any of your duties, including by embezzlement or theft from the Company or its affiliates, misappropriating funds from the Company or its affiliates or securing or attempting to secure personally any
profit in connection with any transaction entered into on behalf of the Company or its affiliates; or (ix)&nbsp;your active disloyalty to the Company or its affiliates, including willfully aiding a competitor or improperly disclosing confidential
information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General Release of Claims</U>. As a condition to your receipt of the Severance Payment, you must execute,
return, not rescind and comply with a general release of claims in a form prescribed by the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Code Section</U><U></U><U>&nbsp;409A</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent applicable, the Offer Letter shall be interpreted in accordance with Section&nbsp;409A of the
Internal Revenue Code of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;) and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other such guidance that
may be issued after the date hereof (collectively, &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;). Notwithstanding any provision of the Offer Letter to the contrary, in the event that following the date hereof, the Company
determines that any compensation or benefits payable under the Offer Letter may be subject to Section&nbsp;409A, the Company may adopt such amendments to </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Offer Letter or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect), or take any other actions that the Company determines are necessary
or appropriate to preserve the intended tax treatment of the compensation and benefits payable hereunder, including without limitation actions intended to (i)&nbsp;exempt the compensation and benefits payable under the Offer Letter from
Section&nbsp;409A, and/or (ii)&nbsp;comply with the requirements of Section&nbsp;409A, provided, however, that this Section does not, and shall not be construed so as to, create any obligation on the part of the Company to adopt any such amendments,
policies or procedures or to take any other such actions. In no event shall the Company, its affiliates or any of their respective officers, directors or advisors be liable for any taxes, interest or penalties imposed under Section&nbsp;409A or any
corresponding provision of state or local law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any right under the Offer Letter to a series of installment payments shall be treated as a right to a series of
separate payments. Notwithstanding anything to the contrary in the Offer Letter, no compensation or benefits shall be paid to you during the <FONT STYLE="white-space:nowrap">six-month</FONT> period following your &#147;separation from service&#148;
with the Company (within the meaning of Section&nbsp;409A) if the Company determines that paying such amounts at the time or times indicated herein would be a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code. If the payment of
any such amounts is delayed as a result of the previous sentence, then on the first business day following the end of such <FONT STYLE="white-space:nowrap">six-month</FONT> period (or such earlier date upon which such amount can be paid under
Section&nbsp;409A without resulting in a prohibited distribution, including as a result of your death), the Company shall pay you a <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount equal to the cumulative amount that would have otherwise been
payable to you during such period (without interest). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to you under
the Offer Letter constitute &#147;deferred compensation&#148; to which Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv)</FONT> would apply, any such reimbursements or
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid or reimbursed reasonably promptly, but in no event later than December 31st of the year following the year in which the expense was incurred. The amount of any such payments
eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement in any other taxable year, and your right to such payments or reimbursements of any such expenses shall not be subject to
liquidation or exchange for any other benefit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms and provisions of the Offer Letter not amended hereby, either
expressly or by necessary implication, shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please indicate your acknowledgement of, and agreement to,
the terms and conditions set forth in this Letter Agreement by signing a copy of this Letter Agreement and returning it to the Company as soon as practicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Exagen Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kamal Adawi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kamal Adawi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Acknowledged, Accepted and Agreed</U></B>: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">September&nbsp;4, 2019</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ron Rocca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>10
<FILENAME>d692844dex1037.htm
<DESCRIPTION>EX-10.37
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.37</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.37 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN DIAGNOSTICS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">May&nbsp;16, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kamal Adawi </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Kamal, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am pleased to confirm our offer for you to join
Exagen Diagnostics, Inc. as Chief Financial Officer (CFO), with a start date of Monday, June&nbsp;12. This offer is contingent upon the successful completion of a <FONT STYLE="white-space:nowrap">pre-employment</FONT> background check. This position
will report to <FONT STYLE="white-space:nowrap">CEO-Ron</FONT> Rocca and will be part of the executive team. We are offering you an annual salary of $225,000 with a 20% bonus which will be subject to the company meeting certain performance
expectations. In addition, you will receive options to purchase the company&#146;s common stock contingent upon the approval of the Exagen Board of Directors, the timing of which will also be subject to the Board&#146;s discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are eligible to participate in the Exagen benefits program, a summary of which you will receive separately. Exagen currently has a safe harbor 401K plan
and contributes an amount equal to 3% of your annual income into your 401K. There is no vesting period in the 401(k). In addition, you will accrue 3 weeks (or 120 hours) of paid time off a year in addition to the ten holidays currently recognized by
Exagen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will become eligible to participate in the Exagen benefits program on your date of hire. You will receive the benefits enrollment information
upon written acceptance of the offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employment at Will: This letter is intended to communicate certain terms and conditions of employment with Exagen
Diagnostics, Inc. but is not intended to be and should not be considered an employment contract. Your employment is not for a specific duration and may be terminated by you or Exagen Diagnostics, Inc. at any time, for any reason or for no reason
whatsoever, with or without notice and with or without cause unless otherwise specified by law. Your employment is &#147;at will.&#148; The &#147;at will&#148; status of your employment may not be altered except by a separate written contract signed
by the Chief Executive Officer of Exagen Diagnostics, Inc. No one other than the Chief Executive Officer has the authority to enter an employment contract with you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I look forward to working with you as a member of the Exagen team. We are excited about the contributions you will make to the success of our company. If you
have any further questions, please do not hesitate to contact me. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and return a hard copy to me. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ron Rocca </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; CEO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>www.AviseTest.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>www.Exagen.com</U> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kamal Adawi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">I Accept the Offer Stated Above</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;4, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Offer Letter
Amendment</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Kamal: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing
you with this letter agreement (the &#147;<B><I>Letter Agreement</I></B>&#148;) to inform you that Exagen Inc. (the &#147;<B><I>Company</I></B>&#148;) is amending your offer letter with the Company, dated May&nbsp;16, 2017 (as amended by this Letter
Agreement, the &#147;<B><I>Offer Letter</I></B>&#148;), to provide for severance upon a qualifying termination of employment, subject to the terms and conditions set forth below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severance Payment</U>. Upon a termination of employment by the Company without Cause (as defined below), you
will receive an amount equal to six months of your base salary, as in effect on the date of termination (the &#147;<B><I>Severance Payment</I></B>&#148;), payable in a lump sum on the 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day
following the termination date. &#147;<B><I>Cause</I></B>&#148; means any of the following events that the Board of Directors of the Company has determined, in good faith, has occurred: (i)&nbsp;your failure to substantially perform your duties
(other than a failure resulting from your disability), including your failure to follow any lawful directive from the Board of Directors of the Company or the Company&#146;s Chief Executive Officer; (ii)&nbsp;your violation of any code or standard
of behavior generally applicable to employees or executives of the Company; (iii)&nbsp;engaging in conduct that may reasonably result in reputational, economic or financial injury to the Company or its affiliates; (iv)&nbsp;your commission of,
indictment for or plea of nolo contendere to a felony, any crime involving fraud or embezzlement under federal, state or local laws or a crime involving moral turpitude; (v)&nbsp;your failure to devote substantially all of your working time to the
business of the Company and its affiliates; (vi)&nbsp;your unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its affiliates or while performing your duties and responsibilities
for the Company or any of its affiliates; (vii)&nbsp;your commission of an act of fraud, willful misconduct or gross negligence with respect to the Company or its affiliates, or your material breach of fiduciary duty against the Company or any of
its affiliates; (viii)&nbsp;your engaging in misconduct in connection with the performance of any of your duties, including by embezzlement or theft from the Company or its affiliates, misappropriating funds from the Company or its affiliates or
securing or attempting to secure personally any profit in connection with any transaction entered into on behalf of the Company or its affiliates; or (ix)&nbsp;your active disloyalty to the Company or its affiliates, including willfully aiding a
competitor or improperly disclosing confidential information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General Release of Claims</U>. As a condition to your receipt of the Severance Payment, you must execute,
return, not rescind and comply with a general release of claims in a form prescribed by the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Code Section</U><U></U><U>&nbsp;409A</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent applicable, the Offer Letter shall be interpreted in accordance with Section&nbsp;409A of the
Internal Revenue Code of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;) and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other such guidance that
may be issued after the date hereof (collectively, &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;). Notwithstanding any provision of the Offer Letter to the contrary, in the event that following the date hereof, the Company
determines that any compensation or benefits payable under the Offer Letter may be subject to Section&nbsp;409A, the Company may adopt such amendments to the Offer Letter or adopt other policies or procedures (including amendments, policies and
procedures with retroactive effect), or take any other actions that the Company </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
determines are necessary or appropriate to preserve the intended tax treatment of the compensation and benefits payable hereunder, including without limitation actions intended to (i)&nbsp;exempt
the compensation and benefits payable under the Offer Letter from Section&nbsp;409A, and/or (ii)&nbsp;comply with the requirements of Section&nbsp;409A, provided, however, that this Section does not, and shall not be construed so as to, create any
obligation on the part of the Company to adopt any such amendments, policies or procedures or to take any other such actions. In no event shall the Company, its affiliates or any of their respective officers, directors or advisors be liable for any
taxes, interest or penalties imposed under Section&nbsp;409A or any corresponding provision of state or local law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any right under the Offer Letter to a series of installment payments shall be treated as a right to a series of
separate payments. Notwithstanding anything to the contrary in the Offer Letter, no compensation or benefits shall be paid to you during the <FONT STYLE="white-space:nowrap">six-month</FONT> period following your &#147;separation from service&#148;
with the Company (within the meaning of Section&nbsp;409A) if the Company determines that paying such amounts at the time or times indicated herein would be a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code. If the payment of
any such amounts is delayed as a result of the previous sentence, then on the first business day following the end of such <FONT STYLE="white-space:nowrap">six-month</FONT> period (or such earlier date upon which such amount can be paid under
Section&nbsp;409A without resulting in a prohibited distribution, including as a result of your death), the Company shall pay you a <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount equal to the cumulative amount that would have otherwise been
payable to you during such period (without interest). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to you under
the Offer Letter constitute &#147;deferred compensation&#148; to which Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv)</FONT> would apply, any such reimbursements or
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid or reimbursed reasonably promptly, but in no event later than December 31st of the year following the year in which the expense was incurred. The amount of any such payments
eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement in any other taxable year, and your right to such payments or reimbursements of any such expenses shall not be subject to
liquidation or exchange for any other benefit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms and provisions of the Offer Letter not amended hereby, either
expressly or by necessary implication, shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please indicate your acknowledgement of, and agreement to,
the terms and conditions set forth in this Letter Agreement by signing a copy of this Letter Agreement and returning it to the Company as soon as practicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Exagen Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Fortunato Ron Rocca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fortunato Ron Rocca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Acknowledged, Accepted and Agreed</U></B>: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kamal Adawi</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">September&nbsp;4, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kamal Adawi</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>11
<FILENAME>d692844dex1038.htm
<DESCRIPTION>EX-10.38
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.38</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;10.38 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR COMPENSATION PROGRAM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eligible Directors (as defined below) on the board of
directors (the &#147;<B><I>Board</I></B>&#148;) of Exagen Inc. (the &#147;<B><I>Company</I></B>&#148;) shall be eligible to receive cash and equity compensation as set forth in this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation Program (this &#147;<B><I>Program</I></B>&#148;). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically as set forth herein and without further action of the Board, to each
member of the Board who is not an employee of the Company or any of its parents, affiliates or subsidiaries (each, an &#147;<B><I>Eligible Director</I></B>&#148;), who may be eligible to receive such cash or equity compensation, unless such Eligible
Director declines the receipt of such cash or equity compensation by written notice to the Company. Eligible Directors will include members of the Board who are designated by or affiliated with Sun Mountain Capital, H.I.G. Capital, LLC and
Tullis-Dickerson Capital Focus III, L.P. (the &#147;<B><I>Affiliated Directors</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Program shall become effective upon
the closing of the initial public offering of the Company&#146;s common stock (the &#147;<B><I>Effective Date</I></B>&#148;) and shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended,
modified or terminated by the Board at any time in its sole discretion. No Eligible Director shall have any rights hereunder, except with respect to equity awards granted pursuant to Section&nbsp;2 of this Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Cash Compensation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a.&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Retainers</U>. Each Eligible Director shall be eligible to receive an annual cash retainer
of $50,000 for service on the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Annual Retainers</U>. An Eligible Director
shall be eligible to receive the following additional annual retainers, as applicable: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:7%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Chairman of the Board</U>. An Eligible Director serving as Chairman of the Board shall be
eligible to receive an additional annual retainer of $20,000 for such service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:7%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Audit
Committee</U>. An Eligible Director serving as Chairperson of the Audit Committee shall be eligible to receive an additional annual retainer of $12,000 for such service. An Eligible Director serving as a member of the Audit Committee (other than the
Chairperson) shall be eligible to receive an additional annual retainer of $7,500 for such service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:7%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation Committee</U>. An Eligible Director serving as Chairperson of the Compensation
Committee shall be eligible to receive an additional annual retainer of $10,000 for such service. An Eligible Director serving as a member of the Compensation Committee (other than the Chairperson) shall be eligible to receive an additional annual
retainer of $7,500 for such service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:7%; font-size:10pt; font-family:Times New Roman">(iv) &nbsp;&nbsp;&nbsp;&nbsp;<U>Nominating and Corporate Governance Committee</U>. An
Eligible Director serving as Chairperson of the Nominating and Corporate Governance Committee shall be eligible to receive an additional annual retainer of $9,000 for such service. An Eligible Director serving as a member of the Nominating and
Corporate Governance Committee (other than the Chairperson) shall be eligible to receive an additional annual retainer of $7,500 for such service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Retainers</U>. The annual cash retainers described in Sections&nbsp;1(a) and 1(b) shall
be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than 30&nbsp;days following the end of each calendar quarter. In the event an Eligible
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Director does not serve as a director, or in the applicable positions described in Section&nbsp;1(b), for an entire calendar quarter, the retainer paid to such Eligible Director shall be prorated
for the portion of such calendar quarter actually served as a director, or in such position, as applicable. With respect to each Affiliated Director, any such annual cash retainers shall, when payable, be paid to Sun Mountain Capital, H.I.G.
Capital, LLC or Tullis-Dickerson Capital Focus III, L.P., as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity Compensation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a.&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. Eligible Directors shall be granted the equity awards described below. The awards
described below shall be granted under and shall be subject to the terms and provisions of the Company&#146;s 2019 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (such plan, as may be
amended from time to time, the &#147;<B><I>Equity Plan</I></B>&#148;) and may be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms approved by the Board prior to or in
connection with such grants. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of equity awards hereby are subject in all respects to the terms of the Equity Plan. Capitalized terms not
otherwise defined herein shall have the meanings ascribed to them in the Equity Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b.&nbsp;&nbsp;&nbsp;&nbsp;<U>Initial
Awards</U>. Each Eligible Director who is initially elected or appointed to serve on the Board after the Effective Date automatically shall be granted an option to purchase 15,000 shares of the Company&#146;s common stock (the &#147;<B><I>Initial
Equity Award</I></B>&#148;). The Initial Equity Award shall be granted on the date on which such Eligible Director is appointed or elected to serve on the Board, and shall vest as to 1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the
shares underlying the option on each monthly anniversary of the grant date, subject to such Eligible Director&#146;s continued service through the applicable vesting date, so that the option is fully vested on the third anniversary of the grant
date, subject to such Eligible Director&#146;s continued service through the applicable vesting date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c.&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Awards</U>. An Eligible Director who is serving on the Board as of the date of the annual
meeting of the Company&#146;s stockholders (the &#147;<B><I>Annual Meeting</I></B>&#148;) each calendar year beginning with calendar year 2020 shall be granted, on such Annual Meeting date, an option to purchase 9,000 shares of the Company&#146;s
common stock (an &#147;<B><I>Annual Award</I></B>&#148; and together with the Initial Equity Award, the &#147;<B><I>Director Equity Awards</I></B>&#148;). Each Annual Award shall vest in full on the earlier to occur of (i)&nbsp;the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the applicable grant date and (ii)&nbsp;the date of the next Annual Meeting following the grant date, subject to continued service through the applicable vesting date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d.&nbsp;&nbsp;&nbsp;&nbsp;<U>Accelerated Vesting Events</U>. Notwithstanding the foregoing, an Eligible Director&#146;s
Director Equity Award(s) shall vest in full immediately prior to the occurrence of a Change in Control to the extent outstanding at such time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e.&nbsp;&nbsp;&nbsp;&nbsp;<U>Post-Termination Exercise Period</U>. Except as may otherwise be provided in the applicable award
agreement, any portion of a Director Equity Award which vests and becomes exercisable will remain exercisable until the earlier of the maximum term of the option and the one-year anniversary of the Eligible Director&#146;s Termination of Service,
unless such Termination of Service is for cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation Limits</U>. Notwithstanding anything to the
contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of <FONT STYLE="white-space:nowrap">non-employee</FONT> Director compensation set forth in the Equity Plan, as in effect from
time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">***** </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>d692844dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P ALIGN="right" STYLE="font-family:ARIAL; font-size:10pt"><B>Exhibit 23.1 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><U>Consent of
Independent Registered Public Accounting Firm </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Exagen Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Diego,
California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated May&nbsp;31, 2019, except for
Note&nbsp;16 which is as of August&nbsp;23, 2019 and the &#147;Reverse Stock Split&#148; paragraph of Note&nbsp;17 which is as of September&nbsp;9, 2019, relating to the financial statements of Exagen Inc., which are contained in that Prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We also consent to the reference to us under the caption &#147;Experts&#148; in the Prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ BDO USA, LLP </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Diego, California </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">September&nbsp;9, 2019 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g692844dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844dsp01.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M,)ITU2022 8WL ,G';)H P]6U_1[[XCZLVK+/-9V=JUC$L4)D^9OOGCIU(H
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F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g692844dsp02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844dsp02.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MU8HP P<8YH BT#PHFFZ?>PW[QW$M[=&ZE$2E$5L@@*,Y&,"@#9CTJRBG\Y(
M)-V_))/S8QGZX.,T 7* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
+* "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g692844ex10_13pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844ex10_13pg001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ . ($ P$1  (1 0,1 ?_$ *8  0 ! P4! 0
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MT!N[Q.KHW'KZ1-VQ(8#](;;FV_\ CN8 W]M] 52F P;A[: UT T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M:*)MS[$$##M[%$!'0%\10BA2G(8!*< ,4?;<!#<!V'80]- ;] - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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M?^/_ $T ZB^W4&_]X?CH!N&V^X;;;[_AM^>_Y: UT W_ +?V_OT T T T T
MT T T T T T T T T!H(@'OJ,I**R^@'47\P_GHI)Z+J#03E =A, #[_ .&I
M UZ@VWW#;\_\] :Z : : : : : : : : VF(4VPF* B'L/XA_C[_ (Z#H6"D
M6R5$YE6[=4YS%/UJ-FRAP.0P*)F QDA-NDH &*(CN!@WWWTP@7H))E$! @;E
M] ]/;^X/8-M 4'J1UFZB9/<Q#@'IU  F(8I3"41*4X%,(#L(A[: B2E8;S+J
M2\DXB8CQL)LE.^2,>RC+.AYEPB'09%Q- R:N +(/42&(NF@J+=,PAT&,4.D;
M*W%/,LH'&NH'S9KG745+XPWBH1R#=!1>$Y!KG>N0!P=XV=KKD$S2+%4Y.V0O
M>,'28QC&$1+JS-:?]R0*;B*\V:R*O=9>,%R+%MUUQN$=R#2-'R D4*FHLY<)
MR"":+-0Q-@:ID,=-,  =S;%DIUK6.0;QA_-=\Y9TL;QH))BW7*611BL\FEUE
MC=Q!LD\#MD*X0!F0A5.E1$.G<H ;IV'QRJ?7*?CD=2L$5YMBCU)2?C27+VW?
M<15CL]LP>]9Q!NH7MLW!D$R(_0L0_4)E W*/3N M];?1O[1XFW[1YH% 00>Q
MWC9ED.RB( !,WL2L' J#\LJ+1S$2A%&C9$"E0*4R9U0)_4,&^XMU:^/WC0ME
MXWS9&!DF5GXVOA?%=-G;51?-/]!=5SUI/$DRP@MS-")$$@MP#<04$QSG$@ 8
MG3TP\C0W_;O-HFXC@!'QL'9M4VJ:Z1'&;6B)#_+*#E.+4_3:QVZ#:*W(@*A.
MH%=MRF* F%NICT3U!<KQ7FC3:D!(_CQEGB)$"]]TAEV.:NE/DIJJ+-@^WNW+
M$JC<!'I$RIDEA';K*4HC)NGOE?>-"E+0OF'<2"+@:OXY9SXKE<[&1D R\V>-
MA<,T$$%VY%VT@8ZC!558#=:G2JF %+T;%4/YFKX,:%HA'^9DST9D:'XRCRI)
MQ=-%=5WFY&13KORF[9J7[VG&O%5I!-FV45.(=L3[ID I #</,T]-1H?5-Y/S
M2@HL5U">/$I >,11!O+YPW3CTT3"_(<3LQ347>. V3$ _P!NGT[@J8Q^ABGX
M,:'*NW'F8$C<6*/CM$1?E,Z6<+Y^ OVXQV)A1103("Q7":*3DAU1$VYU4A*F
M!2'$S%'1IC0YM-WY@^^F?[7X\Q;BOTKIA*<@UEOC]KN*+H"+9L4%#KF[:29P
M  Z1,<P ($#S%'?(.*6E?,MLF#>G>.M4YB**+"YN'(=NGU]\$R-4B)0:ZS<"
M-U.L5A[H&43-L38Q=O<4_%@JNICS)HE6^%0?'>N0H]]H5WD'D$BX.D9-\!8U
MXX)4ED@=(* V,+@A!(J'<+T$]##XE0^[&"B>R^9,C<#EQ-X\EW0L!'L%R[GI
MNF63230'<[A7'KK=J[445*"8)B*8)E^OZQZ(3]&"SE]06S2R^90Q2HR>)O'Z
M03&;BHYC<L9M7!,$TUQ=B@W>T5L)C.%03!,AC 4H&$3']-M5N<)?0#C#3_FE
M.J@4N*O'N0 ,X%Z=/*.:UTCH'9/"-4HX5*<@Y07;R!4%%.Z!DS)=1"CN;J3G
M6ZT_U.@+UO:/,PD>*^7B/@4NB,4H>8*CDS+J3I.4$Z!$T&(*5P&YDD2"=3ZA
MZ5>D"B9/JZBW?]M\P4&=L\S2KE-61PUP-!HFJGW&B.3<JJK*)@Y,5=9!88%,
M&JHM$P,D0PJE$ZPE,8H)@)_&N.UY<Y!:?JWS1"\265P_P*,Q!@F*K5#)65B/
M D3FZ%C_ "EXU1#9L'4H1,$Q(< *4R@=1A)5.,$O+G(/HT+3Y?C,P*XQ3P7*
M^19 9PLVR3E9=-X][L8J/P&:L&@#<ID >I"FNXV XH'!;I[@!6"BE;_,'WTB
MJ82X)()_ W7<*99RQT&DC-3;]@J-;,J5JD\+Z%,!C*)B "<@[B4#D&EL\NZH
ML$'&'^!;,RQ^F273RUFMXV:%,80^0S1)3R.7RJ9=OZ1P1*?;<52[])0#FS^7
M@7:!6^'^"0LQ.Q(N#C*68^\3Z5R2*QE"U0"@B*H)J)E(10Y"&$@F.8!W ME[
M/Y@RJIJ-L2<#$T?NCLADC9,S4Z73A2N4R,W8G&O))#)G8JG.9%,HE[R0%ZP*
MIN6RM5MXL;2^0+%M9_,LDH7Y&*/'^X0%4I%2(9*S4@_76,V0!1T@*E:69(,B
M/3*G^HQES) 4O1U";:[;QOC(%-K<O,UVDDGN*?'Z=58J1%UV61,U?[%4H)$=
MBBW7AB)2!?\ R*)@*R ](%*;81$0;.-C5R0*3FX^91$#_&P_P*D@3E3$343R
MGEQEWHA(&8%<*IK5Y4$UW?\ N# '6(I *11 X]8@V<?XR!61NOF%7;O4W.">
M$;5\" C'O$LN9(7CU70=  E\+]/)O#-]TU# J=9,QNI/Z"_7T^>GQ_\ -+[@
M<D-K\MZ(%[>%N%#@J7<6$A<N903*NL!$"HIE,I7!%LW44^0JHL8%3)F,D0J)
M@ QPC*-"Z2EGP!10M_E[3<."OL(\'/A" "T-&9=RJ94QQ%(ITW23^MMT.D2D
M5-W2;C]1"]L=C#J&VO\ S/[@6K*\>855\Z3D< \&&<8DQ5!HZ:9MRL]>.97N
M+?&7.B>H-TTFA&X)]2([B93J_J 7;?R2@EY6VP;F-Y\O*C.15DL!<+F\BLB/
MV]HSS%D!9HT<*I+=@[]V>"15<I(K&(94J90/LF;H,.Y!UY%1?U/ .<1LOE@'
MI[V*>&#;I$0$@9"R8](8PM5%$T4EAC6@]!W($+UG3 _J8X^FV_LE%+1Y8+9M
M=O+&*Z)7F$.'G9(@V.NE_P JWP%U%C@F#H&:2<<HELW$YBD,H=,IQ3,/H!BA
MJ *2=P\N2BRZBV$N%2*!E%1:D#*F2A,S*JQ$6A7(A#&*X,A(% CD4A3$S98Q
MDC=Q,"*@<\-G\J8D9]&+>&:!]D%7Y%LG9./N!RKJ+H("A73%!9(HD)UB $.;
MJ-N( 4! .['Y5TS=;+&_"SH^*)#%/D'*BB@/O3I<H$/$)$<,ND0(9(QT3]11
M$#B'3H!^K/*J1S($#$W"U9$A%#13D,L94364*9(QTPD6QJRHF59)4R9#@F/0
M/U])P#H$0-[BQ>5P[93XV-N$39X:/(LB=7)F7W+5"453)_M#A^F6ZB[=L8XF
M,;8H*='24  W5H"H:Q>584#+(XYX3(.#M7BGPULBY<=B5R=/>.3,X+!-$ *D
MJ4._T)@0Y3;D$!+L<"W&P>5]14YRT'A,U(+%MLB:]9<=C]S,5#Y)CJ!$HI)L
MTOJ$2$ #]6Y0$P=)S 4U+3Y95A<D0QCPB9@FY1(V77R+EE^"[8B8IN%1;HQ3
M R:BJH=PI!6#H+](B<0W$ $_Y;E5U5!H?!9HU['6BV3NV8W;@53-C!VCNE85
M)(.V[]0.">QRAMZ;^@%^A)^615FX,I5^"J#T0'L%-:,TK((G,5,A2_TH1(5D
MT3B<YA,)14 "E+T>HZ W)2/EC,JV%2N<%2("<WSR%F\U**)HD3 J81ZXMR]U
M=PH'6<RR9"I%$2E*<0 Q@*#J=\M(.%RM\?\ !)5H!>XV4&\YI37,)CJ 5JJ4
M]?,F!FY0*)U@V!7J$"D3Z>HWL5%OS= 6R\[Y9/F@4<<<&Q9*D2V-_P B9B3<
MH+;N.\0 _2QDUD!(5, /L4X"8?I';UE)5K6#;8.+<S?E[ H"VQOP4.<CA)$$
MSW[+YRJ-0='!1THX& ;'(H#(I3 F5/\ J*F$O4F4.H8 DEVD_LO1TH?=>SV]
:]EOA?.^-MW>WW>_\'YOKT]?7V_3??UT!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g692844ex10_13pg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844ex10_13pg003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 5P$L P$1  (1 0,1 ?_$ *X  0 !! (# 0
M       ) 0<("@8+ @,%! $!  (# 0$! 0            (# 00%!@@'"1
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MDHL\)@3A!QT#@2HTCK[6<YSZB'C&<#P'KOS(S8H;P4?PKG1Y 7+]%C_.3;Q
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M !8-H7/FH) MX7/8]JT_87LQO;&+)+GMZG+3.6=R;DG7O<Z $V[ZF_46V/\
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M5^G-P0\QL6LTM4?0C0K4Z=6>,/N$@,(S@WG5QN$,W'IR<N1!#B/(T8WEK[E
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M6-A2UH$^!P@RLPHSV8R> R$X_P#OYIL6-MP'HM*!/8_S^G8V7N22#;6U8_\
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M6C,%-[&V4L%:YML<1%+$F FM!@S,Y+,P(-D>*TD<,@(O,TEAW"1*'DD:]K(
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MW(LU8F&'.1*2C\>CP?[W,]IX*</@X69%C&>2:220*T<K-:[H9$]0)& 8]P8
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MML,PTI\F*71N290D -[P$C]9+,D?N%,=6$;PXRQ(6-@K^E8&_0?43J; &N-
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GQ2G%*<4IQ2J9QC./7[<?/./GZ>N/OXI5>*4XI3BE.*4XI3BE?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g692844g12m29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844g12m29.jpg
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M$0'_Q #.  $  @,! 0$! 0          !@<$!0@#"0(!"@$! 0$  P$! 0
M          $" P0%!@<($  !! ("  0# P@&!@8' @\% @,$!@$'  @1$A,4
M%18)EA=7(=255M;7&%@B(Z75EY@QTR15N!E!,C5V=SAA)3:V-[=X44(S0S0F
M<:%25"?PD;'A8GD1  (" @$# @4"! ,&!@( !P ! @,1!!(A!08Q$T%1(A0'
M82-Q@3(5\+$(D:'!0B06T>'Q4C,E8A=R-(*20R88_]H # ,!  (1 Q$ /P#_
M '\< < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < H:)?]XO#Q\B5U]1#GR+ D
M=/'?>S5)&!P'+$1S-C]XV.2S,REYYUOV:,8>SZ/F\?!>.?>6]@\'AL65U>0.
M=$=?G&?V%ZYVYDO9XN>8]%%^X_I^K&.C/R?7\N_*5FG3=L>(*K;GM^W97_=M
M67MT<8O[CFJ\3ZN4?:6)_1G.)(])E]W:S&+.Q- HFR(=C;&BHOWK56-\8KRD
M$E.6;+S@]2!V6UQ8R?9.84]GW7CYOZM7CFGL/A,[*HW=_<*YZSG.7V-[]NW,
M,4X4\SSRF_<6(_1Z?4C>SY;^4*J=B>MXBK;J]Q5U1_NNK'WM=JW.SR=>*\.-
M:]F69OW<Y^B6?8C>MT1OFGX?H=!/X44B1*S_ /Q2J\+YL&//S42BV?6'J^ ^
MT989<]!_SN.>OY<9QE"O'&OV+PRS[7[COSJ]VJ4KO^AOE[$THN-?2?[O)N2Y
M1PEQR_ZD<NYY5^2Z?OOM/%%?[%\8:W_VFK#[JIRFI6]:W['",82]N>92YX3S
M%GZG7G<T=VQHA:*1/;&1!;U>=^]"L1/F:7*>'()0\H=@*4%^%,R9"_4>\R7_
M &WE3C&7$^$H['X;9'6=_?77*V<U:OLKI>S&*FX2RI?N<VH+$<.//+SQ9=OR
MG\E4SW%J^**Z%-=3UW_<]:'W,Y2K5D,.O]GVHRLERGE3]K$<.<<?QV\[F0\0
M0UHE#K4:L0"D![[T:PW\2LDAD2N=5?35 RJ'@>]+E(]\OQ8>]GYDIQAU'@CV
M/PQPK<N^M3EM2A)?97/A2G8HWYY?5S48/VE]4?<PW]#)/RK\E1LNC#Q12KAH
MUVUO^Z:J]S9E&IV:N/;^CVY3MC[[S"?LY22LCC^IO.YLNL(5HE"6EU-\N\[]
MZ-8SZ%I;B2GF*?Z>('F=Q(E--,_$,?[.CU?/E/@G/#['X;QDUWU\EMJM+[*[
MK0Y13V,\^F(N4O:_K?'&<M%7E/Y*YQB_%5P>A*UO^YZWT[2A)QU,>WUY248?
M<?\ QKGR:Q%B+>=S.O T2M$HB-3PI6:;>^]&L/\ P Q$R9^& \-MP,**X+8A
M0\^Y:\K4?WO]+&?17XK>Q^&PA>ZN^N<Z[H1K7V5R]VN7M\[<N7T>WRL^B692
M]OH_K6)K^5?DNRS5C?XHJZ[=:V=S_NFK+V+H>][5&%7^[[O"G]V.(U^_]2?M
M2R'7G<TE=720T4@8@K(GMV9?WH5B;\IL1Y&&X,C"68"<GOB$?^M\C'DRU_U5
M>.>-CL?AM:VGK]]=KJC%TK[*Z/OMK,EUG^UP?3,L\O5&M/RG\DW2T5M^*JF-
M\YK9?]SUI_:QC+$)=*U[_./U8AAQ]'U/&!?-V2&J\N=H- YTB?>'GV?O5JTO
MY;!(4)PS8L.-#TI,Y?Q+E9]FSY74^S_*K^M1X;V.P^%5SV%1W]V1KUU.I_8W
MQ]ZU^YFG#G^WCC#]R68OW/3Z&<.IY9^3[H:<MKQ)4SNVY5["_NNK/[:A>SC8
MRJU[W+G;^S#$U[/5_N1Q^,7[=V8:'LZ 1B6JR9&+A?>O5<^G7<-(7BS^Y^'>
MFO.7591[+&/6_H^/F\,\K[#X3[S@N_OV?MN:E]C?UMR_V<<\^G7W/Z>N,$7E
MOY0>LK7XBEL/<]MP_NNKTU\)_<\O;P^N5[/]?3.>I^I]]W;'8.N0= H(/P+"
MT."1_O6JL3X^ 7@KZECRZZ/4@5EK,2+_ +&[YGE>[_(K^J7XJ.P^$V3HC?W]
MUPLUW.Q_8WR]JWZ,4X4_KSRG^Y'$5[?I]:PV_+?R?35M3U?$5=;5N*NF/]UU
M8>_0_=SL9=;56.%7[,LS?N^O[<L^Q&];GC*M.!^B4$TBIL)BLJSM&L0OFR&_
M(>;F3LX>@+^ ^Q80ASTG_.IWS^5.<93GG'K]C\,L6K]QWUU.V$G=_P!%=+V)
M))QCTG^[R;:Y1PHXR_4YMSRG\E4O>6IXHKEKVPCK?_9ZT/NH.4E.?6M^QPBE
M+C/+ERPNJ9_9EYW,RZ?1$T2B:T/%BI8)[[T:Q&^8B<M8E),3EMR I0C E$R4
MKUWO,W(]GX)QCU4>"GL?ALXZ[N[ZX2LMG&U?97/V815G"S*G^Y[CC!<8X</<
MZ_T/+9\J_)54]N.MXHK84T53H?\ =-6/W%DW4K:L.O\ :]I3M?N3S&SV<12]
MR."[SN;#LM*=$H6VS5(A>*[]Z-83[RT/1A[LJH^3,#S1\0Y,A]KX@KQCN>W\
MV$XPXGP+L?AKC!OOK4GMRKDOLKOIH3FH[&>?7DE&7M+ZUSPWF+#\I_)2G9%>
M*)PCH0MB_P"YZWU[,HUN>ICV_IX2E9#WW^W+V^26)K!%YW,IV&A>B4(:>JLP
MM+=^]&L*]E9V8Q!V)4O3Q PJ3B;(C1VOB"?!AKW/FRG.&U>)]C\-49M=];E'
M:C7%?97?52W!2OSSZ<4YR]I_5+AA/ZD%Y5^2G.N+\42A+0G;-_W/6^C9C&QP
MU,>W]7.4:X^^OVX^YR:Q!Y_D*\[G?=KZ)FB406B(TI)/._>C6)/RX1B.ED#!
MF&VX"5&/BS42*OUV?*B/[SP5C.6E^*[L?AD([#I[ZYRKMA&I?971]Z$E7SGE
MS_;]MRFN,LN7MY7]:)J^5?DJV>I'9\454+J+97O^Z:LOM[(.U5585?[ONJ%4
MN<,1K][$DW7+(;>MSR<U;!'1"!F"T^9'L^<;1K$WY2@LR([<0CC#,!'Q[WK#
MCCGHL>1;?I^7.<Y5CC9['X97]U]OWUV^U7%T_P#171]^33<H=9_M<6DN4LIY
MRO0NGY5^2KGHK;\45*V+IQV?_L]:?VM:E%1LZ5KW^<7*7"&''CAO,D>,&^[M
M?C@W)N@40'YUB=&FH_WK565\! (2+RW9,/-#TH*Y=S+DX]FUY7D^T_*K^M3X
M<E_8?"867QI[^[*Z]=3K?V-\?=M^O-.'/Z,<8?N2S%^YZ?2SAU/+/R?=3JSV
MO$53;;N.NZ/]UU9^Q0O:QL95>+<\[?V8XFO9]?W(X_B[[N[$-UY&@4+EHLN!
MC4+[UZJGUJ[EIQ>;/[G(_+;><.I2CV6<>M_2\?-X8SPNP^$NY0??VJ7K<W+[
M&_I=E?LXYY?3+]S^GIC EY9^3UK2MCXBGL+<]M0_NNJLZ^&_N>7MX75)>S_7
MUSGH?HA?-UQVK&J!H-!%P:>9'U]K[U:M#^90:U%</6'+CP]20N6$Q(N?:/>9
MU7O/#&?ZI?C-?L/A5DM97]_=<;-=SM?V-\O9M^C%6%/]S/*?[D<17M^GUHNW
MY9^3J8;DM7Q)73IVU7KK^ZZL/N:&[<[&76_9XJ%3]F>9OWL9_;EGV(WG<T9=
MH2/T2@D@4] 167/O1K$/YL:D2<-3GLI>@*R!^'Q\Y=\K_GR[X>5/AGF-?L?A
MMD=5['?77*U2=R^RNE[#2S%=)_N\W].8XX^KZ'-M^4_DFF6\M3Q571HE!:S_
M +GK0^Z4I8G+#K?L<(_5B>7+^E=3^2;UN=IXVB-HE$IJ"$%S@KWWHUACX\9E
M?!OB0++:X&5"\"O>S/\ :G?,T_['^CC'K(\%78_#)0HE9WUQG9?.-B^RO?M5
MQ]SA;E2^OGQK^B.)1]SJ_HD8N\J_)<+-J-/BBG75JU3I?]TU8^_=+V?<HPZ_
MVO:YW?NRS&SV/I2]V./[F\[FPZZC&BD9:14F3#3OWH5C'K6I<..\[3O3]AYF
M\,RW'&?B.?\ 9U>GY\)\%8QPNQ^&\4WWU\GMNMK[*[I0I-+8SSZYBE+VOZUG
M&<IFWY3^2?<E%>*KVUV^-J?]SUNNTX1;U,>WTXS<H?<?_&^/)+#1_&KSN9;H
MY#NB4--2:R0*$'OO1K#GPRR1F"ZX%6PVF!A4W!)Z'%;]\CP89]YYE)SAE?BE
MV/PU0L<>^MSCLPA!?97KG2W6I7YY?3P4IOVG]4O;PG]:,P\J_)<K*8S\44:Y
MZ-EMDO[IJOV]B,;G7JX]O,_<E"J/OK$(>]EIJN6?[!O.YGW:VF;HI$!LG%)N
MV)W[T*Q+^6),5\@V-B80U 2HU\59CL.>HSY$L>Y\JO'+:O%?V/PVN.RZ>^NR
M54H*I?971]Z,E!SEER_;X-R6)9<N&5CDBZGE/Y)NGIK:\55,+Z[7L/\ N>M/
M[:496*N&%7^][L8URY0PH>YB67!Y_ Z][HDXJ_Q#0Z!F2I65$LN/O3J\WY4%
MM/P&XQ?'HCT_'O=LR'W/;L>1QOV_ESGQ<3X78[%X77]U]OWYV>U5&5/_ $-\
M??FU)RKZS_:XM17.64^>5_2S.IY5^2[OL?N_$U3[^Q*&S_\ ::L_M:E*M1NZ
M5KW^493E[<,2C[>&\S6/&)?MW/1A3LK0"(<F78UC2<7[UZK(^$U]*!RD67UV
MQR43\K7)D)]DWC#V/;>/F_K$^&[NP^$PMMC5W]SKAK*<)?8WKW+<S_9PYYAC
M$'[CS'Z_3Z6<6MY;^4+:*)['B*JNLW'79'^ZZLO:U\5M;/)5XLRY6+V8XFO;
MSGZXX_K]^W<W$G/,: 1(E,61(R%#^]>JM>_KN6IBE6?W"Q^6XN4N,LI]DO&7
ML^MX^;P1GQ5]A\)E="$^_N-4M;G*7V-[XVYC^SCGF71R?N+Z?IQCJBW>6_D^
M&O;95XBI[$-Q5PA_==5>YKXFWL\G7B&&H+V7F;YYS]+/0C>]U1DV;(_0J"2A
M9J/!K:?O4JT+YI#N.DT2#F<O#U8!YC-18R_:O^=U?NO#&?%I7CG7[%X78];[
MCOSK5M+E=_T-\O8L2ABKI/\ =Y.4USCB*X9:^I&]ORO\FTK>^T\35SHVHPUO
M_M-6'W5+=JE?UK?L<5&M^U/,G[N$_P!N6?0A>=RQW+.F!HI!%L6D=FMN9VA6
M(?S4J3(C-D$Y0[ 5D%\-8=<<\7_/ZWI>5/AE6.9U^Q^&V1UG?WUURM<_>7V5
MTO8PFX=5/]WFTE]../++]&<FWY3^2:9[L=7Q570H5?V[_N>M#[IRE%6+#K_8
M]N+E+Z\\^.%AR1_)%ZW.V\70QHE$AF'71I(4]]Z-89^,GY20V2-;RVN!E0[
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M/W.O.Y8[MC3!T4@@V,B"WJ\[]Z%8B?,TJ4\/02AY0[ 4H+\*9DR%^H]YDO\
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M-%5S8O:M?%\UU)E2RZ0N9WG]MB3G+_I>7SY\WCP9>/AZ$CX X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X!2G8P*4-:3V2D';+M2C0FI'K&(/Z^*H#V9@I714PN/CQ93D FAR/+
MEQ$-O,Y87A]O.4>'Y>"KU/E29V3W#UQJ':.-;'#FS7(/TU*/O:;;-O[ )"[K
M3=NVT=OHD9.T:$(TO;(=O/Q?EV#ED)+<&1XRH,5G'Y)"UIAO$6^OS+-ZG[8M
M-Q[/['#7W=$<B6&[=W[7@.MB?8M;5C^7ZV=+1*O&1UF1IP;%BBA]7C)DL3\6
MN2M;+:)N4K];+;=(U]/H;P]MLRSV)V8.NN\]GT;;E8WI2ZCU\ZY5:' EU7:F
MHR].H\Z,5G4YVJ$IERK=R/%+!BPW#$M.*<D>ORR(.!SJ9 8Z?H<@6?=V\R&G
M17W/=G-NFM_;%T+:WNS@DB)#DL]6-O2DU <+-":A(IK3.HSU0VB8DU\=6)+;
MK9H/Z\IQJ8H>LCP:PL]5])E7;L?W$VA;FW@$[9-2$6")UVU&G7-9Q%US*QLZ
ME=E!NL^S9X=>"]1L$H P?M)(O7H\Y3;T10:NMRXR$XE>X5!B*19$7<G<[3VQ
M:/#O#FP[GK;K]:X;_86<)D4V[!(5%[#W68-K%;V->9@F@W*\V/K#JMP3:I1*
ML5Y_$I!-4>:I[T,R7A,)KIZLU6E=G=UK_-T;H6W[1NP"Y;$TAOO=%!WZW0Q_
MR^<]C8-9D*-6-F1/@;8-RT:<MQ)\&2%HQ!59J<1C2VU^\7,<B4-175?,[#H%
MB[';.Z/73>S]GGUO>6W:&]NN@4D$PW)!ZFS!KHTS2]/@<& 4$B:8(,@D,G)L
M^-B3.(E9JFD1V,16&!GHI8^!PX3[,=L+)5-IG0%IV.&&7_KYV ^H)J*>_3XT
M$A1].Q]1;'U[J/1BFGZXI*K!$N3]-NRX4I#I1<N7*97E4="F4C6(_P"_!T*_
MW(8"Z_.0+#O,.,V-1>\$,%?AA$@%B6&J:"SVO%U)_-B%NPVW15*^[TM&8R0=
M:3C$*0AWU_%6'.!QZ_IC_@73W!V%>;QK?K5+ZOW%\[&VYV(K=;=.4'8J:0.M
M%(^[G;APC&^]$71=H+K0?XW58JW)4<5(4\['3%\S>'U+P,KXY^10NP]W[8U!
M)W+I0OLBQ"MMF:OU#C=<:P3*MW6T6DU:C#-;VNBBV673P4G9SD$_&E-F9ZA[
M*X,)*)LJ/ 8<3G@J2>'\.IR:7V_W0%U2T6*9L7;&OF-BZ[[G_(%_78X&SHMG
MM]4V-8@FO0]4UN0U,)&Z<ONO*Q#1813,H@3AV$2.EQL(EK0\XP-8C_D786[,
M]KG-E7>C64Y=M<VC65C%ZVN<ZN:KFWBHS343I;W8V$C;FMJM$#S2E\I%QL-5
MI=ICB(S[\R.2C8 N95*9?:?$XQQGX?\ FC%T)V#[$$[=K&HZQM6-WY=V\Z/L
MI*P;Y=V#HJT"2'6W9=HF0ZYOP9U\BWP:0%VNM0B9&KEJ^X^!GRHL=N;B++0P
MT#2^/3H=#P=V[PK_ $$!=D+F2LSEZU/M*UW[;(*N#\V$C9=5T3L3<J]L"DC(
MZZR((G8 [4[+ZA3S0Z'-F*'17?(E3BDY$:7/"]#GD)MKN:)8,4*]7B\*MNE;
M'UP?OEDCUP=$:N:.YO:#KT:%UV"XQ7<09D+2.O%7JG..14X6Q!RS(E+R_P"1
M_@UB/K\'_P "PE2>Q.L[=9'M?[-VWM K#[ZTS1H&H[EOSL>DSM4RM#5G8)=@
M@?$ZQL1$7'=M!F8K)5N!-=SEIN'E:4XRI,,]'Z_(@PK>6SCENN CMMOJ[]8:
M,'L?9!RF6#6I]#0LSL2I[J/5\=1!M],ZS'R[BUKG7,03+KP!X0PNUY+2EN0R
M6(/D9I<)>G4D5*[2;UGTUW6^V+<9I/:K8>WNB<RIZO17O@EN5K.\57J_+W[-
MJE>=#R%LU>)*B;#=/O\ C(16Y#,YAU]C+#.. TLY7]/7_B=B=0:M<!5M[+/V
MK:VZ-@Q:CNTSK2FCMGV9@P,@5$91];6:+-&M,@ ^94YTS89R%3E*>4MK/I>;
M/IX\!F6,+&/0X#1V V.SIN9;*WV'VQ8^X12FMS]P=>R V/\ (^J;_'W#K@$6
MKA>#&H):=HL;5Y)2971"\I?=LX>0\1](LZPF:W#6.OI]))-M;S[V&+SO'2M&
M!EQ&Y9NR:,;HH341:M7X!1]7Z_T77]@GIC-SV]6M+@9 78VY"M=K9QF0TJ8R
M./3U#U+>CXRU0E'&?@1J!V,[#[*V>SN^NSMG4C1I?L=U8JSI@I<WD5;457NF
MG=#V*]Z[OF@U:EF3#P^Q[!LQ>H3+-@_&77["::F/9CPQ3J\PN$ECXX*]L/:7
M;0?7-C(B-O;I-]@SW5C?UJW95D6*HLA^NVZJG23]@>K9;3DBAR;9I\'KFQ"F
MQ%;LC"GHA[W3"I+9A;R)::./7],GT]ZGSHNS=2[&#M[I7<9DXW)$2;-K[LR[
MOXM4F9P >F(L3?9.JM8.54QXJ<?;AY&24MJPE_#RO5RVV,/HSBRI6&ZUVHZ2
M5O#L]OVC:AV1;^TS.R-MV6W0PL\7;M5[/E4_0VMW[]FK08VLZU;Z5',E'9&,
M1%G"0**Q[KPDJC3!K^"ZEL7[<&YXWTZZ_L4E=["#MLW;VO:TQLVP2D::/V+2
M!'ML&HE<V)<3#=&/(UB]L70KL0H6)-5Y6("2+LAN&QX8::$23ECX?^13-M[*
M;Q#5?5SG7XK=MW"]*L67L3V-+ZOV;4.PH>P4@=<T5H=IXCM"[5[4I$TW8J#%
MN1AN" "/'1YFO"V$MO,/^9\7BOB9]D[!&7P&[[E#[,[<@=DF5=O$U3K]6PD(
MO41VL:E3-K&M!6S%(>IDJ96ZH1H@BK6N)>7'\_%31% [,AU$Q(ML,+ITZ=#L
MGKYL7L59>P]PK&Z0M=JX&#U>T';Z\"IER+WVO2K+9+QND?:;#,-F]7:SEC[+
M.A@![,@>VW+9:88:<PM*G,XR,M+'3YGSMI?8_L%',GA5.VQ8MT7XM=M1R96<
MVV1&HXYPCW+U%1BM0W%K4UI&)L3I?<2=$M\\,L%'^:!LT9%(36\XD#TR'8::
M7^/X?[R<;+[$=Z9M@VOKJA4ZS3=PT;?UFVHY4M4DZO<JQ#TOJ;06@+#6]3-V
M_:0+4""=7WGMZ[NQ)[\6*H[&8P61"0Y[9+J Q%=7Z8/[&WGV"N.\V]MU:U;$
M$=<K)VRTK4@-^FVB2[2ZMK&\:%T==H]'MG7U[5;TM(_9-FNDJO,V==@CN ;.
M98<E*99AJ;51A)8^."": [!;U+:>T]8ZKMX7M#=UJM_52'<:24[/S;^M4>W&
ML-;)B;#J4/KF(D]?H\F4YEB4F(Q8,Q7?&%A2,,X?<A6EGKZ%@0]X[4-;&N5>
M[:;NMW6/5XJ^=AVPEEUI;&X061?JF8UW'J.N8&U3VL@DLJ/K=()RBP82\+C+
ML\R9+0IJ>V+RURDPO^7J84'N3M:-UA[8#]K[4=HG:6#HFJW'7-/E0!-5V(+E
MR.JU+N!FS5:B2!:I,6>_8TDBTN'F-*2))9DQ<I2F-EI()+DL?TFAVGO:X@\S
M1&HNSUROO7;&[M  F]W7+:,&B#(AZSZ_[)E=L:R:[(B]4V]MVI!7JA12*I"!
M9-V,4,*%YEMI?]&)"X^:ZX-/L/:O9A$JS6;5NSKJ9UCKC4W6 M,VU4]XN[0I
M>M)=TV5N2#LO9Y0*WHA$SM+4:K KT1RP-)0$E1Q,%:6V&?*N1BC"^/KU_P ?
MH=V=V;+OD5<M4T?2UZMM4QV=!V30H*S5P&,/0]5[)=,56^P-O85-$DXL5\-I
M8!>G&U3// ?G0X#64*<<3A0Q''J_@<U:G['=SMC62!L"N@(L\=L+3W8<RK5N
MR[$7U>"U^8T>0ZZ:AEE0\\1J/8)@B;(;9@W>9"B2T1V90T@AYMU;:&L8%:21
M7-4[![L(:^$6NT;OV>-[80H'59.ANOF(@Z)7MYU*[:ITD8LY\Q1?E5E^\Q[]
M<+%;FK(?;?;Q2L#U91D;\.<6^+A9_3J=+?41VW=M97&DRP&XK!1Q8O6UPLT;
M7]>LKFL+3?+9 .@\#9^KK,<UCL376\]C!8;#L1G5YAX2@O\ $V7L.KPKS,"1
M62*B-S[#E[5 2OOAV:CLB4[=2* <ZESQ\1JJ!^K[FQIXMBQRZ&D'F4,#0.O:
M(UWQ=\3UX?L2LC?>+;<P*P+A8_3'J:ON3?\ M "WKN<CK:P;  ZUU=KGJ\7?
MMP&X+B5K4*KO?-MQ+]L\]I]C5MQ?WK6*Z%KL&981S9*')8$1%^CAOS+?2)%+
M"SZ]2L1_8#;^8_9<X#W8^4V8!OO8H2!J C>&-BWZI:]K_9<I4Y%L!]2/N6@P
M&I.M-#QGS(;*3YWWOL8KJHTW$Y3>!KBNG3IT_P OF22J]N1%<W4T,UQVAM>T
M>J.N=JZ8;VWM+84U)QNG$;_KSM0#LE7*; FU84X5U-,N-?H!!LSEQX:-,D/;
M-D<1W%Q(@G'IU74AO\1FQ+1N<*Y;]^N5#5]D@;"NNO95H[ .]:AMFI1#N7V!
MKE&-5AAO2%[>V?&D:9K]<]A'=DBDJ%*AO>JY@A[A(86/3K_Y%J:JV)?-B=AM
MF:H-;ZVS8<6AO?,N5)UA=<@S&KXU%V(-FTX'L?35NU0'LW6PP!"I0!#EA98X
M)O<9;TQY+BI,9YH1K"SC_'_$JG8>RMMZRZ\]4K47[*[80=N/6YS<MK#V^_*U
MQ?[QM S4]:%<MZRO!+3UQUQ>;G4Y:IR!VI3+ N,;48]3U'$1U):GP-))M]/B
M?4#>78 @"ZTW"Z:CCD+=M>=\(U71ZK"CB,6>#O.]2P]2 5ZQ"9<]L,$,U0_8
MV9AB--E,1H,>*]E]YMI"G,4PEUZ^AS:*W%N1WHMN 5=KG>-5[]T,=EZ@N&R[
MU48!*T*A0#U:F4[:=LC:KB7D *:V+IBT"29ZP 8Y,?5I,^?-0RO MQA(N%R_
M1E+::[@3J5/%%=H[>/C--1Z=VDJ8J[VR]!]NZYM6TJ[/ZZVC7H[6N^Q6OJ/,
MVY'8KA^T1@BR V*;E38I48MN<\,2[D5Q^7J<[FNQW>FL:NWI3RMSV>SLN^ZA
MU68UG8WZ0-64TM;M(=2]([=[4L.-XJBH2"EV1;LJ@,3VWLILDF:RPG'H^@T+
MB/K\"UIO9'M0-LUCUY/O-WALI[TP]N,WYZHPE0A'3,?W$;Z]V/2WO4UO,+,>
M-:(*/Z[/F*?*<UQ_#W@WB1@3"]?T_P!^#5$>RW<2Q##(L@*W!4<]GMK:)VEU
MIP5DTVC.1=1GNP]4US=]3!;I38.Q#=('9TK8*=8)4FPAVCK)"P'?(PEJ(E,>
M#"_V>I8%9V!W*'4$5.';*."K^1[/7#J/<M7[*9^\$GHL1LZ56FZ#LQ5W8HM5
M1MBT:P6VJS YZH<<%8:O:F8$U[+T!J2D/IS^F#L#M%8I-&L/7:C7C==^T_H$
MD!V'%V/NL<;AUPZ5V#4Q5(:U74KGM#(A<2DQ;M"F6,J_*;2.^)E T>$EY*9&
M8DJF5U^'4Y8ZZ6+MGNC>=<58++L4KJ^DZXU=8&CI+8<G1TVTU,EV![6!:ALN
MPZN'Z5-1=@67:VG]<U0B6&.D:NQ&0\E3;,?$W*&QI\4OU.O-O5&WS>X77MD7
MMO=U>IMPJVU3ULIM6M#$&AR">KU:P?JK,R&NOS7H<8O\?GIFLIEL_$$JSC/_
M .#QX#*?TL^;M^[)]UXO7[05AN!$?K^-;.JN+<8N]:V049.60X[O?I36Y]HV
M5-):&A0M)DXU$O\ 8,N2(*3[8]LA.=PR[[)M>1I*.?Y_^)V03V1;A_TZ^R-]
MUAM)5WV)6Z1MJ76;?2=W?Q"S1%K@5Y+X: &V%.UA14X*0_4CO(B. G4P77\9
M\9"<_E(F/J6?0J8FKL9JP_4*_P!F-VW[2_6G8=RL\EZXIVL+N-XHQ.MT4+BK
MT>Z]@H^N:>Q2JEM"S2"I*-XMJ=9E V(&"N$E<#L!T?IZE7RMV=SY@RO5>FWG
M9):5L&NW7<&IKV7HPZ'-LVI.G^TMPRWLV6(_4QT,24[74&3JB#(QF+#=EQ3Q
M"=!8B+5E+(UB/^/U/U3-_P"R;AO"D'-C[R(T*C;4H>H]ZT"F7O?V>O4\94-S
M;ZW[.K57%T=G2EN=VB;%Z?#U*&0&3"@=Z/+\([BT*F+>0)A?#_Q(]KC;_;T?
M 38K[LG9FMA^P] ]MK!6;X<R0WN*LUYJEB)1ZFX$TX"U.'*ZLMFI0$?%A;#L
MRRV; $:E,1F9SD.0Y'#Z3NGH7O%JU0+Q3K-LB9<I[5\CBZ*=D[=$[RHEM5]W
MPFTV$7I[<2J+K2U7I@$VAZ:9&EA:B%=DR%1\/KB^@VP,R6"A#6Z;S&[%[4%U
MG?>PR6Y@W<VA:ZJ?6EMT67J!'KF3HFF"&Q+ 0IN*RLF!!5FN6"R6%JS^^C)0
M4'MQ\ONH<S"=&DNG5=,%!:OWM?CO5839R7;(8/V"=#]=)FP"4WLU9KTD4R>S
MF;>Q>QIU;ZY#)G3%JTEO 4]841+#%#SWT05J8QA,G,ZEQU].G\/\9)H%[*[R
M*U5I?WB;=!ZQ;I>@A^P-F2VZM=+!2J 2[5]G:!LW;]-O0"@C0ET!SZ52:[!B
M7+(AI6*H\U97XD>1AY[%)A?S_P#0QZ?V9[#,W9![4MDVOM;2^D(?9&Q7"MDR
MU*W-G>FKPRNL:,S-0;?K5;&2;S;]5,WXN6"1G'9,^>0CDJY(>DKQ&D10XKX^
MK-S4^RW9"\3>N5AFO;J7H./ISK7I7L/L&N#J57FGMO=GM85T\>VH_+)2(6QP
M]HU7<+90&6GA85T3!CV*P^^]-<+&(P8BL^F<_P"1CS=@=J=8:1UE8Z)LG=VP
M=AW8AW745BW6%$OQ)A.IA^RPVOUBJZW5(F)4FOC 3!6$-0UXGRD5IK.'O<9;
M6'1O#2^![V3:>[9=T TKI;V<N.WJ--N>B"C&R-C*&[$K2MGR(FY[#:M('[Q"
MJL.1BG;/K%-$ILD2-_MU)<E,R(OM%S&HG Z?\R*QN';G<UAK\799396U=6XA
MW#LU(#:/-3L:9VU*+T?=[]9$5C7SAW55YUOV$O\ 0HP5\$QKHE*&LG6948A'
MF26IK,AJ%45Z'^@.L6H#;QKI.ODXI./$)% 1'VSS+K@P^!G/BCX(DAEQW$,P
M#+178TN.K/G8?;4A7Y<<IQ$BX X X X!SCVPWE,ZYZ2-;4'C:^3EP+;JNIM(
MM9,R(K4#[R]J4S6JSIV=7@5F.I&5UNV9G.MPX$F0^F/Z:$^*_-@6*R\'S>MO
MU4KS48[*3>M=:@<M5C9EE@6<T6WM\E[3CTFT46K5Y>LG!VAY=LAB[B;NF1;<
M\V+B1,%H+K<14^/EN0L;X(MYOOYLM^U[LANZFKP$3I,%9RAJKG,[A?NCY&K=
M<P.\20*;<@>IB6B@9.*6._!W6WK,I:?;+6G"GG&8ZA.*_P!I&F_J&[2<UQIR
MY(HNM)$_<E^G5(8N,&[4J'UZ$*U%-VB17,KKO75O9AZ8\MAF*S)'!70_IJ6M
MR6EQ'I9#BO\ &#92_J)78;NT-IYV@4(L;EWGKY0<5H7-W+ N=PF;CU]2=AVF
MPTO!S3T*J#(>N*O9YY5\98B @LX+K\Q<AN&M3:<AQ6#25SZCNW#FIC6W16CJ
MW=L-'==!JYK*IR]R@+<<>OF\ZSJKX</N>R=-U'5MC.Q@Y>3)BL""DYF<2:98
M2\B*]F:@.*]"W*QWDLN]KJ[KWK%4M>6PC-=MMEKUUOURL8"D3=8TW7_7&SS"
MDU@'3C5DBW0E:^Q,0+D3F/C(O R6_,<P^VB Z'''5F13^Y&TK;V"GZ<EZYI-
M2:K!/70>W0WIFXKL8BDK9I^G[3L,<;>Z7I^;I!MH')M+@V*Z2L4#W>869#B(
MZ)#"%".*2R3+JAVLO&]K;<J;L>B5C6-H 5L-;%T!PK>AVS*BV5)31TJNW&H[
M#U_1EV&**<8:2U;*P\7JQ1];C<=_"4,.RP<<+*.>L?5+@FP^W2&N-6#=J%M>
M;PU?3ZI4J+LP$:LNQM+;"V98-6+V6.@1H*U!;L@]KFU.CJM+\KI%B.*\93&2
MS?HB\/F34+WHV/N*\2*QUHU_J;8 9@-MNY"K-;=HV.M"KK3M<1]!OA55Z8%U
M[9DC"UN5NSR*]ZWAH:J#X.X6M;B&@<4EU+!V]W7:J'7OK-OFFU\7@7V6-:ZC
M"DWU5OQ'IX78.I+?MB-.,#];52]V0J0BQ:PB!EB%#6SAZ3ZRWD,-*7P11ZM/
MX'/]7^HULF]DM4BZ_K2B"L;#U^YL&*=GX[!VX'::Y+W%<M9U*VTE.O=#GB@J
MF7NOU1BQ#I5H8!.^S*LHRVI++S^(7BCI^X]P&JAU8MW8296Z[$/0-@WO4U)J
M%BO0^KUVR;!&;\L/7[7@\U>RL)N!6 ]JLPZ'*(SEL/-B83[[OE?3'SE=(HYE
M@@E$[>;2V];^O4S5]4TR3T_OW4EFV]$L!/8%N5<JZ/UK.U6"V=5'A0:BD:R1
ML@NR;'>AQ%H)(BK6*=]52,K3C <4NC]<FCU[W_,76A5(A(U1#%;-V&OKT?HM
M';MCTH49UGO+4*=RE+\]8' $5V/$H(*G7N)*:Q%7A^=5<(\[?O4>F+QZ_H6A
MTH[.WGM#4$7>T5JIU@82IE"M@P=7Q>[H<V&Y=1;Y?(Z<3VMJ?6X.P-P8R4(Q
M*!O$&%KQE2LH;<94X)))%=]BN\%UTYO\CIFI:[J5X?"4/3]V;K3IS8#>SMBN
M[3O6PZ@_7]<AZMK:W5MJ?78U"S)R^:(#X;BY6,//18[3TI JCF.2JF?JHA+)
MK6^W*E5ZASB->W]JS75<QB]E;>$(Z=W?8"(?5>YCS6N*G:+0((65FO%%+K;4
M"3.B.Q,)<<PA65I#AU)=1.Z78C:P;1UEH6KM'NU7=.W[MI^OVH[L#:(T79<T
MNH[-OWWETV$_J..;>I!L+K5\>RP3C0)S9C+GAAV$AN4\#BEG.?0E%'[B[MW2
MF8UI?3&O)Q:D4Z=?]@C[[M I66" N3N7>.J:A4:(6A4DK&Q8;&SH0M/E$"J(
MHP8M^(PKU\./O11,)>I3^R?J:76L7.QU.JZHI)8E6$[R?@UDM;-AR;CM"3J#
M<AC5(ZGZW'4+55X97<+FH2EQG$W+<1F5-9;PMUK#CR15#H2HC]1TI8L]MANJ
M*CJXI8^M-8M>R @>U[65B7L/7NI_FJJ;JS/'TNNV@A0[93-NTZ2%CQI:'X\Z
M#*A$$NI;DX;2'#TS\3-O7U -B:=LP&K[)TN /O1I>G"NRBNKKD=,1ZIKC9M*
M[07ZSWL&'.4P8;M.-65?KVU/(#VVVI<V'+F*C84[%99E!Q3]#U)?4!M)T1?+
M!KBK:<8K.HA=DMNP;MLO:AL'2"%9<[ ;IT?JB)33E7HUH5)D;+:TI.*OEWVO
MA89N7%;QB=AQQQD.*.Y[7N:LT_0=C[#$&UD:?6-0EMR36J],'FW9];"TV1=G
MV@9&+(P*+KE#(ZL17FW?;OY4E25^16%<&<=<'"6V^\F[M "1+&X]4ZA 6?8@
M2DVK7$D+LVWGJ6#&'-UZ8T_=PNRR$?7";"T2H'WX""+,X2/F13B4R&6VXBF4
M*?&E%/T,ZM=O^S=WCZAEUO3VFH(S:&ZK=I >?M%WVX$$V*75:'L'92-ET.,0
MTX/.%->G 5!?'1U38L-[)C#N6E2("&ICX<8KUR?D%WGW!L<%L&Q:MTWK^9&T
M;3;%?MLCKCLLT"FF1XW8VZZ@&JFMI4*CD8*CY2O:4E$GIY;,4=&DD(L/'J8Q
M*DQ0XI>K/[K[ZDHV\W6-37M9OUM=FWN!HNM"ABQMLQ-BZ9,@\RBFUQ#:A;;T
M2PT.RI2-L-><\RQB)@^6J5EB>SX XX,G1?U(*UO6"%DUVLUM<P[V,I^K8D(/
ML$;9W&]1[6I=JV)I[;,]T./<:&&+76:XMN97WLI?%DF)<9Q]66,*6#AC_8=5
M;XW#;:$<U)K?6E;KEBVANRS6,%5E78T3 4BO#*;33%WM-CL4X*(.&9V8X\4W
M%ACXC&'9<R8WE;K$=M]YL92SU9\[]C_5)N% *&:Q.UGKD;=*(#N46W@25KVD
M8@V_:%1VN2U6/H.LK!2M/6..EG8,Q@<X'G'F!J\233$-V/ZT>3Y)DVH([XVS
MN^_U\MI'6^N*(#?V[O*%:#,*!LFP2PE3H("A5X2=N<NSS:P-L1$V8A3K /&1
M1\!&$R)$I;^9#;$9S*Z827J_0Y\$=N>P5OM6F*]6-6Z:@9O^S]P:3N[%BV3=
MW)=1V-U^F; :V6_7I(G6ST"UT\G$H2G <EW(Z6[[QM,N/&6VZVF&N*7J59:/
MJL"1^N0]FK>KBTZURZ)V"MQD+81&U*[5P\C2A)D5#B"KK)U:H1?8YR3(2I[X
M#DA);;QG,=F3^3QOP"A\S(O_ -12ZZV!T0A<1.G*ZQ;XN[SLZV60?VDKU4KP
M+3(_4\EY$\,5Z],;";?)O;(=><(K%("QHH_.$R79#GHI!1SZ'4FP>R&U:YU@
MUGNX/HLU'O%\@Z]F6O7Y9BVVI_3D2W",%;&9M(76U2LNP[>/HZ\>A)CA@JYZ
MLN)>>:B1VI3L<1)<L9Z')DKZE]V=L=:!5C7>J+S/E:\U9<I59HVP-C6ZR[#(
M[ VMM769,)J#(33TF%[FOMZP5,=9M6*])A2):H11 Y<.4^V+Q1+07U!KV0'[
M4L[VM:G.#4VZVW7%0K@YS<XDQ8K>SV,A=;M?-EMA6G3PK3T8-8K84BR2;XHP
M8?&PWEK98F>W=QP.*+?LG;#8FCS%=#=EJ+KVMCYD?<EE.7K7E\)V"NQ=>ZDT
M[(VT0LS04Y6@IT=.;4/F#'X<S*$*Q%Q+8?<0[EAD3"?H:WK+WI1V%DZC"KIU
M<"6>X*WJ'V2-K6PA]]%Z[M^G4ZS+0@,"R!AK(NU-6BH;3&$LOMYC^U2\EK*5
MJ\WE!QP>O<SNC+ZMVRB5U,37T$99]9[;V26M^QI6SVP@F/K$UJX*V'RSJW6V
MQRL3!ES8_JN3Y;#,6*F'Y<8=<=0C 1CE$,8[U[)LIZ1K@)IFO:_VBQ 9LIZ!
MMVZ%(0#6E1 =<M#[SV9*NJZU52!8C9JA8-\CZVT,@-?[5EA^>M]AMI3"A>/Q
M^!&ROU0JI7->;"MI:I1#I:G]<0VZ0GW6.[$VQK^UV21;M\4HS55['I^KY8BG
M H1C3"/(1/-C)#>"#J)42.Y!DXPR.'7!8QGLUVC VKLP%;TAK&\1]"5JKG X
M>@7B_E;O>)&Q$D)5/C1Z^]K9/AD4+'.2"L<>HD1D91Z(V-+D+:9<$Q'IU]26
M4;N0S*ZN[F[#W8;5B:]',7M^PAM9E+0IXLJFUB!9VADZL[,J5"ONL+;.021%
M?#6(='?B*\DK#KT&0Q(6#CUP4INKN_NOKHI-;VWJ'4[.R;.UJ\I39M,N>QKC
M3$UB[[9KVJK4,LS(;5$K8\@[KXQ<![[.!@>6R?9F*4TW$5'?1P513]"\=I]I
M+EK'JO2MY.5BIF[;<;;JVJ-BX\?;D2KQ,;0V,(ID(M\'>UDYN-_X8-,MR7!_
MRRDBY(2IK#24_P!9@11S+!5FQ/J%P]+U'KV:V8,H#)+;UM/OW!6++;-<0*3I
MFJVH)2;1L<6$W'2J5?;(7KMBO(##H90J([*@OS)<=U;,7&787CG./@38OVIW
M2R VWN %J&@D]$:R,]BJAA\ALR<(VA-,]=_O"!&+0_7UU*37<5JP[(US*#QH
M#$]XJW!D,D\X7_606Z3"]/B2OKWVPI6[=IGM=T2FE@8^'IC7N[C9HU2KYKV7
M,LNR[+<@TX4R$OE&ITL\S%;J:7U&(^7VY"WO35Y%(QY@<<++^95\;N7N9S4:
M>R;FFJ$O1-O"X.ZY]+9T]K946#,N0.O51V]5^14$"4NW4&3>)*8%2I;H)QE$
M61[C"W)+ 87I\2R>TO=6E]8-AZ(H=A9K,AO:-A\]RGG+R&J<FAZX^9:AKENZ
MBQ!)MV5<IK>RME &5CH^67$!TE)^',X'J:<!1RF5&4[Q[<$W[<E*<T4)DV&H
M@]LD]7ZN?.7RO[7V-C7!IL973590=UK'HNU:UL40OXOX4<I82@&.XQ$D1),Y
MUQJ.'%%Q:?[;,6G06Y-TW^-5L-Z+3>)MQBZYDW!V<X*I%)AWR<@G0MG5+7NR
M-=7#X;*6SD&='LR%>FU+:><BRV%\!QZX7Q.=-N=]=X:%K]*E;5TWK(>=W0*I
MUBU0Q5[[?KH+!0S>V-,ZWMM=V.Q7]7S+40.4^#NX80CR*Z-(LFG&),9#,;*&
M'9(JBGZ'6!#>>RH'59S> C7</8FP7!$8B-HM*A[*B12+1"TL!D3XP6ST 9MB
M2V  R5%)HUFN.&Y:8CL:!$D2'(Z7!,+./@<V0.Y6_P"U5;41V@T[KA95[!W8
M0T$8D/[*VJ';"W%FOV*VP2$VLDM11KQ3WO@=?RV0 'X \Q EO(5CUXBV93PO
M%)]<FP)=\K?4JE"W_==:5=GK$<ONR=;B2E<MIDEN.(0UT]L86Q;BM+FU<?7'
M@-RL>LY<6./CE%$1L:=$DR<JSB8Q$#C\/B9MV[I;;T3K^M[7["Z?IPFB78OK
M' /.I;G;-H6\9$V&Y/1*J$BE#]?QK%;[R%\(#<1P+'?@F)4Y3"?:^DAR0)Q3
M>$7))[,V4;U:K/8.91*V1L6R)NM86M*)7-@Q#($C*WML"L4334,]LF$(DAH[
M4IZ\"WST\='(PH.,R?8J(H;9<D!CK@YGVUWUV[I*SC-0WW6VLV-LR+Q3Q<@V
M!,[<N6N)-"OFL-XW^O6@>(HNJ;7M)-@:-:'+!98O(EUEE.69_N\L.Y::%44^
MOP.F>PN[=QZFZ]!MR4ZHZOM)B)!I\R[ [/9KU50Z46R6#"HS5I3=$)GW/;F3
MB%>F3'P7\149PXA#WBC B2;P4_:N_#NM3E^UQL&A*<VK0]B];-=KC4H3M.PZ
MY-2M\3-70B)7.QV]:9K-5CUES8+^6&"\F+(F8A(RO#&)+>>!QSU7H2WIYVPO
M'9F:6G&ZK4JQ7&A)@@.B!QV[LF6'H5L>K\2-.L=YU+2M;'4JBQ'5O+!ER6/6
M\N6O4C^+W E'!J)G<390RE;)[#S-55"1UAH$OL&,<EP]@3&-TNXZ^2MA@B-D
M742=8B5-\=<KGK:6-AC62V2$.-,BSGU93[N/%#BO3XE6;U[M[BZVX'_?7UXU
MQ8=@*@4Z^TZ+K3898^Q U^8V?2];;L@K)V"@"RL>\ZWK]VCD(:HT=,&UHRN.
ME4%3:O,*HI^CZ&MV-]3$D$V9<J)4J9KR)6 VZ:EJBI[6OUUMC=3MD GI?;6Q
M[+:&AM$H5M,HCC+MJ,A6H26,2&IBVW)2G6D)2VL%'IDRJW]4"&2M@6D6?68B
MFV8AH*Q7PC7BU_PQ:ANYA=$M^WPFK54<M6@MV;K-ITK29-G8.RQ\.1'C3(46
M2/9EO+9:#A\OF9U;^I60/52+:W]*2A#U U'5]M=GJ4[:5DKMI<9BRQ@^TF18
MT6 DXO,6AU,E&N0Q]K$95JJBDOP&O</QF' X'25C[2D*7U2LO9NZ4@?3TOQE
MSM8TFS6J,">.1;G98E4T1#O9TA!:@4$OL:><$.$F7$245W!%33RWG(SOB)CK
M@Y;E_5,"Q1=:LV-:Q9E'LG6 [M1R]#;S#(UBM;_"G-EU6-H&P$8PE49L99K?
MJ0\%&6=EQR+(,Q8\+V_K$(>'!>'P^.2SJ=W0V86LXDS9=6T:#I:Q=DW>L \T
M#OIZ=LL/;Y+&8U?LQBJ3Z0/KL^M%;*VF"^W$*YEPF9+<K*74-OMH!Q7\\9+)
MW'O#?6O-WUVA5JC:>-4&Q:VV=M%@X=O%T#W%D/I[.M6;B+4$@40J!45*2MCM
MY&KR00QZ<5>7\I4O&,"))K/Q.5[#]4^%)J]')Z^UI/FE[;J72FP2";S6-WU4
M97S6W]N:PU?\''1,Z=D6C88H(WL!^7B778)!<E4-MOTVTR$N8%X?,^B77ZTE
M;OK 1;306L@B)\E8R$F%4PM\KXMUY9\BAZ>X*V72]?W1@D1D-K>E+F"V,OO+
M4ZA3K:TNK&7T9=/!!P!P!P"GM[S]2AM<2[#NQ;;=$J]GU[;,*],_*F9N=7V!
M63VLVPHNK(>L1ZQN[''BDC!D-F3()3\LQ4L/Y=])8JSGIZE%0MA]2]\77(\Z
M'FRMDWVM7KK2=H6R:1?ZG:%U8C5(VU+=KZY42U"QC0P38:<AHHQ*F1D-$8:L
MIBR'<96C@N))?H516JUT+FV"C5"OV_8"I':&)LX#7J*O<?9=%/VHC5-+:T[L
MCYIJ,VY8J$@C&J561 7+,QVI19V#[EER3*;R]P7ZEZ_ LW84_J->]9=>[O9;
M%91-)96<F:#ME+MVY=<'X*0>F=@6(^F&<U^7K=PC1,:@I)U;[1%WTI#<7R92
MN2IE*A/JR_F5F/N_14G0USK0.V'6:M?RU6VRW;]X5OL/4#UH,]>]=!=B5K:<
M*\;0BP+6].HM"UC!F9,-3$N/9AI;><>??4AV%Q+)HZX7Z&ZWUM=[X2D;OH>N
M-(&-<6XY1]PDNV\$71I,S8PRY:FLU1TKLB?(] =.O@1EP4X&$*:2J._"4E"&
MY49-'U-XZ9?\#'M0GZ?]>V'<Z J@[6H-Q>-;-[.6B[ZOJ?9R@C\MWFN!&=N[
M,@;FUHP'"LT6]C:K!:+H@%DAB1.,TXIE9#"'.!]1LZG.Z&538P*/KY_:=3C3
MB6G:>[(I!?LU7NM3=JE4"BUS4&N[_'"$H>A&;49H$FNCT"3+/JRL2(,6:A4J
M2PTZ)]7Q_P"!^=1WOZ=FNM?0=O:NN9:32[SK*^5NHEWK+O2[SJ_K;6MTK%'M
MVKM; K)..']81PVP;<('1ZR&C#)4D@[#:BQG?;1L,BM2;P7?JO4G4W:XK7%L
MI6JI8%_K[F!KBIB+!6-A:NMFOW*;*HMI$5BRU:P(KI@I@0_6@1*"LJQ.:<;\
MDB.XMN4ZMX1MK^95Q3KUT!35[3?HU?)5"K)W+M77MSEZ_O&[]=02VSMZ;IJ5
M!VS53P>AV>O_ !P)>MR!A;,V,XPZ%R^C+Z$H8<?<6+F7H3)'9+HY9Z3UKML6
MU@5TY6U+M6.N; VO7(,V+V1H^A;<K5Q%CZP.$0)86)2Z)6+-$\I&*T,RSZ6&
M?.N1!RX)B2R4K75]"2VR&X-)'=@=?GGJ.5VF[9J*YW#TUKA&J]@6"U[CE6XE
M;ZS.J6N8^MS%O(&R$7+\A(Y@A)EL,(;4XMK(OU8^'^X_8*R="!<K2.Q*N#WO
M?P>Y[6=VOI.(,KO;K;.K7MBVYK:%@M$@7KN4S9-?T:_PX[]K(3A4H8/G"/+)
M?7'CK;0I 8EZ=.A/1^X^BVLI0B\U*&?DNH&[XO;\VB4+<MTBZ]I^QMG99WI>
MK:& AB\375)LFT=4ONN2)D>)&=E"IS\!/I(GN8A,29ET\U]/:/9!4FG2J:]9
M>M8^K])A;\5ZX$)%$ ;2K-/L=.H^')+DA@M7K+5EP71UD<S+CI87-:9(HRLD
MVJCZO]O4R.KXSK/;1PD+U\MG9 * I8W5UPK0.\7;LY'KQK5T=@Q&UO/H8[>9
M6<*+:FLD2"ZSY@R,-2HT5EN1Y488QD'E>N#V-]D.EI EN>R'2=AA1;IJFX5:
MX[&=J.W@M.VEKSK\-V66N875M[BBHE?NI37X^QV:1_\ FO)<*26O<OQ%26XF
M7& Q(WVN*AU!V[=H:*QK$K5]AZ(KFK$Q*Q:*'L_3)^O4X?8"AS4!3Y5L@^HM
MV>MP;+3":!4U3$YAB3$GQO.G*I32P?)+KZ,K&L[\Z("HH^^!PU] QI5JL7;.
M@.3]2=@!3%VM&PLB=/6G8>GP)&L-1KG(M4O=\-J8."1WT/S;3@FN+[B6N6H7
M$O3^1$+W!Z QZ_6HMKUCO2KQIM=VE$FTP5K[MG4K0<T]!N,>[[7E[:I%<@CK
M-;-#0+KL[$B1\PQ9@3$@P_'BHRA^4RH/J_3_ '%A1=T]*-"[+V>4@5/950MU
M=I5IO>P;7#TWV!(U1&O[;;;5L$G:X=C;K!&ES:[:KK!*.#9 ]Q:)4M"HL/\
M)Y&>"8DS6Q"/T]9(@/K\Q6G-=-Z^J%ZTFFM["J>VM36 -KW:.GKO>[Q$M3]J
MAUTR3IUUUEI8V2?.DWY,9^=7WG,2\$V/R"_5ZF03WOTF&3RG8<O3-L0#NNA-
M!.33T[178YDX,H0ZF[GJ^OMB8J#E1Q+EZY^5+S<8*"^8"XF'9JVI:DRDQ<(#
M$O0K^74/ISU:IU^E!*1L[6LBJ"FZB#U1K(;V=U?MDJ!W]9MH;03JIVC49^N[
M M5<L1>LVDY\O2FI$ # 9E2<-0(6<JR'U>I>>O\ L1TW&PB^L1NPL+&V_7&Q
M]DLZCN]?M42-5]6Z/&@=.;2U^)HEEKT3-8AZ\76\,$Z>XPDDT^],D>S4TMU>
M!,2]2 ZK#=#I6P1=!I 38%G-)*:Z!U2UVI/86X4JN&=5)#=B*!I^F[2NTDK5
MJ>JH-#(5A^5(1")%<S$0S(CO.1LQVA7RQDOK;N_.M0#9%9K^R99F58M/6JOV
MMZT#J=L(Q1]+VF_UL_1*K/V7>ZV(DTFD/6:LWB:PTV;EH:8B3VYDA+#*X\G(
MRD\="EZ;J?I1O<N<IU/UIM1 NMYVA0;26AB>R&M=8; 'AMO7)6Q]<VFY*>K5
M(W168NVCQ]6 \Z46@X5(((C-^S=DH<&GR7Q1%]ES?IR61ZU5S8U-GK$ZAON\
M-E/W=5(W2,J0G9D.FV:E;^C4?:H.!$%S+*,IYHG!*A!)%24X:>2S&4\/7F*"
MY? FN\J_T:%VQP-<P!X=LVGP--5T'7M*HW+7]C2,NN;3LFG@]''Z3DB31PJ*
MA5JWRF\P/5=%BDD%RUL0G'<J!<OY$F,V_J+M+3DEP[8;Q+J77>A0MX2K.1)[
MRKNX-4B N=J4EVU/W1]\9N45>QZM;VP45CN3%&G&XTJ/.:<:D>1X3JF8&PZ3
MTPT.+&:_L6KK*>QO37-^U;\H5.C[FW;8]@Z_43+W_97S*.JT.Z6 F^0/;!ED
M2APCXDYDXGE3DIQY>. N3ZKX$>,[IZ2[L$:UJRS.R3E=J5HU;7=;;HJXGL,"
M@TZ\[/H]59UT/8[)UV&,F5ZS7BI[1$CY/O3K3DUXXW!(95)?4SD7$D>=.W/T
MLK.O]5W.K4';0:B:Q*CI>E#K^B.QK6+'8]^3Y5+C3Z1(+5%9;;EFV;+O$A^1
M*S\5F3<D'23Z\J6N3P3$F8A/'2N^1*?H27IW=I! 6H$8HRJP=.]GQA'7%7WY
M8#X.8];38T'!):^>M!*J39+<@I+BRH,:-B8TMAG+;N7Z%^KU,"N[JZ+5-UZX
M$#.Y3#==J._D5^Y;F@]I=CC;/40K@"%O6MZZ/[8;LP^]Q5?=M#=<##');DMJ
M"[(A,.(5)<4&)/I_X$J0;Z8G:GU[ZP'!VS-6Q9]DFUWK'6+T(["Z0O\ #LVH
M::DPG&M+Q8FZM>A$JMT@X[$AOH)M(EP<R!S:GT8>C<$^KJS]:IW!T@U(0%O:
ME^9/-L.J:PQ9+N(J>Y[T-@A;G<KX=UD7W/>2 T^Q5C]\O&RCL]1&Q26"L]XH
MN80=RPII_ -2?J5X)G=$WJ9M,C@'V)DZ=,*NL:QC+4/[BS-'6HWL3;38 F,U
M=5+.Z_KXS=;5N"RIP :J\3)+XE(]85Z?AZB1?J_3):%#T%TNV?K\K=G*A:C(
MP1:K(6OIC>)[=4;8T.R@@H>OV,?M&3MDVS>)8\55*]$AX@E5/"LA\?U"%Q)*
MU/"9DNA#VU?3TW3>M%;" V0J#V!VH#7BQ:7L.O[KO72!O8;&L (0)?X644PS
M1<C;&'KZ(4:>,)MQ2,MH4E*F7<C?]G%^I?R)QGLITOV/=JX0G*.6:22I0+3L
M*]'-7[;EZL^6NT@?5]Y!ZYMUV)U?.M(L[:@]=56B*9D(DK?E1H><H?E98=$Q
M)$"VS4NB.C%XU]9JOM*N$J-5J[NN5;M71^S!RV:NIU6HK>BA-[);;UD^5M=+
M#1]<ZY^#S,+)M)GC1*W)C3^$+=S"KD^ILUD^AE/IMSUQ7*W8+E V:,M>@+;1
MM?U[=>T;QL +1Y-BNU]1)C@FS]P.0AL_L#/(E[7E[*IDZRH]8@_*D1D*I/J]
M2>6.U=*=A4K>5SL#T<O4K53-)6#<AC,+9 N6[6YZ')NE2[:8S(X_7CH>1GW$
M5X6F(7$3F4.O98DLH4A_D/J]" U'=/3.AUG=NM/EK=<P>_8XE:W3&VUJ+LG>
M+#LB^[&%4JB5RBFK+M*M'#FS+=>:J<!0! E,N:I\(IC##:(+.<MBM2?7H6=I
M+0?56WUL9?Z/5KF<PS9:IF)/VO9-TD-@U UH:WE7JI29$?;IU^[U(5K:Y(EJ
M;!+2R.5(RIU3+Z7,.+$;DNC,'?._.E]NHNY0VY=D)B5'KIM/3XC:Y845V539
M^L]D&+949^K"\:XT500_#:A7 E"2X6%S%P!\J++9FO->RG(9!*2]/B0*W%^C
M]"/6Z@VP-LS;EP.U&Y:>ND*?7>Q_:*Y8UZ#!U'8MU#32C\79-AA5.*%[#AI#
M\J.\EM[!6/&0XM45MF/!]37Z&'L/7/0R@ZOA]B+!7+O;M,6BO3+4U.I,WL#M
MG7?PZ\:M(5@QN&10:61LH42?LFM)\B/-N"QS1-Y4UQUR9[V4XZ[2IR;Q\2\Z
MQL_K,-DV?;\*.=J1ZD5S46D+>_:Z?LJLV>M ;$=CR]54XQ4;,+BDHKLDML9M
MY+JH>9#:)Z527<-IQY!&GZ%%ZUU#TAW]/M\*GZRW"0KIH7L-J%./B>S=(U"'
MC6:[19.P9.BB=C> :_HY.TV\>B6N33EP)4I#3CK"_;Y=RH7,D2MX/T9'TVVS
M+7,DVH)LW[RNM%R,;6M.VMCVJ3"T_'W/8MD44@=V"7L-QJX6G#QMM(/2VWH<
M?VR4/M/K1F K(GU9*G>K_P!.Z97Z-9!M2VAM*L]@=<[&V/KZI505VAVJ.%U(
ME/JSFU;Y6=7A5'?N6N$FQW4=@F0BC0MB:-374X4B:N7C(OU>GR+9H^Z.B^HM
M6W>V"-AI)4"W6S5,+8-YOA39NTB]Z.[UU]09>LEV2TW[YIM5K#$]5V,*OSNO
M/#@H)M>9/M(\65EH3$F_U*MQCH#J*Z6^JFZ/N<>6T@,H=FG&;Y3NU-IJ6JZ/
MKR_2;;K%%$NEKBF:O5]7N[#UDM\3 !RVPYF2&;:]*2W'8;0+]37P+VVCV'ZF
M[+A6W46S)=F(5'!>S!Y%F52]K@J*2OVEU%;O8@&O=Q@0XP7+VCKB=KV9.80"
M+8*Q201],->9D%Y#(B4EU175;V3T&JVOM;6:K6 K?A-B)T#M'K@U%D[CVUL3
M9-QV>U-U/0+@@E.<L-\O=X-1O5"-"R#DB4.BQ,,O1HL>$GT Q(F$&F],(%:G
M=KY0(T/IT.QW.S$!5P^]Z/4Z?L2TF#>M]E&U]=K2]\ IFQS!HT3&&GT5R,0<
M>F35N9\9<IU\/J_I(GI*K_3_ ")>G2=53G[6;1M2Q:>HF3=QW#;I]'O/567;
MYY;55?;NQHD]KNLZ]>@$9<<.C$(+.8S'?9;DL*@KX*W+XDCDVKI<!@7?J;+J
MU@C:_+;;QKJUB'->[>?T^#V_N$B!V&-IH[8Z [U+H98U9M@#)@A@<3@11IDE
M&:@YC2U,MX$^KU^)!:M?>AE F4:^5I.Q+L6D0ZKV.7M58;L/N8]5PFQM>6;6
MM(V'N2_DX]K+UD#.UL2+01L6R26V!PW,F4W&CM-NR4BXD=-;1VAU\NFN7!-\
M43N%-M^RK9J2/70M8O94Q9ME:?FW.PV&J!Q-6&YL9 B&(:>+.,YCIRS-<'^F
MRM[UFDNC*3ST.=)?8CI3=0UE/O4W;YS&X]ABSA<.SH?L<BU7VV]<)M=9DV4-
M4FJ@Q89HC3Q/7HV.7DCXR8+$R,S%D^K(DI:?AK$D="ZNUKH72%(D;9UZ<OH_
M62*(4N<5@IMS=%TU\)HY)G-[EEJWKNWW"P5X"UB'YGV,01K$AAA:F&4H0M36
M:9;;Z/U.08=W^GD=N#=N52MLE+9?3$BQ!-/V+5?9^1!LQ7?%$V8Z:V?3>MMB
M YJ<K[QJ+5+8V6L@X#Y'$((IE2$/S7_<C6)&QH\[H3%)A8%-I>\-FV&7'IQ-
MM$JC=L-QV778O5&T[K3:G2K._91]F,ZI!4;:E,/1%U@@H?%1+&R%R8CB6_/P
M/JQ^AM-=F^A&KQ\.WZWUEL4)7NOI$7K^I6P5J'L61K:C]/M%OZNAJI02TH#.
M'[/L7S/MDT"9:@J*22#T]Z5G+WHXD- U)]/G_P"IDWVU]'9PDL#ONHMN.2]@
MG[9V(L@B5H/LGC8S<NE2ZU7[#LTNR/J>+]60,-F3 &1_#,>%*&I5#CM.1$NM
M8!<O@>\6R]""-CVK8 % LIILMU^"Z/VWM:I:JW<3UV1T-7-72-J5^K']H@@3
MM-EL#=:["]Q&FHFJ*>F29BI?R[Z3*0^K_>6)8=\]*+EK[4A:;81]\I L#IW=
M^F!8(+>;2NQ,6R:6HFF)%:K(8?+)W:RD#.)$>$#>CRY\:='Q(?BM.Q</,B8D
MG^I2)E_Z>%N&;)I<K2VP+KCLW5[\,V_K -HOL39#"PHBY9A7L?;Z&'K4F7JJ
M=&O]A7+2XW'%2'B4G)&&XM2\2LB_5GU]"P=9 NDTWL3)8I('8<G8HK8NPS86
M8>SV%G:/1N:O#)=8VI)H"+7-DZ&;VI7(&9D,BL8T@E'4F>AI7G;GX0#Y8Z^A
M<6TMJ]5X6RKL+V2<A.;(T9ULV+LBW0TPKA+F5GK[<W1JMC34(!17!Y9V=G74
M!R1!C>Y-1VD15MM-HFM*?&4GC]&SG[8A_P"GX9J^I$2DV2U0Y.LM"BM(+TPC
M?)BYOZ[L)POL;1RZ'.U*XJW^M@MUWEDD2F7<$(S817O'$-.^5X:7)'9'7LQK
M,]K$84U+9[G:Z@\6LD3WVP[/LRTW8=8!!V>%M%;L[VX"!#8H0U6K .D09(HE
MEEX:\PIGT6\)\O!EYSU+MX(. . . 4OOO4;NZ* U5Q]C^4+*!NFO=E4FT."4
MV"$%O&KKL"OU5DF*\J>*P?K[Y< W'(0TRXCK\)YU+,B.]Z;[8J>&<6B^G79-
M&S"G82P[QU =W['V *LM3)HT_9QNM(NOXVMM@ZW^Z@W38NSL'Y2@36P91*'8
MV32)LN5A#,F)Z#>,+&N2QC'0TPOZ:#@V((-/;_MR=AT1.J)VM3PD7( 4P-8]
M=[(L.ZCI2T:_BV9V':H-]VE>SWNHBYC.6*]*C#L.NKC9E.AS_0E@KI5M*9J[
M66H+AN#7LBJ:3?NK5 (U/5]C$V"3 MNA-\:,RU<'3.T;"-F3AT;<48EZD-B&
MAQP8XUZ:4R4JCD.2SGXF(?\ IHZN(:CU;IVGG\4$#1JO=AMBF@Q<LG-M%EM^
MDW-1Q;G$0=L)%H-+"SF8I5,5?NXLCVWMEI\JUN9#D\Y)Q:.K>YMZS:NWV&["
MC"=6J-T'6M5&T722FJA[Q:LU.T! $AVQ3KW=+>W,GE;DLL2CO3'H7F&C&([#
M66I4F:)E+T74QJGTD(56F8J!+<$D^P/ZEW3I_7C)BN>)9BH&;//SKLV;F+L"
M\G3U4IK@X5,SGTEF9D5<OSL*?]% <NN?UR:,1T>NH.O9T_'V_6EZ L.R-;;:
MNP)_7D_&RYMLHT_7UD,URLW5-Z2#$TV]777K)![W(>:4'1ILN'&D>545^$'+
MX_$@$/Z9WRX_7I=2W %@K8ZY%M/7>G6O4E>O&K=D7^=*U!#>VM8J"<-^AY+;
M0M3-5JSC&Y"7"X[V<AF9"(0$2W1>?3^9TYUAT=L;KZ-Q49MLIIZB&2EQM4VO
M@VKW" ZQF2H6NP],HNGAUVO6P"PK7[F!!XL3CRR+C:"Y/_U>S"B?[,D1M,@R
MNJNT)P78>MR6U==JU;<.P3'82NMC];V%C8(LPWV:JO8QZOESLC9DNN&ABO@L
ML2EZ.*A.I2^S(SC.6EM/!R7\\?\  I2N?2\:KKX7+>Y%2AU=^'DP(==%;:A!
M+<9U[:J#M^SCU)LZG</[39Q59;S:O'$)\#*\JG<DW%,"\RW;)T5D62E)H;FV
M" L,6ZO:+ZI7*4%!.CC)G7^MK?,*[$?$$F3WJ "&T*85FA&U)P\H/[K,E*I*
MD);X)R_S)-KOIU]V]EKCXS:Q\_3J3V8NG8^L@[>B78[(-E;*TM?=>[!J<NW3
M3>7ID(QL;81&V,R51DJC.S'X7IJ1EMYL&_\ (KNL=)=J:L#F8>GMZU,+,V#K
MXOK+9).XZJEVA"0B]H;JV/4;=0HD+8 )H/;JHSO0O <9(K)BB?IQ7ULLY9=:
MDAR3]41=CZ9]9KA/5Y>B[@,4F7KO<U:M#;\<$,).7;5-4JM6$U34MLR1GJC&
M3-2M=,B6 .<6TM4&8N:PF$J*1FMNB\OFBY^IG4VS=<[1=316]TJ0-LM?!!&M
M?ZCH9G5FMI9@//)3"6V".NIE^NE3K6PK:F>AB:U68@05AMG&%,O_ -1[824L
ME.6GZ?-SN>H176VQ;OKV=(ZTJ&TZYI*% UM*B[ @R;[J?9&F:?(V98UWI8NV
M0=64C9Q%AIH8/#/'9#<>1*>:4TZB0')9SCJ=/Z%ZM5?K=?MO6#7Q!B)0-J,4
MHN_4BD:>8/5:W54:0"%GANQ#QHI8IE +"<Q'XE?EJ=C!">"$F(XE!)UEL&\I
M9]3B3'TG*R$UD)IFOK^#C326BZ5J;8TJXU*P7.MW@I0-CZ_V>"MP,>YL2$<U
MR/LI&I3(5D$A"D>(<AS8;BE-R!$-W@USZY_4FEYZ#7>V4*H5!JU]=*D_72%X
M0#4"TQL&!\EDKFD$]#V1J>XQ][0MP4;:H%X3)]3$:RY"EF'6</0VG(B'E"<D
M7?MWITO; /;]?);1G.N[:ZH4[K&0+&PC10UE=8-7XO/OQ=Z 5"()D+$F\*P_
M&81#PVZTIQ#N,+PEL12P\_)E06/Z9- -2;Q7 -R?K^G;]<35Y(55 V:?NPLO
M;>L>Z.M-L&"]G6"Q$RTRLYC;/B'P\$BQ.:!D(DZ/'_V(@AB$+R_VETV'0V]]
MG:BW3KC=V_Z279V#J]&L@#M%U1\H5VNNY:+-%MD6""8O-H-F+79O?,)=@L%(
M(B"S"2AAI3CCKZA,I/*1A[(ZDVD[OHAV4H&R0E=V./FZWGTH9::7-LE0CXJ-
M&W%KRTA[5&&VRO%"@^X -NK<COPWX4D5.&LN>,IE;T9P%+IQ^!1UN^F<_? 6
MU)MAW6Z-VWLZM7@E%V=5*)'&KUYNJX6<Z7CWJE B5D+>2FB*J615I%?E2GEF
MP'NF9TYQ<Y]>!>>/X%@47I!;*9ONE;88V94((NHY&9(3J;KDI1]H[" B]<8H
M4#5NT;&"OC5&V-K\1-2T3@RS-<FV"*F#"BIF^:-[Q8G+I@E.TNI]VO9??U>J
M>VZ_6]0=IYH9_?%;(T)VQ7P?(BZ_J6K[6SK.X,VT4)K_ ,_:SIPV XDJ)*9#
MR4N3XWJ*>PPV'+T^:+)ZW]4->==/G(R$AQ)]]OUYVQ;;5<F6RL)XK#V1MZY[
M2'A71<LV6@M8K3-I:'^NUAM4KVGK92CU,MI$<F_X'+VP?IZ'=C[ VZ:*;6J-
M1 [8";=#ERNN]:3:=LBZP=DU8]7J\"W%D;?6=5;2'ZGDEXLT82D5=BPRUA1Z
M'YZ<IG.D!I2PB6O=1MU%=AH[#'-RZP7V2"V>GDJN\(U38H6GF*G4=>[2UT_5
M#50F;1)7.=)L\#<)<@Z2:.,K@3&X*&F76(\A$T3DL8^!I]E?3O&;Y&;:([]O
M-;V;MC977QG38F].:\2"AZV--V?=]FCV&HUH=:O%5>!XVW AP($R7(GY8K[3
MDLC*?DO.8%4L>GIDZ'WAU6J&_;WI*TWDJ277M0C]E1WJX),6NK2K+(OX( %;
MD*LU-M-:*P(HI@.ZIR,K,B/+P_X+2G+:5<&4\(H9SZ<NLQ>PL[5H9 )4;8"W
MOJO:.NH#%>DS:!7*-KG4VLM.O:C)Z\58VJ@:C.5RCS)@4RU$AE*Z:DPYL92E
MP/+(&N3QAE6T;Z8B NKJ_I:X'=,S*,(L>B"YDA3M:[#KEOV/&TEL -<VX%TG
M&=UV86V]:F!CJ7W1D:#B/,D9>;1EE.(^0Y]<_$MXOT6;%]@ &W]<YTW#K=?I
M^F*8"K%^HNPK,?I</45IO!YA^EV@'MZK0VWBN+LKR8)CB.6)45"U9=;5EK G
M+IA^I3I3Z4U7:IIL/2]BP!ELN^M>Q^L=BF['6#5M"645O.TE[H--A:W)OL;Y
M!L-2.RV8LYT+)B-V .[)BRT85B ] %Y_/TZ%F0>@#!@:$%7PWK>M"ZW&V:JO
ML:0I=OIDD+:[QG4Q2L;+"E[SLO8Q$/L+6]JU-#(C9;"L,Y<2TE36,(<]8.7R
M,K2'3'>'7P  JNN>Q];:&V"LZ6'[JLI/3D>5;SEJU/5*_1CUQU@G-T75*6K:
M5-K$*%)@$AYR,$?;5+A^HI>6< Y)_ A-#^GK9:'2]E4&#8^N,B#=(Q]+Y<MH
M6R6F?:HA;:K&R%5O;5?N&XCU2LU3-0?7&D\"X80CC+J)<"7!?:;S@.6>O4N"
MM].;-&ZJ[#ZSF-NOQH6T3\UHW(J,>VI"T#55IEUZ%>-1:E;NE[N5NK84Q3(!
M.)!E22\O J>:?DQ8[49J,/:$Y=<X*^3]-\*^9N6$[GM\RFS'-J6/5RIZ'S>R
M--[;V6=T=<INR*OL0@:D9D%*MM72.;#"CN04-^Z-3HC^7(BULN"\_P#::>A?
M3]V-4ZJQJ KO6E&M1&Y75HWL>/%U*5$[(M!CK1KK2E/]C7[ G:$JL5&N7TQI
M*'.DI^#3ID&)-D16'_4]&6T')>OQ+5[,="Z-VCN]QOUEM,D:5)Z0":GI$D?%
MFRD4NT5B^VF[Q[86&)/Q:WL.O2RA:-%*5@S"?&DH41Z+(RIF4ZC BEA8_4BC
M_2:^#2=DO]'V_3HU_M9G>D6U1B],N#-$(4O?&-52;=51RZ/M6H; J!RK6C4L
M24)+CSC4AAAYZ*ZTI>6I,<.2]'Z$%D_2QI]BIEK@7[8>=E;*-472M2KNX+<!
M-F+36YNHS90\LPE\M>RY0RV4F%,MQ6YQ"3+B1V6TORYJ\*<4^!>;3.D-H]52
M%S%=CVX5NI"\;VV%KB_R@&RM7"]B:]^':]H&O:5,I=RKQ(S DEQ-B30\RDDA
MTL04$2'FGXKOJ1<9=$3Q@D/6K4FR]#58?KX]>Z[<Z:F%8"XR<ZNXYD5NSV6U
MS20?7U);MUQN9A.J*A6GFX@YB>5FD,*1X-N-1O2BQQ&\]3F0-]-9H&0J1+&\
M;-9B!15:(=AQM\'2+;5]PE@G8^M]GYA %5IUA0/U[!G[&^:6$PTX(QT#;;)8
M7ZN&$><:<AK_ *"[2T7<EW#2/8*KJ<'V'<T:JQ=PZO.W_%)UALNG=::C4Z%&
MF -JT<C8)&H!G7*+"&32#ZUS!4EIB4G+T;,I\.2?JCI>7U<!M],<]1J[<940
M,K3+6IQ]\*0HQ2:]Z@1(YRT3!D24+A29)"3E<I4=AUAC&7/(WY$83C SGZN1
M5^V?I^:ZVS?]L[3.R0V;Y?;[U]NE5M$NN2)9/7\;14^AD<AXKB;!$8)HL3U.
M?SA[*&/:9GYSE+V&\84*I-+'P,_J-U"-=93IQU9/3IL22BVAE9ZK4"]5K8YA
M9^YR+;"=M!<SMFWU64EI,US$C$,1"]=_"'&_1;QEK,$I9(UMOH) VYL7:MF;
MVN0KU%VFT%C&:.#"(9F BAHEKX5V(+ +7!-Q)0TUN?5^HP58RYB/A85N29DI
MS(=*+0U2J6$14C]+^B6>>4#7K9=YMFM(\+LNB@C9!JRCME40GV?,:?NEQ,1]
MG#;/&D&Y ?9%#/&(+4R Y%\MFS%=:<:AIR^'-KT,9OZ;L:XNY:VYN607I!49
M#FG:QIVNYTF-,V]CK%0>JK96&Y7;&3B!::K6P>RX9 Q&4Q6%6?TVW?3@->J'
M+Y>O_GDLHGTOLUAUEL&F6S=>#UJV#UAT?UY*WN54,IE29VF;'LTNG8Y(:NT.
M^])6]G8+6)<5+[:&Y49QU+JDOI::$Y=?YD>L?1B\62K+TU*W#6XN@P-]VCM*
MB!HVN2/WE0;3L)6R"H4#:;DY>U!#5.H-NV2^08]J)@$R3$&'$DR<83+>FARZ
MY^)#B'TV/9E=@3Z5LNGS*O>-?ZMKK^G=GZB#[#U$W:JC:2UKV462&^/B"P@)
MN S+BF'&!DJ'/ 6F.Z8AS%KF2HS@O,O*%U3*+Z=%NMI_;JRTDQ(GRDW>3&.&
M M5'R=B(NHVFUB';+I8[0NF4R"TV$$H)'ITMF%';\SW@E+*!.7U9(K0.@\77
MF\-0;J";/G,/4<GNHKL6GL5J.S7MK%MBSM@JH%HE?^MEO5VY:PK^QYX94]O$
ME1L7Z#,E*$PH.(X.65@]#G06K3]U&.P8ZU,QMLR.S%6WV)FE!)$W5T5<3K.@
M:J.:Z/4B79\5LO,DAZI+(![&U&BE0!MZ'*8RO$1UJ6'+ICX8*K5].G8M=UFS
MJK6W8*/5PUFU7I>@;#LF:YL4+=1MNTIKYK68';.I[!K3<VO9U=,SJO"A8="F
M7#83WH]B0MMU&94:4+R7JUU+;J_T_M<U78=%VW!DB/O,J79[<'80W=L5]]!R
MU"MJ#=T#<42:[D\N-$4'C;6B^<@EI6).!&/]G:R_G+8G)XQ\,&HO_1H[8]34
M+6HRV:ML"*9?=T75UK:>J2YT>Y-VUL6QWP8?J1^D[#H.T=;7G7J+$["BD0MA
MC((QGI*)#*5.1W88<NN3H@-JR^S-'7?0UVOS5G<7K2/JJM[,)(E%;S8!<S4@
M6I%;_LN+)G>W(6TO>LEYJDL.M-/1?12M>7O5=4&5G*.>O^6GH7%6TG5TCG74
M:YL=--W\Q.-[ )6;9L*C:9VCJVO@&K=.OC]OI@827V:^:AQ(<]<.*^AU"6?-
M(<=P')]2K /TVC=&LM ,@+?I>WCM:4H?KFI_>GJ6Y33PNKUK<&Q-G50JZ7HF
MX:-!,W]<&^MPSQF?#DO'R8U)5Y*)$N6VL7G_ !)_-^G)1&]#[2UQ79M8SL/;
M&SY>R;7L&Q5^R% 5F0KM*OLG#JUDJ(R^!WG!'E\H.0Z.(CY#C?FD(4VK.&L!
MS><O_'0C!SZ9E8V<.8';3.5(2T&U%M;6%7'Z1!WRACJJ3V3;ZA<HEZC-6':-
MTD&2 J?5U>Z%E5S@Q5#V&GX_M\O,OARQZ'E"^GY;V[1M:QR[EH21-W"!GB3]
ML'Z=O >XU66<ZY5G0I9FB)A;M^2Q-?;77E3H$!\5(S$B2E0_57EM$GC]1R_W
M&Q3]."36-CD-G:SW"FN3Q;>GK7K2F&Z,T:H='VS02NP9FRCK8V!8P9%ZC;UA
M[$GK)A6)$9P6:F2RD.5ZTE320Y_,S-C=(-O;1OM*VS?]E:0V1? %6N]:F0+U
MI>Y-TD#$L]RKMJ"0-?#J3N6HFX,&KQJ\B(MTS.,S"+CBY"G6,93';!226%Z%
MB43J)<*IV>D[YE;"H\.'),78Z<C:^UX8UY<]J1;:.)#Q%4W5(#7Y>M;^)UVX
M08<%EW*NU9'LBA^'YWF1.<(B<EC!7&TOIURMB&]C7YG?UN#[3V7:]SN'9\B/
M.(T!O6VX-3R=&(U]$UVBRCXK$FO:Z$5EQ!/$KU)1NNHF9:0F0XRD52Q\.ACD
M/IYV.J[9+[8TQM\!6&6[YJ?8U(UM>->3K-0*$;IPSL8QL8:%17KS33356V39
M.PTRP-P$2&V@QA$K+/J1IF(\8.2QA_X]#M'KYI^1IFE&1)>T,72WW785^VI?
M;/!#9K8<G<]AV.98"[=>K:BQYT!7!*'VH,&,[/G2,1HR%/R'WUN.K&6\LO3@
M@X X X!S-VW%VPGJ"(]3*O9;F8KFX>NUWDUJG?#E68I6Z'O[6MQMZ [!8N!'
MS93%5"3'?;N2V?<);RWC*E*PG(J]3YP[^U#V,V]NJ/V U[J790A-/MNA-TT&
ML64W7:J9(6K1>I>W[4VCFQL>X28,*/?C=J$5M_U751E-61E]Q7IL.K8&DTE@
MWW7CJ1M!K<LPAOW7";31MB6#M3L+9D&XS -NJ$JR;QJ/1"UC@+U?FDRD:6'!
MWJB6D2,;Q&4Q%17\K3AM#K"WA7)8Z>O_ *E/U;J3V8HU=ZWGM<Z/IE8@]5=2
M:<*FM<Y(# 1_=.S[V)$#>W4.)" D%TJUV$[IX6Q58\ZS.X;494\ZT[EM"7E,
M%Y+KGX_X1;<CI9<:?7K%'T7JBLZENA?O/:+:"M=7$U0'@)J-NA7<;KVRSL"'
MF'I5*JEK.,26!'E<<95E2D1,>.>"<L^OR*F/=0[?L>GTZA43K3LKK^.BZTUW
MKCM+/B6JKU6Q;@M[?8#KE8';37KI4[M/*;#M>NPU3N-A3?)RFB*D3L,LKDOS
MI4:.')+UZF/L+KIV;LV+Z_OG5=KV29$;V.LUJW56HZGW?0MH QW7#1&L:SLZ
MZ==+I<J,F%&V.FLDO6D!S80W2K,Q-1%>P*(9FX%37P9TCM_4ILV6ZJE]U=/C
M6^A=>Z@;(UY;-;4R95]A0:!NNR3>NTD:/AV[:-]#DHSK<.IG(42V*(2)K*6E
M.NS,+=]5R&4_7#^)4W7?KCMRD[\@RNPNL9^R+'*1HP89VA/T1J;:@\NZ%ZFZ
M?UM;RV.P-FND?9U;@1K^#,M3&VP^<OK;=DX2Y@BXKE*Y+CT_QU-1?^DTJG58
M<[2NM8"(QCOAMFZGAM1TOJ+9KD[1\G76Z0NL9$W7-FL57KECJ8T_:1^($)^3
MZH5Q],EJ,A36?+!R_7X&LL73K=%FM)O:%?UB(#U &OIBN!36]/ZRH6\I55UC
M,S,V9GK_ &4=>9@3KU9@4]&)OP6,VN&190]$CRV7YB)4<.2QC^)XT?J=VM%S
M=6TLI4K0WK?6G:N7VS&2,W,4YEVS[CV+L$3<ZA(@XL*IN0&NQ4L]:/07E<5>
M+L/9CH4] =;8HY1]?TP-5=4NWFN@FOC8RLV22FY[8^G;7M\ZY-W@6OX)3M"Z
MXZ<2"&\*8ZY8)4!DU1+9KZUURTC8ZTN6,4ZB4A+[HZ-[L,Q_W,CFJ^M5]K_6
MO%&M'6&T&[7 (]49^RP#?7/15*+7JN:\[&ZPM^W*U(V"$V63F;VS,KHF;)6T
M;5%069C+?7C+[_H9A6^N4SI<YUNV9<NJG8W7E&U7/U+4ML=GM'6O3.D+1 IQ
MQ.MM5B+[UP=V=-*T&-;)E&@5@Z;J%KM#U1:(XCO09JVG&VI$QV(W3*:4D_T/
M/8'5GY"-N!;IUIB=HZ'+T!BBZK&:>H>M]8U?6^ZIUYV0?O%@B:]?MH,'J4SL
MH38*LVU=!CSDH>Y6GE/2(BG&<20Y9]'AE4Z^Z8=FZYLFE;5V;! WDH [1Z/-
M[#.5JJ52)OFQ"ZUUYTM1RNSZOO0I8?C,S5.=N!)WS35'1T&<8K:B:F%>HYB+
M-A7)>B+?^[.\4WNQO7;Q30=AO;$_98ZZ:Y-P-":9MDLN+%=:M;UB%$ []LM\
M@WS7F57:O$(:8:!S;$>1E:O'+4QQW@F<Q2S_ (R4O6>MG;ZB"<5[<FNXFY]9
MWG9FMNU&]Z/K>RY--7:Y26K<)WQKLB'OAH/'-QI-N.TZW0:\PK $C$J9*&CS
M.OL195+F+]/4G9OKGONT-["FZ!I%EZCT OU:WC4*MK0A"I=[DF3EJV'9S=?
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MK+:/IY>;D?>$(V.:$C9KZ([@&TA7!S^<NS8"4.IKBO3X]2UNHO9G:]ZN_7:
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MK,N J(+RB)+R*>D8<RWZ65!QRV7-0>Z=>V;?-?ZVQI780';5H14=@A*3<AL
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MN2$+?QC@?5T(;NJ%T[ [A-W8IV:NVG]R2+G=7SLG6EHASS:3#VJ>O=3N==E
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MFIPJMB!A-<<I%=M;,.-%*)(8SAM8B;^'J<^QZM]-07)#[-;VN[[ZP%4"Q_\
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M_!7P/:-$38[)6?JMD]%#9!GD0H3;J(283X]3"X+K$]\2\UG)]..OM.O=&IQ
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M_P!Y&MB?30V4:^,RJ'LFE5W&Q)W=<YM^K389Q%<M5UWM3NRU-T=L@-*'0_>
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M'ZCYRLWX37O]*ZO_ 'B\#'ZCYRLWX37O]*ZO_>+P,?J/G*S?A->_TKJ_]XO
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MS!0FVZW'B$B>%-LN,,3<P@X$8F?5<U>>AERE JEM)A:G:?5,F/; )D8[KA[
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M?^B0L1M9RO3!.M-]/ZWIYTZN'L2_V#U-4BM$T)R<NMBINLM15^>?)@*Y7YX
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M@N-"&19!%]"GEMQV6F$*7E+:$HQA.!DV/ ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M;\ZL(1YU)3YEJ_ZJ$^;./,K/A^3&/R\&3]\ < < < < < < < < < < < <
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M9"D*<]G,RT_B.]XMX\%>17A_]G!4\/)5^>M\*+N&U[BKNVMO5.5?#=2/WBB
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MM>/FX-<V=4TW2U)HE9N]4!,D,#M@V_:=VL,B7*;?)+,[@M9ZY6Y$2:F,TMB
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MBT%G8$C#-59=5!+,V-J%*PA2'%0Q,+#:VW4R'9 %@\$*\J7_ +8;5_[S5_\
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M-:P4ZNE_?Z]O-BH)>0H=/;;>]C+*UMYV,[CQ2Y'6C.?!7F2D1K#P6WP0< <
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MV(<:^0HCXJM0&[7"ET:B66L6,:253)+ &)8W*Y,B"WB;3>&R4XLF4RAO,+T
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M ^(EK-V R?;7\'J52U_L*UW,E,9/WZM3!4&I JM-L,@P/+:JL^)$3$;$AF.
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M"B(; X2'@0Q8L?%1AN-!'#X[<2%#CMX_(VQ&C,I0A/\ T)3C'!#/X X X X
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MI\S%)C2@]J52X/N!Y"+,&SVDN,RH[S+KC:@Y/.?B<NY^F'4!U\J$2LV^0+T
M/-*MM_UE*?M4XKLZQ.-;4;FQ[;+39X]5GC"'WJ/H0Z@6P_!@PF8C:5X:A/0!
M>?3]3JW574RAZ9K1*KT*W;,$Q"L8E$ES&[*/8G^E)  ZR%<:^'@8,!J941(%
MO Z1B/[A4A^1)EKE27W'5".3?J7#C7RL3\3_ )ZV'^0K@I[+-B:]AG&+A,M_
MPW,?X=XY%9Q,^%9:\WC\':;C^;Q3ZF1DUGW5K]C['[RMK?\ 9F!OO/FQGWWC
MBJ&JK\0]?X5X?$\Y,_$_5\OA\6B1G_+X-Y;4+DV,C7JI$Q^9\][%8]><].]K
M'L;3<-GUBU-*^S89R.5EN"UBGYC(;\<^6(5(M^/^TX4V&3RQK=6',.?>!LK/
M@_A[R9LS7I_DGW6?Z.4_#?\ \!GYTPQY?_W<0-1X_P"S9RX&3'=U>IV,['^\
M?:3?J07(7KM6IE$EOU*N$K'O&G/A>?+.1D)\12YX9\"DR2_X>#N$)$-BJ@*5
M,:F?/&P<>D1=(^U386\0W,.WO%Y]@ZS\/\5CFTX^#);\<9P"_P!E\?'^MX!K
MD:O4@>D?]X^TEY3$CQ/?+M3*B&?;THM2_=*D?"\8S+?R5^+N+\O@HW%8D^&,
M-Y;4*93NN5.J<5\_;(:]200?\K5E:0E'OR53(^BWCX;GRQX6*KF/'3_^+C$Y
MZ/'/KXRV&3TBZ]5%D1I'SUL23[><*G>A*L;3L=_X69M)C,.2W@<C+L$EBT8B
M2F_'&780V"WXIRQE2Q#5:VUC\BV#;UMG%&S%AV_L=5W+2&(68$8<-$U*K:^I
M]?BM9D2%NI$U*FP\R'E*QF00?DNX2A"T-I%;-M4O_;#:O_>:O_\ N%5> _1%
MA\$' ' ' (%</^W]6_\ ?V;_ /+78?!2>\$' ' ' ' ' ' ' .4^UO4ZM=LJ
MP'J5LO-XJ00?&N(XB/JKH&0-/C;O5Y55)9*AK,%.AI1D+$E*D!YCL=W(Z7E3
MF&U^;PP+&7$KR3T#UQD+2X R][$$F-;%-@6:AV)I^L3)0&X7S=^NM^KL#HZ;
M6WQ)7 6Z:SA1V8C[*HSXQ^0R^EQU3;[0O)EG5;JO5*W1-/4>1<+I8<Z=W <W
M>/L99RN,FK/=;(8V.=,YL30BO# Z!4DEL\@I+$&+#RVAME*5>"5><3/K^ISK
M!^F+JL=2).KXNS]L(ULL%9OAU7R_2<K$['MVBI/78SM2.<Q3DEY!E6O)LA3(
MQ]QT*V2E.R,Q5)RTRR-<WG/Q+9W[TKK?8NQ:^L-YV;L1A5&'5.,\*%?*WP0T
M6IU\K6QAUI:%DZ\1A5NRD3U9:CSY@]#+SHMQ45E4?P2XD12:6#+U?TNH^LZU
MORI1[E=# +L".(AK"-\M6K0FOCB4"TCYI"LUZHUP)61]R+LVU]10QB%B06<B
MQ%R4K<8RIP')O'Z%/UGZ9&HZ_9X]J?N]R,$8]AJ=X]U) :PB%W;^"M6L+@>L
MJ[-!HC%D:B6\MJN+E\8S*:@1FR$U#"$HS$3#%<V;>P?3CUO8KV!NDW9NU%1@
M%_D;-A5A^54B B+;)&Z]B;Q??#K)5:7*KT,I8MES(I+$%3,HC"AP4NO^9AQ3
MXG-GJ4^G-K"9$"18-_V".P&UI5]2N(DPM<V8<9IE5U',U'%@&P-MHAP 1R1@
M.1Y\S#D7+3LF/EO"$1WG6E!R98L;I?1\:*H^AR=VV 7!4:Y$KQ .2B0Y9=9$
MI*MLM02*W)&2QXBFA\7%^,+&1FDMCH$:-';7E#7BH.77)DL],=:M:]VEKG)^
MZ*%[5 :K"$B7O@R2X"1IRD5.E4@[7W,!/8I*0_DN"1=3+8EQ'IJ584SF.K+'
M Y,B,WHV-/'9)^X;PVQ;)%MFZZ+;<BD(^OHD/9I73MX,;$U,IQ(REQ)-+$TF
MRE\81"#.Q&YL.'&9E*=5B0[(#D:LM].K4)BA-:]DV[8R!#476<1,IJ?6TD/)
MJW0)GKL#5E:ZTN-YYM1-NRY7@UX*(I2IO#;/BSD.3SDDMIZ-T.P3X-@'WJ_U
MRUUZ_;)VA3C\%RL3OEB\[*V]5MR$";0HK79@PI 'G:LB W$E-N(=%RGT.*5(
M]&2R')GXHW1'65%(!R\2VW\J6';!H>TB$\K,KN7+!=Z2_M(E)+$V8-=A1F6[
M:?V\6G3X\5$=AIWT6XB8[+?IJ#DV=N\&1P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P".V6J K=$'PS\%,UH2>!6<8K#CK#\ [6R<<L((19#"
MVWFG&)<;&%XQGR/,J6TYA33BT* @D3K_ *(@-06(.EM40V!AN191K,;7E28:
M@6&6W%9DG(;;8A*8Q5YF!'0J0C&'<HCM)\W@TC"1<LRAFD-1@R]8.U_7=1KI
M*GYE*KSU=!CP*(6948]$SYF1+$-J6B.U:2F6$/8<0PX1DN(PEQU:LAED5V'V
M@T5JG-K^\"^QJ[BD3X8VTJ>#6.:D3,GZ_L>THK3F1@B;[C#E#J9 AYF?43A,
M?+><^LI#:@PV4?L7ZAV@Z/0SML'8OEJL(1=@8D:X8UIL@%=!SU;D4J//E7 4
M;I\:7KVO+SL< MDL::ACGVB\9QMU3:U*0*HMO!*8O?7JT1D2X(C81$\39M0"
MG#1%>H&Q+ 8M12T$[6% S:4+#56=.N-:GEZ(:8P7'-R!C:ACRUOI:]-:PXLV
M.SNUP?6BNS")-+,F%=:]<:XV*4Q$)0(_S;&V+\Z8B"167T9P/E#,TQSU7'_%
M"_<)\O\ U5<!1SC]2*6OO]H(&.M<P&3/VB73"<J"3%(I=_"2SS0RQW&E&G=<
MNEJ<W"V,^,O%$(AEX&.N14D&<(=D-(<:6X'%FKI7U#="E-?#;?L0@6UJ:Q1X
M]NLU>=J.S;"/"E4#*V6L&OP=H1KH/&O.P:?%N W!,,,C.$XSDA2<Q\^A(RT#
MB\X1)F^_?651UJN.V6]0B2R;X=]9+2VYA@P=/&W$#KRRMEC,^AQQ(MBDWRUB
M@YU]]Y# 8@3C-2UM9<_('%F3N+LK?M3;DJ&O5Z@KY:B6FJW2\O[/G;8P"4 J
M>KXU8G[+(D:8W0#,Y^0"'6EIV$PQ+<R1]%Q*E1\^7*H$DU^IYS.^_6(3!K1<
M_<;35PENJ1&[ CEKU-MFLB90 =5;7>\+7+.4F"F,3)4>D$R\."YA,V5 CH<;
M:SF1&2]2<6;&#WAZYD"U<KL>RV_%JL]@.UJ!39&IMKQ;I#(5U%*>)/'*A(I;
M=C "_;;)KS[4N9&9CO13460A>6%+<0+QD5/K?ZEO7BQT6IVK9Q9_3)NTTF1L
M9ZI6(5="3]5JDL+:[K4(MM,HI0P:(N]NUM4)9R*#QZDI]AO.(:IB'(KTH5P?
MP.A]6=IM-[EMQ:BT,K:I=H "XQ,\,.:VV-4<@LR1M?-($')%KJP:*%LN EK&
M3/ADI;,Y46:AQ#2DH>],9::*]H?>K15X?'CW7;O5"\^^']?NP++KRZ18X$I"
MW/=]$TZ5<3T8')KE+A;5OE!G1:THI+BY*/)]!KQ?PIO KBT03<'U JCIN\=J
M*&<UO;B97K?HRL;E K&3A66]T$;'EZ"O6U02]E"A-J&'RM<A+7,_J%YLD9S&
M?(T[X HMX?S9+:KWTT09G!@A\Q-KMB-%*N.P/AU^ZVD774W0D K57D7JW!ZA
M\ITELS>+"P$9<G3$17)[C>$/J2O.4AQ9G9[]=7$M#77;Q86<G%0)-?8<U;M3
M$RQ5<H M=L@;( PL4Q4HMJB15Z(:(8M+*% ?:"Y"\ROZ&,9#BR8.]L-3R>O=
MR[)5V69,T*IA"92.F?7SM/(V6:Q!B2@(@#'MXP,Y-7<I)6#'%R4)7$E/36\)
M<SGS82)Q><$.KO>/3A&@:VMM@:MH.R7ZN&S!+78.H6K9-CH1*F6?&O-@A[C(
MUX#L T1&IVU$.5ITE(6P/DDF\^BXIM+BVQ>+R7]I?: G=NHM9;B B3P()M&B
M56_"0UH&O"+"+'VL+#-Q()@>_C"H\Z,Q,2E?ERIM><>9M2T*2K(C6'@LS@@X
M X X X X!7E2_P#;#:O_ 'FK_P#[A57@K]$6'P0< < < @5P_P"W]6_]_9O_
M ,M=A\%)[P0< < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < T%@ J/LP64G#X+V,_,[+M?GMCWIN,
MCR _V4Y;D:3A^!C,_P!?#>,)S[AAI?CX(RG($-SK%S,:1&^\?:.,R!DT9[C%
MFBXDL9F ZB$P1CN?"/!LG#S4\S&7?#.$3BD]W*<X?2AL7)L,4%>)CDOYYV#G
M#A*,2]KD_'S#1B->B%XR/;9^&^*1LA$_X*XWYLY4"8:C>;"D9>4(5EL0,C75
M+P7>O6VS+[DVET(7&;M\*/.(G[WD9IBO2'R"PCC<60X>MD<K(E^DO#1)K$O#
M:L(]%0J/GU2OJ"T:SMTXX8';OKT,U2I][MD*+>A=EE5&SL[)IN!FK8X<76$O
MV F=KX",0C*\\-GY=LN4J5C)%I;0VXLO-':33ZY@L6S9^S;Y8M<&=9P1;<2
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M(&,Q3=@CS8A7V%9?K6<EVD#(^9>9JG_B,CPRCU":$O8\,8]/(9+#X(5Y4O\
MVPVK_P!YJ_\ ^X55X*_1%A\$' ' ' (%</\ M_5O_?V;_P#+78?!2>\$' *
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M,AYQ:G'GW5K5G*E9SP0D7 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MP\.H?Q$*0HQ"-AYOS8;>PQ+:=:]5O"L^57AXX\<^' (]]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV
M8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV
M8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV
M8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV
M8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV
M8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV
M8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV
M8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/
MRQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6OOU%IOV8"?F/ RQ]W6O
MOU%IOV8"?F/ RR0"@H<%'7$""1H>(X\J0N**@11\=;ZTH0M];,1IEM3RD-IQ
ME6<>;.$XQX_DQP#9< < < < < < < < < < < < < < < < < < < < < <
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MO#G!>#+CU_W*U5L"]7.A-0+169U&$7XX7+V)RE/A<C]7& H&^NJ^4[I:#(5
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M_+J?2'K\KOIAP9W]P9' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M+OC_ ()NP_ C_3+^7^9]/N# X X X X X X X X X X X X X X X X X X
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M<#+'W*Z;_"767V#JO]U<#+'W*Z;_  EUE]@ZK_=7 RQ]RNF_PEUE]@ZK_=7
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M?]X? POF/O1VS_+1?_MYI?\ >'P,+YC[T=L_RT7_ .WFE_WA\#"^8^]';/\
M+1?_ +>:7_>'P,+YC[T=L_RT7_[>:7_>'P,+YC[T=L_RT7_[>:7_ 'A\#"^8
M^]';/\M%_P#MYI?]X? POF/O1VS_ "T7_P"WFE_WA\#"^8^]';/\M%_^WFE_
MWA\#"^8^]';/\M%_^WFE_P!X? POF/O1VS_+1?\ [>:7_>'P,+YC[T=L_P M
M%_\ MYI?]X? POF/O1VS_+1?_MYI?]X? POF/O1VS_+1?_MYI?\ >'P,+YC[
MT=L_RT7_ .WFE_WA\#"^8^]';/\ +1?_ +>:7_>'P,+YC[T=L_RT7_[>:7_>
M'P,+YC[T=L_RT7_[>:7_ 'A\#"^8^]';/\M%_P#MYI?]X? POF/O1VS_ "T7
M_P"WFE_WA\#"^8^]';/\M%_^WFE_WA\#"^8^]';/\M%_^WFE_P!X? POF/O1
MVS_+1?\ [>:7_>'P,+YC[T=L_P M%_\ MYI?]X? POF/O1VS_+1?_MYI?]X?
M POF/O1VS_+1?_MYI?\ >'P,+YC[T=L_RT7_ .WFE_WA\#"^8^]';/\ +1?_
M +>:7_>'P,+YC[T=L_RT7_[>:7_>'P,+YC[T=L_RT7_[>:7_ 'A\#"^8^]';
M/\M%_P#MYI?]X? POF/O1VS_ "T7_P"WFE_WA\#"^8^]';/\M%_^WFE_WA\#
M"^8^]';/\M%_^WFE_P!X? POF/O1VS_+1?\ [>:7_>'P,+YC[T=L_P M%_\
MMYI?]X? POF/O1VS_+1?_MYI?]X? POF/O1VS_+1?_MYI?\ >'P,+YC[T=L_
MRT7_ .WFE_WA\#"^8^]';/\ +1?_ +>:7_>'P,+YC[T=L_RT7_[>:7_>'P,+
MYC[T=L_RT7_[>:7_ 'A\#"^8^]';/\M%_P#MYI?]X? POF?G.TMM8PKPZS7]
M7@GQQC%]TKCS9_+_ $<>.Q,>&?R?]/Y/R\#"^9>D5UU^+&?D1G(3[T=EUZ&Z
MXRZ[$=<;2MR,Z[&<>CN.,+SE"E-K4C.<>*<YQX9X(9' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' (Q;H]SDB?3H9:L!CONF%>\MU>*V83[+'G]RS\-#6>I3/=.
M>*?3<]WY$>&?%"O''@!67PCLQ^(.B_\ !Z__ +\N"]!\([,?B#HO_!Z__ORX
M'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z+_P>O_[\N!T'PCLQ^(.B_P#!Z_\
M[\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#HO\ P>O_ ._+@=!\([,?B#HO_!Z_
M_ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z+_P>O_[\N!T'PCLQ^(.B_P#!
MZ_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#HO\ P>O_ ._+@=!\([,?B#HO
M_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z+_P>O_[\N!T'PCLQ^(.B
M_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#HO\ P>O_ ._+@=!\([,?
MB#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z+_P>O_[\N!T'PCLQ
M^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#HO\ P>O_ ._+@=!\
M([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z+_P>O_[\N!T'
MPCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#HO\ P>O_ ._+
M@=!\([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z+_P>O_[\
MN!T'PCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#HO\ P>O_
M ._+@=!\([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z+_P>
MO_[\N!T'PCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#HO\
MP>O_ ._+@=!\([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S'X@Z
M+_P>O_[\N!T'PCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([,?B#
MHO\ P>O_ ._+@=!\([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0?".S
M'X@Z+_P>O_[\N!T'PCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=!\([
M,?B#HO\ P>O_ ._+@=!\([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#ORX'0
M?".S'X@Z+_P>O_[\N!T'PCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^_+@=
M!\([,?B#HO\ P>O_ ._+@=!\([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K_P#O
MRX'0?".S'X@Z+_P>O_[\N!T'PCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\'K_^
M_+@=!\([,?B#HO\ P>O_ ._+@=!\([,?B#HO_!Z__ORX'0?".S'X@Z+_ ,'K
M_P#ORX'0?".S'X@Z+_P>O_[\N!T'PCLQ^(.B_P#!Z_\ [\N!T'PCLQ^(.B_\
M'K_^_+@=!\([,?B#HO\ P>O_ ._+@=!\([,?B#HO_!Z__ORX'0_.1'9KP5Y=
MA:)QGR_T?'3NP,XPK\OY58QO3'BG_1^3\G_Z>!T+OBXDIC1TS7&'IB6&<2W8
MK+D>,[)PVG#[D>.Z_*=886[XY0A3KBDISC&5*SCQR(>_ ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' /
MA%7^Z?8QDTP)B[6IVQ+C?[QKMFCCXGW4E](DJ\;[<:AU292!M%"@HW9IO$"E
M;*P(* ]@UH@:^*X<6-(N21\QA4.3BOY?^18]F^J_)JF:AF=JBL3Y$@:9'7T,
M*V&;61 7H:SO1J)"$D9^O(%>FUPO/T<^Y$6[*;+.CR'N'(+'M%(D4<"4S/J0
M;)KUHN%2LF@:K\8I%9)9,-CMS#1 EZ[,]=X_8X>T/L=_K=+'/4%\*2C 7BJT
MMOM%?6D^U]@RM[ G!8R=S]7MZ)[#ZEA;"='#@Q9FR6^H6((-=L3K(>P4ZQ3P
M)" _BTUJJ%X\Y&8:5OLYC.,LN+RAJ1*;2F0X,R6'@Z&X(. . . 4YO8W1*[0
M'BVP[3<:H!0=K@Z+)H!*XP;B8L9XO%K]9J]?B4%+UML)6QFRK$5@=#:?<E/.
M)QY,XQXX%7J<9ZZNNK]K[1M]*H=B[0&:92-,U_:YG8SNV=]#&7R=BN-_IZ->
MC*V2C1I;UK 3=9&&B\1^1&(P",?V.8:WVY7MF33REEX*JU7VGZL;#&SC%BV+
MVOU((9JM;ND(OLG8.^0P20#.=>:QV4F1IUC0\[6 ]I":_.2WW [T[)&3'$OR
MXS3L933BV2M2_0NN?=NO;>C-B;]!;6[+6:K:R?G!['7XFU=Q@[RQ<XR!'L*%
M)JMO-5TF&M1Q^QC$Q&B"8C2VB4:0IQ,9U+W!.N<="/JM(+7@^2KLTSV5TF9>
MG835H%8["[;WQ$NP9BNS[18C%?1K9+UP0WKX4)DN614P)%AC$):<;E26I#2U
M!_##/*=O+IQ!L$FN9[#]D9TF*\^TZ6#6SM <J*FAS]/9/$F+N''3:?)!U1&P
MP+Q@@W.5!%QS$1V2ZVAW&>,C$ODCU'[KZ?$[,JJ1^PG9-N>V9:"/$I]J[0BJ
MG&=D6BS46*4E7<H.ATZ)6YM^II0"P4<G)'OF(3D5MY3OAC+(Q+Y(P9>^^FT
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M=8=H.KVP/!^P;"[6:I%RJ)1-A"SFQ-D;T$ ' UVT-GL.L<<LB)+M7JUG!T"
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M:/@SG^ _A[K_ .(N^_\ ';9W[1\#/\!_#W7_ ,1=]_X[;._:/@9_@/X>Z_\
MB+OO_';9W[1\#/\  ?P]U_\ $7??^.VSOVCX&?X#^'NO_B+OO_';9W[1\#/\
M!_#W7_Q%WW_CML[]H^!G^ _A[K_XB[[_ ,=MG?M'P,_P'\/=?_$7??\ CML[
M]H^!G^ _A[K_ .(N^_\ ';9W[1\#/\!_#W7_ ,1=]_X[;._:/@9_@/X>Z_\
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MS 8Y&@9,?)U))Z]J5AF'6Q:KD.L-?JY/TFEC2D",^]&C/R&'GHS*T!R>,%?
M_IF=:P$JMDH+=OP8!&RI><5]Q3XJ[+%,F*F>GU^<*&TN#7*R&?*TN$\I5:A
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M!<B*AYEUEJ$AR*I"VW%8X')_X_V'7/!D< < < < < < < < < < < < < <
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M-2Q T1-E1U1EOL/>"<BXE\S)8[+]=L32 4ITDL >QLVB=K\*#D4/KQ,=L^Q
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MU?\ !_Y'T#X,GS2MO5S6VT-N[B(T3;=(K5R+V*QR[< UU,##K8@E8*AU['L
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M*P;'CHS*UJD8+M!*&:.##CKA.,\ZTZ2P0)RER$3%O-Y2(^OP/LIP8. NK?\
MYO?J:_\ CGU[_P"#30W(:?HO\?$[]Y3(X X X X X X X X X X X X X X
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MS84+6ENDERA(PS5$5F=6EA;#,48V/7:]-$-5MN+DE- C9>5NQ7X[K>61<M_
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M#?(1BKT.:6CW"P&"MOJ$BU[O.ZLUO1Z:8"V<U/\ '8^P])C;Y0;*]"KHI(B
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MD8B_'^DT\VMM7_3C/!,G-7U%O_A1HW_ZZ^A'_%KJ7@U#U?\ !_Y'??!D< <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< X"ZM_^;WZFO_CGU[_X--#<AI^B_P ?$[]Y3(X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X!P)]1;_ .%&C?\ ZZ^A'_%KJ7@U#U?\'_D=]\&1P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#@+JW_YO?J:
M_P#CGU[_ .#30W(:?HO\?$[]Y3(X X X X X X X X X X X X X X X X X
M X X X X X X X X X X X X X X X X X X X X X X X X X X X!P)]1;
M_P"%&C?_ *Z^A'_%KJ7@U#U?\'_D=]\&1P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#@+JW_ .;WZFO_ (Y]>_\
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M)BE@L(A.8*5]#[T\#/!%GWQ[[4G"<NNQE.LY6PMMQ0RUAX+:X(. . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . <"
M?46_^%&C?_KKZ$?\6NI>#4/5_P '_D=]\&1P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#@+JW_YO?J:_^.?7O_@T
MT-R&GZ+_ !\3OWE,C@#@#@$5NU&INRJL8H^P*N!NE/L$=$4U6K*+B& Q)EI]
MJ6QB5 G-/1W'(LR.V^ROP\[+[:'$92M"58!-KT.;;UT@Z_VW7L'75?IX;6(P
M;*CR(9&D5+7\HCZ31B58)$*<S>J?= Q>,1/3%3Y"I41Y]<Y*)&',/)PO@TI/
M.28UWJ9UWKNL:[J%.J*:<I-:!UX'$@V4$,-R)J*QK2'IX25*RI43*YQYG6T%
ML1[S.$O8A)PTC*48PG CDV\_$_KW4;K%($M@WM$ZR<&-M6!I,?-5&87E5K-U
MNS626N5AG$MPF;L]/%DY$M3F93A* Q+RY[AM+G Y,W&>LW7O%.?U^SIC7$.E
MR&*_'57!U4$C!K2*I+G3ZNJ(T/C1E07Z[.*27H+K&6W8KLAQ3:DY6K.0R_7X
MF6O2PD+#A#M4V EH\='CP(DL=K.M:T9@%(H8*)KE>BR8=MHEKCPX]=!!F8D-
M$),5*&,80K"\)1Y0S\SE/7F^]9;2%5@Y3N[.U)8FU$MOAXLXC2M* 6 Q+1$G
M,;:$6VJ-Z&@?*.:ZGRR,+(^W;EPG6I4=3L9UIU8TTU\"8P]@4\M<A% KO=V\
M6JUFP58M< ;51_7,^ARHW*;<AE=MB9XW3#XY^O3R= *Q_<-.N):=CXPO"<.-
MY4)CIG!)X!:NE6*Y*%][B9*+<3DJL5&3 +]5IC%JLL%:&YM>KCT?4[C9PY#<
M=2EV)%R[(;RK&%(QG..!_+_,CVV[4[IS5Y#<9OL?V'MM #QR) R8U?K726R%
M"@8: 4)&[',B531Q"3@"$C!G_=24)6EE:<(SCS9QC@+J\8632Z^VA7-A60O1
MF.VVY:9L4# B%2VM-F4[0>O]A0QDP0X?02Q4K)I6$6E#V K?N7WV$.LQVL^+
MJD9\<8##]<="V@PI^QU55[KW<JY'J0B-/FJN0;'68I54PQ2GT%):K#!T^^(3
M&&JC.8D.9>\K.6U>?./+GP$_3!#%VJM-1%&'^\-GC53X.#-L7N2_U>8H,Z+8
MS9ZNB6(%R<U*D!-G23%;EL89;?4O*T>7'BK/A@7^7^9N$$ ;DHW!;[TF')M:
MK^+98X:"G5A4JOU7*6%XLQN.G4V7A5?RF2WGWK^&XW@XG^G_ $L>(?R_S-*$
MM]1LMR'T"N=ZK*>MA>FB]@AQ8?'6PDDS339\O5A)T-/AZ:>&EHL^P )L5O$9
MYUS+L=>,IQCPSD/Y&?//544F:LIWUFC4C8P::15/.=4H:8$.QO9CUZ7-S(U2
MWB+&/2,91"<<\J92\>5K*L_DX'\O\S8V];5!-Z_KES[C;"K9O:9LM7=?P"HC
MKW%<LY@%5#EX+Q!ZUZ3]'_U?5JY,EN+<4AO"&L)\WG6VE0?R-.?LM:K.J+!O
M0IWBM>=/5<60-'-C#&NMYVIPQPM]42>_@N$TR0BRE1IB<L*0RIQSU_ZO"?/^
M3@?'&.IH:UL2JW)XW"JG=#8U@+UJ_.:WL=?&!NNTBQ@; W>)6O$R3 #[F4E1
M]?E66$XB,1<:3$EL8P\PMQM259@Q^G^98X <JU@2-JJ_<ZWV2KB'2+!:R %=
M93 $6^(:P\69(F!VH) ^$Z+9SYY"77$Y83^5?EQRD_E_F:2 5KQ2/598SO:4
M(Q;W/G"J1)@%^JTN/<B8Q[$8D.JKT?4[C=AGCY&<-OLQ,O.-+SY58QG\G!?Y
M?YFNQ9JZY'23B]W[1.K:8%J($+G >ZOS*4$:I<NMPK"R?M;&I5A0TN#)M<)*
MFWWD*QES\OAX8\0_E_F;)DG7Y$L*/C]["K\^R"9AZNPF2W5=V6?!CH\V80,A
M8R-3J>*"8,09)=>DL)<9:;CN*4K"6U9P'\O\S'$'ZK8??8 =]IIS(L(6LQ/
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MW_ZZ^A'_ !:ZEX+#U?\ !_Y'??!D< < < < < < < < < < < < < < < <
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M!RMH+P9VWSXF ;&Y)-C!>$O.(C,I9P[&%7#)H*9KCMQJ$IFTCQ.X(K6Q;=L
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M .!/J+?_  HT;_\ 77T(_P"+74O!J'J_X/\ R.^^#(X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X!P%U;_P#-[]37
M_P <^O?_  ::&Y#3]%_CXG?O*9' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' .!/J+?
M_"C1O_UU]"/^+74O!J'J_P"#_P COO@R. . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . <!=6__ #>_4U_\<^O?_!IH
M;D-/T7^/B=^\ID< < < < < < < < < < < < < < < < < < < < < < <
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M='C-./Y;0E/GSC*O#&,>/AC@AO> . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M.7MSXJ-C<:WG&,623C!^DFFHY:9_6+%7Y7P[VQT/(^,9G8$^@3A/?%,C//\
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M7\ZYX(X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MB*\U'=9SAY&/,Y]ZYW;%NK*:O<+,2C8\/$E5*/U<GA3>%)R333:?1GY\]O\
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MG7;EI<=B[2.MHVW2+H9[&3)UDC&J!>;S,D6C7J&KU,JYBNF-</EHXNJ,16X
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MJ!&;<(XFRD,2'L-*:0A.6FV<B<$NN<LWR[W];'"%Y;ZY_3D4YA*LH2KLIO\
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M3LIC*U:NLJIJF$[O9KLIHLE!SAKS:6E):;ZY[JC)KD7=%T(@++8KS'$4@39
M;(>$9V +LFP;H#8#3ZD]*^,*CG)Q+&267R@?*,M,.1DMJ9YR0[EWGMDO>EK5
M1NA"&9N,LN-;C7"65/&,QC'Z<1GZM2SD]#4\_P#RQ^/+GW:[Q[MU7<]34TY6
M[ENO<[9U:-FOHZESMAM*/M<J:=?%'#7VD^=L+G-6$*?A]7P-D-T$5M?8P"'7
MS *Z')T(G7$U6)L*J6"X% %ACRSE:DS+79@)G6LD?\.@H("WGHC;3L1V4TZI
M':4N^W41V[->F<IQE"*:ES=<XP4HM1DE",HV*7*7&23;4E%K/T5=_P"9>Y]H
MU_)]WL?:=K8VM>[4IA.N][,M'9HU:[Z)1IV(QUM>ZKN%=_OW.C8C&V<X7PIG
M!2P&=3=2&J%2]EF-C;-!4W-O?%"<V.>WZEEL.G+$TM\I/ IJ<V="F1U:4>(2
M)33$"4P+1+]?V[2G6VMON'D+V[=&NFB>S[>7Q7],;H^BES2:_>44FY)RXXY/
M#?:L\X_.D_)^X^'Z':>S[/D'V$;+?8@\:]'=:&E7"[[F$)QE_=XT5URG=7/8
ME1[7NS4)SWBM>=4QQL+18VR;Z<+G+'5M8E1XV1')(M; IJM,5X$9(Q:DW$76
MZQ/U)$CRR EYAR+-P[&G2?-(4USB^\[_ #JEMRIIA7"$[4WTXYY<I13GGE)7
M-J,T\K$HQZ9/-7E?YNV^W;'DMW:.V:VAK:FSW&N=D95O6E8]AWW55RVG);&Q
M#N=LZJ-F,XV4\+M:GC4IG;VN=65G5\8A%K2R:VR<6I0Y.24IJ4KTJ73 -$#Y
M;RU&C)0M02NQ\O?DSA;^5JQA.,X3CY?<W[]Z2E=QS%S:PL?USE-_%_\ -)X_
M0_G+RSS7O'F=M5W=U2ITSVIQ]N+CUV]N[<MSF4LKWKY\/E#C%Y:R[(YTCY$<
M < < < ^;]B[.=G]B=QKIUMZQ:VTHJ@=<Y&FY79[:F[KE<(!=QO;0U5O8IFE
MJ)2 ,]TI8X&OVTS<E3,V**S-D(BX;7EIY:<Y><(WA*.7ZE,=T/J,[?I">R-3
MZ.ZDH6Z[1U%U=;=G]E=K[6LYROZ&U+.JM/GW>/IF-(I\&=8MD;V. 8/N'@D!
MZ%% QGV'"4QEQ]MC+/R-P@GAR>,^GS/IKHZ]$-HZ5U!LPM#ACBNQ=7:_O9.
M.];X?!(6ZIB#\R'!]RX](]G&D$%(:]1:E^1./-G.?'/-(XFL-K]2TN"#@#@#
M@$%+W\8)L<6L9'E9\]YB#*?5 ;A+3#B$9CL&-*S'D3H\^>PA]A67LQ&9&8Z,
M>9S"<<UQ;6?@7'3)H(6WPA >@C##G)&)<F'"$0XZ@<H@7FSG)"&(S,.,:>>@
M*PW%6ZM4S$9"&DYSG/Y,XXX2+Q,U&T@V!UCGSA-B%.510ELT.(CVF)S+IB1F
M-&3'PF4Y'FL^;&%>LTXIE:,^*%*XX2Z?J8<HK.7Z&*'V\ +D0POX8<@2S_LE
MB\2V1SC;\6?'(R&)3C@\E-3%3Y1J\*;=\CV,J3GR>'CG#A)+)I+*RC<$;Y\/
M/3*_BJV:;)B"I)KW$-L.N+)&QL>53\7U##4EQ;DK^I0WEO"\N9Q^3RYPKF2\
M>F38U:Z!KEB<\"]S)@P<#L9)*:2B%)D$(#1%42*YZBEN2!\>0WB2G*<>DZOR
M>.5)5C$^)&FO4_<BWC(R;@I:)2ODJ.F26PAMO.74J$)-)1#QEW'J+S%7C']+
MR8\_Y/\ 1^7FN+Z?J,?[R#2=WU)#H>/ C%BTDZ'B&Q[$5 Z*IR+(412]'6LL
M2',H*PEC'4.1/-[A3G@AM*U>.,:X2,MI/#?4V4K:4*$L[[RLVB+'KP)%B(2W
MXXMMM(U]J4["SAE1;WC<F;F&M*6G&D*;7C.'/)X9\)Q93W$[0#%"LH(L:9'%
M((^<3E1IC0]U#<6#'@2591*'$9T1YQYHBCRI0O.4YQG"_+GP\7"1.44\9ZF!
M#VW!)PVB@BI7(L'?QEMDM"'C?9KF-1U2)D57N"S#["(*6UH=D.(1&PZC*$N*
M5X>,:P\/U-+$EE-8)+7KO"L#HAA PL-?-A)-A@-$FX25+$L/CV&Y#F8<Z6EM
M4OXDVIM'CE7EQGS>7/AC.<]<!Q:(H<W17*]&64("+-\OY+K!1+#'',2!Q HS
M,=A2&8C34W)'+3;T=WRNK80T[Z*_34K/E\VHQ<O0S)J/]1[KW%656&17($0L
M5F1%PO<.P&X"V<Q2$:!*BSH*'R#$LNPIDBA:DQ&GW4(2I2D83X9SKA+&?@:2
MRLHM?&<*QXXY@A_> . . . . . . . . . . . . . . . . . . . 5G]YP
MQZQQ0HX65(C7"^:],M+3;;(*,?4F1EH3$=D+;>,OMJBN)D+B(<:C9QX+7XX5
MA.<]<&N/3)9G-&1P!P!P#GS;LC3";IKT;L<G.BVPY&(CZ9"@(L+JI4,9==:7
M,E)DX"PY4>)$@VBI <N2)2FVVVUJ1E6&W'<X]?MR[E]M=/2BGKQ:<V^/1N%L
M$OJ:RW&=F$O\TC]3\$J_(+\?[KM^)4U3['K3KGMSFZ%QG9J=PU*XQ]Z492E/
M7VMWC"M2DY)22YQ@GR.Q%Z%^\ASV+J4KTNY0H\:-B<U:Z\32X7B 4@-ARWCM
M;C'@D:2+MPID>4E.LA7VY+']%QQ"U(^A<O*^+BZHSC6^N.$ET<N5:XR<7UA-
MRBLS33]$T?NMEW^IO[>S6L[=3M4=OLE*7!ZU]>*I7._1BJ;Y4W2C9J[,[]>N
M,MN$J[.L82C&2\3NLR?D/(4;M,RY8@T/6\2<%5>Z^0F:QG2R!BR?$XY4 W.)
MZ[-UVY22#T^$RXJ?Z<5N(ZA["%MW5CWQ^[[DJ(J$G8U+A)*U84<8EA61E!14
M9/Z<R<ECU>.:_P"87_<UW&[LNO'4V)[\H6K3OA#N$(PJU_;E5>X5[U-^I71"
MFV453RNG?"5;E&=Y5B/H;4@4CLJG[ M[-+#EZU7YL<6L_;@$8$*!VDY6-?!!
MD0*1?8J G&U7"&%1<+RRXVRR[(PF-EEORKWW;N%JTMFFM[,HRDL\82Y.48RL
MDW)?6_:4>OKU:7U9?YOWB[\F^==QJ\0[]VO0EY#L4;%\)6*G5OE=9=K4[&]=
M9*VN,MJW^VQHQ8TIQE.R%3=WN2U=IJG55^/->M!<P< [U@0MCR&DR+<7KBJ?
M\=D6M!Z?(#0'6*=19UAO#KSDD@[%C9<(*1AQ*$>5K=&QWY22HC&-VJW6ND%+
MGQX\5R?US48))13?T^F7U[O9>^?FRJVNOLU&OK=S\:MGH1?'5JO^Z]F.LZ81
MMFGM;D*-.,8UT1LL4:%+@Y2S.$U@AT_IR6( 8Q<B-B6V.M/P5VO7.#:IR-6D
MPVU:_,)5YNL 6AD=>'1KL-V3&B,$HCS./.[ZBEJ[5\/(MC,K(U1IRXYY0<%[
MJE5)*7*6?^9-)MQ:?18/H>\:GYZ[^Y;/<-?M]7:4[-;W5?J3UH/N-=O;;X5W
MO8N=DEC8C;&NRV>O9"Q\8<%%?R]UKJ99]@U>W;$J%L:(;\H<NZK,D&[<D#%&
M62JU/3*0UM@"\/Q*@HF,V##:2N6F-$;+>5_U<2\(7RZE_D%&I9K:=E;AJ6J'
M%<.3<9SNS!OK/#K;Z9;ATQQ+XSW?\Y=F\6W>Q>*;^C+5\8[G'454'JNZ5FOL
M[/=?=UIV<9;7MV:-LFJG99+6S7P=#E$E%.O75& $KNN*_:S!.= V([;8(R6#
MM(D^[=:QFO6I$X[%BU4-&#BFXQ\4K"G8T6#F-(:QG_0[Y>OL:G?I6SW+:XQA
M*G@VG%QX2Y1Q%\GEYC/T;EE/]#QN_P#C7YNV>X[?EO=='7IUK.U+5G9&[6MH
M6IL>_K.%,I;-LK;'*G96(V67>Y7-KUAF#4/3W32] =A&0Y2QR! 76[]=N\N7
M8;5&@4^M31=2($\B;F_!'2%R0;NL(3[;\::]D4_#6N.B,F0K#O:V^Y>2:MM-
M5D8*R5ZE!*,6YR3FEF&7_5[LEAQ7--)\FNGTGDWGW^H'QKN?:NW[].I'>V.[
MQOTXQHUI3VMB%FS"OW=13LBHW+N-T)0LIC]S"V,;97.I<) N\]5=,V"T[6!Q
M+2,MMIK5JGP:C+I=HJF"4B.#P:+"P\>T58(V--607KW#\:--E)8RW'RN,VVF
M0K+W"M3OW<JJ^WVNN6O"<$YJ<9X^KBFW&4LJ+LPVEGKAM\>GEQ\;_-GY![5I
M>$]RGI7=CTMS6A/:CMZVS[<97>U59;+6V;G93KV;W"RRFMS4K%&V4W4E7J:7
M3>JE=KDJNF[_ '*S&PVLR%6*WRP-7D8\5JNMIU"%33=.)X$M")0RCVRE#UP'
MACTWVLS#N?5D*<<6OEV=GO\ =<KJJ:X52O4E7'@\3L5C49K.4YPG+DI)96.B
MPDN[Y#Y!^;>[=VAW7MW:^WZ?;MCO$-FK2H>G8JMG?ANV0IVJ_==L;-S6V[U=
M#8A5[E7#Z*E"$8PE][J7)!OQC3^X$E[P3BG#])2]8BLR[7>#LZ.+@[$*(AP'
M*G:+57K$;C$EQVW7(3$1MG+L%>(;+;/92\@5J=7VWMU1<8S^E*$'4VZUE\XQ
ME&+CG";;>)KDV_I*Z_SE3W*-W;H]A>AVVF5-&WBBN&IIS[=*R>C6YS6SKZU]
M%-FNIRC&V=KL4-F/W%D[-TZ Z;%8P.83L-NC36*<&J4",*B60[!FSK!*KI)%
M>A/"J;-"W.UDGK>/D2:TE$N)E)!,E8M.?,ZCB5ODE;G"N%;C[DI-OC%I14ER
M>9IP@N$DK.C^GCS^!YT.Y_Z@-*[9HT]31GKRW[=J<K9:],X0HC?6[YJS:A=J
M:U:U;X5]P;KM3H=,=UKC"6VFZZZ7T*O5/8B3=O#C+2+@%*>>&1+J9/CI^OHE
M2:D7MY<>LE[4(-5R)4![9%9CPA1O2=;=CH4](2YB.YY+MW6:?&N5E<FIQ;A&
M+5CG]']2BXR<Y./#J^C3Z+'1U_*_]0GD_==[Q1ZVAL;FE=.O:ILEJ5460WI;
M3CII2V*M:VJ^6U?*A:O[UG*$X6RC74X:[9AGI;.UY4*39;3=2<'5]+MLH/4(
M^+A\Y$(PM!OXV!L$,V*:E-;!D3M8DL1T2\PC278$I+3B&7G\/:TJ_)8[EFS3
M75&=]L,S^C@F^/&47%X]O%L<XY0^J.4VECM>']O_ -0VMY7O^1=HTNW4[/>>
MX:T;=J7VOVL)6>S[-U$J;'%Z,8=PUW-U*W4<;J'.,IUUNO+$67KC#UMO2E 3
MUNIYW:12_!;%%N%*OEM)Y6/F7NCD[37JX!'B5V08*@T(K+E$H+SDF.N+ZA25
ME]&,<EM'>9;NKLVPKLIHC7*+A.N"ZJ$U&4I-\6W9%*,EAYQ7'#.#>[1^6MCR
M[QKR+N>KH;_;.RTZ5M$M7;TM:O$X:>Y7K7WW3M6O99/=UJJZ+H1KFK.&E2JI
M,WE UWUHV':26NZ+)OI497:0$L$"P0RIJ#3,GQSL+63=\I9.5"CPK#=HV-:,
ML22D-<T=Z[#N5)]=^1EWBV]SO>G1'<VE5&<[91<6HN?%YM]N:3;C!^ZVHOC+
M#7P2QYWE'E?Y@\5[+3Y7Y+#ME&YM]RNHG1.NF>W[-BGW!Z6W7&<IT:DO[A.=
M>O:JK^$X8?MU5*O]2[-UE'DF]!W$;L'X'3R.V*^1LENC6J2"GE-C8" [RJR6
M6&PXA(FU/[Z2PT2EKBP6Y3^4(<;REKB-'>YP_NVM*GW;(U248.*DE7RE#C%_
M&'L9<5F32ZI]24=G_,.UIO\ )_8+NU?W'N%7;+X:^K+6C="O0]Z[36OKS:_=
MUH]E<Y:]2MNE7#E*,E*97#03IE:1]7"U#:MH:9-6JJXM34$3:7A]\#B+35I(
M,;LF$*K0@8!K\ES98^*(*NX&L)R<;=PN1GS>7N>[Y)1.=FQKUYC7/AEP3KDX
MS4G6W)N4OVY.<5R?T-81]9+N7^H+LNUN]Q[]V32E/7TMG[9SMUE/2MMUMF-U
MFA.S8MLNOBNWWV;6M%WS?V<X.-2QF>E-==-Z+>%L6[8)E&PA#TF98)=IL!:5
M8B;%?:U?#A8)DEB$NPX%:S<*Z]#<&N0O!,I:\K=9;E^GU*]SR3;U>6O3'[22
M2CQBE%<O=;PL]7+A8I<N7HEA-QS\QI>6?G_R3QM6]B[5KOQ6^,841UJ*HT5N
M]]QG/VZU;B<]C[7>A;'8C=UKC'C"R5'.,.4#J'(U5!NE6F7NX5P'?ZS3<N@6
MB4PZ,MU_ME>9$DV:'+K6&LS8T*^I>C1H@?R2!Q=UUMAUY_#O.=;?D*WWJWJF
MNZ=,I_5A1<*X2RN:EZ-UX;<^DH)-I+![,?*/SQ3YM9X]WJOMFAW;9[7L;>+G
M7&FS5TM:]VUO=CL9X2GI.-EENUF%^K"$K85U.!9='+]5*3;JQFH;!MH5VQ5\
M;(HHAYZZQZ=&#W2S46R%F0228-(V%)MQY@8^;:?>R^PF0_AW$9&7\(Z6U7W_
M &M>?W%-<E";YOZ.;<(SBN6)9:A%R4&EAX6.3QGY#R31_-OD78MQ=^[5H[$-
M3:LCN6I:DMJ5NIK[FO4[O;N]R<=6F6Q#4E"/";A4X.Z2J<I^_<.M/8RYP:K$
MMZ+):PE>L;,&$,?/B$.BITVBF["W&E.1(<$C,B*'A9#B&W%O,QI*%X3Z;N<\
MZ:U^]]FUG?*OA1*<<M\7U2G&/3+:3S-?)M?-'R]78?R_^)O'K>]WZ#U.R;&W
MKN<[(T6M60AN4T.45*<X0ESVX)N*A.RN4<\H)%!WG8/6*^;B-WF]W,L%A!M>
MTVL4DZQ7[;7<2'W;D9V&WL>O&'&7_C,&E3J*Q)AGVX#8>%%E2$JE2F9JVT^O
MJZ??-3ML-74KC*4KIRG'E"7_ "1K]N2_Y7-3:E7R<Y-+Z8N*9^G^-^+?F3QG
MP'6\;\:[?1L;&QW7;V-NF5^M?Q2U*M%Z%]2:]J>W#<G7;I2NEM6V5U-44V:\
M9R:RM'5NN64!?2)78=!.8L>P# 07=)MPDC;:?A*O-(-[,-(2&4*EW6Y@X)23
MF/[A:D14X<PPVOPY-VCOMU,]2$:;JN%:DX*"<(OA.-2ZY4(2<5G'5],M$\Q[
M-^:.[]HVO&-2CM7=.V_::55UFI#5C9K43^SW*>WTMVJR.IJ73UZU9P2=C<'9
M.)J;9_"&+V.>KMDD[%1#A/E3K%FCEC[E*UZ<"6/>,@W%"HAMXFU\B#V##,NQ
M?,S(]R6?AM1<NM,L-(Y=?_N*>E"^E4\FE%Q:CSLC*-'%RSTDI5N"?58@I.6&
MVWWNQ_\ [WW/$M7NO:(=I>Q9&NEZ\JJ%M[U-U'9XU2M<WPOKNT9:D;,2A[>M
M"^=RA.RR<K6"V+K=<F=7:CKI>Z;!0<M.T6$&\JM*W UDOU)W65O>+W9Y0Z!
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M]5U56&AS+64.05.#',OO^1I&52?$6WC\F4I_+G\G)@O+)#YNHQTY4**]8#N
M(JS(MPBO-_#4PH!E)-1;.?<>PS.E0<2WWLH8<<4E&'<XQG.,)\*I\/1]1E/U
M2;-6K1-;PZ13')EF!A4NHO)$+0*F18CN5Q7$-!)$P<[/!Y9S%PE#D=U+B6L^
M3&?!*/*YSD\\F$TNB1=^,>'_ /7_ -.?_P"_!D_O ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' *:.6&YVLI'#Z];]@!3(EQ#UUFQVTLXS$GP8DQBKK=<>]>?'
M;5*PEUV(Y'4^SY<9\OBK$3R_T-I)=6;5XJ:H<E^392!2R5%]N+XV!<,?F=7)
MF77FY"BL(- @9<!OH6UE,EMIS,=25>KX(SY\4G1KIZD=DV\1<3&83=PEBJ>X
MPS%9EAEX@8+E752\SA1@[(C^]K;S;$=.(["<PWY"5Y6VZKQ3C%P3&/XFO/6^
MH0F:TY67!D5NHNXG!DG&9M>J9*++A2Q+T&%89414:.07$E*>C2,I<:>SC/@I
M6%K4EQSZ%ZDRK^VJH9R/BSI'P$J2=PQ#A3W&GX<]Y3F6F\!S\)3X$PAYU.4H
MRQ(4OSXRA24KQE.#3CU9,-^A:'(0< < XW[,SM?NWO3%=O=,*'V9LPB<CV3Y
MAL(FNU#(FY:S!#9LX0&A$8MC-+M]N$KA,R6V&D89<PN2VTXZV[]'V2&VM79N
MU;8P:27'C%RGF%LFDVTXQX0GEK+ZK$6TFOW_ /#VMY3#QKR'NOC7<*=6RNNN
MF6O[%%M^U[NKW"ZR$+;9URHJ6KJ[*NE7*<GR@XTSG"$H<WU)?3Z% UV/'5?:
M]YN(\5IV*P5/Q;Y!M]CJ]UL&MJ+5)5C;/$HDF33/2P&)('.(]@B.TIEM'K*E
ML*]K97D4IW3G9KU:SE<\1=;A&4(V3DH\4_K_ *X\E]6>K>%%GZWWV/YZV=GN
MVUM;O8^V]@MN[K)UTRTIZM&QJ4[^YLQH=-<HQV\_=Z[OB_><Y*R<O;C1:KEG
MJZW:MN\>NRAMJ;M%$+Q1U7+KF[.O\6EP,"-8L0IA7WDAT8 J%;=V "B-1L/N
MQ\-.^?QPKW66O.@N];VJ[HRK]BV+<EBJMS>;<I8ZRG+VYMO">5C_ -N?S_5C
M^7/-/')]VINT7V7N=$K-BI0[?I2VY^[W!SA5PBK+]K86CN6RLX1L<H\<->SS
MPMBTO5^F-;Z)Z_F*85NM<FV<D4?L+9HS4X8 I$>>EG;5.=KD0M,PX8-7=<:$
M-\OMFFI.4^NUB,VOFM/9WNY;NWW>NV-5ZK2X\5-R3Z1@N32Z1AF4O5M>CY-'
M8\3\A\S_ "#Y;Y+^4M#N%';N[5Z==:H=-6S.ZN24:=:"OE5#%56FK+MC/N2E
M7GVYNV<30&=G]5"P2OC1],V86:U]KBM P-6AC[Y67K)J<O8*S5P0PC$)$1+M
MUILE?LIS7Q'$F/(9:7CS*<<?9<Y:]'OU=LYSMHB[KI2E)NN7&U1E*332?"?]
M47QPT\?!)KU>W^&?FW2[CM;>UW#L]$^Z]WV+KMF4]+86OW.JC8V;K*Y5PM6I
MM17NTR]CVYURE%\5"-=D=_=J_P!0=>69@1=XMQDS:H1'$"!DF3V9: V+/-K3
M*JH"L)M4\@S.LS-,K361D9Q2G&A\9MO*L>NA#_%K7>1;E#LUG6HV)I)*J+XJ
M7URC'"Q'G)\FNCDV_@VO+\=[K^>?*^SRW_')]OAK[U-D(55U]OUK?MX;#^YN
MHIX0<-=[>Q+[BR*497V2DE^W*5>V(N]=+9FX#2M?O)&N]5-;JADRTHW;XH8S
M7*[8K+$,52<A9N*Y>7Z_8]&H?4LBA[#S[+2VW%H<=ROC@N\Z_MSKG4KM^[*2
MC!N,I1BU-?2^'*-^/IQA-Y2:6.CJP_+'8UH;FEM=MJ[MYMW?G75&G5E;5??1
MKRJV8-4R6FKZ.\."5#APA.<9PC*,.- !Q.C0QNYUUS2+\2-J:X4#)H:_N#9!
M$M+M,T9I00(EO#'ZTW2Y4*J8L(N,VZDUF:O Q:LL93(?\_K6V=TMKJN6UE[%
M=G%^S6DHIW-K/+FG/C-OZ./U+KT6/U#N&]^2=_MW;^ZQ\CC9=WS0W?:L7:]"
M%4=:%G=[;8JR.P]N,]GV-BR47J*E?<1BK<U5<9/J2TZZ)CR&:+H\7-,[M5]S
M4&M&-K7F7!E5"O ;T5,C+@6M%#1&K84;7P\K+307%A4_(FI80MME&%HX.X4;
MD)K[K:DJ]7]YR54$U.4JU%P49YE)R:RY^WA1SU?1^-YSV7RS3VJEY+Y)=7V_
MQU?W6>Q5VW3C..U?=IUU6:M6ONN6Q=9?;6I2V_L5"%+ME&=DN,MJ%IG6BZ8.
M679%&O$$E6=>6NUV69:=E7JZD<-ZM.[(U-L<>J9$.S)1ARAOMSHD5QC*FYL$
MDPZTUAY*4M8MV>]ZW&C2MJ<)W0C%1KA!?NQKMK>'%)>Y]+>>L91:;QZ]+N/D
M/Y@\>>MVCQ'N7;;=3<[KK:VO#6[?IZE>>Y4Z'<]"?"5,8U+=BZ;;(SPZ;M>V
M$YNMMSP3UFZ5J:F_,P_;%=<23/#H-=,R-NU3,W)$RN;=J%5Q4@P.'X -D\M$
MRHN/EJ'G"F%9PI+2&F]54>3)KV9:\UQBW)>S+&(XA9)X;Y8^F$GE^OS;?9[9
MV?\ U#QG7_9[>Q[<'339.^J/:]GA[=2AJ;NQ;&JR?ONOEKZVS/E;E6+,7.4Y
MZ)@KTY3?IK[NN[\%"..SIC.SVBM\16(3I%W4[D&X-+@E5O !9N3> V(\]_T?
M;/QLY])I/KN<Y77Y&]1)74RMZ+VL5\GCW<PZKZG%0GF*SE/U?1'IV:7Y]?C%
M=<.[=KV.XI0@^W.O2>Q-5KN:GJM3K2OLICI[?.F'+W(68YS?MQ)8W9NI8<G6
M'ZE1+^3LD&T:LDP*:ZQL49%J+A:SZKKM3VN9$EGU"P:"8^0#R@HZWZQ*+%<C
M.YQG$_">O[/D%E=BV+:HT.%J<_VVYXC;*=46NLL/G]*>(MJ2_P"0\.?9OSEW
M#3W*N^=S[73VBS3[E&>VGH62VE5K]ROV>VU6UI67.N<=S.O&7#7LLA=!-/5;
MGG8XUK#3 _7=+?UL/LT$K6-R_!1Y"^V.L*0/0BOD[370JAP:T$K!9KC*--H@
MQEI9QA;2L)?:\<8SU>S5[W<IW;*O=<HV4\FJXRZ_4H2>7%1C#C]3Z^OHSYG\
M2]O\R_(6UW;R&ON]NGLT[G:O>G#2HV,S;OKUK[?<MUZZ-?5C3)W6)RRI)NN>
M&U6@VU=-K?;3XZSU6P5*^FW-KB[36,DK@X2?3*+;<F$<V>)7YRL-6<K'DV>3
M!CHP\Y R[AE#B7$C\<[MFOY)KT0G19"S4C[3C+$,=%2EQ<E_2OVTWTY8RUCF
M?7[?9?S_ -A['J[?9MW5WO&-9=MLUMCV]55QXU=LC7]O*^'77JE'M]=TVXQO
M479*+B]IF1-V#T9,0H,HA)M(UX2#ODMVPMDM@#C0:# /7N9>H4JQ"B_NI;]B
M)V,RB5[5Z4E])!IMQ:/6A8SF.IY37)Q@JY*4H?3BMQ;<:U!J+6$HJ,,92QQ;
M2>)'%K^*_P"I'0V+:-6&E=7?LZ450Z]*RFV<Z=*&G.-%M7&,:*Z-1U^Y"MP=
M$Y1C+V]AJUJ?_#E6*N#VQK%N^P(-CM#51 5FDNW$M-D$:R;MEA-:ZK]%;D$A
MPT)@K&,D24> TU$D-,N.I=6RECPZ&P^\WWR[?O>TYPKYRE/@DE*,(QLE/HW+
M#A&+DVTVEC.3XGOW_P"V>\]YV?!_,GVNW9U-)[5VQMK5JA&O8IUJ*=^_<<:[
M++O:EJT43NE*V$IQ@X1L=A%K#L+J%-)VX^7!7@],N\QR?,AIK&RYD:VPZLY%
M.V U7 *FVXWP +,T8G)?+;+",O#?(ZA?O$8E=BG4\BC"NJN54(U+"?*M.#GF
M,8REZ\FK_HRWTEE-<7Q]KM7BOYXU]/0[7H[/;=:CMM:A"?W';X2UI;*E313?
M<FY>]=#O#6KRG-J&QRA*/V\G3Y5LCTM!/V"LBHQM*:I@A"DNS%[ GM)@5 6.
MVHY#'/ORY#Z1H0;I>+(BMJ2U[AJ"CT</-S,KD+H>36J%UCC]>&L>VNLVZLOI
MZR=S3]<<NN''"WW?4_U#=SKU>\;T];.]PG%16C!\]JRSMJE8E&*]RZSNUD+)
M)RX2NE[GMRHXU>XHMUJW/8=D[>N&I2;1+7@"':K#;"39@H.*UVN3-^:P@R(0
MP9)\A)3%7A&7I<7,+*E(EQL.8>?@QELK*^]]MII[=K;$>%TW&,%A-2DJ+6FW
MZ?4X)/E\)8PIR3XM[1_+_P"/>U]H\#[!WVF6IW7:GK4:U;JKLKOOAV7N,XSL
MLCFM2V)ZL*K/>PG5<XNNO9MC9N!.Q.IE# $:7!DV-RHU*Y)L$T\_&OQX%'O>
MMT9LH@4Q:GLR_?D80G7>)4&(PXY%EQ(*<_UBI"</\5FGY!MVQV9*'W%E7%1_
M;C+V[/I;X=,)NS$FTFG+X8Z>?O>)_G+R;NE7D&S#47?=[M_L0I4M*FZ6EOO[
M>VQZRX\*YV[WMW63C&RJVY_T*INK4,4#J(5L.RQ 6C6VP$Z-KR[#[G%AN;#;
M"0@S0LWJHT#8*2R<07\RGAE/E1(6&7LR,8@9ELJ:6KUW.5[?D-=-%EMM<(6W
M0<&_;Y-YC;&6$F^,7-.65CZN+SZ+T+/*/SOI=J[/O]P[EHZNGW+NNI/4E-:+
MNG:[*>Y572KC7*S[>FS:KMMYPX9N]BQ3BO;AYU+:_4;6UADWE \[K4ZK4X&^
MV&,1B6C(:M4Z77]90R9DD*BOSQ4-VN@BE>:*DO0])IAIQS#RO3GKPV.W^0[M
M*U6X7U?<2KBTXYE-2M:2;PWRDK'&.<MM+'6!KOOA'YV\N[5#QN5NMW?MJ[Y=
MI42KEK^[L;4;^X3KJKLE&%DE?=7O2UJ.?*4Y1BZUSUHO+NE(ZD4)[7+MR#W$
M&Y?9("%4'2A?8<5=:%3I<8((I66IA9I^F5A<VZMQ' C"&DQ_5\[K+;<7+K&=
M;:\AVU<M:5<U2I.>%6^32<G/HOKEB#:F\Y]$VY8?!X]Y'^=?)Z^[0\?OT-F'
M;(7SVE75HR6Q9",KK=O,*FMO84-25L=N;DY\>,+)RNX65GB7TSMQ>V%2]#N
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MXB/,HD3UPX4KS-P92'FI*$>KX?T<X0I/AX^/(^AK"R8SNQ(F98D3#@/OES)
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MVNU23KYPLC7!7J[M(W86JWKPHY".5_-A2=/"B3%4N037T_7#$]8*),,2,MM
M2(BM^Y:>A0L3'&D9\)&4R,XZ6[7WW0J@[KH\XSX\8M<X2L5F.32_YD[,-2EC
M+].A\EY;I?F?POMVK/N_=:5L:VU['LTVURV=6[>AON"NE"J.7="W?]N4;KG4
MI26:LU)T;7MB]1)]B -AM16G $#+;(6"Y++E)KU/) #FBE4E-PD0[F3Q8Z,Q
MFR5V2/C^[),"%C4IQ 8Q'>RSZEVGY%&F?N[%?NS6(PPES4E?SX9@N,WQL4GB
M+GR_K?)9_2.Z^)_G?6[3M2[AW[2_N>S6X4:BJK@MJNZGO/W;U8RU*_8W']OO
M5WS]K7GM+8;>S9[M:LZ($]A]$OS0Y9P#=8)FC:P)VNK2#@B=)+.:HL<BAQ&;
M% E*,$ESAUR=E#,LXFN8(^:&[[AMAQM25>/9V?NJC*M3J=5MZA)1:2]V/N/B
MUA8</JSQ^GJN+:9^4[WXI_)=6OL:,=KMUO;^Y=YKUMF--L(U+N5$=V3HG%55
MJ%FHH['/V8^QBV'M3LA)-1-J-U]LU<IUX,Z,LJK%O6#>91&C!W)),C.%3%V5
MR\G[=!@64?6C,:''N4Q:'U>XGM)+8:@M^=?II[#EW>BZS5JVH>SJ."4WT2:X
M\(P;BY)O@NG2+X9D\=3W)V_E/L_=M_QOM_DNFNT^-6:<:]RU1KKA9%:ZTZ-6
M<]>>Q5*<M2I."X4R>MSV9\8\W7DHSTJSFNP26I;?*C6DI *5Y=@P9?#6 ?LE
M%C&U_:4F=8;O\)>39\H)MBY1!Q%D2OU%1XS>?!7.Y&KR;ZY0V*U*N+4N..47
M7Q<JDHPS]/TN2BO;],R9]73V_P#U#XV]G4[[H0NTJ9UWJCVE;1/0>O9?VZ,*
M-/W5]OG7ELUT1>@UP5MLET)X5O\ JUC4^CF[!I^]-:_O-3M&XYV(EC,$K?JM
MH-"$'C-L,66)8V;-*:Q"NTS,Z=$).3G(SBV4L/I?6RGIUZF^]_:=.Q5]W59&
ME9BE"W+<8P47'CG,%QBX\<K.5A,^9TO%_-+/./))]K[]VU^4]MWM?M4.5%5>
MKW)VSMIJUJM>5#UXOGJ5>S39KJF-D8V.RN54;'%&-B=,JU8C82%K8NR0%61J
ME2%,,-R:^(A7%O:-8>?&3G;BY7J;5"ZDV-MT>E8Z3)E2LN)@N27FE9[$M/R2
MZF-L[H\)0YK+Q)N'M2ZKARG)?MXE]226.2BF>W;XI_J#[QVG6[CL=WHEJW:C
MVXY;C?;/5?;MA1L@M57[>S5_T$HWM7UUUU\7LQJKFEOZ$"ZH;PM,^JJUM-S:
MY]&&V2?,E%;6+@2:T4$8CR0]3D2K&+LN*K*'[#?8GLQ(,8--<E267_5?0\A/
M%MV]_P"UT*_WE]NK7%)*#:DGT<THN/).M.+<G-)1:PFF>7Y/W/\ -_XX[+5W
MI=WK_LE7<K*(1C7K63CL5V\HV[,8T6:_W,9Z,)TSMNLVJ8UTV5\*Y0D^M!FG
M:/6(5D:HXIFG$+)6Y-:?(P$J(LLQG"EI/Q9*P9IP@ GOPCUS(RD^XC.8<]RI
MISS,^#>/GY]RVKY0>U)V0A-2P^GPC%KE'$EF,(KH_AE=>I^&[GG_ ))WG8U)
M^27R[AJZFY'8C7/Z&Y*O6HE'WJE"^$9TZE%;X61X^VIQQ9F3A8?JKHH17Z_6
ML4:+/&5VBCM>QF9T\FJ/,!#*K/I4>63&19D4+-LGRR6EP_BN8V"#;$IUMMY"
M%Y3SLV=^[K9=._W6ISM=CPETDY*>$VFU'DD^.>.4FTV?0;_YL_)>_P!TVN[O
MN4ZMS;[E9O2<(5\H76;,-N4:[)0E;#7^XJJM^V5GL2G7"4ZY2CDGE.T]K>@Q
M#T.JUEF U:6G6;*Y*(%S4T^F02L)B2LR1.$"1 E(DE+61?==>=6ZXN6O*E9_
M)X=39[CN[<H2V)MNO^G"24<*,5A122PH1226.B/FN_\ GWEWD]^KL=ZW)6ST
MI)ZZC"JF%'&NBJ*JKIA7"N,:]:B$8QBHQ54<)=<P2-U2Z^QI#<C[MATOR1(T
M%<8H6LAD=*AQ6*I%Q&("BQF:,),RV*,'3+3(9=Q-P.8]QZN48YVY=_[O)8]Y
MKJWE**:;YO*:BFL<YXPUCD\8R?2W?F[\IW5.K^[VPS.4U*NK7JLC.4MF7*%E
M54+*W&6YM.IPE'VO?L]KAR9)C&@]1V!ZFR#-.8(O4$:&#U9<@J>SF$+KQ@+8
M0D";A)5*3L46=KL*6R@AB5A$B.E>/Z7FSG@K[MW"E6*NQI72;ETCU<E*,FNG
MTMQE)/CCH\'CZ'Y/\Z[77W"KM_<)55]TNMMV5&NGZ[+ZKJ+IP_;_ &964WW5
M3='MMPFX^F,8(OKAI,.F$B%01N<#+"Q:A?O9QDHH6;AU A0![XM90G,4-B"Z
M84>'1(C&6XD2-E*66D>FWE.[.]=SLSRNE]4.+PHK,7-6/.$LMS2DV^K?JWEG
M9W/RW^1=]V2V.Z79NU):UG"%5?N4RVH;LXV*NN*LE9MUPOMMGRMML3=DY<I*
M6ME=6]#S)+DU^@L^]7!CBF)S-@M<::,$L090UP."F1CK,FO!R,"<^U.B051X
MY!#R\2D/>=7CM=][K&/%7/CG..,&F\IYDG'$FFDXN67'"XM';I_-'Y-UZ5KU
M]TE]LK96.#HUI0LM<XV*VZ,J7&^VN<(2IMN4YT.$73*OBL6(WK&@M %59FK#
M&*ZJPL6O =A#K$%%@BFH]AC$666G4887',Q6WT-H\K2<HPG"<)QY>=-[VV[?
M?=DG=PX9^/%QXM?_ -K:^9\I+S+RB?=/[U9NW2[K]I+6]UM.;HE5*B5;;3RI
M52E!R>9--MRSU(U8-(46R2M4MD!S"ZUI])3-4J*X(Z4'R].I<_7L+WKTZ+*)
M.0A-3-3HZ(R7D,OKD(=>PXMAG*>:GNFU1'8<&_?V<<YY:?2:L>,-++G&+SC*
MQA839Z_:_P C^2]HI[W/5MDN\=_=?W.TIV1MQ#;AO3X*$HUJ=NS338['!S@H
M2A6XQLL4M+CK#HWR"$+HR7E!23)6)(DV.VRILB5%DU*7";,SY!YV;8AXZ10@
MBHL0@Y)B1?A47#+:,,-X3R_WSNF9?N_U1P_I@EAJ:>%QQ%OW)Y<<-\I9;RST
M7^9/R3ROE'N3BMBEURC&C5C",91V8S=4(TJ%$[([NVK+:(UVV?<WNR<G9)N^
M^>2?F(X X X X!\<>\'U@M-=6]QRNKE>DA<;Y8""#=BMFVQ^P*UH'5HFPPFB
M B;:+35*A9;%?#\N!);D1Z_6XK[[R5>65-'X\7$QLY85.2Y/T_WGS4U#]5GK
MGJWOX,N&X_J7WC>NMK)U%V/C8F4ZNVS3]%5;=$3;VLWJ>)U7HJO4 A- QH5!
M070DM+>.SY2$KQ+)J=<;9S#;BW'$8X>?YG^I^MV$-;JZ!M==EX( +.%%V('/
MQ'DQ/?!S4%@D,F>UFLQIL;W,*2A?IO-MNH\W@M*58SC&C@>4\/U-UP0< < <
M A!HQ64$D0C##BI7J(&)6MO/HHCRV&S7KJ5AU/EA*?$MIRYX?D?2E'_3P:2?
MP-/+/U=YD[A(<O(<3%%6@HF(C$.8O+L.,IN5&DK(PO*1$0V8WKI:<0XUAQK"
M?-E6>"X9G-E@422- Y#367H"(QIMJ3*&^J/>FX)Y]P]EXPJ9/EY2V^IW+6)&
M<Y<_+G.<Y\&"8;ZFK#VFG_$(<QB"2B3C,V+ 8]RZF9'C.6*-,,MK;Q&)3QPU
MHED=E3R6_3<R]EOU$8RI.>"M,QH9_7<O,R?'#*<4*8L![+CT%K#:USR'M3;D
M=4B1[54J>IIEY6%93C$=]I><IPO.,:^K_:9,IDW2GHK8I,"5'=DR6X,4:R^E
M,V1-KN8#<:,.E#R:VW7H#3S2DK9?REMIM65J3Y%8Q.I</^1.%5P.['<C/P\R
M&GLQU/>ZDRI3KRHN%8CY>?D/./NY:2O./Z2L^.,^&?'F<$R5XV1U\_*9@" ;
M1LB=@FY#L :@?(D-P4RXF369^9$]MN MV6\UG"5*2I;F$X3^7'Y-)O'J7#]6
M;1DE5_AE8*#ZZ1FLS1\N6)CL1VL38D!II4B7[F/.GQU95A,M6,MXRZM2EYQC
M&>9;><CJN@EPZM%@#'X84P1&V%,-B.T+(R6HBD2XC"("GHDHT/:;\8C+>$*P
MG*FL-I_ZN<8Y4^@ZMFVK18(O+,$8/G0F2S4PO!ES,86DXTRY&8ESTOKER9BW
M,X?:SCW&$+4TI.4X\N/#$^. U\PRBJE6PS7PQ+K1(.0@CD2&,Y2P+BYCXEQO
MZ3BO;>;/I^&4_P!+/EQ^7'ACA-KHB=?4CZC])4V*&RV)(@?'A325>G/DD"FG
MXL/"8SRXC[!=HFVJ4U*SEM+R4^NWXJ_+X<JZK(ZY_4W=;=$'8T>=#$%AB!,J
M3[1V;(8P\ZY.6B9/3YXQ.<MYJ4]Y''</*QA:\XS^7\O(P8\NS0#+#XJ56[ \
MMZ3+8P/QD>U)>R%=CO3)3,B*9PAA$"0XSX*RZVXIQQ&$8S^7.'J7&/0Q5M45
MF/!)>R=]L1&23[3V'9>6R;0S+)/*2;:I6,DYS:Y/J-(DX<SXI5C&<>'ARX+]
M3Z&L)VZH&83CI:O2YD$@*F,R/<OU]7J"XJVIDMEYA)_UFE-.I2O#6<8?RO'@
ME.<XX'%^AFLRZ>-17B0\3+DJ/Q4D0J5RV6EQ(D9+"T-,-G"T5F TC)1/EC,?
MDRI6?Z']''@QEDZ_$D\$H#M6,R&X;TO ?*7<XE1O#$4B\Q)9D0%,K5E.2D%G
M*D/(5C/I9=QC&?'.? QAK^97D@AK%"&_.(G*83) X:89;F^VC2"PUV7%*L1V
MYJ6(TD*,B*S(EMXP_#0UX85^3'">?0/EZLV>4U,;\PNN5LY&1!*CHI3URC>(
MYDK.R.;AR7L.6)4>8\XQ+CK6_+\F?)A.%9\R<)P"R^AOY-O"LD12I0^6F:]&
MBH8?]44][1H_.]DTUGVY1U4K$B4-3ES,9+Z6TIPI6<8\>7BWU0PS1DK[19C8
M$C.B39JY(TF1&^ ];DF$PX\@"1:?:2[A3+[S4I["D?TL988>7X^"/RWA(),S
M7;)4@_IU[$!]$"N881#]!41Z,PL4#18(J([62&2/E8&XPI+KC6&?-X8RO\N/
M'+3]6$F;F) K-I@,2&(7N($69+>%3VW7H^%NO2,2)),1+BR$R$MOR\*\KR5)
MROP5Y?Z"L943:]/0G5&3&I=:BJ>RP+0VF0F5A]K,F8MEYR:TMB;+<97(4TLA
M,9<4EV1G'KN8S_27GAYEZERR028D:9%=A264O17VE,/,+\?(XTI/E4A7Y<9R
MG*>"(T#U-K3TR604*:1+(OI?)+8=D1DD5I0TC"2+4=YMF<SCT4Y]-U*T95XJ
M\/%2LY%Y,W+ R!%<9=8C-M.,-RVF5)\?%#<Z0B7+3C\OAX/R6\+S_P"G'(3+
M-,Y3*TY(BR\#$L3(4)L?$FQ),R'-C0FG5O(C,RHLAE]MKSN*QG&%?TDJRG/B
MG\G&,C+-]"A11T5B%"91'BQD8;891X^1M&,YSY<>;*E?Z<_].>7&">IE< _F
M>8FVET! 02\C+M;P2DX0P59&7 =X9QC"U2F?@III*?-XYRS+%,O*SX>'C*_^
MW/-XZ9-/T3)_P9(G8*M@Q+@EX!6:!/BV94:"4AHCR$YBS7(SLN#.@2VW8\V%
M(=B-J4G^@O"D8RE:<XY4\/KZ%STP5PMBYP=BT]ZPC,V1IN.;$0[$!B/PA8Z.
M3CM2G9Y<<N;)P/G1UCTQORK=9D-/X4CR.(RG-;6,((\MO7(/&\M*P,:*&28Y
M3Y.>Z-8)0*169DED?.M!;#N<>DAO#F<L(QG'G6WYU?T$9\9C)4GZHTFG8AC+
M8J:"08P#]V<8LY(_8OC,$ZZQ(F18;E:;1((9E^S<CLM8G^I';>:;5C+:\Y3E
M,PEZ!_J=)\&2H-HG]'UY4>;M\Q0@[C=8L<^(]<YPN$[FIASE*GV>1%^(.MN.
M"X-B37UR<HQE*9>8>,_TU-8SZ.C5W2U./;XVR7.*?!-_4XS4<X^+C[F/TY?#
M)]YX9VS\C]TC+7\#U^Y[$'N40DM2%DU]S;3MPUXRX)I63H^]5><-U+8:^E3:
M\V-%:5E1VGH^OJRY&D%46:.XU$4E'NI#7CC$?*7$Y9#/LNYPH>CRCUI5G&6<
MXSGE?=>YQDT[I\E'B^OP_7]?_P OZOU-V?DO\B4VRKM[KN*Z-#UY)RZ\8O\
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M+AE8_P")]'*9;ZWL&GU6^TTK&/5&[UP);ZL;AY5F(8KMD&1C(4I%RM#;GMR
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MOX55X[.JRZ'/3VM?4JTON*'[+Q4G0[8TRYSC;.Q*]\8M53(Z$WBI.2;A8^U
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MY6PMI/\ U$.9Y,I=67Z?7_<;#.LW)"I9 E=+:0L2\-*&&L$,CV0CS+24IS"
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MFEI=[4/).Y4U15>CL/9C8JY1<;'QC[<(PC[CS-W2:Y=8KZ&HI--8^DT_S_\
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MRKT,OU-[RD' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M[J+.[;"U;90=E*KI:G+%JMCR?I?:)0T=B8LE]S L6KR^M"$5Q=1>4CXQ4"U
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M'7)KFTL([;0A#:$-MH2VVVE*&VT)PA"$(QA*4(2G&$I2E./#&,?DQCFC)^N
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2R>/_ -_T_'P_]/)U-?3^I__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g692844g12z65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844g12z65.jpg
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M 0$! 0'_P  1" %7 EX# 1$  A$! Q$!_\0 'P !  (#  ,! 0$
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MU5-1=ZDB-55\31JALSK';[;L.GU.#& U27=J5M+7P:G7!5>&-1Q,:R$ MON
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MEO$^)@R3L-;,\%/%QW8N:.&E7BEC+GPM=SULS+O)3=I[U!+2@D@I5<AT;(V
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MPOQ3FH#0X;R>,BXAPEN>!M;!Y.D9IHX+;ARSXJ<L;:JR3->9J[XW.A:'![&
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M=*%)3TRZDJ5G"4IZQ:%4I2LXPE*<:JJF<YSG/X8QC'XYSG\,8_'/".(',20
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M;BO),R^>P0NY%F+CP@M,R.6I/=B89[%F.A(VA?JQS5Q/;L2%DK'\QE(<7 -
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M\F(PE_(6L3ACVSGR,&*I4VQ&201!C7N!E:S5P-<:W8*C8X?S&O6D&6KAT?\
M$2HGQP8Y D#"D/XJ$]&FQOB8,I]GXB)(8E,^OW([S3J4+360' @]Q!!\.AZ'
MJ.OHNFR-"IE<?>Q=^+MZ.2IV:%V#GDB[:I<A?7LQ=I"^.:/M(9'LYXI&2,WS
M,>UP#A%+_6S2DL1IL!,HT6:%T"*6#U2,FEC\R%7!#E(>URZ/EL22KJ+1%?I<
MAX&^W;<'</M.KE.^N=GXKE!BC/("T$1C3!UT!R\NM;Z_5Z==KF7^S_A"2KPG
M1EPT<U/@BJ:7#-::U>EAQ]5V'=@'02LDM.&2C?B'OIO;E/?0]KC(_FG_ )51
MI3NB/5ZCF Y<5KX@3;K ZQ"*;7+E?]BWZD487;84@;9A](HMVM9^H5:*;'RY
M,":@,&BY^!?>A,99B.+9S0VM"T@AI.@0T.<]S6@C1#6N<6C8Z'0[NBY_%>Q?
MV<X>U4LUL%/8;CH+]7$T,MG,]G,/AJV4B?!D8,/A<QD[V+QL=R"62&9M2I%_
M(O=$SDC<6'7*KX=_5RC;)UUM:H5:UA[9JF4YFAXE[(O=L UP*] L,-VIA:U>
M#UG!@JOAZS$BL0< @B7A97VY0B6/0J4S)AM:%KVO:UP<S]GZ[B&C1'*UKB0U
MOUB= #KW+ QOL(]G&&X@P/$V*QN2J93AF1WT+VN?S63I4*CX+T+L94Q^9NY&
MG2QW/D+%F*"C#5=6L\LE66 &1LEX.9"]A3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A%&>PM.:QVK)K$[8%-$V,E2YTLC4R\C$F(:KLH@PB*2R(,C9$,I!CE(S3+
M!6&Q+3#*,L,-SX\A##.$4N8Q_*7-!+3MI\0>XZ(\_$=Q\5SV=X4X=XEDQTV<
MQ-:_8Q$TMC&6G]I%;H23L;'8]UMUY(;,,=F-K&6H62B&RQC&SLD#& ;V)$"@
M(^*)"#8 <5"1EN&-&1&(,&*WE:G%(CQ8S;3#25.+6XK"$)]3BU+5YJ4K.9
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MHPPXI*T>2F\S0KD\6EQ*DJ:5/2XA6%H3S&MO+*\A&P3INQX!Q /X;'WKQ/\
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MSOUN[#]M=-4L.+GB:L(;@:#N_9B8/(FB=@()AM.QM6Z"D^\G#^,G;:]%;=R
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M$1JG=>WK/.(6,_9'HQ3SKNFB8\(.B5X4ZW8" J'-F/"Y\\Y7B ?'X>/P_?\
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MWX[J5L28ZW8\AMQAUQM6-=I5<C4LT;L++%2W"^">&0;;)'(-.!\B.]KAIS'
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M4Y0_!.8_K]^R?U*_-AZ(&Q5QK%TU5LF$-.1MR8V(5F7BMLV: &&MW/O#M)I
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M:01"6"U@(D1NP7RG$!!DP4]/Q'V>/=XZ[OBI:%VSO/#00N1,I>E4NCD]:S
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M9K.@HMAO+DBN=6+.$$;&DXK]<@UVA"S)[LT&BFJ,(JUJDLT8,,('B5@R!1L
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M77LP]<M?P+KUMJX'90Z5 VVZ,I=&P.[!0K38\;+8JY>O50.?LMM;I42JO1+
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M7'I4N5(=6I2W77%9_D2GR0E*<?4<,$-:*."O$R&&)C61Q1M#&,8T::UK6@
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M*ZP_$;SY^CW9D^>F4\G_ /Z<^%8:7G']$='_ )<T64)[:-O]41@C[2YVS_\
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M*V42"+M$)X@*B.;6IQ+8=E\R0@1YY1WVU*9@0'94EUO+;J&U-.M+6) \?U0
ME8B!JS81(3:SL6J%/E%(5+:M)"4AF!'$R(#F&IT-:IST;,DA"7E.)8^$F3.C
MI4A;L="%I5EL=.O?W*-'O\%[PO3FR#=5D7077%3*_%&S3+K[90+@AD0.>=CS
MBC0)9))U\?%?8>;=F,C7&/4VYZ5JPA>4MC>ON^3W*=%1ER5"<(G"*4@NE=GV
M&I/WD-59$^M1X4XDJ8T0$)EN#AC[T4A.BAW2#9J9$BR([[#K\4>\W[K+J$J5
MEM>$QS#>M]5.C^OW=R\;.F]E2*@N]-5>0JM(&/&\RLSA29Z@D=[V'S;8)<])
MYP.R[^#A1L:J"E'F][_LX4YAL;UOX?)[DT?G\_L^/<L.9US=Z]5@ET.5V<*K
M5CD9C!",[,=A1%?P^9:7&8"WL$L17HV/?C37(:(<IK.%QWW4J3G+8WK?4)H]
M^NB$M<W4/30NP28&1"J%AFY'AB[TB#C$Z5A,U>$(@XE9)-MK0.F+9DOPVHSZ
M&?6R\M*V\K;&]>*:.M^!6D\E0G"+])2I:DH0G*EK5A*4IQG*E*5GR2E.,?CG
M.<YQC&,?CG/X8X12M:-';5IHT<6L-0F18)0HR$B.19HHN[@S(QG,<5*BAY\^
M5 (/>7I:B3F8[ZW?\3A'O>;>(#@>XJ2".\+P6?2VSZA@3\\J<MO)PID&-;&R
MQAYUT[A"5_(W60,TD[#-90O"DBIB&)Z\87Z(ZLM.>@"#X_'R_--'R^?+[?AW
MKQOZ<V3&NP_7,BLNL70I ^9P@;I(,AUR%\OE%,O.RU$<#HN4084I]QJ5+9>:
M]E33C:7LI;4V-;\/D)H[UX_W;6OW*C6>@$V ]K@,#B$F"V2988*B"Z50W7Y,
M9MW,@+/(QFU*>B2$>RX\A].$86IK#;C:E@0>H4?/?O\ ):ER43A%GJS6#MR-
MPZ[6AZR9B?[^8T1#T:/A2(L9V9*==DS'H\2,Q'BL/2'Y$E]EEIIM:W'$XQY\
M=R+>YNC=JC[9"I,NI26["0%+.0V$D [H]T*TEQ;Q;)UH@L$T.8PTK$B6\2;9
M85Z&WEH<<;2N-C6]]%.CO7BO$C26TW;@U0V*<0E6AX>P79A1'Q\N&X(E?A',
M)-1YC@/Y2\O.&6R>26(69&<1O?Q(_P 5QL:WM-'>O%8>NZSN]K+F@8,)F3.K
MF7\'W)! 6-&!OAY2H3F2)HE.B!XV%2D+88RY.Q\4M"L1?>PG.<"0% &_G2U0
MN)G BD\,3:;9(#93L.8TS*B3FD2&590XEJ9!?DPI+?GC]A^+(>8<3Y*;<6G.
M,YE%CN$3A%(%#U;>]F.SF:4"^;J'*B-S%N$A IAI\A\1\#&Q(,3Q[#LJ9\))
M^'BLN.2'<,.*2WZ4*5B"0._YTI )[OG:RX'1^T[)-.#Q52DYEUPM\A+-$" <
M-AD[G#F4AH[I@A 9(E'$M*<;@CG)<EQK+;R&\M/-+6V/PWX]WFFC^GEU\NOC
M\%AH.K=@D0EHL<:JE, Z8N0U924I#4".,D0W4L3(><SW8RY<Z&ZI"9<""F3,
MC>M"GV&TK2K+8Z#??W*-=Y\N];&"T'M>R@H]D!UAF>'E#WBC$A%DJC3ZH$=+
MBWI"A\@XT1;PVAIQ2FW8B'?)/GA&?-/FYAO6^JGE.MZZ*'N2H3A$X12D)TKL
MXY4'[T*JLB;68\"847,;(",2UC![S\><08#.$$&I,*,]&?;<DQQ[K7J9<]*E
M8;7E,; ^?U[E.B?G].]>-&F]E+IZKVFKR,UI(Q1O,KXX5B?\C0]F.HW@%F=@
M\H,EW&?,HD;F#[>,O^_[&,N8;&];^'R>Y-'6UB3&MKS7ZX!MANM$!@&T2,Q@
M$N7AAIXF[[*9",L#LO?,\,/L*2]%DNPVXTQM25Q77DJ3G,['HHT?59:UZ;V1
M2 ^3UFKF1XQN7&'S'6RH0A(%SIK&9,2&:@#"4P@$DR&,>MMDM%AKSG*6_+#N
M<(Y (/=\_>IT1\_GY?>HQY*A.$3A$X1.$3A$X1.$3A$X1.$3A$X13IHK>MDT
ME9,3H.7"58).-(LE;6[E+$]A.?3B9#RKS1$+Q$9SF+*QCTN)\XLK"XZ_V((!
M"D$@KMS2;M6]A5L=:ZH1;)!R3?J;<3Y)?C/IQCWX,YCSRN).B+S[<F,Y^TA7
MDI.5M+;<79((.BKP((V%\^UR_P"]]J_K(<_^3E<OJPM;X1.$5R]15]NI:Q.7
M2OVVB2=BWL$8J8\89OE9!)H]6DR%-EB,Z$5)1I<JP%%Q<?*(33.(\%A29TAU
MUQ_,-5)[^XZ'7N)V?AX*H=WQ/3O Z>OC_?Y+>V3U9:C"MH?557Q6X75G&M70
M7SX?]1*N;8F0'S54UKW\%58<F.XFXEYB? YB^J:M[#?DYF/AH_M;^&N_J>[^
M_2GX['[.OCO6M =_>M'7%Q!T-0'3-IIY6?7MGQ[\4$)O5<)G/I5\."APXZ!J
M2KLYZ<RACX185#69<-MG+:V&T->6)W]8]_</ ZZ;4:^J.[O/B-]=+/[;(@A%
M;[&$LVZKGV=SVR@SZ'&!V >8GO0 Y66=($)P^(^[*#M0HCR!.<$&HSOQ6%1L
M(\O:]<#J6]/V0=^FO[_L0^/Q/3]Y]=:_<J)<K5*<(OVVC+CB&\*0G+BTHPIQ
M:6VTY4K"<*6XK.$H1CS\U+5G"4I\\YSC&.$70!38C4 /6M>&6ZBV*J"-F4W8
M>TK' N]<*DRYELJ+C8A *U$(R##@.NQTIDR'UQ?BR$B,N>MF)%:<2]1W[.CL
M@@#7=W]23TZJONT-C0(/?X_#6SK[O-:[?TM!:I<JW#NU2(6/9G8)-NITD-<P
M[[4(&I)++-I*%XT_X6N-RG2$:-[A&3$D(RE]Q6/9CN.)D>'0]&Z/?\.@]"H/
MEL=7=^QZGU_-:[O*NS3%PUHJMW&CNONZWK--=(0=B5AMF"6 UV2T=8)$&B^&
MQ\)]EQZ&U+ENM1":GLPV5O+>PTL.X]"-$^!\3TTA[_3Q'D%JO:]F+*W"=LXP
MW7#H:R,!%C95?L(@YE.!%9 ")B9S8N7*6/7\;&>2PB7AI4EMM3K&%MXSG!O<
M!^GQ1W>3^OP5:N5*E.$6]ZUJ4.\70-6R5F$4\;/<>R2L)N;'@0H,".PX_+]+
MLIYAAR8^RVN/"C./-HD2G6FW'&VLK6F"=#>M_!!U5V2)N))LUIIRCE&" "6A
M3VJ]2>W?:R92AL5*#/1XUI-CB+\$25M*&W%>J:^Q$6IEN"RY(4PM]ZG70=_[
M0<>A_#Q5?B1W?5('4?B>[KU^=+"#9D+[L:#"Q[G4VV=54BF1=@E5W,+!!+='
M6!\E)"Q"4B>Q L+P;$N*KX: [,2EY+OM8]<5S*773OB>G0_/7[!\4'>WJ#H=
M>[\_'73]%K-"H02/MN[W:P6^AR$TNR9ME5KS>PZK"8N!Z<0D%Z[C!MTG\NC"
MQBL,2CCJ''Y;2D8'IB..N.-X=>4#KU&CT/3SZ?DH Z[.NGAL=3X==Z^U5BV1
M*-S[Y:B%CF!R!PB9EDB<H 0A%0KDD@K$U2!L\>_)AOQ64OI8;]F0[AK#?L+7
MEQM?*AW!0>\K2>2H3A%9#KE4Z^2L$RZ6*PUZ&U07QIL+52]J#5>5;K*RZ[("
MQDS#,N+'C"($F-B28FXP^\EG*(D>,\N4K"*7'P\_'1.A]RJ \3KIX;'7U\/-
M39$ER;L)4.-W/7PRZ .R$79MN7]9 (H1=>(A!BL&@13)#,$NP#PRL<J,/DS)
ML3#2&7<9?5G"X[CO1(Y==WQ[BI[_ !T>;?>-?=]GZKPU^9"N9CLV=@VZI#P%
M[AW4'3(=@NH$$[+)D#PJ>F<V(+DHLB#%*Q&$25$'8S33RT>RXYEUG*4CO31Y
M$$Z!\%'>7=W7NV1Y@K":1B!*O2[E*LLW7( :=HMM$OWX/>(,O8C#LM6&D5F/
M6'R)!M;DQ47VTX@ 8DB3"<:D1BJU+:6J3WCO[QTUT^W8'W]Y^Q!W>'=W[Z_9
MK?GW]/WJDG*E2G")PBN7J&OMU+6)RZ5^W423L6] S%2'##-\K()-(JTF0ILL
M1G0BI.-*E6 HN+CY3";8Q'A,*3.D.NK?S$52>I\=#1[B=G[O!5#H-]"2".\=
M/N\S\]ZWMD]66XHC9_U55\5N#U9QK5T%\^'_ %#FYMB9 C-636LOY*JP[,=Q
M-Q+S$^!S%]4U;V&O\8J.O=K^MO?@!T.]J=]QW_5UK8WY=WXJ/YH>([U\I,.S
MVZLSE#MCHN%A&C[U6B5J;I1(&$%H1 &J++ENF(T9"XS8;T?$PLL);=9:::SA
M,_UMZ\-=Q[]^>OQ4?U=?'?>.[[-_@LYN&[:UN.CRJJ[;2#SR-M#)-8J<P*-$
MR0XD;38H" %8&-6(A)CUD4"0I39]#2\3SR%Q7H3+LQZ6B "'=WAU/QW]G?\
M#R0Z([_'H/AH?'PUWJCO*U2G"+RL-Y>>992MMM3KK;:7'G$M-(RM>$X6ZZO.
M$--ISGU+<5G"4)QE2LXQC/"+H%C ?4 S5U<&6ZC6"F@]F5+8.S++!NU;*E#%
MA7.'PO2$K<,C),) 5F*E#[KZXWQ<Y^(H@MB(TTKWZ._9T02" -'\3K2K[M#H
M0""3L?@-K5+XT@+3K'4HEUJ4ZS[#["/7*JR1%S#O1X(!4$BPU9RAJ-/^$KR9
M[I"/'3DC*B2/1B0M6/;8<SB1W[T1IOE^'=^2@]VNA).][_,_/CM9.\++B=O:
MWM5./ZH/38NM!U50P8O==D!'20^ER@)X<4=A6"$J+E]@F^T*>D$(4>?,2E++
M[OI4TMW@CJ.I\#OOV-=$\1W=VN\>6CXJ#M^#**,GTY%7C5<=9'ZPA[8 BD&'
MCE2&V#,IW#+(R<Y/*-ID9B8Q\?$BD),>,M+*<.+=6Z^](.]]_?TWY:"@^GGK
MKUV?B5 /)4)PBWO6M2AWBZ!JT2LPBGC9[KV25A-S8\"% @1V''Y?I=E/,,.R
MWV6UQX49QYM$B4ZTVXXVUE:TP3H=V_L4@;/?KXJ[) W$D6>T4W)VC!*^2T+8
M-5:D]N^UDRE"!<D,\Q'M1L<0?@B2MI0TZKU37X\1>66X+"WULK>>I[M=Y/-L
M]#KQ[A\%5W^0^KH=0>X@]>NAM80;,A8VQH(+'NE3;9U52*;&V"57<PL($MT=
M87R4@)%)OSV(%A>"XE1%8C0'IB4O)=RSCUQ7,I>#NAZDZZ=>H_?YJ/%O=TUO
MJ-=^_P#'X[7BJBQHZ-O:GI=U/8K&<O=;M8R!:[>,54C]=40,2'%MEQ]@&CY<
MP(U/1.>&O$E.15O+<Q!?E,)0B3_5/4=_AU&]?/=^:#Q'0GH>_ITWX_W_ )*J
MVXF*3&V;<&-<K9<IC13T!517W9,/*<18_P =B#(>6XM\>DG\:F ][CB'(>&%
MM+6UE"LR-Z&^]0>\Z[MJ-.2H3A%9#KE4Z^2L$RYV*Q5Z$S07QIL+52]I#5>5
M;K*RZ[(#1DS#4N+'C"(,F,F28FXP^]AG*(D>.\N4KT4NWW>?>=$Z'W?@JFZ[
MSX=W76RISB39%U@0HQNZ:^&7"L=CFMEW3.+D C!\@" L1)0< DLD%0S,8*W'
M4*^''R9DZ*ME$=Y/N9\U4]W@>K=#H?CW]=]?L[O+2GO\1O>^\>.N[P/K^:QM
M>DQ+G+[-&X5MJ(\'?TVX728%ANP$$_(FSK5"*YEX$%R45\<P2AMHE+F.QVFG
MW4Y:4XMQKRQ5W<O0]-;T-^!"COYNHZ[ULZ\05#5+(BM<Z?V#9FRHMV^WR0K6
M@$?$(0Y),-5\X3+MYUV/'?<>8C%FVV0T&5G#2\K_ ,?'R['>RK(]2/(=?O\
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MMMM"4H0A"<)0G&$IQC&,8Y:5U>3A%\Y=R_[WVK^LAS_Y.5S(6.M;X1.$5?\
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M3;BVU/8T_%-%_!O"5?A9YUD,UGLCDL@3]60XW$6),;BFO [X+<D4E^$^8)V
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M9,(C<7@ ;7 U/:-P_9?7,K;E"M:KSVH+USW#W5T%>Q!5,DHJ7[=FHV2:S R
MW:U82F1H82>BVV^;ZZ)[>VKJJQ,]C"5#VV"?<I54NE-EV2FN-M[#B1SC6JM@
MF;#4I5'@/W&*$'6>OT;821]CFM,#;'58C;1&--F\]-P=Q (WVG8RP&UXY92Z
M*2!\CZ\3PR>:*%DKY+5:&0]G-/!'+#%*',>]KV.#=3GJG!/$F<P.9_C!D<-Q
M#B6ST*&7PUJ;'3.JY9L4\V%R;[-.?'S5KIJU[<-'(Q=LV2.*U3[-TG/)NU:[
MZ]"Z\E;(K?5;^,*QJQ/^;EX]XGF[K LAIJJTHZ//F0CQ"^!K&8DY$4PT'F&
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M-?27M,6;$5+K@V:HP5<A05-/-XQX7S3XH+'T=F'L?+&RO(*LKB^2RXP0M8!
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M"E8%"36H0^M6A8UQ:]\)8'P/B> X9C.!L#'MK&W6P2MK-N5!=F]VR/NEJ>[
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ME#;:$H2G&,)QC&.<FYSGN+GN<YSB2YSB7.<3WDD[))\2>JZ9K6L:&L:UK0
MUH#6@#H  -  #H %[7*54G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(O3F$( [$91"=#@XF3(X^)F9)9C8E3Y:_;B08V7EHP_,E+_ &(\
M9KU//+_9;0K/X<(OZR0@2)<R!'FQ'YP[X?YA#9DLNRX/QC>7HGQD="U/1?BF
M4J=C^^A'OMIRMOU)QG/"+V^$3A$X18\D5%AH[<PP2'BHCQ 4*9E$ID>#'=*'
MBD,&#&MORG&FED#)HB/#BH:59D$2DZ&/AMO2Y3#*R+(<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(J>]T.NQ[LO1-?TNOE8=?FUK:H_8+%H?<5B
M;3C-=HNP(M'O !C#3J9EBI&QRU-MH>*[EIK,H-AY;F<,^TZ4@Z^?B/T5$"O3
MCN>Z3M&RH-P&U/8&\GM9VWL%'U3LBTUDY)LXZO\ 94;BM5&YPY=&GDZ[I9K8
M.D:=5I!@@%BW&J:W;.F@<PB*;J5B)L>/EH>'C]_Q\U(-XT/WN+V#<I 5<9<8
M>8B1&J,-![VVN*&6"P5J]))U$O86,7D<0IE<L-2<;B;8%Z3(:/D/3)!L4 &F
MQE>K4FS%.QTZ?:?'J/T\-[^Y;H?TCW,N11JJFKJ2K](A7JYS3%FIV][R!/W"
ME7SNYI;=+(46Z"@ K14D4/K,&V5I(-.BV.,::;(3P->>!@B,0M(("!_A\"/C
MXZ/Z+23O7+NXC[S31NT;F9.S]BV,UK08K=U[":W-5AS85U/:K$67 ^XP+]60
M53HI2J4O8T+6)76!4VX-?,R']MRA;*+ 38Z=.[]WV??UWU^"EOL9U5N^V-S%
M[:(4637KA7.GH8D0';AOE0374=?NWT/=%[S#K(4I$@M'CE"(OYHUO"L1[$#/
M 2+,<I7WSB)\THWT^\^ \1KO[_N[EA=7Z![;UK?5".W7;-M-:EJ#1B")'Q]H
M6@UYUV!8-X10X+98NQ&E1]ADBM/L^J)&+L;$6R\NFZ\[DC:0SU=9(VPI)&OC
M^?=O[.[S^[1Z=,>%2G")PB<(G")PBI[W#U;L7;PS1U4U^J(S'1NUTE>YI?ZD
M>K0VGMZ0W9 C$K*,I]UU[93,"'>B-)=&0!%K%RF;3BO%<2&&QJY+!2-==_/4
M? JO).O]T]=5^0$:V?O>ZUX'L8%KR'8*G3] V+9:M8TWK1'0'V$,C7FI$L6
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M.H>T^O,6J;6J]4*>/2<(6/<^K+>O-E<O]K@RM6#9!;9EQ. :L9B%&^GQ\_\
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M[L*GT.A!WR5@EJ9UU7JEMC9=<C4QW#P=\;=3F9C,F8['EQB;/K_=^X+<]/\
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M!L2V]8DYFHY1(29&WBO6NMV61/1I2E0Y,JP@B6%Q<%O)E,DAB2P4[^?+[%Z
M7JSIG4Z8]E39[D$I%!L$/:D0):+\X_1:C8:U37:V:N\XD?2X76LF!9=)VN=9
MK,0@8(_-+ RD9,,6&24)O]W0?':U$-X>?7"O.3ODX4K$C%:%3* 7:S]-RR1*
M'0=>4W5%;,.7";69-^@E8^O:!5*Y+@A[8-J9!L9DI,K+IR9-*2";/Z_K^_U4
MAE.H&E33P]XF+-2DCK3;[>U'<-OYC/%KSV( =H+"B4S[?D_!D[4K8V0U$SG"
M&0.) 1*LL/Y<P39^?@-?DI4U'JX7INCB-? K#<+$!K\>$,KZ[J:;/$PU?$BQ
MX,#7(D]$*"XZ+""!<*'%>GIF&9[J9!4\6,'"!$G+*%)G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(J5=LM.[ZVK8M2R-2['L=)JE?9O,:[0*CL(QKJP.V,W,H;M O#,X</
M(C+(/HL0'>(LZGVB&7KI9RWQ)<^L61(O$#!2"!\[^?[E6>^]5^[1\:;@Q-^6
MC J!M0H"K ZK[LV!4+(2Z_#PNXINN+ 3MJ(>9D?;X2T;;" ;PF3((P+E7-/4
M6VDC1@V*@U-9.GAY>('?X_=KS]/%>SL'IIV$M([*IVR;==')>P+%?K2!*]C=
MQ (%@Q2NZ6B=VZ,'5?(9^.(UH2%:2IFTJBJ;1 U6@B;58J]EUF='%BS%=*00
M/3\VD'\?3PTKD==*%MVB%-U(V27?,@++M Y:M=/&=AVW85IA SLZ>3F!YT@W
M\)70=8"ORXPF@ JH!K^1=7AQ1EBC%3$!=C-%!UT_%6<X4)PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+CR2Z
MI=M9WST^W9['B[CM9=U=9:HN4GLAM--QKI+=U'TW+U7?+IZ3LVF$7:_L37]S
M'QAM0K]?K@,;/UI=AFN -H$EHX,JMC\CKPWUZ?C^?P6Q[SZF=E[@O=-'H-VL
M2Z+;:/LRHTPE=NP6T+2(>UO:^G9W40?4]IH-JD6* 6N*>SI1K=D_<1G)BU_2
M:$UU5LD1D8J*7S\_F@(Z?;Y?'>_3IKN_7:]?Z%[C#-R:A/[ VQ82U.IU<$CK
M2^ V=97!MLN0BY[EF7ZYVJDEYS%?>";GKUHUV3"4M &T,:>D#'Z#1)M1 T>M
JVBPE!(\/R'=T\?AK[UTXX4)PB<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g692844g50a84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844g50a84.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +D F # 1$  A$! Q$!_\0
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M7[9B?D35@W8$!P&=&8B#*SW<YS8O:2?^]"L?_DFP_P#[%C?!"SN . . . .
M. . . . . . . . . . . :+]BO#AZ<]J)\M8USUJ8*S4M#FT E9"(6Q;M5Z
M6/7H]XY>-879XFKIW#A=E19HZ(./1#9JQ-HHMW*@[7;4<LHS4&DB5+.Z(K<'
M16>]CIG_  RNE4DM!M;KZI2K"5,Y724^:C(O;%RPJO$9[UP:@1M(SCX4PVP
M-9JRNNPL8 QP$:7B:KO$98;1UUNY#/R;)Z&\N-RI8CLMJ/;>I)PGA\=08X)@
M8,-4?J8NLH9V*KV#M??ZSW'L2(=L9!F47^(].ZFB[@E[_'<Y?>OEUGY2+?\
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MP_HW8LCKZ6RZP$GTEKH! V,?D#&FJ2#R,.>J>0F9=692)RD;"$)3"8['Y4]
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MK,G_ )AS#@0?*G/U4]"N#0X X!_.7UPZ05SXBW9?O9W([9U[9F 12\&]%=;
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M;"B ,K%A:&@IUG75JOL-?X2VSE%7R?/0+.G1714IXG?!885A6=VZS72/QO\
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M2IT$%'##0U9*"A_]J@2AHD@@_1H_Z*'=_3AE"A-.<!]@X X X X X X X X
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MK,G_ )AS#@0?*G/U4]"N#0X X X X X X X X X X X X X X X X X X X
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MK$MQ%CM'8U!('HX>UN5:5+6$5ESN8CZLAH$U61*+2.!N7;EL)*CK@ VB0)@
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M3?H^^MGZLR?^8<PX$'RIS]5/0K@T. . . . . . . . . . . . . . . .
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MJ>W7?N'LFOC.%]-O#'[.9T6QE/5+.%=<SOS5,92TU3SC?&?*GKKI_P"CC&,
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MC_;+[/\ W\X#+EU34?*(S?ZOO<C_ &R^S_W\X#+EU34?*(S?ZOO<C_;+[/\
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ML_5F3_S#F' @^5.?JIZ%<&AP#SH[?_\ WX7A/?\ X4]__P#Y/KMSP:ALC_\
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M1RX847%1*IY-8U@N&^LO27AS5W7-A-XP\N&ZL\N.EDK;+,4/3#@R. . . .
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MHBM<L&$-&2\_0=J2(NG&LMM*P>S-C-'JR9_4<HD+&9KJ>/FI;?74<:#0^2G
M;HB("D7K85EP\EJG4R#?M'UU=N]1[>Z:Z4([EA0#4=[SC="&3QI,TJ.">HJ+
M:NO;"R4</*JC,H^NLTA+Y1X@WT0WS@1C%)]N^M*S_(]O<D+<J:@<215VU([.
M12 I:1#(H-V7,()*"T7Q\Z8&LXN*4=ZE)1H[1>1YF28J:.=@\\2TZ [N3UL,
M&2081:T7);AFS5\3(($6R0I,>3#5F:!D13QXJUQ+&$A2N.L1P1W#$Y&B^.S,
M("UVT*.]&V167#R>BEF0N[J?L<VZC< LV$3,XR"C9$Y&QB1BS3A,&8%1\\-*
MXP/<KZ*,W026Q,QJLEMOKH,E,:?J^8U/"E78A:/ ' ' *8O2^(%UYAS:;6"N
M\T&/C& 0]L/V$IO7Q#0(;DSQ-%4Z6!B4]6$;C4@-N?6BC?=1H*<(,='A%5HQ
M<BHCD%DO<;K_ !M0(US.1I8H9DP6,. [%^('OXLL6!3>4.BLWS*"D>90\-&X
M[6=C$)*X//&3L<[@LGC:3)U+ABL?R(WFF/(S[KM?UK9-UW3R\*V:(M!*YQ]Z
MS*!J"HX4T,R://79-!1;5<;JQ,PF;,7Z3]-NNQWA4R4=I(H14^J.!C,H]CJ%
M<DGP9M;U?.2PV6Y@CX:WDXM=\VE^A.1AEP*C5)QNMZ\S+0Z8#2&NNF4QSZ)2
MEL_4;JQTQJR!M2'SSMW1,$K9.UO?,;+HBXDN8BT=PXH ?^M'$XR_F[AJF[*&
M0P=+",'%O9FDHZ*M\%(WJS(A/:FI<-H0%1',B\[:=:1C8BZ,7;7@+ ;#/!MN
M>D3((^"+/6$D))-# \INU>C7R+>%S31\Q>((NQSV%S :_1;$(L>:CP9<.DS,
M/.R_7T>[D#!]<M<M7L5-(1Z1MEI4*T6#&%UI4W]4?:9<>5'U9>"3I(@XSY6H
MO:#S/!)9K[J2#V<(7AP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#SJ\1W_V;
MZ??_ (Q7I;_-AGP:A_[?^*GHKP9' ' ' //7Q6?T??9/]68Q_,.'\&8_E7EZ
MH/"F_1]];/U9D_\ ,.8<"#Y4Y^JGH5P:' -#>Y])]AK$F_46VNMJ%,E9OUFN
M><V,\C5X3";P>*R0-..O-P4<X:-C\"KVR2Z!,<K:"1Q%)4$FU<)C%$-WB6RF
MN,BHK.BWHW=%]C1R<=,NW]E'; DT]Z?^'+*S=F"W 63O3/=3N\ZPV&/97$YR
M4:PMKMUTPSK/4W,H)#9/(%*V;Q-:0&XR%(FE'[E@@IJ*[2=?I3.V<[5,_775
MWO34]A_%:!=:.A06>JB!@,@;6[Y]]#B9YB%CFD1$;RH-(* *@9:2&1Q-(6P-
MR<86--44&ZB)#1=!%70)8K]*:GX-]4NYLA6=/B73?PR<&W=ERRX598-[6]N0
M<XTLF< Y)&9/*6L["=7ATQ8NR$<ETA I-&1QN,&B'V@X4R8M&(])H#IBO3[D
M*6Z(]I7@T8%+=,/#?D800$L<*T!RSNKWBEX112WE9NM9\K(AY/UW+#3%F3G:
MRI[K([:+M7UH$4969;JR_+=ULE@'S6[_ *I<S7W,DC(#.D_;<.XAC\=T]\.=
MN:@AV420/)\]V>\:TR*EYJ2C!B6+3V:..O"LKM)J?)PF&/B0NS#$N%+N(C&-
M\LL9 "O5 ?-9_P!J9YRM6S%3$C>@_9D3Z\DPZ0>&<F/)5P\J5Z!5[B=U7<66
M@9.FX]U[,"<1-YUP7C*3X]2L1B=<R*2HB4Y1(8Y%XX@;-/U@8M=J#YK:]B6V
MR5Y<C,9Z5=OMV<P&..I'A[/0]APMO Y^ )=Z>^!..3D0TA@6O&I>81TAU_<@
MY-8#:%1N/1U"U33![9Z3 &(QI+]51S15('3%9*Z?TI+OVL)0"ZM=UH[7S>JV
M'4+PU'4!0M(==B\>/]N.X4K1,6N**CSS2<R9[*.L9@I+#F3XH<?>*R=\71)'
MFB1HDB[)XRZR#IBMC?*EG4PNG3?MND\E[YOTG\+]FK.W!%S*$6':CMP/'OU2
M\UA-CD\-A++J\@+#HOIW74.E+EL%9CFRA@3NZREYQ,OA^#I:Z]$P;' X8/TQ
M[=UO(4I5#>F_ALBCK:51&9#GBW<CNF83"FX$[M!_"M(ZQ-];B0^. HL\NBTE
MP<3!-!T4'[S0MZN%TQZKAL#HMZXV)>V>2%?U/X?7<2LZ=K.G'_5CPVIP'J\O
M=1L.0+]GNSP38@Z["%)$_MD4:#13J<%!F8=*6,C5C;F#&F)2*^[8B.C%!:V
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M=?D7;+N?VW:+R""G<KNI!%3BZ/5'59R-/&W+F2E7#=1H6<'G9)WJ231,&&I
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MNS']HO EBO1-1[R^+=]"WAS_ ,3W9C^T7@2Q7HFH]Y?%N^A;PY_XGNS']HO
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M/1Y 8>3GSL8S'(GC3_#\NV)H8SMY<X_Q?)IF!8QGS,_D3SY^/28_+MA+/Y.
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MQ$61C-7U]&E@B#]D-]WY>=#ML,B3XV8<-G@P="&@XB@B8DTD(#6Y%%ZD)>2
MX^%>HN"Y#U@"U1*Y];T_MP8''>;JAEO[)./37I=]O2^LZK^N1X#ZOJEG"/H-
MD_6<N/2*Y4T;>BTPL!F. . . . >>OBL_H^^R?ZLQC^8</X,Q_*O+U0>%-^C
M[ZV?JS)_YAS#@0?*G/U4]"N#0X X!YX=?7GB#K=O.R;>^AU0-^L"*,)^$"\8
M(2I8KC;804SM[KX(1]CH\67\C;>SL2!]E,;(L,F\-R[%;N5<"JS(SO>[-R(_
MVP[(7U5<T["!:T")&0$&ZN5#93(SN\B3+X=2>5V/?D>,R99@='N7LP1)!X."
MTT!Z[KM6.P!11!LDX+N%%PDR+FN,V1/.94\;[J3F*,+GE,JLN$R(DQ[>3*@
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M .U'$2[89MH/$R4D(>O,[I@W+CQ9>EYN_P $' ' ' ' ' ' ' ' ' ' ' '
M' //7Q6?T??9/]68Q_,.'\&8_E7EZH/"F_1]];/U9D_\PYAP(/E3GZJ>A7!H
M< < < XMT$5/29W12WRJGJDKG=/3;TB6F=]M$U/+C/GIZ[**9UTV\NNN=]\X
MQC.VWE B4GKV%3),>E)HX-+)BY$&EC+59/=+S)#'W67H<BMEMNAL[V9N<Y5P
MW>97:+>7;1R@LGMG7($J69M'*.&[AJW<-]?-\U!9!)5'7S,>33R);Z[:8\S'
MY-?)K^;C\F/)P#YLS:;Z-T]VK;=-GNDJT3V02VT:J(:YT04;ZYUSJANCIG.J
M6Z6-=D]<YUTSC&<XX!^-1[#7TWFL6>OK*RCEQYK9''K#A9'+=9PMY-/\595O
MG*"BN_G*;HYREMMG3/F\ [&Z**FV-E$D]]L>;Y-MT]=ML>8IJKIY,[8SG'F*
MZ:*Z_P#\*FFN^/)MKC. .KN,&J).4-Q['=%YMG=VCNT0V2=;[*[K[;.4\IYT
M7VV7WW6SLKC;.5=]U,Y\_;.<@<R[-HY1<-W+5NX0=XSAT@N@DJBYQG35/.'"
M:FNVBV,IZ:)YPIKMC.FFNO\ Z.N,8 X]QP]3#K"C!FIAZWT:O<;M4-L.VJ6J
MFB;9UYVF?6&Z>BJNFB*OGIZ:J*:ZZXQOMC('ZRQ8Y6V<99M<N-F^C39?+='*
MVS5-3*J;;97.GGY;IJYRKHCG;T>BF<[ZZXVSG/ , +D4)/J"E@IV+&EGF)$\
M"*BR8DBHZP"(I I8Z%;M%UME\!B[U$-(EVF=L#B+M(>2V1<KZ([@=XD1CL-
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MM\)H-#0T_>V62HC<'LR2<R=,>K':R7P6=0JZC"DN-V+7D,A[N3M>P%CY@D7
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M#^#,?RKR]4'A3?H^^MGZLR?^8<PX$'RIS]5/0K@T. . . . . . . . . .
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M"^T#GKB3V<!%X"G.OIR,]B[+/VA$64*F1\\LBO6G5&XR<7;R0> (OM]8P::
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MM$\3NL\] '!3"M'Q(8JFJ"HW?FUO2^[,YH+XC%26BT@CBMJ]MZ<K6=-(;$H
MTC[>JU]9&PG=:6O;H.99-.K7:1>.A4('2\X+G8S+ST>M6.*)Q]B<KE@]E<=0
M)!NJG1_;Q;,S$&/$^ZZBA 4NW$649U,15K+E!K 5#&)D6U1@D*L67@'0V23L
M"X(SVNX]9E:)RRN(U@_/')B>@@T-CTM?MI B$%W5GE]T]EM9,2U8%VI6LWL2
M-JJ-0.1"Z]VA_9QTI84G; 6[>83/KE=M54D?:P)(/,RQI&/AY1)9T,.JS>(Q
MA\6<#8V8BFSZ.NU'S\1I=.[KYQ-Q."#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'G
MKXK/Z/OLG^K,8_F'#^#,?RKR]4'A3?H^^MGZLR?^8<PX$'RIS]5/0K@T. .
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M<4R/68-)@,AL@?I@] ;QK\.7F)MOP0< < < < < < < < < < < < < < <
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MX7'FQV7*.-,K-\/ACATV].EA1/*B7I?2:8WTSMKC&VOE SW ' ' ' ' ' '
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M!P!P!P!P!P!P#SU\5G]'WV3_ %9C'\PX?P9C^5>7J@\*;]'WUL_5F3_S#F'
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M!1L=(O<OV2:F[E^#"GI2&&/%5/.V=- \B,BDU\[^SB#AGE'?(RLI%P< < <
M< < < < < < < < < < < < < < < < UFZ^V)-YE,NU,5G,CBLC6J/L,U@L
M47BH%2.(LH49Z_T-:8T:39.)%)W3XN,-6-(1C\XJ01T++LMUFXH*AIH(9"K=
MFGNJ>Q3,A[,3098EG0-L4C&"X#O)U]HR)1]5LWR>?518-'=?[+F3Q(=EWJ^)
M/$7,JMLBW/H-\HCQ,;(><GNE&""J8-)%R]VT*GW[NVG&46TG&UP*M*/V^:WL
MJ!Y,6/K7K*,4K*+PK;K32V8LFPK.9.9-I8K>11^^""Q]\*4&,9M(A[=\MJ.
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MB.RLB/$O74R7>C1.#TE-O1HABY;C1&I%PV8-4F^V$]0<SBM3,EUA[Q8#3:Q
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MXSYV=O+"\ZXRM_S4\S73&,XQZ'"6/+C(#,<,9SKG$^ENODQY,XPS@ODV_/\
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MN3<X6($WKE<"59CAC./)[^RS&?.SMYV&<&\ODSKYN-/RPO.OFZY_/QGS?/\
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M_<?&/Q1OJ']3/]PV=_V&\!H/W1?2G^X^,?BC?4/ZF?[AL[_L-X#0?NB^E/\
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MED6[5-,DU*$6[S59)\YT5%?+O%J=9MX>78!FX/.VGB$SIJZE+LF_D[EMTXZ
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M7\-?2/\  #@.F"=]1_PE]U/]56^OX:^D?X <!TP3OJ/^$ONI_JJWU_#7TC_
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MR:8_"+@#W!E?TW6?^R:8_"+@#W!E?TW6?^R:8_"+@#W!E?TW6?\ LFF/PBX
M]P97]-UG_LFF/PBX ]P97]-UG_LFF/PBX ]P97]-UG_LFF/PBX ]P97]-UG_
M +)IC\(N /<&5_3=9_[)IC\(N /<&5_3=9_[)IC\(N /<&5_3=9_[)IC\(N
M/<&5_3=9_P"R:8_"+@#W!E?TW6?^R:8_"+@&*&1Y^;V(Z!NPTZ+[AR*X@MH,
M2HQ_L++-<:;.19'5K5"N61%OJHGE=DYPDY1QOIE1+7&VOE YMHJ7TV6TWO\
ML#7=N_;"U]-FM(:[($WB+5PT'+:YJ;&4W[IN^9+MF>^-7"Z+QJJDGMHX2VW
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M]?%9_1]]D_U9C'\PX?P9C^5>7J@\*;]'WUL_5F3_ ,PYAP(/E3GZJ>A7!H<
M< < IB=F@0V;P>*D[U+5[)[.<&!5>P9IO6.KJ8$8J"=R62:QQI*H)(#9-T+
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MPY5]-=F_LJFOPDX#I@G?4>X<J^FNS?V537X2<!TP3OJ/<.5?379O[*IK\).
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M=/XH_@P06/$L[E9*,TY:I%JM3E#S>&$AZ @:V;SR/6@<BYD-(&[[W>L+2.'
M[QJ#CFD:!T:SSS%^5^YGQNICZ7:P_?Z*?U;@@^-U,?2[6'[_ $4_JW 'QNIC
MZ7:P_?Z*?U;@#XW4Q]+M8?O]%/ZMP!\;J8^EVL/W^BG]6X!0=]'JSLY&J\!;
M3HLAI!K4:S@P+E%C0-NQ)"D8%8$6]6;9+1.RQZCY(G*QCY/1:/MEL-V;I5@=
M$$DF;C@)YXZ%!3:.")@"'C'MG=:GJT:6O#6/)O+T#.!K]2P;8AEAPPY(!4AJ
MZ7QQY[)8QXB..Q S&94)U<.&C@08]=2:%Q0MGOX^A9M7DFT.L:5SB6=ANO\
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M%D%$9;"WRR @J+:LAS-L#3NX;R)[^7ESPTS%XG"8I$?7+?5<1YRB2(%15(7
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M%"(*8&NQ;H!C+H5Y-Y=IW4H33I/,!-EBI!&-^QXN);5UO#Y&^S(:$0LUT>U
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M>F_V24&M-(VL]<,B2K-(61RQ:3.%DGZ ]ZZ<LA$UAIATBB+ED>=DA,RV^ .
M. . . 5G9=I@:M2ANYQH^>JSJ:-H("09$(J+QL;<QV22?3+I],))%A*2'LV+
M$]4TTR"Q%V]V9LAX]VNYQKJ! I;V9@4/& R;P;)'J<A4FJ3#1#6,BFZ.8%/
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M[K9.)@+KS8" -BQ2\?:=6Z<OB-LY6W(2@N[-EV)BR'X@T8&NHXS,M&3=9B"
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M$/7:0K<.N%OBMD9([V4C .1QV$NP18=.)"I$%$HJ=(QEH58CY):,.K5\X?M
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M5DZ8L.D]=+DGL=.#6'K!$01:M@7>16=>JSX$8SWG\-9,^/@CF'U.SM8J2@;
M=53P7UU0DA!.P[ZD77X*Z&R7:;_"TLY:'XL7EIB,";#?3=C#M6*.D7<3DJ,A
M+L/ZL5:<YM)'X^8&U:,LZ+D*ALR]X\/Z^RZJ*@%S0O/YG$8O!)"%"-:^CV95
M*M=GP\>JT<*CP'HB>N$%]TG+1RT<-U5$'**NP/%8ZOQ4KVL;T\/^RZBBERK1
MRG:S RF(VE-MX];T&@$"F\6"T=-6-<71M,(Z_27W!K55.RHJ*3KSG2[4"9*C
M&KEUY7[794/ZL56Q)*JVV=;C""NTOA:D@$DD[N9]5HR#BEL3BDS+^9B:^B*2
M-A5V]>-)8-1]O,&.7(\:BQ7+[G4<;A<1_*1U1\F+5T=9#^O.Q%MN6:$S[6V=
MTMZ;0",65<E4PO$:ELW&0<7F)U-$9$_T7= I!+S4D>--&C3T$/A$%B,KGLV.
MZJ*I@XC&RQ7T#G*";=4$6);UZJ8ZSK[\-.GR-H1Z>23JT*F=.0N2SZPJ]1&5
MT_L,#'(G%1LU+K;PEFR5D+A]B+F1)AB,08*/R3(BV79-UTMM]] 3>5FWIR2:
MWRM->=O$%\+E.11]JY'46/KR12DS$6MW$6W7]"K&Q4'3\>N1[J7?(2AU*(SN
MF(D2,?R/E\6CIK)\>3=(BUXFDTD[P&C_ +N3K>WG%#:DA:?AQB9#.HF3EW4%
MA(ZRBA*<V"'=KU.@\A\1"CPY8U(#VBFFN& T*+D4=(F5U=L8%,9%'W1##= V
M+W=@\7]TY);,HJL.X'AVVBK+7["&4['8#$5K(T7M:3#J!90,PE7%IQ:H-G('
M5M*7DR)MYA+Y@$9PUZC#\C"3IRA'WA =,'XF-D0_J2]7P=<'-FX2?Z)V5(Q$
M0KS?K).),>A0ZQ@X6)C*Y/O2$&+^?[*DS=,6S<XV%DM4UE6*V=M=G2"#APAI
MNBW743!XDMWDNO+L^!E)_0[5GV?1+^D<$=<5ZJ/@92?T.U9]GT2_I' =<5ZJ
M/@92?T.U9]GT2_I' =<5ZJ/@92?T.U9]GT2_I' =<5ZJ/@92?T.U9]GT2_I'
M =<5ZJ/@92?T.U9]GT2_I' =<5ZJ/@92?T.U9]GT2_I' =<5ZJ8][477X<X$
MLR%84XP=GB"@D&U>PJ$M7!HHB*)G5AHE!<9HJ1()! I@PHS9ZK.-!0DF0V3P
MT8.ED@=<5ZJ8I*ONLJ["*%6T$HYV+G2C%*%$F<3@KL?+=R@=W(1ONV];#E6Q
MK1^!8/33-0<JX3<BFC@@EONT2W5P#Q8KU4DOP,I/Z':L^SZ)?TC@.N*]5'P,
MI/Z':L^SZ)?TC@.N*]5'P,I/Z':L^SZ)?TC@.N*]5'P,I/Z':L^SZ)?TC@.N
M*]5'P,I/Z':L^SZ)?TC@.N*]5.@G4/7]8H[!I5?3JIH>P'%7XA.%0K<HR%F'
M!1H)).Q^HS+MLP*.P9IJ.>+):-WK@.41;**J#W>J(.N*]5.=K2]$/4]EF53U
M([1T<.VFZK6"0YPGH['NUF#]KLHD*WUU<,GS9PR=HYSA1L[;K-UM=%DE--0=
M<5ZJ=CX&4G]#M6?9]$OZ1P'7%>JG7S2]$:NTV&U3U)J^6;K.T6>8)#L.U6C9
M1!%PZ3;Y%>FW;H+.FJ2RVNF4TE'*&F^VNRR>-@=<5ZJ=+X5==O:.@CX;TO[6
M4<+M-!?N?!O:.[IJ/9EG3;1E[.]9V<-A9!@271PEE1$>^9O%-=6[E%3<'7%>
MJF5^!E)_0[5GV?1+^D<!UQ7JH^!E)_0[5GV?1+^D<!UQ7JH^!E)_0[5GV?1+
M^D<!UQ7JH^!E)_0[5GV?1+^D<!UQ7JI%9E!^K=<@U9/84/H*"1M!=NU6D,RC
M]=Q<&BZ=[9T:ME2QMHQ8)KN=\9T;H[N,*+;8SJGKMG'DX#KBO53E-5[UHCK,
M,_-U]2PYG(RPL%'EW$*AF-3I@WYVPH<'QH*VV).GJ*:SM))GJMG#!L[(;^8Q
M:.7"0.N*]5)+\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO52*S*#
M]6ZY!JR>PH?04$C:"[=JM(9E'Z[BX-%T[VSHU;*EC;1BP37<[XSHW1W<846V
MQG5/7;./)P'7%>JDE0I.C'2"+EM4=3N&SA)-=NX0@4/50705TPHDLBJF)V35
M253VUW34TVVTWTVQMKG.,XSP'7%>JG+\#*3^AVK/L^B7](X#KBO51\#*3^AV
MK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO51\
M#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#
MKBO51\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^
MB7](X#KBO51\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO51\#*3^
MAVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO5
M1\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](X#KBO51\#*3^AVK/L^B7](
MX#KBO5303O\ 5?6D5%].R\7KR#1LLGXB'3)#0F!B0 .1T17M9GJLCH]'CV[G
M5);7&-54\*XT4UQY-\9QP:A55WG5?E4]3N# X X X!YZ^*S^C[[)_JS&/YAP
M_@S'\J\O5!X4WZ/OK9^K,G_F',.!!\J<_53T*X-#@'FOWTTG\:MWP_[MB%,V
MO=H"BNQ%IRFPHW30$1)9H/CTSZC=A*E$%FP@W((RQ<-=)C/HZV>[;ET-D&JZ
MRZ>JVZ6J"@U#_P!D=$>&3_\ E"OHAYA6I3M06A,NPMB[](_%4B,][--K_CEH
MRZ+4=0#8Z9K;L/UKA7761U8Y(.[#=NB4)BB]=Q*X(&Q,+$%X]9[(@]376!GC
M09Z-(Z;LX/Z6::W*J^_0ZED4M4UD6"]L@ATJ\4UN9+SZPY:;%/\ KQUHET3+
M ;3@_7&$3&$N8O,IJ=$Y'*I=8*\,B"N4-RK D\DJ#I4F))-QS$)LSP-*];E5
M4LXKVP :H86+L!M-W/6#Q?C; %:;&S8-"2=(]:-(W!\->YHKO.ZBHUV-E@^3
M&0Y.XVA)BZ>2H^<-(PPFF&8$&;L:W*;AS@ZK@WH<;ZG89F.M8_'.M'C'0K5&
M%0BOGCR,U30C3)Z+0NX;XN7V1)F"U@+C9 --G>P,F;$Q!)HL&4]W(:0W'+/!
MC_)4)XPK;:LYHB6\I<S['JH!P@3#6$ Z[>,!$GM<-.K#^ E4J$ZN&U0$_P"J
M-(;]=(I/%VA^4D69IQ+JD6< )=&R:2L=P1=N9!'F00KHQ68A>JO"ZN\UFZNW
M4C+?KA6($((&P+J_XQ4%*AF080WE@^F>LIPZN%TH&7]=9PS=-)5)3<7V=6'#
MIP=-%7[>.-MP$LRS=Q)$($;[@%Q&MG"KY^*7#<D%J"_X95->VOT;\7(Y#::Z
MSRCK1"P8&,16OV^!<Q"0F-R"=GU*_OF,KRN3/ 4!!C-@,F4+5TJV4):/84\]
M=V\P5'1YP35YLN-CI*VZ>9E0Z#(''8ZP9]7/%M4F$>[7QKN#M8SVCNN[^2&[
M-$5./I@ZT.-'D]7 O0DOAB);VIC M(JR,&E2(HDTU8,6R0C6S@G<\K7D1.NZ
MXK2MSM+GQ73#Q7W[BD G64+'FY*F*(V;%M.K;OLV]ACPWJVLAOON\.N.TDPW
MD:C'=GC;:.Q?<5J-W2*;$05%7_M#:JV_N9_0Q*55PAINU0']4_%R9!MQE7#I
M $UI+KJNWD>U-=W)'WJKUXY>.9TJ3'.!ECS.7Q,AH(>,FQ>%%VZ3I'!P4T,9
M!$:^&^_]R,I,@4?BPOKC<?6 AU)\6TI6EXV>&GLO&CZ?HR$L0T:9EH&]DU3U
MR @=EQN.UE7]C,80[93AC!Q8-VN_GD]/1MS&B1=AL)>X:;O!)&M7R5W*XI2;
M=;*UD;&6@XMUL\:2OHU,G785N5$-X#2=D/=HEVC848]N:&[2^Z[&LN;/6,JL
M>@8M:"T@)2)Y,T)%))VT;R-(:>:)"!I%64X%9EM::.RR:Q[$E9(FMA5B$G:\
MXW;]=O&$B*,ZD_;-X];@:&ZL.\#8!WAWCS_LC68U222(YO[-E!Z-#C<9E#WU
MR7PM5/U 675&J.6KD2>,$FO6U+%S::83X$TM2MNMEO+A&4B\-[Q40L(%1RXQ
M;V P6/L(&'D\DNL#%X=*)S*C$3['"96=+MX*"-0IN ?'E8*3C\[F+62Q4YE^
MUV9A.W>A5<59<<47$AC*I*^S&",<DO4[Q>9>X/+39S)Y,7J&@TY'(75@=$83
MT$DCQ\\9V"BWU>.:XA#2=)KI-,8UL4F2>*)J@-FX) '7&#K_ '+%ZKT(W+:4
M&R[8D8<4?XQXF='F+D7(9P'Z^=2/7BXPQU@B74J3L=@98R6C+!,Y5T5]/A<<
M);/A<F(JE&#O1NW28;!.4X)(UO\ <L7JO0XC/76J"X^1QC'4_P 8%A7RB-D$
MJT@S6G>N*C*HIY:J4 S*IZ //)@YE,I?IOZY"D0L?L S*(JP4)R%HZ#$6#D.
MV!!D\"V7K-$NX3NG>[G"=Z\5]*VQUY+>L?C 22;'S\@F[N<OZ+ZPMGF;!D/8
M& ]D74F4C8J4CH<NTQ.Z_9B]HWN U#J1(L4'823+8''6(C3=X;&M6QFXV&P5
M'^[M#W!![?B'3+Q0F3J%U*\JE>(1WKAUHKR(35L_?^U=C,_'5S.(LI,%0Y18
MJ6B# XN\1B960'78U?.K_P! D%S/#Q=7EA<G0W^^4'/_ .GOXB_V)UK^-W!-
MW^Z'J/E!S_\ I[^(O]B=:_C=P-W^Z'J/E!S_ /I[^(O]B=:_C=P-W^Z'J/E!
MS_\ I[^(O]B=:_C=P-W^Z'J/E!S_ /I[^(O]B=:_C=P-W^Z'J/E!S_\ I[^(
MO]B=:_C=P-W^Z'J/E!S_ /I[^(O]B=:_C=P-W^Z'J4)V"[*GKW!0P)CI-XD\
M+S%ISK)71(50];.B!*.F(7-:SG<89.D[_&. #^45Y8<M!C98R65(Q,F]9R(<
MT<OAK=/(;N</4U&<I390Q+#3/J_X@(ER8D2IP$D+Z>U\Q18H)*]A!PT=*-FO
M;U%S)-$H%V$*UD]4!N80AB$0B!@HRRB8V."V3(:;.'KPRQ1RX:.M"95;:96V
MIIU+\1^U)*1#%&S1P\ZZ1&-KQ\K+'S8_.T@6B/:\R%1@TAF"LAE@Z%$ 1):-
MDY IAE)7"3%OC89W<X>OK+S"9NG\H.?_ -/?Q%_L3K7\;N!N_P!T/4?*#G_]
M/?Q%_L3K7\;N!N_W0]1\H.?_ -/?Q%_L3K7\;N!N_P!T/4?*#G_]/?Q%_L3K
M7\;N!N_W0]32ZY;$*718QB>'NFWB0LVI$#&@;$ VZZUSMJ(WB/MY*-FT7Z79
M%IHX/QY&Q[D=QTFJ.PJ!D<TC4H&^A+UZ,5*"M_=#U^V2>*4ZP%D4B>Z[_J)X
MA'LAR#*B78F,=6(?!\IO9I8MC2.V#XM:.]OF[!B6MF!66:@TQ6=B"GIC3*/3
MAIZ#,0@\9BP-G#S5[N'3*6+]>.J39RO(B\EZ=]_8LY*3.>'X['J^ZQU\U&1L
M,]7[$(5,P+KDNS+@7+B-2,[CA;R'^2,@8Q'%*FCPH#&&6KIZ74!LX;&^;[<>
MO7YH*-#F+7V%TT[JMS:</C,8?/9!TLATP$$E0TXFLT.:KBSG=10IK$)L[D$2
M(2F!8DFP,O+:Y!R$FH0&%Y)%R@*F<*<\FN1/%4^C@Y6/.<D8WT\[U)$\IM1I
M5:1=,ZY.MK%C@\7UW$C8]=&K+MR *60P'MNOS3.J>#,<:DMY.0TD#,R@K(T9
M<#8Q0KS])2+\H"T2%%2AM+<]-_$TG!I*"[P)Z5.T37*9D\-9LJWCT:<2$CMV
M%>Z$%8S$JKC8\<V2:-&*4A-V)+6;=@^L XUV!4>^&:O;]LU[8&W_ ,H.?_T]
M_$7^Q.M?QNX)N_W0]1\H.?\ ]/?Q%_L3K7\;N!N_W0]1\H.?_P!/?Q%_L3K7
M\;N!N_W0]36GM%?AWLM"1$.VZ9>)I7VX,G*SPXY'*7AR!),\:J6R:S!.E%P?
M92+O%AT?(6$G*WP-5]N.E. *4:+Z8#E'_E%1&OAGF:CG6TP+G)6VUZ6=_P!%
M.1EK>G &TT>N\);S2N9'(@UGPNEHU'XYMV9>"EF510Z[IXP&RZ+$JS.MAL7K
M6/AD6+2-1I>%BM_=#<C/UN:>"O:JDE*BTRH@(*4Z8^(:@@SD87)P>WZW@401
M>L6\:F_O%5HILCW$2D$1$G;5L(_;XYZ!E"36+2 77[(2"S\,X.2"B-G#UGSE
M/!<9XJ9C0O+FLD5DS+JIXAJKPQJ5*2IL=ZH5X=8D;%+$Y3(DKF$-%NUK9N,M
MB*R&:R+6OY$:2E0R(1/,?B3<"\;PZ*$! -G#]7VR3OC+LF2)$SUZB5')]1O$
MMCA*.')M,7LZB-&# BYB;R6I+$JP.?U&*=PGY4<T%*38=+9#'=):Z"SLS'WB
M1QNFC+3^RH-_="LFFOGV(@:%FI(XL[VQU/\ $*T&SIS*% S$)U-KT/N"1(#N
MS(N%;'5\=L7B$O?5RR[!1QE&U=64>%CQU"U(/ !HXA'F&!X-9.&3?]N'JW?@
M1V(O[E/34[++9Z==]413JT69Y_%(_P!?8WMBS8T$(S8T-E4Y,B>U$;(CK?1)
M6/)AH69#';L4'C@B&^I0T/L CX** V"P_5]K+)*]EIZL_*#G_P#3W\1?[$ZU
M_&[@F[_=#U'R@Y__ $]_$7^Q.M?QNX&[_=#U'R@Y_P#T]_$7^Q.M?QNX&[_=
M#U'R@Y__ $]_$7^Q.M?QNX&[_=#U'R@Y_P#T]_$7^Q.M?QNX&[_=#U'R@Y__
M $]_$7^Q.M?QNX&[_=#U'R@Y_P#T]_$7^Q.M?QNX&[_=#U'R@Y__ $]_$7^Q
M.M?QNX&[_=#U'R@Y_P#T]_$7^Q.M?QNX&[_=#U'R@Y__ $]_$7^Q.M?QNX&[
M_=#U'R@Y_P#T]_$7^Q.M?QNX&[_=#U'R@Y__ $]_$7^Q.M?QNX&[_=#U'R@Y
M_P#T]_$7^Q.M?QNX&[_=#U'R@Y__ $]_$7^Q.M?QNX&[_=#U'R@Y_P#T]_$7
M^Q.M?QNX&[_=#U'R@Y__ $]_$7^Q.M?QNX&[_=#U'R@Y_P#T]_$7^Q.M?QNX
M&[_=#U-=.P-XV9VG-=6H%$NDO=*!YB_='K+:DGF%J5C"(W"H]"J\L)H;DY0J
M5$6A)'R6&8[&RVFB0I;TGF;8SMIY,9R*B-O?U0_*MY[1<&!P!P!P#SU\5G]'
MWV3_ %9C'\PX?P9C^5>7J@\*;]'WUL_5F3_S#F' @^5.?JIZ%<&AP!P!P#0^
MZ.X9ZJ^T$ Z_CH ,DC*8(49E4FN3E@XLJM<]D67"7VPMZSA!F #]Z^CM9FK"
M=BYQ,XB0G8ED6 07VG*&+880%:3OCV3WNEQ8KV!>)=73BH:[F%L1"402P9I$
MJ7-LX>Z<0&.BI@YN.%6C, A:"2B:6.'B3*+.FM%7.H-^(LLALC<-X/C1,.Y<
MR>%Z28589JT[>WY3(M\QWWH0-"3=A*;SAY&@;<L[7591!W[2=-@_6F+]KUU&
M85XX9ELK+U3+@^6S!VS:$LRC9R 79MU$,N-A&5T3&SJQTA7?"N7SN4C"M=VM
M#"\3"664?,)SK548:N7]/3.OH/8T>;2A_:NL):OXX2M>N7VQLU)A,')C)1KL
M&EQ$C'I>.CP-[=_/$(U%_$-@DO,$TP-66:4BN:XHB81"3BWM9$%9Q,+[MBS:
M;C56"!"-@ZZH'6TQK ^W4ESHIBMLLA,D/$9@&B8^.228@RI;*WLB+[W3,NU[
MXP,A(]8^'A\^D9PJWBHF/UX#!"\6-K/UY%VS!6-$3>I>3"X4V<5QOU MC!A5
MG+'+1ZZC#ME&'\I?2&',C(-YTU,$Q[C34D$Z,JM(5'LF.V%*(6Y)5O5;*,#X
MEN@+HQV1"AQT%ADW)Z-W+FXEO59#+5P<9#H D4SIQ)4H@IJ"I;DK>NA+QG?&
MJ3YLO#HO%IY,+"&SQG 6=?Q!Y5,G.G'CR*SZ;8+LRP:TGD(#CVD9J^=O20B9
M2V+S48\"( 7\2;R*0Q<2;!O.FO CS;Q 8BQAYR6S2G[:B^L<D':U0T.:9KN3
MKBZEZ?6JK5=MW<_6%3S5/$5"%5A&7,38:D;-?/W9%K"X7-@XC,D>@WMW1T3V
MPS8L<WVM'9J6W+7BD"E3@15EDR"KD'<LP)CXF;R"$VXZIJ<NXLH/*G3GL0!+
MQ)UBB1. @GMC<?HX%(NQSC5]J"(ZHF.CFMMG^)_#(RB:<UY64HF[&!6B$BUE
M%B1F*BQX^OD%;Z6L*7Q=I&S4SD[^5Q$/UNL\BSK681N#20MLQ"(O= J,E"NW
M0-WT=.KHGX-E*.[/?&V\^P]8BHLT:PFG1]<OH98K4_[2ULO62RJZJYG"R8C4
M:V3"-(59U%S6&MEM217![88N61RU9JM,+A<B\>S:FVG!!P!P!P!P!P!P!P!P
M!P!P!P!P!P#7.*VW.B?8J<TP;BL/WCT>@;*=LY3$)69-DH\D4DBP*,1ZQA1.
M* V >03H<R-R>/- I8OADQC)YH0RJW]B&C0K2?-NW&XKSK)VCDM[&FK:0P4'
M% DXI*O.Q55O@LG?R @[KFQSDL%BQ$Y8O8Z$1 S)@-"1XT^2%.S I1Q)B0%N
MXVVB.YB0 J-?BB\C)F>S[X5(+(":PYJOK ^WE)]8$G&32VFQ)C;594!83F8J
M)8&[X:N@:EU.AB077==%\E'D':A)KL1409B89ZJGL5BIWV QET8=2V"S:0@C
MTZDS>MEZTC+(JHVK&/6K$^MPN62YX;F(U,RO/KV)N7,,S#&#E1W74MAYA0-N
M.!RZ5)BMZ3XVLG+N712?9H7>%@R^) XN6 CXE 8Y(B&9&JR1DHR9J7/V(I"?
MP,T,$NC +5U!IAU^+L-S *2G@QM9VNN(?.Q23$D1!4;S)%]S:+@AJ_-^WE.U
MS;1&FIB],A)2.C\ E'M!ZQ9MHN[!3V7.X9L_:G7))!#5&$D] [N>;/$V> HF
M4QY^SR5U7(:#0:3\C,C^UM"EWPL6*FSDF6+I/U&H8?#9X],MU!X:72'# N(;
M1A0D +E@,"F1B,!#K4<7F V-E7D58F4&VV^08C"'=7K^ZE V+MY$?\\D:CP#
M$B?PJ5@8:S*2>.GI&+8.Y7(A(@-DOHG'28PO&FCIW*XZ3:%<2 $,'1B8$8Z*
MWCOZ?@M.&7O4=ARAY#(5.!4BD;$6X,K,1Z;_ &24&M-(VL]<,B2K-(61RQ:3
M.%DGZ ]ZZ<LA$UAIATBB+ED>=DA,RV^ . . . . 5G9=I@:M2ANYQH^>JSJ:
M-H("09$(J+QL;<QV22?3+I],))%A*2'LV+$]4TTR"Q%V]V9LAX]VNYQKJ! I
M;V9@4/& R;P;)'J<A4FJ3#1#6,BFZ.8%/ %='%#!V5R>.1:/-5)!)!VHQ\>/
M#6+_ $WT9IN=33P6)( B.3N.VY#I-+YG"6"SY(U"2P40]W<L_(-+*G6!5PV=
M "#95TW?LVI..2V+$]U<M5QTHB$A%.6^GJS9=X!'97V#KN+(Z.M';B2,M)Y&
MJX($8\N$R,82R4F5 #(,W)&S(1C*3S(LELR,PZ"N)7.Q;C9!!Q%L+.FJ:P-J
M287:0 K94DJY)N[;'XP.2)NEGQ&+-TB#91E'7VZP<)F1[35\.;IR8>V<R'$4
M2BR1-)Z']N9*MO4MP:3D=M"_8%418"(EWMG&\EA-IS@0]&,4'P]PTJ,0%/R(
M+LXR]1V1/$@Q=9]'45DM!A# 4LU<E6#_ "*:% /WGL/3GM%N(TFB+@F[-,P;
M5BT#2)ZY<K$9 /B8XL@FT$+;*Q$A*2HV-L)UIYT*>GGB =L?5(;^K\!O//&G
M88$OVEIP(JX3(%S[9-@S:/S3QY"I<)'QMJZDB48VS*B!L,,9Q=VB\61=ZBCZ
MP\N3'.AC@$P+*' 2!,5E\TM+!'VY7!:5:0H;*F#V2*+E&6C)!)[NWV)!79YD
M3#8*^J^R/;K96+293('+_P!L*LHZ=(H,51XE^Z;B$9E]ZQB$5=*+:,C"^T9B
M!N:!C23=Y%63]+$(EI^'$7K?WDDD>'/-7I( KD0,:D5CI39\/8CQ;HDX]3P*
MUWECD@=VI'65I-ZE<HN6Y]U$F<P0(.B458C'#%X\DC/5DP9/Y&UE9@BU]UB#
MHG[%C)$<)9KCER9%KAYIK@00.U8[8+V;L123A@O I,5BYA,F3BJCK9T),F >
MY#V6%DA@R'&$'8-ZN&4E0Z//"X[*!%BR6:*^EU P9:]X."GDC@!;+YJ_BL>C
MLA*D,+ '6FZ<L+)@HZ+$QED=<V(=*F#+AD(')A82_8O3)$<$:/UC+U!AN#'[
MW[ 5+D&E(F4O8$QJV@AQKLR\_#C#$PM7NJ3[+9[AFME-LUM2!D'#337<HHWD
M+%NP'O2:R0]0#D?7_3@Y\X'NI\'PHT8O"+ITAH_>"&[1D+/&5=USK-FX"I*K
M#HK*EQ[;<AAT5VBLG;C$7;F/&460',_NN$,G8D;G<][5-.XR@P%/XO(8X]6;
MR62QV*>O))RD:$U<IQ\K*@2<L9-=URT;V),6Q8>U>OF35P!G][$ MM)ZX(:$
MF3&NY(.C9QXF->E-<JD8S#Y1J32:AD"#[00R93-A@J0<-D6PA%B4*DU&@9DL
M0T##/\&"AMSPN=S&5PZ..DGRL59!2>3:!V&O!,A%G8_'I(S,1MJ,D[^2O@.&
M,G&H9D3J/,(^X(:NV0\F]5;Y\X/&P,+8/86O:QF("'RU=TQV.B?;F\@R[CB(
M,.*RJ02P^((OC[.1O6:7LQXY*/(Y'SS.."4%I!*' 2/M7A5N!D4KYK1UZ5,>
M5)/WK7<#H3%:1N0L"P3:23;2OQ+<^/,C1C@&6>R/UM =&BNK24G4!I%6.!#&
MS?"6X$>C':*E9/&W4LUE>T="M6(@KLI,QA&)/E!!F.1F4MRNH@XW:%DF#85+
M0S@BLZ9-\L&SA,LYTT /!I=\*R^3+BBTJ S0(VD4;>[/Q+IP29Z+*LWXYRB^
M#$W@4N/>C2C5D2'$11<>^&$1Y!FV>LGS1PU<H)+);Z8$)#P!P!P!P!P!P!P#
MSU\5G]'WV3_5F,?S#A_!F/Y5Y>J#PIOT??6S]69/_,.8<"#Y4Y^JGH5P:' '
M ' -?+%JI&5RDB=^%%>2U8FWJG5V>D=D2^+&%5Z6GQ*TJRQH."P&1-6FT)L
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MF6Z<6:PV&FYPZ=J"4ASM4BQP%CAE0@YP\8J,-M&/JS<KZRYPP$*E"=IQ<KI
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MLBE?XW< >R;G^?U8?9%*_P ;N /9-S_/ZL/LBE?XW< >R;G^?U8?9%*_QNX
M]DW/\_JP^R*5_C=P![)N?Y_5A]D4K_&[@#V3<_S^K#[(I7^-W 'LFY_G]6'V
M12O\;N /9-S_ #^K#[(I7^-W 'LFY_G]6'V12O\ &[@#V3<_S^K#[(I7^-W
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MI"@Y3:LA#!W _P!J%:\;2E"]\G+!V3=) S T^ 2D3!P''C68-)%RGU_!5O\
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M!E?TW6?^R:8_"+@#W!E?TW6?^R:8_"+@#W!E?TW6?^R:8_"+@#W!E?TW6?\
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MUS@#L_#N2^5/;XT67YR7G>BS[&I7RI^?Y//]'GX0^73SO)CSO-\GG>3'E\O
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M2!VF_/)0+KYUHAZ9M^EZ;T3TOI'K\':DG:?K+CT;EYA9;3UA;S=\>EW\X/\
M).^A8'R@$P_TYO$7^RZB_P"X[@,F*=]!\H!,/].;Q%_LNHO^X[@,F*=]!\H!
M,/\ 3F\1?[+J+_N.X#)BG?0?* 3#_3F\1?[+J+_N.X#)BG?0?* 3#_3F\1?[
M+J+_ +CN R8IWT'R@$P_TYO$7^RZB_[CN R8IWT'R@$P_P!.;Q%_LNHO^X[@
M,F*=]!\H!,/].;Q%_LNHO^X[@,F*=]!\H!,/].;Q%_LNHO\ N.X#)BG?0?*
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M$=6O2W!53U0US6\9FM8UV;[FU1+6L,,5WUMALZ/0W-=3$&>N>3FZ$=UY'>P
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M/7Q6?T??9/\ 5F,?S#A_!F/Y5Y>J#PIOT??6S]69/_,.8<"#Y4Y^JGH5P:'
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M.:=?VF(/J =! 8TB[CC6-XU!;K+[&LNSZSD>E'!D< < < < < < < < < <
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M?S@.N71-!\)(K_FMF_;7<OW\X#KET30?"2*_YK9OVUW+]_. ZY=$T'PDBO\
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M?S@.N71-!\)(K_FMF_;7<OW\X#KET30?"2*_YK9OVUW+]_. ZY=$T'PDBO\
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MS=D[:9+1EO7YAH/7P0-CI4^D.?;".%FD3B((SIQ1W+"LPI:[*P8TWB4?DYB
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M'R<XWZZWB+_Q;2O^D\!URZ)H/DYQOUUO$7_BVE?])X#KET30?)SC?KK>(O\
MQ;2O^D\!URZ)H/DYQOUUO$7_ (MI7_2> ZY=$T'R<XWZZWB+_P 6TK_I/ =<
MNB:#Y.<;]=;Q%_XMI7_2> ZY=$T'R<XWZZWB+_Q;2O\ I/ =<NB:#Y.<;]=;
MQ%_XMI7_ $G@.N71-!\G.-^NMXB_\6TK_I/ =<NB:#Y.<;]=;Q%_XMI7_2>
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M]<5JPR]2>L(M.89(GC;='"K<+*H^25TU:%F2JP.N"?2FACQ'3RJ9 0@(V/\
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M'R<XWZZWB+_Q;2O^D\!URZ)H/DYQOUUO$7_BVE?])X#KET30?)SC?KK>(O\
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M.8FNMC92&NHH=DNR1$F6D#*?@_K/Q^+V:8C<<]-FP!L]V#IX8Y])&_;/NMV
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M:\ [+2SJV?N]1[&PH.]?[!P<BU9-)8!<.]H_)EVC6-G=6R+_ '6R'D#H@P;
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M30KH"=CTR3)1\U-J TY.F'<--5LKHE=XTLC(=!ZB>KO8&JF6U1RPWU<9 R_
M.G@@/R\T'X?,\OU$G:Z;'#E'+S=%ANQ3?+:-O/\ 3;),E"8W1VIKIG1ON08Z
MK9TV=H84 ^$B+ ..?ERKUJ-%BV3HB2(O5DVS-@P8H*.7CUVX5VU2;M6K=)1=
M=97;5-)+3=3?;&NN<\ PYB9P^//V@H_*XT#*/V)(FQ&F#HL8_>#0S1<@8(-&
M;UT@X<,13!JY>DG:*>Z#%HW7<NE$D45-]0.HO8< :QE":NIS#VT-<[8T;2U>
M3!48RXWV<*-==$#RCW44KMETBLVQJF[VSEPDHCC'I--M< 9,3*8R>>F1H*1
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MI 2*-EX?'*Z!*ZA-5&L9;(.4&8\16P;SS$V_X(. . . . . . . . . . .
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M\^5]%@3W>O7V_;$=B%K3VU'L(BY+#&T:K5K44-M 'U"[3D2\-#1YF*C0YS$
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M&00>5'U;!=^HP2<S28P7,>I;L/.9UN^[9%%ZT*E=8?8H9E#6^[ <(BRPXY:
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MGOE337?.,>?KHILFELIIKMY<:[[))YVQC&V4],Y\W A^^ . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. >>OBL_H^^R?ZLQC^8</X,Q_*O+U0>%-^C[ZV?JS)_YAS#@0?*G/U4]"N#0
MX!6]PQP[+JNGD7C :#2&0GHT3%APEFY*;5X2?NT,I-VTU;A6CXF0C.V^V-C
MEHVVV,,M5A:BC=%XHX2 PE#04O6-8Q> %!8<9B-#M&Z> TG5DS=P\>N'1,PM
MIOK *V%BF62KQSL*"QZ*A8X'';H"(^!CP0>/$-@-!!73[N)"XDS:0WL-'WLO
MC=.EZFAQ*3'[']2'>V3%;SO27D%4-7ZK^3@9NVL8$,=.&#@<0K(/5\;-"7?I
MI@FH*Z/9]\.'K:KEVRFB^T14M*4&5R#WT7DF;O?-FYD\32W!/YJC:8>M0FT>
M3@Y,&?A,6 2.LMGP5VN/=,I#7VY=B_*Y/2=.3">>3]B82*F[JUD/8P[7TMCD
M57M7-7NXJZ)%R)8KH\B2K)A+F#@NRAH<W P$DA[->/"V@\Q8CV,'#)2;19]&
MW.WL)87#SWGV(Z[IGM&-K.9QZ*VT,<6)))C%CK";S*8S,I[*8L*>BD;-J#V8
MR/C1@=QK:P)[,$8N/![P&1BWSY(O'QN#CT.T$XG>F-#W06JBL8E%)M'XU-JA
ML;X@@3FYR5K YDL$@\V5C ::M1PT63Q&2%D2,,/F<=;O"&I* B7SQF51-D6P
MD:">>7>7%4ANLW<"#1TU%XEV!%'F. $E9QU[+3\R8/E3DJO20SDL;D2XD0]+
M;F5(&;T1''A1YJH&DC=*/:""$,36R^%DWNV4L.9*W]2=X5!1D<,NV%M7Q=:8
M91DBY0RX)BE"+"%KQHFB-VK_ " 4]2,#I<*0CHL='18&+/0KAX[G4M4D)TF$
ML,.&:6V9V]3(F*&[3O'DL:BNQA(4$WF @E"WB1994PG% \(LD8/$GF[V'O\
M1 DC+#E:O3ZS4L4&SEO!ERQEDP>&SH<\#I*5T]4\D8->A.YCAQ)&_P#Q*I-1
MBHW+*).F3QSJ2:^H5.ZC\>]O).H8[3<O6%L(M)P6.L7J+F4AS!H+)F!?03&4
MF02G+[3T[ECOJ?[ -P84-&[2V9Y0N"TY85($9I*")#>(3&T'<MA/FO2<=+/"
M24%A;UY"_A/NY$1,EATS<MID*2CPQ%4)>GIY/L0IMUR[$1>'U+ Z\N9K%H]!
MZ$W@!K=J^?8).+3WA\F%/)WA<G&9![TM2\I+QZ3:+FMQ1J.D(CH\9J%&\IE
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M+ERY9+M47SA(:^U]<:M5VC@@-T:/WHO/KJ89\Y<"4#!U!DD:?B&2X X X X
MX X X X X X X X X X X X X X X!YZ^*S^C[[)_JS&/YAP_@S'\J\O5!X4
MWZ/OK9^K,G_F',.!!\J<_53T*X-#@$)L@$\D\#EL>8" L@=F0;X<D"D95\#
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MURP9INW]I(3R6Z$"3M@(<.SD?>$QS(6+:QT"*C883G+H=-2A.\"#UR3!7U$
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MVD]KA>1FHX9'.XQER8U(C]FJI<)2D_YL7'I>9!*D^ZSH>29N^PXP#MJ9BST
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M8.+FT(;',GBS5Z97&(N7RVVXA;O ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MD=JV8$ A4.H5RZ]D[GF2T?1?*&_,8;"%S>PBGSSDO_S6'_=/@#V$4^><E_\
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M% 8-&@H%\^37>@!C8BT#.&*4AD>"PCES< < < < < < < < < < < < < <
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MJBT?\M0[&KFSXH5BB_5_7K%=J-8@5(=W=6C2CJ](D42QHJ1+"B0JBJJ;;\Z
M[H< I^]ZS?VU7#J)!S#(&<92^K[!CK\JP7*!=I+45H0ZV8X.D ]J\'O'<<-'
M(2/#2)%D]:OM@;]_EDNFZPCMP/OWD4>!J&_QMUB+K(/:16?&0LCBTWC0=A*
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M*Y9G!,K BXU*L6866=D<#3[]^UQH@\)A'3-B7%DR8WK.7=E?L9*6I=ZYG1,
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MZ>5/$HO*JW5F;W1D@36BC30-$AH.E,L7IAMH14EY\:=?&;^W*)@=V$N&$(C
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MW%0?HU&BB5*)J9:6GAHJ?^5_]ZCC6FBJM&L-&E.D5&E8JU/5H.N]N"2^A#D
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MNS>,V6VF"H%:-8]:T$\#BS3P=V5K)VXF K^Y/$,D($;(9'!8FSQ&H[9T[D0
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M8KZ0NG"(;US1G*0&%=47JNB+XAH*5WT*(.F: -J3(1)HW(%RS4#( AMR ?\
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MMJ9H"+-!3TN_?EGH9Q)DECCUZL.(A@?SSBOC'RR^I?7P[7P0!-[3F36'Q.E
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M//78@N->$W;2,SD+N/FPA'*;K!MP2PL\7!_;LC>EI2([PJ:6&M@35"P[<52
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M0K@T. . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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9/A[53.[==/;?739/;.4]]]<@L2K)5]#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g692844g69j63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844g69j63.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *.BA
M!H6GB-F9!;1[2PP2-HQD9./SK:O?VLK]W^9S82RP].VUE^1>K$Z1, ,6P,],
MT +0!GWFC6=]=)<S?:%F1-@:&ZDB^7.<?(PJHR<=CII8FI2CR1M;?5)_FF17
M7AW3KN422QR;P0WRS. 6 P&(S@GW/7OFA2:V*IXRM37*G^"V[>G](;'X=L_*
MVS[W8[@Y21HQ(I8MM8 X8#=W]_4T*35K>7X*Q3QM2]XZ;=$[:)76FFW0F71+
M*.\:ZC^T1R,_F%4NI50MQU0-M[#M0IM*QF\54<.1VMM\*O\ ?:_XDR:99QK
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M_.38[2RM(Q7^[EB2!R?SI-MJS)GB*DVGM;5626OHATFEV<LD3R0AC$%5,\X
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?7\Z #S$_OK^= !YB?WU_.@ \Q/[Z_G0 >8G]]?SH /,3^^OYT 'F)_?7\Z
M#S$_OK^= !YB?WU_.@ \Q/[Z_G0 >8G]]?SH /,3^^OYT 'F)_?7\Z #S$_O
MK^= !YB?WU_.@ \Q/[Z_G0 >8G]]?SH /,3^^OYT 'F)_?7\Z #S$_OK^= !
MYB?WU_.@ \Q/[Z_G0 >8G]]?SH /,3^^OYT 'F)_?7\Z #S$_OK^= !YB?WU
M_.@ \Q/[Z_G0 >8G]]?SH /,3^^OYT 'F)_?7\Z #S$_OK^= !YB?WU_.@ \
MQ/[Z_G0 >8G]]?SH /,3^^OYT 'F)_?7\Z #S$_OK^= !YB?WU_.@ \Q/[Z_
MG0 >8G]]?SH /,3^^OYT 'F)_?7\Z #>G]X?G0!";ZS5F4W4(93@@R#(-*X
M+ZT.0+J$X_Z:"BX!]NM!UNH1_P!M!1< ^W6?_/U#_P!_!1< ^WV>,_:X<?\
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MF@ S0 9H ,T &: #- !F@ S0 9H ,T &: #- !F@ S0 9H ,T &: #- !F@
MS0 9H ,T &: #- !F@ S0 9H ,T &: #- !F@ S0 9H ,T &: #- !F@ S0
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M]7\G7UQ^GUYIV%H+-8M:@&79/-@%G;YL=L 'Z=?0T; 4Y8<Q^?&"H#8*[B0
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M=E!>)9-X0^F[ S^5-V3LB4[HEW#MD_09J1AN]%8_AB@!<M_<;]* #+?W#^E
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M"?\ GE_[,/P%.(SI N3N;D]O:K,P+<[5Y/?VI &T#YFY([GM0 !BP^4<>IH
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M_'_,+W;;Z_Y)?H4V\%6KEKF75+V;5#*)1?*R>:I"E0 -NW;@GC'>FG;;3?\
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MM0]Q .?D&#@'DX;'2AKEW&\/.-7V4]'_ %VN,AURQN-/N+V&1GAMP?,^4@C
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M 4 @9)^K < ]?3) !;L;U-2M%GC5XURRNKC#*RL593CT((XH$6B=H  YZ 4
M 7!SG)[F@!O^LZ_<[#UH 4G'RKU_E0 85/F)R?4T  4M][@>@H 0'^%  !W[
M4 (X51ELL?0_YQ0 F7(ZA%]0*8#,9)V*2W]XDB@!K*3@%O,]@N1^IH 8WG+U
MQ_NH2#0 Q[GRVQ)$T>.GR@_J.E "BY 'R*PXS@8;\S0 P3NY*P1#W9&./QH
MF6%I$PT@?'50, 4 21HBG8-T9[#<<'Z4 .8L@^<;D[\9Q0 [8&&Z-\'L>M
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MASPU "@;OGC^5QSM/>D NT2C*Y1^O2BX"\. KC#=/_U4 (I9,H_*_P![V]Z
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M*X]A^.:N>L?(]''\WNW5ETU3_1/[RKX8EB&JO;(T9\M68)-N^T+G !;'RC@
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M(3[G.S(P./E(S@9S5*34G+J_\K?UT$U=6_K>YV&VI&&V@# \9#'AR0^DT/\
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MZ=,_2BS!4JCVB_N%^TV^,_:(L;MGWQ][T^OM2U%[.?9]S"UW2M/UPJS:W+:
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MCFQ/P?-?F;!)5]B]^<^E!N!Q$01T/!^M ; 04/F-U[^PI !R'$C< <8/8>M
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M6MW >(H'\IXK:5[<K&TDG \K><*".N<]?2GRZV#ZE)73:OK9=[;_ / [B?\
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M4<GZ_P#ZOYT -B'^D%O[REOSQ_A0!:"\9)P*0PR!T'XF@!"23R:!"[#WX^M
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MS675WV\O7]0DTO4KBW6S^R;/L*2^7(SKMF8L"@7!R.!SD#!]:2:5I>GX6O\
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M<]3GG_/UI@.(*.$!R6')]/\ /- "GY9 B\ ]2.W^1_*@ D.TKMX(X/L* ',
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M7]/^F)_:#>3')]AN<NC.4VC*D?PGGJ>U(?L5S-<RT:7_  ?EU%%^QD"_8KD
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M<A X4GY1VR%[TE=P7;6Q35IOO9'39./F((]ZD PAZ$_0T '(X"<T -.\N%Z
M<GM3 'R%)WC/0=Z  (@4+D$8QTH$1J%0EBV5Z9QT H 'C61UPX&.<X_*@+"D
ML 1D!SP.>M "A9(1A=VW^[_A0 U&$B;\#)/!Q@B@ 5@9&#\=@>W^>E "%6C=
M<?,@!/'..E !D[U*$$<G'8]OZT *-K2;D^5L<J?PH @D4JK 9&QMP&.1_GF@
M19BE,D?S 9'7_P"M0,<5P,@Y%(8@)!XH 4[=I;.,<D4 5%(DE,C!L8&!C]/Y
MYIH1(>8B.#*5_*@!SY564<MCYB>U #@0N$ RW7)[?6@!JCRT&02Q'XF@-@4
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M'&H75E.DT$BH5=#D']XOZ^U*C%QJI,RRJE.CF,(5%9J_Y,DUOQ':Z!X0A+R
MW<UJJ6\(/S.Q4 ''H*4*;G/R(PN"GB\8TE[J>K\KEOP3I,NB>$[*SN%VSX,D
MB_W2Q)Q]0"!^%36DIS;1CFF(CB<7.I#;9?(Z"LCS0H * "@"GI+,VC6+--YS
M&!"9,D[SM'////O6M;2K*RMJSGPK;H0;=]%KWTWUU+4G^K;Z&LCH/,@R/91'
M:J .Y*@GL%]?I6(Y"6.HPZ;KMO<7C&&#[-(@;82,[D]![&J3L<522A6BWV9T
M(\7:&1D7W'KY3_X5?,C3ZQ3[BCQ=HG_/[TY_U3_X4<R#ZQ3[A_PEVB?\_O\
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M=[_/\!L?BRR'VC;9WA-L2LF$7A@VTJ/FQUI=+^GXV_S&U9V^?Y_Y!)XRT^%
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MFAR9.X^9<PG)SG/4]^:5K#U_K^O)?</E\1^#Y@QEUS1#O7:P^TQ'(P 0>>>
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M%"-*7QQMW,?2M)TVZM1,]K SAL QHZ#\FYJFVCMQ&(K0ERJ3^=G^1OU)YP4
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MZ=1WIV6]_P"E<VE&%-<ZK.[5UHU>U[?\/T+,>FQQ7GVF2WTY/*C0%DM]LB*
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MN[D2?-)LQ]#_ .0OXD_[""?^DL%!)M_PMV^4_P J0(X6_P QZG>OT/GN%'_
MCS_+\ZS>XGKH5Y%-NZ["H0#(P>#GGIU__50):DXP<21XQW&?NT$"W,D)C5)8
MM\G^UQC/OUZ4PBGNB*"2TBDW"V"@=^6([]Z6A4N9K<GD#M(23\H&[)]*"5L5
MI9"TBK$WRJ>,'&<=?PX_2@I*P-&$S"I (&[Z'G(/;TH"_4V-*_Y".B J0=LF
M#VZM36Z-5L=K6H@H AN@39SA0Q.QL!5#'IV!X/T-!=/XU?N<]#)J$154.H(F
M>0+.(#]#5:'I25)ZOE_\"D=/4GE!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P#GTH#R1K^%2#J;\@GRNQ_VA3CN5U.MJQA0 4 .'"M0 V@!>B'ZT )0 O\
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M(!X?OP?^1JU8@_[%J1_Z)H 0:#?KT\4ZH/\ ME:__&:0A1H>H8/_ !56J_\
M?JU_^,TQA_8>H?\ 0U:K_P!^K7_XS2$+_8>H;?\ D:M5Z_\ /*U_^,T#$_L/
M4/\ H:M5_P"_5K_\9H$*=#U#:/\ BJM5_P"_5K_\9H&)_8>H?]#5JO\ WZM?
M_C- "MH>H<'_ (2K5>G_ #RM?_C-,!O]AZA_T-6J_P#?JU_^,T .;0]0S_R-
M6J_]^K7_ .,T )_8>H#_ )FK5?\ OU:__&:0A6T/4 Q_XJK5>O\ SRM?_C-
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MU:B9[6!G#8!C1T'Y-S5-M';B,16A+E4G\[/\C?J3S@H * "@ H * "@ H *
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M_6@6@D@;RRK=/0C/./3\Z!KR&C)+K&&4Y^8$YR<GITH'ZB,=K$N"1['M^7%
M>AO:46_M#10H;;MDSSGNU4MRUL=G6@!0!7OO-&GW)@B:6;RFV1J^PLV. &_A
MR>_:FK7U-*7+[2/,[*ZZ7_#KZ'+VNJ^*[6'RQX0EE&<[I=6C8_F16W)3_F_
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M<\G.:2DDNHOK5&,5RRG>Z>^GKOO]Q(=)U"1V2:UTF2!-IB+Q%G) X)X XX'
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M #6.32 $Z_3F@!* '+W/H*8#:0#AT)H$-H =T0^YIC&TA!0 4 (>$;_=/\J
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MY&1D9.#52O*#L[E8M2JT+J]2-UO>Z]$_6SL9L$\PUF/4;MM+N=LK6JH\1V@
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MIM0 Y!QE2?Z?E0-/L=!I6[[3H>TX'[S(W8SR>U4MT:+8[:M1!0 4 % !0 4
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MQ%&51.:5E_=2[^7IT?H.CLM3A.G[3.WE$>9F5@#\_.=TC$\>I?VVT^9.3?\
M7Y$NK1ES[:[:+MY177MR^=PN[+576[-L+E'E9\L9\J5W#;M7>"O&>FWZU,6M
M+_UJ53JT%R\]K*W37;6[MKKWOZ$=K8ZM;S1X:X8!&4EIFQRIP<-(QZXZY/\
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M,\X",C(%  3MP!VI@8]W'K#ZF\MK@6^PQ(K.,9*D[\?[V!U]>*:M;7^OZU_
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M<ER[/SZ=3T:U6O+%Q4(NS:?QM)Q6CTOIKJ:UM;:I:+;ZA<0W]Y";+[-(\#+
MRH-KJRX;!'49X/%2W&[6VM_GL<,YT*EZ4'&+YKI.\E?5-.ZWZVU1G337%WJA
MU!KF>#S+U91&2&,<:J0"3NY//04*R7+Y/\;?U_PQUJ,*=+V2BG:+5^[;OVV+
M%I;3V6J1WT;W=SH\/F%C'A&BD<8( W=R0>.]2VG!Q>]K(QJ3A5I.DTE4=M];
MI?+Y&;'K>I:7I46C+<S64J*4D:2-9(PN\Y;C)'WL9 [#ZUJX1J2YGJO^ =;P
ME"O5>(<5)/56;3O9:=%T[FG9>'DN[FW-Y#<:SI9M$MK>XBA2+RP&]"P. ._7
MK4RJ6N_A=[G'5QKIQE[-JG/F;:;;OIZ6U[;&1>6OE1FPMA)-IT5VLL43;2-F
M#D$%@,C]<]:<9W]Z6]G_ %_7ZG=2J<S]K/2;C9O7?3RV?X&A;0L='U1+#2IH
MB\6'DA2)>,-\IP^<'J?IT-3)ZKFEU\_\OZ_$YIR2K4W5J)V>S<O+76._^97O
M=1NYH(-.EN[K3[:6U6&19U\U=H526 4DDX![#KR1BK27,Y;ZW_/^OD:TJ%.,
MG6C%3DI-JVFMWH[V5OO.AU%M1U9&L=/U2>[M9$@29$MECVHX!+[\@G@$X _B
MQ6*2B[R75_AT/+H*CAFJE6FHR7,U=MZKI;7KU\BA+$UKJ$=SI]]J/[A/L]PE
MRZLT<><9!W#OMX^M'-S1:DM_S.F,E.FX58QU=U:]F_/3M<SH[*[FT:VCL[J=
MM3BA:)80HPRG.Y-V[ICGIVJVUSN^S_K^O^"=3K4XUI.I%<C=[^?1VL+97MWH
MGB;R83>EM\*-#O5A*Q3;M)9O[P(!&< 53M.#>G7_ #O]WYBJTJ>)PO-+EVD[
MZZ:WOHNV_<U_#D]Y--*T>NRW%Q/-YE[:0684KGY<[VVD8 '(_#WB:2BE;3O?
MYG'CHTXQ2=)))6BW+MKLKWOYE::ZU"ROFGO+/4(KPX6!FG1_+A'&!EP<L1DG
MO0DFK)KS_JQK&G2J04:<HN/71J\O_ ;66R10O(WU#6X9I89=0WP+&!(D;,K[
ML[<,_OU!IP=HM)VU\_Z_KR.BE)4:#C%J%FWI?:V^B+-S8637EC;W>G2:=:62
MRBX\U$= SIE6"J2.Q_(4*35VG?;\S*G6JJ$Y4YJ<I6M:Z=D]5=V_JY!96XFO
M+G0M(UL-I][&SD16 4\X^4[L'&#D$'IGBJ;?*I26J\S2M/DA'%5Z7OQ=M97V
M]+K?2S1JZC>ZE'HXLY[/4+6]F18_.>Y_<X7@L!NSSG.,<\9K*T&[WT_$XZ%*
MBZWM(RC**UM;77IMT[EO1YDMHXK6+5KEHX8&55,>  $//W^V,TIWDVVOZO\
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M[27W\P^+6+E+D3)KEA)9_9R%%W^Z=I.@8\# + Y%5RJSTUN)X:#CRNE)2O\
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M">+>;?665EG(*SV^U<;1\H.SG&<Y]SSQ4)+JOZO_ %^9E2HQE\5/IT=_GO\
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M !UYI !XX%, (SR*0 >#@=J #&>1WH ">W84 -I@% !0 4 % "-_JWQ_=/\
M*@#SG5,C6;P^D[_^A&LGN2R!5^^@/S @K[?YXI$-V:8OF+L,FT9'4#CFF+E=
M^46*/>"7Y'WBQH2%.3CHB6:)>2BAFQR*=B(3?4@1ARC'[G.3Z>E(T:MJNHN<
MJTF,  A0.P_R: M9I$3# 4>@SFD6M3HM* ^U:%EP#^\..YY-7U1<=CN*T *
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MQUH 0CY10 -R1B@ ;L12 #]W'<4P!>!SWXH ;CG% #FY&1VH 1?EYH 0C!H
M=T&.] #0.U(!QY'':F BBD -R,BF +QSZ4@!NN:8 O'- "$8- #E^7F@!I&#
M0 Y?E'/>@!I&#B@!RG:.>] #<8H 2@ H * "@ H 1O\ 5O\ [I_E0!YUJ?&L
M7I _Y;O_ .A&LGN0R!!MW G@8!-!#UL-"$VSX Z CCD@4 VE-$T3[@4)4%E
MZ<4(B:L[CC&MLC*K;@?:GL2FYN[1#&I,DS87&W:..](TDTDD(F/*=<<CJ/\
M/XT%2^),:PQ@=@,YI#3N='HXB:XT57=Q(!(54*"IY;.3FK6YI'8[6M "@ H
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M "@ H * %H 4\<4  YXH #QQZ4@ <\4 !/;L* %'S<4P$)H 4?-QZ4 -)YH
M<.1GTH ;GF@!W;=WH 0<&D I&!QWI@(.N*0 W!QZ4P%'3Z4 )G!S2 5N  .!
M3 %Z?3I0 B]<>M "]'H .CX_"@!0>OUH :_#&@!M !0 4 % !0 4 % !0 4
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M"HH9C:@!ZKZ=A05NS?TC'V_1 1_#)@YX'+=J:W1K'8[>M0"@ H * "@ H *
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M#;C&_;[R._U345@UC4H]0,2Z7*42S$:%90%4X8D;LMGC:1U'!K.&O*WU=O\
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MTUNC6.QVU:@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M';'2G=IWZ@]59FA)%%+(DKQHTD1)1BH)7(P<>G% %2?1=*N;5;:?3;62 .9
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MLKI.G)IW]G+I]LMCC'V<0J(^N?NXQUYH>NX+38=:Z986*HMI900! 57RXPN
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MU4#O0 #E,?E0 #[@]0: '=01^- %-KZTC<H]U"K@X*F0 @_Y(_.A:[!L3T@
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MOTS_ %H!:Z,1\'!4'![T C>TD+]OT0[AD+)V]VIK=&JV.VK4 H * "@ H *
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M*FGJM?._WZ?I_6VD]-O*WZ_K^'S3Q'<ZW#=W_P!@:^^U+''_ &?'#"6BD/\
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M_@59.;3TNW]SOK]]CJ/#%Y<ZGI(U2Y#H+QS+%$W_ "SCZ*/Q S^-7*/+:/\
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MOQV_(;TW_JRO^18/BS3DB(=+A9O.,/D&(B3<%#]/3:0<Y_7BC;^NV@?U]_\
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M#:(C=O3R_%+]6:&D:_8ZP[QVQD#!%D"R(5+(V=K#V./KZT[-+4=S+O/&5LD
MELK>><"YC@)\IL,&?8=I'<'L?Y5,?><?/_)M?E\@E[J?E_FE^OSZ%N7Q;IT&
MG_:W2Y\H;_,Q"<Q;&VMN],'/'4]LT[:I=[?CL.SVZD<WC#38KR2U"7,DB2>5
M\D)PS!0Q /3A2#_]>ETO_6CL_P 1:?UYZH?_ ,)!H^KLFG!'NXKF-6(\DLFU
M@<;AVSCTX[XI\MVUV_X<+\O]?(VT58T5$4*BC 4#  H;;U8)65D/_@^E(8V@
M04 %  ?N/_NG^5 'G^HL%UB[/;SWX_X$:S>Y+U*ZJ45NS(W'?([_ .-!+L2@
MJ5\T9$8&2?3VH)\B,F2Y.S<4!)PJG@4#T@ASV[6K;DDD0'_/^%%@4U(<CF8
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MPG.>:7:W]:6_+^KZC]?ZZ_G_ %8@?P;8&VEMY)[AO,MI;9V!1<K(P)( 7 /
MQ@8]J=[;>7X7:_,2T:?K^-E^A&_@JPE:Y>6ZNWDN8WCD8L@)WB/)X7&?W2_F
M?P%*VW=/[FW^;)Y=+?UM;\B5O"<#VEQ9-J%Z;.6-HT@#J$B#-N.!CYN>F[/&
M1W-3T2[6_#;^NI:=GIY_C_7]:%*/X?:6LDSM<W+&9&210(D0A@@X54 &/+4C
M'<<YYIW=K>GX.X;V_KO_ )FM9:&FG:==V\4S2R7 .7=409VX'"* !^%143E!
MQ7F.#Y9J3,_3?!Z0V-D-1OI[F[MT@&_*X7RCN"C"C*[NYY/K6TI)S<EW?Y-?
MD_O,E'W%!_UJG^B(]1\&B;2[FVM+Z;=Y,D=I'*RB.WWG)P0N3[9SBLXZ./E;
M[DT_T-'K?SO][37ZEM_!EK=?OI[R>2]\SS#<ND;,?EVXVE-N,#T]Z=ET\_Q_
MX9 MM?+\+_YO[RS%X5L(&5UFN"5,!.6'/E$E>W<L<_IBJYK._FW]ZY?R)<4]
M_P"M>;\Q-$T5K#4-5U">-(Y;V8,(TD+A$ X ) ZDLQXZM4K2"C_6O^14M97_
M *]?R^Y%3_A!M."W4(GG6WF1T"*(U\L,<G!"Y/MN)Q1%\MO*WX;"E[U_._X_
M\..U#P997UY?W4=Y=VLVHQ^5<F$I\\>T+M^93CIG/7D^M$?=T\[E\S3B^JT1
M,?"MJ9G/VNY^SF0S?9P5V"0KM+9V[N^<9QGG%)JZ:?G\K[_FR8^[:WE\[6M^
M2^XC7P=9?:-/F:YN&2P6-8D;8>4& 0VW<N>X4@'TZYMR;FY]7?\ $E12@H="
M!O NGI<K+%<3Q&&0RVVQ8QY#DYR#MRW4C#9X)J(^[:W33Y;%2]Z]^NOS-C2M
M(&D0"*.]N9ANDD<2[#O9VW$G"CD'.,8'/>JOI;Y W=W?]:6%GTF"ZU'[8[2"
M7[.]O@$8VL02>G7@5#5XRCWM^%_\P3M*,NW_  /\BA+X1L&@MXQ/<@0Q00J5
M< XA8LISCKECG],5<I.4G+NV_O5OU$DE!0Z+_-/]"?0O#UOH;W,D4TDLEP5,
MCNJ+G;P#A% )YY.,G\J+Z6"UW<KS^%+:1I+=KRZ_LR20RM8;E$18G)YV[L9.
M=N['X<5%M+/T7]>70J[O=:?U_5_^'&6/@RRME1/M,[K')$Z<1KM$;;E'RJ,\
M]2>3ZU:DT[]=?Q37ZD.*:Y>G_!3_ $&W/@S3[J_U6Z>XN@=2A:&6,,NU P4$
MK\N<X1>I(]J(-Q5EW3^YM_FV4]9*796)3X2M_M5U=6]_>VDMRQ,S0NH+*0H*
M@[>/NC!'(R>:2T5NG_!;_5_(25M>O_ 2_1%)/ &F(MPOVFZ*30RP$?NP=LA!
M8EMNYFX'+$GZTTVE9>7X;>15];_UM;]2]:>$[2UU);];F9F#^:RLD?SR;<%B
M0H;GK@'&>U"=MO/\?ZZD6TMZ?@0:UX,L-<OY+J>XN(S($#",1DC8<C#,I91G
MJ <'\ZA*UUW_ ,K&G,]"P?"=D8H/+N+B.2W@AABE!4LGE%MK<C!/S$'L?2M)
M2<I.76]_O5B(I*"AT7_ _P D2+X=MAX>NM&DN+B6&Z\WS)7*^83(26/  ZDX
MXJ6]K:6M;Y%)M2<G_6EAA\+613;--//NN#<N7*_.QB\LYP!P1GICG\J)6:MT
MU7WNXH7A>WE^%K?D/T3P];Z$SF&>27*+&N]47:HZ#Y5&3[G)I\S:U)LEL4QX
M*L5U)KV2YN9)O,5P3L!^5PX#$*"_(ZL2<=#URH/DV_K1K]1S7/O_ %JG^A'?
M>!=.U D27-P@?S@V!&QQ*Q9L;E.TY.,C!Q26FWE^!?.V[_ULE^A-<^#[&8,1
M-,DWGF<2%4<JQ0(1AE(P0HZCK0_\_P 7?\S-*VGI^"M^0X>$+(WMC,US.PL]
MAC1MAPR]"&V[ESW"D ^G7-)VES?UM8;5X\O];W-^I <O0CVIC&T@"@04 (>$
M?_=/\J!GGVI8_MB\S_SW?_T(UF]R610[@S!C\V!SZ^E!#Z6(^/L4WRL#\N3V
MZT=!_;1;@ ,3[ P8H, $9Z4T9RWU'A9A')]J//'<8(Q1T%=77*4D ,USA6(V
M<C/?BD:RV0Y>+5B>G.!T]/\ ZU /XB-N-H;);^7I04O(Z+2/-^V:*%W^7MDW
M8^[U:FMT6MCM*U$% &-KN@:;K;0-J#8,.[9PG?&?O ^@JHR<7H=V$QE;#)JE
MU]?T:)])^SQVL\%K=RW8@D,;>:<E6"@[0< 8P1^=*=VKV,\1SN:E.*C=7T_,
MYK3;FQFU*!+?3;5[B.0&9=K*\$A;!VYZX!Y(X_.M;-==/Z_4]2O"K&FW*;LU
MIM9I;7MW?3<N^)+JS@U)!=VL#2-&%MVE#$2,3\P)'"@#U]?:H@F]OZ7]?UJ8
M8*G4E2?))VOK:VG;S=WV+4K)'X2Q_9\4<*_*80"41-V-P Y(Q\V!2>LE=_U;
M^D8Q3>+^-M]^K=MOT(/#4UG<7DDMC96ZP,A"7$60Q4$;0P/(R"3SZ54N9*TO
MZW-,;&I""C4D[]GWZV*NLSV/]M36]S8VKW4A542<-B2/'+%ON]<#'7CW%*-T
MKK^NW]?Y&V&A5]BIPDU%=K:/M;?;6^QHZQ-;1Z%927]FL=IE#,&5F\@;<]%Y
MZ\>V<T6]^R9RX:$W6DJ4O>UMMK]^GF'AJ2.2"YDAL+>$.%?? >)"<\'W  _.
MB=U&S#&IQE%2FW;OT_X!D:;<V,VI0);Z;:O<1R S+M97@D+8.W/7 /)''YU=
MFNNG]?J=M>%6--N4W9K3:S2VO;N^FYH^*Y&B:U9+];1]K@9D9-W3T4_TK*.[
M.;+XJ2DG'FVZ7_5%KPI-<3:0?M3AY48*2LF]?N*>.!@<]*NHDGI_6K,<?&$:
MWN;>ENK-P@'J.E9G -88C8 #H:4MF-;GGG@RX-[K(%NT<4D<.;@BV5<G</E1
MLG<O?(_V3WKJG'EC?I_P^_\ 7<^DS.'LJ/O7:;TU?9ZM6T?EZ]BUXSM5O-5$
M1T&2\D, $=Q%$Y96RV!N VC! Z_WL]!4T&UJG;7_ ",\LJ.G2O[7E5]4VK=.
ME[OY=K'1>)UW^'9U,44@)0,LR!QC<,\="?3/&:Q3M),\S .V(3NUOMIT_JYE
M> K:W;2VO196D-UN\MF@C5&QA20VWCKGIVQWK:LWM?0Z\WG-5?9\S<=]6WWV
MOY?C<H^*[6[M-5-^942"XS&)-Q^7"YVG"'J1@#/4UG#:WS.C+ZE.I2]E;5:_
MCONMCLM,:5M*LVF5EE,*%PQR0<#.:)V4G8\.LHJK)1VNRU4&04 % %'18WBT
M+3XY$9'2VC5E88((49!%;5VG5DUW?YG-A(N.'IIJS27Y%J<;K>11U*D?I6+.
MD\Q8 :? %8'$C=!CLM8]!L1?D>,MP$^8^YST_E2,]T.!"Q[PH+R#EB>!SVID
MVN[,<8GD;>HW9^\HZY]10%[:,7[7+L$?DS;\],__ %J+B]FGK<18I$;S'^7
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MJ*EM9O!V\]R?8;C6;W!Z%=&)4H3AI6&?4#\/K2)M^!+N7=L"8C QCU^M,GS
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M9@>YS_A3!=V;/A7G5Y&R23%S^:TX[E([ U8!0 4 9JZ_H[23QF^AW6ZL[Y/
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M#0K(?E4KNY[4/W;W)B^9)HS1XDT1HI)UU" (FP,V<?>X7Z@GH>_:BS0R"_\
M%6CV&EMJ)NHI!Y3NBJ?F?9U'MSQST-%G>WI^.PXKF=AOB._TU+>TM+^.5H[]
MRJI&Q4-M0L0Q!'! QCOGTI2]UO\ NIO[A0]Z*?>R^\32_%6@3V4=XES%"UP$
MD>/J^67@8ZGA3TX^4^E7*/*[>I,7S).Q;U76(M-TA-0@C6YCE>-8]D@56WL
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MQ-CYH?*QEG8GUR30]8N/DU][3_0=]4^UOPO_ )E)OA^5N=/NHM1'VBQLHK1
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MDJ>%;L_98'U1!96DXFAB%L-YQ('PS9]L<8ZY(-$'RV;Z*WX-?J$US)I=7?\
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MNA76FWD3FTMDM)'E@RH5(W&[&\'DN!@=/>M7/FE-_P U_P#VW3\ :]R*[/\
M.Y._@>;=:HFJG[/!Y)VO&QYC?<< .%^8^H)'KZ3%\LK]O\K#;;3\[_C?_,MR
M^&4MM.0.7O$B@NHS#'& THF<-@9; (QCW]JEM\MEO:*^[K^I479OUO\ GI^)
M+8:#=Q^#O[,FO&CU"="T]P.3YC<D\$?3@C@<$552S:4=E_7XD0TN_P"NR^Y6
M(=-\(R6-_%=RWZR,MP;@JL;8YA\O&6=C[Y)-#?NM>37WM/\ 0)>];RM^%_\
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M1.T44=I;R2RK YVRGY-O7TW]/Q]*JFDU*7:R_,J>BBNY9UWQG_86KBSFMU*
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M#[/'Y:N<L%VC&3W.*=6_.[[W/+Q/-[>?-O=W^\OUF<X4 % &?H7_ "+VF?\
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M"6CNB*;0-*O&9IM'LY&<AF:2%<L0,#)QSQQ]*0%Q+:"W,@@M((MY!<HH&X@
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M-! !M4# Z "@%IH@)Y)I &: #- "$_*W^Z?Y4 <#J6?[5NV7AA</DYZ?-_\
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M/]&=U"9%C\IXHXRA( C;<H7/R]ASC'';U-0Q[:(D"@?U)I !RWJ!V]?_ *U
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M]SU_3I0 BY.=A$A'=N/\_E0 JD,?G4MZ[.E,!BGYBL;X(ZJ!G'UI .5B25V
MY[YW<_T_.@!?,4G!9@?0D+_]>@9(JDC&P'TRQ-,!, =8\?3%(!R@.OR.01[Y
M_G3  [)]X9'J* '%%=<H=K>W>@!JLP.",-_.@!Q7<=R\'NOK_P#7H 3@CVI
M*O/R$_,.A]:8".I4AA]X=,=Z ) 5D (ZGGB@!OS1G-(-AWROUX-   Z=!D4
M*5#CA2#]*8QRJR\,1MH 4%1]W@4 (6YP5R!W-  7X^7YOK0 ;QWX/IVH %;C
M!&W% "Y0GGKV- #61F/48H$)C8,*I)]2*!C=K'EN![TA"[@@PO7UH 0(6YH
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ML2?0?YXI &T[<D  ?WF/\J (BR@X558^R' H$5;V_LK%";V[CBVH9-A)'R#
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ML&HPF6TF6:('!(XP< _R(IM-?U\A)I[%C('"G\#TH&1I<QR7$L ?][$ SKZ
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MOKQ0/S(3^\1&SDGY2?4CW/MB@I:&YIQ*W>AJ .1)GY>G)[]J:W1:V.TK404
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M &@P"YW6;)*K""(2L<$E\@%<=%.1@=J<'MS;]?2VW]>M^U5+:\NUOQMO]_\
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M6N!&Y)B9><2%?O8^88R><#&:I<KDF]OTYHO\D]/\R)7M[O\ 6DOOW7](UO\
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MXWW_ *[??K^#+#4;"&[2]MFBC)7RS*P\QCC#9 =E]/F&,^G<W*SCIY_U_P
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MOT?WZ:^79=OQ+_KY?Y]?P\BS/H>LRI:I<VES=2(;0QS&X7$"HX,@;YAD\9R
M<_A5Q:4[OOO\K?G^8?9?H]//7]+=>AJ^(["\N[W=:VD]Y']F9(O*F$8AF)X<
MY8=NXSC'O62O=VWTL^V]_P!/4I-:7VUOY[6_7[SEKCP3JAUW5]2AMBUU/#(J
MSI.%#,5AQ_%QR)?Z]JVBXQ5EW7W<S;_"QG*[BD][?CR_YE[4M-UJ6:^BMK:X
M-[([&*Z6Z\N(1%<!0,YZY & ,G.<]<UHOS\];_E_D5_2\M/\]>O^2:/X:UA]
M7EGNH[J*SCA?R8&G"%)?EP0 S8S@X)SCD]Z'\$N_3\?Z_K1?:CVZ_@:WA.QU
M"QCGCN+"9HG=0/-92ZG:=Q8>81U &5P23]W S5-IK[_T_JPK:G6Q#Y2\3$;3
MC:3G!_S_ )%2,0!7<\;)1R?>D \$!@)>#_"?4TP$):$9ZKWQ2 D 5E$BG_=8
M4#$!W AA[$4 (,H=IY!Z'^E "L,'>O7N/6@!3AU]CR#0 @;Y7!ZA3_*@$<1J
M($=_>G'S/.ZY'& 6Y_I^M9O<3U9#<1D8E3=LP#G;@C(_G_\ 6H$F2K)'-R#M
M;N#P"?;_  IW)LT/:[?9Y<!!QPT@Z?A^1%(2B N[F-V:1,@=4./3/;^=%[ X
MIC7>(@R^:"G7Y>I/ICUH&M-"!LW$Y,8PJ#(&,D 9_4_X4%K1"R>7YKP]L=2.
M-PST'IR*!*^YLZ;%*;G164'8@?<<^[8XJENC1;'95H(* "@ H IQ:1IL%V;N
M'3[6.Y/65(5#G\<9JN9VM?0WEB*TH<DIMKM=V'7FF6&H;?MMC;W.S[OG1*^/
MID4DW'5"I5ZM'^')KT;1,;>!K?[.84,&-OEE1MQZ8]*6YFIR4N9/7N0V>FV.
MG*RV-E;VJMRPAB5,_7 JG)RW9=6O5K.]23?J[C;G2=-O9UGNM/MIYD^Z\D*L
MP^A(I*3CLRH8BM3CRPFTO)LFN+6WNX#!<P1S0GJDB!E/X&E>SN9PJ3IRYH-I
M^0EI96MA#Y-G;16\6<[(D"#/T%-MO<=2K.J^:I)M^>I%%I&FP79NX=/M8[D]
M94A4.?QQFGS.UKZ%RQ%:4.24VUVN[%RI, H HWVH/9RQ116,UW)("0L+Q @#
M'9W7/7MFJBK]3HI4543DY**7>_Z)CM,O)KZS$T]HUK)N*E#(C].^5)%$DELQ
M5Z<:4^6,KKT:_-(N5)@% !0 4 % !0 4 % !0!3TG=_8UCOV;_(3=Y>W;G:.
MFWC'TXK6M;VLK=W_ %J<^%O["%][+:UMO+3[M"Q/_P >\O\ NG^59,Z#S51M
MT^W"E3^\<\'V7UK$;';%=$ (5U/?^+OC/U H,]@9HF3$C,9EQD8'/;J/IW]:
M U0HCF52%98DQ_#U[8H !%)T$S%<8SCYOIC]?UH 79*5QN21<<!NPSDF@+I#
M8WBC7Y2PD8D#@<<>I^O;TH!Z@L8C1LD%R<9'./7GUSF@-S5\+@C4I0< B/IG
M/\0ZTX[E'4J-J@>E6 B\LQ_ 4 #<E5]3S0 XG:"3T% #%)V[4QGN>V: !,!F
MSEG/"^M,0UA\X,AX'..WM2 <^73:QV@G YI@(Q*IA0$4#Z?_ *J0P!"0[0=J
M_P!X]2:8ACJ441@%1W]3ZDT ,AC,S!F^6$?=% $\UNKC!X/8B@" ,\;*DH!;
MMD\-]#V- $GHZ_,G1@>HH =N*,'0Y&<,IH '52-T9*LO)&.GK]: %;E=L@Z\
M9[4ABINV*>N1T-,!J@,[]00>W4<"D OF%9%$@R,'YORI@*Z#83&V..AZ&@!X
M+ X(*G^=  K=20#D_P#UJ0"$J9%&".IX/^?6@!S.$1B,\#.#3 550* "1CC!
MH 1% D9A'\PXS0 _/'.%/J* $(XR22/:D H)/\''J?\ &F FT$_?S[4  8CY
M57\^:  @$\M@^G6D 9*< 8^M  1GEOE- !]T?)R/6@ ^]RPQ[T  &W[IW'TH
M 1E64;'3(],?TH < %.-^?:@!"Q P5P/;BF 8P/O%?8T +D_P@'W[T ,4?.X
M*$<YZT (Y160X)P?_K4 .+ ]<F@!D941J-O(&.32 4,0[ <# /% $<@9@I P
MN>K?ETH <%BA4=^P %,6PU"SQ("=J8' ZT "X$C!0.@^G>@!6 7:6.3GOTH
M1][+@< X'3GF@!2RQJQ1=[#WX_.@-AA^1<']X_IVS_2@!K?(N'.6QD^@]S0
MP1M<8R=L0''O]!VH L?9T:(H1M7U'6@96^=&$3#E>4(_I_A0(ER"%EW8']\>
MGO0 Z0Y=2?D8< CO0 .-V-PPPY#"@!SD%2L@!3IFD,1-P _B'?U%  ,;F\H\
M#G'8_P"3FF(-W[Q>QZ$&D,<PRI'0]J !3N4$<9&: $4;25[=10 -QR.N"/TH
M X>__P"0Q>' P)W/!]":S8,C $3>=&V$P2PX!'!_/G^5!(C*CR?N '8C(#\
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MAM+0(7N)SYTTB_,Y'" ]E'9?\F@".>3[=>I:,Q:WMF5I6[-(1\J'Z9#'WVT
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M"1;SX^<#NC#AQ].1W I :_S#[G3VH 09/WE&/4\4 &4!XS^- !\W4/\ D<4
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MB@%?H-;R#\^QF(]B,\9]?:@-266VD*%$\M2!D1J#TSG'/4T"N,X=3'*I5ER
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M$ 0!6D"Y(..P/'3'//6F!B74DPBDD@U=S8J<R33! K\\JC*H()Z;AG&> 3T
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M)SU]ARQ]@:8A4>PTJ.&RGNHTW'.99 &D)/)(/4EO2@"]_P M1&6RO7)[^QH
M&#QN!@^6.3CMZ?A0 2;B<* <_>'J* '-(K)PHW=O4&@ 1D0;7!! SG/7WH :
MJA#O ;!ZKZ?2@!?W<I!R2HY!]Z #>N?+YW^O3CUH 5BL2[E3@=1ZT *C C=M
M&6YI /&_L,?AB@8$'^)A^>: $^4=23]!0 ;@.B_G0!4U/58])LC<S!VRP2..
M,9:5SP%4=R?_ *YX% '.VME=ZOJ"W5^R/<!/,MYX2DMO:,&VF-5S\TF <N1Z
MXQTI@:::E8VNJ76G6%N#=%C(XD?9OD*@\#DXQC+ 8'UXI7T;[?U_5]QM6L8@
MU[Q%K/EPV=C+#;W$#;G$+*4R&VLKDA3_  =".O'?:[66OE^FGSU7W?-[.WG^
MMO\ @E"%=326&276[?3PC.1;2ZB6*@L3SG.\'.!NZ8XQ2:=GZ/\ 6WZ:[BTO
M\U^G_!T\_F;\":@GA^XAMKMKZ9I8UCECF#NJ$(';/K]\CZBJDU=-+O\ @VTO
MFK(B"=FGV_&UK_?K\B71]=OY;J6PU6 FYC9 6B@(1-RY .2<\Y&X<''046TT
M\_G;\O\ ANXV[/\ JZ_K_/LR?5=$M9+*55M_-B!DN'MD^_-*1D%7)&QL]"".
M3VJ1E32-7GLKN+3-2E#B3 @N'8%PY&?)EQP) #P1PV/7JP.E)8?>S^-(!-RG
MJOY4 'R]FQ]: %&X?=;\C0 '>.H_2@")Y!&_W0=WZ&F(SM<O'L;.&2)UB+S+
M')._(C4]2<\>W/ )%+[27];#Z-_UO_3,2?7G,2J=5@2 02.ERT6%N65B-@!/
M. !G;][/&!0V]6EK9:=[_P!?B-)72>U_NV^7?[BGJ7B[4+?3%2W,*:I]IV&W
MD&2B>7N!8=<;B!FKM[R2UU_]NM^1$7[DI2TT37W)O]?N+5CK.HWNJ!#*UL#>
MFUDB:(90B#S&P3U^;.#W&*(I-)]+-_<[%2]W3KI^-_\ @%:/Q->W,1,<RR3>
M?Y?E1/"S[?,*G"[@1P!][%1'51?=?^VMBEHY>3_]N2_(6;Q5?QVME(\\$;8<
MO&$'F9$FT*5) ) X94.<],C&;23DDO+\=_\ @=NH2T3\K_A_7S5K#4\6WHBW
MS3A&\T(L*(FZ8&1E+89E) P!A<D'L>E3#7E\[?BD_P!7Y:";LI>5_P &U;\%
M]Y4D\8ZJ@LXKL10R3!V:3 5&C\Q4!#,< C+ Y]CWHA[R3\E^,6_T_-%R5E)^
M=E]]G_7_  2_%XFFEN"O]HV\KJ\");?(S2ASAR"I[<G(X&.:<5=V\_T3N0]O
ME?YW>GX+[QNK^+=1MKV[^RPQK;$F"SEEC)4S+C<"<\YRPP.GEGUI1N[=VU]U
M[/\ S]&5*T=>RU];77]=V-A\47,MZZW-W%IB+<20,9U'R%8E<C+8SEF//<8I
M/:Z[-_<[ TU9>E__ ";_ "1J7FLZF-)TBXCMY1/=1&26*!%+C";N Y'?MUHF
MN6;797_%;_?T!>O6WY_Y&58^,+V:UN)#=6LD\:\+$R%?NJ2P7.\@9)^@JFE^
M/X<UOR%?5Z?U:]O6^@Z7Q7>+YL=M=Q2JDKH+B54*,!&6!S&S#&>>0"!U'>I6
MN_\ 6L5^K\K@]&DM?^&D_P!%Y]MT7['5;Z]^P[;[B2Z>WD_=(<[49\AE)4]
M,C\@<U275]K_ (I ^J\U^**2^);Z\MG1)UDG-P(A%$T)8#S"O"[@0<8^]BIC
MJHONO_;6PEHY>3_]N2*-GXLOI#<K/=01R11G$>Z-6S\P"LI.2PP 0O?.*).T
M')?UHF-+WU'II^9N:1X@DN7$0O+6[@=(&,P8(%=R=T>1D$\# Z_-SUK1QLVE
MW?ST_J__  "$_=3[_AM^=]/-'2M\N(_X6X'MZU!0,QB'J.@]C2#84#RAQ]WO
M_C3 0 L?-4\GH/44 !*RD ?P\Y]#2 7?A2& W>GK0 */*4 DE?7WH#853N9C
MV (% '&7G_(6O4)PKS.#CL=QP?\ Z_UK-[C96&)SYL@.%8*X7+8STY_#]!0+
M8NLK&4*RXZ84= .V*9(R>Z3R1##;FXVDKNZ 'KQBBX*/5B1W,L-QNFT_;C^*
M/MWXS2N-JZW'N4<+(C;D?H13%Y$-S&&G#.I5U&Z0X)&![^O7]*0UL1%V:#<W
M!<$'!XVC/?ZDT#M8V-+5_P"T-%(0[=DF3M]V[U2W1?0[.M!!0 4 % %6'3+"
MW<O!96\3E_,+)$H);&-W ZX)YIW>QM*O5FK2DWTWZ#IK&TN)XIY[6&6:+_5N
MZ LGT/:A-K8F-6I"+C&32>Y)Y$/DF'RD\LYRFT8.>O%(GGE?FOJ+'#%$ (XD
M3 Q\J@<47!RE+=D$FFV,UPUQ+96[S,NTR-$"Q'IG'2FFUHBXUZL8\JDTNUR=
MHHW:-FC5C&<H2,[3C&1Z<$C\:1"DTFD]QEO:6UH'6VMXH0[;F$:!<GU..].[
M8YU)U-9MOU)J1!R'CB_M]-6TFEFA24AEC1Y74L>.@'R_BW2M*<7)M(]K*J,Z
MW-%)VTOHO^'^2-'PC=W5[HOG7=Y!=2>80##*L@08'RDJ ,C_ ":=6*B[)'+F
M-.%*MRPBXJW5-7\[-MEG6;/4KHQ_8+@185E.9"FUCC#\ [L<_*>#FHC9/7^O
M^',\-4HPO[57^5_ENK7[[DNCV,UA;2).R%WD+_)SC('4X&3QG..^.U#:=DB,
M15C5DG'HK?UV-"I.8* "@ H * "@ H * "@"GI*LNC6*M#Y+"! 8\$;#M''/
M/'O6M;6K*SOJSGPJ:H035M%IVTVUU+$__'M+_NG^58LZ#S4(8]/A&5.7?.#D
M=%K(;'(Q62%#]Y6#@Y.,?UZ4$$L*?\3+RT4$/@.&Q\P]?\_E1U!["1!KN:9R
M  90@ Q]WT_E1U#9%X30BZ%C]F;S W7<.F/O=?6F19[E*5&M9(9 HPLN#G&0
M/3^=+J6M4+-&?[1$)C7"9$:KC&>N3GZ__6H!?"0-DR3*#R3N!SU'7\.M ^QK
M^%_^0E(>PC_]F%..XSHRI8B3'(Z#VK0D<<294?=QR?7VI (&VCRQ]X=/IZT
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M+C!V*0!DCD?2A"DQY:'4(7DMXV54; ;.,G'IG_/\F%N5E2W:1)KJ+8AVIYR
MXX(QS2*=MQL0_P!&F?/SL3N;@9.,XX]L]>^* >Y$[;PI PH 4 ^W7]?\^H-&
MWIB'^T=$;*X"2=^>K=J:W12V.TK404 % !0 4 % !0 4 % !0 4 % '/>(]'
M?5[JTC7:P57^2:-FB!^7#':1AACCZFJ@[7/2P6)6'A)ORV:OUTU3T?7Y&U96
MYM+&"W:5I6B15,C=7(&,GW-$G=MG#4GSS<DK7>W8@OKF\BEBBLH;29W!)6>Y
M,1P,= $;/7V[412>YI2A3DFZC:7DK_JAVF2WDMF&OA;><&(S;2%T(^I YHE;
MH*O&G&=J=[>:L_S9<J3 * "@ H * "@ H * "@#/T+_D7M,_Z]8O_016^)_C
M3]7^9RX+_=J?^%?D7+C_ (]I?]P_RK!G4>:<+IT&"P&]\$\8X6L>A3'1+O>V
M0C(9\^N!G_\ 7018E4!Y?M;NNT#* ]6QWQ_]:@72P@'D73B+CSFWID9]\?6@
M>YHB>S,/G>7#NWYR77&[&/\ (IW1FT[F<S"XN5W@GRF\QCC&!Z?4TBTK()
MYNDVE2N9%'49XSC\?P- +:Q#(,/<A1GYMV<8R,_AZB@?8U_"I_XF4F.?W77_
M ($*<=QG3ER?E'#_ ,O>M"1.(!R?D_D:0"[,_,1A^OT]J L(C"0YQ@+QCWH
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MF.HVC7-FJDRH8A(,#DDJ>HHW:0U=;&1-+H$GV>SO=%B$-JT:11R6B%(&<X7
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M_C1L I(BYQA/Y&@-@VL#O_B]/;TH"PX,'R%/&TY/X4#1PVI<ZQ=J."9W '_
MCS6;W*$BD"B>4##%E1%P?FX./Y \4$L7[.@MWMRZF60<L.=I'(&?\/Z4"OK<
MDM)U12LJKY6/+97P.@Z$FA,)*Y<O9HT+K"J(Y'S$8)QCKCTQ_2F3%/J9UO''
M\\LB\3_* 1SM[G\QQ2*?D 3RXI;<LK90LA'.X#GW].G;F@+ZW()6R(V^Z-H&
M/3'&,4%6-W3,?VAH9(8?))@8]V[TUN/H=I6H@H * "@ H * "@ H * "@ H
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MU #(P&12O# #(/\ 6@0@RR #Y7 Z?WL4 4[^^MM+MVOIY1%$@&<^_0 #KG@
M#G.,>E &?9^(=3GNX6N-#:TL)I!%')).#,2<X)C .T<<Y;(STH*.BS2$&<#)
M. * *FYII0V#M)PJ^PZFF(R]3OKFXU,:)IDPCNY$\RXN.OV>/.,@?WB3A<^A
M/.,4#1'X*-[)X9A:[GDE=I)"LDARQ3>=O/?C'- &\G)=4X&>OX"@!?NR!4'.
M#D^G3K0 /A%'5F+#ZGF@!VW!WN1Q^0H JVDMU-),D]L(8$($3B3=YJXZD=5Y
M[?KVI 6AQ(?H/ZT *WW?Q'\Z %S0 U#\OXG^= !G$B_0_P!* %;[C?2@!: #
M- '/:]&\>LZ7=12"*69)[%92F\(74.K$=QF(#\<=Z!FS8W27EC!<1.721 P8
MH4)]]IY'TH$9=^1I_B>POSA8;N,V4K8Z-G=%D^F=Z_5Q0,T=3O7T_3Y;E(#.
MZ8 C#;2Q) QD_6E>U@2O?YG._P#";AXS/%8AHEF,90R[9=@)W2!"O0!3^(([
M56UK[?EI_P $+=OZ>UO4=)XR>-)W&G!O+C65$$^'D#8*X7;UP12V^+2S2?EM
M?[KA:^W9O[K_ )V_$I6WQ&6ZN+U$TT".W<K&[7&#(N%96QM^4$-FE%MJ[_K6
MP.R=E_6C?Z&S9^)'NM2@M/L2K'+QYRS J#LW8'')]OJ>QJDKW\O^!_F)Z)?U
MW_R)_$MW)!HSV]L^V\O2+6W[D._&['?:,L?932&:=O EK:Q6\0Q'$@11Z #
MH$<[XIF-S;7=@DNX3HEF\/DD',SA=P?T"[B0/2F,Z<<# & *0@S0 UNJGWH
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MY0J<Y'?J: -#4+&#4[":RN 3%*N"5."/0@]B#@@]B*0&=I>J31W(TC5B%U!
M3')T6Z0?QK[_ -Y>WT(-,";5KN_M,-9P+*GE.Q'E,[%@,J, CKTJ=6[?UND/
M16;_ *5F5=4U74K2PMS90I=WARLBI;R%"RXW<@_(.H&<\X]S5.SEIM_7]6"*
MT][?^OZN5VUC6@T0%EA6R"_V20Y^9P#@'*\*G!_O>U)Z7M_7]?@"M:_]=/\
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ML%=ZX&,]>,^OO[4"'*5CM4 /S2?,S^H[<^F1^E BU ]O#$3< OO!01@9+'U
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M^]-(399G:'4(9'M)&*IU8J<9QG'3_.:>C"UC,MFV2SP&%RL8$R*N?QQ['/\
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M;:R_(N/_ *ML>E8G2>:J)#81ER0?,;))SV6L2F2QIB:VWD^9(X53WQTQ^O\
M^N@DG@5S>_:3E8HB 6S@$CC X_3-'43V& -97<J+(2CR>:@W$94<_P#UOPHV
M':Z-55M-PN_+D^T9SG)ZXQC.>E/0G78RBQO+B*-I"$5Q(ZY. OJ?3]:0]D27
M!(O1>"1A$^1YF3^[/3GCZ'WI@MBLXS+<[!B1&P<=ATP/R'_UJ0S5\,Y&H2\D
MCR^#Z_,*J.XSHAAAZBJ,QN=G#'CL:0"E<\C@]C0,H&P635EU"ZDWF%=MO&5P
ML1(PS9[L>F>PX[G(!?VE?N'CT/2@0F<C#(?YB@ X[,X_#/\ .F <]-[?]\T
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M8V3B)E##GOWY^H- &S8[Q>:%C=@"3=S[GM36Z'T.RK404 % !0 4 % !0 4
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MWJB!-X'#C;]>E( "[?NM@>G44 &YAU7/T-,!/D'0,OT!%(!,_P"V_P#WS_\
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M+\.O.: M81)EA&VWE>(@9,<B94G@#U(/'Y4;!8([>24M/.7=%)R0<YXXZY]
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MO_/O>?\ ?"__ !5',@_M"EV8?\++T7_GWO/^^%_^*HYD']H4NS#_ (67HO\
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M&KL>W2@XP47T1=^S2>WYTS2P?9I/;\Z L'V:3V_.@+!]FD]OSH"P?9I/;\Z
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M "R.RLJ(H+$$\G@4 ()OW!?;R#C'OG% "QNQ=D< , #P>* !I<3K&!U')]*
M$:1Q+L10>,G)Q0 KR%%7@%F. ,]Z %5G*ME &!P.>#0 U9)#*$9%'&>&SB@"
M6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"G
MI(VZ-8C8B8@3Y8VW*/E' .3D>^36M;^++U9SX72A#T6VVWS_ #+E9'0% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 12_ZV#_>/\C0 DTNPJH*JS=VZ 4 *&CBA!4[E'4@YH 9%@7#A#N7:#G.
M<'TS0 P"19H0R#))).[K0 ^7R=[[SA@O4G'Y4 -<$Q6[2$CD;ORH D@P&D"G
M* \<^U "P<JTAZN2?P[4 2T 0?;+7_GYB_[[% !]LM?^?F+_ +[% !]LM?\
MGYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_P"^Q0 ?;+7_ )^8
MO^^Q0 ?;+7_GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O\ OL4 'VRU_P"?F+_O
ML4 'VRU_Y^8O^^Q0 ?;+7_GYB_[[% !]LM?^?F+_ +[% !]LM?\ GYB_[[%
M!]LM?^?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_P"^Q0 ?;+7_ )^8O^^Q0 ?;
M+7_GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O\ OL4 'VRU_P"?F+_OL4 'VRU_
MY^8O^^Q0!4TFYM8]&L4\Q8ML"#9)(-R_*.#TY'T%:UG>K)WOJSGPJY:$%:VB
MT>ZT+?VRU_Y^8O\ OL5D= ?;+7_GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O\
MOL4 'VRU_P"?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_[[% !]LM?^?F+_ +[%
M !]LM?\ GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_P"^Q0 ?
M;+7_ )^8O^^Q0 ?;+7_GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O\ OL4 'VRU
M_P"?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_[[% !]LM?^?F+_ +[% !]LM?\
MGYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_P"^Q0 ?;+7_ )^8
MO^^Q0 ?;+7_GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O\ OL4 'VRU_P"?F+_O
ML4 'VRU_Y^8O^^Q0 ?;+7_GYB_[[% !]LM?^?F+_ +[% !]LM?\ GYB_[[%
M!]LM?^?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_P"^Q0 ?;+7_ )^8O^^Q0 ?;
M+7_GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O\ OL4 'VRU_P"?F+_OL4 'VRU_
MY^8O^^Q0 ?;+7_GYB_[[% !]LM?^?F+_ +[% !]LM?\ GYB_[[% !]LM?^?F
M+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_P"^Q0 ?;+7_ )^8O^^Q0 ?;+7_GYB_[
M[% !]LM?^?F+_OL4 'VRU_Y^8O\ OL4 'VRU_P"?F+_OL4 'VRU_Y^8O^^Q0
M ?;+7_GYB_[[% !]LM?^?F+_ +[% !]LM?\ GYB_[[% !]LM?^?F+_OL4 'V
MRU_Y^8O^^Q0 ?;+7_GYB_P"^Q0 ?;+7_ )^8O^^Q0 ?;+7_GYB_[[% !]LM?
M^?F+_OL4 'VRU_Y^8O\ OL4 'VRU_P"?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GY
MB_[[% !]LM?^?F+_ +[% !]LM?\ GYB_[[% !]LM?^?F+_OL4 'VRU_Y^8O^
M^Q0 ?;+7_GYB_P"^Q0 ?;+7_ )^8O^^Q0 ?;+7_GYB_[[% !]LM?^?F+_OL4
M 'VRU_Y^8O\ OL4 'VRU_P"?F+_OL4 'VRU_Y^8O^^Q0 ?;+7_GYB_[[% !]
MLM?^?F+_ +[% !]LM?\ GYB_[[% !]LM?^?F+_OL4 'VNU_Y^(O^^Q0 ANK-
MNL\)^KB@!1=6@&!<0@>F\4 (MU:(,+/"![.* %^UVN<_:(O^^Q0 ANK0XS/"
M<=,N* %-W:D8-Q"1_OB@ %W:*,"XA ] XH !=VH&!<1#_@8H AFU:Q@8*\^2
+1GY%+C\P#0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g692844g70h03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844g70h03.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@"Y )@ P$1  (1 0,1 ?_$ !X  0 " P$! 0$!           &!P4("00#
M @$*_\0 <!   @(" @$ ! @(!P@+"@,9!08#! ('  $("1,4%1$2%A=7EI?6
M&!DY6':WU=<A-U9WDYC3(C$V57B5M;8C)#0X05-Q<X:QTB4R-4)188&1H;0G
M*#-#5'1YL[CF)DB"DK(*4EE:8F9H<G64F<'4_\0 ' $! 0$! 0$! 0$
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M/\3$E@N"'XJ;T?GYN #ZW[*^^G'>1_B8DL%P0_%3>C\_-P ?6_97WTX[R/\
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MFX /K?LK[Z<=Y'^)B2P7!#\5-Z/S\W !];]E??3CO(_Q,26"X(?BIO1^?FX
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M.-QPIQ-ILC2D[%<]ANAZ*3\GSXU_HRS_ *PW#F*3QQ;RJY;ER.AG,%' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M, M,=%I'628Z.U%7JGVM<DQN1Q1R]WDYI,*)23#&&:?#NK,3"6Y:,G>>,LM+
M.O+/#6FSDKQ 9" J,M7KHRL1H6"0SJOD2'P7*\UX?U;P[EJ]W:D<F4]3JS'U
MW)7[GCCZFPZ[SC^-CU\/ /?P#XSV*]6/UUF>&O#UG%'ZV>7"&/UD\N$$$?QY
M,L<?CS3R1PQ8_#\:263"/#KO/+'KL#[< < < < < < < < < < P*JQ46]76
MVT9':A&M $.Q#XKL<45V*B;'UR52.W%#-8ACM85[,>-B.*Q/%A+UGC'-+AUU
MGD#LL/="6%6;LXVN3'SD:N/>5JA#=K2W:V/7>'7>4]7"3*>''KN2/KON2/'K
MKO/#KO\ ARZ^$#V330UH9;%B6."O!')-//-)C%###%CWG++++GWCA'''ACEG
M))GEUCACUWEEWUUUWWP#]XY8YXXY8Y=98Y==98Y8]]=XY8]]?#UECWU\/7?7
M?7?P]=]?P=]?P]< _O ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M .>?I6_R?/DI^C*Q^L-/YNC\<.\CN>Y\AZ*3\GSXU_HRS_K#<.*3QQ;PKEN7
M(Z&<P4< < < < J/?FV*VB=*[0W);!7V>OK5*/-\B^-EZKVRWN:C+:PI]6\H
M;.-"O+)AC[:1RK6<1U+JQ>RK6,:_<.>*2-4=''2--J"%Q25[DKOKLO9^7[;=
MIJ/L9V1[1]JZ6I4VD:/L_HBNZ4BJ-7B4%)6OU6ABI(:'O7!2*AHXHDN^K#HZ
M15>AUZ9T=(J/4?/[T?GF::](J"V83=$Z37@76]\"%M*2Z2(60+ADTP&;F-DL
MT28T"=V,?4%8T+B?4AI#?56N[QZPP5#U 2O\M5K#K2C;AU% TM5-M13MFXI)
MV2EJK&;G-)?P_P#0=^EFM_IXJ?:&L:6T5%H*J=GZ:I52ET94*Q3QU+2KTE!6
MZ54E9TBU05FEAH**K*AI=%44-#5]6E=-7:2O45=H:K4;61M;JFD_/219U(!&
M(B%M;Q?:GI[0U2G"$3?E\A[30E]<<ZJX/CA$##I<$Z'Q1*<?4J>]HQD5NUC-
M;KSSS>D,,-'690)0PQT+BBAALAUH8X5"Y*Q-J*).24Y6S/TNAM :,[(?IKBT
M=V7J=6T+H7M-^CG26FM-:$T90P5/1/VWH7M)H2HU#2]'4*"&"JU:N5JI:7KU
M5K$=!147ZU#5X:6D45+1QQQ]!^=)_<R.LC>IIM2"^WM"ZJT;5CV2M<9#8T'4
ML6O4R6/9H+!.S5AEL>HAFF]3'GE)ZF*23XOQ(\LNO:@JU8K,3@JU!35B*%:T
M4-!11TL4,,TM9JCAB:4VE-J4VE>SQIJQ5ZM"HZQ3T-!#$]6&*FI8**%Q2;U4
MXXH4W)-R3G)-W(D&&>$N&$L6>,D<F..<<F&76>&>&?766&>&>/?>.6.6/?66
M.6/??677?7?7??7?/%IIM-2:L:=C35Z:/9.=JM3M36T_7 ' ' ' ' ' ' '
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MP9%245F]W#6KP5XNY_B0PQ1XXX8C!*N . . . . . . 59HS^)/3O\UFOO\
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M0+:U^W@I;??V-#<?"[9^"_;T4@:U/:SUHX[!T+M-6V*?=T@R7T0GZD\1==:
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MW\MF!LQI#0@#1U9H]WMST^FV^TL2&FK8=]?NG,AZ8F@D57 T855940 P&'#
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MB<]AZD,BQZJ<L/NMW)PQ23MGLBOQ<UL.D8+TJ6UR#YK+6LSSIKI_-^ED\O\
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MV^JO7<M;XO>?M,?797^[@^)UWEZ['X8_B]=Y?&^#KX>>GV7I.W_1U>L>J_\
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M,H/:,Q&YN9I<E>C)T^C^,R+ID8.4Y=FKNN=+Z\9MRWUJZ7(,@W7#5K-M<JE
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M@H4G)GBDMP\9+DKHAY-K::0=TBUT2_5&.:%2::SJLWU)_P!@:T8@314"G5V
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MR/)#KM?/."U2N5YJUB'/*.6//#+OKL"-!M3ZN7%,$A@-<(@9(5S%)A6U :I
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MAZ*3\GSXU_HRS_K#<.*3QQ;PKEN7(Z&<P4< < < < < < < < < < < < <
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M6O:F$(SHS^)/3O\ -9K[_5(1P5WO>^9S\-^D+:ZP1_E!:ZIF+2[O8?K;%O\
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M>1W/<^0]%)^3Y\:_T99_UAN'%)XXMX5RW+D=#.8*. . . . . . . . . .
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M)//+'%AEET!F> . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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MW1^.'>1W/<^0]%)^3Y\:_P!&6?\ 6&X<4GCBWA7+<N1T,Y@HX X X X X X
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MR.AG,%' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MN64,N/6>'?7!&I-IWJQ^19' ' ' ' ' *.WQ_P"!]=?SXZ;_ ->Q/ +QX X
MX X X X X X X X X X X X X X X X X X X X X X X X X!JGYW_[Q[S*
M_P E/R'_ %1-_!5>MZYG/GT?5@V(]#?X .(--:M@9:ZU/IC8A921JHPBYEU]
M1RF*FX5<.5+!8#QS"A%+*/ UK^)0S/AB/$5KQ.Q5I3C5)XXMY$HO21^+$ \X
M)@]$SZ1>$4S6AUYD&1>B_8HQ[#=#W)2 BX<I85>JQ:T+OSSWAUB_'8EHW)I;
M-;.*:3//L75?XX;+OOJSU,#CZ0CQ@^=63<<_HPO2EW7+%10TX3W?]'2[W!*Q
M2UPS[*;EHLJ#9X\HUUDB,[9<9;9T9)!=LPVJL7QX_9\LI0U'*6M!_MK+/(G4
M_I2O'VR7-L%GT77I,[!YFBQ@9#<_HU7&4NP08A[B]C";)28972L6( A?!XQW
MYK&'0>]<&==>Q69H,Q-1_B@_VT?*7TN?CNAZ^OA)O1O>DN3-5+84E<*")?1V
MMR[KX"NT\+!<Q:OC\YJ:X+"U<,;9,E/8B@HP88V+MK+'KJ23@:C_ !0?[2,J
MV^EATCL$3@#>O1G>E#=P75RJ2C#MOHXWEE$]7Z?>6=*_@/,97:?5RKWGGE5M
M=0^N@[SR[BDQ[R[[[#4:NB@_VT>^3TNFI9>BO4OHW_2I2='A\(DYU)Z.[8.?
M1D56@LU:XPKUE-WT1'P5;ERM#3N>NK106[,.$>,<\N.0:C_%!_MHB\_I/?'&
MTL6DJSZ*_P!)583;M030NJ4_HSFR58MT0,<,0.E: R19"K%0+%7@B$UI:F<(
MZ."'"GA#C'AUB&H_Q0?[:,[EZ672V=66EGZ-'TH^=*<%15YJF7HY7O*K,M#,
MI\QJ[+7[S[BD!#\[5K*B)SP[H5,K,^4%>/N:3O(-1_B@_P!M$S]$@6:76/T@
M>WV#3^[=*A]V^?COLI"5]_:O9=2/U],NZ&\>P%4W,J,]:"UU0G+KYFA%>IRW
M:$EH=<KQV\K%6Q%$$?[*FG*%)R:>UX'7S@P. . <\_2M_D^?)3]&5C]8:?S=
M'XX=Y'<]SY#T4GY/GQK_ $99_P!8;AQ2>.+>%<MRY'0SF"C@&CCBA["VII#R
M\U?JUC'IKGLC8KJ@U7&_;MTLT\*Y!TM<<6T)-2%&I,V]9321\XD5;%#(;?<:
M *B7M#15BX2J"IR:>%IKU-Z/K:2DL^2:<@;8'-0I[K^.^[-#%MB55M5+Z[\M
M_&WL0/4K1<9J'5:HKU-1FEC4'CNMEK04-<:_=:Z]4B0IAJGJ\?8LTY3S3VV/
M";OMB=^TE CPMV*N"-$6;@S3.US2?XY>82GO53?BQ\6B[EWAY?.^EMG;(DGE
MZU^Y21:R<7-7VIB;M%UPF3%!F%>K1J#+'D2ITPG??>I;6DII<%(H.+P&\DX>
M]9$[ /6+.LZZVYM]G2?'P_YD^2@83I_5^P-1ZU2 J&F>2 O2AS:#,/'OBFZ;
M C4RR<!6%$6]UM>J]JRMIX?*4)K.[!6[;IV>5]YOCY$:SWNV,OBEL[4RSJ0Z
MX:*V$TN+8D;$VNZ(:T0I..B=D:LN4U[8"]I3:)>]:#&G>I>K2%=>B<#(NC9E
MGS$7)(ZG!%*V<U-;%/:GBN9J*X>*'D[,W9E;@G3F6LUGR,\@?+3.TO/KZP[-
M,%-O^$&\M#?-D%29-1!PEJ5>V-MRU-58Y'&&9H4Z(XA&N CLME<X+K*3SA4/
M!ISOR*6T5X+>1'>I]5;#I:T\?]..Z=J3T>-1<U$&9G-=&;&)^,6RR&VVTQND
MGUI0.3UD\&Q+425PP2LF;1MI[+D?[.LQZD1ZZIBMJ>W]JVR=JDKK'+UV2+J5
M/"SR2"-&H'_.CI$+LL/Y#[JV;L!M%[)86M:&:FWAY<S>0+AJ@9KUU\>;$3R5
M[4,:-%9V0+9-(.*GLH<./4R-A7KWU\N)-6WW2NP4IW_-A8?E?X*.&^MR[!W8
MNG0-9A&Z6\;P^F0)]WV +1C>U=";UV[N2X#WHA!*!!(<]3N55M5%;VMC7-AF
MU3*RS,RFM!F80"*$ 35SNMG8FY.5T]J\BIX?1T.EEXW[:?UU0VVL;#-^8AU;
M(W]_L&M+S #\L.FF.]K%S%*7C.6< XD*ML]?6L;-AN-ZA# T9"<0";[U$"E9
M8;^NNK[&M=LNG9.[>Y/&4EA,C#YX.>:A_3[FI#R?CXPM^UO%#RX\4C<[:[&5
M>OKY=W<WXF=8M.9K6OCD%$[98E]<F(#7R?#6NI9C!WH<3]L.V<S9PB*HEGXE
M%OQO;XS9?MCPOV/0WPM;G@"Z9=^A'FDU;NR&M)DR+(B]6//B^@Z0N$ Q/YMF
MGKO8JFYIL;>+4_54 )RG5&2Y/Z\6BPZK#/'ZF,\CO YS\B,/"4<.R3_'9<\?
MO(K:VU-C"O'S8;B@F::NXH&Z54=/J!N6$%7(4W)G./H1B>^K-)1ACR,N\54\
M:L85K9H512UMLTE;;MA=O TNWKZ&=FL-S<B>.*EXZBM"/^K_ !'U:E/&R6)Y
MFWAX8#_&G:3)L%D,:&K9H;Q([F-GR,,S!;(D-IZQ+2;'SL'VHHQ5\\NY15%9
M;.:<3E)2<U*VVS"YV621E8_1:>2OSK[()K]C1.O]+L'FQXV>4XA&L/AO9;/>
M*:Y\O;7D)N=KJ/ECQU1'90KORQ+!V T6QMFWE8-L><S(*V0KJ\T/<XNLL+=5
MPMRE>I+:YRQLLV&"UKZ%TV-=4X*[Z\\50NIE;>7I#KC*U:YR)T]I;/\ '3S.
MUSNQ53$\N*^9\%0"%M:9[6&K,2I(\'U@6O )"*^8RDAH!)1'%MMGJPISNG#+
M/+BRM!WH;_,B346M6/9VS]-[>\F5+?J8W/PVNY&U'7.S=-:B\4<_%#3P3%P=
M?'_<E8(_*PV0UM&S,;T6WA)7+8#Y%0N#[5N@P0NNL2ZZF['*3DY6IMS=S6Z_
M8GD=E]8>(-M3\1_'CQMH[-VSHW/2R^F4<[FE-JU6$KZI:"WQN2'/L1XU6.LM
MZ'6R(XQ5YY-=I%^["$!R0C ->OF*X,-S;=\\I;<%=Q\S4KTC7H[MT^7K_M1J
MULSZQ"#GCT=6X?$85"[&FH9=K['V!O[1^U QJ_@!3&.&%*KKVM3U,D2K6;1V
M S:$P55VY2GMD* W#&H4K)RB47DDU[E";)]$?L83MMK>-*:[\0&+3%/S06O(
M=$\0MD>_5#09U-L^#HWQ>:.W)=6=1."\O.RUL3WELM5J"4]K$F8(X[A(N).6
MLJ< BCLDY^&4[WXG%BK-C-?T_P!"#Y#+$?CH&;#.H]EJR5HO5NG744!W$Q:D
M[UJ9U7Y+;&WJ-<]4%27B[N)A.B2,#@"M2+(@OH\]&W*M*M==R@2:"^)%UU)R
MG-Q-VVV1*4G;\ISN-AD?T6WD*C;?\W]N%$_PTW&#\Q%3:,=+0.SS>TIM5:I8
M"N]^W@"L!9X-=7I"*+NA5[H;!\B+-1=7R.>^EL-<711E<ZPNTA'%9"E--2MV
MW>S;4.5^6^GI*-"^3'DCJS6FN_'(/HNY,"WIIG<S:3W9L]_UW%5QT3ME"VLO
M 5R!%TMMW,SDXV5<B",WR>:_TKP24B5&LS233T*HD+2=L[FK%.]-8K$B?E)X
MD^3WF0)C#.FS]>:%IZM<P.QM*P:RBFVQ3:6JSI"ZK'X=S#MGH8@/G71]GM+6
M0U>87 ]JQ&-IJKY;"A'L0.K"032V3GY2MV6[5?OEF]D/ S1+_P",'AEXS>/&
MTFX.\OVF=.)6O&1C78.H%V:TLB81U<4O9Y!U^W? +="&HM!314(,.GA@BJ;8
M*D1L@0ZX$33B;5S;9MKP9' ' ' ' *.WQ_X'UU_/CIO_ %[$\ O'@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&J?G?\ [Q[S*_R4
M_(?]43?P57K>N9KSZ&C\E?X(?Y.:'_[G)P:I/'%O.F7!@< < UI\T/\ >=^6
M'^33O;]5S3P57K>N9LA7_P!SP?\ ,Q?_ (F/!#[< < < < < < < YY^E;_)
M\^2GZ,K'ZPT_FZ/QP[R.Y[GR'HI/R?/C7^C+/^L-PXI/'%O"N6Y<CH9S!1P#
M4=#W+I]!8]U+[UM;6R6>QW*PWNPC8\JZX7ZI75U3EIW.QI@I3N=5;<7^R5K'
M</JIX_[N+//'^'@LF[DRR?PFO&[\X/2'VKH?[?X$G@^#'X37C=^<'I#[5T/]
MO\"3P?!C\)KQN_.#TA]JZ'^W^!)X/@Q^$UXW?G!Z0^U=#_;_  )/!\&/PFO&
M[\X/2'VKH?[?X$G@^#'X37C=^<'I#[5T/]O\"3P?!C\)KQN_.#TA]JZ'^W^!
M)X/@Q^$UXW?G!Z0^U=#_ &_P)/!\&/PFO&[\X/2'VKH?[?X$G@^#'X37C=^<
M'I#[5T/]O\"3P?!C\)KQN_.#TA]JZ'^W^!)X/@Q^$UXW?G!Z0^U=#_;_  )/
M!\&/PFO&[\X/2'VKH?[?X$G@^#'X37C=^<'I#[5T/]O\"3P?!C\)KQN_.#TA
M]JZ'^W^!)X/@Q^$UXW?G!Z0^U=#_ &_P)/!\&/PFO&[\X/2'VKH?[?X$G@^#
M'X37C=^<'I#[5T/]O\"3P?!C\)KQN_.#TA]JZ'^W^!)X/@Q^$UXW?G!Z0^U=
M#_;_  )/!\&/PFO&[\X/2'VKH?[?X$G@^#'X37C=^<'I#[5T/]O\"3P?!C\)
MKQN_.#TA]JZ'^W^!)X/@Q^$UXW?G!Z0^U=#_ &_P)/!\&/PFO&[\X/2'VKH?
M[?X$G@^#'X37C=^<'I#[5T/]O\"3P?!C\)KQN_.#TA]JZ'^W^!)X/@Q^$UXW
M?G!Z0^U=#_;_  )/!\&/PFO&[\X/2'VKH?[?X$G@^#*RV9NC3K[WK1;1ML:T
M<V*QNG5%NN!4WM68C4]0:X#[Y&U"+#E;EZ6O0HUY[MV;"#*.K4@FLSY1PQYY
MXA)X/@;><$' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M2R!IECH61+%N.W2GPMB=B[S WXH;HA-CGB@)H&CC$$-S/XM-LW%0P8\AFNT
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M7Y@(#U?71X[=9&+6Z<.+6" \"CGRU^24D&CJ3=^RT5L=3L4QZ8F55\)]?D9
MWX0: -CB F4.T4!AA2W<A&J8UV9:\9E)\AEM06=GK)/.2_//:H%:VOT@C0L9
MR^] YE9H7QY"'NP3COBZSY>4KCTLGA1X_,K#LMPL+14>X;3=4'8AYF%,9:L1
M%M^M Q8&J$U6":Q9$K\$=-C;I30:H-[!L]YU<[S&-*66<Q):";NREZSY[;S9
MA=!4UA?!K8[.W+0 "!P6E+?LR7;\M494AI02WKDO^RV[DL<.,EJU+_LEB?*2
M;/\ NL^^"&9X X!K&W?[\?0/^3?Y9?K)\-N"['O7)FE33)Y?*NWO,C>J5D>(
MJ&J61OJ)R8;<MP/M/80OOQET+=70BMXY0!:*C67$W8I%P?;39JQNCV2_F1[#
MK."EA.=EOCA;+/7B]O#+B?N7RI\D.RH,7E1H/.OS#ML]$".*?IO9BRY;8"Q)
M&MBJ;L,&M7&L?(I(2JU,&TD78+<$9;Q[VQ(6-C*:_P!II8GW1$LV3V9RWV;N
M)7*?LCS=),PX0-.1W3TVP@<: A.NN]O#!"B-9O18F']-8&Q\AV50E>==X>3X
M-B1&<9LWY82V'?,L2G*BMA#4B^M"N5OTM^]NPPX7DZ&>8_ER\-VH"J_J<+K;
M6^WCV9E7%;<0-C"VR95'[*4]<E$1FN4.Y?DH_6P-%WVBO97@,6=T.Y(TL@K(
M-KS8$AH2SGM6?7YHW.\[_P#>/>97^2GY#_JB;^ KUO7,T[]%;JG5VW_1+> :
MYMK6R#M%>&Z*UVP#@6Q4Y==@U ]5#DA]4W2%LHXG2JEZU H3HP$H(([D-,C?
MK1S8PW+&$@U2.4<4L3JT!  E4()6E@*)7%P .IAP2^!'4PX0*)'P85: L2*'
MPUZ X=1JQ1UJ=*G!#6K01X0PQ81X8X]#!EN . . . . . . . . . . <\_2
MM_D^?)3]&5C]8:?S='XX=Y'<]SY#T4GY/GQK_1EG_6&X<4GCBWA7+<N1T,Y@
MHX X X X X X X X X X!J]Y+>1,&GT)SSU]$(V+NL)639@^H1&!EP=,Z;H^
MJJ)&UW]<Z_JG-ED%)=R:,& ]: +UN?$..N20=]=]=9XBJUX=>1)?&K;5G=&J
MJ#B4( KC%78&U6:J0)6?$;I>9%1C(@R:T73=G4ASTNG0^52. G3.TH.K4G>!
M41E:!$1=VR#4NOSYE^<$' ' -,?*7S)1]$ZNV690[ZCMK<ZF/.T5W3P=Q$=E
MIG$6KLC9G7>?8)[U]*65]=4F9L;RQ&CU=JK:T8A!CS+-*& DQ4INVQ;=W5QM
M,D'Y&M,46B:*&O,R+ $]-!7SRDKP2EQ54A)#!GEWWEG%%G8RCCRR[[RRPQZ[
MR[^'X>"$HX X X!H/Y0>7I?4VN\=T:@SU1M'4RC9OUMD'Z;&=:.\3]8FN04T
M> KK\>;5]95<PI(\>;=Q;5,C-=ZQ@$ANW&M"&8K3$N K>NOJ;\==_#_#U_#U
MW_#UWU_P\ < < \!0H,!C")LV1H!PP>A;*%BQ2W7'C!8P?7DMWR)&_;DAJT:
M%&K#+9MV[,L5>M7BDFFDPCPRRZ TGV-Y//2]L[3M=#I:AV!J?;STB(:3 O.=
MQDV=LV$X1MQ;6V*DXKF-Q8$HOCZOX1-SG9,>\X3PP>=H8F%0OVKU6@5*<]DE
M/++CL\MEJWGX(. . 1]I;55'!W&9U9E]/6Q^5;&^P-)D<O@Z.5RU#1IXW"Q:
MS4H5LK5VQ7IUNIK&'<]J>&O%\:67##(#7Q7WVUL7E,TZ.F0*8G7@S2P'::9L
MOMJ$&;6QLRK%"'NV0X0'/?@#J5#&Q'3H7S5^ \<*URL^ $< K!3#*!M'P!P!
MP"EO(G;%G1^F'O9P\'"S&5X?1K+B]:OYB:!EK9#0U54QQ0M%4OS"0]ID-BHC
M!2 >0L#A>5N[!0NS085901'_ ![VLX[#SW.G[&&+-+8.A-O=:D;"*7D4Q4&:
M<EJC56ZUYB 4#DMDP'BL)6XEB@6#D"!7.@QCC4=4K?']T[&8KV9KZ>QL3P0<
M < J3?#^V:MT_L'82,@R;-:E);OF0Z9TPB52J3GJX?'DL%F(S)Z@4 $5_7&6
M"S1IFCW0:A>P6UQC/YC@=\56M+KKAO1F]3N%K8>K-:/]ZI7'WGG7Z:X7*%3*
M3.K2M,RZ--6*E;.;O*;.O6FNYPPY2]]R91X8]Y]]Y=]]\$=C:P+ X X X!JG
MY;;CV5HW7MK8"54U=67UH,R'V]BVD788JF=P; /K)&MU-94ZTS&Q.^V6<G L
M+4@WVZ<>0CBJT5=R/& B[=%77OE<;%J1<DP*BP>,K]Q3,&UX*7*JI&>&T06B
M1(;6NWE^_9K==5[%P-:FE'6IZ_74,L];.2+KK#+'@A(> . . :7^4'D-LS0#
M-K0I34T\AJ=F?].:\-EBLCEF>N&]L;3'H!>3$R("3(FK 6MUTC6=\VK9YJ(-
ML0K9J:R!9 62Z/(WA4I^KX+W?"^3-T."#@#@#@&L;=_OQ] _Y-_EE^LGPVX+
ML>]<F;.<$' ' ' -4_.__>/>97^2GY#_ *HF_@JO6]<S7GT-'Y*_P0_R<T/_
M -SDX-4GCBWG3+@P. . . . . . . . . . . <\_2M_D^?)3]&5C]8:?S='
MXX=Y'<]SY#T4GY/GQK_1EG_6&X<4GCBWA7+<N1T,Y@HX X X X X X X X X
M X!IWYKFM&ZOT0\[?W&';*@4*3U70NN&I>H0VW1A0CMY"$H%U>9*Y(#>QA";
M!NJQ>^/N%Y MT71NTBX<\+GM@R(JOX\K<=A?&IM3*FFE6944\C-N,BPL;@Q'
MV4O:/M#6X-Y:R<9F=B,W._66R10E:DRP@KQ4Q(@?%1! !HD +%BZ8EY9G '
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M<.\CN>Y\AZ*3\GSXU_HRS_K#<.*3QQ;PKEN7(Z&<P4< < < < < < < < <
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M@#HW+X?9?&'QXA_\GM&JE"S\'_+ZL14^'_T?!SZ4'8NI+^TK=:C_ +BHJ/\
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M]^FCB7DJ%0_[QP4G;_1$-E'5J_2/%T=!!"_-UAQ<85[&&GWS6Z^'JJM3R?\
MD[G)QP_^GO&.E/\ #_R=9]?\O7.R#L52/^TTA!#E!5XH_6*FH^7D<-)^D2B7
M]EHJDBSI*W#1^D-!2<S1IIW.6D](1J G6##H98?#7R0H81SRV;.'<=K=WBK8
MRSR[CRJY=YXY4\,<?@[QZ[ZSR^'KX?@^#</9&K0UNCJU)6Z>.&.K4U,XH(*.
MC<Z*DH*-0K6[Q2?>MN<W8LS$7;JN1Z/IZW15&K4<5'7*K5X8*2.EI87#3T-<
MI'$W"Z%SA=7A2E)2B<]A&/(?:S5+O7T>/4<(P=V%\@=E=TH(()+'L^7X%GDV
M-]5)-;M6^[/JJUB2/UF>67>>?74O?>7?]_H?9?1M''4(8H:S%^L4L4-+!24\
M+<*54IZ;545%1T:FJ2CAG$K&E9),X(>VNF*:BTO%!%4X?U6K04E!'15:.%1-
MZ2J57UG!3TM*Y145+&U#%:FU.U&V]C:K[8^'K(_)'CW_ .+7I#H/@_Y,XJ>,
MG_KS[[_\_/L0=F]"P75*&)XQTU8CGY14KA]#\_2=L.T=+?I&*!84=!5:/_>@
MH%%_O&$G=6^S\/K68YWUW_?QC)6X<.__ #=X0RQX=]?^;X/@YUP:(T71^'1]
M3LN<57HHWQCAB?J<%)I_3=+X]+:0EA#6J:C7^S1QPKT,)8(D+?P^U7[EGX?[
M_M%J>;X?^7UF>7.R"@H**7=T-%1RNU*.""6[52/GTE:K--/OJS3TL[^\IJ2.
M>_6B9C+6/QZUC#U?<WQH)<?4]2>J[E^-'EUZOJ7^#U?>?P_%ZD^'KXGP_&_X
M.:I5.CI$H==N"-:BBU-><+6KK_LZUVM^S.>PS0O5IJ*)QJC4-+1OO'!WBHY1
MIZ[HY/74/BU)/6E*5I]^;/(_RE__ )1P7\FAFP/%K'0!3>P^C*G[/R9<=/7=
M@5*DMO RG=#>SG27+'#G8QA[M]4>[_PR=1]V.H/@Q[DY^)[6Q5V&EJ7ZI%6H
M4Z.GU_U=TJ3>M1ZNOW7G*><MI_4/T>PZ,BH-*?:$-1BB[VJ]U^N*KMRU*;6[
MOOK93EK:MDY3V'1CT$E[;9#P&"6-UW-BWGCO:FR<)I]I6&:RU]C,;@WW?C)*
MV9YE_8,<>Y/8\<LO9^L>\_4=?!\;GU^S3K#T7 ZRZ9TO?4TW3N-TDM:R?>?>
MEALP/SO;=52'3M(JDJNJ#]6JTE551*BUM5ZTNZ^YK?BVXG93GWS\B?&QC\>/
M'KU?K?@FK9?%ZS]7\'Q+$6?K/C?P?#ZGXOK>\/\ YKUAZO\ A^/\'/.D6M"E
MJ:_]91.2BU9:M+!%KSVZDM=P_MJ'4MUI'I11:L3>OW?]730ZVKKSUJ&DAU);
M.\GW>M^QK:_[)]N>AYC@#@#@'QEQ^-)6[]7\?XDV67QOC_$]3\->QAZSO'_Y
MK\/Q_5?$_A^#N7J3_P"9_#UB-3BHGJZVK&W/6EJ?U=)#K-?M3GJ:O^OK?LGI
M1Q2AIEKZNM1J'5U=;O/ZZBBU)_L2U>\UMO=ZG[9]N;/,< < < UV9\?_ (U^
ME,_5]_!\P'DOCZWX_P#!U\.P?%3OU?J_A_A[[^#XWQ_@_@ZQ^+\/\/.*-?Z1
MJT6K_P!RKJU]:Z=/H]ZNKMG*>MLDUM/IT;_T/78==?\ 6>C'W>I:Y572RU]>
M5B4]74G;.<ONFQ/.T^8. . . <VJO^&WI_?_ *7UX_\ ZC_-?G\M[6_];Q?^
MGH.41_<>P?\ ]O4'_K:W_P 5$=$_0T?DK_!#_)S0_P#W.3GYD_94GCBWG3+@
MP. . . . . . . . . . . <\_2M_D^?)3]&5C]8:?S='XX=Y'<]SY#T4GY/
MGQK_ $99_P!8;AQ2>.+>%<MRY'0SF"C@#@#@#@#@#@#@#@#@#@','TR7Y.S=
M?Z9>-/\ ]=1I/@JO\GR9T^X(. . . 8^[%U)9$9]UL)_4$))>I<Y_4Y4N^Q1
M.'VF*/X>O:L\^INZ?<'?P_%CMR6O@^&M\/0&0X X!\);5:#_ .7L00_!_?\
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MBU&_V$M7O-;:X%!^V??GH>0X X X!KLSX_\ QL-*9^KZ_B \E\?6_'_NNO\
MX0?%3OU?J_\ AZ[^#XWQ_P#@[Z^+_P /.&-?Z2JSU5_]#75KZUJG3Z/>KJX.
M4];)+:?3HG_H:NPZ[E]IZ,?=ZMC_ .BZ76OK[&IN%0[4V_V38GG<?,' ' '
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M^ GY['BC_6!U7]Z>/M;1?[QJ/\50?SC^C^G?W+I7_#ZW_E#\8GX"?GL>*/\
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M "A^,3\!/SV/%'^L#JO[T\?:VB_WC4?XJ@_G']']._N72O\ A];_ ,H?C$_
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M=W7.W,4HU+-&!T>*514 Y4AUBX6RL&+$4,\8_.E#WE;LU\<@]#FW\]'FU_\
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M3Y\:_P!&6?\ 6&X<4GCBWA7+<N1T,Y@HX X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MP.+==;RJ*4K[%$K\85#9YV\#5B#PC/K7E#IY4S9]4M>J-<ZQJZWU[NY?V9H
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M[Y2#Q=*IU"(2'*<[\FKUP..* U+KJXV@X(. . . . . . . . . . . . .
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MIL9-?N4Y(&K^MK4KLI^V'C4?*W;VN"I;7C$*N&B#5Y+3 ]8VF\"_GS[(N/\
MZ5G?.E=HT:!"&]W!TMZ6\:\=<-"?UUA3#) &^ODB>1-*D%"(0DO3+9"FN+X[
MROW+R5W_ ++TVOL%<K#2=636NS"S0JZG5-P(#1X_.E4-K\CCJ!T(2;$-CVW9
M"<1)%0)8[.OK5CN:I*0"*2S 7P[MA)3RFK]JMM674R61^:6\E/9*/K8/KRZV
M9E]A;WJGE,DFM,QPNO4-T>6RZBE4_9S+N:V7CCRAU(@US%+K3S&C*U5O71U9
MJ6Z3PC+X )+'#VG9*V_%7&V'A'O7:V_M=&F[:E- K7(B(",7TC4Y@E@=F03P
M19A56]7L/^S+ %H56&X0'VJY!D'&O99*M0\G+!<?;CO".6?GZ>ANCP0< < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < U*\</[Z5_DE>-7_ %[$X*[WO?,VUX(. . . . 4UI3_
M 'O>I/YFD/\ U(%<%=[WOF9S37\4&J?YMD;_ %7%\$+)X X!SS]*W^3Y\E/T
M96/UAI_-T?CAWD=SW/D/12?D^?&O]&6?]8;AQ2>.+>%<MRY'0SF"C@%5ZP_W
M3L_^=1A_T4O\ KJ_Y::?#;>VCI]A(DEJYI_5Q#;+H]'H!]#7%0 M#UP]L$9"
MPY%,[N)_6*D^ZM<WNO?#T1@U8VLBWAY8K/:-5 82ZZZL(0Z^D \7$NA5OY[#
M@8<""WM-B']KM2>S4S[U#46KK4(*E[O5 ,JD9*K>N7!EAN( @M@05J,5@M47
M;$!:463Y+CU=>6=M?R)7-4%]/+EI4:VQDW><O 4D*NDM;B.Y+8P-@>(86#6Q
M=@(:Q;O1CL\IZ"V .FV\_#6)W5U>+# AV\,!*?7P8K\,GQ:^5UE"^?37ORPI
MMV:)9 >^X_;H6R!WLZSN!\NOB>J]:,V-6^0)BSU+W2"NEP2KE;-,V;#T;PDG
M@5>Q^D'T&M2L] A<*P&DHCJ;%MHSXC\QH-;VUY,EO%^@UV6T5?+*&=->:U\V
MPL8R,WD9&@:7LUJE >P("1HLO?T4V7J0\B=6UE'73X*-_*A/V<^B]=+Q]>[I
MS4:IXC>,B[61W(E=&2"*ZZ57RXIHK3QY&0)2A;&WA.%ZI;KP!)VY6^15]WS@
MTF1Z%U-42G=\LA<@7JUE36/2S2OUAB\JKCL?:RIW:3/K5&$*(M7=D(QV=(ME
M> M4?T?->P,?*@3U9"6-G76YWFTBL=R9UH QYB"(#,Z''%\@9>P"ME0^1"I%
M:[&D;:N:8UJU=I=R^SV;*^P' L\L>4HPL0I90VY1#/< \MZE4)4K@Z_7BMT;
M]6Q2NU9\>LX;-2U%G!9KS8=_P9Q30R9QR8]_P989=]=_W^ ><.'$KP@4  C:
M(8&#&T0X4.+JPT1HH2,JQ4APT=2K81UZ=&C3@AJU*L$<<->O%'%%ACAACCT!
MDN . . . . . . . . . . . 5"[;D"(FRM.:S*+;E=N[K8F%47F@6-&R)P,
M\ UX\[.Z',Q.^9'WX[!A9URV=C(U\2Q207*-; Y@%JDQURT$K\C.%ME 0VT$
M?4UJL5S9']-V,\!;D%>IF%KB=8%=<"#\!*S)>BNPD+5G9Z_F(AK#KE>Q!4+Y
M7+="2O3BOAGUM^#7T9YLZC(@=./-N:13USMC02OY"WFUVOCPGS>+.RC.M%S4
M"XW4:4QJK@W;/8MB3@UT?1+V*5@DEM=6F1(RUZ>%L63]9?D9R'S1\<RX7(VD
M[$$[(CA<=))=V@C6*A(D/O;ZW$OZ,3B%RM?M"\,!8I_/2#'/N*:8DL6%YG#7
M!F;6'E79 EUN4^1M1P0< TE4_/S0C2>/+TDK0IVE;>^Y]",MMVI@%T4#(Z-6
M=L-33LH@1L,LE>/3Q6AI38=1;=X\I?:#*^4$F!82X#9(P@LGZ)\7(LRYY<^-
MP\>!)7=MK5:)E.65L34DQ*=&<CE,JJ K(\BO^[^SH26(R^(8OO,V.'0Y7GM(
MK8292MZ[B2"3PZO]C$-OFAXX)<]2L7V'%/:LOP;7$U00$8"]Z@P,0UL*@K5T
M?1&2W_DT9KH[5&(:JE:T +VPA*H+OW)Z%["L$GUUU>915\M-!,R&+V%8V.IJ
MX0AA![1BQLRY#F'L3:P(;I[K%+XTN3!Q]PZG$%M@6;=8M:'UUD45(37,,!9#
M&L$GUOES+>1-A)FS0/RE16"FPA\2! 18GK8V*]@>7%6.ZI,06&WH:I,.6H3]
M=86Q92G3OP=9Q225\8YHL\Q"9\ < < < A)78J>'9A*99*36FDSEGW6!!!!M
MC(5*T<HR"4F=A7AQ3Y,A(930K&<\Q]B@L/M];N6_AC)UWP#W.3JJZ\7;C:['
M**VM#K JL0-DL\XA]&0T7H@AV=R?'#/&K7F*$J5>6Y/\2I3PF[M79Z]2&>>,
M+S]4G-3(8Y956(1E\2=IK]X2WH*TWK$DU:7FW+&"SG#-G77C5*R/*6L(\JM6
M:/KO.;U<D6>8&-O;.UN-'XEB#^F4Q>>(?/$C89PL=+N-A.1+ *;JUE=ZA]07
M8YX00Z?X_J;9:3&A!GG9^&/H#)5G-4M!NF+!@%Q!/4RV>R=VW&.JX5HNHL\[
M,N9#NMZFMW%8K6([$O6$,M2U4MQ9YUK=>64#VS, F!@%J\MKXILT&.L VIU#
M/GC8$K=U<'F;7M6$652+V6VV 8L89IXY['5WN2M%-'6MYP 80!L)490AAD%W
MKN( %8*0$#!8"P+P_+$-UGD2OCK+ +&1F@T'44WQ3P;*^%L>IFZJWYNX9.L0
M,$$W1K-B)J8@,S87;KR #LJO\44=AJ$QK !)-02'LE9&0C:!LFL!B[%36"5N
MFRS Q1(KB)]AHVIX@)*S.Z\H6%^F:F*>V-)7L,#I!UQC9KER[A5FNSY25%H2
M7L4:%2I!+8O%R$=430BQZRN78/CQ_& RU<^"M]VNJIH39[HR78;W5<C3F[IS
M#INZY"*UU'-E[/)0GQR@NQS?$RJS8]QS]89]=X\ \G38M=">CDYH>/%^S>V2
M6RT^(;&M6^&IUW)=B*^QST/B97Z.,F%V*#.+*Y5QDQQRL1=9@?6=F6ZMG.E9
M8 =>Y%=&#9*DY:A#9C(F\<LPU#."2QC+A=+X89Y#*N6'4]_''+*K'+UCWWT!
MBJ;\ID*B=>IE.YZC\3L!U2;JB1CZ*$*H-@8YX.\):D<M'K .K'+7K2&%6'+N
MGU7PDRLV:L4X'].; 2UP5&;+L8R 7*RT4Z.W!-V0PR:"!Z-9@!_$'8VY>B$)
MR3NB1A[CZ]T]P7;!7NG5H79ZX'P6=CICB:9%Y<-=$2ZE8RK'*WL!2GA!)&8.
MKT^=&Y?I5:1JK58%AB W+H6P0ITC8,H)MSPD*5BO@!\26SD<.[4==E#GL+82
M%PF*=*P-+QCY:=FLUWJV&3%W0^3D!"R/17(E6#V"T1>P,6#A*&CG1'6;$8&1
MNO:;0HX$[#,&[H2#Z)C"S5O0WH^PA&_7&U3W?L.5C+%?]KM0XV3V6/0>C!ZV
MY=NUZ<$\\8'Y6GY+<A\Q969@YX3#)0C][#;L5@78]Z5*=P=+0(X]^Q$:MR._
M!#!<'SV:F=_&T,ZF]Y4;U6N!(AY$>6I5B0J]3)CKL6,].^/LPW*5N#/_ +V:
MM:K9R03Q9?!W\62*3+#O_@[[X![. . . . :)>/6QTJJ']_8GJ=VAKSP_P!
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MO?Q&U^6/44ZC%L!1IN>MR0)B&[BV.JGO1P;#W#=VZV6J['&NP:FQW0P5]?1
M\T?.AAM36L=J%ZS,P=*0T)*7E9OFE+A;YJS:;C^6&RMAK_BOY5-*HOM^LFW7
M^O7R1(:BY5)BP,6!8>S-1=5JXL'GVT&#=98^OALMR^'8!^&/=NTJ]=P]Q=C*
M->1/D%O 2N%<]0D=5;C4]7^/ES>C!>&O#/Y&E=JF(]A;0%E-8:UW0(DU<$G,
M1!D;.L-(ET&_F+9):BM<"34L\CM(64L<+;)76N_$I-T\J?)/8T5L\HOR2C)6
MT]::1VCXYJ424Q46YK6F;S*OJX1UZ:L7<:>(TS>A9]6L^W$VHL_ "$O]</WV
MO933E#@LE=)V3FYY7<4Y6VEP2^7GDY3#;")RI^MB/>E]>>0Q]QZHHFQ(LGY@
MU1OS<&C%2ZJ4HW<K:2E@@.0@NVFJC/WLT[$!Z+*:[(2G+#6\4$E9?:Y<LLWZ
M'I3_ #,V>T[%5==RO'CR.7#+D\+ZGY"9J+?8U9Y)YKV>A,!"MHL3#MS.,<U3
MDMMNJF0LY;"V7%;.Z>9+Z^")!LC\J8$E;8]V&^RW9LVE>B?-_P C72QJ1_I
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M6&G\W1^.'>1W/<^0]%)^3Y\:_P!&6?\ 6&X<4GCBWA7+<N1T,Y@HX!5>L/\
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M8]&S3A#:T6IK%;4Y(:E[DQ#;??-M2]^1%#IDO2MQ<98>,:B68KQV.EQK#R[
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M5A#%F,6*#M*O?,".%J3>WZ?*ZF;^\$' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M'X?@DBEPZSCSZ^'KKOX,L,NLNOAZZ[^#O^'KK@A]> . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . >,C_X/O?\ T'9_^HY\ @6FOXH-4_S;(W^JXO@%D\ <
M YY^E;_)\^2GZ,K'ZPT_FZ/QP[R.Y[GR'HI/R?/C7^C+/^L-PXI/'%O"N6Y<
MCH9S!1P"J]8?[IV?_.HP_P"BE_@%J< < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < \9'_P?>_^@[/_ -1S
MX! M-?Q0:I_FV1O]5Q? +)X X!SS]*W^3Y\E/T96/UAI_-T?CAWD=SW/D/12
M?D^?&O\ 1EG_ %AN'%)XXMX5RW+D=#.8*. 57K#_ '3L_P#G48?]%+_ +4X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M)N^'][@C8WJVRW6X-VY;)XW&^WCQYX[TWMMS7VH[7BTJI5TJE.VU=FLMC?\
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MG[$++FS';9K^'LZWVBFKMM@;/-EN\V8#6JAZ7Y&B+22:&-S;DLX].Q+:0>Y
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M<S[YKMQALD\DV#5\*=JRHGZ#3UY/23:L'=R3B+>GIZVAVXK+,>+S'"B1JT,
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M7'7FFEP1[57H]$"J,H5JW=NUWEU!!UGD(_ASSZPDD[^#KOJ.&*:>3O"&&63
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M_P#Q\/\ 2X?]K@#VBO\ \?#_ $N'_:X ]HK_ /'P_P!+A_VN /:*_P#Q\/\
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M+/E@;.^T5_\ CX?Z7#_M<$'M%?\ X^'^EP_[7 'M%?\ X^'^EP_[7 'M%?\
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M?89Z&)/H TWZ6$XI1:KX8)==7F, -_A$Q7MK4Z@C28^'2SW2UGL(TR(JTJK
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M#]9[AP0M/@#@'//TK?Y/GR4_1E8_6&G\W1^.'>1W/<^0]%)^3Y\:_P!&6?\
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MU>9(QY$L$TFDI$[5[ 0QVT-,'Y@9V"Y@Q!P0=OUPLV;,TR74=E>A#[K?IFR
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M\69;+$K7CU+=(@)L?[F4/<FF'2=?P9UN^N 9L%0V6K!:JVL:<T>N+M*.6&D
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M5*L^/0>MA[1C1*Q'*]BSEACCE9(]%X8R$Q6?N0G:L]926K<WQY.L@)%\VB5
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MI_-T?CAWD=SW/D/12?D^?&O]&6?]8;AQ2>.+>%<MRY'0SF"C@%6JO\9VU_\
MF4'_ $*0X!4#1X.>+3C5-0GM2AI[S(<W ?86:I>-#'8];WPN[&4]FTS+P-)5
M&TH",K>U&X..7+QF<"L4^US!7'!^TM0R!BS?7'V,Z[^)&BMA%FPXR+)G,H]W
M'2VX6A+P[K_;#%L/5"1I5S%$8PC!0AE!'=?ZV0Q]D)C'@-C)JXUBK5X3WM)"
MP$WPW8S)CL;0^N-HU5&)BIL0TB@D9BB:SHSNYZZ<EZS;#6%XE%1;D4\OL.8X
MP$M2CS(BV1LBBN.%.U>I37Q@NW2$(-#XA:4AD?<<JNPK@[9N8FT[ 2VY-N&U
MTV5"T$D9189PAEUOC\&CNEKQ5BO,T4.!TIE3N3DK]NP8+RWA9M2RR7.5M^TR
MRKXJZ'2'XYLU418P;BQ[9/[Q,7Z9UDZHV=H-6O.]7,K1&"E+R J4IU2DLXE1
M] ;5%7F"^4;[-&1K*$#-D2<Y96$6\K?$Q+\IU2,4;LQAV:@-J@!+!;C9"0O%
M5GV[I3<34JF *VY(A"^*<#NA$*D0O"6A>:!=*I9Q7V(7C?)17Q4Y=9->Y$ G
M@=J29/6@.QB;L['1:D/0V8X&V#L_7PU]1%]N8&])U\XKJ\_R=N2/K>5DOKR!
M4V(8>FH6JYVA1EQ89S[9?80GUUUP1N]P0< < < < < < < < < < < < < <
M < J'8&CT79CGJU]:9'+M@TVT9N:%T!V&]*P6@R2A#BS8(E5Q;8!8!ERM++.
MQKEN!C'%*UH$=*BYX<ZER6/L/<_.U=&:_P!R2K=QNQ;1YE1[.8+K,@["?-8-
M@VBT4H!S.'B:-=L2R=D!L%2I0[*")[\M"6^*!FXH(3H &3' 0A:\6=1K5)D
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M;>BY@L[F -R,?UA4D;LVMWB,PVJ5_.MTV6/DW:7H0:M7!BSZX?![L/%#3L,
M*.J,-4["P-*TP%^ ]>[LC2%U]RV6(9L(YNYJ-EH2V^R8O))B]3M2 *;,UAHH
MY@[,:HW0F^MTN75A^,_%C7O89E7XS+K"'=3.#<Y#O>PNS1:7^4^/82SZ9H7@
M5NA8.'[(RK4*BHZL*7C1PPP&*@VU6I6ZH3?L2\7H]46M;K^KU*2X%7%QN3&R
MA[3+*7L^L4MC MB94I)K,T<F6!.X%['Y3Y2994X;?<^$<_<&,,@A[W?2Z0^P
MMV1BN0B,.2L42[C)%>[(F0:V='1B3XM-Q9(CPA-KL ^*.$]@N"AV)F>. D2Q
MLE:M2] !^5?3BVKN-E[C)L1=@M4+E:7,O<'^[\2)D:E"F=B@%BA0JA5,M5?7
MBE(6QJP0AZMNA?M+XD',R,^1D#,,NJ=>-HV4,=4 %P3;;1CR4&]B!W5$XT";
M56[4+'JG=7*N9M>T4:6<\Q".>:?V2MZR3OU$7Q F5R?\9-=L<Q3._;9L:U^X
MQVZ(^*^,SJ+/;NTT7A^Q5\[@:W>%6'%Q&CV:R:ZN3L:L:HT[VNC*7-5@RC%G
MUZ=? L^,&L+0HJ#SQ8XA!7*6Y[%6.25LQIZ='):[E:0Y*&# P.8NE:Y0KT[D
M)'U @BN@CH6H.-PW[Y$2?7J2#7N@M::M:#+4D!*X6T:$C0\U2*@$SPJU!@=9
M 184S.8GMMZKSBDU:@L"K+':!=V!>)* 5 4M7KMH)V2+HX X X X!J5XX?WT
MK_)*\:O^O8G!7>][YFVO!!P!P!P!P"IM"?Q%Z6_FFUS_ *GAN"N][WS/MIK_
M  &_Z9[0_6>X<$+3X X!SS]*W^3Y\E/T96/UAI_-T?CAWD=SW/D/12?D^?&O
M]&6?]8;AQ2>.+>%<MRY'0SF"C@%6JO\ &=M?_F4'_0I#@'+W9=_SE6MO>16_
M]?(#=9".>O\ R6TIJ%:A,&FDD .:=U?=.^.VPRFEKBW&MT0S+NK7&Y^@K-2-
M7[^P0_D?J84;IYBA N2B-6;7*[SMMX+RL>-OAWX$\U,R>P5ZMLWR.*A%5?\
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M3:&:QJXO\L3J[L&S-U!HM[EH(9>GI-EV&BT&SOM_)8CV.VS#5H; MV([$;:
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M_P '?P?\G?\ Y. . . . . :E>.']]*_R2O&K_KV)P5WO>^9MKP0< < < <
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M-;PA)9=89=]5N^L>_@ E_ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' *LTU_@-_TSVA^L]PX!:? ' .>?I6_R
M?/DI^C*Q^L-/YNC\<.\CN>Y\AZ*3\GSXU_HRS_K#<.*3QQ;PKEN7(Z&<P4<
MJU5_C.VO_P R@_Z%(< XZ;&]'-HMC\AAF\^O*>9&=QGD=M_:+_47U+NM.ZI#
M[1DB!:K*7<V?+L<P:C<)"[,B;+AK6YQW;0ZB.E+"!DFM5QK6LE+"_%.?K<UD
ML"OM:^C?UJ@5]<%Y_)W019WU0Z>(EY3FH^,$H'7=]'\2$+;FMA$#:A1;DOWB
MVUMC =S'RCGLP:X@QV1Y8U_[(B^ZEGNC>%<4YWVSVSOEBKK/KM+4\3_"'3OB
MS=L6ZF\])[$N1O&JRE)I>]4;0;76PD:N;]MN(NF0E?/(QU006U:U_;)7-:VQ
MJ_76N/DX2G:S$Z@<Z;X!BP(XIRV);+,E@L$==OGOU/\ RZ!_TLW]AP9'SWZG
M_ET#_I9O[#@#Y[]3_P N@?\ 2S?V' 'SWZG_ )= _P"EF_L. /GOU/\ RZ!_
MTLW]AP!\]^I_Y= _Z6;^PX ^>_4_\N@?]+-_8< ?/?J?^70/^EF_L. /GOU/
M_+H'_2S?V' 'SWZG_ET#_I9O[#@#Y[]3_P N@?\ 2S?V' 'SWZG_ )= _P"E
MF_L. /GOU/\ RZ!_TLW]AP!\]^I_Y= _Z6;^PX ^>_4_\N@?]+-_8< ?/?J?
M^70/^EF_L. /GOU/_+H'_2S?V' 'SWZG_ET#_I9O[#@#Y[]3_P N@?\ 2S?V
M' 'SWZG_ )= _P"EF_L. /GOU/\ RZ!_TLW]AP!\]^I_Y= _Z6;^PX ^>_4_
M\N@?]+-_8< ?/?J?^70/^EF_L. /GOU/_+H'_2S?V' 'SWZG_ET#_I9O[#@#
MY[]3_P N@?\ 2S?V' 'SWZG_ )= _P"EF_L. /GOU/\ RZ!_TLW]AP!\]^I_
MY= _Z6;^PX ^>_4_\N@?]+-_8< ?/?J?^70/^EF_L. /GOU/_+H'_2S?V' '
MSWZG_ET#_I9O[#@#Y[]3_P N@?\ 2S?V' 'SWZG_ )= _P"EF_L. /GOU/\
MRZ!_TLW]AP!\]^I_Y= _Z6;^PX ^>_4_\N@?]+-_8< ?/?J?^70/^EF_L. /
MGOU/_+H'_2S?V' 'SWZG_ET#_I9O[#@#Y[]3_P N@?\ 2S?V' 'SWZG_ )=
M_P"EF_L. /GOU/\ RZ!_TLW]AP!\]^I_Y= _Z6;^PX ^>_4_\N@?]+-_8< ?
M/?J?^70/^EF_L. /GOU/_+H'_2S?V' 'SWZG_ET#_I9O[#@#Y[]3_P N@?\
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M R9"2U:6;H2?6^7,E:KYUZ7(S;"%NLYY!8M?N6X%O(1:3-E&J[<,U3O.CH?
MGKXY30:XG8[ PMC1KBAV@:YL-[4'9]CK";E5(F+M3*X$GRPVJ?D2G#S7\;Y.
MPN'3J?PE+D.Q=V"75FVH;"/<^<*UJF/';<$J-A-I>"UL*@26:-W;6"72(VQ9
M>U0L61HDE=J!)];I\AK'RXUQM[:CP@I<92PLHVM0>Q+6R38-Q4%TU7*N;ZH6
M<EB5R45\8V*5/)#N$:FQE(\P*)J"SE[ON95ZV%VV$I2S^GR5T<\^M7WB^F5K
M4PIHV Q[CVLDZ_I4#VOMXZ^B!K+MKW9&S@^S[>%_31DY<2#RSJQLB3VBN!P2
M#Q(:9FNN8)=37M@6 2OR4]F5E^=U^1['?S6%H[[Y"IQ%+IXX^/ZR)8K-*^\T
M0^Q'ND6%:_*1-:=KJ\$ZF)ZFZLODJ?\ .;28+U2+8B<W)Y (/GHT[M\)79V9
M>?5Q/L_):M)Y66?&"F.1(2(I&5'DE>8-JC@+P3HML6PLZV"%JSM=OE'2J&S0
M)>V0E@>#UQ-8GA:[PGZIR1S"2LF;2\ < < < < < < < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < JS37^ W_3/:'ZSW#@%I
M\ < YY^E;_)\^2GZ,K'ZPT_FZ/QP[R.Y[GR'HI/R?/C7^C+/^L-PXI/'%O"N
M6Y<CH9S!1P"K57^,[:__ #*#_H4AP#!//CYKG89399=CK%I+FV=;(NJ&_*H5
MEJQS*.NV78#8MPT(\8\NJ-^,OLQHSN7L/CYVX):4&6./5/#O(6=V3GR^"N6[
MPPU W9NEB>9G&7'ZML2BR3UK*\:JW1VU6A-;'<;. =%IJ5KP\M?1@M;&J5!$
M(J=+NWU4QANYU[M40_.R_"G26U;&E)6>!H[BT*-!AD:O$=Q(=Y#%MEUXWA82
MA)DHGCG=ZLPZN3KMMA#E0S.<K4KH9A-%@1<H,MBS:\S$Q>#&GNB$)*\4="L^
M>\@_D.9PN3IT$3%LM:[2LE<L2Z%)8V2A8"_(!>BL&EF0 VN%3(\/V&RN YI9
M*A4)OTEY==7&%$^CXT0#UE5TV*G:J.M*)A1N4EBK$@UO9@:'%G"HJF!VNA1,
M\L*_UW%*(?+)N?<HNW6KWQVS:M[#*SF$W:YVN_.9GI?!?2-VSL4@8S;S)3:6
M>R/E<3G+"Q=B[#M'7O6KF+#V9:! ADU^-.QPH5V8A0O.!">&K=9F)@LTJ6=<
M$VNL',^S?X.:-<7#Y?VZAJDXY,9)@S-QY+9SON [KO26L6-?C&.BTTA*8@^M
M^/&IY+=R@,JM \LN9D5]C"R%">%H)N4NIVR>]39E6'PUTXQT.J4W38.G@FW7
M>%E1;!W"3"F=\>0:?Y0-YP=E9IVZ?9$;N)#6#ZQA?I7APVE0R"W*!,9:LUY0
MG[>BD2/;OC&@;J@NXMY%DQMD]<W-5E;U7)9OXETTH:#GC(\J#:5AC52,A>Z%
MJ=6IKB_-[/CEG.,P'WXJ5VH"<NNL2,[,\,-+;7-Z8.-$#-W-HF)5KI->$WA>
MPRK)3FA; 6L"1!BHG3V%JFU:U4[Q T#,!&!EJ4[(5J+&P=VR.S!.4\_K\D?K
M^"6FL;-.R0(N1KXF[JGD(9@(RIL4#/LP5 C5@9DKB)2QD@Z097UXO5[UY2E6
MCCO5G9Z6RC#K3=&^N;"?*77%GE#>!>H5VJN9!&O;HYF18T 7K=\P=X;#CKQ-
MU<H[10$-!7;EX):%75@"E[LVL ]<V!V9H*].EPR;9"3*)6S80)^\\Y_DKL#[
M7_ ?09%[5=AV(6[,\I/&6Q*'4YVL1@F:,=WF_(2O<RLEA1 P+BBV.QF+5^!:
M*@L6@1,.$.?;)66U?L*$WZ2])'I5_!?2Z@PZS9PUEJ[*ZJ6UA%79B^:@PYV-
M=H+*;:=:H=VT?3B1"D&UW?8S59;+K5U?=+(TA/4:&IB^-W)P)];[^)-](>*F
MLM"8FX52VXGJ9C7.MM/0CWIBR:* +5&H.WF+6^OPE6Q3@CA K-#8;(-ZDO>\
M#!NO/%:92IDMW;)6P;GZOS94VOO1R>,>LJL515"-T6$2HH*6,I)T+EK'=91V
M[6W;D9SFOY392,[:["ECMX/9_#>90B6GAK6>%8!3^ )OGZJ7ILP)UGX7Z>G%
MG MZ=S(BC(;>:U!2N,,?> %9\A=AJ6TM@@ DU<=7LX4.G-.'$ $A*<F0#U[1
M$=A>FH2U8*83]O2Q'NV=X?:?VWN18WDWQ,$KHJ"U@6-PID*$0SN--OO)!=G_
M -L";9@?)5DV0X1D*H(P(%LF%\;(TCS=I74[(,)[-_K+X,A5\3=0T];[&U5#
M3/=*6T]++N@VR+(Y-E?FUZKZ^*:S%5Z-WU76=(K@K&+L4Y/##*2:[E'<[CZS
MCZQ[$5EIAV7PSTNT1Q=W8FNG>HD]K, 4N+9)Z9-?:-N;^UKY.&6D/-ZB2&(T
MO;GU&AM2AE;KW* OH-V,NT"@VY;K3"S]O12Y'\9_#C4[HM,X%MNN#(2;&373
ML3<CQ,099>G?5U.E156F&N4 6U+.UC!3[A)A+JM<4"=*W=#V%SL%8]UXA/\
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M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%6::_P&_P"F>T/UGN' +3X
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MX<4GCBWA7+<N1T,Y@HX X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M(:N%W/M96I9;T@8EI';*_E1<1XQ5!K8M/N1=DIU_#BV_ZZ6,]<'-77,:D(;
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M?(_%7R9\9R 4&9';6*6OE9LV/4J8'E<V(0QO+5EL)<UK)82 1\R)(MRO =;
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MC<F]0*]51V@ZH.<#9N>%<O*AD&WM23C@QU"+=%($KGBZ6P3*\Q/V7I@%T\B
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MMB@Q(RZBEG(!075T=NXT: &5L!=L!(6F[*\NNRB$(WIA9& IFR, X$ LUZ6
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M,S4P((*[ZUF;MB[%M"KMF],T4 J]A5MGR(RA8"QK"7K/XN];+3H!P0< < <
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M#Y'4D'0YJXM;,H&.F]4AV4/7D@5,P;4H%,[= L.6:T6O]DU4> !?RID#0;8
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M1I1U, S=TM15M3EPY#89CY8^2V0KNDR7UF,T$IVPVKM34!(RZK6V(<*>!\A
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M6 U=?C&+6+=M-K1Q[)3B9L#%("C;=\<O'9L.$\Z%,R.ISC=Q;9V+!0]X51E
MV+00(VM8KV&SHY0!+/J3?M+S/G;\[R:ZE^-C:V =:5,_)8UJ$\$&T'V_EBI:
MKVJ?U\M=YW+]L#%$U;""E-E+_= 0&AI4&@6/<C%;L9 J9PE0D[;+KR:(?FJ
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MZ0IYH9@=K[ ) PSZ2BP5:B_-5.&.Q]\B<!T;=?HP%HV<LZ\8F.7Y%,NOI&Q
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MRP"1-FV!Q#'SIBILO5+94!+?92X.Q'+MH] *OY*^%D2[JTUN!^9?AZYQAO(
M/HET8LD=25%FNWBUC5[7'K56;&2^DZV&+D0#91L59S>'HHPZRIQZDB9BX-C$
MLJ?LOY(5UR]7I"RV=73W]6%^ZPV7X@LJ4ROBYKI$3E+2P+/$O?G14"+Y(53$
MI V?! :2;(?LVZV)*M)+>NJ4)!3:6.>Q05S30>%L-82$G@[;IDDGW9XAJQ8B
M+[P6!3&*+!3DX.AJ1D^4]AK,EJ9&ET(!#DG,X=?*3)MNG(<#@Z1!O5F?8^%=
MCHB3C5E%="WVOY\+""..\/"\(.![/A"5&46A,"Z<%L^LT$U?J1%P>D6LLFRT
M.EVA1PV7"N:F:B_08( @=JZ'&=&%K@M:EHTRXL)/\Y66YW6[B3S^0GBHV5@[
M07"A;[+7W#4!@@;6B#J6Q*&QX6XWJH4V0B&>K4*@"/K-<E:M0O>D&,M"FL8J
M%JK2=!\:;$$N4^N,B0I.W?%W?"EK6(>("&!UX:$9M>:_=M6$Q;$#I]IQ4X"+
M"-?LZQ"4"58U,>6@"'1PR,1;AQR$@B=N2]4K6A).W*\K%4\G?#O8NN$YV;UH
M$J#CZR$:12\^:I(2V@U0L!O7U!=LY_)&V&@V%?UR\2LU'70N[=;,$5UO'18T
M@FFI#A 64K/R?F3/9V]M"@=HP"7?6-DXY+>L%S8 MJ,JNOZYJHIN;CBMQ#%H
M<\L +9]JP//UAMEQK@%2P&4YKH*)H(C3=Z@/S#KA\[/,RRHW^/[\U[\TY3U(
MO94M0EQM?9E:TMZJ+!3Q>6"EMJE-$A+Y\]L"_)&5<[C*.(,VO1$)-MG/WUZP
M3*RR6K089_E[&(PWUX61>KHRW4(;'8560S;B*:R+!:@I=3!6YUQBHL\A-/IU
M5>Z)!ZFWT#S56;,6<E#I&QAU01/1'&H>@D\.K/E%=/ODOXK+FN!&^VC3$Y0>
MR[.VMX_CI+FLDT0\3EQA?;-5N"WA^R;:84IXOY=8<Z%-#M28NSRW.%13JIQ9
MM:91<P).[<\MEON1LCY,^#LG33[=J-1*+V+K$HMINBF:3::=BWKEALHP RP+
M8%H,._5<3?'7L$0,;4H7JTM!SS,I*4ZFK,Q8,$G[\;>5[]2_#C)XKBCRYNI[
M JXIV<M %3-<^9!1.-I;T9JX.8:V_"X;5L7!+5E9;J[3*460N*,P@VRRQ#E^
M$RTX?)RIB%O6>7EZ%?#GOT?:^TQL=:AK!::(M;'%3U9+7!9=E4=>)%O=QY@5
M;2Z75Z-37&5R2GO8G?7K8M</; H!6F;.DR#5^/N@%O+;N^FZS(Q1OR'\60&S
M=8H%;1URV7R/SIJ\=PTI6$U-;YD)?'H;C7N^]@M KKCWB7\@M3C+(=FJ)U__
M &"UE+3EGP3J;2'GG?O]?G,SEG>?AE"*U\@0:_'%=?FBP QKZB%T(2+I,-YH
M!;5:!#B%5**C,0'@2"_KQV-T]F4U:-.*"B41,4TD*! C9K!:MMUCMMLDB2;+
MW-XOAQ:$0OJJ>_K+ILZJ@8LE%-&&TI3G#ZV>]S%W%F8Y0]H.+5U+7TSR>M'<
M)9:="VPG:UFT.PLMUT<$G[K9/<9A=8_$#9)Q@3A2>AEF%KED<W]<-Z6O"265
MQ7L2VH&':XUF2!TR^4I2DO>(&[L2(81N1&J9,%E9KG*5FZ%N-V?+Z%8L7E%X
M9@K!=G$I]=K.,8)F=F L T<<ZO%1ZQ0UD,)DFHX13J&?4A)-W>DD5BX<L>H<
MT]FI]+-LK6/!:Q8)/IK=[&5FV?X""< \OLVKU_M?%C2HWV'61)=L@,4AV(O(
MY/MQ4%*A9#M:R_)Q9VZU"3PK-XUB5235,GQV@5HA5"V[&R_K8[-DC)[<V%XD
M))SV5QU4%9FYTO:?>F<94T&39&CO%V:"J'JYR<:>"/;*2-&!FJSC%4 2CEV1
M)[H:X%T!-T'.8U 4\9;+Y9RZQS,T5V/X7;P9*RZ8O:S?V=F5)%8*4M+DEP@:
M47]:IRD@B>]]B,.[@^\M/HW%DJ*S!GD$@<AD#!B,G8*4=L+5UMS7EMP,#:W'
MX)[)<Z'1.KK-U;WFDHK]1@,Z?(&OE$+,DD*\J"YW0FCSB[0B!A=]4Q]5[AKW
M> :WC60TAT.86]0JDPMEE?\ 7T]##DM\>&U>O3TO.ESL %R;L+192-Z2:LT\
M6UM>VT]=M3;#Q?U@< 3+]=PV0LL%:@XYB;70(@ F4J5S$JE#"P<,+UL1(&S<
MOB7IO5!SR3'I8. 4;I,#91N+&G" AVV/>4=?.;-V0I4Y%$8=OUY$#INN47DS
MA74ZZ<8)F9V2LJE;5^P)U>9:7<GBKT'-KEZF-$#->N8.8DL"4@K?HTFW66UI
MM4ZW]14U\*,B"C)7<]4#\]?)T$MMQIB5$,0[5Q<*SG$'%D_:_*;7K:>CYS_#
MZTP+T,0]'(,9=F6]C(T]/4Q0E=:VO90N<N)V1KDA43+'RS)E0X"P0//B78+Y
MAJ :2PTF!D%#O*(0RZMN+Q6V'LP"84[*@T[:(5C"\O,H_7Y.XYYK(FD)*$+]
M%H[5^R5?65BHVA9QSGT2BUX>S8:$88X1G)11RBV]/JW*\HZSY@>,6HFTF &Z
MKO 2$K)LWO.\C*.OJMXV>%M^R$)ELCEVJ>#O3>Q.^P= M"YG$FK+9=SL#$HJ
M]6%\4?!7>@D^7K;Y8VRVYD54O*_PK9XE*89I470H.Q@KLY0,2)FC[:N>V#%L
ML]J6XQ VY<<S:F8;[5I<.,EQ_"F2 >DA4+)H\XCLL,AW02?G99;A-?$KS<1F
MW/HU%,W19BWA ;0<0BAW #U^V,=H):>:HR\$1 <BLKENISK$/I@B,:, DL&[
M(V,$0F#>Q9C)\Q"N5KR$\-U^B&6$(VBPC1LM9A25S7* 4(4RMQ@&1%K1+5H9
M,5;<3@4JAFO$FXYZ]K&B"J,.6+CCT(JW+,F02ZZN*=J^0_AT+V601K.EA*O"
M!^5<T[[:U"O0*.#$SU-N"W<,)/#!EJD=8VT'I(Y2*A%>X9;7&.V. 2+Y&8(X
M5E463OG+"W-?,_4L83N7Q&H.0?4,*$.5;(>\M]+,%S2=D(JARLES5MI1J]21
MK6-= 8\&?RC6QXD V5%-H%,;@=L2BJ$!RL1.A;U?M]EP)!F\>%>OPJJZX5M.
M*HA?1:VR40U00Q@[,4@N5)D:>V9+]WKN%VN+*C4UB93.2_'U) .$YFS<5>I+
M4M3!;=Y=>A.G_8.J=5)B]MX@E6\QYMO0!@^8/K@GV[P%]I-MA:%D?DGB!C>O
M?'O39S%8(!ZX7-MEG:&>K&*G*&R-6V)+W]"KJVT?"&YC-*&&:V8/DD(FVS5^
M2>G[K5+6'N(Y(*&W17C6DDI*6O6@[MKTF\75?&^5$"V18ON/5"G>H39BR:ZP
MG\,KZYY3^)-D^;(9:NL'SRR53 /RC":6L-\9!?V9M"70"X36FI>7#$)S W>5
M8<*R:'N66\PJ#!^(M=)0T<JU()>_I:RU:^YO%;#Y)D$NEK]CA=7I/L9WE9;$
M83T2SDTK6"<]DL<AE6;*4J^[U2+@DMGET3NY;3F<Q.=VA*<(=!)X==)\"];F
MG=6WB:X8D0UJ DJ&%PZ$M#AL(C*$BG &)83^[L8KJG$8I*(9K/0*PHS&0%+M
MFY&4#TJ16@.NU!)_!G<D!$R/DFO)*4LF@ST%Q,,F2V&[/E<5NY3(+N)(QW2]
MXWN@%\</O!>K5F7H7<HT[-'U$U6#/ "6\ < < < < YY^E;_ "?/DI^C*Q^L
M-/YNC\<.\CN>Y\AZ*3\GSXU_HRS_ *PW#BD\<6\*Y;ER.AG,%' *9V#H#5FT
M&&@U.(8W8.#A]$9%;!O+XG86JP<I.>6Y"M1.9@-,S?36*U9944J6KW"B*S3R
M,2C<#&LO;N 0NUX?>/\ >UT U,043A) 5 OR?6 939.SBDP 9B;7&"*,2>(N
M-IEI6*A!3!1C[L)C&V-%5K8(?/5"F#0\@+/J2)#L3QFTQM.Y*2<5<E.2F%A0
M<A$$ZO2=?["  NQ5N@'PN)S*!L1#) &V=@B"=.*3"$Q38.\2N-R04#D&!-]>
M7P9<GH761/71+4^(HZ$0S!IP/$@RB]/B5-;NO["Q-+C7S-*3*%.XASIIK/V+
M*_&3P!00WHZ5$=5I#QE>F(0X#XDZ,5B88JM!'8!87&9H;5^J'W/NH<&!EG<[
M,S.%<0O5-A1 1RXS'9Y"9Q-J#85 E8ZB]J!R1P081BSZDCU]^*6A>]LE-X9(
M\N>SS)6F;(,>;8ZY12DZ%1;HUK,0'MB[7*OQ:J@NQ2151$,$_NW#*>.3.>UE
M.)/KU/GKWQ0T7JJWC<0%@\NY0(Y/70VK!LC9ML8!4S=))HFZBP((.%L6KE#>
M.NDVX99EZH-9RA@-@<O&)S-PA>M@5>-]'OXS4LV&I=5F RL&+%>X*32.P-AY
MK*H2C V@4[$!&1M>%>LZ28%#L]%][C^6@*,W<& 3HT5'4IUQ9OKR^$675\2M
M$4NY\*ZP?PIV_<$UX1WLC9F2^1*+-<11"LA)<[;^P)!NJC  0-DWVQTS+8!"
MZ0*R4E$08TN"3ZZWGPE\/_'Z25AEC3S-'%O4[:,X516QMF!Q[<IVTFEKS$(T
MCA;A4HL-0:J4(J8#LO7N3+E^<B? RCF J3*6P/>%\8-7+FUE3;(2B2J&% ?N
MR,8,LF3)@;[ZWR[ GMQ8?BFR)&2K:'EA[)741]#NJ(4AFQM@C0%$?09;E7()
M^WH>Y(\9-*Z[-"&%45+U0PNY4XURV1<GAA^3@H6%;%T(KK\#"QE:P5)70[VW
MTUE'&PUE%;Z8"$X,+0LR8S8"S?7$P%/P^T%0K&:-579(QS%*(Q/B\MH;3F%&
M0P(DU%Q2:3&3.DE&[KVL0>&Z;+7=B#-)M0L)0?< V!MJ2GV$WPZ]B31>-VH*
M[UGLRNOF*KY/?B)W&:B\/0\@2MUVF^V5<BW5!DK5BL-6T5) *]4C!9JX:_O6
M=8^I[UU+DK]B&2?M!:DVA$V0O:C&?A>8]<P-<4IEAI1F*^J&>ZX(M:7 86I8
MUZPL\2(37J]/JO"QT+MH(RQF D\@[(+B%I?B!X]:[(I1%+1;0'+7U2K36!]9
MU?IP,. XUL%C$3EURZT60+-?!G=J[!*@2+*.+W@MYDGLC+%66@(R'A/U/&Q>
M&?CFUSV;1Y%(7[4[:=>8;/;[L6"<4SLYEN8&&^OR5FR');B+EW]WN7!P'L<,
MR[:SD4=.."])%P"P"6A-7$U&HD9!2PT&->V'9@F5=<W9780KRULK,VL; #<%
MQB%MH6R7,.35C;KBS=2EV'/$ES"K@NV,A?0$!L>&OCI<P88[R*0(0L^3)[Q@
M(/VQ[L%6JV@-O++ * 16FV6-7!WA.^=M1X UO$4)HVF^4@.IU+X9=LAPZN/F
MT^%_CBZ$V,JR(Q6_(X53M-K'Q[%V:/7V.-A([',7932P-<::X1NTRVV]@E%\
MC9%R7U8@P>VK-D39%!9!P3ZX?'4SX/?A+XR[+IE*#GKB4K5-%R!PI'$[;!%=
MW"14YNUC(RYR!VNA)A%<,>1FY;,M2+..IU@X]U8X,*@!7@""IM7'K+^&_CX<
MF-V;RFQ1W3["::+Y ;M#:H8C$59".W2C!T)("'6C< ##-O?.WO;P@*<<&F@>
M"5;JCC7JBHQX3?#=UL)75\<-0B +@ 7%"@%J.B@[I):OW,2*BLP6P&ER>&0?
MV#)D; ONA<;7YI*=T(J\$$-8E[DJ>R@Z@\?4$(,M^%7CTMX:SL1J)$@P:I%K
M0Q::[K<W8'K'2RO)"Y%9.3T3E2L:D,5=<IUQEK$*L]!A+!HBI:I;O36IYPG;
M/'W,=GX&^+6=7JAWKPK[NB70*Q1%=[+VID(#C5J;45D3."$9NV0P(;QLZ'U/
M9(L8NI4/G)U+&0X2(Y&V/WP+-]>?RR> ?%K1ZVQ&F@2JE(R1]*-:])UKCWL$
MJOYJK*&UZOLE.JJE6FZL#B#"*U4@P'#XX158"LR_C>NE)KY,S:(A-]>?RR/K
MOAGX\JIFDP!5%@B,U2BZ;M7KVSMI&<F(HF8 ,46X[0&7,A5?,]?YJR_:0,'.
M ["E$!<!)9C&$,Y[,P3?7G\VX[23 /&'2BM \0KZK?%=[(7ABRZ6:KB[=730
MT6(J \9LKF;%G8I&"H^C4Z9V =)3.-]R'HDTD#!&2:U((8!'\.?'/6UJI:2=
M?9@NZ$J)/2K0M[S:H5;.MJ"\-4+<0Z^RVZ7M5&HJ@>KUC*#*4[9I2D#V1(@3
M+6KXLWU+;F8FOX/>,E:C='PZ^(]5[J:M:_RRSV'LR6U54$[7[;J]6#C+\KCG
M>%= DEZ:10Z\.L5B<$Y/$OC=]\C1-^B$WUG;[$DB\2?'V)AA;.D+*1D@KW:O
MOFPUNUJ[/$0W;WY%V>[LEACEQOS?/))9<8+5W&Q9I]D"@&G- L%2(6T).R6R
M\^J#XP:NUGL<5L=1HDJ5]<T[7T>L#[ADR;B!HN#N4>Y1D1 \1*%;-. G=I45
M\?9MY4U4*-Q# 8J@NQW3A%;;,56\-_'6ID"Q@1;^%):A2\08;)\V+*O#R&O5
M5=1%%FC796S,)(ZBD94 )>3S8H2MY!3HY+Q,U<$W2%6T(2G:'C=J3<Q. KLD
M2SL,U.G-5&4X]E[-!A@EB>E=&2'5X$NMXD,NMWNPD0'1N8.B/:X:-ZW5B,80
MSR8Y!/KKE<?D9XV:E%#-FAH1[I=$[C"VP.QQQ_;FW6>FQT[ZB,12-OU#(\EH
MQ!\DK!QPTDU L1C.1S@R(W2\Y2Q9NS 0BAX0>,(U9R4*NM<_D_(/8!<M*=TV
M!9SEI-6._<3\4ERPU27N\B'7D_O+X9>K/4M7MWZ[I9UODTH>X!9N<]OP9@YX
MB:&9=?TM8GUED+*-([L%C[AN[/VG*;(E-K0M=79'9UM[<_E8P#W*F[M-(R'-
MFKXB2F5[K5Z->*D-QIA-]2/WEXB^/\E5OH64FW>%OEWNXU"";F]%!!&'"[L(
MO1#0BR++:HB5D(P[4>6I;5@L Y?6&PO79E\:--! %T6$WUP,9L_P]TQM+7E;
M7I4<P#ZH16VLNJ!:HY.$Y!9O;C46I-<FWO&X?FK,K3;&N;%/&8;(S=R.Z3MV
MHYHYYLI>"3/+^!#XT97BQ2PAEKY=@569+8S938^SRAYE MMEXMF(V(Z0<K)<
MV2PL;(<\PQXE=L'5SWO#BO$1> 4!B+%F^O+X1+8/%O249/HW86#!<YV9I,,Y
MMA?MAL9>Z:'D]'&*I B2.M1"V0EC(^-VEYN\+DLT&<:9C4SB[IGF:N9$/(M>
M)VC5')0D KK-6L(.23BF7+6S]I%KJW1UU"U4TX&*N%G.]9KK0D4\-H+-9ZE[
M E%\\0"&!Y 9-[-T!XT[Q(TLK:70M%75K!E2$#%QE&425F_6@L7MAK6PE%XF
MLU!URM!+1.KNU7T1@&L>TC1E W'C0ABM"A5RF&>TFB+X_P"JM=$&0PN "4YQ
MS&X"7$\UMSD^'FRE%\:.'%E,O!]A)')H*?<(FO;)6;-NN!HBP$,V 44-H50(
M&)\,_'@+7'UZ:@P2=#:Y"C#8([/VJ8OV1A(9K@/('+$2SK=OFPM0=J'6< D2
M8LWJ :1.%W!=>I>SNV;8L]W!'WQ\.O'.-B86J'7V<!ILLF;S)/7;WFO6,D#[
MH;V"4(WAT++@.D(3M+"5N87<:N-BO1EI@JTD0$0&&CQ)["U3>I=?L33(Z& '
MM;++\W7K"7O4U7^-\T[ W-*!_M.J1AH=>X3KVU7OX*O7O3WI[,9]XTZ0ZO4
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MQP[R.Y[GR'HI/R?/C7^C+/\ K#<.*3QQ;PKEN7(Z&<P4< < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
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6X91Y=]QYYX]U44$+34YK,CC;4K#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g692844g91e59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g692844g91e59.jpg
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M%18A(C%8%Q@9&B,YE[;7)"97=I66M]8R,SA"0U)U=WB8U?_$ !P!  $$ P$
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M13J3-:3;MC4FBDP0-JL D7)V<DD2N1&&RCYN=>!;:>/^TPL8.9*GM1[;XZY
M@8-P<'!(ORW6?DL>YJS*O'4>.3P/<DG] 'G25D<WBL5-2K7[L4%K(O*E"IP\
MUNX8%1K!K5($DL31UQ)'WY4B,<)EA$KH98PV=!VN(MP0\C4I 29BG_=PJ9$<
MPZ"RX.\X,2%C./12Y48IEX8P!:6W(Q]E]N2PP2VV&0!@W!'D'SS]/Y/_ />/
MKY\:]:F1K9*)9L=-':KL75K,;=42/&[1R0_B;$<BM'+">EJ[HZS]$BK$\0=]
MM6P@>\5HK6FO]K;/D:F[J":M>Y:3(7:9DJ$)EZ%V(H7W*?\ (178E\A ]*?:
M0%%#-,GEP<@QALEY]U:>[/\ :4*)(_3VF:5.H]/L_'R^P/YI\#\#]=5@S.2S
MD/\ 52[.V_A-R[AGQC;7MY+=6(FRUJ?#1%JF<[?.*ZUHUGD$>)=1#70)-+4G
M3ID9V,TG2EJU^CHT:.C1HZ-&CHT:.C1HZ-&CHT:.C1HZ-&CHT:.C1HZ-&CHT
M:.C1HZ-&CHT:.C1HZ-&DQM&[=,TBTQ%&NFW-8U"ZV#V/L-/M%^JL!:9OY+F6
M1OM%?E9826DOD.XRTQ\,1[W7,90WY*QZ==L&-R-F"2S6H7;%:+GNV(*L\L$7
M'OW)8XVC3CZ]3#C7'-D*%>9*]B]3@L2\=N":S#%-)R>!T1.ZN_)\#I4\GVTI
MW7%KLU0%[R7]>"]_K=Q1_NMKCJU/I]_6S_P;/?Y^YJM>^?ZX?^$87_,U-7^N
MJK:LIHZ-&D1Y'["V9J?26P]E:AU.WO&]TF!?L<9JK\5O4LVXB1BD$S,;"S;%
M7N#F; B';.*@XE,$0J>DV!H5IX1XYHAM3P]2E?R52GD+YQE6S*(7O=@6%KL_
MRQO+&T]<=GN%5ED[H[2$R$,%(*?E;5NEC[-NC2^T;->,RI2[QKM.J>9$CD$,
M_P![T=31IVSW7 C!!8$1)=LKOCZ\[@FV[%HVUZE1Q^V0B#5/Z[BR-CIOH6Q6
M(I)+ULB0S7J317(VQP("&)D>(2+)KEH5J=D$.B)@2$$/S>GIG;VI0AR<%\Y6
MGW>U<<4_A6IE^D02,HLV0\,KDQF0L@CE,2$,91PRMI>H=7<UV7'34OLRUV^[
M50VQ96T$Y,R*QKUBLL:\2"/I<O&)&Y';(*[]PSBKR9V[L?46[>*%UBH78NL(
M.?JTG"3DIF'%=BK <&>P?$'NC$Q^)+"VWDRH17Q5N@LQA#16'&&!3(CM1SLR
M20=#$*59)"0#Y!5E8<$,/(/!'*GCZ\&+_7#TX]0MRY_:^\?3/,UZ.X-N4[^,
MGJV["UHVJY"6&825I)8IJQF8H?BH9A&6BCK2I*KQQI*M7%77D]PEXHVJ:Y([
M""G;"#(WK=6T[ &^^7#PSQXHQ)<- NE, O'X8"B!L(;:#&^XV$XMD!AQ) ZW
MO2(-! 6G9>5!=^GGH0 #Y5Y))X ^OEF)]R=.STXP=WTC]-\G<W]G8[U]+.9W
M=N7(1NTE:M)91)9JM-G2 S=$5:-42.&%9KDLD=>,JT99DW;E,#E'.5/=-Y'2
MT30(G:<E-!5F=MD@Q'Q%+T[436&Y!Y<H7E#2HM!,+7:;'K]4E$O41W#33[DH
MQAW3"T[62M]5>"6Q;O3""K!$A>5_/ 5% )/L%_ ",LQXY(C'^IYJ6<]>W[Z\
M[I"TIMX7K%+"FRP"T=N8^9$D"2MP&KB2K2Q<3>'8X5VX/>!,>?*OZG#X]J,H
MO!W1X5[;0=F+C-F[?8L/Q;,6M[XS2ZOJNLEPEC6&6OQ<BBIVT1DL5[K39M2!
M=2IE=A\%Z+\P+:W-DVJGIZWI8\P]4*@<GOWIUEAZE'[HL4#QKP>F=AY$F9GU
M;XF:OM['K9 ;H2W>$O3*W/ [-.%HY>DG@HTDR.W/#0*?&F^!=WOOSQK.+N?Q
M FI*G)3\U2Y/AMNH:H9#QCW,YS.1I<:8D7V_S^1]_P#7"/U>]GT]>E5M@>ES
MGX5-P1I8_,X3<.-:QU>W[DZNO5S].U_)I,7>_J.H%AL'(\'YWS8*^("O_.(R
MMQ^GN?RZDJX"_4-:?Y$W.'TMRCI _&W:\Q(-0,)9T2I!NI[#8G'L"HAI$F9:
M%F]<2Y9BL!QX=@=FH5Q]"F3+6"<^& 0SMU>DN0Q%:3)82R<Q0C0RRPE M^&$
M#J,B+&6BN1JOS.T0CD /*P,BLX=FVO4ZCE+$>/S%<8J[(XBCEZRU*67GI[;-
M)Q)5D9OE59>Y&3X:96*J=JV5WFME47NLQW;R%TM1SZ>;N#5&M%;%(L4^U94
M[$K%.GC)-,2VQF+R5'.V9\<9G+GLO-BM+=SA2UXQX4_3JG:V,^[6R5E+"X^_
M=^#$,1A+4YK$2IW">OI<0 L>.06/'MKVM;\M5]Y+MA<?7:!KU.I\499.[TV8
M8)&?H Z.I3*0!SP0!SJP=G.,8SG.?3&/SSG/Y8QC'[<YSU$^I,U7%Y[?44Z'
MXWV:=U5QKJ8_)#8\"23%SUN5.YAM.5N6'6MI\(.:CV#I78)H+[:FCVJ_B)K^
M//& [@42R4(Q+^UO2/*9B&*]F9VP].55>*OVNYD)HSY#-&Y5*BL#RAE[DO\
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M"E'1F7',8<6TPX4IIM:\86I",*5CUSGJ,K<(KVK-=6+""Q-"&/@L(I&0,0/
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MLM&:*0_4QPV.J+G]33R\:]?ZCV<ED:/[8%;2MUN"*U??YQ]O&<X8,E@*CH<
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M>U71G2(DLSROTLDA;+V-6VQ&UJRZ6\O,G1).H/9K1G@M#5ZP'/40.Y.RJ\@
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M+-J39D4)*?<'WF60(J'8;8;C@116\ORAE8,X2 U^>79N>'[LI8LQ)YC<<\^
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M=?Q8RZB7,04&1,6=FKV@$T9@"(RO4Q1 Y$;RDCHED<],:,9 LC*A*,_0/E)
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7%54D)X\R*JJJO^<JJH!  UD]&O37_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
